<SEC-DOCUMENT>0001213900-23-018373.txt : 20230308
<SEC-HEADER>0001213900-23-018373.hdr.sgml : 20230308
<ACCEPTANCE-DATETIME>20230308082032
ACCESSION NUMBER:		0001213900-23-018373
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230308
DATE AS OF CHANGE:		20230308

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protara Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001359931
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				204580525
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36694
		FILM NUMBER:		23714911

	BUSINESS ADDRESS:	
		STREET 1:		345 PARK AVENUE SOUTH
		STREET 2:		3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		646-844-0337

	MAIL ADDRESS:	
		STREET 1:		345 PARK AVENUE SOUTH
		STREET 2:		3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ArTara Therapeutics, Inc.
		DATE OF NAME CHANGE:	20200110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROTEON THERAPEUTICS INC
		DATE OF NAME CHANGE:	20060420
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2022_protarathera.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 08 08:29:58 UTC 2023 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:tara="http://www.Protaratherapeutics.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-K</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Mark One)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric> <b>ANNUAL REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric> <b>TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;
to&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-36694</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName">Protara Therapeutics, Inc.</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its
charter)</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="width: 2%; text-align: center; font-size: 10pt"><b>&#160;</b></td> <td style="width: 49%; border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20-4580525</b></span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of<br/> incorporation or organization</span></td> <td style="text-align: center; font-size: 10pt">&#160;</td> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)&#160;</p></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">345 Park Avenue South</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2">3<sup>rd</sup> Floor</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of Principal Executive Offices)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">10010</ix:nonNumeric><br/>
(Zip Code)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">(646)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">844-0337</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section 12(b)
of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td> <td style="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td> <td style="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common stock, par value $0.001 per share</span></ix:nonNumeric></td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TARA</span></ix:nonNumeric></td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric> Capital Market</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section 12(g)
of the Act: None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>
&#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and
&#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 62%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</span></td> <td style="width: 38%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric> &#9746;</span></td> <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 0.8pt">&#160;</td> <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If securities are registered pursuant to Section 12(b) of the Act,
indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to
previously issued financial statements. &#9744;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether any of those error corrections are
restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers
during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Act). Yes &#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, the last business day of
the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock
held by non-affiliates of the registrant was approximately $<ix:nonFraction contextRef="c1" decimals="-5" name="dei:EntityPublicFloat" scale="6" unitRef="usd">19.6</ix:nonFraction> million, based on the closing price of the registrant&#8217;s common
stock on the Nasdaq Capital Market on June 30, 2022 of $2.93 per share.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 3, 2023, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">11,306,753</ix:nonFraction> shares of the registrant&#8217;s common
stock, $0.001 par value, were outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Portions of the registrant&#8217;s definitive
Proxy Statement to be filed with the Securities and Exchange Commission by May 2, 2023 are incorporated by reference into Part III of
this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROTARA THERAPEUTICS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM 10-K</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt; text-align: center"><b>For the Year Ended December 31,
2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt">&#160;</td>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; padding-right: 1.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_001">PART I</a></b></span></td>
    <td style="vertical-align: top; padding-right: 1.8pt; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom; width: 10%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 80%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Business</a></span></td>
    <td style="vertical-align: top; width: 10%; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Risk Factors</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Unresolved Staff Comments</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Properties</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Legal Proceedings</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Mine Safety Disclosures</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr>
    <td colspan="2" style="vertical-align: bottom; padding-right: 1.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_008">PART II</a> </b></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-align: left; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Reserved</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Financial Statements and Supplementary Data</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Controls and Procedures</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">Other Information</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C. </span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_018">PART III</a></b></span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">Executive Compensation</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">Principal Accountant Fees and Services</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_023a">PART IV</a></b></span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt">&#160;</td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023b">Exhibits and Financial Statement Schedules</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_024">Form 10-K Summary</a></span></td>
    <td style="vertical-align: top; padding-right: 0.8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This Annual Report on Form
10-K, including sections entitled &#8220;<i>Business,</i>&#8221; &#8220;<i>Risk Factors,</i>&#8221; and <i>&#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operation</i>s&#8221; and other materials accompanying this Annual Report
on Form 10-K contain forward-looking statements or incorporate by reference forward-looking statements. Statements, other than statements
of historical facts, contained in this document, including statements regarding our business, operations and financial performance and
conditions, as well as our plans, objectives and expectations for our business operations and financial performance and condition, are
forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown
risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from
any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify
these forward-looking statements by terminology such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;potential,&#8221; &#8220;continues,&#8221;
&#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seek,&#8221; &#8220;approximately,&#8221; &#8220;predict,&#8221;
&#8220;intend,&#8221; &#8220;plans,&#8221; &#8220;estimates,&#8221; &#8220;anticipates&#8221; or the negative version of these terms
or other comparable terminology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.25in">These forward-looking statements include, but
are not limited to, statements about:</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">estimates
                                            regarding our financial performance, including future revenue, expenses and capital requirements;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our
                                            expected cash position and ability to obtain financing in the future on satisfactory terms
                                            or at all;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">expectations
                                            regarding our plans to research, develop and commercialize our current and future product
                                            candidates, including TARA-002, and Intravenous, or IV, Choline Chloride;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">expectations
                                            regarding the safety and efficacy of our product candidates;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">expectations
                                            regarding the timing, costs and outcomes of our planned clinical trials;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">expectations
                                            regarding potential market size;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">expectations
                                            regarding the timing of the availability of data from our clinical trials;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">expectations
                                            regarding the clinical utility, potential benefits and market acceptance of our product candidates;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">expectations
                                            regarding our commercialization, marketing and manufacturing capabilities and strategy;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the
                                            implementation of our business model, strategic plans for our business, product candidates
                                            and technology;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">expectations
                                            regarding our ability to identify additional products or product candidates with significant
                                            commercial potential;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">developments
                                            and projections relating to our competitors and industry;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our
                                            ability to acquire, license and invest in businesses, technologies, product candidates and
                                            products;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our
                                            ability to remain listed on the Nasdaq Capital Market, or Nasdaq;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the
                                            impact of government laws and regulations;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">costs
                                            and outcomes relating to any disputes, governmental inquiries or investigations, regulatory
                                            proceedings, legal proceedings or litigation;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our
                                            ability to attract and retain key personnel to manage our business effectively;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our
                                            ability to prevent system failures, data breaches or violations of data protection laws;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">the
                                            timing or likelihood of regulatory filings and approvals;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">our
                                            ability to protect our intellectual property position;</td></tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"></td><td style="width: 0.25in; text-align: justify">&#9679;</td><td style="text-align: justify">the
                                            impact of the COVID-19 pandemic on our business and operations as well as the business or
                                            operations of our manufacturers, contract research organizations, study sites or other clinical
                                            partners and other third parties with whom we conduct business and regulatory agencies, and
                                            the extent and duration thereof; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>the impact of general U.S. and foreign economic, industry, market,
                                            regulatory or political conditions.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We undertake no obligation
to update or revise any of the forward-looking statements contained in this Annual Report on Form 10-K after the date of this report,
except as required by law or the rules and regulations of the U.S. Securities and Exchange Commission, or SEC. We caution readers not
to place undue reliance on forward-looking statements. Our actual results could differ materially from those discussed in this Annual
Report on Form 10-K. The forward-looking statements contained in this Annual Report on Form 10-K, and other written and oral forward-looking
statements made by us from time to time, are subject to certain risks and uncertainties that could cause actual results to differ materially
from those anticipated in the forward-looking statements, including the risks, uncertainties and assumptions identified under the heading
<i>&#8220;Risk Factors&#8221;</i> in this Annual Report on Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><b>SUMMARY OF RISKS AFFECTING
OUR BUSINESS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.95pt"><i>Below is a summary of
the principal factors that make an investment in our securities speculative or risky. This summary does not address all of the risks
that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, and other risks and uncertainties
that we face, are set forth in Part I, Item 1A, Risk Factors, and should be carefully considered, together with other information in
this Annual Report on Form 10-K and our other filings with the SEC before making investment decisions regarding our securities.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have a limited operating
    history and have never generated any revenues.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect to incur significant expenses and significant losses for the foreseeable future and may never generate revenue or achieve or maintain profitability.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need to raise additional
    financing in the future to fund our operations, which may not be available to us on favorable terms or at all.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business depends on the successful clinical development and regulatory approval of our product candidates, including TARA-002 and IV Choline Chloride.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never completed a clinical trial or made a BLA or NDA submission and may be unable to successfully do so for TARA-002 or IV Choline Chloride.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TARA-002 is an immunopotentiator, and one indication that we plan to pursue is the treatment of lymphatic malformations, or LMs. There are no therapies approved by the United States Food and Drug Administration, or the FDA, for the treatment of LMs and it is difficult to predict the timing and costs of clinical development for TARA-002 for LMs.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if a product candidate
    obtains regulatory approval, it may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial
    success.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates,
    if approved, will face significant competition and their failure to compete effectively may prevent them from achieving significant
    market penetration.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently have limited
    marketing capabilities and no sales organization. If we are unable to grow our sales and marketing capabilities on our own or through
    third parties, we will be unable to successfully commercialize our product candidates, if approved, or generate product revenue.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain stockholders have
    the ability to control or significantly influence certain matters submitted to our stockholders for approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to obtain, maintain or enforce global patent rights or other intellectual property rights that cover our product candidates and technologies that are of sufficient breadth to prevent third parties from competing against us.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are subject to stringent
    and changing obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could
    lead to regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations, including
    our clinical trials; harm to our reputation; and other adverse effects on our business or prospects.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1. <i>Business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;We are a New York
City based clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare
diseases. We were founded on the principle of applying modern scientific, regulatory or manufacturing advancements to established mechanisms
in order to create new development opportunities. We prioritize creativity, diverse perspectives, integrity and tenacity to expedite
our goal of bringing life-changing therapies to people with limited treatment options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our portfolio includes two
development programs utilizing TARA-002, an investigational cell therapy based on the broad immunopotentiator, OK-432, which was originally
granted marketing approval by the Japanese Ministry of Health and Welfare as an immunopotentiating cancer therapeutic agent. This cell
therapy is currently approved in Japan and Taiwan for LMs and multiple oncologic indications. We have secured worldwide rights to the
asset excluding Japan and Taiwan and are exploring its use in oncology and rare disease indications. TARA-002 was developed from the
same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432 (marketed as Picibanil&#174; in Japan and Taiwan
by Chugai Pharmaceutical Co., Ltd., or Chugai Pharmaceutical). We are currently developing TARA-002 in non-muscle invasive bladder cancer,
or NMIBC, and in LMs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our lead oncology program
is TARA-002 in NMIBC, which is cancer found in the tissue that lines the inner surface of the bladder that has not spread into the bladder
muscle. Bladder cancer is the sixth most common cancer in the United States, with NMIBC representing approximately 80% of bladder cancer
diagnoses. Approximately 65,000 patients are diagnosed with NMIBC in the United States each year. Very few new therapeutics have been
approved for NMIBC since the 1990s and the current standard of care for NMIBC includes intravesical Bacillus Calmette&#8211;Gu&#233;rin,
or BCG. The mechanism of action of TARA-002 is similar to that of BCG. TARA-002 and BCG are both intravesically administered, elicit
a Th1 type immune response and produce a similar array of locally activated cytokines and immune cells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are conducting a Phase 1 dose-finding, open-label clinical trial
to evaluate TARA-002 in treatment-na&#239;ve and treatment-experienced NMIBC patients with carcinoma in situ, or CIS, and high-grade papillary
tumors (Ta), known as the ADVANCED-1 trial. In the initial dose escalation phase, or Phase 1a portion, of the trial, patients receive
six weekly intravesical doses of TARA-002. The primary objective of the trial is to evaluate the safety, tolerability and preliminary
signs of anti-tumor activity of TARA-002, with the goal of establishing a recommended dose for a future Phase 2 clinical trial. The trial
is ongoing and we expect data from the Phase 1a portion of the trial in the second quarter of 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are also pursuing TARA-002 in LMs, which are rare, non-malignant
cysts of the lymphatic vascular system that primarily form in the head and neck region of children before the age of two. In July 2020,
the FDA granted Rare Pediatric Disease designation for TARA-002 for the treatment of LMs and in May 2022, the European Medicines Agency
granted orphan drug designation to TARA-002 for the treatment of LMs. In addition to the clinical experience in Japan, we have secured
the rights to a dataset from one of the largest ever conducted Phase 2 trials in LMs, in which OK-432 was administered via a compassionate
use program led by the University of Iowa to over 500 pediatric and adult patients. We have an open IND for LMs with the Vaccines and
Related Products Division of the FDA, or Vaccines Division. We received feedback from the Vaccines Division on the protocol for our proposed
Phase 2 clinical trial evaluating TARA-002 in LMs. In the second half of 2023 we expect to initiate this Phase 2 single arm, open-label
clinical trial to evaluate the safety and efficacy of TARA-002 in pediatric patients with macrocystic and mixed-cystic LMs. The trial
design includes a safety lead-in phase followed by an expansion phase. We are conducting trial preparation activities and have identified
multiple trial sites.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The third development program in our portfolio is intravenous, or IV,
Choline Chloride, an investigational phospholipid substrate replacement therapy initially in development for patients receiving parenteral
nutrition, or PN, who have intestinal failure associated liver disease, or IFALD. IV Choline Chloride has been granted Orphan Drug Designation
by the FDA for this indication and has also been granted Fast Track Designation for the treatment of IFALD. Following a positive end of
Phase 2 meeting with the FDA, we received feedback on the design of the studies necessary to complete a registration package for IV Choline
Chloride for the treatment of IFALD, including a Phase 1 pharmacokinetic, or PK, trial and a Phase 3 clinical trial. Prior to initiating
these clinical trials, we are conducting a prevalence study to enhance understanding of the PN patient population and we plan to use this
information to determine the next steps for the development program. In September 2021, we reported results of the retrospective part
of the prevalence study, which supported the significant unmet medical need in patients dependent on PN who have IFALD. We are currently
conducting the prospective part of the prevalence study, which is a multi-center, cross-sectional observational study to assess the prevalence
of choline deficiency, as well as cholestasis and steatosis, in patients dependent on PN. We expect to have results of the study in the
third quarter of 2023. In April 2022, the U.S. Patent and Trademark office, or USPTO, issued to us Patent No. US 11,311,503 claiming a
sterile aqueous choline salt composition with a term expiring in 2041.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have devoted substantial
efforts to the development of these programs but do not have any approved products and have not generated any revenue from product sales.
TARA-002 has not yet been approved for use for treatment of NMIBC, LMs or any other indications. We do not expect to generate revenues
in the near-term, if ever. To finance our current strategic plans, including the conduct of ongoing and future clinical trials and further
research and development costs, we will need to raise additional capital. See &#8220;Item 7. Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources&#8221; for additional information about our liquidity
and capital resource needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Product Candidate Pipeline</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following chart summarizes
the current status of our product candidate pipeline:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TARA-002
                                            Granted Rare Pediatric Disease Designation for the treatment of LMs</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted
                                            Orphan Drug and Fast Track Designations by the U.S. FDA</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            1 PK study to be conducted in addition to Phase 3 study</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Corporate Strategy:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are an oncology and rare disease company focused on applying modern
scientific advancements to established mechanisms to deliver efficient de-risked clinical programs. Leveraging the drug development and
commercialization experience of our management team, our goal is to build a leading biopharmaceutical company focused on bringing life-saving
therapies to patients with significant unmet needs. Our current key initiatives are listed below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>1. Progress clinical program supporting
TARA-002 for the treatment of NMIBC.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Complete the ongoing Phase
1 clinical trial to assess the safety and tolerability of TARA-002 in patients with high-grade NMIBC, involving a dose escalation phase
in which we are evaluating the safety, tolerability and preliminary signs of anti-tumor activity of TARA-002 to determine dosage for
a future Phase 2 clinical trial. We then intend to further assess safety and preliminary signs of anti-tumor activity of TARA-002 in
both BCG-na&#239;ve and BCG-exposed NMIBC patients with CIS in an expanded cohort of our Phase 1 and Phase 2 clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>2. Progress clinical program for TARA-002
in LMs by initiating a Phase 2 clinical trial in patients with macrocystic and mixed-cystic LMs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based on the robust dataset for the originator product OK-432 in LMs
and the full Clinical Study Report, or CSR of the randomized Phase 2 clinical trial of OK-432 in LMs led by the University of Iowa, we
are encouraged by the potential for TARA-002 to treat patients with LMs. Following feedback from the Vaccines Division, we expect to initiate
a Phase 2 clinical trial evaluating TARA-002 in pediatric patients with macrocystic and mixed-cystic LMs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>3. Complete prospective prevalence study
of patients receiving PN and who have IFALD to refine a development pathway for IV Choline Chloride.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are currently conducting
a prospective prevalence study to enhance understanding of the PN patient population and plan to use this information to inform the next
steps for the development program. We received FDA feedback on a potential design of the studies necessary to complete a registration
package for IV Choline Chloride for the treatment of IFALD, including a Phase 1 pharmacokinetic study and a Phase 3 trial. We intend
to use the results of our multinational prevalence study of the PN patient population to inform our strategy for IV Choline Chloride.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>4. Explore opportunities to expand our
pipeline of uses for TARA-002 alone and in combination with other therapies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are exploring the use
of TARA-002 in combination with other therapies and are working to identify additional opportunities to develop TARA-002 in indications
beyond NMIBC and LMs. We are conducting non-clinical experiments and modeling to better characterize the potential benefits of combination
therapy with TARA-002, particularly in NMIBC. In addition, our leadership team has a strong track record of licensing, acquiring and
optimizing product candidates and we intend to leverage this skill set to identify opportunities for potential combination opportunities
for TARA-002, in NMIBC and other oncology indications. The immunological activity of TARA-002&#8217;s originator product, OK-432, has
been effectively interrogated in patients in numerous indications. We plan to continue to carefully evaluate the case reports and the
literature and perform non-clinical characterization studies to better understand the mechanism of action of TARA-002 and its potential
activity in indications beyond NMIBC and LM in which there is unmet need.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Pipeline</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>TARA-002</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">TARA-002, our lead program,
is an investigational cell therapy developed from the master cell line of the same genetically distinct <i>Streptococcus pyogenes</i>
(group A, type 3) Su strain as OK-432, a broad immunopotentiator marketed as Picibanil&#174; in Japan and Taiwan by Chugai Pharmaceutical.
We are using the same regulatory starting materials as OK-432 and manufacture TARA-002 using an updated version of the same proprietary
processes used to manufacture OK-432. We have designated this product candidate as TARA-002 in order to differentiate the regulatory
path in the United States and other geographies from that of OK-432 in Japan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We entered into an agreement
with Chugai Pharmaceutical in June 2019, as amended in July 2020, to support our development of TARA-002. The agreement provides us with
exclusive access to certain materials and documents relating to OK-432 including the master cell bank of <i>Streptococcus pyogenes</i>
used in the manufacturing of OK-432. Additionally, the agreement provides technical support during a certain period. We have utilized
the materials, proprietary manufacturing process and technical support provided by Chugai Pharmaceutical to produce TARA-002 at a cGMP-compliant
facility in the United States. Under the agreement with Chugai Pharmaceutical, we have sole responsibility for the development and commercialization
of TARA-002 worldwide, excluding Japan and Taiwan. This agreement is exclusive through June 17, 2030, or following any termination of
the agreement by either party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In Japan, OK-432 is indicated
for: the treatment of lymphangiomas (lymphatic malformations); the prolongation of survival time in patients with gastric cancer (postoperative
cases) or primary lung cancer in combination with chemotherapy; and the reduction of cancerous pleural effusion or ascites in patients
with lung cancer or gastrointestinal cancer respectively, head and neck cancer (maxillary cancer, laryngeal cancer, pharyngeal cancer,
and tongue cancer) and thyroid cancer that are resistant to other drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We plan to pursue development
of TARA-002 for the treatment of NMIBC and LMs initially in the United States, and plan to also seek approval in Europe and other regions
in the future and may also explore additional indications where its utility as an immunostimulant has been hypothesized to be of therapeutic
benefit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>TARA-002 in NMIBC</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disease Overview</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Bladder cancer is the sixth
most common cancer in the United States, with NMIBC representing approximately 80% of bladder cancer diagnoses. NMIBC is cancer found
in the tissue that lines the inner surface of the bladder that has not spread into the bladder muscle. There are three subtypes of NMIBC:
Ta (non-invasive papillary carcinoma), Tis (carcinoma in situ or CIS), and T1 (carcinoma invading the lamina propria). Among the types
of NMIBC, Ta accounts for most NMIBC cases (70%), whereas T1 and CIS account for 20% and 10%, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are approximately 65,000 incident cases of NMIBC in the United
States every year, and based upon currently available data we believe that approximately 45% (approximately 30,000) are made up of High-Grade
tumor types that are considered higher risk, and therefore candidates for immunotherapies, such as TARA-002. In addition, NMIBC has one
of the highest rates of recurrence with three-year rate estimated at up to 80%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Treatment</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Treatment for NMIBC is typically targeted to reduce unresectable persistence,
recurrence after resection and to prevent disease progression to muscle-invasive bladder cancer. The initial treatment for NMIBC includes
cystoscopy and complete transurethral resection of the bladder tumor (TURBT) for papillary Ta or T1, or biopsy for CIS. A single postoperative
instillation of intravesical chemotherapy is recommended in patients with low risk of progression, and for patients with intermediate
and high-risk disease, a longer course of intravesical therapy is administered. The most efficacious intravesical agent to date has been
BCG, a live attenuated form of <i>Mycobacterium bovis</i>. BCG has been the subject of multiple supply shortages in the US in the past
decade due to the inability to meet demand to treat the large population of patients with NMIBC. There has been a significant increase
in bladder cancer recurrence and progression with an escalated number of patients who require cystectomy. As such, with the current BCG
shortage and limited effective alternate therapies or dosing strategies, there continues to be a significant unmet need for treatment
options for patients with NMIBC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Clinical Development</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are currently conducting our ADVANCED-1 trial. In the initial dose
escalation phase of the trial, patients receive six weekly intravesical doses of TARA-002. The primary objective of the trial is to evaluate
the safety, tolerability and preliminary signs of anti-tumor activity of TARA-002, with the goal of establishing a recommended dose for
a future Phase 2 clinical trial. The trial is ongoing and we expect data from the Phase 1a portion of the trial in the second quarter
of 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><br/>
Preclinical Development</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We continue to conduct pre-clinical
studies on TARA-002 to better characterize the mechanism of action to help us understand how TARA-002 may perform in potential combinations
with other agents used to treat NMIBC. In addition, we use pre-clinical data to help us define other cancer targets for TARA-002 both
within the urothelial cancer space and other types of cancer affecting different parts of the body.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Regulatory Interactions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In October 2021, we announced
that the Office of Tissues and Advanced Therapies Division, or the OTAT Division, of the FDA&#8217;s Center for Biologics Evaluation
and Research, or CBER, cleared our Investigational New Drug, or IND, application for TARA-002 in NMIBC, allowing us to commence our ADVANCED-1
trial. The primary objective of the trial is to evaluate the safety, tolerability and preliminary signs of anti-tumor activity of TARA-002,
with the goal of establishing a recommended dose for a future Phase 2 clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Manufacturing</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We manufacture TARA-002
using an equivalent, but modernized, proprietary manufacturing process as is used to produce OK-432 by Chugai Pharmaceutical, starting
with a master cell line propagated by us but utilizing the same genetically distinct strain of <i>Streptococcus pyogenes</i> (A group,
type 3) Su strain as OK-432. We have contracted a contract development and manufacturing organization, or CDMO, to manufacture TARA-002.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>TARA-002 for the Treatment of Lymphatic
Malformations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disease Overview</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have worked with the FDA to align on a regulatory pathway and development
plan for TARA-002 for the treatment of LMs. The International Society for the Study of Vascular Anomalies classifies LMs as either macrocystic,
microcystic, or mixed-cystic. Macrocystic and microcystic LMs are differentiated by the size of the fluid-containing portion of the malformation.
Macrocystic LMs are characteristically large, fluid-filled cysts with a thin endothelial lining. Macrocystic LMs are composed of cysts
greater than 2 cubic centimeters in size and present as a soft, fluid-filled swelling beneath normal or slightly discolored skin. Macrocystic
LMs are usually located in the antero-lateral cervical region of the neck; however, it is possible for this type of LM to originate in
other areas of the body. In contrast, microcystic LMs have very limited internal space with a thick irregular endothelial lining. Microcystic
LMs are comprised of cysts less than 2 cubic centimeters in size and are often composed of micro-lymphatic channels that integrate and
infiltrate normal soft tissue. Microcystic LMs can involve both superficial and deep aspects including muscle and bone. Microcystic LMs
can thicken or swell causing enlargement of surrounding soft tissue and bones and can be found on any area of the skin or mucous membrane.
Mixed-cystic LMs are comprised of varying degrees of both macrocystic and microcystic LMs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">While the exact prevalence
of LMs is not known, in the United States, the condition is thought to be present in approximately one in every 4,000 live births and
we believe there are approximately 1,400-1,800 LM cases per year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Treatment</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are no approved pharmacotherapies
for LMs, except in Japan and Taiwan where OK-432 is approved. In these countries, OK-432 has been the standard of care for LMs for over
25 years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Treatment of LMs varies
depending on the symptoms and complications that present themselves. The standard of care outside Japan and Taiwan for the treatment
of LMs is either a partial or complete surgical excision of the cysts. While surgery is the standard approach to the treatment of LMs
in the head and neck, the region is a difficult area to operate on because of the large number of important anatomical structures in
the area. Major venous and arterial trunks travel through the neck, as do important nerves. Surgery on such malformations frequently
results in high rates of recurrence and complications including life-long chronic conditions, such as damage to nerves and other important
structures of the head and neck.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clinical Development</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Historical Data on OK- 432, predecessor therapy
to TARA-002&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">When OK-432 is administered
locally for LMs, it is hypothesized that innate immune cells within the cyst are activated and produce a strong immune cascade. Neutrophils
and monocytes infiltrate the cyst and various cytokines, including interleukins IL-6, IL-8, IL-12, interferon, or IFN, -gamma, tumor
necrosis factor, or TNF-alpha, and vascular endothelial growth factor (VEGF) are secreted by immune cells within the cyst in response
to the presence of OK-432. In concert, these immune activities induce a strong local inflammatory reaction in the cyst wall, resulting
in fluid drainage, shrinkage and fibrotic adhesion of the cyst.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A randomized, phase 2 clinical trial led by the University of Iowa
studied the use of OK-432 in patients with LM from 1998 to 2005. Most eligible subjects were between 6 months and 18 years of age with
macrocystic or mixed-cystic LMs (with &#8805; 50% macrocytic disease) of the head and/or neck. There were three treatment groups: immediate
treatment (ITG), delayed treatment (DTG), and open label treatment group. The immediate treatment group received treatment with OK-432
upon diagnosis. The delayed treatment group received OK-432 treatment following a six-month observation period; the cross-over design
was intended to investigate spontaneous resolution. The open-label treatment group included infants younger than six months of age, adults
older than 18 years of age, patients with LMs involving sites other than the head and neck (such as the axilla, thorax, and extremities),
and patients treated on an emergent basis. The open label treatment group were treated immediately with OK-432. Response to therapy was
measured by quantitating change in lesion size. Clinical success was defined as a complete (90% to 100%) or substantial (60% to 89%) response
to treatment based on radiographically confirmed shrinkage in lesions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Results presented in this
report were based on a retrospective analysis of source verified data that included the full dataset of subjects enrolled in the Phase
2 randomized clinical trial between January 1998 and August 2005, including data in the published study (Smith et al. 2009) that included
subjects enrolled between January 1998 and November 2004.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Overall, 310 subjects were enrolled with intent to treat: 246 subjects
were randomized to the immediate (ITG, N=171) and delayed (DTG, N=75) treatment groups; 64 subjects were nonrandomized and assigned to
the open-label group. Analysis of the primary efficacy endpoint (N=150) demonstrated clinical success (complete and/or substantial response)
in 69% of patients in the ITG 6 months after enrollment, while 7.5% of patients in the DTG experienced spontaneous regression of a LM
during this time interval (p &lt; 0.0001)). When the results were analyzed by lesion type across all treatment groups, a successful outcome
was observed in 84% and 60% of patients with macrocystic and mixed-cystic LM, respectively. None of the patients with microcystic LM demonstrated
clinical success with OK-432 therapy. The results of the retrospective analysis were consistent with the results observed in the original
analysis (Smith et al. 2009).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 1: 69% of patients in the immediate treatment group had a complete
or substantial response to OK-432, meeting the primary endpoint, while 7.5% of patients in the delayed treatment group had a complete
or substantial response after six months of observation and before treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img alt="" src="image_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#450;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
                                            Success was defined as complete or substantial response.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
                                            data prior to dosing with OK-432. After dosing, the clinical success rate was 66%, which
                                            was not statistically different from the ITG.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure 2: patients with radiographically confirmed
macrocystic lesions had the greatest likelihood of clinical success and in those patients with mixed lesions, clinical success was also
present.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img alt="" src="image_003.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#450;</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
                                            Success was defined as complete or substantial response.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects
                                            data prior to dosing with OK-432. After dosing, the clinical success rate was 66%, which
                                            was not statistically different from the ITG.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
                                            were analyzed by lesion type across all treatment groups.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><i>TARA-002 Clinical Development</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have an open IND for
LMs with the Vaccines Division. Later in 2023 we expect to initiate a Phase 2 single arm, open-label clinical trial to evaluate the safety
and efficacy of TARA-002 in pediatric patients with macrocystic and mixed-cystic LMs. The trial design includes a safety lead-in phase
followed by an expansion phase. We are conducting trial preparation activities and have identified multiple trial sites.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Historical Safety Profile on OK-432, predecessor
therapy to TARA-002</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The most common adverse
events with treatment with OK-432 were local injection site reactions, fever, fatigue, and decreased appetite, with resolution within
two weeks. Treatment emergent serious adverse events or SAEs, (treatment emergent SAEs are defined as any SAE occurring or worsening
on or after the first dose of study drug and within 35 days after the last dose of study drug) associated with OK-432 treatment were
reported in 4.1% of patients, with the most severe events being airway obstruction and facial paralysis due to massive swelling post-injection
that required tracheostomy and hospitalization. Both of these events were reported as resolved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The safety findings from
the sponsor-conducted retrospective analysis are consistent with the original analysis reported in Smith et al. 2009, and with safety
data in published studies in approximately 865 patients with LMs after treatment with OK-432.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Historical Preclinical Development&#160;on
OK-432, predecessor therapy to TARA-002</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A comprehensive preclinical
development program for OK-432, including <i>in vitro</i> and <i>in vivo</i> pharmacology and toxicology studies, was conducted by Chugai
Pharmaceutical to support the filing of a NDA with the Japan Pharmaceuticals and Medical Devices Agency. We believe these studies may
help inform the design of a development plan for TARA-002 in LMs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>TARA-002 Regulatory Interactions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In July 2020, the FDA granted
Rare Pediatric Disease designation for TARA-002 for the treatment of LMs. The FDA grants Rare Pediatric Disease designation for serious
diseases that primarily affect children ages 18 years or younger and fewer than 200,000 persons in the United States. Under the FDA&#8217;s
Rare Pediatric Disease Priority Review Voucher program, a sponsor who receives an approval of a NDA or BLA for a product for the prevention
or treatment of a rare pediatric disease may be eligible for a voucher, which can be redeemed to obtain priority review for any subsequent
marketing application or may be sold or transferred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The robust dataset for OK-432 in LMs has informed our development of
TARA-002. At the FDA&#8217;s request, we submitted the full CSR of the randomized Phase 2 clinical trial of OK-432 in LMs led by the University
of Iowa to our open IND with the Vaccines Division. We received feedback from the Vaccines Division on the protocol for our proposed Phase
2 clinical trial evaluating TARA-002 in LMs. In the second half of 2023 we expect to initiate this Phase 2 single arm, open-label clinical
trial to evaluate the safety and efficacy of TARA-002 in pediatric patients with macrocystic and mixed-cystic LMs. The trial design includes
a safety lead-in phase followed by an expansion phase. We are conducting trial preparation activities and have identified multiple trial
sites.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Manufacturing</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">TARA-002 is manufactured
using an equivalent, but modernized, proprietary manufacturing process as is used to produce OK-432 by Chugai Pharmaceutical. Starting
with a master cell line propagated by us but utilizing the same genetically distinct strain of <i>Streptococcus pyogenes</i> (A group,
type 3) Su strain as OK-432. We have contracted a CDMO to manufacture TARA-002.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>IV Choline Chloride for the treatment of Intestinal
Failure Associated Liver Disease</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">IV Choline Chloride is an
IV substrate replacement therapy initially in development for patients receiving PN who have IFALD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Choline is a known important
substrate for phospholipids that are critical for healthy liver function. Because patients receiving PN cannot sufficiently absorb adequate
levels of choline and no available PN components contain sufficient amounts of choline to correct this deficit, they often experience
a prolonged progression to hepatic failure and death, with the only known intervention being a dual small bowel / liver transplant. If
approved, IV Choline Chloride would be the first approved therapy for IFALD. It has been granted ODD by the FDA for the treatment of
IFALD and the prevention of choline deficiency in PN patients. We are currently undertaking a multinational prevalence study to enhance
understanding of the PN patient population. We expect to complete the prospective part of the study in mid-2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have entered into a license
agreement with Dr. Alan Buchman for exclusive rights to the IND, ODD and other regulatory assets related to IV Choline Chloride, as well
as exclusive rights to the data from previously conducted Phase 1 and Phase 2 clinical trials led by Dr. Buchman.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The results of a randomized,
controlled, Phase 2 clinical trial demonstrated that treatment with IV Choline Chloride resulted in normalization of plasma-free choline
concentrations, improvement of hepatic steatosis, and statistically significant improvement in cholestasis in patients dependent on PN.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We had an end of Phase 2
meeting with the FDA in November 2018 and received the FDA&#8217;s feedback on the design of studies necessary to complete the registration
package for IV Choline Chloride for the treatment of IFALD, including a Phase 1 pharmacokinetic study and a Phase 3 trial. We intend
to use the results of our multinational prevalence study of the PN patient population to inform our strategy for IV Choline Chloride.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disease Overview</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">IFALD is a rare hepatic/metabolic
disease. IFALD, which occurs in patients dependent upon PN, is characterized by choline deficiency, hepatic steatosis, cholestasis, and
rapid progression of liver disease through to hepatic failure and death, in the absence of intestine-liver transplant. IFALD carries
a relatively poor prognosis, with a 15-34% death rate within one to four years. When IFALD presents in children, mortality is even higher,
with studies reporting death rates of 23-40% within 18 months. A patient is considered to have IFALD if she/he:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
    dependent on PN for more than six months (e.g., has chronic intestinal failure);</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">has
    evidence of steatosis, determined by imaging techniques or histologic assessments;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">has
    evidence of cholestasis (e.g., elevated alkaline phosphatase, or ALP, elevated bilirubin and/or histology); and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 0.8pt">&#160;</td>
    <td style="padding-right: 0.8pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
    have evidence of ongoing, progressive liver injury on the basis of multiple abnormal liver function tests, in conjunction with findings
    of fibrosis, cirrhosis, and/or end-stage liver disease.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Many patients receiving
PN are entirely dependent on PN for their nutritional needs. PN delivers nearly all the macro and micro-nutrients necessary for survival
in their patients, with the notable exception of choline. Consequently, patients dependent on PN support have been shown to be choline
deficient. Patients dependent upon PN are unable to synthesize sufficient levels of choline and malabsorption limits the bioavailability
of choline chloride from the PN diet. The American Society for Parenteral and Enteral Nutrition and the Academy of Nutrition and Dietetics&#8217;
Dietitians in Nutrition Support both recommend that choline be developed and routinely included in PN products; however, there are currently
no FDA-approved choline chloride PN products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dependence on PN and resulting
choline deficiency often leads to IFALD, which is the most common adverse outcome in chronic PN adult patients that is associated with
death. Low free choline plasma concentrations are associated with alanine aminotransferase, or ALT, aspartate aminotransferase, or AST,
and ALP elevations as well as steatosis (fatty liver) and cholestasis (when bile from the liver stops or slows), all indicators of ongoing
liver damage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Clinical Development</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In a Phase 2 randomized,
double-blind, controlled 24-week clinical trial, patients (n=15) receiving nightly PN for &gt; 85% of their nutritional needs (for at
least 12 weeks prior to entry) were randomized to receive via IV infusion (10-12 hours) their usual PN with placebo (n = 8), or PN to
which 2g IV Choline Chloride was added (n = 7).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the IV Choline Chloride
group, mean choline levels were within or greater than the estimated normal range (i.e., 6.7 to 26.9 nmol/mL) throughout the 24-week
trial and quickly returned to baseline levels when treatment was discontinued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Steatosis:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon conversion of the quantification
of computed tomography, or CT, values to magnetic resonance imaging proton density fat fraction, or MRI-PDFF, significant differences
in the least square, or LS, mean change from baseline in estimated MRI-PDFF were observed in the IV Choline Chloride group in comparison
to placebo group at Week 4 through Week 24, demonstrating a clinically meaningful and statistically significant reduction in steatosis.
When LS mean percent changes from baseline in MRI-PDFF were compared between treatment groups, significant differences in LS mean changes
(range, 31.7% to 53.6%) were observed from Weeks 4 to 24 with p-values of 0.0009 to 0.0297 favoring the IV Choline Chloride group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Figure 3. Liver CT Images: Before and After Treatment with IV Choline
Chloride</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_004.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Alkaline Phosphatase:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At baseline, LS mean ALP
concentration was 239.3 &#177; 118.93 in the IV Choline Chloride group and 148.1 &#177; 100.2 in the placebo group. The mixed model
for repeated measures, or MMRM, analyses demonstrated statistically significant decreases in ALP concentrations at Week 12 (p = 0.008),
Week 16 (p = 0.005), Week 20 (p = 0.007), and Week 24 (p = 0.005) for the IV Choline Chloride group, demonstrating a reduction in cholestasis.
A trend towards significance was observed at Week 4 (p = 0.076) and Week 6 (p = 0.056). At Week 34, 10 weeks after discontinuation of
IV Choline Chloride treatment, LS mean change from baseline in ALP concentrations still demonstrated statistically significant decreases
(p = 0.002), demonstrating a significant improvement in cholestasis with treatment with IV Choline Chloride (Figure 4).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the subgroup of subjects
with ALP concentration &gt; 1.5x upper limit of normal (ULN) at baseline, (n=7), mean values at baseline were comparable between the
IV Choline Chloride and placebo groups (294.20 &#177; 87.947 versus 277.00 &#177; 128.693, respectively). In the sub-group analysis,
improvement in ALP was consistent and substantial, with 20-30% improvement over 12-24 weeks of treatment. Statistical significance was
observed at 12, 16, and 20 weeks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>In the description of the trials above and
elsewhere in this Annual Report on Form 10-K, &#8220;n&#8221; represents the number of patients in a particular group and &#8220;p&#8221;
or&#160;&#8220;p-values&#8221;&#160;represent the probability that random chance caused the result&#160;(e.g.,&#160;a&#160;p-value&#160;of&#160;0.001
means that there is a 0.1% probability that the difference between the placebo group and the treatment group is purely due to random
chance). A&#160;p-value&#160;of&#160;less than or equal to&#160;0.05 is a commonly used criterion for statistical significance, and may
be supportive of a finding of efficacy by regulatory authorities.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Figure 4. Improvement in Cholestasis<sup>1</sup>: All Patients</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_005.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protara
                                            Therapeutics re-analysis of patient CRF&#8217;s, data on file.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MMRM
                                            method used for imputation.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#450;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            placebo subject was excluded from all analyses due to likely IV contrast-induced imaging
                                            abnormalities, confirmed by independent radiologist in subsequent re-analysis.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Preclinical Development</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Table 1. Preclinical Studies Conducted by us
for IV Choline Chloride</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; width: 23%; border-bottom: black 1.5pt solid; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Study
    Type</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 76%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Brief
    Description</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In vitro </i>protein binding</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation of Protein Binding
    by Choline Chloride in Plasma Using Rapid Equilibrium Dialysis</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In vitro</i> cardiac ion channel study</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In Vitro Assessment of
    the Effect of Choline on Currents Mediated by hERG, Cav1.2, and Peak and Late Nav1.5 Channels Expressed in Human Embryonic Kidney
    (HEK) Cells</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In vitro </i>drug-drug interaction</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation of Transporter
    Inhibition by Choline Chloride in Transporter-Transfected HEK293 Cells</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation of OCT2, MATE1
    and MATE2-K Inhibition by Choline Chloride in Transporter-Transfected HEK293 Cells</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation of Transporter
    Inhibition by Choline Chloride in Caco-2 Cells</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation of Time Dependent
    Cytochrome P450 Inhibition (IC50 Shift) by Choline Chloride in Human Liver Microsomes</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation of Direct Cytochrome
    P450 Inhibition by Choline Chloride in Human Liver Microsomes</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation of Cytochrome
    P450 Induction by Choline Chloride in Human Hepatocytes</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluation of Transporter
    Inhibition by Choline Chloride in Caco-2 Cells</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating of Cytochrome
    P450 2C8, 2C9, and 2C19 mRNA Induction by Choline Chloride in Human Hepatocytes</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>In vitro BSEP inhibition</i></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assessment of Choline as
    an Inhibitor of Human BSEP Mediated Transport</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assessment of Choline as
    a Substrate of Human BSEP Mediated Transport</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nonclinical pharmacology studies</i></span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-GLP Pilot Single Dose,
    Escalating Dose Tolerance Study of Choline by Intravenous Infusion in Male Beagle Dogs</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GLP Single-dose IV Cardiovascular
    Study in Surgically Instrumented Male Dogs Monitored by Telemetry</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GLP Combined Single-dose
    IV Neurobehavioral and Respiratory Study</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Regulatory Interactions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have received feedback
from the FDA on a number of key aspects of the overall clinical program necessary for registration, including a Phase 1 pharmacokinetic
study and a Phase 3 clinical trial. We completed a retrospective, observational study of patients dependent on PN for 6 or more months.
The objective of the study was to understand the incidence of cholestasis, a hallmark pathology of IFALD in this patient population by
measuring serum alkaline phosphatase (ALP) levels greater than 1.5 times the upper limit of normal ULN as a key marker of cholestasis.
Results of the study showed: 31% of all patients, irrespective of baseline levels, presented with ALP levels greater than 1.5 times the
ULN at any given time during 6 to 36 months. In addition, approximately 28% of all patients had persistent ALP elevations greater than
1.5 times the ULN at 36 months. At baseline, approximately 23% of patients presented with ALP levels greater than 1.5 times the ULN with
approximately 76% presenting with greater than 1.5 times the ULN at any given time during 6 to 36 months and approximately 59% with persistent
ALP elevations greater than 1.5 times the ULN at 36 months. While medical management demonstrated some improvement in ALP levels, it
was not sufficient for managing ALP levels over the long term in patients on PN. Results support further exploration in patient population
to determine rates of choline deficiency and steatosis. We have initiated a prospective observational study to further characterize the
prevalence of choline deficiency, as well as cholestasis and steatosis. We plan to use information from this prospective study to determine
the appropriate next steps for the development program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Manufacturing</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Through our CDMO, we have
manufactured sufficient amounts of cGMP drug substance and drug product to initiate the planned clinical trials. Scale up for commercial
demand, if and when applicable, will commence when appropriate. Our end-to-end manufacturing of IV Choline Chloride is conducted in the
United States by a cGMP-compliant CDMO. However, due to current macroeconomic factors, such as rising inflation and supply chain shortages,
scaling up may be more difficult than originally anticipated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Collaborations and License Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Chugai Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June 17, 2019, we entered
into an agreement, or the Chugai Agreement, with Chugai Pharmaceutical, a company organized and existing under the laws of Japan. Chugai
Pharmaceutical has developed and commercialized a therapeutic product, OK-432 (or Existing Product), in Japan and Taiwan, or the Chugai
Territory and owns and controls certain materials and documents related to the Existing Product (or the Chugai Materials). Pursuant to
the Chugai Agreement, Chugai Pharmaceutical has provided us with certain materials and documents relating to the Existing Product and
has provided certain technical services to us for our development and commercialization in territories other than the Chugai Territory,
or the Protara Territory of a new therapeutic product, or the New Product or TARA-002 comparable to the Existing Product beginning on
the effective date of the Chugai Agreement and ending on June 30, 2020, or any other date to be agreed to by the parties, or the Chugai
Service Period. Under the Chugai Agreement, Chugai Pharmaceutical will exclusively provide the Existing Product and Chugai Materials
to us and will not provide the Existing Product or Chugai Materials to any third parties during the Chugai Service Period, other than
for medical, compassionate use and/or non-commercial research purposes. Additionally, beginning on the effective date of the Chugai Agreement
and ending on the fifth anniversary of such date or upon the termination of the Chugai Agreement, whichever comes earlier, Chugai Pharmaceutical
will not provide Chugai Materials or technical support to any third-party for the purpose of development and commercialization in the
Protara Territory of a therapeutic product comparable to the Existing Product. We are responsible, at our sole cost and expense, for
the development and commercialization of the New Product in the Protara Territory.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On July 14, 2020, we and Chugai Pharmaceutical entered into an amendment
of the Chugai Agreement, or the Chugai Amendment, with an effective date as of June 30, 2020. The Chugai Amendment extends the date through
which Chugai will exclusively provide the Existing Product and materials to us from June 30, 2020 to June 30, 2021, extends the date through
which Chugai will not provide materials or technical support to any third-party for the purpose of development and commercialization in
a given area from the fifth anniversary to the eleventh anniversary of the original effective date (extended to June 17, 2030), and provides
for further such extensions on the occurrence of certain events and milestones. The Chugai Amendment also provides that, in addition to
the designated fee payable upon the initial indication approval in the Chugai Agreement described below, we will pay Chugai a designated
fee in the low, single digit millions for each additional indication approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As consideration for Chugai Pharmaceutical&#8217;s performance under
the Chugai Agreement, we agreed to pay Chugai Pharmaceutical a payment in the low, single-digit millions, which will be made in two installments
with an initial payment made in July 2020, and the remaining majority of the total amount will be payable upon FDA approval of the New
Product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We granted Chugai Pharmaceutical
a right of first refusal on terms to be negotiated between the parties for a license related to the New Product-relevant information,
data and documentation and inventions to develop and commercialize the New Product in the Chugai Territory. We will be responsible for
manufacturing and supplying or causing our CDMO to manufacture and supply the New Product to Chugai Pharmaceutical.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Chugai Agreement will
remain in full force and effect until the first anniversary of the date of FDA approval of the New Product, unless terminated sooner,
or the Chugai Term. Following the Chugai Service Period and during the Chugai Term, Chugai Pharmaceutical may terminate the Chugai Agreement,
in whole or in part, without cause, by providing us 90 days prior written notice. Following such termination, we would maintain exclusive
access to Chugai Materials, subject to the termination clauses outlined below. We may terminate the Chugai Agreement, in whole only,
by providing Chugai Pharmaceutical 90 days&#8217; prior written notice if (i) we decide to discontinue the New Product development; (ii)
we decide that the FDA&#8217;s requirements for the New Product are not likely to be met; or (iii) the FDA identifies a safety issue
regarding the New Product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, either party
may terminate the Chugai Agreement, in whole or in part, in the event that the other party materially breaches the Chugai Agreement and
fails to cure the breach within 30 days of written notice. Either party may terminate the Chugai Agreement in its entirety immediately
upon notice to the other party if such other party: (i) is dissolved or liquidated or takes any corporate action for such purpose; (ii)
becomes insolvent or is generally unable to pay, or fails to pay, its debts as they become due; (iii) files or has filed against it a
petition for voluntary or involuntary bankruptcy or otherwise becomes subject to any proceeding under any domestic or foreign bankruptcy
or insolvency laws; (iv) makes or seeks to make a general assignment for the benefit of creditors; or (v) applies for or has a receiver,
trustee, custodian or similar agent appointed by order of any court to take charge of or sell any material portion of its property or
business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the event that we undergo
a change of control, Chugai Pharmaceutical may terminate the Chugai Agreement upon 90 days&#8217; written notice to us, absent a written
pledge by the new controlling party of its agreement to fulfill and undertake all obligations of ours and to be bound by the Chugai Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sponsored Research and License Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 28, 2018, we
entered into a sponsored research and license agreement, or the Research Agreement, with The University of Iowa, or the University, pursuant
to which the University will provide access to certain program data related to Chugai Pharmaceutical&#8217;s OK-432 and will assist us
in conducting certain clinical studies. As consideration for the University&#8217;s performance under the Research Agreement, we will
pay the University $30,000 per year in funding for the project, taking into consideration the time spent by University employees required
for the Project. The parties also agree to discuss in good faith potential additional funding required for completion of the project
pursuant to the Research Agreement as applicable and necessary. In addition, within 45 days of approval of the TARA-002 BLA by the FDA,
we will pay a one-time approval milestone to the University, the amount of which depends on the usefulness of the program data in TARA-002&#8217;s
BLA filing, and the milestone amount will range from $0 to $1 million. We will also be responsible for certain tiered royalties on annual
net sales of products for the indication, which royalty rates are in the low single digit percentages. These royalty rates are also subject
to a reduction in the event that regulatory authorities determine that the program data is not sufficient for regulatory approval on
its own and additional pediatric efficacy and safety clinical studies are required. In the event that the annual net sales surpass certain
dollar amount thresholds, we will need to make certain additional milestone payments following the close of the calendar quarter in which
each milestone is reached, with the payments ranging from $62,500 to $125,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may terminate the Research
Agreement upon 30 days&#8217; prior written notice to the University. Either party may terminate the project under the Research Agreement
and all commitments and obligations with respect thereto upon 30 days&#8217; prior written notice to the other party. In the event of
any termination of the project under the Research Agreement by the University, (a) the University agrees to complete certain phases of
the project and (b) we will continue to provide annual funding until the completion of the second phase of the project. Upon termination
of the project by us, the Agreement will terminate and we will reassign to the University the IND for LMs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Choline License Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On September 27, 2017, we
entered into a choline license agreement, or the Choline Agreement, with Alan L. Buchman, M.D., pursuant to which Dr. Buchman granted
us an exclusive, worldwide, non-transferable license in and to certain licensed orphan designations, a certain licensed IND, certain
existing study data and certain licensed know-how to develop, make, use, sell, offer for sale and import the licensed product during
the term of the Choline Agreement. We are solely responsible for all fees and expenses under the Choline Agreement, including all due
diligence obligations, regulatory authority fees, attorney fees and consulting fees. During the term of the Choline Agreement, Dr. Buchman
may not work with any third parties on any product competing with the licensed product. In consideration for the rights and licenses
granted under the Agreement, we made an initial upfront payment of $50,000 to Dr. Buchman.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain milestone and royalty
payments may also be payable to Dr. Buchman. Pursuant to the Choline Agreement, we paid Dr. Buchman $50,000 in October 2019 because we
had not received at least $5 million in working capital from any source or in any manner as of October 15, 2019. We then paid Dr. Buchman
a $550,000 milestone in January 2020 following our receipt of at least $5 million in working capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Regardless of whether development or commercialization is undertaken
by us under the Choline Agreement, commencing in November 2022 and during the term of the Choline Agreement, we will pay Dr. Buchman a
minimum annual royalty that ranges from $25,000 to $75,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We owe Dr. Buchman sales
royalties based on aggregate net sales of IV Choline Chloride in each calendar quarter, with the royalty rates ranging from 5.0% to 10.5%
of net sales. In the event of development or commercialization activity by any sublicensees, we also agreed to pay Dr. Buchman a royalty
in the mid-single digit percentage of (i) net cash receipts, after payment of taxes, received by us from sublicensees for their sales
of licensed products and (ii) any other consideration received by us from such sublicensees; in each case, including a fair monetary
value for any transaction that is not a bona fide arms-length transaction or that is for consideration other than monetary. Further,
in the event of a sale or transfer of a priority review voucher regarding the license product, regardless of whether any development
or commercialization activity is undertaken by us or our sublicensees, we agreed to pay Dr. Buchman a milestone payment representing
the mid-single digit percentage of (i) net cash receipts, after payment of taxes and (ii) any other consideration; in each case, received
by us, our affiliates, or our sublicensees, including a fair monetary value for any transaction that is not a bona fide arms-length transaction
or that is for consideration other than monetary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will also pay Dr. Buchman
up to $775,000 in additional milestone payments upon the achievement of various regulatory approval milestones.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Choline Agreement will
remain in full force and effect until the last sale of the licensed product under the Choline Agreement. After we received the FDA&#8217;s
written minutes from the initial FDA meeting concerning the development of the first licensed product for one or more of the licensed
indications, we paid an additional payment of $100,000 to Dr. Buchman and elected not terminate the Choline Agreement at that time. The
Choline Agreement may be terminated by Dr. Buchman if, following regulatory approval of a licensed product, we have not made our first
sale of a licensed product within such country within a specified time period. We may terminate the Choline Agreement for convenience
upon 90 days&#8217; prior written notice to Dr. Buchman. Dr. Buchman may terminate the Choline Agreement for non-payment of any payment
due that has not been cured. Either party may terminate the Choline Agreement if the other party is in material breach and has not cured
such breach within 60 days&#8217; notice. In addition, Dr. Buchman may terminate the Choline Agreement upon 60 days&#8217; prior written
notice if (a) we cease or threaten to cease to carry on our business; (b) a petition or resolution for the making of an administration
order or for the bankruptcy, winding-up or dissolution of us is presented or passed; (c) we file a voluntary petition in bankruptcy or
insolvency; (d) a receiver or administrator takes possession of our assets or (e) any similar procedure is commenced against us in the
United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>License Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 22, 2017, we
entered into a license agreement, or the License Agreement, with The Feinstein Institute for Medical Research, a not-for-profit corporation
organized and existing under the laws of New York, or the Institute. The Institute owns, by assignment, a U.S. patent related to the
treatment of fatty liver disease in humans. Pursuant to the License Agreement, the Institute granted us an exclusive, worldwide license,
with the right to grant sublicenses to non-affiliate third parties, to develop, make, have made, use, sell, offer for sale and import
certain products for use in the field of fatty liver disease in humans receiving total parenteral nutrition, by administering, as monotherapy,
a pharmaceutical composition comprising intravenous choline, wherein the fatty liver disease is selected from IFALD, non-alcoholic fatty
liver, non-alcoholic steatohepatitis, or NASH, NASH-associated liver fibrosis, or non-alcoholic cirrhosis. Notwithstanding the exclusive
rights granted to us, the Institute will retain the right to make, use and practice such patents in its own laboratories solely for non-commercial
scientific purposes and for continued non-commercial research.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As consideration for the
license grant, we agreed to pay the Institute tiered royalties of between 1.0% and 1.5% of all net sales. In addition, we agreed to pay
the Institute a low double digit percentage of net proceeds resulting from agreements entered into within two years from the effective
date of the License Agreement and a mid-single digit percentage of net proceeds resulting from agreements entered into thereafter. We
also agreed to make certain license maintenance payments of $15,000 beginning on the second anniversary of the effective date of the
License Agreement and continuing upon every anniversary thereafter until the first commercial sale of a licensed product. Beginning on
the first anniversary of the effective date of the License Agreement after the first commercial sale of a licensed product and every
anniversary of the effective date of the License Agreement thereafter, we will pay the Institute $30,000 as a license maintenance fee.
Such license maintenance fees are non-refundable but are creditable against future royalty payments due to the Institute during the 12-month
period following each such anniversary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We agreed to make certain
one-time milestone payments in the aggregate amount of $375,000 upon the achievement of certain regulatory approval milestones, of which
$100,000 was paid on January 28, 2020 upon us having consummated the Private Placements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless terminated earlier,
the License Agreement will expire upon the expiration of the last to expire patent under the License Agreement. We may terminate the
License Agreement by giving the Institute 60 days&#8217; prior notice. Either party may terminate the License Agreement in the event
of a default or breach by the other party that has not been cured within 60 days of such notice. If we (i) make an assignment for the
benefit of creditors or if proceedings for a voluntary bankruptcy are instituted on our behalf; (ii) are declared bankrupt or insolvent
or (iii) are convicted of a felony relating to the manufacture, use or sale of the licensed products or a felony relating to moral turpitude,
the Institute may terminate the License Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our intellectual property
is critical to our business and we strive to protect it, including by obtaining and maintaining patent protection in the U.S. and internationally
for our product candidates, novel biological discoveries, epitopes, new therapeutic approaches and potential indications, and other inventions
that are important to our business. Throughout the development of our product candidates, we will seek to identify additional means of
obtaining patent protection that would potentially enhance commercial success. We also rely upon trade secrets, know-how, continuing
technological innovation and in-licensing opportunities to develop and maintain our proprietary position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The patent positions of
biotechnology companies like us are generally uncertain and involve complex legal, scientific and factual questions. We recognize that
the ability to obtain patent protection and the degree of such protection depends on a number of factors, including the extent of the
prior art, the novelty and non-obviousness of the invention, and the ability to satisfy the enablement requirement of the patent laws.
In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can
be reinterpreted after issuance. Consequently, we may not obtain or maintain adequate patent protection for any of our product candidates.
Any patents that we hold may be challenged, circumvented or invalidated by third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our commercial success will also depend in part on not infringing the
proprietary rights of third parties. In addition, we have licensed rights under proprietary technologies of third parties to develop,
manufacture and commercialize specific aspects of our products and services. It is uncertain whether the issuance of any third-party patent
would require us to alter our development or commercial strategies, alter our processes, obtain licenses or cease certain activities.
The expiration of patents or patent applications licensed from third parties or our breach of any license agreements or failure to obtain
a license to proprietary rights that it may require to develop or commercialize our future technology may have a material adverse impact
on it. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights,
we may have to participate in interference proceedings in the USPTO, to determine priority of invention. For a more comprehensive discussion
of the risks related to our intellectual property, please see &#8220;<i>Risk Factors&#8212;Risks Related to Our Intellectual Property.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>TARA-002:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">TARA-002 is a genetically
distinct Su strain of <i>Streptococcus pyogenes</i> (group A, type 3). TARA-002 is produced through a proprietary manufacturing process.
We believe a significant barrier to entry exists, as we believe only Chugai Pharmaceutical and we have the specific strain and possess
the know-how to manufacture the product. We anticipate that, if approved by the FDA, TARA-002 will be protected by 12 years of biologic
exclusivity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>IV Choline Chloride:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">With respect to IV Choline
Chloride, we have acquired an exclusive, worldwide license to U.S. Patent 8,865,641 B2 from the Feinstein Institute for Medical Research
providing protection in the United States until 2035. The patent applies to a method of treating a fatty liver disease in a subject.
In particular, the method comprises administering to the subject an effective amount of a cholinergic pathway stimulating agent, wherein
the fatty liver disease is selected from non-alcoholic fatty liver, alcoholic fatty liver, NASH, alcoholic steatohepatitis, or ASH, NASH-associated
liver fibrosis, ASH-associated liver fibrosis, non-alcoholic cirrhosis and alcoholic cirrhosis. In addition, in April 2022, the USPTO
issued to us Patent No. US 11,311,503 claiming a sterile aqueous choline salt composition with a term expiring in 2041. We would expect
to list such patent in the FDA&#8217;s Orange Book List of Approved Drug Products with Therapeutic Equivalence Evaluations if IV Choline
Chloride is approved by the FDA for the treatment of IFALD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The term of individual patents
depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we may file, the patent
term is 20 years from the earliest date of filing a non-provisional patent application related to the patent. A U.S. patent also may
be accorded a patent term adjustment under certain circumstances to compensate for delays in obtaining the patent from the USPTO. In
some instances, such a patent term adjustment may result in a U.S. patent term extending beyond 20 years from the earliest date of filing
a non-provisional patent application related to the U.S. patent. In addition, in the United States, the term of a U.S. patent that covers
an FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent
term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the
expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review.
Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only
one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other foreign jurisdictions
to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect
to apply for patent term extensions on patents covering certain of those products, when applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We also rely on trade secrets
relating to product candidates and seek to protect and maintain the confidentiality of proprietary information to protect aspects of
our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect
our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties
may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets,
including through breaches of such agreements with our employees and consultants. Thus, we may not be able to meaningfully protect our
trade secrets. It is our policy to require our employees, consultants, outside scientific partners, sponsored researchers and other advisors
to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide
that all confidential information concerning our business or financial affairs developed or made known to the individual during the course
of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances.
Our agreements with employees also provide that all inventions conceived by the employee in the course of employment with us or from
the employee&#8217;s use of our confidential information are our exclusive property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We rely on CDMOs to produce
our drug candidates in accordance with cGMP as well as regulations for use in clinical trials and for commercial product. The manufacture
of pharmaceuticals is subject to extensive cGMP regulations, which impose various procedural and documentation requirements and govern
all areas of record keeping, production processes and controls, personnel and quality control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The CDMOs that we partner
with have the capability to produce clinical supply required for clinical trials, as well as support commercial scale-up activities for
both products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We manufacture TARA-002
using an equivalent, but modernized, proprietary manufacturing process as is used to produce OK-432 by Chugai Pharmaceutical, starting
with a master cell line propagated by us but utilizing the same genetically distinct strain of <i>Streptococcus pyogenes</i> (A group,
type 3) Su strain as OK-432. We have contracted a CDMO to manufacture TARA-002.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Both TARA-002 and IV Choline
Chloride are or will be manufactured in the United States. The starting materials for TARA-002 were provided to us pursuant to an agreement
with Chugai Pharmaceutical. The regulatory starting materials for IV Choline Chloride are available commercially.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sales and Marketing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We plan to become a fully-integrated
commercial biopharmaceutical company pursuing our mission of supporting and improving the lives of patients suffering from cancer and
rare diseases.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If approved by the FDA,
we plan to commercialize both of our current product candidates in the United States first and then in other geographies. As we advance
TARA-002 and IV Choline Chloride through our respective clinical development programs, we plan to grow our commercial organization in
support of anticipated product launches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The process for commercialization
of new drugs is very competitive, and we could potentially face worldwide competition from other pharmaceutical companies, biotechnology
companies and ultimately generic or biosimilar products. Our potential competitors may develop or market therapies that are available
sooner, more clinically effective, safer or less expensive than any therapeutic products we develop. Numerous companies are engaged in
the development, patenting, manufacturing and marketing of healthcare products competitive with those that we are developing.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">With respect to our lead
product candidate, TARA-002, for the treatment of NMIBC and LMs, the active ingredient in TARA-002 is a genetically distinct strain of
<i>Streptococcus pyogenes</i> (group A, type 3) Su strain. TARA-002 is produced through a proprietary manufacturing process. We anticipate
that, if approved by the FDA, TARA-002 will be protected by 12 years of biologic exclusivity. In addition, based on the prevalence of
the disease, TARA-002 is likely to have seven years of concurrent Orphan Drug Designation exclusivity for the treatment of LMs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are no approved pharmacotherapies
currently available for the treatment of LMs and the current treatment options include a high-risk surgical procedure and off-label use
of sclerosants, including doxycycline, bleomycin, ethanol and sodium tetradecyl sulfate. There are a number of drug development companies
and academic researchers exploring oral and topical formulations of various agents for the treatment of LMs including macrolides, phosphodiesterase
inhibitors, and calcineurin/mTOR inhibitors. These are in early development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">TARA-002, if approved for
the treatment of NMIBC, would be subject to competition from existing treatment methods of surgery, chemotherapy and immunomodulatory
therapy. For example, the current standard of care for NMIBC includes intravesical BCG TICE (manufactured by Merck &amp; Co., Inc.). Other
products approved for the treatment of NMIBC include Merck &amp; Co., Inc.&#8217;s Keytruda, Endo International plc&#8217;s Valstar and
Ferring B.V.&#8217;s Adstiladrin. Additional product candidates in development include Japanese BCG Laboratory&#8217;s BCG Tokyo, Pfizer
Inc.&#8217;s Sasanlimab in combination with BCG, ImmunityBio, Inc.&#8217;s VesAnktiva in combination with BCG, CG Oncology Inc.&#8217;s
CG0070, Sesen Bio, Inc.&#8217;s Vicineum, enGene Inc.&#8217;s, EG-70, Seagen Inc.&#8217;s PADCEV, Janssen&#8217;s TAR200 combined with
gemcitabine plus or minus Cetrelimab, Urogen Pharma Ltd.&#8217;s Jelmyto,and Auro BioSciences, Inc.&#8217;s Aura-0011. Additional pharmaceutical
and biotechnology companies with product candidates in development for the treatment of NMIBC include but may not be limited to Verity
Pharmaceuticals, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Roche Group, Asieris Pharmaceuticals, BeiGene, Ltd, NanOlogy, LLC,
Linton Pharm Co., Ltd., Lindis Biotech GmbH, Theralase Technologies Inc., Taizhou Hanzhong biomedical co. Ltd., Shionogi &amp; Co., Ltd.,
Rapamycin Holdings, Inc., Vaxiion Therapeutics Inc., Incyte Corporation, LiPac Oncology, Inc., Anika Therapeutics Inc., Surge Pharmaceuticals
Pvt. Ltd., and Istari Oncology, Inc.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are no treatments
currently available for IFALD. With respect to IV Choline Chloride for the treatment of IFALD, IV Choline Chloride is the only sterile
injectable form of choline chloride that can be combined with parenteral nutrition. Further, if approved, IV Choline Chloride will be
protected by Orphan Drug Designation exclusivity for seven years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation and Product Approval</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA and other regulatory
authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research,
development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution,
record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of drugs and biologics
such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical
and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek
approval or licensure of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the United States, the
FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, or FDCA and biologics additionally under the Public Health Services
Act, or PHSA, as well as their respective implementing regulations. The process required by the FDA before biopharmaceutical product
candidates may be marketed in the United States generally involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices,
    or cGLP regulations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant
    changes are made;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is commenced;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials to establish the safety and efficacy of a product candidate and the safety,
    purity and potency of the proposed biologic product candidate for its intended purpose;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation
    of and submission to the FDA of an NDA or BLA after completion of all pivotal clinical trials that includes substantial evidence
    of safety, purity and potency or efficacy from results of nonclinical testing and clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the application for review;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA Advisory Committee review, if applicable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced
    to assess compliance with cGMP, and of selected clinical investigation sites to assess compliance with current Good Clinical Practices,
    or cGCP; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval, or licensure, of the NDA or BLA to permit commercial marketing of the product for particular indications for
    use in the United States.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preclinical and Clinical Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prior to beginning the first
clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer
an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the
protocol(s) for clinical trials. The IND also includes results of animal and <i>in vitro</i> studies assessing the toxicology, pharmacokinetics,
pharmacology, and pharmacodynamic characteristics of the product candidate; chemistry, manufacturing, and controls information; and any
available human data or literature to support the use of the investigational product. An IND must become effective before human clinical
trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period,
raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the
IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND
therefore may or may not result in FDA authorization to begin a clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Clinical trials involve
the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with
GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical
trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be
used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for
each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent
IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent
form before the clinical trial begins at that site, and must monitor the trial until completed. Regulatory authorities, the IRB or the
sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable
health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group
of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, which provides authorization for
whether or not a trial may move forward at designated check points based on access to certain data from the trial and may halt the clinical
trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.
There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Human clinical trials are
typically conducted in three sequential phases that may overlap.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
                                            1&#8212;The investigational product is initially introduced into healthy human subjects or
                                            patients with the target disease or condition. These trials are designed to test the safety,
                                            dosage tolerance, absorption, metabolism, distribution and elimination of the investigational
                                            product in humans, the side effects associated with increasing doses, and, if possible, to
                                            gain early evidence on effectiveness.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2&#8212;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate
    the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple
    Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3&#8212;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically
    significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical
    trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to
    provide an adequate basis for product approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In some cases, the FDA may
require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the
product. These so-called Phase 4 trials may be made a condition to approval of the NDA or BLA. Concurrent with clinical trials, companies
may complete additional animal studies and develop additional information about the biological characteristics of the product candidate,
and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing
process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods
for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally,
appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does
not undergo unacceptable deterioration over its shelf life.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Application Submission, Review and Approval</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Assuming successful completion
of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies
and clinical trials are submitted to the FDA as part of an NDA or BLA requesting approval to market the product for one or more indications.
The NDA or BLA must include all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous
results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls,
and proposed labeling, among other things. The submission of an NDA or BLA requires payment of a substantial application user fee to
the FDA, unless a waiver or exemption applies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Once an NDA or BLA has been
submitted, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing, or,
if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority
reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews
the application to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured,
processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene
an advisory committee to provide clinical insight on application review questions. Before approving an NDA or BLA, the FDA will typically
inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that
the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the
product within required specifications. Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical
sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are
not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding
the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory
criteria for approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA may issue an approval
letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information
for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the NDA or
BLA. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the application in
condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of an application
if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing
and surveillance to monitor safety or efficacy of a product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If regulatory approval of
a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which
such product may be marketed. For example, the FDA may impose a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits
of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product
and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician
communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls
and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements
is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market
trials and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit
further marketing of the product based on the results of these post-marketing trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Orphan Drug Designation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Orphan Drug Act,
the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition
that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there
is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of
disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan designation must be requested
before submitting an NDA or BLA. After the FDA grants orphan designation, the generic identity of the therapeutic agent and its potential
orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of,
the regulatory review or approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If a product that has orphan
designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to
orphan exclusivity, which means that the FDA may not approve any other applications, including a full NDA or BLA, to market the same
product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product
with orphan drug exclusivity. Orphan exclusivity does not prevent FDA from approving a different drug or biologic for the same disease
or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation
are tax credits for certain research and a waiver of the BLA application fee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A designated orphan product
may not receive orphan exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation.
In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation
was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients
with the rare disease or condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA incentivizes the
development of drugs and biologics that meet the definition of a &#8220;rare pediatric disease&#8221; defined to mean a serious or life-threatening
disease in which the serious of life-threatening manifestations primarily affect individuals aged from birth to 18 years and the disease
affects fewer than 200,000 individuals in the United States or affects 200,000 or more in the United States and for which there is no
reasonable expectation that the cost of developing and making in the United States a drug for such disease or condition will be received
from sales in the United States of such drug. The sponsor of a product candidate for a rare pediatric disease may be eligible for a voucher
that can be used to obtain a priority review for a subsequent human drug or biologic application after the date of approval of the rare
pediatric disease drug product, referred to as a priority review voucher, or PRV. A rare pediatric disease designation does not guarantee
that a sponsor will receive a PRV upon approval of its NDA or BLA. If a PRV is received, it may be sold or transferred an unlimited number
of times. Congress has extended the PRV program until September&#160;30, 2024, with the potential for PRVs to be granted until September
30, 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.25in"><b><i>Post-Approval Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any products manufactured
or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things,
requirements relating to quality control and quality assurance, record-keeping, reporting of adverse experiences, periodic reporting,
product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product,
such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user
fee requirements, under which FDA assesses an annual program fee for each product identified in an approved NDA or BLA. Biopharmaceutical
manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are
subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural
and documentation requirements upon sponsors and their third-party manufacturers. Changes to the manufacturing process are strictly regulated,
and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require
investigation and correction of any deviations from cGMP and impose reporting requirements upon sponsor and third-party manufacturers.
Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance
with cGMP and other aspects of regulatory compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA may withdraw approval
if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market.
Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with
manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new
safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions
or other restrictions under a REMS program. Other potential consequences include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of a product, mandated modification of promotional materials or issuance of corrective information,
    issuance by FDA or other regulatory authorities of safety alerts, Dear Healthcare Provider letters, press releases or other communications
    containing warnings or other safety information about the product, or complete withdrawal of the product from the market or product
    recalls;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning or untitled letters or holds on post-approval clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product
    approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal of the FDA to permit the import or export of products; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions,
    consent decrees or the imposition of civil or criminal penalties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA closely regulates
the marketing, labeling, advertising and promotion of biopharmaceuticals. A company can make only those claims relating to safety and
efficacy, purity and potency of a biopharmaceutical that are approved by the FDA and in accordance with the provisions of the approved
label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply
with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil
and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling
and that differ from those approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that
such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians
in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of
their products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Biosimilars and Reference Product Exclusivity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or ACA, signed into law in 2010, includes a subtitle
called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological
products that are biosimilar to or interchangeable with an FDA-approved reference biological product. To date, a number of biosimilars
have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents
outlining its approach to the review and approval of biosimilars.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Biosimilarity, which
requires that there be no clinically meaningful differences between the biological product and the reference product in terms of
safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials.
Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be
expected to produce the same clinical results as the reference product in any given patient and, for products that are administered
multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously
administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.
Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by
which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still
being worked out by the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the BPCIA, an application
for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed
by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which
the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version
of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data
and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also
created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products
deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy
law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The BPCIA is complex and
continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference
product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the
subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other U.S. Healthcare Laws and Compliance
Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the United States, our
current and future operations are subject to regulation by various federal, state and local authorities in addition to the FDA, including
but not limited to, the Centers for Medicare &amp; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human
Services, or HHS, (such as the Office of Inspector General, Office for Civil Rights and the Health Resources and Service Administration),
the U.S. Department of Justice, or DOJ and individual U.S. Attorney offices within the DOJ, and state and local governments. For example,
our clinical research, sales, marketing and scientific/educational grant programs will need to comply with the anti-fraud and abuse provisions
of the Social Security Act, the false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability
Act, or HIPAA, and similar state laws, each as amended, as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The federal Anti-Kickback
Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any
remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering
or arranging for the purchase, lease or order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other
federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute
has been interpreted to apply to arrangements between therapeutic product manufacturers on one hand and prescribers, purchasers, and
formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities
from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be
intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe
harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make
the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case
basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria
for protection under a statutory exception or regulatory safe harbor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, the intent
standard under the Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act, as amended by the Health Care
and Education Reconciliation Act of 2010, or the Affordable Care Act, to a stricter standard such that a person or entity no longer needs
to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable
Care Act codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes
a false or fraudulent claim for purposes of the federal False Claims Act, or the FCA (discussed below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The federal false claims,
including the FCA, and civil monetary penalty laws, which imposes significant penalties and can be enforced by private citizens through
civil qui tam actions, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false
or fraudulent claim for payment to, or approval by, the federal government, including federal healthcare programs, such as Medicare and
Medicaid, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim
to the federal government, or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money
to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government.
For instance, historically, pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing
free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been
prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, off-label,
and thus generally non-reimbursable, uses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">HIPAA created additional
federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to
defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under
the control or custody of, any healthcare benefit program, including private third-party payors, willfully obstructing a criminal investigation
of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact
or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits,
items or services. Like the Anti-Kickback Statute, the Affordable Care Act amended the intent standard for certain healthcare fraud statutes
under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in
order to have committed a violation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Also, many states have similar,
and typically more prohibitive, fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and
other state programs, or, in several states, apply regardless of the payor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may be subject to data
privacy and security regulations by both the federal government and the states in which it conducts business. HIPAA, as amended by the
Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes requirements
on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their
respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information
for or on behalf of a covered entity as well as their covered subcontractors relating to the privacy, security and transmission of individually
identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to
business associates, independent contractors, or agents of covered entities that receive or obtain protected health information in connection
with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA
to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file
civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with
pursuing federal civil actions. In addition, many state laws govern the privacy and security of health information in specified circumstances,
many of which differ from each other in significant ways, are often not pre-empted by HIPAA, and may have a more prohibitive effect than
HIPAA, thus complicating compliance efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may develop products
that, once approved, may be administered by a physician. Under currently applicable U.S. law, certain products not usually self-administered
(including injectable drugs) may be eligible for coverage under Medicare through Medicare Part B. Medicare Part B is part of original
Medicare, the federal health care program that provides health care benefits to the aged and disabled, and covers outpatient services
and supplies, including certain biopharmaceutical products, that are medically necessary to treat a beneficiary&#8217;s health condition.
As a condition of receiving Medicare Part B reimbursement for a manufacturer&#8217;s eligible drugs, the manufacturer is required to
participate in other government healthcare programs, including the Medicaid Drug Rebate Program and the 340B Drug Pricing Program. The
Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with
the Secretary of HHS as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished
to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities that participate in the
program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, many pharmaceutical
manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best
price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may
be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation
of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. It
is difficult to predict how Medicare coverage and reimbursement policies will be applied to our products in the future and coverage and
reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement rates may also reflect budgetary
constraints placed on the Medicare program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, the federal
Physician Payments Sunshine Act, or the Sunshine Act, within the Affordable Care Act, and its implementing regulations, require that
certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the
Children&#8217;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or
other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors),
other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, or to entities or individuals
at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment
interests held by physicians and their immediate family members. Failure to report accurately could result in penalties. In addition,
many states also govern the reporting of payments or other transfers of value, many of which differ from each other in significant ways,
are often not pre-empted, and may have a more prohibitive effect than the Sunshine Act, thus further complicating compliance efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to distribute products
commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological
products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers
or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to
establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt
new technology capable of tracking and tracing product as it moves through the distribution chain. Several states and/or localities have
enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports
with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register
their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing
data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing
practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Ensuring business arrangements
with third parties comply with applicable healthcare laws and regulations is a costly endeavor. If our operations are found to be in
violation of any of the federal and state healthcare laws described above or any other current or future governmental regulations that
apply to it, it may be subject to penalties, including without limitation, significant civil, criminal and/or administrative penalties,
damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions,
private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, or refusal to allow it to enter
into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional
reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations
of non-compliance with these laws, and the curtailment or restructuring of its operations, any of which could adversely affect our ability
to operate our business and our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Coverage, Pricing and Reimbursement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Significant uncertainty
exists as to the coverage and reimbursement status of any product candidates for which we may obtain regulatory approval. In the United
States and in foreign markets, sales of any products for which we receive regulatory approval for commercial sale will depend, in part,
on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products. In the United
States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations.
Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the United States, and commercial
payors are critical to new product acceptance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ability to commercialize
any products successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments
will be available from government health administration authorities, private health insurers and other organizations. Government authorities
and other third-party payors, such as private health insurers and health maintenance organizations, decide which therapeutics they will
pay for and establish reimbursement levels. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including
the third-party payor&#8217;s determination that use of a therapeutic is:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    covered benefit under its health plan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe,
    effective and medically necessary;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate
    for the specific patient;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effective;
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither
    experimental nor investigational.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We cannot be sure that reimbursement
will be available for any product that it commercializes and, if coverage and reimbursement are available, what the level of reimbursement
will be. Coverage may also be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory
authorities. Reimbursement may impact the demand for, or the price of, any product for which we obtain regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Third-party payors are increasingly
challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of medical products, therapies and services,
in addition to questioning their safety and efficacy. Obtaining reimbursement for our products may be particularly difficult because
of the higher prices often associated with branded drugs and drugs administered under the supervision of a physician. We may need to
conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition
to the costs required to obtain FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. Obtaining
coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process
that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our product
on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. A payor&#8217;s decision to provide
coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination
to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party
reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment
in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully
commercialize any product candidate that it successfully develops.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Different pricing and reimbursement
schemes exist in other countries. In the European Union, governments influence the price of biopharmaceutical products through their
pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers.
Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has
been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that
compare the cost effectiveness of a particular product candidate to currently available therapies. Other member states allow companies
to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs has become
intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border
imports from low-priced markets exert a commercial pressure on pricing within a country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The marketability of any
product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail
to provide adequate coverage and reimbursement. In addition, emphasis on managed care, the increasing influence of health maintenance
organizations, and additional legislative changes in the United States has increased, and we expect will continue to increase, the pressure
on healthcare pricing. The downward pressure on the rise in healthcare costs in general, particularly prescription medicines, medical
devices and surgical procedures and other treatments, has become very intense. Coverage policies and third-party reimbursement rates
may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive
regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare Reform</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the United States and
some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding
the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities,
and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors
in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of
containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a
particular focus of these efforts and has been significantly affected by major legislative initiatives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For example, the Affordable
Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the Affordable
Care Act provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described above,
are the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents
    apportioned among these entities according to their market share in some government healthcare programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the
    average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs
    at 100% of the Average Manufacturer Price, or the AMP;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off
    negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#8217;
    outpatient drugs to be covered under Medicare Part D;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid
    managed care organizations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional
    individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty
    level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    expansion of the entities eligible for discounts under the 340B Drug Discount Program;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
    research, along with funding for such research;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    expansion of healthcare fraud and abuse laws, including the FCA and the Anti-Kickback Statute, new government investigative powers,
    and enhanced penalties for noncompliance;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled,
    infused, instilled, implanted, or injected;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    requirement to report certain financial arrangements with physicians and teaching hospitals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower
    Medicare and Medicaid spending; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    licensure framework for follow on biologic products.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There remain legal and political
challenges to certain aspects of the Affordable Care Act. Starting in January 2017, the Trump administration signed several executive
orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. In December
2017, Congress repealed the tax penalty for an individual&#8217;s failure to maintain Affordable Care Act-mandated health insurance as
part of a tax reform bill. Further, the 2020 federal spending package permanently eliminated the Affordable Care Act-mandated &#8220;Cadillac&#8221;
tax on high-cost employer-sponsored health coverage and medical device tax and also eliminated the health insurer tax. On June 17, 2021,
the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety
because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the Affordable Care Act will remain in effect in its current
form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order to initiate a special
enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order
also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare,
including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies
that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is
possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges
and the healthcare reform measures of the Biden administration will impact the Affordable Care Act and our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We anticipate that the Affordable
Care Act, if substantially maintained in its current form, will continue to result in additional downward pressure on coverage and the
price that we receive for any approved product, and could seriously harm our business. Any reduction in reimbursement from Medicare and
other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures
or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.
Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which
we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Further legislation or regulation
could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed
and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control
Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in
spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion
for fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes
aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April 1, 2013
and will stay in effect through 2031 unless additional Congressional action is taken. However, COVID-19 pandemic relief legislation suspended
the 2% Medicare sequester from May 1, 2020 through March 31, 2021. Under current legislation, the actual reduction in Medicare payments
varied from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Additionally, on March 11, 2021, President Biden signed
the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s
average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. In January 2013, the American
Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers,
including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government
to recover overpayments to providers from three to five years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, there has
been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically,
there have been several recent U.S. Congressional inquiries and proposed federal legislation designed to, among other things, bring more
transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer
patient programs, and reform government program reimbursement methodologies for drugs. For example, the Trump administration used several
means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives.
For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription
drug pricing that attempt to implement several of the administration&#8217;s proposals. The FDA also released a final rule and guidance
implementing a portion of the importation executive order providing pathways for states to build and submit importation plans for drugs
from Canada. Further, on November 20, 2020, the Department of Health and Human Services, or HHS, finalized a regulation removing safe
harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy
benefit managers, unless the price reduction is required by law. The implementation of the rule was delayed by the Biden administration
from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions
reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and
manufacturers, the implementation of which also was delayed until January 1, 2023. On November 20, 2020, CMS issued an interim final
rule implementing former President Trump&#8217;s Most Favored Nation, or MFN, executive order, which would tie Medicare Part B payments
for certain physician-administered drugs to the lowest price paid in other economically advanced countries, and was effective as of January
1, 2021. As a result of litigation challenging the MFN model, on August 10, 2021, CMS published a proposed rule that rescinded the MFN
model interim final rule. As a result of litigation challenging the MFN model, on December 27, 2021, CMS published a final rule that
rescinded the Most Favored Nation model interim final rule. In July 2021, the Biden administration released an executive order, &#8220;Promoting
Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive
order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing
reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. No legislation
or administrative actions have been finalized to implement these principles. In addition, on August 16, 2022, President Biden signed
into law the Inflation Reduction Act of 2022, which, among other things, contains substantial drug pricing reforms that will reduce drug
spending by the federal government. For example, the Inflation Reduction Act of 2022 limits the prices paid by Medicare for various prescription
drugs and requires drug manufacturers to pay rebates to Medicare if they increase prices faster than inflation for drugs used by Medicare
beneficiaries. Although the effect of the Inflation Reduction Act of 2022 on our business and the pharmaceutical industry in general
is not yet known, the Inflation Reduction Act of 2022 could affect the prices we can charge and the reimbursement we can receive for
our product candidates, if approved, thereby reducing our profitability. We also expect that additional state and federal healthcare
reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare
products and services, which could result in reduced demand for our product candidates if approved or additional pricing pressures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Foreign Corrupt Practices Act</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Foreign Corrupt Practices
Act, or the FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of
value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision
of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies
whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that
accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an
adequate system of internal accounting controls for international operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Additional Regulation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to the foregoing,
state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act,
the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our
use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations.
If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages
and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance
therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our
future operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Regulations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are also subject to numerous
federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection,
fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such
laws and regulations now or in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2022,
we had 25 employees, all of whom were full-time employees. As of December 31, 2022, 13 of our employees were engaged in research and
development activities and 12 of our employees were engaged in business development, legal, finance, market development, information
systems, facilities, human resources or administrative support. As of December 31, 2022, all of our employees were located in the United
States. None of our United States employees are represented by any collective bargaining agreements. We believe that we maintain good
relations with our employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>COVID-19 and Related Macroeconomic Conditions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The COVID-19 pandemic and
related macroeconomic conditions, such as supply chain shortages, inflation and economic volatility have, and may continue to have, an
impact on our results of operations. We will continue to monitor whether such conditions would have a material impact on our operations,
liquidity and capital resources. Further, rising inflation has, in part, caused a disruption in the capital markets, which may lead to
a recession or market correction that could impact our access to capital, and could in the future negatively affect our liquidity. A
recession or market correction, continued supply chain disruptions and/or inflation could materially affect our business and the value
of our common stock. See &#8220;<i>&#8212;Risks Related to Our Financial Condition</i>&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 9, 2020, Protara
Therapeutics, Inc. (formerly ArTara Therapeutics, Inc., formerly Proteon Therapeutics, Inc., or the Company or Protara), and privately-held
ArTara Subsidiary, Inc., or Private ArTara, completed the merger and reorganization, or the Merger, in accordance with the terms of the
Agreement and Plan of Merger and Reorganization, dated September 23, 2019, or the Merger Agreement, by and among the Company, Private
ArTara and REM 1 Acquisition, Inc., a wholly owned subsidiary of the Company, or Merger Sub, whereby Merger Sub merged with and into
Private ArTara, with Private ArTara surviving as a wholly owned subsidiary of the Company. The Merger was structured as a reverse merger
and Private ArTara was determined to be the accounting acquirer based on the terms of the Merger and other factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We were originally incorporated
in Delaware in March 2006, and at that time, acquired Proteon Therapeutics, LLC, the predecessor of Protara, which was formed in June
2001.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our principal executive
offices are located at 345 Park Avenue South, 3<sup>rd</sup> Floor, New York, New York 10010, our telephone number is (646) 844-0337
and our website address is www.protaratx.com. The contents of our website are not incorporated into this Annual Report on Form 10-K and
our reference to the URL for our website is intended to be an inactive textual reference only. The information contained on, or that
can be accessed through, our website is not a part of this document.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless the context requires
otherwise, references in this Annual Report on Form 10-K to &#8220;Protara&#8221;, &#8220;TARA&#8221;, &#8220;we&#8221;, &#8220;us&#8221;,
the &#8220;Company&#8221; and &#8220;our&#8221; refer to Protara Therapeutics, Inc. (formerly ArTara Therapeutics, Inc., formerly Proteon
Therapeutics, Inc.) and our subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Available Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed pursuant to Sections 13(a) and 15(d) of
the Securities Exchange Act of 1934, as amended, or the Exchange Act, will be made available free of charge on our website as soon as
reasonably practicable after we electronically file such material with, or furnish it to, the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1A. Risk Factors.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>You should consider carefully
the following information about the risks described below, together with the other information contained in this Annual Report on Form
10-K and in our other public filings, in evaluating our business. If any of the following risks actually occurs, our business, financial
condition, results of operations, and future growth prospects would likely be materially and adversely affected. In these circumstances,
the market price of our common stock would likely decline.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Financial Condition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We have a limited operating history and have never generated
any revenues.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a clinical stage
biopharmaceutical company with a limited operating history that may make it difficult to evaluate the success of our business to date
and to assess our future viability. Our operations have been limited to organizing and staffing the company, business planning, raising
capital, developing our pipeline assets (TARA-002 and IV Choline Chloride), identifying product candidates, and other research and development.
Although our employees have made regulatory submissions and conducted successful clinical trials in the past across many therapeutic
areas while employed at other companies, we have not yet demonstrated an ability to successfully complete any clinical trials and have
never completed the development of any product candidate, nor have we ever generated any revenue from product sales or otherwise. Consequently,
we have no meaningful operations upon which to evaluate our business, and predictions about our future success or viability may not be
as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing biopharmaceutical
products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0pt"><b><i>We expect to incur significant
expenses and significant losses for the foreseeable future and may never generate revenue or achieve or maintain profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Investment in biopharmaceutical
product development is highly speculative because it entails substantial upfront capital and significant risk that a product candidate
will fail to gain regulatory approval or become commercially viable. We have never generated any revenues, and cannot estimate with precision
the extent of our future losses. We expect to incur increasing levels of operating losses for the foreseeable future as we execute on
the plan to continue research and development activities, including the ongoing and planned clinical development of our product candidates,
potentially acquire new products and/or product candidates, seek regulatory approvals of and potentially commercialize any approved product
candidates, hire additional personnel, protect our intellectual property, and incur the additional costs of operating as a public company.
We expect to continue to incur significant and increasing operating losses and negative cash flows for the foreseeable future. These
losses have had and will continue to have an adverse effect on our financial position and working capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To become and remain profitable,
we must develop or acquire and eventually commercialize a product with significant market potential. This will require us to be successful
in a range of challenging activities, including completing preclinical studies and clinical trials, obtaining marketing approval, manufacturing,
marketing and selling any product candidate for which we obtain marketing approval, and satisfying post-marketing requirements, if any.
We may never succeed in these activities and, even if we succeed in obtaining approval for and commercializing one or more products,
we may never generate revenues that are significant enough to achieve profitability. In addition, as a young business, we may encounter
unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. Furthermore, because of the numerous
risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount
of increased expenses or when, or if, we will be able to achieve profitability. If we achieve profitability, we may not be able to sustain
or increase profitability on a quarterly or annual basis and may continue to incur substantial research and development and other expenditures
to develop and market additional product candidates. Our failure to become and remain profitable would decrease the value of us and could
impair our ability to raise capital, maintain our research and development efforts, expand the business or continue operations. A decline
in our value could also cause you to lose all or part of your investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The effects of the COVID-19 pandemic and
resulting macroeconomic factors could materially and adversely impact our business, including our clinical development plans and non-clinical
research.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following the COVID-19 pandemic
and associated health and safety measures imposed from time to time to contain the continue globally, we have and, in the event of a resurgence
of the pandemic or the onset of another public health crisis, may again experience disruptions that could severely impact our business,
including but not limited to delays or difficulties in clinical trial site operations and in the enrollment, scheduling and retention
of patients in our clinical trials; interruption of key manufacturing, research and clinical development and other activities; and delays
or difficulties conducting and completing non-clinical studies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are not able to respond
to and manage the impact of such events effectively, our business will be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, macroeconomic
factors, including supply chain disruptions, rising inflation and resulting increases in interest rates, which are, in part, tied to
the lasting impacts of the COVID-19 pandemic, have and will continue to have an impact on our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To the extent the impacts
of the COVID-19 pandemic adversely affect our business and results of operations, they may also have the effect of heightening many of
the other risks and uncertainties described elsewhere in this &#8220;Risk Factors&#8221; section.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need to raise additional financing
in the future to fund our operations, which may not be available to us on favorable terms or at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will require substantial
additional funds to conduct the costly and time-consuming preclinical studies and clinical trials necessary to pursue regulatory approval
of each potential product candidate and to continue the development of TARA-002 and IV Choline Chloride in new indications or uses. Our
future capital requirements will depend upon a number of factors, including: the number and timing of future product candidates in the
pipeline; progress with and results from preclinical testing and clinical trials; the ability to manufacture sufficient drug supplies
to complete preclinical and clinical trials; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing
patent and other intellectual property claims; and the time and costs involved in obtaining regulatory approvals and favorable reimbursement
or formulary acceptance. Raising additional capital may be costly or difficult to obtain and could significantly dilute stockholders&#8217;
ownership interests and divert our management&#8217;s focus on achieving our business objectives. As a result of economic conditions,
general global economic uncertainty, U.S. and foreign political conditions, and other factors, including the effects of the COVID-19
pandemic, we do not know whether additional capital will be available when needed, or that, if available, we will be able to obtain additional
capital on reasonable terms. Specifically, because the COVID-19 pandemic has at times significantly disrupted financial markets, it may
limit our ability to access capital, which could in the future negatively affect our liquidity. Further, rising inflation has, in part,
caused a disruption in the capital markets and an increase in interest rates, which may lead to a recession or market correction that
could impact our access to capital, increase the cost of capital, and could in the future negatively affect our liquidity. A recession
or market correction, inflation and/or further increases in interest rates could materially affect our business and the value of our
common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we raise additional funds
through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely
affect the rights of our common stockholders. Further, to the extent that we raise additional capital through the sale of common stock
or securities convertible or exchangeable into common stock, the ownership interests of our common stockholders will be diluted. In addition,
any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions,
such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing
and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have
to relinquish certain valuable intellectual property or other rights to our product candidates, technologies, future revenue streams
or research programs or grant licenses on terms that may not be favorable to us. Even if we were to obtain sufficient funding, there
can be no assurance that it will be available on terms acceptable to us or our stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to use our net operating loss
carryforwards and certain other tax attributes to offset future taxable income or taxes may be limited.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Under current law, federal
net operating losses incurred in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility
of such federal net operating losses in tax years beginning after December 31, 2020 is limited to 80% of taxable income. It is uncertain
if and to what extent various states and localities will conform to federal tax laws. In addition, under Sections 382 and 383 of the Internal
Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change&#8221;
which is generally defined as a greater than 50% change in its equity ownership value over a six-year period, the corporation&#8217;s
ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post- change income or
taxes may be limited. We have experienced ownership changes in the past and we may also experience additional ownership changes in the
future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs
and our ability to use our net operating loss carryforwards is materially limited, it would harm our future operating results by effectively
increasing our future tax obligations. In addition, at the state level, there may be periods during which the use of net operating loss
carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, if we earn
net taxable income, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes,
which could potentially result in increased future tax liability to us and adversely affect our future cash flows.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-indent: -8.35pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-indent: -8.35pt"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-indent: -8.35pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-indent: -8.35pt"><b>Risks Related to Drug/Biologics
Development and Commercialization</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business depends on the successful
clinical development and regulatory approval of our product candidates, including TARA-002 and IV Choline Chloride.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">The success of our business,
including our ability to finance our operations and generate revenue in the future, primarily depends on the successful development and
regulatory approval of our product candidates, including of TARA-002 and IV Choline Chloride. The clinical success of TARA-002 and IV
Choline Chloride depend on a number of factors, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timely and successful
    completion of planned and ongoing preclinical studies and clinical trials, including our ongoing Phase 1 clinical trial of TARA-002
    in NMIBC and our planned Phase 2 clinical trial of TARA-002 in LMs, which may be significantly slower or costlier than we currently
    anticipate and/or produce results that do not achieve the endpoints of the trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.75pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of our prevalence
    study and our enhanced understanding of the PN patient population as part of our IV Choline Chloride program; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether we are required
    by the FDA or similar foreign regulatory agencies to conduct additional studies beyond those planned to support the approval and
    commercialization of TARA-002 and IV Choline Chloride;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving and maintaining,
    and, where applicable, ensuring that our third-party contractors achieve and maintain compliance with their contractual obligations
    and with all regulatory requirements applicable to TARA-002 and IV Choline Chloride;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability of third parties
    with whom we contract to manufacture adequate clinical trial and commercial supplies of TARA-002 and IV Choline Chloride, to remain
    in good standing with regulatory agencies and to develop, validate and maintain commercially viable manufacturing processes that
    are compliant with current good manufacturing practices, or cGMP;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a continued acceptable
    safety profile during clinical development and following approval of TARA-002 and IV Choline Chloride; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the existence of a regulatory
    environment conducive to the successful development of TARA-002 and IV Choline Chloride.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any one of these factors
is not present, many of which are beyond our control, we could experience significant delays or an inability to obtain regulatory approval
of TARA-002 or IV Choline Chloride.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;Our clinical trials
may fail to demonstrate the safety and efficacy of our product candidates, or serious adverse or unacceptable side effects may be identified
during their development, which could increase our costs or necessitate the abandonment or limitation of the development of the product
candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We have never completed a clinical trial or made a BLA or NDA
submission and may be unable to successfully do so for TARA-002 or IV Choline Chloride.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The conduct of a clinical
trial is a long, expensive, complicated and highly regulated process. Although our employees have conducted successful clinical trials
and made regulatory submissions in the past across many therapeutic areas while employed at other companies, we, as a company, have not
completed any clinical trials, or submitted a BLA or NDA and as a result may require more time and incur greater costs than we anticipate.
Failure to commence or complete, or delays in clinical trials or planned regulatory submissions would prevent us from, or delay us, in
obtaining regulatory approval of and commercializing TARA-002 or IV Choline Chloride, which would adversely impact our financial performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely and expect to continue to rely
on third-party CROs and other third parties to conduct and oversee our clinical trials. If these third parties do not meet our requirements
or otherwise conduct the trials as required, we may not be able to satisfy our contractual obligations or obtain regulatory approval
for, or commercialize, our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We rely and expect to continue
to rely on third-party CROs, to conduct and oversee our TARA-002 and IV Choline Chloride clinical trials and studies and other aspects
of product development. We also rely on various medical institutions, clinical investigators and contract laboratories to conduct our
trials in accordance with our clinical protocols and all applicable regulatory requirements, including the FDA&#8217;s regulations and
cGCP, requirements, which are an international standard meant to protect the rights and health of patients and to define the roles of
clinical trial sponsors, administrators and monitors, and state regulations governing the handling, storage, security and record-keeping
for drug and biologic products. These CROs and other third parties have and will continue to play a significant role in the conduct of
these trials and the subsequent collection and analysis of data from the clinical trials. We will rely heavily on these parties for the
execution of our clinical trials and preclinical studies and will control only certain aspects of their activities. We and our CROs and
other third-party contractors will be required to comply with cGCP and cGLP, requirements, which are regulations and guidelines enforced
by the FDA and comparable foreign regulatory authorities. Regulatory authorities enforce these cGCP and cGLP requirements through periodic
inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable
cGCP and cGLP requirements, or reveal non-compliance from an audit or inspection, including due to COVID-19 and related health and safety
measures and business closures and disruptions, or if the same prevents the FDA or comparable foreign regulatory authorities from conducting
inspections or other regulatory activities, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or
other regulatory authorities may require us to perform additional clinical trials before approving our or our partners&#8217; marketing
applications. We cannot assure that upon inspection by a given regulatory authority, such regulatory authority will determine that any
of our clinical trials or preclinical studies comply with applicable cGCP and cGLP requirements. In addition, our clinical trials generally
must be conducted with product candidate produced under cGMP regulations. Our failure to comply with these regulations and policies may
require us to repeat clinical trials, which would delay the regulatory approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of our CROs or clinical
trial sites fail to comply with their contractual commitments or terminate their involvement in one of our clinical trials for any reason,
including due to COVID-19 disruptions, we may not be able to enter into arrangements with alternative CROs or clinical trial sites or
do so on commercially reasonable terms. In addition, if our relationship with clinical trial sites is terminated, we may experience the
loss of follow-up information on patients enrolled in our clinical trials unless we are able to transfer the care of those patients to
another qualified clinical trial site. In addition, principal investigators for our clinical trials may serve as scientific advisors
or consultants to us from time to time and could receive cash or equity compensation in connection with such services. If these relationships
and any related compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable
clinical trial site may be questioned by the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Interim, topline and preliminary data from
our clinical trials may change as more patient data become available, and are subject to audit and verification procedures that could
result in material changes in the final data.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">From time to time, we may
publicly disclose preliminary, interim or topline data from our preclinical studies and clinical trials, which is based on a preliminary
analysis of then-available data, and the results and related findings and conclusions are subject to change as patient enrollment and
treatment continues and more patient data become available. Adverse differences between previous preliminary or interim data and future
interim or final data could significantly harm our business prospects. We may also announce topline data following the completion of
a preclinical study or clinical trial, which may be subject to change following a more comprehensive review of the data related to the
particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we
may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline or preliminary
results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such
results, once additional data have been received and fully evaluated. Preliminary, interim, or topline data also remain subject to audit
and verification procedures that may result in the final data being materially different from the data we previously published. Accordingly,
preliminary, interim, and topline data should be viewed with caution until the final data are available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Further, others, including
regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret
or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization
of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose
regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with
what we determine to be material or otherwise appropriate information to include in our disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may in the future conduct clinical trials
for our product candidates outside the United States, and the FDA and applicable foreign regulatory authorities may not accept data from
such trials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may in the future choose
to conduct one or more of our clinical trials outside of the United States. Although the FDA or applicable foreign regulatory authority
may accept data from clinical trials conducted outside the United States or the applicable jurisdiction, acceptance of such study data
by the FDA or applicable foreign regulatory authority may be subject to certain conditions or exclusion. Where data from foreign clinical
trials are intended to serve as the basis for marketing approval in the United States, the FDA will not approve the application on the
basis of foreign data alone unless such data are applicable to the U.S. population and U.S. medical practice; the studies were performed
by clinical investigators of recognized competence; and the data are considered valid without the need for an on-site inspection by the
FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or
other appropriate means. Many foreign regulatory bodies have similar requirements. In addition, such foreign studies would be subject
to the applicable local laws of the foreign jurisdictions where the studies are conducted. There can be no assurance the FDA or applicable
foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable home country. If the
FDA or applicable foreign regulatory authority does not accept such data, it would likely result in the need for additional trials, which
would be costly and time-consuming and delay aspects of our business plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>TARA-002 is an immunopotentiator, and one indication that we
plan to pursue is the treatment of LMs. There are no FDA-approved therapies for the treatment of LMs and it is difficult to predict the
timing and costs of clinical development for TARA-002 for LMs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To date, there are no FDA-approved
therapies for the treatment of LMs. The regulatory approval process for novel product candidates such as TARA-002 can be more expensive
and take longer than for other, better known or extensively studied therapeutic approaches. Delay or failure to obtain, or unexpected
costs in obtaining, the regulatory approval necessary to bring TARA-002 to market in LMs could decrease our ability to generate sufficient
revenue to maintain our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates may cause undesirable
side effects or have other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile
of an approved label, or result in post-approval regulatory action.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unforeseen side effects
from TARA-002 or IV Choline Chloride could arise either during clinical development or, if approved, after the product has been marketed.
Undesirable side effects could cause us, any partners with which we may collaborate, or regulatory authorities to interrupt, extend,
modify, delay or halt clinical trials and could result in a more restrictive or narrower label or the delay or denial of regulatory approval
by the FDA or comparable foreign authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Results of clinical trials
could reveal a high and unacceptable severity and prevalence of side effects. In such an event, trials could be suspended or terminated,
and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product
candidate for any or all targeted indications. Any side effects could affect patient recruitment or the ability of enrolled patients
to complete the trial or result in product liability claims. Any of these occurrences may harm our business, financial condition, operating
results and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, if we or others
identify undesirable side effects, or other previously unknown problems, in connection with a product after obtaining U.S. or foreign
regulatory approval, a number of potentially negative consequences could result, which could prevent us or our potential partners from
achieving or maintaining market acceptance of the product and could substantially increase the costs of commercializing such product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A fast track designation by the FDA may
not actually lead to a faster development or regulatory review or approval process for IV Choline Chloride for the treatment of IFALD.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA has granted fast
track designation to IV Choline Chloride for the treatment of IFALD. If a drug is intended for the treatment of a serious or life-threatening
condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for fast
track designation. Even though we have received fast track designation for IV Choline Chloride for the treatment of IFALD, we may not
experience a faster development process, review or approval. The FDA may withdraw fast track designation if it believes that the designation
is no longer supported by data from our clinical development program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Although the FDA has granted Rare Pediatric
Disease Designation for TARA-002 for the treatment of LMs, a BLA for TARA-002, if approved, may not meet the eligibility criteria for
a priority review voucher.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Rare Pediatric Disease Designation
has been granted for TARA-002 for the treatment of LMs. In 2012, Congress authorized the FDA to award priority review vouchers to sponsors
of certain rare pediatric disease product applications. This provision is designed to encourage development of new drug and biological
products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an
approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive
a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product
receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred
any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The
FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed
in the U.S. within one year following the date of approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the purposes of this
program, a &#8220;rare pediatric disease&#8221; is a (a) serious or life-threatening disease in which the serious or life-threatening
manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children,
and adolescents; and (b) rare disease or conditions within the meaning of the Orphan Drug Act. Congress has only authorized the Rare
Pediatric Disease Priority Review Voucher program until September 30, 2024. However, if a drug candidate received Rare Pediatric Disease
Designation before September 30, 2024, it is eligible to receive a voucher if it is approved before September 30, 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">TARA-002 for the treatment
of LMs may not be approved by that date, or at all, and, therefore, we may not be in a position to obtain a priority review voucher prior
to expiration of the program, unless Congress further reauthorizes the program. Additionally, designation of a drug for a rare pediatric
disease does not guarantee that a BLA will meet the eligibility criteria for a rare pediatric disease priority review voucher at the
time the application is approved. Finally, a Rare Pediatric Disease Designation does not lead to faster development or regulatory review
of the product or increase the likelihood that it will receive marketing approval. We may or may not realize any benefit from receiving
a voucher.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.65pt"><b><i>Even if a product
candidate obtains regulatory approval, it may fail to achieve the broad degree of physician and patient adoption and use necessary for
commercial success.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The commercial success of
both TARA-002 and IV Choline Chloride, if approved, will depend significantly on the broad adoption and use of them by physicians and
patients for approved indications, and neither may be commercially successful even though the product is shown to be safe and effective.
The degree and rate of physician and patient adoption of a product, if approved, and successful commercialization will depend on a number
of factors, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient demand for approved products that treat the
    indication for which a product is approved;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of the product compared to other
    available therapies;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of coverage and adequate reimbursement
    from managed care plans and other healthcare payors;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of treatment in relation to alternative treatments
    and willingness to pay on the part of patients;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the case of TARA-002 for LMs, overcoming physician
    or patient biases toward alternative treatments for LMs;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurers&#8217; willingness to see the applicable indication
    as a disease worth treating;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">proper administration;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient satisfaction with the results, administration
    and overall treatment experience;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the ability to
                                            successfully commercialize TARA-002 and IV Choline Chloride in the United States and internationally,
                                            if either is approved for marketing, sale and distribution in such countries and territories,
                                            whether alone or in collaboration with others;</td>
</tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"></td><td style="width: 0.25in; text-align: justify">&#9679;</td><td style="text-align: justify">our ability and
                                            our partners&#8217; ability to establish and enforce intellectual property rights in and
                                            to TARA-002 and IV Choline Chloride;</td>
</tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"></td><td style="width: 0.25in; text-align: justify">&#9679;</td><td style="text-align: justify">patient demand
                                            for approved products that treat the indication for which a product is approved;</td>
</tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="text-align: justify; width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations or contraindications,
    warnings, precautions or approved indications for use different than those sought by us that are contained in the final FDA-approved
    labeling for the applicable product;</span></td></tr>
  </table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any FDA requirement to undertake a Risk Evaluation
    and Mitigation Strategy;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of our sales, marketing, pricing,
    reimbursement and access, government affairs, and distribution efforts;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse publicity about a product or favorable publicity
    about competitive products;</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new government regulations
    and programs, including price controls and/or limits or prohibitions on ways to commercialize drugs, such as increased scrutiny on
    direct-to-consumer advertising of pharmaceuticals; and</span></td></tr>
  </table><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential product liability claims or other product-related
    litigation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If either TARA-002 or IV
Choline Chloride is approved for use but fails to achieve the broad degree of physician and patient adoption necessary for commercial
success, our operating results and financial condition will be adversely affected, which may delay, prevent or limit our ability to generate
revenue and continue our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Further, even if regulatory
approvals are obtained, we may never be able to successfully commercialize TARA-002 or IV Choline Chloride, or the FDA or comparable
foreign regulatory authorities may require labeling changes or impose significant restrictions on a product&#8217;s indicated uses or
marketing or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. Accordingly, we cannot
assure you that we will be able to generate sufficient revenue through the sale of TARA-002 or IV Choline Chloride to continue our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Before obtaining marketing
approvals for the commercial sale of any product candidate, we must demonstrate through lengthy, complex and expensive preclinical testing
and clinical trials that such product candidate is both safe and effective for use in the applicable indication, and failures can occur
at any stage of testing. Clinical trials often fail to demonstrate safety and are associated with side effects or have characteristics
that are unexpected. Based on the safety profile seen in clinical testing, we may need to abandon development or limit development to
more narrow uses in which the side effects or other characteristics are less prevalent, less severe or more tolerable from a risk-benefit
perspective. The FDA or an IRB may also require that we suspend, discontinue, or limit clinical trials based on safety information. Such
findings could further result in regulatory authorities failing to provide marketing authorization for the product candidate. Many pharmaceutical
candidates that initially showed promise in early stage testing and which were efficacious have later been found to cause side effects
that prevented further development of the drug candidate and, in extreme cases, the side effects were not seen until after the drug was
marketed, causing regulators to remove the drug from the market post-approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Any adverse developments that occur in
patients undergoing treatment with OK-432 / Picibanil or in patients participating in clinical trials conducted by third parties may
affect our ability to obtain regulatory approval or commercialize TARA-002.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Chugai Pharmaceutical Co.,
Ltd., over which we have no control, has the rights to commercialize TARA-002 and the originator therapy to TARA-002, OK-432, which is
currently marketed under the name Picibanil, in Japan and Taiwan for various indications. In addition, clinical trials using Picibanil
are currently ongoing in various countries around the world. If SAEs occur with patients using Picibanil or during any clinical trials
of Picibanil conducted by third parties, the FDA may delay, limit or deny approval of TARA-002 or require us to conduct additional clinical
trials as a condition to marketing approval, which would increase our costs. If we receive FDA approval for TARA-002 and a new and serious
safety issue is identified in connection with use of Picibanil or in clinical trials of Picibanil conducted by third parties, the FDA
may withdraw the approval of the product or otherwise restrict our ability to market and sell TARA-002. In addition, treating physicians
may be less willing to administer TARA-002 due to concerns over such adverse events, which would limit our ability to commercialize TARA-002.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may choose not to continue developing
or commercializing any of our product candidates at any time during development or after approval, which would reduce or eliminate the
potential return on investment for those product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At any time, we may decide
to discontinue the development of any of our product candidates for a variety of reasons, including the appearance of new technologies
that make our product candidates obsolete, competition from a competing product or changes in or failure to comply with applicable regulatory
requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we terminate a program
in which we have invested significant resources, we will not receive any return on our investment and we will have missed the opportunity
to have allocated those resources to potentially more productive uses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other Risks Related to Our Business</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.65pt"><b><i>Our product candidates,
if approved, will face significant competition and their failure to compete effectively may prevent them from achieving significant market
penetration.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The pharmaceutical industry
is characterized by rapidly advancing technologies, intense competition, uncertain and complex patent terms, and a strong emphasis on
developing newer, fast-to-market proprietary therapeutics. Numerous companies are engaged in the development, patenting, manufacturing
and marketing of healthcare products competitive with those that we are developing, including TARA-002 and IV Choline Chloride. We will
face competition from a number of sources, such as pharmaceutical companies, biotechnology companies, generic drug companies, consumer
products companies and academic and research institutions, many of which have greater financial resources, marketing capabilities, sales
forces, manufacturing capabilities, research and development capabilities, regulatory expertise, clinical trial expertise, intellectual
property portfolios, international reach, experience in obtaining patents and regulatory approvals for product candidates and other resources
than we have. Some of the companies that offer competing products also have a broad range of other product offerings, large direct sales
forces and long-term customer relationships with our target physicians, which could inhibit our market penetration efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">With respect to our lead
product candidate, TARA-002, for the treatment of NMIBC and LMs, the active ingredient in TARA-002 is a genetically distinct strain of
<i>Streptococcus pyogenes </i>(group A, type 3) Su strain. TARA-002 is produced through a proprietary manufacturing process. We anticipate
that, if approved by the FDA, TARA-002 will be protected by 12 years of biologic exclusivity. There are no approved pharmacotherapies
currently available for the treatment of LMs and the current treatment options include a high-risk surgical procedure and off-label use
of sclerosants, including doxycycline, bleomycin, ethanol and sodium tetradecyl sulfate. There are a number of drug development companies
and academic researchers exploring oral formulations of various agents including macrolides, phosphodiesterase inhibitors, and calcineurin/mTOR
inhibitors. These are in early development. TARA-002, if approved for the treatment of NMIBC, would be subject to competition from existing
treatment methods of surgery, chemotherapy and immunomodulatory therapy. For example, the current standard of care for NMIBC includes
intravesical BCG TICE (manufactured by Merck &amp; Co. Inc.). Other products approved for the treatment of NMIBC include Merck &amp; Co.,
Inc.&#8217;s Keytruda, Endo International plc&#8217;s Valstar, and Ferring B.V.&#8217;s Adstiladrin. Additional product candidates in
development include Japanese BCG Laboratory&#8217;s BCG Tokyo, Pfizer Inc.&#8217;s Sasanlimab in combination with BCG, ImmunityBio, Inc.&#8217;s
VesAnktiva in combination with BCG, CG Oncology Inc.&#8217;s CG0070, Sesen Bio, Inc.&#8217;s Vicineum, enGene Inc.&#8217;s, EG-70, Seagen
Inc.&#8217;s PADCEV, Janssen&#8217;s TAR200 combined with gemcitabine plus or minus Cetrelimab, Urogen Pharma Ltd.&#8217;s Jelmyto,and
Auro BioSciences, Inc.&#8217;s Aura-0011. Additional pharmaceutical and biotechnology companies with product candidates in development
for the treatment of NMIBC include but may not be limited to Verity, AstraZeneca PLC, Bristol-Myers Squibb Company, Roche Group, Asieris
Pharmaceuticals, BeiGene, Ltd, NanOlogy, LLC, Linton Pharm Co., Ltd., Lindis Biotech GmbH, Theralase Technologies Inc., Taizhou Hanzhong
biomedical co. Ltd., Shionogi &amp; Co. Ltd., Rapamycin Holdings, Inc., Vaxiion Therapeutics Inc., Incyte Corporation, LiPac Oncology,
Inc., Anika Therapeutics Inc., Surge Pharmaceuticals Pvt. Ltd., and Istari Oncology, Inc..</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are no treatments
currently available for IFALD. With respect to IV Choline Chloride for the treatment of IFALD, IV Choline Chloride is the only sterile
injectable form of choline chloride that can be combined with parenteral nutrition. Further, if approved, IV Choline Chloride will be
protected by Orphan Drug Designation exclusivity for seven years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>TARA-002 and any future product candidates
for which we intend to seek approval as biologic products may face competition sooner than anticipated.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Biologics Price Competition
and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable
with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the
FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar
product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this
12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full
BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical
trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented
by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty. While it is uncertain when such
processes are intended to be implemented, the BPCIA may be fully adopted by the FDA, and any such processes could have a material adverse
effect on the future commercial prospects for our biological products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe that any of our
product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there
is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product
candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than
anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent
litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a
way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of
marketplace and regulatory factors that are still developing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently have limited marketing capabilities
and no sales organization. If we are unable to grow our sales and marketing capabilities on our own or through third parties, we will
be unable to successfully commercialize our product candidates, if approved, or generate product revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We currently have limited
marketing capabilities and no sales organization. To commercialize our product candidates, if approved, in the United States, Canada,
the European Union, Latin America and other jurisdictions we may seek to enter, we must build our marketing, sales, distribution, managerial
and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful
in doing so. Although our employees have experience in the marketing, sale and distribution of pharmaceutical products, and business
development activities involving external alliances, from prior employment at other companies, we, as a company, have no prior experience
in the marketing, sale and distribution of pharmaceutical products, and there are significant risks involved in building and managing
a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide
adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure
or delay in the development of our internal sales, marketing, distribution and pricing/reimbursement/access capabilities would impact
adversely the commercialization of these products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have only received the exclusive rights
to the materials required to commercialize TARA-002 in territories other than Japan and Taiwan until June 17, 2030, or an earlier date
if Chugai terminates the agreement with us for any number of reasons, following which such rights become non-exclusive.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to an agreement
with Chugai Pharmaceutical dated June 17, 2019, as amended on July 14, 2020 (effective as of June 30, 2020), Chugai Pharmaceutical agreed
to provide us with exclusive access to the starting material necessary to manufacture TARA-002 as well as technical support necessary
for us to develop and commercialize TARA-002 anywhere in the world other than Japan and Taiwan. However, this agreement does not prevent
Chugai from providing such materials and support to any third-party for medical, compassionate use and/or non-commercial research purposes
and this agreement is exclusive only through June 17, 2030 or, the earlier termination of the agreement by either party. Once our rights
to the materials and technology necessary to manufacture, develop and commercialize TARA-002 are not exclusive, third parties, including
those with greater expertise and greater resources, could obtain such materials and technology and develop a competing therapy, which
would adversely affect our ability to generate revenue and achieve or maintain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we obtain regulatory approval to
begin commercializing any of our products, we would remain subject to ongoing regulatory review, which could subsequently result in a
suspension or termination of sale of these products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even after we achieve U.S.
regulatory approval for a product candidate, if any, we will be subject to continued regulatory review and compliance obligations. For
example, with respect to our product candidates, the FDA may impose significant restrictions on the approved indicated uses for which
the product may be marketed or on the conditions of approval. A product candidate&#8217;s approval may contain requirements for potentially
costly post-approval studies and surveillance, including Phase 4 clinical trials, to monitor the safety and efficacy of the product.
We will also be subject to ongoing FDA obligations and continued regulatory review with respect to, among other things, the manufacturing,
processing, labeling, packaging, distribution, pharmacovigilance and adverse event reporting, storage, advertising, promotion and recordkeeping
for our product candidates. In addition, manufacturers of drug and biologic products and their facilities are subject to continual review
and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations. If we or a regulatory agency
discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with
the manufacturing, processing, distribution or storage facility where, or processes by which, the product is made, a regulatory agency
may impose restrictions on that product or us, including requesting that we initiate a product recall, or requiring notice to physicians
or the public, withdrawal of the product from the market, or suspension of manufacturing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We face product liability exposure, and if successful claims
are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We face an inherent risk
of product liability or similar causes of action as a result of the clinical testing of our product candidates and will face an even
greater risk if we commercialize any products. This risk exists even if a product is approved for commercial sale by the FDA and manufactured
in facilities licensed and regulated by the FDA or an applicable foreign regulatory authority and notwithstanding that we comply with
applicable laws on promotional activity. Our products and product candidates are designed to affect important bodily functions and processes.
Any side effects, manufacturing defects, misuse or abuse associated with our product candidates could result in injury to a patient or
potentially even death. We cannot offer any assurance that we will not face product liability suits in the future, nor can we assure
you that our insurance coverage will be sufficient to cover our liability under any such cases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, a liability
claim may be brought against us even if our product candidates merely appear to have caused an injury. Product liability claims may be
brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with
our product candidates, among others, and under some circumstances even government agencies. If we cannot successfully defend ourselves
against product liability or similar claims, we will incur substantial liabilities, reputational harm and possibly injunctions and punitive
actions. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal or delay of recruitment or decreased enrollment
    rates of clinical trial participants;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination or increased government regulation of clinical
    trial sites or entire trial programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability to commercialize our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased demand for our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment of our business reputation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product recall or withdrawal from the market or labeling,
    marketing or promotional restrictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial costs of any related litigation or similar
    disputes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">distraction of management&#8217;s attention and other
    resources from our primary business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant delay in product launch;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial monetary awards to patients or other claimants
    against us that may not be covered by insurance;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of reimbursement or formulary inclusion;
    or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of revenue.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have obtained product
liability insurance coverage for our clinical trials. Large judgments have been awarded in class action or individual lawsuits based
on drugs that had unanticipated side effects. Our insurance coverage may not be sufficient to cover all of our product liability-related
expenses or losses and may not cover us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly
expensive, restrictive and narrow, and, in the future, we may not be able to maintain adequate insurance coverage at a reasonable cost,
in sufficient amounts or upon adequate terms to protect us against losses due to product liability or other similar legal actions. We
will need to increase our product liability coverage if any of our product candidates receive regulatory approval, which will be costly,
and we may be unable to obtain this increased product liability insurance on commercially reasonable terms or at all and for all geographies
in which we wish to launch. A successful product liability claim or series of claims brought against us, if judgments exceed our insurance
coverage, could decrease our cash and harm our business, financial condition, operating results and future prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our employees, independent contractors,
principal investigators, other clinical trial staff, consultants, vendors, CROs and any partners with whom we may collaborate may engage
in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are exposed to the risk
that our employees, independent contractors, principal investigators, other clinical trial staff, consultants, vendors, CROs and any
partners with which we may collaborate may engage in fraudulent or other illegal activity. Misconduct by these persons could include
intentional, reckless, gross or negligent misconduct or unauthorized activity that violates: laws or regulations, including those laws
requiring the reporting of true, complete and accurate information to the FDA or foreign regulatory authorities; manufacturing standards;
federal, state and foreign healthcare fraud and abuse laws and data privacy; anticorruption laws, anti-kickback and Medicare/Medicaid
rules, or laws that require the true, complete and accurate reporting of financial information or data, books and records. If any such
or similar actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions
could have a significant impact on our business, including the imposition of significant civil, criminal and administrative and punitive
penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs,
debarments, contractual damages, imprisonment, reputational harm, diminished profits and future earnings, injunctions, and curtailment
or cessation of our operations, any of which could adversely affect our ability to operate our business and our operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: -8.35pt"><b><i>We may
be subject to risks related to off-label use of our product candidates, if approved.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA strictly regulates
the advertising and promotion of drug products, and drug products may only be marketed or promoted for their FDA approved uses, consistent
with the product&#8217;s approved labeling. Advertising and promotion of any product candidate that obtains approval in the United States
will be heavily scrutinized by the FDA, the Department of Justice, the Office of Inspector General of the Department of Health and Human
Services, state attorneys general, members of Congress and the public. For example, the FDA and other agencies actively enforce the laws
and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may
be subject to significant liability. Although physicians may prescribe products for off-label uses as the FDA and other regulatory agencies
do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict
promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance
has not been issued. Companies may only share truthful and not misleading information that is otherwise consistent with a product&#8217;s
FDA approved labeling. Violations, including promotion of our products for unapproved or off-label uses, are subject to enforcement letters,
inquiries and investigations, and civil, criminal and/or administrative sanctions by the FDA. Additionally, advertising and promotion
of any product candidate that obtains approval outside of the United States will be heavily scrutinized by relevant foreign regulatory
authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the United States, engaging
in impermissible promotion of our product candidates for off-label uses can also subject us to false claims litigation under federal
and state statutes, which can lead to significant civil, criminal and/or administrative penalties and fines and agreements, such as a
corporate integrity agreement, that materially restrict the manner in which we promote or distribute our product candidates. If we do
not lawfully promote our products once they have received regulatory approval, we may become subject to such litigation and, if we are
not successful in defending against such actions, those actions could have a material adverse effect on our business, financial condition
and operating results and even result in having an independent compliance monitor assigned to audit our ongoing operations for a lengthy
period of time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we or any partners with which we may
collaborate are unable to achieve and maintain coverage and adequate levels of reimbursement for TARA-002 or IV Choline Chloride following
regulatory approval, their commercial success may be hindered severely.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If TARA-002 or IV Choline
Chloride only becomes available by prescription, successful sales by us or by any partners with which we may collaborate depend on the
availability of coverage and adequate reimbursement from third-party payors. Patients who are prescribed medicine for the treatment of
their conditions generally rely on third-party payors to reimburse most or part of the costs associated with their prescription drugs.
The availability of coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the United
States, and private third-party payors is often critical to new product acceptance. Coverage decisions may depend on clinical and economic
standards that disfavor new drug products when more established or lower-cost therapeutic alternatives are already available or subsequently
become available, or may be affected by the budgets and demands on the various entities responsible for providing health insurance to
patients who will use TARA-002 or IV Choline Chloride. Even if we obtain coverage for our products, the resulting reimbursement payment
rates might not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use a product unless
coverage is provided, and reimbursement is adequate to cover a significant portion of the cost.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, the market
for our products will depend significantly on access to third-party payors&#8217; drug formularies or lists of medications for which
third-party payors provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward
pricing pressures on pharmaceutical companies and there may be time limitations on when a new drug may even apply for formulary inclusion.
Also, third-party payors may refuse to include products in their formularies or otherwise restrict patient access to such products when
a less costly biosimilar or generic equivalent or other treatment alternative is available in the discretion of the formulary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Third-party payors, whether
foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs.
In addition, in the United States, although private third-party payors tend to follow Medicare practices, no uniform or consistent policy
of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products
can differ significantly from payor to payor as well as from state to state. Consequently, the coverage determination process is often
a time-consuming and costly process that must be played out across many jurisdictions and different entities and that will require us
to provide scientific, clinical and health economics support for the use of our products compared to current alternatives and do so to
each payor separately, with no assurance that coverage and adequate reimbursement will be obtained and in what time frame.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Further, we believe that
future coverage and reimbursement likely will be subject to increased restrictions both in the United States and in international markets.
Third-party coverage and reimbursement for our products may not be available or adequate in either the United States or international
markets, which could harm our business, financial condition, operating results and prospects. Further, coverage policies and third-party
reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained, less favorable
coverage policies and reimbursement rates may be implemented in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: -8.35pt"><b><i>Healthcare
reform measures could hinder or prevent the commercial success of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Existing regulatory policies
may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of any future
product candidates we may develop. For example, the Trump administration and certain members of the U.S. Congress sought to repeal all
or part of the Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act, or collectively,
the Affordable Care Act, and implement a replacement program. In another example, the so-called &#8220;individual mandate&#8221; was
repealed as part of tax reform legislation adopted in December 2017, informally titled the Tax Cuts and Jobs Act, or Tax Act, such that
the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal
Revenue Code was eliminated beginning in 2019. Additionally, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural
grounds that argued the Affordable Care Act is unconstitutional in its entirety because the individual mandate was repealed by Congress.
Thus, the Affordable Care Act will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January
28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance
coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and
reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration
projects and waiver programs that include work requirements, and policies that create barriers to obtaining access to health insurance
coverage through Medicaid or the Affordable Care Act. It is possible that the Affordable Care Act will be subject to judicial or Congressional
challenges in the future. It is unclear how such challenges and the healthcare reform measures of the Biden administration will impact
the Affordable Care Act and our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Additionally, there has
been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. For example, the Trump
administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive
orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive
orders related to prescription drug pricing that attempted to implement several of the administration&#8217;s proposals. The FDA also
released a final rule and guidance implementing a portion of the importation executive order providing pathways for states to build and
submit importation plans for drugs from Canada. Further, on November 20, 2020, the Department of Health and Human Services, or HHS, finalized
a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either
directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor
for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy
benefit managers and manufacturers. The implementation of the rule has been delayed until January 1, 2026. On November 20, 2020, the
Centers for Medicare &amp; Medicaid Services, or CMS, issued an interim final rule implementing former President Trump&#8217;s Most Favored
Nation, or MFN, executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price
paid in other economically advanced countries, and was effective as of January 1, 2021. As a result of litigation challenging the MFN
model, on December 27, 2021, CMS published a final rule that rescinded the MFN model interim final rule. Further, in July 2021, the Biden
administration released an executive order that included multiple provisions aimed at prescription drugs. In response to Biden&#8217;s
executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for
drug pricing reform. The plan sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative
actions HHS could take to advance these principles. No legislation or administrative actions have been finalized to implement these principles.
In addition, on August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which, among other things, contains
substantial drug pricing reforms that will reduce drug spending by the federal government. For example, the Inflation Reduction Act of
2022 limits the prices paid by Medicare for various prescription drugs and requires drug manufacturers to pay rebates to Medicare if
they increase prices faster than inflation for drugs used by Medicare beneficiaries. Although the effect of the Inflation Reduction Act
of 2022 on our business and the pharmaceutical industry in general is not yet known, the Inflation Reduction Act of 2022 could affect
the prices we can charge and the reimbursement we can receive for our product candidates, if approved, thereby reducing our profitability.
We also expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the
amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our
product candidates if approved or additional pricing pressures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">There are also calls to
place additional restrictions on or to ban direct-to-consumer advertising of pharmaceuticals, which would limit our ability to market
our product candidates. The United States is in a minority of jurisdictions that allow this kind of advertising and its removal could
limit the potential reach of a marketing campaign. Further, it is possible that additional government action is taken in response to
the COVID-19 pandemic.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.65pt"><b><i>We are subject to
strict healthcare laws, regulation and enforcement, and our failure to comply with those laws could adversely affect our business, operations
and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Certain federal and state
healthcare laws and regulations pertaining to fraud and abuse, privacy, transparency, and patients&#8217; rights are and will be applicable
to our business. We are subject to regulation by both the federal government and the states in which we or our partners conduct business.
The healthcare laws and regulations that may affect our ability to operate include but are not limited to: the federal Anti-Kickback
Statute; federal civil and criminal false claims laws and civil monetary penalty laws; the federal Health Insurance Portability and Accountability
Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act; the Prescription Drug Marketing Act
(for sampling of drug product among other things); the federal physician sunshine requirements under the Affordable Care Act; the Foreign
Corrupt Practices Act as it applies to activities outside of the United States; the federal Right-to-Try legislation; and similar state
laws of such federal laws, which may be broader in scope.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Because of the breadth of
these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities
could be subject to challenge under one or more of such laws. In addition, recent healthcare reform legislation has strengthened these
laws. For example, the Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback Statute and
certain criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of the statute or specific intent
to violate it. In addition, the Affordable Care Act provided that the government may assert that a claim including items or services
resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil
False Claims Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Achieving and sustaining
compliance with these laws may prove costly. In addition, any action against us for violation of these laws, even if we successfully
defend against it, could cause us to incur significant legal expenses and divert management&#8217;s attention from the operation of our
business and result in reputational damage. If our operations are found to be in violation of any of the laws described above or any
other governmental laws or regulations that apply to us, we may be subject to significant penalties, including administrative, civil
and criminal penalties, damages, including punitive damages, fines, disgorgement, the exclusion from participation in federal and state
healthcare programs, imprisonment, additional oversight and reporting obligations, or the curtailment or restructuring of our operations,
and injunctions, any of which could adversely affect our ability to operate our business and financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may in-license and acquire product candidates
and may engage in other strategic transactions, which could impact our liquidity, increase our expenses and present significant distractions
to our management.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Part of our strategy is
to in-license and acquire product candidates and we may engage in other strategic transactions. Additional potential transactions that
we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings,
divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may
increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management or business,
which could adversely affect our operations and financial results. Accordingly, there can be no assurance that we will undertake or successfully
complete any transactions of the nature described above, and any transaction that we do complete could harm our business, financial condition,
operating results and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our failure to successfully in-license,
acquire, develop and market additional product candidates or approved products would impair our ability to grow our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We may in-license, acquire,
develop and market additional products and product candidates. Because our internal research and development capabilities are limited,
we may be dependent on pharmaceutical and biotechnology companies, academic or government scientists and other researchers to sell or
license products or technology to us. The success of this strategy depends partly on our ability to identify and select promising pharmaceutical
and biologic product candidates and products, negotiate licensing or acquisition agreements with their current owners, and finance these
arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">The process of proposing,
negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies,
including some with substantially greater financial, marketing, sales and other resources, may compete with us for the license or acquisition
of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party
products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential
acquisitions or licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts.
We may not be able to acquire the rights to additional product candidates on terms that we find acceptable or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Further, any product candidate
that we acquire may require additional development efforts prior to commercial sale, including preclinical or clinical testing and approval
by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of pharmaceutical
product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval
by regulatory authorities. In addition, we cannot provide assurance that any approved products that we acquire will be manufactured or
sold profitably or achieve market acceptance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We expect to rely on collaborations with
third parties for the successful development and commercialization of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We expect to rely upon the
efforts of third parties for the successful development and commercialization of our current and future product candidates. The clinical
and commercial success of our product candidates may depend upon maintaining successful relationships with third-party partners which
are subject to a number of significant risks, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our partners&#8217; ability to execute their responsibilities
    in a timely, cost-efficient and compliant manner;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced control over delivery and manufacturing schedules;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price increases and product reliability;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing deviations from internal or regulatory
    specifications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">quality incidents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure of partners to perform their obligations
    for technical, market or other reasons;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">misappropriation of our current or future product candidates;
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other risks in potentially meeting our current and
    future anticipated commercialization schedule for product candidates or satisfying the requirements of our end-users.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We cannot assure you that
we will be able to establish or maintain third-party relationships in order to successfully develop and commercialize our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We rely completely on third-party contractors
to supply, manufacture and distribute clinical drug supplies for our product candidates, which may include sole-source suppliers and
manufacturers; we intend to rely on third parties for commercial supply, manufacturing and distribution if any of our product candidates
receive regulatory approval; and we expect to rely on third parties for supply, manufacturing and distribution of preclinical, clinical
and commercial supplies of any future product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We do not currently have,
nor do we plan to acquire, the infrastructure or capability to supply, store, manufacture or distribute preclinical, clinical or commercial
quantities of drug substances or products. Additionally, we have not entered into a long-term commercial supply agreement to provide
us with such drug substances or products. As a result, our ability to develop our product candidates is dependent, and our ability to
supply our products commercially will depend, in part, on our ability to obtain active pharmaceutical ingredient, or API, and other substances
and materials used in our product candidates successfully from third parties and to have finished products manufactured by third parties
in accordance with regulatory requirements and in sufficient quantities for preclinical and clinical testing and commercialization. If
we fail to develop and maintain supply and other technical relationships with these third parties, we may be unable to continue to develop
or commercialize our products and product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We do not have direct control
over whether our contract suppliers and manufacturers will maintain current pricing terms, be willing to continue supplying us with API
and finished products or maintain adequate capacity and capabilities to serve our needs, including quality control, quality assurance
and qualified personnel. We are dependent on our contract suppliers and manufacturers for day-to-day compliance with applicable laws
and cGMP for production of both API and finished products. If the safety or quality of any product or product candidate or component
is compromised due to a failure to adhere to applicable laws or for other reasons, we may not be able to commercialize or obtain regulatory
approval for the affected product or product candidate successfully, and we may be held liable for injuries sustained as a result.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">In order to conduct larger
or late-stage clinical trials for our product candidates and supply sufficient commercial quantities of any of our products, if approved,
our contract manufacturers and suppliers will need to produce our API and other substances and materials used in our product candidates
in larger quantities, more cost-effectively and, in certain cases, at higher yields than they currently achieve. If our third-party contractors
are unable to scale up the manufacture of any of our product candidates successfully in sufficient quality and quantity and at commercially
reasonable prices, or are shut down or put on clinical hold by government regulators, and we are unable to find one or more replacement
suppliers or manufacturers capable of production at a substantially equivalent cost in substantially equivalent volumes and quality,
and we are unable to transfer the processes successfully on a timely basis, the development of that product candidate and regulatory
approval or commercial launch for any resulting products may be delayed, or there may be a shortage in supply, either of which could
significantly harm our business, financial condition, operating results and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We expect to continue to
depend on third-party contract suppliers and manufacturers for the foreseeable future. Our supply and manufacturing agreements, if any,
do not guarantee that a contract supplier or manufacturer will provide services adequate for our needs. Additionally, any damage to or
destruction of our third-party manufacturers&#8217; or suppliers&#8217; facilities or equipment, even by force majeure, may significantly
impair our ability to have our products and product candidates manufactured on a timely basis. Our reliance on contract manufacturers
and suppliers further exposes us to the possibility that they, or third parties with access to their facilities, will have access to
and may misappropriate our trade secrets or other proprietary information. In addition, the manufacturing facilities of certain of our
suppliers may be located outside of the United States. This may give rise to difficulties in importing our products or product candidates
or their components into the United States or other countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">In addition, we cannot be
certain that any prolonged, intensified or worsened effect of the COVID-19 pandemic would not impact our supply chain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The manufacture of biologics is complex
and our third-party manufacturers may encounter difficulties in production. If our CDMO encounters such difficulties, the ability to
provide supply of TARA-002 for clinical trials, our ability to obtain marketing approval, or our ability to obtain commercial supply
of TARA-002, if approved, could be delayed or stopped.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We have no experience in
biologic manufacturing and do not own or operate, and we do not expect to own or operate, facilities for product manufacturing, storage
and distribution, or testing. We are completely dependent on CDMOs to fulfill our clinical and commercial supply of TARA-002. The process
of manufacturing biologics is complex, highly regulated and subject to multiple risks. Manufacturing biologics is highly susceptible
to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency
in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal
manufacturing processes could result in reduced production yields, product defects and other supply disruptions and higher costs. If
microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed
for an extended period of time to investigate and remedy the contamination, which could delay clinical trials, result in higher costs
of drug product and adversely harm our business. Moreover, if the FDA determines that our manufacturer is not in compliance with FDA
laws and regulations, including those governing cGMP, the FDA may deny BLA approval until the deficiencies are corrected or we replace
the manufacturer in our BLA with a manufacturer that is in compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">In addition, there are risks
associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems
with process scale-up, process reproducibility, stability issues, compliance with cGMP, lot consistency and timely availability of raw
materials. Even if we obtain regulatory approval for TARA-002 or any future product candidates, there is no assurance that our manufacturers
will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce
it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If our
manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would
be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. Scaling
up a biologic manufacturing process is a difficult and uncertain task, and any CDMO we contract may not have the necessary capabilities
to complete the implementation and development process of further scaling up production, transferring production to other sites, or managing
its production capacity to timely meet product demand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to attract and retain management
and other key personnel, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement
our business plan.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Our ability to compete in
the highly competitive biopharmaceuticals industry depends on our ability to attract and retain highly qualified managerial, scientific,
medical, legal, sales and marketing and other personnel. We are highly dependent on our management and scientific personnel. The loss
of the services of any of these individuals could impede, delay or prevent the successful development of our product pipeline, completion
of our planned clinical trials, commercialization of our product candidates or in-licensing or acquisition of new assets and could impact
negatively our ability to implement successfully our business plan. If we lose the services of any of these individuals, we might not
be able to find suitable replacements on a timely basis or at all, and our business could be harmed as a result. We might not be able
to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel
among biotechnology, pharmaceutical and other businesses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">In addition, over the past
few years the United States has experienced a decrease in unemployment rates and an increasingly competitive labor market, which may
continue to result in difficulties in hiring or retaining sufficient qualified personnel to maintain and grow our business. We are uncertain
as to the employment environment in the future, or how that environment will impact our workforce, including our ability to retain qualified
management and other key personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be adversely affected by natural
disasters, pandemics and other catastrophic events and by man-made problems such as terrorism and war that could disrupt our business
operations, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Our office is located in
New York, New York. If a disaster, power outage, computer hacking, or other event occurred that prevented us from using all or a significant
portion of an office, that damaged critical infrastructure, such as enterprise financial systems, IT systems, manufacturing resource
planning or enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible
for us to continue our business for a substantial period of time. For example, we are expanding our clinical development of TARA-002
in NMBIC to clinical trial sites outside the United States, including potentially in Ukraine and in other countries in Europe and Asia
and may expand to other geographies. If political or civil conditions require it, our sites may need to delay or suspend clinical trial
activities. In addition, enrollment and retention of patients at such sites could be disrupted by geopolitical events, including civil
or political unrest, such as the current ongoing conflict between Russia and Ukraine. All of the aforementioned risks may be further
increased if we do not implement a disaster recovery plan or our partners&#8217; or manufacturers&#8217; disaster recovery plans prove
to be inadequate. To the extent that any of the above should result in delays in the research, development, regulatory approval, manufacture,
distribution or commercialization of TARA-002 or IV Choline Chloride, our business, financial condition, operating results and prospects
would suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-indent: -8.35pt"><b>Risks Related to Our Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-indent: -8.35pt"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-indent: -8.35pt"><b><i>We expect our stock price to
be highly volatile.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">The market price of our
shares could be subject to significant fluctuations. Market prices for securities of biotechnology and other life sciences companies
historically have been particularly volatile, even subject to large daily price swings. For example, the closing price of our common
stock from the period January 1, 2022 to December 31, 2022 has ranged from a low of $2.43 to a high of $6.90. Some of the factors that
may cause the market price of our shares to fluctuate include, but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of current
    and any future clinical trials of TARA-002 or IV Choline Chloride and any clinical trial failure, including any failure resulting
    from difficulties or delays in identifying patients, enrolling patients, retaining patients, meeting specific trial endpoints or
    completing and timely reporting the results of any trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain regulatory
    approvals for TARA-002, IV Choline Chloride or future product candidates, and delays of, or failures to obtain such approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure of TARA-002
    or IV Choline Chloride or future product candidates, if approved, to achieve commercial success;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effects of the COVID-19
    pandemic or any other public health crisis;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential side effects
    associated with TARA-002 or IV Choline Chloride or future product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issues in manufacturing,
    or the inability to obtain adequate supply of, TARA-002, IV Choline Chloride or future product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the entry into, or termination
    of, or breach by partners of key agreements, including key commercial partner agreements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the initiation of, material
    developments in, or conclusion of, any litigation or other actions to enforce or defend any intellectual property rights or defend
    against the intellectual property rights of others;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of any dilutive
    equity financings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability to obtain additional
    funding;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by commercial
    partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships
    or capital commitments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to elicit meaningful
    stock analyst coverage and downgrades of our stock by analysts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the loss of key employees;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in laws or regulations application to TARA-002
    or IV Choline Chloride or future product candidates; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.8pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our common stock by us, our insiders or our
    other stockholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Moreover, the stock markets
in general have experienced substantial volatility in our industry that has often been unrelated to the operating performance of individual
companies or a certain industry segment. These broad market fluctuations may also adversely affect the trading price of our shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">In the past, following periods
of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation
against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and
resources, which could significantly harm our profitability and reputation. In addition, such securities litigation often has ensued
after a reverse merger or other merger and acquisition activity. Such litigation if brought could impact negatively our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We incur costs and demands upon management
as a result of complying with the laws and regulations affecting public companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">As a public company, we
have incurred, and will continue to incur, significant legal, accounting and other expenses, including costs associated with public company
reporting and other SEC requirements. We have also incurred, and will continue to incur, costs associated with corporate governance requirements,
including requirements under the Exchange Act, the Sarbanes-Oxley Act and other applicable legislation, as well as rules implemented
by the SEC and Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We expect the rules and
regulations applicable to public companies will continue to substantially increase our legal and financial compliance costs and to make
some activities more time-consuming and costly. Our executive officers and other personnel will need to continue to devote substantial
time to managing operations as a public company and compliance with applicable laws and regulations. These rules and regulations may
also make it expensive for us to operate our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to maintain proper and effective
internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We are subject to the reporting
requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among
other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform
system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness
of our internal controls over financial reporting in our Annual Report on Form 10-K filing for that year, as required by Section 404
of the Sarbanes-Oxley Act. This will require that we incur substantial professional fees and internal costs to expand our accounting
and finance functions and that we expend significant management efforts. We may experience difficulty in meeting these reporting requirements
in a timely manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We may discover weaknesses
in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial
statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter
how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will
be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements
due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">If we are not able to comply
with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls,
we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our common stock
could decline and we could be subject to sanctions or investigations by the SEC or other regulatory authorities or by Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are able to take advantage of reduced
disclosure and governance requirements applicable to smaller reporting companies, which could result in our common stock being less attractive
to investors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We qualify as a smaller
reporting company under the rules of the SEC. As a smaller reporting company, we are able to take advantage of reduced disclosure requirements,
such as certain simplified executive compensation disclosures and reduced financial statement disclosure requirements in our SEC filings.
Comparatively reduced disclosures in our SEC filings due to our status as a smaller reporting company may make it harder for our investors
to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive
due to our reliance on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active
trading market for our common stock and our stock price may be more volatile. We may take advantage of the reporting exemptions applicable
to a smaller reporting company until we are no longer a smaller reporting company, which status would end once we have a public float
greater than $250 million. In that event, we could still be a smaller reporting company if our annual revenues were below $100 million
and we have a public float of less than $700 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-indent: -8.35pt"><b><i>We do not anticipate paying
any dividends in the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">The current expectation
is that we will retain our future earnings to fund the development and growth of our business. As a result, capital appreciation, if
any, of your shares of our stock will be your sole source of gain, if any, for the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If equity research analysts do not publish research or reports,
or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.65pt">The trading market for
our common stock is influenced by the research and reports that equity research analysts publish about us and our business. Equity research
analysts may elect not to provide research coverage of our common stock, and such lack of research coverage may adversely affect the
market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts
or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts
downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us
or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or
trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-indent: -8.35pt"><b>Risk Related to Our Ownership
Structure and Governance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Certain stockholders have the ability to
control or significantly influence certain matters submitted to our stockholders for approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Certain stockholders have
consent rights over certain significant matters of our business. These include decisions to effect a merger or other similar transaction,
changes to our principal business, and the sale or other transfer of TARA-002 or other assets with an aggregate value of more than $2,500,000.
As a result, these stockholders, have significant influence over certain matters that require approval by our stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Anti-takeover provisions in our charter
documents and under Delaware law could make an acquisition of our business more difficult and may prevent attempts by our stockholders
to replace or remove management.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Provisions in our certificate
of incorporation and bylaws may delay or prevent an acquisition or a change in management. In addition, because we are incorporated in
Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which prohibits stockholders
owning in excess of 15% of the outstanding voting stock from merging or combining with us. These provisions may frustrate or prevent
any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace
members of the board of directors, which is responsible for appointing the members of management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our certificate of incorporation provides
that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which
could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other
employees.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Our certificate of incorporation
provides that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding
brought on our behalf, any action asserting a breach of fiduciary duty owed by any of our directors, officers or other employees to us
or our stockholders, any action asserting a claim against us arising pursuant to any provisions of the DGCL, our certificate of incorporation
or our bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. The choice of forum provision
may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for certain disputes with us or
our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees.
If a court were to find the choice of forum provision contained in the certificate of incorporation to be inapplicable or unenforceable
in an action, we may incur additional costs associated with resolving such action in other jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Intellectual Property Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to obtain, maintain
or enforce global patent rights or other intellectual property rights that cover our product candidates and technologies that are of
sufficient breadth to prevent third parties from competing against us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Our success with respect
to our product candidates will depend, in part, on our ability to obtain and maintain patent protection in both the United States and
other countries, to preserve our trade secrets and to prevent third parties from infringing on our proprietary rights. Our ability to
protect our product candidates from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain
and maintain valid and enforceable patents around the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">The patent application process,
also known as patent prosecution, is expensive and time-consuming, and we and our current or future licensors and licensees may not be
able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner in all
the countries that are desirable. It is also possible that we or our current licensors, or any future licensors or licensees, will fail
to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late
to obtain patent protection on them. Therefore, these and any of our patents and applications may not be prosecuted and enforced in a
manner consistent with the best interests of our business. Moreover, our competitors independently may develop equivalent knowledge,
methods and know-how or discover workarounds to our patents that would not constitute infringement. Any of these outcomes could impair
our ability to enforce the exclusivity of our patents effectively, which may have an adverse impact on our business, financial condition
and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Due to legal standards relating
to patentability, validity, enforceability and claim scope of patents covering pharmaceutical inventions, our ability to obtain, maintain
and enforce patents is uncertain and involves complex legal and factual questions especially across countries. Accordingly, rights under
any existing patents or any patents we might obtain or license may not cover our product candidates or may not provide us with sufficient
protection for our product candidates to afford a sustainable commercial advantage against competitive products or processes, including
those from branded, generic and over-the-counter pharmaceutical companies. In addition, we cannot guarantee that any patents or other
intellectual property rights will issue from any pending or future patent or other similar applications owned by or licensed to us. Even
if patents or other intellectual property rights have issued or will issue, we cannot guarantee that the claims of these patents and
other rights are or will be held valid or enforceable by the courts, through injunction or otherwise, or will provide us with any significant
protection against competitive products or otherwise be commercially valuable to us in every country of commercial significance that
we may target.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Competitors in the field
of immunology and oncology therapeutics have created a substantial amount of prior art, including scientific publications, posters, presentations,
patents and patent applications and other public disclosures including on the Internet. Our ability to obtain and maintain valid and
enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable
over the prior art. We do not have outstanding issued patents covering all of the recent developments in our technology and are unsure
of the patent protection that we will be successful in obtaining, if any. Even if the patents do successfully issue, third parties may
design around or challenge the validity, enforceability or scope of such issued patents or any other issued patents we own or license,
which may result in such patents being narrowed, invalidated or held unenforceable. If the breadth or strength of protection provided
by the patents we hold or pursue with respect to our product candidates is challenged, it could dissuade companies from collaborating
with us to develop or threaten our ability to commercialize or finance our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">The laws of some foreign
jurisdictions do not provide intellectual property rights to the same extent or duration as in the United States, and many companies
have encountered significant difficulties in acquiring, maintaining, protecting, defending and especially enforcing such rights in foreign
jurisdictions. If we encounter such difficulties in protecting, or are otherwise precluded from effectively protecting, our intellectual
property in foreign jurisdictions, our business prospects could be substantially harmed, especially internationally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Proprietary trade secrets
and unpatented know-how are also very important to our business. Although we have taken steps to protect our trade secrets and unpatented
know-how by entering into confidentiality agreements with third parties, and intellectual property protection agreements with officers,
directors, employees, and certain consultants and advisors, there can be no assurance that binding agreements will not be breached or
will be enforced by courts, that we would have adequate remedies for any breach, including injunctive and other equitable relief, or
that our trade secrets and unpatented know-how will not otherwise become known, inadvertently disclosed by us or our agents and representatives,
or be independently discovered by our competitors. If trade secrets are independently discovered, we would not be able to prevent their
use and if we and our agents or representatives inadvertently disclose trade secrets and/or unpatented know-how, we may not be allowed
to retrieve this and maintain the exclusivity we previously enjoyed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-indent: -8.35pt"><b><i>We may not be able to protect
our intellectual property rights throughout the world.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Filing, prosecuting and
defending patents on our product candidates does not guarantee exclusivity. The requirements for patentability differ in certain countries,
particularly developing countries. In addition, the laws of some foreign countries do not protect intellectual property rights to the
same extent as laws in the United States, especially when it comes to granting use and other kinds of patents and what kind of enforcement
rights will be allowed, especially injunctive relief in a civil infringement proceeding. Consequently, we may not be able to prevent
third parties from practicing our inventions in all countries outside the United States and even in launching an identical version of
our product notwithstanding we have a valid patent in that country. Competitors may use our technologies in jurisdictions where we have
not obtained patent protection to develop their own products, or produce copy products, and, further, may export otherwise infringing
products to territories where we have patent protection but enforcement on infringing activities is inadequate or where we have no patents.
These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient
to prevent them from competing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain
countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection,
particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing
of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions
could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our global patents
at risk of being invalidated or interpreted narrowly and our global patent applications at risk of not issuing, and could provoke third
parties to assert claims against us. We may not prevail in any lawsuits that we initiate or infringement actions brought against us,
and the damages or other remedies awarded, if any, may not be commercially meaningful when we are the plaintiff. When we are the defendant
we may be required to post large bonds to stay in the market while we defend ourselves from an infringement action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">In addition, certain countries
in Europe and certain developing countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses
to third parties, especially if the patent owner does not enforce or use its patents over a protracted period of time. In some cases,
the courts will force compulsory licenses on the patent holder even when finding the patent holder&#8217;s patents are valid if the court
believes it is in the best interests of the country to have widespread access to an essential product covered by the patent. In these
situations, the royalty the court requires to be paid by the license holder receiving the compulsory license is not calculated at fair
market value and can be inconsequential, thereby adversely affecting the patent holder&#8217;s business. In these countries, we may have
limited remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third-party, which could
also materially diminish the value of those patents. This would limit our potential revenue opportunities. Accordingly, our efforts to
enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that we own or license, especially in comparison to what we enjoy from enforcing our intellectual property rights in the Unites
States. Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes
in both U.S. and foreign intellectual property laws, or changes to the policies in various government agencies in these countries, including
but not limited to the patent office issuing patents and the health agency issuing pharmaceutical product approvals for example, in Brazil,
pharmaceutical patents require initial approval of the Brazilian health agency (ANVISA). Finally, many countries have large backlogs
in patent prosecution, and in some countries in Latin America it can take years, even decades, just to get a pharmaceutical patent application
reviewed notwithstanding the merits of the application.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Obtaining and maintaining patent protection
depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Periodic maintenance and
annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of
the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee
payment and other similar provisions during the patent application process. While an inadvertent lapse can, in many cases, be cured by
payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result
in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction
just for failure to know about and/or timely pay a prosecution fee. Non-compliance events that could result in abandonment or lapse of
a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees in prescribed
time periods, and failure to properly legalize and submit formal documents in the format and style the country requires. If we or our
licensors fail to maintain the patents and patent applications covering our product candidates for any reason, our competitors might
be able to enter the market, which could materially adversely affect our business, financial condition, operating results and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with our obligations
under our intellectual property license agreements, we could lose license rights that are important to our business. Additionally, these
agreements may be subject to disagreement over contract interpretation, which could narrow the scope of our rights to the relevant intellectual
property or technology or increase our financial or other obligations to our licensors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We have entered into in-license
arrangements with respect to certain of our product candidates. These license agreements impose various diligence, milestone, royalty,
insurance and other obligations on us. If we fail to comply with these obligations, the respective licensors may have the right to terminate
the license, in which event we may not be able to develop or market the affected product candidate. The loss of such rights could materially
adversely affect our business, financial condition, operating results and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are sued for infringing intellectual
property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or
commercializing our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Our commercial success depends
on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing
the proprietary rights of third parties. We cannot assure that marketing and selling such candidates and using such technologies will
not infringe existing or future patents. Numerous U.S.- and foreign-issued patents and pending patent applications owned by third parties
exist in the fields relating to our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are
issued, the risk increases that others may assert that our product candidates, technologies or methods of delivery or use infringe their
patent rights. Moreover, it is not always clear to industry participants, including us, which patents and other intellectual property
rights cover various drugs, biologics, drug delivery systems or their methods of use, and which of these patents may be valid and enforceable.
Thus, because of the large number of patents issued and patent applications filed in our fields across many countries, there may be a
risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">In addition, there may be
issued patents of third parties that are infringed or are alleged to be infringed by our product candidates or proprietary technologies
notwithstanding patents we may possess. Because some patent applications in the United States may be maintained in secrecy until the
patents are issued, because patent applications in the United States and many foreign jurisdictions are typically not published until
18 months after filing and because publications in the scientific literature often lag behind actual discoveries, we cannot be certain
that others have not filed patent applications for technology covered by our own and in-licensed issued patents or our pending applications.
Our competitors may have filed, and may in the future file, patent applications covering our product candidates or technology similar
to our technology. Any such patent application may have priority over our own and in-licensed patent applications or patents, which could
further require us to obtain rights to issued patents covering such technologies, which may mean paying significant licensing fees or
the like. If another party has filed a U.S. patent application on inventions similar to those owned or in-licensed to us, or, in the
case of in-licensed technology, the licensor may have to participate, in the United States, in an interference proceeding to determine
priority of invention.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We may be exposed to, or
threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates
or proprietary technologies infringe such third parties&#8217; intellectual property rights, including litigation resulting from filing
under Paragraph IV of the Hatch-Waxman Act or other countries&#8217; laws similar to the Hatch-Waxman Act. These lawsuits could claim
that there are existing patent rights for such drug, and this type of litigation can be costly and could adversely affect our operating
results and divert the attention of managerial and technical personnel, even if we do not infringe such patents or the patents asserted
against us are ultimately established as invalid. There is a risk that a court would decide that we are infringing the third-party&#8217;s
patents and would order us to stop the activities covered by the patents. In addition, there is a risk that a court would order us to
pay the other party significant damages for having violated the other party&#8217;s patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Because we rely on certain
third-party licensors and partners and will continue to do so in the future, if one of our licensors or partners is sued for infringing
a third-party&#8217;s intellectual property rights, our business, financial condition, operating results and prospects could suffer in
the same manner as if we were sued directly. In addition to facing litigation risks, we have agreed to indemnify certain third-party
licensors and partners against claims of infringement caused by our proprietary technologies, and we have entered or may enter into cost-sharing
agreements with some our licensors and partners that could require us to pay some of the costs of patent litigation brought against those
third parties whether or not the alleged infringement is caused by our proprietary technologies. In certain instances, these cost-sharing
agreements could also require us to assume greater responsibility for infringement damages than would be assumed just on the basis of
our technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The occurrence of any of
the foregoing could adversely affect our business, financial condition or operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims that our officers,
directors, employees, consultants or independent contractors have wrongfully used or disclosed to us alleged trade secrets of their former
employers or their former or current customers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">As is common in the biotechnology
and pharmaceutical industries, certain of our employees were formerly employed by other biotechnology or pharmaceutical companies, including
our competitors or potential competitors. Moreover, we engage the services of consultants to assist us in the development of our products
and product candidates, many of whom were previously employed at, or may have previously been or are currently providing consulting services
to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims
that these employees and consultants or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information
of their former employers or their former or current customers. Although we have no knowledge of any such claims being alleged to date,
if such claims were to arise, litigation may be necessary to defend against any such claims. Even if we are successful in defending against
any such claims, any such litigation could be protracted, expensive, a distraction to our management team, not viewed favorably by investors
and other third parties, and may potentially result in an unfavorable outcome.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: -8.35pt"><b>General Risk
Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.65pt"><b><i>If our information
technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences
resulting from such compromise, including, but not limited to, regulatory investigations or actions; litigation; fines and penalties;
disruptions of our business operations; loss of revenue or profits; interruptions to our operations such as our clinical trials; harm
to our reputation; loss of customers or sales; and other adverse consequences.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">In the ordinary course of
our business, we may Process (as defined above) proprietary, confidential and sensitive information, including personal data (including,
key-coded data, health information and other special categories of personal data), intellectual property, trade secrets, and proprietary
business information owned or controlled by ourselves or other parties, or collectively, Sensitive Information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We may use third-party service
providers and subprocessors to help us operate critical business systems to Process Sensitive Information on our behalf in a variety
of contexts, including without limitation, encryption and authentication technology, employee email, and other functions. Our ability
to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information
security measures in place. We may share or receive Sensitive Information with or from third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">If we, our service providers,
partners or other relevant third parties have experienced, or in the future experience, any security incident(s) that result in, any
data loss; deletion or destruction; unauthorized access to; loss, unauthorized acquisition, disclosure, or exposure of, Sensitive Information,
or compromise related to the security, confidentiality, integrity or availability of our (or their) information technology, software,
services, communications or data, or collectively, a Security Incident, it may materially adversely affect our business, financial condition,
operating results and prospects, including the diversion of funds to address the breach, and interruptions, delays, or outages in our
operations and development programs. In the first quarter of 2020, our email server was compromised in a cyber-attack. We quickly isolated
the incident and have, since, implemented additional risk prevention measures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Cyberattacks, malicious
internet-based activity and online and offline fraud are prevalent and continue to increase. These threats are becoming increasingly
difficult to detect. These threats come from a variety of sources, including traditional computer &#8220;hackers&#8221;, threat actors,
employee error, theft or misuse, sophisticated nation-states, and nation-state supported actors. We and the third parties upon which
we rely may be subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing
attacks); software bugs; malicious code (such as viruses and worms); denial-of-service attacks (such as credential stuffing); malware
(including as a result of advanced persistent threat intrusions); supply-chain attacks, server malfunctions, software and hardware failures;
loss of data or other information technology assets; adware; natural disasters; terrorism; war; telecommunication and electrical failures;
ransomware attacks; and other similar threats.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Ransomware attacks, including
those from organized criminal threat actors, nation-states and nation-state supported actors, are becoming increasingly prevalent and
severe and can lead to significant interruptions, delays, or outages in our operations, loss of data, loss of income, significant extra
expenses to restore data or systems, reputational loss and the diversion of funds. To alleviate the financial, operational and reputational
impact of a ransomware attack, it may be preferable to make extortion payments, but we may be unwilling or unable to do so (including,
for example, if applicable laws or regulations prohibit such payments).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Similarly, supply chain
attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain have
not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our systems
and networks or the systems and networks of third parties that support us and our services. We may also be the subject of server malfunction,
software or hardware failures, loss of data or other computer assets, and other similar issues. A significant portion of our workforce
and third-party partners work remotely from time to time, and reliance on remote working technologies and the prevalent use of mobile
devices that access confidential and personal data information increase the risk of Security Incidents, which could lead to the loss
confidential information, personal data, trade secrets or other intellectual property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We may be required to expend
additional, significant resources, fundamentally change our business activities and practices, or modify our operations, including our
clinical trial activities, or information technology in an effort to protect against Security Incidents and to mitigate, detect, and
remediate actual and potential vulnerabilities. Certain data privacy and security obligations may require us to implement specific security
measures or use industry-standard or reasonable measures to protect our information technology systems and Sensitive Information. Even
if we were to take and have taken security measures designed to protect against Security Incidents, there can be no assurance that such
security measures or those of our service providers, partners and other third parties will be effective in protecting against all Security
Incidents and material adverse impacts that may arise from such Security Incidents. We may be unable in the future to detect vulnerabilities
in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may
not be detected until after a Security Incident has occurred. Despite our efforts to identify and remediate vulnerabilities, if any,
in our information technology systems, our efforts may not be successful. Further, we may experience delays in developing and deploying
remedial measures designed to address any such identified vulnerabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">If we (or a third-party
upon whom we rely) experience a Security Incident or are perceived to have experienced a Security Incident, we may experience adverse
consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits,
and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal
data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions;
interruptions in our operations (including availability of data); financial loss; and other similar harms. In addition, our actual or
prospective customers, collaborators, partners and/or clinical trial participants may stop using our product candidates or working with
us. This discontinuance, or failure to meet the expectations of such third parties, could result in material harm to our operations,
financial performance or reputation and affect our ability to grow and operate our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Failures or significant
downtime of our information technology or telecommunication systems or those used by our third-party service providers could cause significant
interruptions in our operations and adversely impact the confidentiality, integrity and availability of Sensitive Information, including
preventing us from conducting clinical trials, tests or research and development activities and prevent us from managing the administrative
aspects of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Applicable Data Protection
Requirements (as defined below) may require us to notify relevant stakeholders of Security Incidents, including affected individuals,
partners, collaborators, customers, regulators, law enforcement agencies, credit reporting agencies and others. Such disclosures are
costly, and the disclosures or the failure to comply with such requirements could materially adversely affect our business, financial
condition, operating results and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Our contracts may not contain
limitations of liability, and even where they do, there can be no assurance that any limitations or exclusions of liability in our contracts
would be enforceable or adequate or would otherwise protect us from liabilities or damages if we fail to comply with Data Protection
Requirements related to information security or Security Incidents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.65pt">We cannot be sure that
our insurance coverage will be adequate or otherwise protect us from or adequately mitigate liabilities or damages with respect to claims,
costs, expenses, litigation, fines, penalties, business loss, data loss, regulatory actions or material adverse impacts arising out of
our Processing operations, privacy and security practices, or Security Incidents we may experience. The successful assertion of one or
more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including
premium increases or the imposition of large excess or deductible or co-insurance requirements), could materially adversely affect our
business, financial condition, operating results and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are subject to stringent and changing
obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory
investigations or actions; litigation; fines and penalties; a disruption of our business operations, including our clinical trials; harm
to our reputation; and other adverse effects on our business or prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">In the ordinary course of
business, we collect, receive, store, process, use, generate, transfer, disclose, make accessible, protect, secure, dispose of, transmit,
and share, or collectively, Process or Processing of, personal data and other sensitive and confidential information, including information
we collect about patients in connection with clinical trials, sensitive third-party data or, as necessary to operate our business, for
legal and marketing purposes, and for other business-related purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Accordingly, we are, or
may become, subject to numerous federal, state, local and international data privacy and security laws, regulations, guidance and industry
standards as well as external and internal privacy and security policies, contracts and other obligations that apply to the Processing
of personal data by us and on our behalf, collectively, Data Protection Requirements. The number and scope of Data Protection Requirements
are changing, subject to differing applications and interpretations, and may be inconsistent between jurisdictions or in conflict with
each other. If we fail, or are perceived to have failed, to address or comply with Data Protection Requirements, we could face significant
consequences. These consequences may include, but are not limited to, government enforcement actions against us that could include investigations,
fines, penalties, audits and inspections, additional reporting requirements and/or oversight, temporary or permanent bans on all or some
Processing of personal data, orders to destroy or not use personal data, and imprisonment of company officials (for example, under HIPAA).
Further, individuals or other relevant stakeholders could bring a variety of claims against us for our actual or perceived failure to
comply with the Data Protection Requirements. Any of these events could have a material adverse effect on our reputation, business, or
financial condition, and could lead to a loss of actual or prospective customers, collaborators or partners; interrupt or stop clinical
trials; result in an inability to Process personal data or to operate in certain jurisdictions; limit our ability to develop or commercialize
our products; or require us to revise or restructure our operations, or each, a material adverse impact.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We are, or may become, subject
to U.S. privacy laws. For example, in the United States, there are a broad variety of data protection laws and regulations that may apply
to our activities such as state data breach notification laws, state personal data privacy laws (for example, the California Consumer
Privacy Act of 2018, or CCPA), state health information privacy laws, and federal and state consumer protection laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">The CCPA requires covered
businesses that process personal data of California residents to disclose their data collection, use and sharing practices. Further,
the CCPA provides California residents with new data privacy rights (including the ability to opt out of the sale of personal data),
imposes new operational requirements for covered businesses, provides for civil penalties for violations (up to $7,500 per violation),
as well as a private right of action for certain data breaches (that is expected to increase data breach class action litigation and
result in significant exposure to costly legal judgements and settlements). Aspects of the CCPA and its interpretation and enforcement
remain uncertain. Further, the new California Privacy Rights Act, or CPRA, substantially expands the CCPA&#8217;s requirements effective
January 1, 2023. The CPRA, among other things, gives California residents the ability to limit use of certain sensitive personal data,
establish restrictions on the retention of personal data, expand the types of data breaches subject to the CCPA&#8217;s private right
of action, and establish a new California Privacy Protection Agency to implement and enforce the new law. Although there are limited
exemptions for clinical trial data under the CCPA and the CPRA, the CCPA and the CPRA may increase compliance costs and potential liability
with respect to other personal data we maintain about California residents. Other states have enacted data privacy laws. For example,
Virginia passed its Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act, both of which differ from the CPRA and
become effective in 2023. The federal government is also considering comprehensive privacy legislation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Outside the United States,
an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the European Union&#8217;s
General Data Protection Regulation, or EU GDPR, the United Kingdom&#8217;s GDPR, or UK GDPR, and Brazil&#8217;s General Data Protection
Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or LGPD) (Law No. 13,709/2018) impose strict requirements for processing
personal data. For example, under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well
as fines of up to 20 million euros or 4% of annual global revenue, whichever is greater. Further, individuals may initiate litigation
related to processing of their personal data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">European data protection
laws (including the EU GDPR and UK GDRP) are wide-ranging in scope and impose numerous, significant and complex compliance burdens in
relation to the Processing of personal data, such as: limiting permitted Processing of personal data to only that which is necessary
for specified, explicit and legitimate purposes; requiring the establishment of a legal basis for Processing personal data; broadening
the definition of personal data; creating obligations for controllers and processors to appoint data protection officers in certain circumstances;
increasing transparency obligations to data subjects; introducing the obligation to carry out data protection impact assessments in certain
circumstances; establishing limitations on the collection and retention of personal data through &#8216;data minimization&#8217; and
&#8216;storage limitation&#8217; principles; introducing obligations to honor increased rights for data subjects; formalizing a heightened
standard to obtain data subject consent; establishing obligations to implement certain technical and organizational safeguards to protect
the security and confidentiality of personal data; introducing the obligation to provide notice of certain significant personal data
breaches to the relevant supervisory authority(ies) and affected individuals; and mandating the appointment of representatives in the
UK and/or EU in certain circumstances. In particular, the Processing of &#8220;special categor[ies] [of] personal data&#8221; (such as
personal data related to health and genetic information), which could be relevant to our operations in the context of our clinical trials,
imposes heightened compliance burdens under European data protection laws and is a topic of active interest among relevant regulators.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">Certain jurisdictions have
enacted data localization laws and cross-border personal data transfer laws, which could make it more difficult to transfer information
across jurisdictions (such as transferring or receiving personal data that originates in the EU or in other foreign jurisdictions). Existing
mechanisms that facilitate cross-border personal data transfers may change or be invalidated. For example, absent appropriate safeguards
or other circumstances, the EU GDPR generally restricts the transfer of personal data to countries outside of the European Economic Area,
or EEA, that the European Commission does not consider to provide an adequate level of data privacy and security, such as the United
States. The European Commission released a set of &#8220;Standard Contractual Clauses,&#8221; or SCCs, that are designed to be a valid
mechanism to facilitate personal data transfers out of the EEA to these jurisdictions. Currently, these SCCs are a valid mechanism to
transfer personal data outside of the EEA, but there exists some uncertainty regarding whether the SCCs will remain a valid mechanism.
Additionally, the SCCs impose additional compliance burdens, such as conducting transfer impact assessments to determine whether additional
security measures are necessary to protect the at-issue personal data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">In addition, Switzerland
and the UK similarly restrict personal data transfers outside of those jurisdictions to countries that they do not consider to provide
an adequate level of personal data protection, such as the United States, and certain countries outside Europe (e.g. Brazil) have also
passed or are considering laws requiring local data residency or otherwise impeding the transfer of personal data across borders, any
of which could increase the cost and complexity of doing business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">If we cannot implement a
valid compliance mechanism for cross-border data transfers, we may face increased exposure to regulatory actions, substantial fines,
and injunctions against processing or transferring personal data from Europe or other foreign jurisdictions. Inability to import personal
data to the United States may significantly and negatively impact our business operations, including by limiting our ability to conduct
clinical trial activities in Europe and elsewhere; limiting our ability to collaborate with parties subject to European and other data
protection laws or requiring us to increase our personal data processing capabilities in Europe and/or elsewhere at significant expense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">These laws exemplify the
vulnerability of our business to the evolving regulatory environment related to personal data and may require us to modify our Processing
practices at substantial costs and expenses in an effort to comply. Given the breadth and evolving nature of Data Protection Requirements,
preparing for and complying with these requirements is rigorous, time-intensive and requires significant resources and a review of our
technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants
that Process personal data on our behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">We may publish privacy policies
and other documentation regarding our Processing of personal data and/or other confidential, proprietary or sensitive information. Although
we endeavor to comply with our published policies and other documentation, we may at times fail to do so or may be perceived to have
failed to do so. Moreover, despite our efforts, we may not be successful in achieving compliance if our employees, third-party collaborators,
service providers, contractors or consultants fail to comply with our policies and documentation. Such failures can subject us to potential
regulatory action if they are found to be deceptive, unfair, or misrepresentative of our actual practices. Moreover, subjects about whom
we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability
to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights or failed to comply with data protection
laws or applicable privacy notices even if we are not found liable, could be expensive and time-consuming to defend and could result
in adverse publicity that could harm our business or have other material adverse impacts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 1B. Unresolved Staff Comments.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This item is not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 2. Properties.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2022,
we leased approximately 10,252 square feet of space for our headquarters in New York, New York under an agreement that expires in May
2028. We leased 10,098 square feet for our development laboratory, a manufacturing facility and an additional manufacturing space, all
located in North America. We believe that our existing facilities are adequate to meet our current needs, and that suitable additional
alternative spaces will be available in the future on commercially reasonable terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 3. Legal Proceedings.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">From time to time, we may
be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. We are not currently
a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business.
Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources
and other factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 4. Mine Safety Disclosures.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif">PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder
Matters and Issuer Purchases of Equity Securities.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our common stock is traded
on the Nasdaq Capital Market under the symbol &#8220;<b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">TARA</i></b>&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif">Holders of Our common stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of March 3, 2023, there
were 11,306,753 shares of common stock outstanding held by approximately 20 stockholders of record. The actual number of stockholders
is greater than this number of record holders, and includes stockholders who are beneficial owners, whose shares are held in street name
by brokers and other nominees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif">Dividend Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have never declared or
paid cash dividends on our common stock, and we do not expect to pay any cash dividends on our common stock in the foreseeable future.
Payment of future dividends, if any, on our common stock will be at the discretion of our Board of Directors after taking into account
various factors, including our financial condition, operating results, anticipated cash needs, and plans for expansion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif">Securities Authorized for Issuance under Equity
Compensation Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">See Item 12 of Part III
of this Annual Report on Form 10-K regarding information about securities authorized for issuance under our equity compensation plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif">Recent Sales of Unregistered Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other than as previously
disclosed in our past Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, we did not have any sales of unregistered securities
for the period covered by this Annual Report on Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 6. Reserved.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 7. Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i style="font-family: Times New Roman, Times, Serif">You should read the following
discussion and analysis of our financial condition and results of operations together with our financial statements and related notes
appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth
elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and related
financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors
set forth in the &#8220;Risk Factors&#8221; section of this document, our actual results could differ materially from the results described
in, or implied by, the forward-looking statements contained in the following discussion and analysis.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif">Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a New York City based
clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases.
We were founded on the principle of applying modern scientific, regulatory or manufacturing advancements to established mechanisms in
order to create new development opportunities. We prioritize creativity, diverse perspectives, integrity and tenacity to expedite our
goal of bringing life-changing therapies to people with limited treatment options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.5pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our portfolio includes two
development programs utilizing TARA-002, an investigational cell therapy based on the broad immunopotentiator, OK-432, which was originally
granted marketing approval by the Japanese Ministry of Health and Welfare as an immunopotentiating cancer therapeutic agent. This cell
therapy is currently approved in Japan and Taiwan for LMs and multiple oncologic indications. We have secured worldwide rights to the
asset excluding Japan and Taiwan and are exploring its use in oncology and rare disease indications. TARA-002 was developed from the
same master cell bank of genetically distinct group A <i style="font-family: Times New Roman, Times, Serif">Streptococcus pyogenes</i> as OK-432 (marketed as Picibanil&#174; in Japan and
Taiwan by Chugai Pharmaceutical). We are currently developing TARA-002 in non-muscle invasive bladder cancer, or NMIBC, and in LMs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our lead oncology program
is TARA-002 in NMIBC, which is cancer found in the tissue that lines the inner surface of the bladder that has not spread into the bladder
muscle. Bladder cancer is the sixth most common cancer in the United States, with NMIBC representing approximately 80% of bladder cancer
diagnoses. Approximately 65,000 patients are diagnosed with NMIBC in the United States each year. Very few new therapeutics have been
approved for NMIBC since the 1990s and the current standard of care for NMIBC includes intravesical Bacillus Calmette&#8211;Gu&#233;rin,
or BCG. The mechanism of action of TARA-002 is similar to that of BCG. TARA-002 and BCG are both intravesically administered, elicit
a Th1 type immune response and produce a locally-activated generally similar array of cytokines and immune cells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are conducting a Phase
1 dose-finding, open-label clinical trial to evaluate TARA-002 in treatment-na&#239;ve and treatment-experienced NMIBC patients with carcinoma
in situ, or CIS and high-grade papillary tumors (Ta), known as the ADVANCED-1 trial. In the initial dose escalation phase, or Phase 1a
portion of the trial, patients receive six weekly intravesical doses of TARA-002. The primary objective of the trial is to evaluate the
safety, tolerability and preliminary signs of anti-tumor activity of TARA-002, with the goal of establishing a recommended dose for a
future Phase 2 clinical trial. The trial is ongoing and we expect data from the Phase 1a portion of the trial in the second quarter of
2023. In addition, we continue to conduct pre-clinical studies on TARA-002 to better characterize the mechanism of action to help us understand
how TARA-002 may perform in potential combinations with other agents used to treat NMIBC. We use pre-clinical data to help us define other
cancer targets for TARA-002 both within the urothelial cancer space and other types of cancer affecting different parts of the body.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are also pursuing TARA-002
in LMs, which are rare, non-malignant cysts of the lymphatic vascular system that primarily form in the head and neck region of children
before the age of two. In July 2020, the FDA granted Rare Pediatric Disease designation for TARA-002 for the treatment of LMs and in May
2022 the European Medicines Agency granted orphan drug designation to TARA-002 for the treatment of LMs. In addition to the clinical experience
in Japan, we have secured the rights to a dataset from one of the largest ever conducted Phase 2 trials in LMs, in which OK-432 was administered
via a compassionate use program led by the University of Iowa to over 500 pediatric and adult patients. We have an IND for LMs with the
Vaccines and Related Products Division of the FDA, or Vaccines Division. The FDA continues to provide us with guidance regarding a development
path for TARA-002 in LMs. We received feedback from the Vaccines Division on the protocol for our proposed Phase 2 clinical trial evaluating
TARA-002 in LMs. In the second half of 2023 we expect to initiate this Phase 2 single arm, open-label clinical trial to evaluate the safety
and efficacy of TARA-002 in pediatric patients with macrocystic and mixed-cystic LMs. The trial design includes a safety lead-in phase
followed by an expansion phase. We are conducting trial preparation activities and have identified multiple trial sites.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The third development program
in our portfolio is intravenous, or IV, Choline Chloride, an investigational phospholipid substrate replacement therapy initially in development
for patients receiving parenteral nutrition, or PN, who have intestinal failure associated liver disease, or IFALD. IV Choline Chloride
has been granted Orphan Drug Designation by the FDA for this indication and has also been granted Fast Track Designation for the treatment
of IFALD. Following a positive end of Phase 2 meeting with the FDA, we received feedback on the design of the studies necessary to complete
a registration package for IV Choline Chloride for the treatment of IFALD, including a Phase 1 pharmacokinetic, or PK, trial and a Phase
3 clinical trial. Prior to initiating these clinical trials, we are conducting a prevalence study to enhance understanding of the PN patient
population and we plan to use this information to determine the next steps for the development program. In September 2021, we reported
results of the retrospective part of the prevalence study, which supported the significant unmet medical need in patients dependent on
PN who have IFALD. We are currently conducting the prospective part of the prevalence study, which is a multi-center, cross-sectional
observational study to assess the prevalence of choline deficiency, as well as cholestasis and steatosis, in patients dependent on PN.
We expect to have results of the study in the third quarter of 2023. In April 2022, the USPTO issued to us Patent No. US 11,311,503 claiming
a sterile aqueous choline salt composition with a term expiring in 2041.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have devoted substantial
efforts to the development of these programs and do not have any approved products and have not generated any revenue from product sales.
TARA-002 has not yet been approved for use for treatment of NMIBC, LMs or any other indications. We do not expect to generate revenues
in the near-term, if ever. To finance our current strategic plans, including the conduct of ongoing and future clinical trials and further
research and development costs, we will need to raise additional capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since inception, we have
incurred significant operating losses. As of December 31, 2022, we had an accumulated deficit of approximately $130.5 million. We expect
to continue to incur significant expenses and increasing operating losses for at least the next few years as we continue our development
of, and seek marketing approvals for, our product candidates, prepare for and begin the commercialization of any approved products, and
add infrastructure and personnel to support our product development efforts and operations as a public company in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a clinical-stage company,
our expenses and results of operations are likely to fluctuate significantly from quarter-to-quarter and year-to-year. We believe that
our period-to-period comparisons of our results of operations should not be relied upon as indicative of our future performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2022,
we had approximately $102.3 million in cash, cash equivalents, and marketable debt securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif">COVID-19 and Related Macroeconomic Conditions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The COVID-19 pandemic and
related macroeconomic conditions, such as supply chain shortages, inflation and economic volatility have, and may continue to have, an
impact on our results of operations. We will continue to monitor whether such conditions would have a material impact on our operations,
liquidity and capital resources. Further, rising inflation has, in part, caused a disruption in the capital markets, which may lead to
a recession or market correction that could impact our access to capital, and could in the future negatively affect our liquidity. A
recession or market correction, continued supply chain disruptions and/or inflation could materially affect our business and the value
of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif">Financial Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-indent: -8.35pt"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">Research and Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Research and development
expenses consist primarily of costs incurred for the development of TARA-002 and IV Choline Chloride, which include employee-related
expenses, including salaries, benefits, travel and stock-based compensation expense, expenses incurred under agreements with clinical
research organizations, or CROs, contract development and manufacturing organizations, or CDMOs, the cost of acquiring, developing and
manufacturing clinical trial materials, clinical and non-clinical related costs, costs associated with regulatory operations and facilities,
depreciation and other expenses, which include expenses for rent and maintenance of facilities and other supplies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-indent: -8.35pt"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">General and Administrative</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">General and administrative
expenses consist principally of employee-related expenses, including salaries, benefits, travel and stock-based compensation expense,
in executive and other administrative functions. Other general and administrative expenses also include professional fees for legal,
intellectual property matters, consulting and accounting services, facility related costs, as well as expenses related to audit, legal,
regulatory and tax-related services associated with maintaining compliance with our Nasdaq listing and SEC requirements, director and
officer liability insurance premiums and investor relations costs associated with being a public company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt; text-indent: -8.35pt"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">Other Income (Expense), net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Interest and investment
income consists of interest income on our cash, cash equivalents and marketable debt securities and amortization of investment premiums.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Critical Accounting Policies and Significant Judgments and Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our management&#8217;s discussion
and analysis of our financial position and results of operations is based on our financial statements, which have been prepared in accordance
with accounting principles generally accepted in the United States of America, or GAAP. The preparation of financial statements in conformity
with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying
notes. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable
under the circumstances. Actual results may differ materially from those estimates or assumptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">While our significant accounting
policies are described in more detail in the notes to our consolidated financial statements and related notes appearing elsewhere in
this Annual Report on 10-K, we believe the following accounting policies to be most critical to the judgments and estimates used in the
preparation of our financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">Goodwill</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 9, 2020, in connection
with the Merger, we separately valued the assets and liabilities acquired, and then determined goodwill as the residual of the purchase
price less identified net assets. The carrying value of goodwill was $0.0 million and $29.5 million at December&#160;31, 2022 and 2021,
respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Goodwill represents the
excess of purchase price over the fair value of identifiable net assets acquired in a business combination. Goodwill has an indefinite
useful life. Goodwill is assessed annually for impairment as of&#160;December 31, or more frequently if an event occurs or circumstances
change that would indicate that it is more likely than not that the fair value of a reporting unit or the fair value of an indefinite-lived
intangible asset has declined below its carrying value. In performing its annual goodwill impairment assessment, we have the option under
GAAP to qualitatively assess whether it is more likely than not that the fair value of a reporting unit is less than its carrying value;
if the conclusion of the qualitative assessment is that there are no indicators of impairment, then we would not perform a quantitative
assessment. Otherwise, a quantitative assessment is performed and the fair value of the reporting unit is determined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Goodwill is evaluated for
impairment at the reporting unit level, which is defined as an operating segment, or one level below an operating segment. We have determined
that we operate as one reporting unit and have selected December 31 as the date to perform our annual impairment test. As of December
31, 2022, we elected to forego the qualitative screen and performed a quantitative annual goodwill impairment test for our single reporting
unit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31,
2022, our stock price and market capitalization declined approximately 60% from December 31, 2021. Although we believe this decline reflects
the overall performance of similar life science companies with less than $250 million in market capitalizations, or microcap companies,
we do not believe it reflects the progress made in advancing our product candidate pipeline. The life sciences sector, which includes
pre-commercialization and therefore net operating loss generating companies, relies heavily on the capital markets to finance their operations
and fund pre-clinical and clinical trials for their existing development programs. As a result of a shift in risk appetite in the overall
financial markets, the availability of capital for life science companies decreased significantly in 2022. Industry reports highlight
a decline of more than 50 percent in both the number of healthcare follow-on financings as well as the amount of capital raised in 2022
compared to 2021. These challenging financing conditions had a significantly negative impact on stock prices and respective market capitalizations,
particularly for microcap companies. We consider the heightened financing risk that impacted the life sciences sector during 2022 to be
one of the key macroeconomic factors that led to a sustained decrease in our stock price and market capitalization leading up to our annual
goodwill impairment assessment date in late 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The fair value of our reporting
unit was determined using an income approach based on discounted cash flows, or DCF, as we elected to forgo the qualitative screen. Determining
fair value using a DCF analysis requires the exercise of significant judgment with respect to several assumptions and estimates, including
the amount and timing of expected future cash flows and appropriate discount rate to be applied. The expected cash flows used in the DCF
analyses are based on our most recent internal long-range forecast and budget and, for years beyond the budget, our estimates, which are
based, in part, on industry benchmarks and forecasted growth rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The discount rate used in
the DCF analysis is intended to reflect the risks inherent in the expected future cash flows of the respective programs within our portfolio.
Assumptions used in the DCF analysis, including the discount rate, are assessed based on our current results and forecasted future performance,
as well as macroeconomic and industry specific factors, including the aforementioned market factors influenced by financing risk discussed
above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; ">We determined the </span>estimated
fair value of our single reporting unit by utilizing a discount rate of 36%, which reflects these market factors. Based upon this discount
rate, the fair value of our single reporting unit was below its carrying value by an amount greater than the carrying value of goodwill,
and we recorded an impairment charge of $29.5 million in the fourth quarter of 2022 to fully write off the goodwill. &#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">Income Taxes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deferred tax assets and
liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying
amounts of existing assets and liabilities and their respective tax basis, operating loss and tax credit carryforwards. Deferred tax
assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected
to be recovered or settled. The measurement of net deferred tax assets is reduced by the amount of any tax benefit that, based on available
evidence, is not expected to be realized, and a corresponding valuation allowance is established.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Tax benefits are recognized
only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured
as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for &#8220;unrecognized
tax benefits&#8221; is recorded for any tax benefits claimed in our tax returns that do not meet these recognition and measurement standards.
As of December 31, 2022 and 2021, no liability for unrecognized tax benefits was required to be recorded. Our policy is to record interest
and penalties on uncertain tax positions as a component of income tax expense. No interest or penalties were recorded during the years
ended December 31, 2022 and 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif">Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">Comparison of the Years Ended December
31, 2022 and 2021</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
our results of operations for the years ended December 31, 2022 and 2021(in thousands):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Period -to-<br/> Period</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 9pt">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,808</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21,088</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,280</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,401</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,664</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Loss on impairment of goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,517</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,517</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">67,062</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47,489</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,573</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(67,062</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47,489</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,573</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income (expense), net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Interest and investment income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,110</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">873</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Other income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,110</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">873</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(65,952</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(47,252</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(18,700</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i style="font-family: Times New Roman, Times, Serif">Research and Development
Expenses</i>. During the year ended December 31, 2022, our research and development expenses were approximately $16.8 million which represented
a decrease of approximately $4.3 million as compared to the year ended December 31, 2021. This decrease was primarily due to a decrease
of $2.3 million for clinical manufacturing activities associated with TARA-002 due to higher production costs in 2021 as we were preparing
for clinical trials, a decrease of $1.5 million of non-clinical and regulatory expenses associated with TARA-002, and a decrease of $1.4
million in clinical manufacturing expenses associated with the prospective IV Choline Chloride study. This was partially offset by an
increase of $1.2 million of clinical expenses associated with TARA-002.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i style="font-family: Times New Roman, Times, Serif">General and Administrative
Expenses.</i> During the year ended December 31, 2022, our general and administrative expenses were approximately $20.7 million which
represented a decrease of approximately $5.6 million as compared to the year ended December 31, 2021. The decrease was primarily due to
a decrease of $3.8 million in stock-based compensation and a decrease of $1.8 million in expenses related to a reduction in market development
activities.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i style="font-family: Times New Roman, Times, Serif">Loss on impairment of
goodwill.</i> During the year ended December 31, 2022, we recorded a non-cash impairment charge of $29.5 million. There was no impairment
charge during the year ended December 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i style="font-family: Times New Roman, Times, Serif">Other Income (Expense),
Net</i>. During the year ended December 31, 2022, interest and investment income was approximately $1.1 million which represented an
increase of approximately $0.9 million as compared to the year ended December 31, 2021. The increase was due to an increase of $0.9 in
interest earned on investments in marketable debt securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif">Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">Overview</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2022 and
2021, our cash, cash equivalents, and marketable debt securities were $102.3 million and $130.7 million, respectively. We have not generated
revenues since our inception and have incurred net losses of approximately $66.0 million and $47.3 million for the years ended December
31, 2022 and 2021, respectively. As of December 31, 2022, we had working capital of approximately $80.4 million and stockholder&#8217;s
equity of approximately $102.1 million. During the year ended December 31, 2022, cash flows used in operating activities were approximately
$26.5 million, consisting primarily of a net loss of approximately $66.0 million, which includes non-cash activities such as approximately
$29.5 million in impairment loss on goodwill and $6.7 million in stock-based compensation charges. Since inception, we have met our liquidity
requirements principally through the sale of our common stock and preferred stock in private placements and underwritten offerings.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">Liquidity</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December 2020, we filed
a shelf registration statement on Form S-3, or the Shelf Registration Statement, which became effective in December 2020. The Shelf Registration
Statement permits: (i) the offering, issuance and sale by us of up to a maximum aggregate offering price of $300.0 million of common
stock, preferred stock, debt securities and warrants in one or more offerings and in any combination. No securities have been sold to
date under the Shelf Registration Statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are in the business of
developing biopharmaceuticals and have no current or near-term revenues. We have incurred substantial clinical and other costs in our
drug development efforts. We will need to raise additional capital in order to fully realize management&#8217;s plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe that our current
financial resources, as of the date of the issuance of our consolidated financial statements included elsewhere in this Annual Report
on Form 10-K, are sufficient to satisfy our estimated liquidity needs for at least twelve months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a result of volatility
in the capital markets, economic conditions, general global economic uncertainty, political change, global pandemics, and other factors,
we do not know whether additional capital will be available when needed, or that, if available, we will be able to obtain additional
capital on reasonable terms. If we are unable to raise additional capital due to the volatile global financial markets, general economic
uncertainty or other factors, we may need to curtail planned development activities. Specifically, rising inflation, which is in part,
tied to the impacts of the COVID-19 pandemic and resulting supply chain disruptions, has, in part, caused a disruption in the capital
markets, which may lead to a recession or market correction that could impact our access to capital, and could in the future negatively
affect our liquidity. A recession or market correction, continued supply chain disruptions and/or inflation could materially affect our
business and the value of our common stock. Further, recent rises in interest rates have had and may continue to have a negative effect
on market prices for common stock of pharmaceutical companies that have no current or near-term revenue. Further increases in interest
rates, which have been implemented and may be further implemented to counteract inflationary pressures, may continue to exacerbate this
issue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">Cash Flows</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
our sources and uses of cash for the years ended December 31, 2022 and 2021 (in thousands):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Period-to-<br/>
    Period</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(26,457</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(34,502</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,045</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net cash provided by/(used in) investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(98,194</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">113,144</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by/(used in) financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(90</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(228</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">138</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net increase/(decrease) in cash and cash equivalents, and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,597</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(132,924</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">121,327</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">Comparison of the Years Ended December
31, 2022 and 2021</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Net cash used in operating
activities was approximately $26.5 million for the year ended December 31, 2022 compared to approximately $34.5 million for the year ended
December 31, 2021. The decrease in cash used in operating activities of approximately $8.0 million was primarily driven by a decrease
in net loss of approximately $18.7 million, which was partially offset by a $3.8 million decrease in non-cash items including stock-based
compensation, right-of-use asset, and amortization of premium on marketable debt securities. There was an increase in working capital
of $1.1 million, primarily related to changes in prepaid expenses and other current assets, accounts payable, and accrued expenses resulting
from the timing of payments to our service providers.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Net cash provided by investing
activities was approximately $15.0 million for the year ended December 31, 2022 compared to net cash used in investing activities of
approximately $98.2 million for the year ended December 31, 2021. The change of $113.1 million resulted primarily from purchase of marketable
debt securities of $43.6 million for the year ended December 31, 2022 as compared to $124.7 million for the year ended December 31, 2021
and from proceeds from maturity and redemption of marketable debt securities of $58.6 million for the year ended December 31, 2022 as
compared to $27.2 million for the year ended December 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Net cash used in financing
activities was approximately $0.1 million for the year ended December 31, 2022 compared to net cash provided by financing activities
of $0.2 million for the year ended December 31, 2021. The decrease of approximately $0.1 million was driven by the reduction in stock
price of the shares repurchased in connection with the settlement of restricted stock units for the year ended December 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">Contractual and Other Obligations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">Operating lease obligations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our operating lease obligations
primarily consist of lease payments on our corporate headquarters in New York, New York, as well as lease payments for our development
laboratory, a manufacturing facility and an additional manufacturing space, all located in North America which are described in further
detail in Note 8 of our consolidated financial statements included in this Annual Report on Form 10-K. Future contractual payments on
operating lease obligations due within one year of December 31, 2022 are $1.3 million, and future contractual payments on operating lease
obligations due greater than one year from December 31, 2022 are $6.4 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">Other obligations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">From time to time, we enter
into certain types of contracts that contingently require us to indemnify parties against third-party claims, supply agreements, and
agreements with directors and officers. The terms of such obligations vary by contract and in most instances a maximum dollar amount
is not explicitly stated therein. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted,
thus no liabilities have been recorded for these obligations on our consolidated balance sheet for the periods presented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We enter into contracts
in the normal course of business with CROs and clinical sites for the conduct of clinical trials, non-clinical research studies, professional
consultants for expert advice and other vendors for clinical supply manufacturing or other services. These contracts generally provide
for termination on notice, and therefore are cancelable contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain of these agreements
require us to pay milestones to such third parties upon achievement of certain development, regulatory or commercial milestones as further
described in Note 8 of our consolidated financial statements included in this Annual Report on Form 10-K. Amounts related to contingent
milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development,
regulatory approval and commercial milestones, which may not be achieved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We also have obligations
to make future payments to third parties that become due and payable on the achievement of certain milestones, including future payments
to third parties with whom we have entered into research, development and commercialization agreements. We have not included these commitments
on our consolidated balance sheet for the periods presented because the achievement and timing of these milestones is not fixed and determinable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 7A. Quantitative and Qualitative Disclosures About Market
Risk<i style="font-family: Times New Roman, Times, Serif">.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No disclosure required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 8. Financial Statements and Supplementary Data.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated financial
statements required pursuant to this item are included in Item 15 of this Annual Report on Form 10-K and are presented beginning on page
F-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 9. Changes in and Disagreements With Accountants on Accounting
and Financial Disclosure.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 9A. Controls and Procedures.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="font-family: Times New Roman, Times, Serif">Disclosure Controls and Procedures</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We maintain disclosure controls
and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act) that are designed to ensure that information required
to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized, and reported within
the time periods specified in the SEC&#8217;s rules and forms and (2) accumulated and communicated to our management, including our principal
executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2022,
our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness
of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Our management recognizes
that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their
objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of
December 31, 2022, our disclosure controls and procedures were effective at the reasonable assurance level.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We continue to review and
document our disclosure controls and procedures, including our internal controls and procedures for financial reporting, and may from
time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="font-family: Times New Roman, Times, Serif">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="font-family: Times New Roman, Times, Serif">Management&#8217;s Annual Report on Internal
Control Over Financial Reporting</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process
designed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial
Officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with accounting principles generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2022,
our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee
of Sponsoring Organizations of the Treadway Commission, or COSO, in Internal Control-Integrated Framework (2017). Based on this assessment,
management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, concluded that,
as of December 31, 2022, our internal control over financial reporting was effective based on those criteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="font-family: Times New Roman, Times, Serif">Changes in Internal Control Over Financial
Reporting</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An evaluation was performed
under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer,
of any changes in our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change
in our internal control over financial reporting, as such term is defined in Rules 13a-15 and 15(d)-15 promulgated under the Exchange
Act, that occurred during our latest fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our
internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 9B. Other Information.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent
Inspections.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif">PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 10. Directors, Executive Officers and Corporate Governance.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The information required
by this Item and not set forth below will be set forth in the section headed &#8220;&#8212;Election of Directors&#8221; and &#8220;Information
Regarding the Board of Directors and Corporate Governance&#8221; in our definitive Proxy Statement for our 2022 Annual Meeting of Stockholders
to be filed with the SEC on or before May 2, 2023 (our &#8220;<b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">Proxy Statement</i></b>&#8221;) and is incorporated in this report
by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have adopted a code of
ethics for directors, officers (including our principal executive officer, principal financial officer and principal accounting officer)
and employees, known as the Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics is available on our website
at <i style="font-family: Times New Roman, Times, Serif">http://www.protaratx.com</i> under the Corporate Governance section of our Investors page. We will promptly disclose on our website
(i) the nature of any amendment to the policy that applies to our principal executive officer, principal financial officer, principal
accounting officer or controller, or persons performing similar functions and (ii) the nature of any waiver, including an implicit waiver,
from a provision of the policy that is granted to one of these specified individuals, the name of such person who is granted the waiver
and the date of the waiver. Stockholders may request a free copy of the Code of Business Conduct and Ethics by emailing info@protaratx.com.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 11. Executive Compensation.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The information required
by this Item will be set forth in the section headed &#8220;<i style="font-family: Times New Roman, Times, Serif">Executive Compensation</i>&#8221; in our Proxy Statement and is incorporated
in this report by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 12. Security Ownership of Certain Beneficial Owners and Management
and Related Stockholder Matters.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The information required
by this Item will be set forth in the section headed &#8220;<i style="font-family: Times New Roman, Times, Serif">Security Ownership of Certain Beneficial Owners and Management</i>&#8221;
in our Proxy Statement and is incorporated in this report by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Information regarding our
equity compensation plans will be set forth in the section headed &#8220;<i style="font-family: Times New Roman, Times, Serif">Executive Compensation</i>&#8221; in our Proxy Statement
and is incorporated in this report by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 13. Certain Relationships and Related Transactions, and Director
Independence.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The information required
by this Item will be set forth in the section headed &#8220;<i style="font-family: Times New Roman, Times, Serif">Transactions with Related Persons</i>&#8221; in our Proxy Statement and
is incorporated in this report by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 14. Principal Accountant Fees and Services.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The information required
by this Item will be set forth in the section headed &#8220;<i style="font-family: Times New Roman, Times, Serif">&#8212;Ratification of Selection of Independent Registered Public Accounting
Firm</i>&#8221; in our Proxy Statement and is incorporated in this report by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="a_023a"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b style="font-family: Times New Roman, Times, Serif">PART IV</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="a_023b"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 15. Exhibits and Financial Statement Schedules.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i style="font-family: Times New Roman, Times, Serif">(a) Documents filed as
part of this report.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">1. The following financial
statements of Protara Therapeutics, Inc. and Report of Ernst &amp; Young LLP, Independent Register Public Accounting Firm, are included
in this report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 88%">&#160;</td>
    <td style="width: 12%">
    <p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b style="font-family: Times New Roman, Times, Serif">Page Number</b></p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_001">Report of Independent Registered Public Accounting Firm (PCAOB ID:42)</a> </span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_002">Consolidated Balance Sheets</a> </span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_003">Consolidated Statements of Operations and Comprehensive Loss</a>&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_004">Consolidated Statements of Changes in Stockholders&#8217; Equity</a> </span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_005">Consolidated Statements of Cash Flows</a> </span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_006">Notes to Consolidated Financial Statements</a> </span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2. List of financial statement
schedules:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All schedules have been omitted
because they are not applicable or the required information is shown in the financial statements or notes thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3. List of Exhibits required
by Item 601 of Regulation S-K. See part (b) below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i style="font-family: Times New Roman, Times, Serif">(b) Exhibits.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Exhibit
    No.</b></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000104746919005409/a2239754zex-2_1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement
    and Plan of Merger and Reorganization, dated September 23, 2019, by and among the Registrant, ArTara Therapeutics, Inc. and REM 1
    Acquisition, Inc. (filed as Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K as filed on September 24, 2019, and
    incorporated herein by reference).</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000104746919006649/a2240114zex-2_2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    No. 1 to Agreement and Plan of Merger and Reorganization, dated November 19, 2019, by and among the Registrant, ArTara Therapeutics,
    Inc. and REM 1 Acquisition, Inc. (filed as Exhibit 2.2 to the Registrant&#8217;s Registration Statement on Amendment No. 2 to Form
    S-4 as filed on December 4, 2019, and incorporated herein by reference).</span></a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000110465914074038/a14-15225_12ex3d1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sixth
    Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company&#8217;s
    Current Report on Form 8-K filed on October 27, 2014).</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    of Amendment to the Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s
    Current Report on Form 8-K, filed with the SEC on January 10, 2020).</span></a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000121390020011893/f10q0320ex3-3_artara.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    Certificate of Amendment to the Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3
    to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on May 13, 2020).</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex3-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    of Designation of Preferences, Rights and Limitations of Series 1 Convertible Preferred Stock (incorporated by reference to Exhibit
    3.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 10, 2020).</span></a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000121390020027951/ea127215ex3-1_protara.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series 1 Convertible Non-Voting Preferred
    Stock (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on September
    23, 2020).</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">3.6+</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><a href="f10k2022ex3-6_protarathera.htm"><span style="font-family: Times New Roman, Times, Serif">Composite Amended and Restated Certificate of Incorporation of the Registrant</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000117184317004634/exh_32.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 of Current Report on Form 8-K, filed on August 3, 2017).</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed
    with the SEC on January 10, 2020).</span></a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">4.2</span></p></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000121390021014709/f10k2020ex4-2_protara.htm"><span style="font-family: Times New Roman, Times, Serif">Description of securities registered under Section 12 of the Exchange Act of 1934 (incorporated by reference to Exhibit 4.2 of the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 11, 2021).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000104746919005409/a2239754zex-10_5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
    Rights Agreement, dated as of September 23, 2019, by and among the Registrant and the institutional investors named therein (incorporated
    by reference to Exhibit 10.5 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on September 24, 2019).</span></a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&#8224;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000104746914008146/a2221509zex-10_1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2006
    Equity Incentive Plan, as amended and restated August 21, 2014 (incorporated by reference to Exhibit 10.1 to Amendment No. 1 to the
    Company&#8217;s Registration Statement on Form S-1 filed on October 7, 2014 (File No. 333-198777)).</span></a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&#8224;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000104746914007662/a2221427zex-10_16.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Stock Option Grant Notice and Stock Option Agreement under the Company&#8217;s 2006 Equity Incentive Plan, as amended (incorporated
    by reference to Exhibit 10.16 to the Company&#8217;s Registration Statement on Form S-1 filed on September 16, 2014).</span></a></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000104746914007662/a2221427zex-10_11.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment
    of Rights/License Agreement, effective as of February 4, 2002, by and between Johns Hopkins University and F. Nicholas Franano (incorporated
    by reference to Exhibit 10.11 to the Company&#8217;s Registration Statement on Form S-1 filed on September 16, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000104746914007662/a2221427zex-10_14.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter
    Agreement, dated January 12, 2009, by and between F. Nicholas Franano and the Company (as successor-in-interest to Proteon Therapeutics,
    L.L.C.) (incorporated by reference to Exhibit 10.14 to the Company&#8217;s Registration Statement on Form S-1 filed on September
    16, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000104746914008146/a2221509zex-10_25.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014
    Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.25 to Amendment No. 1 to the Company&#8217;s Registration Statement
    on Form S-1 filed on October 7, 2014).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6**</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000104746919005409/a2239754zex-10_4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
    Agreement, dated September 23, 2019, by and among the Registrant and the institutional investors named therein (incorporated by reference
    to Exhibit 10.4 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on September 24, 2019).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7**</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000104746919006649/a2240114zex-99_12.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Amendment to Subscription Agreement, dated November 19, 2019, by and among the Registrant and the institutional investors named therein
    (incorporated by reference to Exhibit 99.12 to the Registrant&#8217;s Registration Statement on Form S-4).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
    and Restated 2014 Equity Incentive Plan of the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current
    Report on Form 8-K, filed on January 10, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000117184320001860/exh_1025.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forms
    of Stock Option Agreement, Option Exercise, Restricted Stock Unit Grant and Restricted Stock Unit Agreement under the Amended and
    Restated 2014 Equity Incentive Plan of the Registrant, as amended (incorporated by reference to Exhibit 10.25 to the Registrant&#8217;s
    Annual Report on Form 10-K on form 10-K for the fiscal year ended December 31, 2019 filed on March 20, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-11.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2017
    Equity Incentive Plan of ArTara Subsidiary, Inc. (incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Current Report
    on Form 8-K, filed with the SEC on January 10, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000121390020008073/ea120117ex10-1_artaratherap.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inducement
    Plan of the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with
    the SEC on March 30, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000121390020008073/ea120117ex10-2_artaratherap.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Stock Option Grant Notice and Stock Option Agreement under the Inducement Plan of the Registrant (incorporated by reference to
    Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on March 30, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000121390020008073/ea120117ex10-3_artaratherap.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forms
    of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Inducement Plan of the Registrant (incorporated
    by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on March 30, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Employment Agreement, dated as of November 5, 2019, as amended on December 4, 2019, by and between ArTara Subsidiary, Inc. and Jesse
    Shefferman. (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on
    January 10, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Employment Agreement, dated as of December 17, 2019, by and between ArTara Subsidiary, Inc. and Jacqueline Zummo, Ph.D., MPH, MBA.
    (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 10,
    2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000121390022024238/f10q0322ex10-2_protara.htm">Executive Employment Agreement, effective as of January 10, 2022, by and between the Registrant and Jathin Bandari, M.D. (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on May 5, 2022).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.17&#8224;+    </td><td>&#160;</td>
    <td style="text-align: justify"><a href="f10k2022ex10-17_protarathera.htm">Executive Employment Agreement, effective as of January 30, 2023 by and between the Registrant and Patrick Fabbio.</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18&#8224;&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Choline
    License Agreement, by and between ArTara Subsidiary, Inc. and Alan L. Buchman, M.D. dated as of September 27, 2017. (incorporated
    by reference to Exhibit 10.4 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 10, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19&#8224;&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-5.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsored
    Research and License Agreement, by and between ArTara Subsidiary, Inc. and The University of Iowa dated as of November 28, 2018.
    (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 10,
    2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20&#8224;&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-6.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    Agreement, by and between ArTara Subsidiary, Inc. and The Feinstein Institute for Medical Research dated as of December 22, 2017.
    (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 10,
    2020).</span></a></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21 &#8224;&#8224; </span></td>
    <td style="width: 1%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="width: 90%; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-7.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement,
    by and between ArTara Subsidiary, Inc. and Chugai Pharmaceutical Co., Ltd. dated as of June 17, 2019. (incorporated by reference
    to Exhibit 10.7 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 10, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22 &#8224;&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1359931/000121390020036343/f10q0920ex10-1_protara.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    to Agreement, by and between Chugai Pharmaceutical Co., Ltd. and the Registrant, dated as of July 14, 2020 and effective as of June
    30, 2020 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on
    November 12, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23 &#8224; </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1359931/000110465920003115/tm201618d1_ex10-8.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Indemnity Agreement between the Registrant and each of its directors and officers. (incorporated by reference to Exhibit 10.8
    to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 10, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24 &#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000121390022024238/f10q0322ex10-1_protara.htm">Restated Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q, filed with the SEC on May 5, 2022).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25 &#8224;&#8224; **</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000121390021014709/f10k2020ex10-25_protara.htm">Lease by and between 345 PAS HOLDING LLC, and the Registrant, dated as of December 7, 2020. <span style="text-decoration:underline;font-family: Times New Roman, Times, Serif">(incorporated by reference to Exhibit 10.25 to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 11, 2021)</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26 &#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1359931/000121390021053303/ea149033ex10-1_protarathera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting
    Agreement, dated as of October 16, 2021, by and between the Company and Mart&#237;n Sebastian Olivo, M.D. (incorporated by reference
    to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on October 18, 2021).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27 &#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1359931/000121390021053303/ea149033ex10-2_protarathera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separation
    Agreement and Release, dated as of October 15, 2021, by and between the Company and Mart&#237;n Sebastian Olivo, M.D. (incorporated
    by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on October 18, 2021.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.28&#8224;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000117184320001860/exh_1030.htm">Executive Employment Agreement, effective as of February 11, 2020 by and between the Registrant and Blaine Davis (incorporated by reference to Exhibit 10.30 to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 19, 2020).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.29&#8224;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1359931/000121390022033756/ea161829ex10-1_protara.htm">Separation Agreement and Release, dated as of June 20, 2022, by and between the Registrant and Blaine Davis (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on June 21, 2022).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1 +</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2022ex21-1_protarathera.htm">List of Subsidiaries.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1 + </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f10k2022ex23-1_protarathera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Ernst &amp; Young LLP, independent registered public accounting firm.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1 + </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_025signatures">Power of Attorney (Included in signature pages)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1 + </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f10k2022ex31-1_protarathera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2 + </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f10k2022ex31-2_protarathera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1 + </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f10k2022ex32-1_protarathera.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Officer Certification and Principal Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101 *</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interactive Data Files
    Pursuant to Rule 405 of Regulation S-T: (i) the Consolidated Balance Sheets as of December 31, 2020 and 2019; (ii) the Consolidated
    Statements of Operations for the years ended December 31, 2020 and 2019; (iii) the Consolidated Statements of Changes in Stockholders&#8217;
    Equity (Deficit) for the years ended December 31, 2020 and 2019; (iv) the Consolidated Statements of Cash Flows for the years ended
    December 31, 2020 and 2019; and (v) the notes to the Consolidated Financial Statements.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS *</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH *</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension
    Schema Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL *</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension
    Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF *</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension
    Definition Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB *</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension
    Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE *</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension
    Presentation Linkbase Document.</span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File
    (embedded within the Inline XBRL document)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup style="font-family: Times New Roman, Times, Serif">+</sup></span></td>
    <td style="width: 95%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules have been omitted
    pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedules will be furnished to the SEC upon request.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates management contract or compensatory plan
    or arrangement.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;&#8224;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain portions of this
    exhibit (indicated by &#8220;[***]&#8221;) have been omitted as the Registrant has determined (i) the omitted information is not
    material and (ii) the omitted information is of the type the Registrant customarily and actually treats as private or confidential.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x5e;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain exhibits and schedules
    have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant hereby undertakes to furnish supplementally a copy
    of any omitted exhibit or schedule upon request by the SEC. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Item 16. Form 10-K Summary.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_025signatures"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif">SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of Section 13 or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 60%">&#160;</td>
    <td style="vertical-align: bottom; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protara
    Therapeutics, Inc.</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 8, 2023</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
JESSE SHEFFERMAN</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Jesse Shefferman</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">President and Chief Executive Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(on behalf of the registrant and as the registrant&#8217;s
    Principal Executive&#160;Officer)</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 8, 2023</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    PATRICK FABBIO</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Patrick Fabbio</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Financial Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(on behalf of the registrant and as the registrant&#8217;s
    Principal Financial Officer)</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">KNOW ALL PERSONS BY THESE
PRESENTS, that each individual whose signature appears below constitutes and appoints Jesse Shefferman and Patrick Fabbio his or her
true and lawful attorney-in-fact and agent with full power of substitution, for him or her and in his or her name, place and stead, in
any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto
and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent,
full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises,
as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact
and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and
in the capacities and on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 31%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Signature</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 41%"><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif">Title</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 26%"><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif">Date</b></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    JESSE SHEFFERMAN</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive
    Officer and Director<br/> </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 8, 2023</span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jesse
    Shefferman</span></td>
    <td>&#160;</td>
    <td style="text-align: center; vertical-align: top">(Principal Executive Officer)</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    PATRICK FABBIO</span></td>
    <td>&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Financial Officer</p></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 8, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick Fabbio</span></td>
    <td>&#160;</td>
    <td style="text-align: center">(Principal Financial
Officer)</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ HANNAH FRY</p></td>
    <td>&#160;</td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Vice President, Controller</p></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 8, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hannah Fry</span></td>
    <td>&#160;</td>
    <td style="text-align: center">(Principal Accounting
Officer)</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td>&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;/s/
    LUKE BESHAR</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of
    Directors</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 8, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Luke Beshar</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    BARRY FLANNELLY, PHARM.D. </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 8, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Barry Flannelly, Pharm.D.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    ROGER GARCEAU, M.D.</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 8, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roger Garceau, M.D.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    JANE HUANG, M.D.</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 8, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jane Huang, M.D.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">/s/ RICHARD
    LEVY, M.D.</p></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 8, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Levy, M.D.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">/s/ GREGORY
    P. SARGEN</p></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 8, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregory P. Sargen</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    CYNTHIA SMITH</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 8, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cynthia Smith</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><p style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">/s/ MICHAEL
    SOLOMON, PH.D.</p></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 8, 2023</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Solomon, Ph.D.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b style="font-family: Times New Roman, Times, Serif">Protara Therapeutics,
Inc.<br/>
Index to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="padding-bottom: 1.5pt; width: 90%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Protara Therapeutics, Inc. for the Years Ended December 31, 2022 and 2021</b></span></td> <td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Page No.</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_001">Report of Independent Registered Public Accounting Firm (PCAOB ID:<ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId">42</ix:nonNumeric>)</a></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr> <tr style="vertical-align: top; "> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_002">Consolidated Balance Sheets as of December 31, 2022 and 2021</a></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_003">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2022 and 2021</a></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr> <tr style="vertical-align: top; "> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_004">Consolidated Statements of Changes in Stockholders&#8217; Equity for the Years Ended December 31, 2022 and 2021</a></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_005">Consolidated Statements of Cash Flows for the Years Ended December 31, 2022 and 2021</a></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr> <tr style="vertical-align: top; "> <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin_006">Notes to Consolidated Financial Statements</a></span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 76; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><div><a id="fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif">Report of Independent Registered Public Accounting
Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Stockholders and the Board of Directors of Protara Therapeutics,
Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">We have audited the accompanying consolidated
balance sheets of Protara Therapeutics, Inc. (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related consolidated statements
of operations and comprehensive loss, changes in stockholders&#8217; deficit and cash flows for each of the two years ended December 31,
2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021,
and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with
U.S. generally accepted accounting principles.</p><div>
</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="font-family: Times New Roman, Times, Serif">Critical Audit Matter</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The critical audit matter communicated below
is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to
the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our
especially challenging, subjective or complex judgments. The communication of critical audit matter does not alter in any way our opinion
on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing
a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 23%; padding-right: 16.5pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">&#160;</td>
    <td style="width: 77%; padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif"><i style="font-family: Times New Roman, Times, Serif">Valuation of Goodwill</i></b>&#160;&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif">Description of the Matter</i></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As discussed in Note 2 to the consolidated financial
    statements, goodwill is assessed annually for impairment as of December 31, or more frequently if an event occurs or circumstances change
    that would indicate that it is more likely than not that the fair value of a reporting unit has declined below its carrying value. As
    a result of the annual impairment test, the Company determined the estimated fair value of the reporting unit was less than the carrying
    value and recorded a non-cash goodwill impairment expense in the statements of operations and comprehensive loss of $29.5 million.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Auditing the Company&#8217;s quantitative impairment
    test for goodwill was especially complex and judgmental due to the significant estimation required in determining the fair value of the
    reporting unit. In particular, the fair value estimate was sensitive to the significant assumptions that require judgment including the
    amount and timing of expected future cash flows and the related discount rate. These assumptions are affected by such factors as expected
    future market or economic conditions and clinical trial and regulatory events.</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif">How We Addressed the Matter in Our Audit</i></span></td>
    <td style="padding-right: 5.4pt; padding-bottom: 8pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To test the estimated fair value of the reporting unit, our audit procedures included, among others, assessing the valuation methodology, evaluating the significant assumptions used to develop the projected financial information, and testing the underlying data used by the Company in its analysis. For example, we compared the projected financial information developed by management to current industry benchmarks and economic trends and evaluated the expected impacts of the Company&#8217;s ongoing operating strategies to develop its portfolio of therapies on the significant assumptions. We performed sensitivity analyses of the significant assumptions to evaluate the change in the fair value of the reporting unit resulting from changes in the assumptions. We also considered the relationship between the fair value of the reporting unit to the market capitalization of the Company. In addition, we involved our internal valuation specialists to assist in evaluating the methodology and significant assumptions applied in developing the fair value estimate.&#160;&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName">Ernst&#160;&amp; Young LLP</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation">New York, New York</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 8, 2023</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif">Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-family: Times New Roman, Times, Serif">Consolidated Balance Sheets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i style="font-family: Times New Roman, Times, Serif">(in thousands, except share and per share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">24,127</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">35,724</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd">60,243</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd">55,505</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,776</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,883</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">86,146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">93,112</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Restricted cash, non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd">745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd">745</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Marketable debt securities, non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd">17,886</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd">39,467</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">1,592</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">1,719</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">6,277</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">7,171</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" unitRef="usd">29,517</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd">644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd">865</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 27pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">113,290</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">172,596</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd">1,586</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd">954</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd">3,237</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd">2,489</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">917</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">855</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">5,740</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">4,298</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Operating lease liability, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">5,467</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">6,384</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">11,207</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">10,682</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Commitments and contingencies (Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Preferred stock, $0.001 par value, authorized 10,000,000 shares:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt"><div style="-sec-ix-hidden: hidden-fact-8; -sec-ix-hidden: hidden-fact-7; -sec-ix-hidden: hidden-fact-6; -sec-ix-hidden: hidden-fact-5">Series 1 convertible preferred stock, <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">8,028</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2022 and 2021, respectively <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">8,027</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2022 and 2021, respectively.</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Common stock, $0.001 par value, authorized 100,000,000 shares:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt"><div style="-sec-ix-hidden: hidden-fact-12; -sec-ix-hidden: hidden-fact-11; -sec-ix-hidden: hidden-fact-10; -sec-ix-hidden: hidden-fact-9">Common stock, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">11,267,389</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">11,235,731</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2022 and 2021, respectively.</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">262,724</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">256,126</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">159,964</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">94,012</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated other comprehensive income (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd">688</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd">211</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">102,083</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">161,914</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 27pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">113,290</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">172,596</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><b style="font-family: Times New Roman, Times, Serif">Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><b style="font-family: Times New Roman, Times, Serif">Consolidated Statements of Operations
and Comprehensive Loss</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><i style="font-family: Times New Roman, Times, Serif">(in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating expenses:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">16,808</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">21,088</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">20,737</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">26,401</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Loss on impairment of goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" unitRef="usd">29,517</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">67,062</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">47,489</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">67,062</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">47,489</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other income (expense), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Interest and investment income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd">1,110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">1,110</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">65,952</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">47,252</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-15; -sec-ix-hidden: hidden-fact-14">Net loss per share attributable to common stockholders, basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">5.86</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">4.21</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"><div style="-sec-ix-hidden: hidden-fact-17; -sec-ix-hidden: hidden-fact-16">Weighted average shares outstanding, basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">11,259,615</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">11,232,576</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other comprehensive income (loss):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Net unrealized (loss) gain on marketable debt securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd">477</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd">211</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other comprehensive income (loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd">477</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd">211</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Comprehensive Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd">66,429</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd">47,463</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><b style="font-family: Times New Roman, Times, Serif">Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><b style="font-family: Times New Roman, Times, Serif">Consolidated Statements of Changes
in Stockholders&#8217; Equity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><i style="font-family: Times New Roman, Times, Serif">(in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Series 1 Convertible<br/>
Preferred Stock</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Common Stock</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Additional<br/>
Paid-in</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Accumulated</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Accumulated<br/>
Other<br/>
Comprehensive</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Total<br/>
Stockholders&#8217;</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Shares</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Amount</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Shares</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Amount</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Capital</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Deficit</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Loss</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Equity</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 20%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2020</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">8,027</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-18; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">11,211,840</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">11</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">245,992</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">46,760</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-19; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">199,243</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement of restricted stock units</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-20; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="tara:SettlementOfRestrictedStockUnitinShares" scale="0" unitRef="shares">23,891</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-21; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="tara:SettlementOfRestrictedStockUnits" scale="3" sign="-" unitRef="usd">228</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-22; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="tara:SettlementOfRestrictedStockUnits" scale="3" sign="-" unitRef="usd">228</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation - restricted stock units</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">4,520</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">4,520</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation - stock options</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">5,842</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">5,842</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other comprehensive loss</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-28; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" sign="-" unitRef="usd">211</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" sign="-" unitRef="usd">211</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">47,252</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">47,252</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2021</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">8,027</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">11,235,731</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">11</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">256,126</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">94,012</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">211</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">161,914</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement of restricted stock units</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="tara:SettlementOfRestrictedStockUnitinShares" scale="0" unitRef="shares">31,658</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="tara:SettlementOfRestrictedStockUnits" scale="3" sign="-" unitRef="usd">90</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tara:SettlementOfRestrictedStockUnits" scale="3" sign="-" unitRef="usd">90</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation - restricted stock units</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">1,273</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd">1,273</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation - stock options</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">5,415</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">5,415</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other comprehensive loss</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" sign="-" unitRef="usd">477</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="3" sign="-" unitRef="usd">477</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">65,952</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">65,952</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2022</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">8,027</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">11,267,389</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">11</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">262,724</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">159,964</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">688</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">102,083</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><b>Consolidated Statements of Cash Flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: center"><i>(in thousands)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash flows from operating activities:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">65,952</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">47,252</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Loss on impairment of goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" unitRef="usd">29,517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">6,688</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">10,362</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd">1,366</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd">1,050</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">248</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">117</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Amortization of premium on marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tara:AmortizationOfDiscountsAndPremiumsInvestments" scale="3" unitRef="usd">1,137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="tara:AmortizationOfDiscountsAndPremiumsInvestments" scale="3" unitRef="usd">1,737</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd">265</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd">418</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd">222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd">295</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd">631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd">40</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" unitRef="usd">748</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" unitRef="usd">576</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">1,327</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">1,009</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">26,457</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">34,502</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Purchase of marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" unitRef="usd">43,550</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" unitRef="usd">124,748</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Proceeds from maturity and redemption of marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tara:ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities" scale="3" unitRef="usd">58,620</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="tara:ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities" scale="3" unitRef="usd">27,150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Purchase of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">120</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">596</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Net cash (used in)/provided by investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd">14,950</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">98,194</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Repurchase of shares in connection with settlement of RSUs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" unitRef="usd">90</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" unitRef="usd">228</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Net cash (used in)/provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" sign="-" unitRef="usd">90</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" sign="-" unitRef="usd">228</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net (decrease)/increase in cash and cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">11,597</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">132,924</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Cash and cash equivalents and restricted cash - beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">36,469</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">169,393</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Cash and cash equivalents and restricted cash - end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">24,872</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">36,469</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Cash paid for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 27pt">Interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Income Taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated financial
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_NatureOfOperations-c0_cont_1" escape="true" name="us-gaap:NatureOfOperations"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. Organization and Nature of the Business </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_2" id="_NatureOfOperations-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Overview</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_3" id="_NatureOfOperations-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Protara Therapeutics, Inc., and its consolidated
subsidiaries (&#8220;Protara&#8221; or the &#8220;Company&#8221;), is a clinical-stage biopharmaceutical company committed to advancing
transformative therapies for the treatment of cancer and rare diseases. Protara&#8217;s portfolio includes two development programs utilizing
TARA-002, an investigational cell therapy in development for the treatment of lymphatic malformations, or LMs and non-muscle invasive
bladder cancer, or NMIBC. The third program in the portfolio is Intravenous, or IV Choline Chloride, an investigational phospholipid
substrate replacement therapy initially in development for patients receiving parenteral nutrition, or PN who have intestinal failure
associated liver disease, or IFALD.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_4" id="_NatureOfOperations-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2020, privately-held ArTara Subsidiary,
Inc. (&#8220;Private ArTara&#8221;) and Protara Therapeutics, Inc. (formerly ArTara Therapeutics, Inc., formerly Proteon Therapeutics,
Inc.) completed the merger and reorganization (the &#8220;Merger&#8221;), in accordance with the terms of the Agreement and Plan of Merger
and Reorganization, dated September 23, 2019, (the &#8220;Merger Agreement&#8221;) by and among Protara Therapeutics, Inc., Private ArTara
and REM 1 Acquisition, Inc., a wholly owned subsidiary of Protara Therapeutics, Inc (&#8220;Merger Sub&#8221;). Thereupon, Merger Sub
merged with and into Private ArTara, with Private ArTara surviving as a wholly owned subsidiary of Protara Therapeutics, Inc. The Merger
was structured as a reverse merger and Private ArTara was determined to be the accounting acquirer based on the terms of the Merger and
other factors, and the post-merger company retained the name ArTara Therapeutics, Inc., which on May 11, 2020 was changed to Protara
Therapeutics, Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_5" id="_NatureOfOperations-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">In addition, concurrently with the execution of the Merger Agreement,
Protara issued a private placement, whereby all of the outstanding shares of Protara Therapeutics, Inc.&#8217;s Series A Preferred Stock
were converted into shares of Protara Therapeutics, Inc.&#8217;s common stock. Shares of the Company&#8217;s common stock commenced trading
on The Nasdaq Capital Market under the new name and ticker symbol &#8220;TARA&#8221; as of market open on January 10, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_6" id="_NatureOfOperations-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Liquidity, Capital Resources and Management Plans</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_7" id="_NatureOfOperations-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is in the business of developing
biopharmaceuticals and has no current or near-term revenues. The Company has incurred substantial clinical and other costs in its drug
development efforts. The Company will need to raise additional capital in order to fully realize management&#8217;s plans.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_8" id="_NatureOfOperations-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that its current financial
resources are sufficient to satisfy the Company&#8217;s estimated liquidity needs for at least twelve months from the date of issuance
of these consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_9" id="_NatureOfOperations-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Impact of the COVID-19
Pandemic</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_NatureOfOperations-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the impacts of the COVID-19 pandemic,
the Company has experienced delays and may experience additional future delays that impact the business, research and development activities,
the healthcare systems in which the Company operates and the global economy as a whole. Due to the continued impact of the&#160;COVID-19&#160;pandemic,
the Company is not able to estimate the ongoing effects on the Company&#8217;s results of operations, financial condition, or liquidity.
The Company will continue to monitor the impact of the COVID-19 pandemic and its related macroeconomic effects closely including whether
the effects would have a material impact on the Company&#8217;s operations, liquidity and capital resources.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. Summary of Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;
or &#8220;GAAP&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Principles of Consolidation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in the
accompanying consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation continuedAt="_UseOfEstimates-c0_cont_2" id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses,
and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Significant items subject
to such estimates include but are not limited to income taxes, the valuation of deferred tax assets, recoverability of goodwill, and
contingencies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation id="_UseOfEstimates-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On an ongoing basis, the Company&#8217;s management
evaluates its estimates based on historical and anticipated results, trends, and various other assumptions believed to be reasonable.&#160;Actual
results could differ from those estimates. The results of any changes in accounting estimates are reflected in the financial statements
of the period in which the change becomes evident.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_PriorPeriodReclassificationAdjustmentDescription-c0_cont_1" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Reclassification</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation id="_PriorPeriodReclassificationAdjustmentDescription-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in prior periods related to the classification of accrued
expenses and income taxes have been reclassified to conform to current period presentation. These reclassifications to adjust prior period
presentation had no impact on consolidated statements of operations and comprehensive loss or consolidated statements of cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Cash, Cash Equivalents
and Restricted Cash</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid instruments
with an original maturity of three months or less when acquired to be cash equivalents. Cash and cash equivalents are held in depository
and money market accounts and are reported at fair value. The Company&#8217;s restricted cash balances consist of cash deposits to collateralize
letter of credit obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides a reconciliation
of cash, cash equivalents, and restricted cash in the consolidated balance sheets to the total amount shown in the consolidated statements
of cash flows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"><ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">24,127</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">35,724</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Restricted cash, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" unitRef="usd">745</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" unitRef="usd">745</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd">24,872</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd">36,469</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Fair Value Measurements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 820 &#8220;Fair Value Measurements&#8221; provides the framework for measuring fair value and establishes a fair value hierarchy
that prioritizes the inputs used in pricing the asset or liability. The hierarchy gives the highest priority to unadjusted quoted prices
in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3
measurements).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value is defined as the exchange price,
or an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly
transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, the three-tier
fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 Quoted prices in
    active markets for identical assets or liabilities.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 Quoted prices for
    similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are
    not active, or other inputs that are observable, either directly or indirectly.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 Significant unobservable
    inputs that cannot be corroborated by market data.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of cash and cash equivalents,
prepaid expenses and accounts payable approximate their fair values due to the short-term nature of these instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:nonNumeric contextRef="c0" continuedAt="_MarketableDebtSecuritiesPolicyTextBlock-c0_cont_1" escape="true" name="tara:MarketableDebtSecuritiesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Marketable Debt Securities</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:continuation continuedAt="_MarketableDebtSecuritiesPolicyTextBlock-c0_cont_2" id="_MarketableDebtSecuritiesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies investments in marketable
debt securities with remaining maturities when purchased of greater than three months as available-for-sale. Investments with a remaining
maturity date greater than one year are classified as non-current.&#160;The cost of securities sold is based on the specific identification
method. Interest and dividends earned on securities are classified as available-for-sale are included in investment income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:continuation id="_MarketableDebtSecuritiesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records investments at fair value
with unrealized gains and losses recorded as a component of other comprehensive loss in the consolidated statements of operations and
comprehensive loss until realized. Realized gains and losses are reflected in interest and investment income in the consolidated statements
of operations and comprehensive loss and are determined using the specific identification method with transactions recorded on a settlement
date basis. Fair value is determined based on quoted market rates when observable or utilizing data points that are observable, such
as quoted prices, interest rates and yield curves. To determine whether an other-than-temporary impairment exists, the Company considers
whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability
of the cost of the investment outweighs evidence to the contrary. The Company has the ability to hold such securities with an unrealized
loss until its forecasted recovery. The Company determined that there was no material change in the credit risk of these investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Concentrations of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, which potentially subject
the Company to concentrations of credit risk, consists principally of cash, cash equivalents, restricted cash, and marketable debt securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company currently invests its excess cash
primarily in money market funds and high quality, investment grade marketable debt securities of corporations. The Company has adopted
an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Property and Equipment,
net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment, including leasehold improvements,
are recorded at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the
estimated useful life of the asset. Depreciation begins at the time the asset is placed in service. Leasehold improvements are amortized
using the straight-line method over the shorter of the lease term or estimated useful life of the asset.&#160;Repairs and maintenance
costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimated useful lives for significant property
and equipment categories are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:nonNumeric contextRef="c0" escape="true" name="tara:ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Asset
    Classification</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
    Useful Life</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><ix:nonNumeric contextRef="c38" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></ix:nonNumeric></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture,
    fixtures and other</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><ix:nonNumeric contextRef="c39" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></ix:nonNumeric></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory
    equipment</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><ix:nonNumeric contextRef="c40" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></ix:nonNumeric></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c41" name="tara:ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm">Shorter of the useful life of asset or the lease term</ix:nonNumeric> </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company enters into contracts in the normal
course of business and assesses whether any such contracts contain a lease. The Company determines if an arrangement is a lease at inception
if it conveys the right to control the identified asset for a period of time in exchange for consideration. Under ASC 842, lease expense
is recognized as a single lease cost on a straight-line basis over the lease term. The lease term consists of non-cancelable periods
and may include options to extend or terminate the lease term, when it is reasonably certain such options will be exercised.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases classified as operating leases are included
in operating lease right-of-use (&#8220;ROU&#8221;) assets, current operating lease liabilities and noncurrent operating lease liabilities
in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations, in our consolidated
balance sheet. ROU assets represent the right to use an underlying asset for the lease term. Lease liabilities represent the present
value of future lease payments, net of lease incentives, discounted using an incremental borrowing rate, which is a management estimate
based on the information available at the commencement date of a lease arrangement. ROU assets and lease liabilities are recognized at
the lease commencement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_4" id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has elected to account for the lease
and non-lease components for leases as a single component for classes of all underlying assets and allocate all the contract consideration
to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included
in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating
expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes costs associated with
lease arrangements having an initial term of 12 months or less (&#8220;short-term leases&#8221;) on a straight-line basis over the lease
term; such short-term leases are not recorded on the balance sheet.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Impairment of Long-Lived Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be recoverable or that
the useful life is shorter than originally estimated. When such events occur, the Company compares the carrying amounts of the asset
or asset group to the undiscounted expected future cash flows. If this comparison indicates that the asset or asset group is impaired,
the amount of impairment is measured as the difference between the carrying value and fair value of the asset or asset group. If the
useful life is shorter than originally estimated, the Company will amortize the remaining carrying value over the new shorter useful
life. To date, no such impairment loss has been recognized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Segment Information</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company identifies its operating segments
in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 280, Segment Reporting (&#8220;ASC 280&#8221;). Operating segments
are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief
operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#8217;s
chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes
of allocating resources. Accordingly, <ix:nonNumeric contextRef="c0" name="tara:OperatingSegmentDescription">the Company has determined it operates and manages its business in a single reportable operating
segment</ix:nonNumeric>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Goodwill</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_2" id="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2020, in connection with the Merger,
the Company separately valued the assets and liabilities acquired, and then determined goodwill as the residual of the purchase price
less identified net assets, resulting in the initial recording of $<ix:nonFraction contextRef="c34" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="6" unitRef="usd">29.5</ix:nonFraction> million in goodwill.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_3" id="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill represents the excess of purchase price
over the fair value of identifiable net assets acquired in a business combination. Goodwill has an indefinite useful life. Goodwill is
assessed annually for impairment as of&#160;December 31, or more frequently if an event occurs or circumstances change that would indicate
that it is more likely than not that the fair value of a reporting unit or the fair value of an indefinite-lived intangible asset has
declined below its carrying value. In performing its annual goodwill impairment assessment, the Company has the option under GAAP to
qualitatively assess whether it is more likely than not that the fair value of a reporting unit is less than its carrying value; if the
conclusion of the qualitative assessment is that there are no indicators of impairment, the Company does not perform a quantitative assessment.
Otherwise, a quantitative assessment is performed and the fair value of the reporting unit is determined.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_4" id="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill is evaluated for impairment at the reporting
unit level, which is defined as an operating segment, or one level below an operating segment. The Company has determined that it operates
as one reporting unit and has selected December 31 as the date to perform its annual impairment test.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_5" id="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022 and 2021, the Company elected to forego the
qualitative screen and performed a quantitative annual goodwill impairment test for the reporting unit.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_6" id="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Company&#8217;s stock price and market
capitalization declined <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="tara:MarketCapitalizationsPercentageChange" scale="-2" unitRef="pure">60</ix:nonFraction>% from December 31, 2021, which reflects the overall decline of similar companies with less than $<ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="tara:MicrocapCompaniesMarketCapitalization" scale="6" unitRef="usd">250</ix:nonFraction> million
in market capitalizations, or microcap companies. The life sciences sector, which includes pre-commercialization and therefore net operating
loss generating companies, relies heavily on the capital markets to finance their operations and fund pre-clinical and clinical trials
for their existing development programs. As a result of a shift in risk appetite in the overall financial markets, the availability of
capital for life science sector companies decreased significantly in 2022. The challenging financing conditions had a negative impact
on stock prices and respective market capitalizations, particularly for microcap companies. The Company considered the heightened financing
risk that impacted the life sciences sector during 2022 to be one of the key macroeconomic factors that led to a sustained decrease in
the Company&#8217;s stock price and market capitalization leading up to its annual goodwill impairment assessment date in late 2022. Based
upon the results of our 2022 annual goodwill impairment test, the Company recorded a loss on impairment of goodwill of $<ix:nonFraction contextRef="c35" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" unitRef="usd">29.5</ix:nonFraction> million during
the year ended December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_7" id="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table provides a roll forward of the Company&#8217;s
goodwill and accumulated impairment losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:nonNumeric contextRef="c0" escape="true" name="tara:ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_8" id="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Goodwill, gross amount as of December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GoodwillGross" scale="3" unitRef="usd">29,517</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Accumulated impairment loss, as of December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" unitRef="usd">29,517</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -8.15pt; padding-left: 17.15pt">Additions to goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -8.15pt; padding-left: 17.15pt">Loss on impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="3" unitRef="usd">29,517</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Goodwill as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:continuation id="_GoodwillAndIntangibleAssetsGoodwillPolicy-c0_cont_8"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based upon the results of our annual goodwill impairment test, no adjustments
to the carrying value of goodwill were necessary during the year ended December 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Research and Development</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses consist primarily
of third-party costs incurred to develop drug candidates, employee-related expenses, including salaries, benefits, travel and stock-based
compensation expense, depreciation and other allocated overhead costs, which include rent and maintenance of facilities and other supplies.
Research and development costs are expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_3" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before a compound receives regulatory approval,
the Company records upfront and milestone payments made to third parties under licensing arrangements as expense provided that there
is no alternative future use of the rights in other research and development projects.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_4" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nonrefundable advance payments to vendors for
goods or services that will be used or received in future research and development activities are deferred and recognized as expense
in the period in which the related goods are delivered or services are performed. Where milestone payments are due to third parties under
research and development collaboration arrangements or other contractual agreements, the milestone payment obligations are expensed when
the milestone conditions are met and the amount of payment is reasonably estimable.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_5" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once a compound receives regulatory approval,
the Company records any milestone payments in&#160;identifiable intangible assets, less accumulated amortization&#160;and, unless the
asset is determined to have an indefinite life, the Company amortizes the payments on a straight-line basis over the remaining agreement
term or the expected product life cycle, whichever is shorter.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain third-party costs are included as a component
of research and development expense. These expenses include fees paid to contract research organizations (&#8220;CROs&#8221;) and other
clinical trial costs, contractual services costs and costs for supply of its drug candidates. Depending upon the timing of payments to
the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses
are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved and experience with similar
contracts. The Company monitors each of these factors and adjusts estimates accordingly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><ix:nonNumeric contextRef="c0" continuedAt="_PatentCostsPolicyTextBlock-c0_cont_1" escape="true" name="tara:PatentCostsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Patent Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><ix:continuation id="_PatentCostsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All patent-related costs incurred in connection
with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure.
Amounts incurred are classified as general and administrative expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><ix:nonNumeric contextRef="c0" continuedAt="_InvestmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Interest and Investment Income</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_59" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><ix:continuation id="_InvestmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investment income consists primarily of interest
income, accretion income earned and amortization expense incurred and realized gains or losses&#160;related to our marketable debt securities
and interest income related to cash, cash equivalents and restricted cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_60" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Stock-Based Compensation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_61" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s stock-based compensation
programs include stock options, restricted stock units (&#8220;RSUs&#8221;), and an employee stock purchase program (&#8220;ESPP&#8221;).
The Company accounts for stock-based compensation using the fair value method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_62" id="_SignificantAccountingPoliciesTextBlock-c0_cont_61"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures all stock options and other
stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense
of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes
forfeitures at the time forfeitures occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_63" id="_SignificantAccountingPoliciesTextBlock-c0_cont_62"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of each option is estimated on
the date of grant using the Black-Scholes option-pricing model. Expected volatility for the Company&#8217;s common stock is determined
based on an average of the historical volatility of the Company and the historical volatility of a peer-group of similar public companies.
The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual
term of the option and the weighted-average vesting period of the option. The assumed dividend yield is based upon the Company&#8217;s
expectation of not paying dividends in the foreseeable future. The risk-free interest rate is based upon the U.S. Treasury yield curve
commensurate with the expected term at the time of grant or remeasurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_64" id="_SignificantAccountingPoliciesTextBlock-c0_cont_63"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The stock-based compensation expense associated
with purchase rights under the ESPP is measured at fair-value using a Black-Scholes option-pricing model at commencement of each offering
period and recognized over that offering period. The Black-Scholes option pricing assumptions are similar to those used for stock options
with the exception of the expected term of purchase rights for the ESPP which is based on the duration of an offering period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_65" id="_SignificantAccountingPoliciesTextBlock-c0_cont_64"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_6" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair values of RSUs are based on the fair
market value of the Company&#8217;s common stock on the date of the grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_66" id="_SignificantAccountingPoliciesTextBlock-c0_cont_65"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_7" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The RSUs are granted to directors pursuant to
the Company&#8217;s equity plan. Settlement for the RSUs is deferred until the earliest to occur of (i) the director&#8217;s termination
of service, (ii) death, (iii) disability or (iv) a change in control of the Company. In the event of a change in control of the Company,
the RSUs will vest in full.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_67" id="_SignificantAccountingPoliciesTextBlock-c0_cont_66"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_8" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of all stock-based awards is recognized
as stock-based compensation expense on a straight-line basis over the vesting period, which is typically <ix:nonNumeric contextRef="c36" continuedAt="_VestingPeriod-c36_cont_1" format="ixt-sec:durwordsen" name="tara:VestingPeriod">one</ix:nonNumeric> to <ix:nonNumeric contextRef="c37" format="ixt-sec:durwordsen" name="tara:VestingPeriod">four<ix:continuation id="_VestingPeriod-c36_cont_1"> years</ix:continuation></ix:nonNumeric> for RSUs and
<ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="tara:StockOptionPeriod">four years</ix:nonNumeric> for stock options.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_68" id="_SignificantAccountingPoliciesTextBlock-c0_cont_67"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies stock-based compensation
expense in its statement of operations and comprehensive loss in the same way the payroll costs or service payments are classified for
the related stock-based award recipients.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_69" id="_SignificantAccountingPoliciesTextBlock-c0_cont_68"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Income Taxes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_70" id="_SignificantAccountingPoliciesTextBlock-c0_cont_69"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax assets and liabilities are recognized
for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets
and liabilities and their respective tax basis, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are
measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.
The measurement of net deferred tax assets is reduced by the amount of any tax benefit that, based on available evidence, is not expected
to be realized, and a corresponding valuation allowance is established. In making such a determination, the Company considers all available
positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,
tax-planning strategies, and results of recent operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_71" id="_SignificantAccountingPoliciesTextBlock-c0_cont_70"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tax benefits are recognized only for tax positions
that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount
of benefit that is greater than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="tara:PercentageOfLargestAmountOfBenefit" scale="-2" unitRef="pure">50</ix:nonFraction> percent likely to be realized upon settlement. A liability for unrecognized tax benefits is recorded
for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and measurement standards. The Company&#8217;s
policy is to record interest and penalties on uncertain tax positions as a component of income tax expense in the consolidated statement
of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_72" id="_SignificantAccountingPoliciesTextBlock-c0_cont_71"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Net Loss Per Share Attributable to Common
Stockholders</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_73" id="_SignificantAccountingPoliciesTextBlock-c0_cont_72"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per share is computed by dividing
the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period.
Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares
of common stock outstanding during the period plus the common equivalent shares for the period including any dilutive effect from unvested
restricted common stock, outstanding stock options and potential shares issuable under the ESPP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_74" id="_SignificantAccountingPoliciesTextBlock-c0_cont_73"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Recently Adopted Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_75" id="_SignificantAccountingPoliciesTextBlock-c0_cont_74"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2018, the Financial Accounting Standards
Board, or the FASB, issued ASU&#160;No.&#160;2018-15,&#160;<i>Intangibles &#8211; Goodwill and Other &#8211;&#160;Internal-Use&#160;Software
(Subtopic&#160;350-40):&#160;Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a
Service Contract</i>&#160;(&#8220;ASU&#160;2018-15&#8221;).&#160;This ASU is designed to reduce complexity for accounting for costs of
implementing a cloud computing service arrangement. This standard aligns the accounting for implementation costs of hosting arrangements,
regardless of whether they convey a license to the hosted software. The standard became effective for the first interim period within
annual reporting periods beginning after December&#160;15, 2020. On January 1, 2021, the Company adopted ASU 2018-15. The adoption of
this standard did not have a material effect on the Company&#8217;s financial position, results of operations, or cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_76" id="_SignificantAccountingPoliciesTextBlock-c0_cont_75"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12,
<i>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </i>(&#8220;ASU 2019-12&#8221;). The amendments in ASU 2019-12
remove certain exceptions to the general principles in Topic 740. The amendments also clarify and amend existing guidance to improve
consistent application. The amendments became effective for annual reporting periods beginning after December 15, 2020. On January 1,
2021, the Company adopted ASU 2019-12. The adoption of this standard did not have a material effect on the Company&#8217;s financial
position, results of operations, or cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_77" id="_SignificantAccountingPoliciesTextBlock-c0_cont_76"><ix:nonNumeric contextRef="c0" continuedAt="_RecentAccountingPronouncementsNotYetAdopted-c0_cont_1" escape="true" name="tara:RecentAccountingPronouncementsNotYetAdopted"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Recent Accounting Pronouncements
Not Yet Adopted</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_78" id="_SignificantAccountingPoliciesTextBlock-c0_cont_77"><ix:continuation continuedAt="_RecentAccountingPronouncementsNotYetAdopted-c0_cont_2" id="_RecentAccountingPronouncementsNotYetAdopted-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the Financial Accounting Standards
Board, or the FASB issued ASU 2016-13, <i>Measurement of Credit Losses on Financial Statements</i>. The new standard requires that expected
credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through
an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to
the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value
increases. In November 2019, the FASB issued ASU 2019-10, <i>Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and
Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the effective date for certain companies. The standard
is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December
15, 2022. Early adoption is available. The Company has evaluated the impact of the adoption of ASU 2016-13, and related updates, and
has determined that the impact will not be material to its consolidated financial statements and disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_79" id="_SignificantAccountingPoliciesTextBlock-c0_cont_78"><ix:continuation id="_RecentAccountingPronouncementsNotYetAdopted-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated other recently issued
accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material
impact on the Company&#8217;s financial position or results of operations upon adoption.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_80" id="_SignificantAccountingPoliciesTextBlock-c0_cont_79"><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Subsequent Events</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_80"><ix:continuation id="_SubsequentEventsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the financial statements were available to be issued. Other than as described
in Note 11 and, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial
statements.</p></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>3. Fair Value of Financial Instruments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_2" id="_FairValueDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tables below present information about the
Company&#8217;s financial instruments that are measured at fair value on a recurring basis as of December 31, 2022 and 2021 and indicates
the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, as described under <i>Note 2,
Summary of Significant Accounting Policies.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_3" id="_FairValueDisclosuresTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables present the Company&#8217;s
financial assets and liabilities that are measured and carried at fair value and indicate the level within the fair value hierarchy of
the valuation techniques it utilizes to determine such fair value:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_4" id="_FairValueDisclosuresTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash Equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds<sup>(a)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" unitRef="usd">13,284</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" unitRef="usd">13,284</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate bonds<sup>(a)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd">2,523</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" unitRef="usd">2,523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted cash, non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds<sup>(b)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:RestrictedCashAndInvestments" scale="3" unitRef="usd">745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:RestrictedCashAndInvestments" scale="3" unitRef="usd">745</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate bonds<sup>(c)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" id="ix_10_fact" name="us-gaap:MarketableSecurities" scale="3" unitRef="usd">78,129</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" id="ix_11_fact" name="us-gaap:MarketableSecurities" scale="3" unitRef="usd">78,129</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd">14,029</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd">80,652</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd">94,681</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_5" id="_FairValueDisclosuresTextBlock-c0_cont_4"><ix:continuation continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_2" id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash Equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds<sup>(a)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" unitRef="usd">26,323</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" unitRef="usd">26,323</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted cash, non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds<sup>(b)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:RestrictedCashAndInvestments" scale="3" unitRef="usd">745</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_9_fact" name="us-gaap:RestrictedCashAndInvestments" scale="3" unitRef="usd">745</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate bonds<sup>(c)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" id="ix_12_fact" name="us-gaap:MarketableSecurities" scale="3" unitRef="usd">94,972</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_13_fact" name="us-gaap:MarketableSecurities" scale="3" unitRef="usd">94,972</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd">27,068</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd">94,972</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd">122,040</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_6" id="_FairValueDisclosuresTextBlock-c0_cont_5"><ix:continuation id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0in">&#160;</td> <td style="width: 0.25in; padding-right: 0pt; padding-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds and corporate debt securities with original maturities of 90 days or less are included within Cash and cash equivalents in the Consolidated Balance Sheets.</span></ix:footnote></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="padding-right: 0pt; padding-left: 0pt; text-align: justify">&#160;</td> <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="padding-right: 0pt; padding-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Money market funds are included within Restricted Cash, non-current in the Consolidated Balance Sheets.</span></ix:footnote></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="padding-right: 0pt; padding-left: 0pt; text-align: justify">&#160;</td> <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="padding-right: 0pt; padding-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td> <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate debt securities with original maturities greater than 90 days are included within Marketable securities in the Consolidated Balance Sheets and classified as current or noncurrent based upon whether the maturity of the financial asset is less than or greater than 12 months.</span></ix:footnote></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_7" id="_FairValueDisclosuresTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Money market funds are classified as Level&#160;1
within the fair value hierarchy, because they are valued using quoted prices in active markets. Corporate debt securities classified
as Level&#160;2 within the fair value hierarchy are valued on the basis of prices from an orderly transaction between market participants
provided by reputable dealers or pricing services. Prices of these securities are obtained through independent, third-party pricing services
and include market quotations that may include both observable and unobservable inputs. In determining the value of a particular investment,
pricing services may use certain information with respect to transactions in such investments, quotations from dealers, pricing matrices
and market transactions in comparable investments and various relationships between investments. There were no transfers of financial
instruments among Level&#160;1, Level&#160;2, and Level&#160;3 during the period presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_8" id="_FairValueDisclosuresTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash equivalents, prepaid expenses and other
current assets, accounts payable and accrued expenses at December 31, 2022 and 2021 are carried at amounts that approximate fair value
due to their short-term maturities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_9" id="_FairValueDisclosuresTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Non-Recurring Fair Value Measurements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_9"><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">During the fourth quarter of 2022, the Company recorded a goodwill
impairment loss of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="6" unitRef="usd">29.5</ix:nonFraction> million, refer to Note 2 for additional details on the impairment of goodwill. The fair value of our reporting
unit was determined using an income approach based on discounted cash flows, or DCF. Determining fair value using a DCF analysis requires
the exercise of significant judgment with respect to several assumptions and estimates, including the amount and timing of expected future
cash flows and appropriate discount rate to be applied. The expected cash flows used in the DCF analysis are based on our most recent
internal long-range forecast and budget and, for years beyond the budget, our estimates, which are based, in part, on industry benchmarks
and forecasted growth rates. The discount rate used in the DCF analysis is intended to reflect the risks inherent in the expected future
cash flows of the respective programs within our portfolio. The inputs to the DCF model are Level 3 valuation inputs.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_MarketableDebtSecuritiesTextBlock-c0_cont_1" escape="true" name="tara:MarketableDebtSecuritiesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. Marketable Debt Securities</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_MarketableDebtSecuritiesTextBlock-c0_cont_2" id="_MarketableDebtSecuritiesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marketable debt securities, all of which were
classified as available-for-sale, consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_MarketableDebtSecuritiesTextBlock-c0_cont_3" id="_MarketableDebtSecuritiesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_MarketableSecuritiesTextBlock-c0_cont_1" escape="true" name="us-gaap:MarketableSecuritiesTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortized<br/> Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unrealized<br/> Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unrealized<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Estimated<br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Corporate bonds - presented in marketable debt securities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd">60,790</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="tara:UnrealizedLoss" scale="3" sign="-" unitRef="usd">547</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="tara:EstimatedFairValue" scale="3" unitRef="usd">60,243</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Corporate bonds - presented in marketable debt securities, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd">18,027</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="tara:UnrealizedLoss" scale="3" sign="-" unitRef="usd">141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="tara:EstimatedFairValue" scale="3" unitRef="usd">17,886</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd">78,817</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tara:UnrealizedLoss" scale="3" sign="-" unitRef="usd">688</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tara:EstimatedFairValue" scale="3" unitRef="usd">78,129</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_MarketableDebtSecuritiesTextBlock-c0_cont_4" id="_MarketableDebtSecuritiesTextBlock-c0_cont_3"><ix:continuation id="_MarketableSecuritiesTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized<br/> Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated<br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Corporate bonds - presented in marketable debt securities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd">55,548</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="tara:UnrealizedLoss" scale="3" sign="-" unitRef="usd">43</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="tara:EstimatedFairValue" scale="3" unitRef="usd">55,505</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Corporate bonds - presented in marketable debt securities, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd">39,635</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="tara:UnrealizedLoss" scale="3" sign="-" unitRef="usd">168</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="tara:EstimatedFairValue" scale="3" unitRef="usd">39,467</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" unitRef="usd">95,183</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tara:UnrealizedLoss" scale="3" sign="-" unitRef="usd">211</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tara:EstimatedFairValue" scale="3" unitRef="usd">94,972</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.05pt">&#160;&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_MarketableDebtSecuritiesTextBlock-c0_cont_5" id="_MarketableDebtSecuritiesTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount of realized gains and losses reclassified
into earnings for the year ended December 31, 2022 was $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetInvestmentIncome" scale="3" unitRef="usd">17</ix:nonFraction> included in investment income within the consolidated statements of operations
and comprehensive loss. There were no sales of securities in the periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_MarketableDebtSecuritiesTextBlock-c0_cont_6" id="_MarketableDebtSecuritiesTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The contractual maturities of all securities
held at December 31, 2022 was 16 months or less. Of the 34 securities in a loss position held by the Company, there were 16 securities
in a continuous unrealized loss position for greater than twelve months at December 31, 2022. The total unrealized loss related to these
securities was $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tara:UnrealizedLosses" scale="3" unitRef="usd">358</ix:nonFraction> and was not material. The Company has the ability to hold such securities with an unrealized loss until its forecasted
recovery. The Company determined that there was no material change in the credit risk of the above investments. No other than temporary&#160;impairment
loss has been recorded on the securities as of December 31, 2022, as the Company believes that any decrease in fair value of these securities
is temporary and the Company expects to recover at least up to the initial cost of the investment for these securities.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_MarketableDebtSecuritiesTextBlock-c0_cont_7" id="_MarketableDebtSecuritiesTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Interest and Investment Income</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_MarketableDebtSecuritiesTextBlock-c0_cont_8" id="_MarketableDebtSecuritiesTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interest and investment income consists of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_MarketableDebtSecuritiesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="tara:ScheduleOfInterestAndInvestmentIncomeTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="3" unitRef="usd">2,230</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="3" unitRef="usd">1,974</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accretion/(amortization) of discount/premium, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" sign="-" unitRef="usd">1,137</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" sign="-" unitRef="usd">1,737</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Realized gain/(loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" unitRef="usd">17</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total interest and investment income</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNet" scale="3" unitRef="usd">1,110</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeNet" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OtherCurrentAssetsTextBlock-c0_cont_1" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. Prepaid Expenses and Other Current Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OtherCurrentAssetsTextBlock-c0_cont_2" id="_OtherCurrentAssetsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">Prepaid expenses and
other current assets consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OtherCurrentAssetsTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" unitRef="usd">288</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" unitRef="usd">279</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd">569</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd">684</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tara:PrepaidSoftware" scale="3" unitRef="usd">122</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="tara:PrepaidSoftware" scale="3" unitRef="usd">79</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued interest on marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tara:AccruedInterestOnMarketableDebtSecurities" scale="3" unitRef="usd">486</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="tara:AccruedInterestOnMarketableDebtSecurities" scale="3" unitRef="usd">634</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd">184</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd">173</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd">127</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd">34</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,776</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,883</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. Property and Equipment, net</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">Property and equipment,
net consists of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Computer equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">205</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">175</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture, fixtures and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">352</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">352</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">866</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">591</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">553</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property and equipment not yet placed into service</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c68" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">99</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">613</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">2,075</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">1,955</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">483</ix:nonFraction></td><td style="padding-bottom: 1.5px; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">236</ix:nonFraction></td><td style="padding-bottom: 1.5px; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">1,592</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">1,719</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $<ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">247</ix:nonFraction> and $<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">117</ix:nonFraction> for the
years ended December 31, 2022 and 2021, respectively. During the year ended December 31, 2022, $<ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">137</ix:nonFraction> and $<ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">110</ix:nonFraction> was included in research
and development expense and general and administrative expense, respectively, within the consolidated statements of operations and comprehensive
loss. During the year ended December 31, 2021, $<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">36</ix:nonFraction> and $<ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">81</ix:nonFraction> was included in research and development expense and general and administrative
expense, respectively, within the consolidated statements of operations and comprehensive loss. As of December 31, 2022 and 2021, <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="tara:TotalPropertyAndEquipmentNet" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="tara:TotalPropertyAndEquipmentNet" scale="-2" unitRef="pure">100</ix:nonFraction></ix:nonFraction>%
of the Company&#8217;s total property and equipment, net was attributable to the United States.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>7. Accrued Expenses</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_2" id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">Accrued expenses consist
of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employee Costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tara:AccruedEmployeeRelatedCurrent" scale="3" unitRef="usd">2,543</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tara:AccruedEmployeeRelatedCurrent" scale="3" unitRef="usd">1,801</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tara:AccruedResearchAndDevelopmentCurrent" scale="3" unitRef="usd">512</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tara:AccruedResearchAndDevelopmentCurrent" scale="3" unitRef="usd">437</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">182</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">251</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">3,237</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">2,489</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>8. Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_2" id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Operating leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_3" id="_LesseeOperatingLeasesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, <ix:nonNumeric contextRef="c70" name="us-gaap:LesseeOperatingLeaseDescription">the Company entered into an
agreement to lease approximately 10.3 square feet of office space in New York, New York (&#8220;Office Lease&#8221;), which commenced
in April 2021. Annual rent is approximately $1,117.</ix:nonNumeric> The Office Lease has a term of approximately seven years and contains provisions
for a free-rent period, annual rent increases and an allowance for tenant improvements. The Company has an option to extend the term
by five years, however, the Company determined at the lease commencement date that it was not reasonably certain to exercise the renewal
option and such renewal was excluded from the operating lease right-of-use, or ROU, asset and operating lease liability recorded for
this lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_4" id="_LesseeOperatingLeasesTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is responsible for real estate taxes,
maintenance and other operating expenses applicable to the leased premises which are recognized as variable lease expense in the period
when incurred. In conjunction with the Office Lease, the Company established a letter of credit of approximately $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tara:RestrictedCashNoncurrents" scale="3" unitRef="usd">745</ix:nonFraction> secured by cash
balances included in restricted cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_5" id="_LesseeOperatingLeasesTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2021, the Company amended the existing
agreement with its contract development and manufacturing organization, or CDMO, establishing a term of eight-years from the amendment
date. Prior to the amendment, the leased spaces met the short-term lease exception under a quarter-to quarter arrangement and were not
included in measurement of lease liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_6" id="_LesseeOperatingLeasesTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases classified as operating leases are included
in operating lease right-of-use, or ROU, assets, operating lease liabilities and operating lease liabilities, non-current, in the Company&#8217;s
consolidated balance sheets. The Office Lease and the CDMO leased spaces are included in operating lease ROU assets and operating lease
liabilities. Cash paid for operating lease liabilities was $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLiabilities" scale="3" unitRef="usd">1,327</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLiabilities" scale="3" unitRef="usd">1,009</ix:nonFraction> during the years ended December 31, 2022 and 2021, respectively,
which is included in operating cash flows. The ROU asset obtained in exchange for operating lease liabilities related to the Office Lease
was $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">6,549</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_7" id="_LesseeOperatingLeasesTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The components of lease expense were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_8" id="_LesseeOperatingLeasesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><b>Lease expense</b></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Operating lease expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">1,366</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">1,050</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Short-term lease expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitRef="usd">102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd">1,369</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd">1,152</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_9" id="_LesseeOperatingLeasesTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Variable lease expense for the years ended December
31, 2022 and 2021, respectively were not material.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_10" id="_LesseeOperatingLeasesTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-align: justify; text-indent: -20.05pt">The weighted
average remaining lease term and the weighted average discount rate for operating leases were:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-indent: -20.05pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_11" id="_LesseeOperatingLeasesTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="tara:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Weighted-average discount rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">7.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">7.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Weighted-average remaining lease term &#8211; operating lease (in months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c3" format="ixt-sec:durmonth" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">67</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c4" format="ixt-sec:durmonth" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">79</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_12" id="_LesseeOperatingLeasesTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total remaining operating lease payments
included in the measurement of lease liabilities on the Company&#8217;s consolidated balance sheet as of December&#160;31, 2022, was
as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" escape="true" name="tara:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">For the year ending December 31:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Lease Payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd">1,327</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd">1,327</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd">1,395</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" unitRef="usd">1,429</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" unitRef="usd">1,429</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" unitRef="usd">805</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tara:OperatingLeasesFutureMinimumPaymentDue" scale="3" unitRef="usd">7,712</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd">1,328</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Present value of future minimum lease payments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tara:PresentValueOfFutureMinimumLeasePayments" scale="3" unitRef="usd">6,384</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>9. Commitments and Contingencies </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Employment Agreements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Executive Employment Agreements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&#8217;s executive officers have entered into at-will employment
agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Collaborations and License Agreements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Choline License Agreement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 27, 2017, <ix:nonNumeric contextRef="c71" name="tara:DescriptionOfAgreements">the Company entered into
a license agreement (the &#8220;Choline License Agreement&#8221;) with Alan L. Buchman (&#8220;Dr. Buchman&#8221;). Pursuant to the Choline
License Agreement, the Company received from Dr. Buchman the license rights in and to the &#8220;Licensed Orphan Designations&#8221;,
the &#8220;Licensed IND&#8221;, &#8220;Existing Study Data&#8221; and the &#8220;Licensed Know-How&#8221; for one or more of the licensed
indications.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2022 and
2021, the Company recorded research and development expense of $<ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="tara:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd">2</ix:nonFraction> and $<ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="tara:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd">0</ix:nonFraction>, in connection with the Choline License Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">License Agreement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, <ix:nonNumeric contextRef="c74" name="tara:DescriptionOfAgreements">the Company entered into
an agreement (the &#8220;Feinstein Agreement&#8221;) with The Feinstein Institute for Medical Research (the &#8220;Feinstein Institute&#8221;),
a not-for-profit corporation with 50 research labs and 2,500 clinical research studies. Pursuant to the Feinstein Agreement, the Company
acquired an exclusive license relating to treatment of fatty liver diseases in humans for which Choline may be an effective therapeutic.
In consideration for the rights and license granted, the Feinstein Institute would receive a royalty of one percent (1%) of the first
one hundred million dollars ($100,000) of net sales of IV Choline Chloride and a royalty of one and one-half percent (1.5%) of all net
sales thereafter. In addition, the Company would pay the Feinstein Institute twelve and one-half percent (12.5%) of net proceeds resulting
from agreements entered within 2 years from the effective date, and seven and one-half percent (7.5%) of net proceeds resulting from
agreements entered into thereafter. Pursuant to the Feinstein Agreement additional payments would be due to the Feinstein Institute for
license maintenance payments and for meeting milestone events. Pursuant to the Feinstein Agreement, upon the achievement of certain future
new drug application milestones, the Company would be obligated to remit an aggregate of $275.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2022 and
2021, the Company recorded research and development expense of $<ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="tara:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd">17</ix:nonFraction> and $<ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="tara:ResearchAndDevelopmentExpenses" scale="3" unitRef="usd">15</ix:nonFraction>, respectively, in connection with the Feinstein Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Sponsored Research and License Agreement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 28, 2018, <ix:nonNumeric contextRef="c77" name="us-gaap:BroadcastersLicenseAgreementCommitmentsDescription">the Company entered into a sponsored research
and license agreement (the &#8220;Iowa Agreement&#8221;) with the University of Iowa. Pursuant to the Iowa Agreement, the University of
Iowa, which is engaged in clinical research to improve the diagnosis and treatment of lymphangioma using a pharmaceutical product (OK-432),
would assist the Company in collecting case reports, forms, source data, and safety data available to the University of Iowa in support
of the development of the Company&#8217;s proprietary <i>Streptococcus Pyogenes</i> investigational product, TARA-002 for the LMs indication.
During the term of the services, the Company would generally pay the University of Iowa thirty thousand dollars ($30) per year to fund
the project, plus additional amounts upon the realization of certain milestones. More specifically, upon forty-five (45) days of an approval
of TARA-002 by the FDA, the Company would pay up to $1,750 to the University of Iowa for meeting these milestones. Furthermore, the Company
would pay the University of Iowa royalties of up to 1.75% for net sales ranging from $0 - $25,000, 2.25% for net sales ranging from $25,000
to $50,000, and 2.50% for net sales in excess of $50,000. Pursuant to the Iowa Agreement, the University of Iowa would be entitled to
additional payments for the Company achieving annual net sales of product according to the milestones. For annual net sales of product
up to $25,000: $62; for annual net sales of product of up to $50,000: $62; and for annual net sales of product of up to $100,000: $125.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Iowa Agreement there were no
research and development expenses recognized during the years ended December 31, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Chugai Agreement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_16" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2019, the Company entered into
an agreement (the &#8220;Chugai Pharmaceutical Agreement&#8221;) with Chugai Pharmaceutical Co., LTD (&#8220;Chugai&#8221;), a drug
manufacturing firm with offices and operations in Japan. Pursuant to the Chugai Pharmaceutical Agreement, Chugai would help the
Company in its goals to develop and commercialize a therapeutic product (the &#8220;New Product&#8221;) which is comparable to the
Chugai existing therapeutic product (the &#8220;Existing Product&#8221;). In addition, the Company would be entitled to the use of
Chugai materials and technical support as necessary. On July 14, 2020, the Company and Chugai entered into an amendment (the
&#8220;Chugai Amendment&#8221;) to the Chugai Pharmaceutical Agreement, with an effective date of June 30, 2020. The Chugai
Amendment extended the date through which Chugai will exclusively provide the Existing Product and materials to the Company from
June 30, 2020 to June 30, 2021, extended the date through which Chugai will not provide materials or technical support to any
third-party for the purpose of development and commercialization in a given area from the fifth anniversary to the eleventh
anniversary of the original effective date, and provides for further such extensions on the occurrence of certain events and
milestones. The amendment further provides that, in addition to the designated fee provided upon the initial indication approval in
the Chugai Pharmaceutical Agreement, the Company will pay Chugai a designated fee for each additional indication approval. The
Company is obligated to Chugai for certain payments upon the completion of agreed upon milestones. As consideration for
Chugai&#8217;s performance under the Chugai Pharmaceutical Agreement, the Company agreed to pay Chugai a payment in the low,
single-digit millions related to such initial indication approval, which payment will be made in two installments with an initial
payment in July 2020, and the remaining majority of the payment payable upon FDA approval of the New Product.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_17" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the agreement there were no research
and development expenses recognized during the years ended December 31, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_18" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Contingencies</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_19" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may be subject
to various legal proceedings and claims that arise in the ordinary course of its business activities. Management is of the opinion that
the ultimate outcome of these matters would not have a material adverse impact on the financial position of the Company or the results
of its operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, the Company
enters into contracts in which it makes representations and warranties regarding the performance of its services and that its services
will not infringe on third-party intellectual rights. There have been no significant events related to such representations and warranties
in which the Company believes the outcome could result in losses or penalties in the future.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. Stockholders&#8217; Equity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Company had <ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction>
shares of common stock authorized for issuance, $<ix:nonFraction contextRef="c78" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> par value per share, of which <ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">11,267,389</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">11,235,731</ix:nonFraction></ix:nonFraction> shares were issued and
outstanding as of December 31, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of the Company&#8217;s common stock
are entitled to one vote per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Preferred Offering (defined
below) on September 22, 2020, the Company filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights and
Limitations of Series 1 Convertible Preferred Stock of the Company (the &#8220;Amendment&#8221;) with the State of Delaware to increase
the authorized number of shares of the Company&#8217;s Series 1 Convertible Preferred Stock that may be issued from <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">3,880</ix:nonFraction> to <ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">8,028</ix:nonFraction>. The
Amendment was approved by a committee of the Company&#8217;s Board of Directors and the requisite holders of outstanding shares of Series
1 Convertible Preferred Stock. No approval of the holders of the Company&#8217;s common stock was required to effectuate the Amendment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022 and 2021, the Company
had <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">10,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock authorized for issuance, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value per share of which <ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">8,028</ix:nonFraction> shares of Series 1 Convertible
Preferred Stock are authorized for issuance and <ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares">8,027</ix:nonFraction></ix:nonFraction> shares were issued and outstanding, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Description of Series 1 Convertible Preferred
Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of Series 1 Convertible Preferred
Stock is convertible into <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares">1,000</ix:nonFraction> shares of the Company&#8217;s common stock, at a conversion price initially equal to approximately $<ix:nonFraction contextRef="c82" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares">7.01</ix:nonFraction>
per common share, subject to adjustment for any stock splits, stock dividends and similar events, at any time at the option of the holder,
provided that any conversion of Series 1 Convertible Preferred Stock by a holder into shares of the Company&#8217;s common stock would
be prohibited if, as a result of such conversion, the holder, together with its affiliates and any other person or entity whose beneficial
ownership of the Company&#8217;s common stock would be aggregated with such holder&#8217;s for purposes of Section 13(d) of the Securities
Exchange Act of 1934, as amended, would beneficially own more than <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="tara:CommonStockIssuanceAndOutstandingPercentage" scale="-2" unitRef="pure">9.99</ix:nonFraction>% of the total number of shares of the Company&#8217;s common
stock issued and outstanding after giving effect to such conversion. Upon written notice to the Company, the holder may from time to
time increase or decrease such limitation to any other percentage not in excess of <ix:nonFraction contextRef="c83" decimals="4" format="ixt:num-dot-decimal" name="tara:IncreaseOrDecreaseEquityPercentage" scale="-2" unitRef="pure">19.99</ix:nonFraction>% specified in such notice. In addition, upon
the occurrence of certain transactions that involve the merger or consolidation of the Company, an exchange or tender offer, a sale of
all or substantially all of the assets of the Company or a reclassification of its Common Stock, each share of Series 1 Convertible Preferred
Stock will be convertible into the kind and amount of securities, cash and/or other property that the holder of a number of shares of
Common Stock issuable upon conversion of one share of Series 1 Convertible Preferred Stock would receive in connection with such transaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The terms of the Series 1 Convertible Preferred
Stock provide that, in the event of a fundamental transaction (as such term is described in the certificate of designation of preferences,
rights and limitations of series 1 convertible non-voting preferred stock), each share of Series 1 Convertible Preferred Stock outstanding
will thereafter be convertible into the kind and amount of securities, cash and/or other property which a holder of the number of shares
of Common Stock of the Company issuable upon conversion of one share of Series 1 Convertible Preferred Stock immediately prior to such
fundamental transaction would have been entitled to receive pursuant to such fundamental transaction, provided that, if the value of
the aggregate of such securities, cash and/or other property the which the holder of one share of Series 1 Convertible Preferred Stock
would be entitled to upon conversion thereof would be less than the stated value, then each outstanding share of Series 1 Convertible
Preferred Stock will instead be convertible into such kind of securities, cash and/or other property with an aggregate value equal to
the stated value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of Series 1 Convertible Preferred
Stock is entitled to a preference of $<ix:nonFraction contextRef="c82" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" unitRef="usdPershares">10.00</ix:nonFraction> per share upon liquidation of the Company, and thereafter will share ratably in any distributions
or payments on an as-converted basis with the holders of Common Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of Series 1 Convertible Preferred
Stock are not entitled to vote.<b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Underwritten Public Offering</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 24, 2020, pursuant to an underwriting
agreement dated September 22, 2020, the Company issued and sold in an underwritten public offering (the &#8220;Common Offering&#8221;)
an aggregate of <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="tara:AggregateOfSharesOfCommonStock" scale="0" unitRef="shares">4,600,000</ix:nonFraction> shares of its common stock at an offering price of $<ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">16.87</ix:nonFraction> per share, for gross and net proceeds of approximately
$<ix:nonFraction contextRef="c85" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd">77.6</ix:nonFraction> million and $<ix:nonFraction contextRef="c85" decimals="-5" format="ixt:num-dot-decimal" name="tara:NetProceeds" scale="6" unitRef="usd">73.6</ix:nonFraction> million, respectively. The underwriters were granted an option to purchase up to <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">690,000</ix:nonFraction> additional shares of
the Company&#8217;s common stock at the public offering price, less the underwriting discount. On October 6, 2020, the underwriters exercised
their overallotment option in full, purchasing an additional <ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">690,000</ix:nonFraction> shares, resulting in the receipt of gross and net proceeds of $<ix:nonFraction contextRef="c86" decimals="-5" format="ixt:num-dot-decimal" name="tara:GrossProceeds" scale="6" unitRef="usd">11.6</ix:nonFraction>
million and $<ix:nonFraction contextRef="c86" decimals="-5" format="ixt:num-dot-decimal" name="tara:NetProceeds" scale="6" unitRef="usd">11.1</ix:nonFraction> million, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 24, 2020, pursuant to an underwriting
agreement (dated September 22, 2020), the Company issued and sold in an underwritten public offering (the &#8220;Preferred Offering&#8221;)
an aggregate of <ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="tara:AggregateOfSharesOfCommonStock" scale="0" unitRef="shares">4,148</ix:nonFraction> shares of its Series 1 Convertible Preferred Stock at an offering price of $<ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">16,873.54</ix:nonFraction> per share, for gross and
net proceeds of approximately $<ix:nonFraction contextRef="c88" decimals="-5" format="ixt:num-dot-decimal" name="tara:GrossProceeds" scale="6" unitRef="usd">70.0</ix:nonFraction> million and $<ix:nonFraction contextRef="c88" decimals="-5" format="ixt:num-dot-decimal" name="tara:NetProceeds" scale="6" unitRef="usd">66.3</ix:nonFraction> million, respectively.</p></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>11. Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>2020 Inducement Plan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 26, 2020, the Compensation Committee
of the Board of Directors (the &#8220;Compensation Committee&#8221;) approved the ArTara Therapeutics, Inc. Inducement Plan (the &#8220;2020
Inducement Plan&#8221;) in order to award nonstatutory stock options, restricted stock awards, restricted stock unit awards and other
stock-based awards to persons not previously an employee or director of the Company, or following a bona fide period of non-employment,
as an inducement material to such persons entering into employment with the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2020 Inducement Plan provides for a total
of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="tara:StocksIssuedDuringPeriodValueNewIssues" scale="0" unitRef="shares">600,000</ix:nonFraction> shares for the issuance of the Company&#8217;s common stock. The Compensation Committee also adopted a form of stock option
grant notice and stock option agreement and forms of restricted stock unit grant notice and restricted stock unit agreement for use with
the Inducement Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, <ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="tara:SharesAvailableForIssuance" scale="0" unitRef="shares">446,639</ix:nonFraction> shares remain
available to be issued under the 2020 Inducement Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>2017 Equity Incentive
Plan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2017, Private ArTara, (a predecessor
of the Company), its Board of Directors and its stockholders approved the ArTara Therapeutics, Inc. 2017 Equity Incentive Plan to enable
Private ArTara and its affiliates to recruit and retain highly qualified personnel and to incentivize personnel for productivity and
growth.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2017 Equity Incentive Plan provided for the
grant of a total of <ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="tara:SharesAvailableForIssuance" scale="0" unitRef="shares">2,000,000</ix:nonFraction> shares for the issuance of stock options, stock appreciation rights, restricted stock and restricted stock
units to among others, members of the Board of Directors, employees, consultants and service providers to the Company and its affiliates.
As of January 9, 2020, in connection with the Merger, no additional awards will be made under the 2017 Equity Incentive Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>2014 Equity Incentive Plan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 3, 2014, the stockholders approved
the 2014 Equity Incentive Plan. On June 20, 2017, the Company&#8217;s Board of Directors amended the 2014 Equity Incentive Plan, or the
Amended and Restated 2014 Plan. On July 31, 2017, the stockholders approved this amendment. On January 1, 2020, Protara Therapeutics,
Inc. amended its Amended and Restated 2014 Equity Incentive Plan to increase the number of shares of stock available for issuance under
the 2014 Equity Incentive Plan to <ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="tara:SharesAvailableForIssuance" scale="0" unitRef="shares">1,048,300</ix:nonFraction> shares and made conforming changes and updates pursuant to Section 162(m) of the Code.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Amended and Restated 2014 Plan provides for
the grant of incentive and non-statutory stock options, stock appreciation rights, restricted stock and stock unit awards, performance
units, stock grants and qualified performance-based awards. The Amended and Restated 2014 Plan provides that the number of shares reserved
and available for issuance will automatically increase each January 1, by four percent of the Company&#8217;s common stock on the immediately
preceding December 31, adjusted for the number of shares of the Company&#8217;s common stock issuable upon conversion of any security
that the Company may issue that is convertible into or exchangeable for the Company&#8217;s common stock, or such lesser number of shares
as determined by the Company&#8217;s Board of Directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Terms of the stock awards, including vesting
requirements, are determined by the Board of Directors, subject to the provisions of the plans. Certain awards provide for accelerated
vesting if there is a change in control as defined in the plans.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2022, pursuant to the Amended 2014
Plan&#8217;s annual evergreen feature, the number of shares authorized under the Amended 2014 Plan was increased by <ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">840,181</ix:nonFraction> shares to
<ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">1,238,785</ix:nonFraction> shares. As of December 31, 2022, <ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="tara:SharesAvailableForIssuance" scale="0" unitRef="shares">603,218</ix:nonFraction> shares remain available to be issued under the Amended 2014 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2023, pursuant to the Amended 2014
Plan&#8217;s annual evergreen feature, the number of shares authorized under the Amended 2014 Plan was increased by <ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">861,933</ix:nonFraction> shares to
<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="tara:SharesAvailableForIssuance" scale="0" unitRef="shares">1,465,151</ix:nonFraction> shares available to be issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>2014 Employee Stock
Purchase Plan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_16" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 3, 2014, the stockholders approved
the 2014 Employee Stock Purchase Plan (the &#8220;2014 ESPP&#8221;). The 2014 ESPP initially authorized the issuance of up to <ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">3,513</ix:nonFraction> shares
of the Company&#8217;s common stock. The number of shares increases each January 1, commencing on January 1, 2015 and ending on (and
including) January 1, 2024, by an amount equal to the lesser of one percent of the outstanding shares as of the end of the immediately
preceding fiscal year, <ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">7,025</ix:nonFraction> shares or any lower amount determined by the Company&#8217;s Board of Directors prior to each such January
1st.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_17" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2022, pursuant to the increase
per the 2014 ESPP, the number of shares authorized under the 2014 ESPP was increased by <ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">7,025</ix:nonFraction> shares to <ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="tara:SharesAvailableForIssuance" scale="0" unitRef="shares">32,062</ix:nonFraction> shares. As of December
31, 2022, the authorized number of shares under the 2014 ESPP is <ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="tara:NumberSharesAuthorized" scale="0" unitRef="shares">32,062</ix:nonFraction> and the number of shares available for issuance is <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="tara:SharesAvailableForIssuance" scale="0" unitRef="shares">32,062</ix:nonFraction>. During
the years ended December 31, 2022 and 2021, no shares were issued under the 2014 ESPP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_18" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2023, pursuant to the increase
per the 2014 ESPP, the number of shares authorized under the 2014 ESPP was increased by <ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="tara:NumberOfShareAuthorizedIncreased" scale="0" unitRef="shares">7,025</ix:nonFraction> shares to <ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="tara:NumberOfShareAuthorizedIncreased" scale="0" unitRef="shares">39,087</ix:nonFraction> shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_19" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Restricted Stock Units</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_20" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes restricted stock unit activity:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_21" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restricted<br/> Stock Units</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average Grant<br/> Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Non-vested 12/31/2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares">96,201</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c107" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">28.87</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">178,425</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">6.08</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">26,400</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">11.01</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares">51,388</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c108" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">21.67</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Non-vested 12/31/2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares">196,838</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c109" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">12.49</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_22" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of RSUs is amortized on a straight-line
basis over the requisite service period of the respective awards. As of December 31, 2022, the unamortized value of RSUs was $<ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="tara:UnamortizedValueOfRsus" scale="3" unitRef="usd">1,412</ix:nonFraction>.
As of December 31, 2022, the weighted average remaining amortization period was <ix:nonNumeric contextRef="c104" format="ixt-sec:duryear" name="tara:WeightedAverageRemainingAmortizationPeriod">1.53</ix:nonNumeric> years. As of December 31, 2022 and 2021, <ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="tara:NumberOfSharesRestrictedStock" scale="0" unitRef="shares">289,500</ix:nonFraction>
and <ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="tara:NumberOfSharesRestrictedStock" scale="0" unitRef="shares">286,918</ix:nonFraction> RSUs, respectively, have vested that have not yet been settled into shares of the Company&#8217;s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_23" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company issued <ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">31,658</ix:nonFraction>
shares of the Company&#8217;s common stock from the net settlement of <ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">48,806</ix:nonFraction> RSUs. The Company paid $<ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="tara:ConnectionWithTheNetShareSettlement" scale="3" unitRef="usd">90</ix:nonFraction> in connection with the net share
settlement of these RSUs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_24" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Stock Options</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_25" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determined the fair value of stock
options granted based upon the assumptions as provided below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_26" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_25"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">$ <ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">2.77</ix:nonFraction> - $ <ix:nonFraction contextRef="c111" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">6.90</ix:nonFraction></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">$ <ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">6.56</ix:nonFraction> - $ <ix:nonFraction contextRef="c113" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">19.82</ix:nonFraction></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 66%; text-align: left">Dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c114" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">92.00</ix:nonFraction>% - <ix:nonFraction contextRef="c115" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">99.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c116" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">89.00</ix:nonFraction>% - <ix:nonFraction contextRef="c117" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">98.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c114" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.46</ix:nonFraction>% - <ix:nonFraction contextRef="c115" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">4.23</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c116" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.45</ix:nonFraction>% - <ix:nonFraction contextRef="c117" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.33</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c114" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.27</ix:nonNumeric> - <ix:nonNumeric contextRef="c115" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.08</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c116" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.27</ix:nonNumeric> - <ix:nonNumeric contextRef="c117" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.08</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_27" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes stock option activities
for the year ended December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_28" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_27"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term&#160;(years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding 12/31/2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">1,356,639</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">20.51</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c119" format="ixt-sec:duryear" name="tara:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2">8.59</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" id="ix_14_fact" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">844,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">6.13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">246,977</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">15.35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" unitRef="shares">125,733</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">25.40</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">1,828,329</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">14.23</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c119" format="ixt-sec:duryear" name="tara:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm">8.16</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Vested or expected to vest at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares">1,828,329</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">14.23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c119" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">8.16</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable as of December, 31 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">755,234</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="tara:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" scale="0" unitRef="usdPershares">18.71</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c119" format="ixt-sec:duryear" name="tara:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable">7.50</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_29" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_28"><ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate&#160;intrinsic
value&#160;represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31,
2022. The&#160;intrinsic value&#160;of options exercised during the years ended December&#160;31, 2022 and 2021 was $0 as no options
were exercised.</span></ix:footnote></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_30" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average grant date fair value per
share of the options granted during the years ended December 31, 2022 and 2021 was $<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd">4.80</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd">12.60</ix:nonFraction>, respectively. As of December 31,
2022, there was approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="tara:ShareBasedCompensationUnrecognized" scale="3" unitRef="usd">8,333</ix:nonFraction> of unrecognized share-based compensation for unvested stock option grants which is expected to be
recognized over a weighted average period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1">2.50</ix:nonNumeric> years. The total unrecognized share-based compensation cost will be adjusted for actual
forfeitures as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_31" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_30"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Summary of Stock-Based Compensation Expense</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_32" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_31"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following tables summarize total stock-based compensation costs
recognized:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_33" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_32"><ix:nonNumeric contextRef="c0" escape="true" name="tara:IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">RSUs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">1,272</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c105" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">4,520</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">5,416</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">5,842</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">6,688</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">10,362</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_34" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_33"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock-based compensation expense was reflected within the consolidated
statements of operations and comprehensive loss as:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_34"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">1,511</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">1,409</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">5,177</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">8,953</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">6,688</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">10,362</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Federal and State income tax expense is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Current</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in">Total current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Federal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd">7,954</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd">8,918</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd">1,068</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" unitRef="usd">4,294</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in">Total deferred</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd">9,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd">4,624</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">9,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">4,624</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total income tax expense (benefit)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income taxes, if applicable, are provided
for the differences between the basis of assets and liabilities for financial reporting and income tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tax effects of temporary differences that
give rise to significant portions of the deferred tax assets are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net operating loss carry forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd">26,768</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd">23,350</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="3" unitRef="usd">3,418</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Stock option expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitRef="usd">2,477</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitRef="usd">920</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd">3,710</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd">1,551</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tara:DeferredTaxAssetsOperatingLeaseLiability" scale="3" unitRef="usd">1,481</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tara:DeferredTaxAssetsOperatingLeaseLiability" scale="3" unitRef="usd">1,564</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">RSU expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tara:DeferredTaxAssetsRestrictedStockUnitsExpense" scale="3" unitRef="usd">2,199</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tara:DeferredTaxAssetsRestrictedStockUnitsExpense" scale="3" unitRef="usd">1,960</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" unitRef="usd">408</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" unitRef="usd">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd">40,461</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd">29,352</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">38,983</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">27,803</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Deferred tax assets, net of valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd">1,478</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd">1,549</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Operating right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="tara:DeferredTaxLiabilitiesOperatingRightofuseAsset" scale="3" unitRef="usd">1,456</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="tara:DeferredTaxLiabilitiesOperatingRightofuseAsset" scale="3" unitRef="usd">1,549</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" sign="-" unitRef="usd">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" unitRef="usd">1,478</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" unitRef="usd">1,549</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Deferred tax assets, net of valuation allowance and deferred tax liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the provision for income
taxes with the amounts computed by applying the statutory Federal income tax to income before provision for income taxes is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">U.S. federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" sign="-" unitRef="pure">2.2</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" sign="-" unitRef="pure">0.6</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" sign="-" unitRef="pure">3.3</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" sign="-" unitRef="pure">2.8</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">True-up to prior years return</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" sign="-" unitRef="pure">0.7</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" unitRef="pure">8.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" sign="-" unitRef="pure">0.3</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" unitRef="pure">0.6</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State rate change</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" unitRef="pure">1.5</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="tara:EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost" scale="-2" unitRef="pure">0.1</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="tara:EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost" scale="-2" unitRef="pure">1.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" unitRef="pure">10.4</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure">17.0</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure">12.9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c7" name="tara:EffectiveTaxRateDescription">For the year ended December 31, 2021, the Company&#8217;s effective
tax rate was 0%, which consisted principally of a federal rate of 21%, and the Company&#8217;s estimate of state taxes, net of federal
benefit, of 0.6%, offset by a valuation allowance 12.9% and true-up to the prior year&#8217;s tax return of 8.2%.</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="tara:EffectiveTaxRateDescription">For the year ended December
31, 2022, the Company&#8217;s effective tax rate was 0%, which consisted principally of a federal rate of 21%, the Company&#8217;s estimate
of state taxes, net of federal benefit, of 2.2%, research and development credits of 3.3% and a true-up to the prior year&#8217;s tax
return of 0.7%, offset by goodwill impairment of 10.4% and a valuation allowance 17.0%.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_10" id="_IncomeTaxDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022 and 2021 for U.S. federal
and state income tax reporting purposes, the Company has approximately $<ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd">114,800</ix:nonFraction> and $<ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd">100,200</ix:nonFraction>, respectively, of unused net operating losses
(&#8220;NOLs&#8221;) available for carry forward to future years. As a result of the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;),
for U.S. income tax purposes, NOLs generated in tax years beginning before January 1, 2018 can still be carried forward for up to <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="tara:IncomeTaxCarriedForwardTerms">20</ix:nonNumeric> years,
but net operating losses generated for tax years beginning after December 31, 2017 carryforward indefinitely and can be used to offset
taxable income. Of the total Federal NOL, $<ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOtherTaxCarryforwards" scale="3" unitRef="usd">600</ix:nonFraction> can be carried forward until 2037; and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOtherTaxCarryforwards" scale="3" unitRef="usd">114,200</ix:nonFraction> can be carried forward indefinitely. The
New York state and city NOLs may be carried forward through the year 2042 and may be applied against future taxable income. Further, the
benefit from utilization of NOL carry forwards could be subject to limitations due to material ownership changes that could occur as the
Company continues to issue additional shares of common stock pursuant to its capital raising plans. Based on such limitations, the Company
has significant NOLs for which realization of tax benefits is uncertain. The Company has not performed a study to determine whether or
not there is such a limitation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protara Therapeutics, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Notes to Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(amounts in thousands, except share and per
share data)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_11" id="_IncomeTaxDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company remains subject to examination by
tax authorities for all tax years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_12" id="_IncomeTaxDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on a history of cumulative losses at the Company and the results
of operations for the years ended December 31, 2022 and 2021, the Company determined that it is more likely than not that it will not
realize benefits from the net deferred tax assets. The Company will not record income tax benefits in the financial statements until it
is determined that it is more likely than not that the Company will generate sufficient taxable income to realize the deferred income
tax assets. As a result of the analysis, the Company determined that a full valuation allowance against the deferred tax assets, net,
was required. As of December 31, 2022 and 2021, the Company has recorded a valuation allowance of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" unitRef="usd">39.0</ix:nonFraction> million and $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" unitRef="usd">27.8</ix:nonFraction> million, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022 and 2021, management
does not believe that the Company has any material uncertain tax positions that would require it to measure and reflect the potential
lack of sustainability of a position on audit in its consolidated financial statements. The Company will continue to evaluate its uncertain
tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does
not believe there will be any material changes in its unrecognized tax positions over the next year.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CompensationAndEmployeeBenefitPlansTextBlock-c0_cont_1" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>13. Employee Benefit Plan</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_CompensationAndEmployeeBenefitPlansTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains a defined contribution
benefit plan under section 401(k) of the Internal Revenue Code covering substantially all qualified employees of the Company (the &#8220;401(k)
Plan&#8221;). Under the 401(k) Plan, the Company matches <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="tara:EmployeeContributions" scale="-2" unitRef="pure">100</ix:nonFraction>% of employee contributions up to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="tara:EmployeeCompensation" scale="-2" unitRef="pure">4</ix:nonFraction>% of employee compensation. For the years
ended December 31, 2022 and 2021, the Company recorded expense of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLaborRelatedExpenses" scale="3" unitRef="usd">223</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLaborRelatedExpenses" scale="3" unitRef="usd">215</ix:nonFraction>, respectively, representing employer contributions under
the 401(k) Plan.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>14. Net Loss per Common Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_2" id="_EarningsPerShareTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the computation
of the net loss per share attributable to common stockholders, basic and diluted:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_3" id="_EarningsPerShareTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Net loss attributable to common stockholders</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" unitRef="usd">65,952</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" unitRef="usd">47,252</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-110; -sec-ix-hidden: hidden-fact-109">Weighted-average common shares outstanding &#8211; basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">11,259,615</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">11,232,576</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-112; -sec-ix-hidden: hidden-fact-111">Net loss per share attributable to common stockholders, basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" sign="-" unitRef="usdPershares">5.86</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" sign="-" unitRef="usdPershares">4.21</ix:nonFraction></td><td style="padding-bottom: 2pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_4" id="_EarningsPerShareTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the Company was in a net loss position
for all periods presented, net loss per share attributable to common stockholders was the same on a basic and diluted basis, as the inclusion
of all potential common equivalent shares outstanding would have been anti-dilutive. The Company excluded the following potential common
shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to
common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_EarningsPerShareTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="tara:ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Stock options issued and outstanding</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="tara:StockOptionsIssuedAndOutstanding" scale="0" unitRef="shares">1,828,329</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="tara:StockOptionsIssuedAndOutstanding" scale="0" unitRef="shares">1,356,639</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted stock units issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="tara:RestrictedStockUnitsIssuedAndOutstanding" scale="0" unitRef="shares">486,338</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="tara:RestrictedStockUnitsIssuedAndOutstanding" scale="0" unitRef="shares">383,119</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Conversion of Series 1 Convertible Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="tara:ConversionOfSeries1ConvertiblePreferredStock" scale="0" unitRef="shares">8,029,039</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="tara:ConversionOfSeries1ConvertiblePreferredStock" scale="0" unitRef="shares">8,029,039</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total potentially dilutive shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="tara:TotalPotentiallyDilutiveShares" scale="0" unitRef="shares">10,343,706</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="tara:TotalPotentiallyDilutiveShares" scale="0" unitRef="shares">9,768,797</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-26</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="us-gaap:Goodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-3" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" decimals="0" id="hidden-fact-5" name="us-gaap:PreferredStockSharesAuthorized" unitRef="shares">10000000</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="0" id="hidden-fact-6" name="us-gaap:PreferredStockSharesAuthorized" unitRef="shares">10000000</ix:nonFraction>
<ix:nonFraction contextRef="c3" decimals="3" id="hidden-fact-7" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="usdPershares">0.001</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="3" id="hidden-fact-8" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="usdPershares">0.001</ix:nonFraction>
<ix:nonFraction contextRef="c3" decimals="0" id="hidden-fact-9" name="us-gaap:CommonStockSharesAuthorized" unitRef="shares">100000000</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="0" id="hidden-fact-10" name="us-gaap:CommonStockSharesAuthorized" unitRef="shares">100000000</ix:nonFraction>
<ix:nonFraction contextRef="c3" decimals="3" id="hidden-fact-11" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="usdPershares">0.001</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="3" id="hidden-fact-12" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="usdPershares">0.001</ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-13" name="us-gaap:GoodwillImpairmentLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="2" id="hidden-fact-14" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">4.21</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-15" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">5.86</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="0" id="hidden-fact-16" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">11232576</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="0" id="hidden-fact-17" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">11259615</ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-18" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-19" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-20" name="tara:SettlementOfRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-21" name="tara:SettlementOfRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-22" name="tara:SettlementOfRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-23" name="tara:SettlementOfRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-24" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-25" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-26" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-27" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-28" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-29" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-30" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-31" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-32" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-33" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-34" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-35" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-36" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-37" name="tara:SettlementOfRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-38" name="tara:SettlementOfRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-39" name="tara:SettlementOfRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-40" name="tara:SettlementOfRestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-41" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-42" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-43" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-44" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-45" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-46" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-47" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-48" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-49" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-50" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-51" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-52" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-53" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-54" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-55" name="us-gaap:IncomeTaxesPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-56" name="us-gaap:IncomeTaxesPaidNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c42" id="hidden-fact-57" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-58" name="us-gaap:GoodwillAcquiredDuringPeriod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c43" id="hidden-fact-59" name="us-gaap:Goodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-60" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-61" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-62" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-63" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-64" name="us-gaap:RestrictedCashAndInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-65" name="us-gaap:RestrictedCashAndInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-66" name="us-gaap:MarketableSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-67" name="us-gaap:MarketableSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-68" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-69" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-70" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-71" name="us-gaap:RestrictedCashAndInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-72" name="us-gaap:RestrictedCashAndInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-73" name="us-gaap:MarketableSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-74" name="us-gaap:MarketableSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-75" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-76" name="tara:UnrealizedGains" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-77" name="tara:UnrealizedGains" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-78" name="tara:UnrealizedGains" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-79" name="tara:UnrealizedGains" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-80" name="tara:UnrealizedGains" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-81" name="tara:UnrealizedGains" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-82" name="us-gaap:RealizedInvestmentGainsLosses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c119" id="hidden-fact-83" name="tara:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c119" id="hidden-fact-84" name="tara:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c119" id="hidden-fact-85" name="tara:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c119" id="hidden-fact-86" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c119" id="hidden-fact-87" name="tara:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c119" id="hidden-fact-88" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c119" id="hidden-fact-89" name="tara:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c119" id="hidden-fact-90" name="tara:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c119" id="hidden-fact-91" name="tara:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c119" id="hidden-fact-92" name="tara:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c120" id="hidden-fact-93" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c120" id="hidden-fact-94" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c120" id="hidden-fact-95" name="tara:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-96" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-97" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-98" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-99" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-100" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-101" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-102" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-103" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-104" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-105" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-106" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-107" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-108" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="INF" id="hidden-fact-109" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">11232576</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="INF" id="hidden-fact-110" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">11259615</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="2" id="hidden-fact-111" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">4.21</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-112" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">5.86</ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001359931</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="tara-20221231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><ix:relationship fromRefs="ix_0_fact hidden-fact-60 hidden-fact-61 ix_1_fact hidden-fact-62 ix_2_fact hidden-fact-63 ix_3_fact ix_4_fact hidden-fact-69 hidden-fact-70 ix_5_fact" toRefs="ix_0_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_6_fact hidden-fact-64 hidden-fact-65 ix_7_fact ix_8_fact hidden-fact-71 hidden-fact-72 ix_9_fact" toRefs="ix_1_footnote"></ix:relationship>
<ix:relationship fromRefs="hidden-fact-66 ix_10_fact hidden-fact-67 ix_11_fact hidden-fact-73 ix_12_fact hidden-fact-74 ix_13_fact" toRefs="ix_2_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_14_fact hidden-fact-84 hidden-fact-88 hidden-fact-90 hidden-fact-92 hidden-fact-93 hidden-fact-94 hidden-fact-95" toRefs="ix_3_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:Series1PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:Series1PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tara:Series1PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tara:Series1PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tara:Series1PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tara:Series1PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tara:Series1PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tara:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraERpGibwnKDuAJiNyIYG2H8s4SQ1D2uYlD5jFc0teK32BeW1Fr2o1Ni9NHX7+JbcT6d9/LlbyRbJSUzPIQg0nOkdo5WNEqHQXf9xzR45imSnjrybOQNzpPFlStmTd3tNMP/V17WoireM4++Z8KBdOTup6WP0OPJ7JL5pzC5fEliqx4tW2skLfFbEtpya7tUtv6utPlPNxxao1J664Ea+AVghzTKIOb7zE=] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tara:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tara:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tara:PropertyAndEquipmentNotYetPlacedIntoServiceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tara:PropertyAndEquipmentNotYetPlacedIntoServiceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tara:CholineLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-09-01</xbrli:startDate>
    <xbrli:endDate>2017-09-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tara:IowaAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tara:IowaAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-12-01</xbrli:startDate>
    <xbrli:endDate>2017-12-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tara:FeinsteinAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tara:FeinsteinAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-11-01</xbrli:startDate>
    <xbrli:endDate>2018-11-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tara:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tara:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-24</xbrli:startDate>
    <xbrli:endDate>2020-09-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-06</xbrli:startDate>
    <xbrli:endDate>2020-10-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tara:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tara:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-24</xbrli:startDate>
    <xbrli:endDate>2020-09-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentyTwentyInducementPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentySeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2014-10-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tara:BoardOfDirectorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2014-10-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2013-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2014-01-01</xbrli:startDate>
    <xbrli:endDate>2014-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2014-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tara:USFederalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tara:StateIncomeTaxMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001359931</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">tara:FederalNOLMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.6
<SEQUENCE>2
<FILENAME>f10k2022ex3-6_protarathera.htm
<DESCRIPTION>COMPOSITE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE REGISTRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 3.6</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">THIS COMPOSITE CERTIFICATE OF INCORPORATION OF PROTARA THERAPEUTICS,
INC. REFLECTS THE PROVISIONS OF ITS SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION AS AMENDED AND RESTATED ON OCTOBER 27, 2014,
AND ALL AMENDMENTS THERETO FILED WITH THE DELAWARE SECRETARY OF STATE THEREAFTER, BUT IS NOT AN AMENDMENT AND/OR RESTATEMENT THEREOF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>COMPOSITE CERTIFICATE OF INCORPORATION OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROTARA THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE ONE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">The name of the corporation is Protara Therapeutics, Inc.
(the &ldquo;<U>Corporation</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE TWO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">The address of the Corporation&rsquo;s
registered office is 1209 Orange Street, in the City of Wilmington, New Castle County, Delaware 19801. The name of the registered agent
in charge thereof is The Corporation Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE THREE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">The nature of the business or purpose
of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law
of the State of Delaware (the &ldquo;<U>DGCL</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE FOUR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Section 1. <U>Authorized Shares</U>.
The total number of shares of all classes of capital stock which the Corporation shall have authority to issue is One Hundred Ten million
(110,000,000) shares, consisting of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">One Hundred million (100,000,000) shares of common stock, par value $0.001 per share (&ldquo;<U>Common Stock</U>&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Ten million (10,000,000) shares of undesignated preferred stock, par value $0.001 per share (the &ldquo;<U>Preferred Stock</U>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Such stock may be issued from time to
time by the Corporation for such consideration as may be fixed by the board of directors of the Corporation (the &ldquo;<U>Board of Directors</U>&rdquo;).
The following is a statement of the powers, designations, preferences, privileges, and relative rights in respect of each class of capital
stock of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Section 2. <U>Common Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">(a) <U>General</U>.
The voting, dividend and liquidation rights of the holders of Common Stock are subject to and qualified by the rights of the holders of
Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">(b) <U>Votin</U>g.
Except as otherwise provided by the DGCL or this Restated Certificate and subject to the rights of holders of any series of Preferred
Stock, all of the voting power of the stockholders of the Corporation shall be vested in the holders of the Common Stock, and each holder
of Common Stock shall have one vote for each share held by such holder on all matters voted upon by the stockholders of the Corporation;
provided, <U>however</U>, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on
any amendment to this Restated Certificate (or on any amendment to a certificate of designations of any series of Preferred Stock) that
alters or changes the powers, preferences, rights or other terms of one or more outstanding series of Preferred Stock if the holders of
such affected series of Preferred Stock are entitled to vote, either separately or together with the holders of one or more other such
series, on such amendment pursuant to this Restated Certificate (or pursuant to a certificate of designations of any series of Preferred
Stock) or pursuant to the DGCL. There shall be no cumulative voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">(c) <U>Dividends</U>.
Except as otherwise provided by the DGCL or this Restated Certificate, dividends may be declared and paid on the Common Stock from funds
lawfully available therefor if, as and when determined by the Board of Directors and subject to any preferential dividend rights of any
then outstanding shares of Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">(d) <U>No
Preemptive Rights</U><I>.</I> The holders of the Common Stock shall have no preemptive rights to subscribe for any shares of any class
of stock of the Corporation whether now or hereafter authorized.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">(e) <U>No
Conversion Ri</U>g<U>hts</U><I>.</I> The Common Stock shall not be convertible into, or exchangeable for, shares of any other class or
classes or of any other series of the same class of the Corporation&rsquo;s capital stock.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">(f) <U>Liquidation</U>.
Upon the dissolution or liquidation or winding up of the affairs of the Corporation, whether voluntary or involuntary, holders of Common
Stock will be entitled to receive all assets of the Corporation available for distribution to its stockholders equally on a per share
basis, subject to any preferential rights of any then outstanding shares of Preferred Stock and after payment or provision for payment
of the Corporation&rsquo;s debts.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Section 3. <U>Preferred Stock</U>. To
the fullest extent authorized by the DGCL, shares of Preferred Stock may be issued from time to time in one or more series, each of such
series to have such powers, designations, preferences, and relative, participating, optional, or other special rights, if any, and such
qualifications and restrictions, if any, as are stated or expressed in the resolution or resolutions of the Board of Directors providing
for such series of Preferred Stock. Different series of Preferred Stock shall not be construed to constitute different classes of shares
for the purposes of voting by classes unless expressly so provided in such resolution or resolutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Authority is hereby granted to the Board
of Directors, acting by resolution or resolutions adopted at any time and from time to time, to create, provide for, designate and issue,
out of the authorized but unissued shares of Preferred Stock, one or more series of Preferred Stock, and, in connection with the creation
of any such series of Preferred Stock, to determine and fix the powers, designations, preferences, and relative, participating, optional,
or other special rights, if any, and the qualifications and restrictions, if any, including without limitation dividend rights, conversion
rights, voting rights (if any), redemption privileges, and liquidation preferences, of such series of Preferred Stock (which need not
be uniform among series), all to the fullest extent now or hereafter permitted by the DGCL. Without limiting the generality of the foregoing,
the resolution or resolutions providing for the creation or issuance of any series of Preferred Stock may provide that such series shall
be superior to, rank equally with, or be junior to any other series of Preferred Stock, all to the fullest extent permitted by law. No
resolution, vote, or consent of the holders of the capital stock of the Corporation shall be required in connection with the creation
or issuance of any shares of any series of Preferred Stock authorized by and complying with the conditions of this Restated Certificate,
the right to any such resolution, vote, or consent being expressly waived by all present and future holders of the capital stock of the
Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Any resolution or resolutions adopted
by the Board of Directors pursuant to the authority vested in them by this Section 3 of Article Four shall be set forth in a certificate
of designation along with the number of shares of such series of Preferred Stock as to which the resolution or resolutions shall apply
and such certificate shall be executed, acknowledged, filed, recorded, and shall become effective, in accordance with Section 103 of the
DGCL. Unless otherwise provided in any such resolution or resolutions, the number of shares of any such series of Preferred Stock to which
such resolution or resolutions apply may be increased (but not above the total number of authorized shares of Preferred Stock) or decreased
(but not below the number of shares of such series of Preferred Stock then outstanding) by a certificate likewise executed, acknowledged,
filed and recorded, setting forth a statement that a specified increase or decrease therein has been authorized and directed by a resolution
or resolutions likewise adopted by the Board of Directors. In case the number of such shares shall be decreased, the number of shares
so specified in the certificate shall resume the status which they had prior to the adoption of the first resolution or resolutions. When
no shares of any such series of Preferred Stock are outstanding, either because none were issued or because none remain outstanding, a
certificate setting forth a resolution or resolutions adopted by the Board of Directors that none of the authorized shares of such series
of Preferred Stock are outstanding, and that none will be issued subject to the certificate of designations previously filed with respect
to such series of Preferred Stock, may be executed, acknowledged, filed and recorded in the same manner as previously described and it
shall have the effect of eliminating from this Restated Certificate all matters set forth in the certificate of designations with respect
to such series of Preferred Stock. If no shares of any such series of Preferred Stock established by a resolution or resolutions adopted
by the Board of Directors have been issued, the voting powers, designations, preferences and relative, participating, optional or other
rights, if any, with the qualifications, limitations or restrictions thereof, may be amended by a resolution or resolutions adopted by
the Board of Directors. In the event of any such amendment, a certificate which (i) states that no shares of such series of Preferred
Stock have been issued, (ii) sets forth the copy of the amending resolution or resolutions and (iii) if the designation of such series
of Preferred Stock is being changed, indicates the original designation and the new designation, shall be executed, acknowledged, filed,
recorded, and shall become effective, in accordance with Section 103 of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Section 4. <U>Reverse
Stock Split</U>. Immediately prior to the Effective Time (as defined below in this Section 4) (the &ldquo;<U>Reverse Stock Split
Effective Time</U>&rdquo;), a 1-for-40 reverse stock split of the shares of the Common Stock issued and outstanding immediately
prior to the Reverse Stock Split Effective Time shall become effective, whereby every forty (40) shares of Common Stock issued and
outstanding immediately prior to the Reverse Stock Split Effective Time, automatically, and without any action on the part of the
holder thereof, shall be reclassified and combined into one (1) share of Common Stock (the &ldquo;<U>Reverse Stock
Split</U>&rdquo;). The par value of the Common Stock and the Preferred Stock following the Reverse Stock Split shall remain at
$0.001 per share. The number of authorized shares of Common Stock and Preferred Stock set forth in the first paragraph of Article
Four of this Restated Certificate shall not be affected by, and shall remain unchanged following, the Reverse Stock Split. No
fractional shares of Common Stock shall be issued or issuable in connection with the Reverse Stock Split and, in lieu thereof, any
person who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split (determined
after aggregating all of such fractional shares) shall be entitled to receive, following the Reverse Stock Split, a cash payment
equal to the fraction of which such holder would otherwise be entitled multiplied by the fair value per share of Common Stock as
determined by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Each stock certificate that represented shares
of Common Stock that were issued and outstanding immediately prior to the Reverse Stock Split Effective Time shall, from and after the
Reverse Stock Split Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number
of whole shares of Common Stock into which the shares formerly represented by such stock certificate have been reclassified and combined
as a result of the Reverse Stock Split (as well as the right to receive cash in lieu of fractional shares of Common Stock after the effectiveness
of the Reverse Stock Split). As soon as practicable after the effectiveness of the Reverse Stock Split and, if applicable in the case
of shares of Common Stock represented by a stock certificate, the surrender of the stock certificate or stock certificates (or lost stock
certificate affidavit and agreement in lieu thereof) for such shares of Common Stock, the Corporation shall (a) issue and deliver, or
cause to be issued and delivered, to each holder of shares of Common Stock immediately prior to the Reverse Stock Split Effective Time,
or to his, her or its nominees, either a stock certificate or stock certificates or a notice of a book-entry made by the Corporation in
its stock records, as applicable, for the number of full shares of Common Stock into which the number of shares of Common Stock held by
such holder immediately prior to the effectiveness of the Reverse Stock Split has been reclassified and combined upon the effectiveness
of the Reverse Stock Split and (b) pay, or cause to be paid, cash in lieu of any fraction of a share of Common Stock resulting from the
Reverse Stock Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">For purposes hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&ldquo;<U>Effective Time</U>&rdquo; has the meaning given to such term
in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&ldquo;<U>Merger Agreement</U>&rdquo; means the Agreement and Plan
of Merger and Reorganization, dated as of September 23, 2019, among the Corporation, REM 1 Acquisition, Inc., a Delaware corporation and
wholly-owned subsidiary of the Corporation, and ArTara Therapeutics, Inc., a Delaware corporation, without amendment, restatement or other
modification in any material respect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Section 5. <U>Automatic Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">5.1 <U>Effectiveness</U>. Subject to, and immediately
following the later of the Effective Time and the consummation of the Private Placement (as such term is defined in the Merger Agreement)
(the later of the foregoing, the &ldquo;Automatic Conversion Effective Time&rdquo;), all outstanding shares of Series A Convertible Preferred
Stock, par value $0.001 per share, of the Corporation (the &ldquo;Series A Convertible Preferred Stock&rdquo;) shall automatically be
converted into shares of Common Stock, at the then effective Conversion Rate (as defined in the Certificate of Designation of Preferences,
Rights and Limitations of Series A Convertible Preferred Stock (the &ldquo;Certificate of Designation&rdquo;)) applicable to Series A
Convertible Preferred Stock, after giving effect to the Reverse Stock Split and as otherwise determined in accordance with the provisions
of Section 7(c) of the Certificate of Designation, all pursuant to and in accordance with the terms of the Certificate of Designation,
as if each Holder (as defined in the Certificate of Designation) had delivered a Conversion Notice (as defined in the Certificate of Designation)
at the Automatic Conversion Effective Time but without any such Holder being required to actually deliver such Conversion Notice, but
without regard to any limitation on the conversion of the Series A Convertible Preferred Stock, including, without limitation the9.985%
Cap (as such term is defined in the Certificate of Designation). The automatic conversion of all outstanding shares of Series A Convertible
Preferred Stock into Common Stock pursuant to this Section 5.1 is sometimes referred to herein as the &ldquo;Automatic Conversion.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">5.2 <U>No Inconsistent Provisions; Termination</U>.
In the event that any provision of this Section 5 shall conflict with, or not be consistent with, any provision of the Certificate of
Designation, such provision of this Section 5 shall govern and control. The provisions of this Section 5 shall automatically, without
further action by any Holder or the Corporation, terminate and be of no further force or effect upon the termination of the Merger Agreement
prior to the Automatic Conversion Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE FIVE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">The Corporation is to have perpetual existence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE SIX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Section 1. <U>Classification of Directors</U>.
Effective as of the closing (the &ldquo;<U>IPO Closin</U>g&rdquo;) of the Corporation&rsquo;s first public offering of shares of Common
Stock registered pursuant to the Securities Act of 1933, as amended, the Board of Directors shall be divided into three classes of directors,
Class I, Class II, and Class III, such classes to be as nearly equal in number of directors as possible, having staggered three-year terms
of office (except to the extent otherwise provided in the next sentence with respect to the initial term of the first and second of such
classes of directors). The initial term of office of the directors of Class I shall expire as of the first annual meeting of the Corporation&rsquo;s
stockholders following the IPO Closing; the initial term of office of the directors of Class II shall expire as of the second annual meeting
of the Corporation&rsquo;s stockholders following the IPO Closing; and the initial term of office of the directors of Class III shall
expire as of the third annual meeting of the Corporation&rsquo;s stockholders following the IPO Closing. At each annual meeting of stockholders
of the Corporation after the IPO Closing, nominees will stand for election to succeed those directors whose terms are to expire as of
such annual meeting of stockholders, and such nominees elected at such annual meeting of stockholders shall be elected for a term expiring
at the third annual meeting of stockholders following their election. Directors shall hold office until the annual meeting of stockholders
in which their term is scheduled to expire as set forth above in this Section 1 of Article Six and until their respective successors are
duly elected or qualified or until their earlier death, incapacity, resignation or removal. Those directors already in office immediately
prior to the IPO Closing shall be allocated among the three classes of directors contemplated under this Section 1 of Article Six pursuant
to a resolution or resolutions adopted by the Board of Directors prior to the IPO Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Section 2. <U>Removal</U>. Subject to
the special rights of the holders of any series of Preferred Stock to elect directors, the directors of the Corporation may be removed
only for cause by the affirmative vote of the holders of at least seventy-five percent (75%) of the outstanding shares of capital stock
of the Corporation entitled to vote in the election of directors or class of directors, voting together as a single class, at a meeting
of the stockholders called for that purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Section 3. <U>Vacancies</U>. Except as
the DGCL may otherwise require, any new directorships or vacancies in the Board of Directors, including new directorships resulting from
any increase in the number of directors to serve in the Board of Directors and/or any unfilled vacancies by reason of death, resignation,
disqualification, removal for cause, failure to elect or otherwise with respect to any director, may be filled only by the vote of a majority
of the remaining directors then in office, although less than a quorum, or by the sole remaining director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Section 4. <U>Number of Directors</U>.
Subject to the special rights of the holders of any series of Preferred Stock to elect directors, the number of directors which shall
constitute the Board of Directors shall be fixed exclusively by the Board of Directors from time to time in accordance with the by-laws
of the Corporation. No decrease in the number of directors constituting the whole board shall shorten the term of any incumbent director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE SEVEN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">The Board of Directors shall have the
power and authority: (i) to adopt, amend or repeal the Corporation&rsquo;s by-laws, subject to the power of the stockholders of the Corporation
entitled to vote with respect thereto to make, alter, amend or repeal the bylaws; provided , that with respect to the powers of stockholders
entitled to vote with respect thereto to make, alter, amend or repeal the bylaws, in addition to any other vote otherwise required by
law, the affirmative vote of the holders of at least seventy-five percent (75%) of the outstanding shares of capital stock of the Corporation
entitled to vote in the election of directors or class of directors, voting together as a single class, shall be required to make, alter,
amend or repeal the bylaws of the Corporation; and (ii) to the full extent permitted or not prohibited by law, and without the consent
of or other action by the stockholders, to authorize or create mortgages, pledges or other liens or encumbrances upon any or all of the
assets, real, personal or mixed, and franchises of the Corporation, including after-acquired property, and to exercise all of the powers
of the Corporation in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE EIGHT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Except as otherwise provided for by any
resolutions of the Board of Directors providing for the issuance of any series of Preferred Stock, effective as of the IPO Closing, any
action required or permitted to be taken by the stockholders of the Corporation may be taken only at a duly called annual or special meeting
of the stockholders in which such action is properly brought before such meeting, and not by written consent in lieu of such a meeting.
Subject to any special rights of the holders of any series of Preferred Stock, and to the requirements of applicable law, special meetings
of stockholders of the Corporation may be called only by or at the direction of the Board of Directors pursuant to a resolution adopted
by a majority of the total number of directors. Any business transacted at any special meeting of stockholders shall be limited to matters
relating to the purpose or purposes stated in the notice of meeting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE NINE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">The Corporation reserves the right to
amend, alter, change or repeal any provision contained in this Restated Certificate, in the manner now or hereafter prescribed by the
DGCL, and all rights conferred upon stockholders herein are granted subject to this reservation. Notwithstanding anything to the contrary
contained in this Restated Certificate, and notwithstanding that a lesser percentage may be permitted from time to time by applicable
law, the affirmative vote of the holders of at least seventy-five percent (75%) of the outstanding shares of capital stock of the Corporation
entitled to vote with in the election of directors or class of directors, voting together as a single class (in addition to any separate
class vote that may in the future be required pursuant to the terms of any outstanding Preferred Stock), shall be required to amend or
repeal the provisions of Articles Four (only to the extent it relates to the authority of the Board of Directors to issue shares of Preferred
Stock in one or more series, the terms of which may be determined by the Board of Directors), Six, Seven, Eight, Nine, Ten or Eleven of
this Restated Certificate or to reduce the numbers of authorized shares of Common Stock or Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE TEN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Section 1. <U>Limitation of Liabilit</U>y.
To the fullest extent permitted by the DGCL as it now exists or may hereafter be amended (but, in the case of any such amendment, only
to the extent that such amendment permits the Corporation to provide broader indemnification rights than permitted prior thereto), no
director of the Corporation shall be personally liable to the Corporation or to any of its stockholders for monetary damages for breach
of fiduciary duty as a director, notwithstanding any provision of law imposing such liability; provided, however, that to the extent required
from time to time by applicable law, this Article Ten shall not eliminate or limit the liability of a director, to the extent such liability
is provided by applicable law, (i) for any breach of the director&rsquo;s duty of loyalty to the corporation or its stockholders, (ii)
for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174
of the DGCL, or (iv) for any transactions from which the director derived an improper personal benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Section 2. <U>Indemnification</U>. The
Corporation shall, to the fullest extent permitted by Section 145 of the DGCL and as further provided in the Corporation&rsquo;s by-laws,
each as amended from time to time, indemnify each person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that
such person is or was, or has agreed to become, a director or officer of the Corporation, or is or was serving, or has agreed to serve,
at the request of the Corporation, as a director, officer or trustee of, or in a similar capacity with, another corporation, partnership,
joint venture, trust or other enterprise (including any employee benefit plan), or by reason of any action alleged to have been taken
or omitted in such capacity, against all expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually
and reasonably incurred by him or her or on his or her behalf in connection with such action, suit or proceeding and any appeal therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Indemnification may include payment by
the Corporation of expenses in defending an action or proceeding in advance of the final disposition of such action or proceeding upon
receipt of an undertaking by the person indemnified to repay such payment if it is ultimately determined that such person is not entitled
to indemnification under this Article Ten, which undertaking may be accepted without reference to the financial ability of such person
to make such repayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 36pt">The Corporation
shall not indemnify any such person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person
unless the initiation thereof was approved by the Board of Directors or except and to the extent otherwise permitted in the Corporation&rsquo;s
by-laws or in an agreement between the Corporation and such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">The indemnification rights provided in
this Article Ten (i) shall not be deemed exclusive of any other rights to which those indemnified may be entitled under the Corporation&rsquo;s
by-laws, any law, agreement or vote of stockholders or disinterested directors or otherwise, and (ii) shall inure to the benefit of the
heirs, executors and administrators of such persons. The Corporation may, to the extent authorized from time to time by its Board of Directors,
grant indemnification rights to other employees or agents of the Corporation or other persons serving the Corporation and such rights
may be equivalent to, or greater or less than, those set forth in this Article Ten.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Section 3. <U>Mer</U>g<U>er or Consolidation</U>.
For purposes of this Article Ten, references to the &ldquo;Corporation&rdquo; shall include, in addition to the resulting corporation,
any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate
existence had continued, would have had power and authority to indemnify its directors, officers and employees or agents, so that any
person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such
constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise,
shall stand in the same position under this Article Ten with respect to the resulting or surviving corporation as he or she would have
with respect to such constituent corporation if its separate existence had continued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Section 4. <U>Amendment or Repeal</U>.
No amendment to or repeal of this Article Ten shall apply to or have any effect on the liability or alleged liability of any director
for or with respect to any acts or omissions of such director occurring prior to the effective date of such amendment or repeal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE ELEVEN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">Unless the Corporation, as authorized
by the Board of Directors, consents in writing to the selection of one or more alternative forums, the Court of Chancery of the State
of Delaware shall be the sole and exclusive forum for a stockholder (including a beneficial owner) to bring (i) any derivative action
or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director,
officer or other employee of the Corporation to the Corporation or the Corporation&rsquo;s stockholders, (iii) any action asserting a
claim against the Corporation arising pursuant to any provision of the DGCL or this Restated Certificate or the Corporation&rsquo;s Bylaws
or (iv) any action asserting a claim against the Corporation, its directors, officers or employees governed by the internal affairs doctrine,
except for, as to each of (i) through (iv), any claim as to which the Court of Chancery determines that there is an indispensable party
not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of
the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum
other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. Any person or entity purchasing
or otherwise acquiring any interest in shares of capital stock of the Corporation (including, without limitation, shares of Common Stock)
shall, and shall be deemed to, have notice of and to have consented to the provisions of this Article Eleven.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE TWELVE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">If any provision or provisions of this
Restated Certificate shall be held to be invalid, illegal or unenforceable as applied to any circumstance for any reason whatsoever: (i)
the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Restated
Certificate (including, without limitation, each portion of any paragraph of this Restated Certificate containing any such provision held
to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected
or impaired thereby and (ii) to the fullest extent possible, the provisions of this Restated Certificate (including, without limitation,
each such portion of any paragraph of this Restated Certificate containing any such provision held to be invalid, illegal or unenforceable)
shall be construed so as to permit the Corporation to protect its directors, officers, employees and agents from personal liability in
respect of their good faith service to or for the benefit of the Corporation to the fullest extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>3
<FILENAME>f10k2022ex10-17_protarathera.htm
<DESCRIPTION>EXECUTIVE EMPLOYMENT AGREEMENT, EFFECTIVE AS OF JANUARY 30, 2023 BY AND BETWEEN THE REGISTRANT AND PATRICK FABBIO
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.17</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>PROTARA
THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>EXECUTIVE EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">THIS EXECUTIVE EMPLOYMENT
AGREEMENT (this &ldquo;<U>Agreement</U>&rdquo;) is entered into by and between Protara Therapeutics, Inc. (the &ldquo;<U>Company</U>&rdquo;),
and Patrick Fabbio (&ldquo;<U>Executive</U>&rdquo;) (collectively referred to as the &ldquo;<U>Parties</U>&rdquo; or individually referred
to as a &ldquo;<U>Party</U>&rdquo;) as of January 5, 2023, and shall become effective on Executive&rsquo;s commencement of employment
with the Company (the &ldquo;<U>Effective Date</U>&rdquo;), which is expected to be January 30, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt"><B>WHEREAS</B>,
the Company and Executive desire to enter into this Agreement to define their mutual rights and duties with respect to Executive&rsquo;s
compensation and benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt"><B>NOW, THEREFORE</B>,
in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt"><FONT STYLE="font-size: 10pt">1.
</FONT><U>Duties and Scope of Employment</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-size: 10pt">(a) </FONT><U>Positions
and Duties</U>. As of the Effective Date, Executive will serve as Chief Financial Officer of the Company. Executive shall render such
business and professional services in the performance of Executive&rsquo;s duties, consistent with Executive&rsquo;s position within the
Company, as shall reasonably be assigned to Executive by the Company&rsquo;s Chief Executive Officer. Executive will be based at the Company&rsquo;s
headquarters in New York, NY. The period of Executive&rsquo;s at-will employment under the terms of this Agreement is referred to herein
as the &ldquo;<U>Employment Term</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-size: 10pt">(b) </FONT><U>Obligations</U>.
During the Employment Term, Executive will perform Executive&rsquo;s duties faithfully and to the best of Executive&rsquo;s ability and
will devote Executive&rsquo;s full business efforts and time to the Company. For the duration of the Employment Term, Executive agrees
not to actively engage in any other employment, occupation or consulting activity for any direct or indirect remuneration without the
prior approval of the Company&rsquo;s Chief Executive Officer. For clarity, service on a not-for-profit board of directors shall not be
considered engagement in other employment, occupation or consulting activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt"><FONT STYLE="font-size: 10pt">2. </FONT><U>At-Will
Employment</U>. Subject to Sections 7, 8, and 9 below, the Parties agree that Executive&rsquo;s employment with the Company will be &ldquo;at-will&rdquo;
employment and may be terminated at any time with or without cause upon written notice, for any reason or no reason. Executive understands
and agrees that neither Executive&rsquo;s job performance nor promotions, commendations, bonuses or the like from the Company give rise
to or in any way serve as the basis for modification, amendment, or extension, by implication or otherwise, of Executive&rsquo;s employment
with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt"><FONT STYLE="font-size: 10pt">3.
</FONT><U>Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-size: 10pt">(a) </FONT><U>Base
Salary</U>. During the Employment Term the Company will pay Executive as compensation for Executive&rsquo;s services a base salary at
a rate of $445,000 per year, as modified from time to time at the discretion of the Board of Directors of the Company (the &ldquo;<U>Board</U>&rdquo;)
or a duly constituted committee of the Board (the &ldquo;<U>Base Salary</U>&rdquo;). The Base Salary will be paid in regular installments
in accordance with the Company&rsquo;s normal payroll practices (subject to required withholding). Any increase in Base Salary (together
with the then existing Base Salary) shall serve as the &ldquo;<U>Base Salary</U>&rdquo; for future employment under this Agreement. The
first and last payment will be adjusted, if necessary, to reflect a commencement or termination date other than the first or last working
day of a pay period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt">(b) <U>Signing
and Annual Bonus</U>. The Company shall pay to Executive a one-time signing bonus of $25,000 (the &ldquo;<U>Signing Bonus</U>&rdquo;),
payable within thirty (30) days of the Effective Date. The Signing Bonus is subject to the following repayment obligations: as a condition
of Executive&rsquo;s employment with the Company and for receiving the Signing Bonus, Executive agrees that if, at any time during the
twelve (12) months following the Effective Date Executive resigns from the Company, then Executive shall repay the Signing Bonus to the
Company in full. In all cases, Executive specifically authorizes the Company to deduct all of the Signing Bonus required to be repaid,
if any, from Executive&rsquo;s final payroll check, and to the extent that there is a balance still owed by Executive, Executive will
provide payment to the Company of such balance within thirty (30) days of Executive&rsquo;s separation from service. Executive will also
be eligible to earn an annual discretionary bonus (the &ldquo;<U>Annual Bonus</U>&rdquo;) with a target amount equal to forty-five percent
(45%) of Executive&rsquo;s then current Base Salary. Ninety percent (90%) of Executive&rsquo;s <FONT STYLE="font-size: 10pt">target is
attributed to Company performance and ten percent (10%) is attributed to individual/team performance. </FONT>The amount of the Annual
Bonus, if any, will be determined in the sole discretion of the Board or a duly constituted committee of the Board and based, in part,
on Executive&rsquo;s performance and the performance of the Company during the calendar year. The Annual Bonus may be greater or lesser
than the target bonus amount and may be zero, based upon the achievement of agreed upon corporate and/or individual goals. Executive will
become eligible for the Annual Bonus beginning in 2024 (i.e., with respect to Executive&rsquo;s performance and the performance of the
Company during calendar year 2023). The Annual Bonus is not earned until paid and no pro-rated amount will be paid if Executive&rsquo;s
employment terminates for any reason prior to the payment date. The Annual Bonus is not earned until paid and no pro-rated amount will
be paid if Executive&rsquo;s employment terminates for any reason prior to the payment date except as specified in Section 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt">(c) <U>Equity</U>.
Subject to the approval of the Board or a duly constituted committee thereof, and as an inducement material to Executive&rsquo;s entering
into the employment with the Company, on the Effective Date, Executive shall be granted an option to purchase 300,000 shares of the Company&rsquo;s
common stock (the &ldquo;<U>Option</U>&rdquo;), at the fair market value on the date of the grant The shares subject to the Option will
vest over four years as follows: the first twenty-five percent (25%) will vest on the one-year anniversary of the grant date and the
remaining options will vest monthly over the remaining thirty-six (36) months of the four-year vesting period. The Option shall be governed
in all respects by the terms of the Company&rsquo;s 2020 Inducement plan (the &ldquo;<U>Option Plan</U>&rdquo;) and option agreement
between Executive and the Company (the &ldquo;<U>Option Agreement</U>&rdquo;), both of which documents are incorporated herein by reference.
Executive will be eligible to receive awards of stock options, restricted stock units or other equity awards pursuant to any plans or
arrangements the Company may have in effect from time to time. The Board or a committee of the Board shall determine in its discretion
and guided by market benchmarks whether Executive shall be granted any such equity awards and the terms of any such award in accordance
with the terms of any applicable plan or arrangement that may be in effect from time to time. Executive will become eligible to receive
equity awards as part of the Company&rsquo;s annual equity compensation program beginning in 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt"><FONT STYLE="font-size: 10pt">4. </FONT><U>Employee
Benefits</U>. During the Employment Term, Executive will be eligible to participate in the employee benefit plans currently and hereafter
maintained by the Company of general applicability to other senior executives of the Company, including, without limitation, the Company&rsquo;s
group medical, dental, vision, disability, life insurance, and flexible-spending account plans. The Company reserves the right to cancel
or change the benefit plans and programs it offers to its employees at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt"><FONT STYLE="font-size: 10pt">5. </FONT><U>Business
Expenses</U>. During the Employment Term, the Company will reimburse Executive for reasonable business travel, entertainment or other
business expenses incurred by Executive in the furtherance of or in connection with the performance of Executive&rsquo;s duties hereunder,
in accordance with the Company&rsquo;s expense reimbursement policy as in effect from time to time. Executive will be reimbursed for reasonable
expenses associated with overnight or late- night commitments at the office or other locations of meetings in accordance with the Company
reimbursement policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt"><FONT STYLE="font-size: 10pt">6.
</FONT><U>Termination on Death or Disability</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-size: 10pt">(a) </FONT><U>Effectiveness</U>.
Executive&rsquo;s employment will terminate automatically upon Executive&rsquo;s Death or, upon fourteen (14) days prior written notice
from the Company, in the event of Disability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-size: 10pt">(b) </FONT><U>Effect
of Termination</U>. Upon any termination for death or Disability, Executive or his or her dependents shall be entitled to: (i) Executive&rsquo;s
Base Salary through the effective date of termination; (ii) the right to continue health care benefits under Title X of the Consolidated
Budget Reconciliation Act of 1985, as amended (&ldquo;<U>COBRA</U>&rdquo;), at the Company&rsquo;s expense for a period of six (6) months,
to the extent required and available by law; (iii) reimbursement of expenses for which Executive is entitled to be reimbursed pursuant
to Section 5above, but for which Executive has not yet been reimbursed; and (iv) no other severance or benefits of any kind, unless required
by law or pursuant to any other written Company plans or policies, as then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt"><FONT STYLE="font-size: 10pt">7.
</FONT><U>Involuntary Termination for Cause; Resignation Without Good Reason</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-size: 10pt">(a) </FONT><U>Effectiveness</U>.
Notwithstanding any other provision of this Agreement, the Company may terminate Executive&rsquo;s employment at any time for Cause or
Executive may resign from Executive&rsquo;s employment with the Company at any time without Good Reason. Termination for Cause, or Executive&rsquo;s
resignation without Good Reason, shall be effective on the date either Party gives notice to the other Party of such termination in accordance
with this Agreement unless otherwise agreed by the Parties. In the event that the Company accelerates the effective date of a resignation,
such acceleration shall not be construed as a termination of Executives employment by the Company or deemed Good Reason for such resignation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-size: 10pt">(b) </FONT><U>Effect
of Termination</U>. ln the case of the Company&rsquo;s termination of Executive&rsquo;s employment for Cause, or Executive&rsquo;s resignation
without Good Reason, Executive shall be entitled to receive: (i) Base Salary through the effective date of the termination or resignation,
as applicable; (ii) reimbursement of all business expenses for which Executive is entitled to be reimbursed pursuant to Section 5 above,
but for which Executive has not yet been reimbursed; (iii ) the right to continue health care benefits under COBRA, at Executive&rsquo;s
cost, to the extent required and available by law; and (iv) no other severance or benefits of any kind unless required by law or pursuant
to any other written Company plans or policies, as then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt"><FONT STYLE="font-size: 10pt">8.
</FONT><U>Involuntary Termination Without Cause; Resignation for Good Reason</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-size: 10pt">(a) </FONT><U>Effect
of Termination</U>. The Company shall be entitled to terminate Executive with or without Cause at any time, subject to the following:</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 82pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">(i) If Executive
is terminated by the Company involuntarily without Cause (excluding any termination due to death or Disability) or Executive resigns for
Good Reason, then, subject to the limitations of Sections 8(b) and 24 below, Executive shall be entitled to receive: (A) Executive&rsquo;s
Base Salary through the effective date of the termination or resignation; (B) a lump sum severance pay equal to nine (9) months of Executive&rsquo;s
Base Salary; (C) a lump sum payment equal to Executive&rsquo;s Annual Bonus at target; (D) reimbursement of all business expenses for
which Executive is entitled to be reimbursed pursuant to Section 5 above, but for which Executive has not yet been reimbursed; (E) reimbursement
of any benefit plan premium costs paid by Executive for the same level of coverage Executive had during employment for nine (9) months;
(F) any unused and accrued vacation and (G) no other severance or benefits of any kind unless required by law or pursuant to any written
Company plans or policies, as then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-size: 10pt">(b) </FONT><U>Conditions
Precedent</U>. Any severance payments contemplated by Section 8(a) above are conditional on Executive: (i) continuing to comply with the
applicable terms of this Agreement and the Confidential Information Agreement (defined below); and (ii) signing and not revoking a separation
agreement and release of known and unknown claims in the form provided by the Company and the Executive (including non-disparagement and
cooperation provisions) (the &ldquo;<U>Release</U>&rdquo;) and provided that such Release becomes effective and irrevocable no later than
sixty (60) days following the termination date or such earlier date required by the release (such deadline, the &ldquo;<U>Release Deadline</U>&rdquo;).
If the Release does not become effective by the Release Deadline, Executive will forfeit any rights to severance or benefits under this
Section 8 or elsewhere in this Agreement. Any severance payments or other benefits under this Agreement that would be considered Deferred
Compensation Separation Benefits (as defined in Section 25) will be paid on, or, in the case of installments, will not commence until,
the sixtieth (60th) day following Executive&rsquo;s separation from service, or, if later, such time as required by Section 25(b). Except
as required by Section 25(b), any installment payments that would have been made to Employee during the sixty (60) day period immediately
following Executive&rsquo;s separation from service but for the preceding sentence will be paid to Executive on the sixtieth (60th) day
following Executive&rsquo;s separation from service and the remaining payments will be made as provided in this Agreement, unless subject
to the 6-month payment delay described herein. Any severance payments under this Agreement that would not be considered Deferred Compensation
Separation Benefits will be paid on, or, in the case of installments, will not commence until, the first payroll date that occurs on or
after the date the Release becomes effective and any installment payments that would have been made to Executive during the period prior
to the date the Release becomes effective following Executive&rsquo;s separation from service but for the preceding sentence will be paid
to Executive on the first payroll date that occurs on or after the date the Release becomes effective. Notwithstanding the foregoing,
this Section 8(b) shall not limit Executive&rsquo;s ability to obtain expense reimbursements under Section 5 or any other compensation
or benefits otherwise required by law or in accordance with written Company plans or policies, as then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt"><FONT STYLE="font-size: 10pt">9.
</FONT><U>Definitions.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-size: 10pt">a. </FONT><U>Cause</U>.
For purposes of this Agreement, &ldquo;<U>Cause</U>&rdquo; shall mean: (i) Executive&rsquo;s willful and continued failure to
substantially perform the material duties and obligations under this Agreement (for reasons other than death or Disability), which
failure, if curable within the reasonable discretion of the Company, is not cured to the reasonable satisfaction of the Company
within thirty (30) days after Executive&rsquo;s receipt of written notice from the Company of such failure; (ii) Executive&rsquo;s
failure or refusal to comply with the policies, standards and regulations established by the Company from time-to-time which results
in a material loss, damage or injury directly to the Company, and if curable in the discretion of the Company, is not cured to the
reasonable satisfaction of the Company within thirty (30) days after Executive&rsquo;s receipt of written notice of such failure
from the Company; (iii) any act of personal dishonesty, fraud, embezzlement, misrepresentation, or other unlawful act committed by
Executive that benefits Executive at the expense of the Company; (iv) the Executive&rsquo;s violation of a federal or state law or
regulation applicable to the Company&rsquo;s business; (v) the Executive&rsquo;s violation of, or a plea of <I>nolo contendere </I>or
guilty to, a felony under the laws of the United States or any state; or (vi) the Executive&rsquo;s material breach of the terms of
this Agreement or the Confidential Information Agreement, which breach, if curable within the reasonable discretion of the Company,
is not cured to the reasonable satisfaction of the Company within thirty (30) days after Executive&rsquo;s receipt of written notice
from the Company of such breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-size: 10pt">b. </FONT><U>Change
in Control</U>. For purposes of this Agreement, <U>&ldquo;Change in Control&rdquo;</U> shall have the meaning attributed to such term
in the Option Plan, but shall <U>not</U> include the merger transaction pursuant to that certain Agreement and Plan of Merger and Reorganization,
dated September 23, 2019, by and among the Company, Protara Therapeutics, Inc. Private ArTara and REM 1 Acquisition, Inc., a wholly owned
subsidiary of Protara Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-size: 10pt">c. </FONT><U>Disability</U>.
For purposes of this Agreement, &ldquo;<U>Disability</U>&rdquo; means that Executive, at the time notice is given, has been unable
to substantially perform Executive&rsquo;s duties under this Agreement for not less than one-hundred and twenty (120) work days
within a twelve (12) consecutive month period as a result of Executive&rsquo;s incapacity due to a physical or mental condition and,
if reasonable accommodation is required by law, after any reasonable accommodation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-size: 10pt">d. </FONT><U>Good
Reason</U>. For purposes of this Agreement &ldquo;<U>Good Reason</U>&rdquo; means Executive&rsquo;s written notice of Executive&rsquo;s
intent to resign for Good Reason with a reasonable description of the grounds therefor within ten (10) days after the occurrence of one
or more of the following without Executive&rsquo;s consent, and subsequent resignation within thirty (30) days following the expiration
of any Company cure period (discussed below): (i) a material diminution of Executive&rsquo;s duties, position or responsibilities; (ii)
a change in Executive&rsquo;s reporting structure wherein Executive is no longer reporting to the Chief Executive Officer; (iii) a material
diminution in Executive&rsquo;s Base Salary (other than a reduction of not more than 10% that is applicable to similarly situated executives
of the Company); (iv) a Change in Control; (v) any other action or inaction that is a material breach of this Agreement by the Company;
or (vi) a material change in the geographic location of Executive&rsquo;s primary work facility or location; provided, that a relocation
of less than fifty (50) miles from Executive&rsquo;s then present location will not be considered a material change in geographic location.
Executive will not resign for Good Reason without first providing the Company with written notice of the acts or omissions constituting
the grounds for Good Reason within thirty (30) days of the initial existence of the grounds for Good Reason and a reasonable cure period
of not less than thirty (30) days following the date of such notice if such act or omission is capable of cure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">10. <U>Acceleration
of Options and Severance Pay in Change in Control</U>. If within twelve (12) months following a Change in Control (as defined above) the
Company or the successor corporation terminates Executive&rsquo;s employment with the Company or successor corporation for other than
Cause, death or Disability, then Executive shall be entitled to acceleration of one hundred percent (100%) of Executive&rsquo;s then-unvested
and outstanding equity awards and, in lieu of the payment referred to in Section 8(a)(i)(B), a lump severance pay equal to twelve (12)
months of Executive&rsquo;s Base Salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">11.
<U>Company Matters.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-size: 10pt">(a) </FONT><U>Proprietary
Information and Inventions</U>. In connection with Executive&rsquo;s employment with the Company, Executive will receive and have
access to Company confidential information and trade secrets. Accordingly, enclosed with this agreement is an Employee Confidential
Information and Inventions Assignment Agreement (the &ldquo;<U>Confidential Information Agreement</U>&rdquo;) which contains
restrictive covenants and prohibits unauthorized use or disclosure of the Company&rsquo;s confidential information and trade
secrets, among other obligations. Executive agrees to review the Confidential Information Agreement and only sign it after careful
consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-size: 10pt">(b)
</FONT><U>Resignation on Termination</U>. On termination of Executive&rsquo;s employment, regardless of the reason for such termination,
Executive shall immediately (and with contemporaneous effect) resign any directorships, offices or other positions that Executive may
hold in the Company or any affiliate, unless otherwise agreed in writing by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">12. <U>Arbitration</U>.
To ensure the timely and economical resolution of disputes that may arise in connection with Executive&rsquo;s employment with the Company,
Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach,
performance, negotiation, execution, or interpretation of this Agreement, Confidential Information Agreement, or Executive&rsquo;s employment,
or the termination of Executive&rsquo;s employment, including but not limited to all statutory claims, will be resolved pursuant to the
Federal Arbitration Act, 9 U.S.C. &sect;1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration
by a single arbitrator conducted in New York, New York by Judicial Arbitration and Mediation Services Inc. (&ldquo;<U>JAMS</U>&rdquo;)
under the then applicable JAMS rules (at the following web address: https://www.jamsadr.com/rules- employment - arbitration/); provided,
however, this arbitration provision shall not apply to sexual harassment claims. A hard copy of the rules will be provided to Executive
upon request. <B>By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute
through a trial by jury or judge or administrative proceeding</B>. In addition, all claims, disputes, or causes of action under this Section,
whether by Executive or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant)
or class member in any purported class or representative proceeding, nor joined or consolidated with the&middot; claims of any other person
or entity. The Arbitrator may not consolidate the claims of more than one person or entity and may not preside over any form of representative
or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable
law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather
than by arbitration. The Company acknowledges that Executive will have the right to be represented by legal counsel at any arbitration
proceeding. Questions of whether a claim is subject to arbitration under this Agreement shall be decided by the arbitrator. Likewise,
procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. The arbitrator
shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise
be permitted by law; (b) issue a written arbitration decision, to include the arbitrator&rsquo;s essential findings and conclusions and
a statement of the award; and (c) be authorized to award any or all remedies that Executive or the Company would be entitled to seek in
a court of law. Executive and the Company shall equally share all JAMS&rsquo; arbitration fees. The successful party (as described in
the Confidential Information Agreement, shall be entitled to reimbursement of legal fees and expenses. Nothing in this Agreement is intended
to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion
of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts
of any competent jurisdiction. To the extent applicable law prohibits mandatory arbitration of sexual harassment claims, in the event
Executive intend to bring multiple claims, including a sexual harassment claim, the sexual harassment may be publicly filed with a court,
while any other claims will remain subject to mandatory arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">13. <U>Assignment</U>.
This Agreement will be binding upon and inure to the benefit of (a) the heirs, executors and legal representatives of Executive upon
Executive&rsquo;s death and (b) any successor of the Company. Any such successor of the Company will be deemed substituted for the
Company under the&nbsp; terms of this Agreement for all purposes. For this purpose, &ldquo;<U>successor</U>&rdquo; means any person,
firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly
acquires all or substantially all of the assets or business of the Company. None of the rights of Executive to receive any form of
compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and
distribution. Any other attempted assignment, transfer, conveyance or other disposition of Executive&rsquo;s right to compensation
or other benefits will be null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">14. <U>Notices</U>.
All notices, requests, demands and other communications called for under this Agreement shall be in writing and shall be delivered personally
by hand or by courier, mailed by United States first-class mail, postage prepaid, and directed to the Party to be notified at the address
indicated for such Party on the signature page to this Agreement (and, in the case of the Chief Executive Officer, with a copy to the
General Counsel of the Company, which shall not constitute notice), or at such other address as such Party may designate by ten (10) days&rsquo;
advance written notice to the other Parties hereto. All such notices and other communications shall be deemed given upon personal delivery,
three (3) days after the date of mailing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">15. <U>Severability</U>.
In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void,
this Agreement will continue in full force and effect without said provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">16. <U>Integration</U>.
This Agreement, together with the Option Plan, Option Agreement, and the Confidential Information Agreement represents the entire agreement
and understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous agreements whether written
or oral. No waiver, alteration, or modification of any of the provisions of this Agreement will be binding unless in writing and signed
by duly authorized representatives of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">17. <U>Tax
Withholding</U>. All payments made pursuant to this Agreement will be subject to withholding of applicable taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">18. <U>Waiver</U>.
No Party shall be deemed to have waived any right, power or privilege under this Agreement or any provisions hereof unless such waiver
shall have been duly executed in writing and acknowledged by the Party to be charged with such waiver. The failure of any Party at any
time to insist on performance of any of the provisions of this Agreement shall in no way be construed to be a waiver of such provisions,
nor in any way to affect the validity of this Agreement or any part hereof. No waiver of any breach of this Agreement shall be held to
be a waiver of any other subsequent breach</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">19. <U>Governing
Law</U>. This Agreement will be governed by the laws of the State of New York (with the exception of its conflict of laws provisions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">20. <U>Acknowledgment</U>.
Executive acknowledges that Executive has had the opportunity to discuss this matter with and obtain advice from Executive&rsquo;s legal
counsel, has had sufficient time to, and has carefully read and fully understands all the provisions of this Agreement and is knowingly
and voluntarily entering into this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">21. <U>Counterparts</U>.
This Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original, and all such counterparts shall
constitute but one instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">22. <U>Effect
of Headings</U>. The section and subsection headings contained herein are for convenience only and shall not affect the construction hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">23. <U>Construction
of Agreement</U>. This Agreement has been negotiated by the respective Parties, and the language shall not be construed for or against
either Party.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">24. <U>Parachute
Payments</U>. If any payment or benefit Executive would receive from the Company or otherwise in connection with a Change in Control or
other similar transaction (a &ldquo;280G Payment&rdquo;) would (i) constitute a &ldquo;parachute payment&rdquo; within the meaning of Section
280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &ldquo;Excise
Tax&rdquo;), then any such 280G Payment (a &ldquo;Payment&rdquo;) shall be equal to the Reduced Amount. The &ldquo;Reduced Amount&rdquo;
shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject
to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined
by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and
the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&rsquo;s receipt, on an after-tax basis, of
the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction
in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding
sentence, the reduction shall occur in the manner (the &ldquo;Reduction Method&rdquo;) that results in the greatest economic benefit for
Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata
(the &ldquo;Pro Rata Reduction Method&rdquo;). Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method
would result in any portion of the Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise be subject
to taxes pursuant to Section 409A of the Code, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall
be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows: (A) as a first priority, the modification
shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an after-tax basis; (B) as
a second priority, Payments that are contingent on future events (e.g., being terminated without cause), shall be reduced (or eliminated)
before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &ldquo;deferred compensation&rdquo;
within the meaning of Section 409A of the Code shall be reduced (or eliminated) before Payments that are not deferred compensation within
the meaning of Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify">(a)
Unless Executive and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax
compliance purposes as of the day prior to the effective date of the Change in Control transaction triggering the Payment shall
perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the
individual, entity or group effecting the Change in Control transaction, the Company shall appoint a nationally recognized
accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the
determinations by such accounting firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause
the accounting firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting
documentation, to Executive and the Company within 15 calendar days after the date on which Executive&rsquo;s right to a 280G
Payment becomes reasonably likely to occur (if requested at that time by Executive or the Company) or such other time as requested
by Executive or the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify">(b)
If Executive receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this
Section and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax,
Executive shall promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the
first paragraph of this Section so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of
doubt, if the Reduced Amount was determined pursuant to clause (y) in the first paragraph of this Section, Executive shall have no
obligation to return any portion of the Payment pursuant to the preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 35.75pt">25.
<U>Section 409A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits
to be paid or provided to Executive, if any, pursuant to this Agreement, when considered together with any other severance payments or
separation benefits that are considered deferred compensation under Section 409A (together, the &ldquo;<U>Deferred Compensation Separation
Benefits</U>&rdquo;) will be paid or otherwise provided until Executive has a &ldquo;separation from service&rdquo; within the meaning
of Section 409A.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify">Notwithstanding anything to the contrary in this Agreement, if Executive isa &ldquo;specified employee&rdquo;
within the meaning of Section 409A at the time of Executive&rsquo;s termination(other than due to death), then the Deferred Compensation
Separation Benefits that are payable within the first six (6) months following Executive&rsquo;s separation from service, will become
payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of Executive&rsquo;s
separation from service. All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment
schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if Executive dies following Executive&rsquo;s
separation from service, but prior to the six (6) month anniversary of the separation from service, then any payments delayed in accordance
with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive&rsquo;s death and
all other Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment
or benefit. Each payment and benefit payable under this Agreement is intended to constitute separate payments for purposes of Section
l.409A- 2(b)(2) of the Treasury Regulations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify">Any amount paid under this Agreement that satisfies the requirements of the &ldquo;short-term deferral&rdquo;
rule set forth in Section l.409A-l(b)(4) of the Treasury Regulations will not constitute Deferred Compensation Separation Benefits for
purposes of clause (a) above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify">Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation
from service pursuant to Section 1.409A- l (b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not
constitute Deferred Compensation Separation Benefits for purposes of clause (a) above. For purposes of this Agreement, &ldquo;<U>Section
409A Limit</U>&rdquo; will mean the lesser of two (2) times: (i) Executive&rsquo;s annualized compensation based upon the annual rate
of pay paid to Executive during the Executive&rsquo;s taxable year preceding Executive&rsquo;s taxable year of Executive&rsquo;s termination
of employment as determined under Treasury Regulation Section l .409A-l(b)(9)(iii)(A)(l) and any Internal Revenue Service guidance issued
with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 40l(a)(17)
of the Code for the year in which Executive&rsquo;s employment is terminated.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">(e)</FONT></TD><TD STYLE="text-align: justify">The foregoing provisions are intended to comply with or be exempt from the requirements of Section 409A
so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section
409A, and any ambiguities herein will be interpreted to so comply. The Company and Executive agree to work together in good faith to consider
amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of
any additional tax or income recognition prior to actual payment to Executive under Section 409A.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Remainder of page is intentionally
blank; Signature page follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.75pt">IN WITNESS WHEREOF, each of the Parties
has executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.75pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&ldquo;COMPANY&rdquo;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; width: 60%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; width: 5%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Protara Therapeutics, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Jesse Shefferman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Jesse Shefferman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Date: </FONT></TD>
    <TD>January 5, 2023</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><U>Address</U>:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">345 Park Ave. South, 3<SUP>rd</SUP> Floor <BR>
New York, New York, 10010</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&ldquo;EXECUTIVE&rdquo;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Patrick Fabbio</P>



<P STYLE="margin: 0pt 0"></P>

</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: normal">Patrick Fabbio</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Date: </FONT></TD>
    <TD>January 6, 2023</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.75pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">9</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.75pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 35.75pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>f10k2022ex21-1_protarathera.htm
<DESCRIPTION>LIST OF SUBSIDIARIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>List of Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Subsidiary</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jurisdiction</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proteon Securities Corp.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Massachusetts</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proteon International Holdings, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proteon Bermuda Limited</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bermuda</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proteon Ireland Limited </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ireland</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ArTara Subsidiary, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All subsidiaries are 100% owned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>f10k2022ex23-1_protarathera.htm
<DESCRIPTION>CONSENT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the incorporation by reference in the following Registration
Statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Registration Statement (Forms S-8 Nos. 333-263392, 333-254124, 333-237497, 333-235918, 333-229123, 333-222415 and 333-200587, ) pertaining
to the Amended and Restated 2014 Equity Incentive Plan, as amended and 2014 Employee Stock Purchase Plan of Protara Therapeutics, Inc.,
and</TD></TR><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
             </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Registration Statement (Form S-3 No. 333-251224) of Protara Therapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.5pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5pt">of our report dated March 8, 2023, with respect to the consolidated
financial statements of Protara Therapeutics, Inc. included in this Annual Report (Form 10-K) of Protara Therapeutics, Inc. for the year
ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Ernst &amp; Young LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 180pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 8, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>f10k2022ex31-1_protarathera.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Certification of the Principal Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&sect;240.13a&minus;14 or &sect;240.15d&minus;14
of the Securities Exchange Act of 1934, as amended</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Jesse Shefferman, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 10&minus;K of Protara Therapeutics, Inc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were
made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included
in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&minus;15(e) and 15d&minus;15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and
procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control
over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures
and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s internal control over financial
reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the
case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s
board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal
control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize
and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have
a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 8, 2023</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jesse Shefferman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jesse Shefferman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>f10k2022ex31-2_protarathera.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Certification of the Principal Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&sect;240.13a&minus;14 or &sect;240.15d&minus;14
of the Securities Exchange Act of 1934, as amended</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Patrick Fabbio, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 10&minus;K of Protara Therapeutics, Inc.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were
made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included
in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&minus;15(e) and 15d&minus;15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and
procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control
over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures
and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s internal control over financial
reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the
case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal
control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s
board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal
control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize
and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have
a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 8, 2023</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Patrick Fabbio</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick Fabbio</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>f10k2022ex32-1_protarathera.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Certification Pursuant to 18 U.S.C. Section 1350</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(as adopted pursuant to Section 906 of the Sarbanes&minus;Oxley
Act of 2002)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirement set forth in Rule
13a-14(b) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and Section 1350 of Chapter 63 of Title
18 of the United States Code (18 U.S.C. &sect;1350), Jesse Shefferman, Chief Executive Officer of Protara Therapeutics, Inc. (the &ldquo;Company&rdquo;)
and Patrick Fabbio, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s Annual Report on Form 10-K for the period ended December 31, 2022, to which this Certification is attached as Exhibit 32.1 (the &ldquo;Annual Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>In Witness
Whereof</B>,</FONT> the undersigned have set their hands hereto as of the 8<SUP>th</SUP> day of March, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 8, 2023</FONT></TD>
    <TD STYLE="width: 40%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jesse Shefferman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jesse Shefferman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 8, 2023</FONT></TD>
    <TD STYLE="width: 40%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Patrick Fabbio</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patrick Fabbio</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;This certification accompanies the Form
10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into
any filing of Protara Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended
(whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #N G # 2(  A$! Q$!_\0
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M\\Y/^^37L&3ZFC)]30(\?\J7_GE)_P!\FCRI?^>4G_?)KV#)]31D^IH \?\
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M5?OK]10 ^?\ X^)/]X_SJ.I)_P#CXD_WC_.HZ "BBB@ HHHH **** "BBB@
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M]QOY5%4MO_K&_P!QOY5%0 4444 %%%% !1110 4444 %*OWU^HI*5?OK]10
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M^">?Y%&17H'_  FNJ_\ /#3O_ 1:/^$UU7_GAIW_ ("+1RU?Y5]__ "]/O\
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MZWY5"R-_=;\JU1FR!J@>K#(_]QOR-0O&_P#<;_ODUJC-E=ZA;K5AXW_YYO\
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M4@[<8QGK4BZ%</%#()H/WI7:"_.TG ;Z4K?]/'^'^07_ +B_'_,TO['\+?\
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M'_?'_P!>F'PPQ_Y>U_[X_P#KU:KT^Y#I3[',GK4#]*ZH>$W8G_3%Z?\ //\
M^O49\'N?^7U?^_?_ ->M5B*?<AT9]CDGJ%JZ\^"W/_+\O_?O_P"O3#X(<_\
M+^O_ 'Z_^O5K$TNY#H5.QQCU ]=L? <A_P"8@O\ WZ/^-,/@"0_\Q)/^_1_Q
MK18NC_,0\/5['#-UJ!Z[P_#R0_\ ,33_ +\G_&F'X;R'_F*)_P!^3_C6BQE#
M^;\R'AJO8X!J97?GX:2'_F*I_P!^3_C3?^%92_\ 063_ +\G_&K6-H?S?F1]
M5K=C@J*[W_A64O\ T%D_[\G_ !H_X5E+G_D+)_WX/^-/Z]0_F_,/JM;^4X*B
MN^/PQE!(_M9./^F!_P :3_A64O\ T%D_[\G_ !H^O4/YOS#ZK6_E."HKO?\
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MX9&B3AG"\"I?[.O1*(C:3>85W!=ASCUI^QH]OQ_X(O:U._\ 7W&W_P )I/\
M] ;1O_ 4?XT?\)I/_P! ;1O_  %'^-8R:7>M-'$UO)&TA(3>I&2!G'UJ,V%T
M&V-!*),@",H<G.<?RH]E1[?C_P $/:5>_P#7W&[_ ,)I/_T!M&_\!1_C1_PF
MD_\ T!M&_P# 4?XUA?8+SS&C^RR[T7<R[>0/6G2:?=1*IDA9=Z*Z#&=P8X&,
M4>QH]OQ_X(>TJ=_Z^XV_^$TG_P"@-HW_ ("C_&C_ (32?_H#:-_X"C_&L0:;
M?&8PBTF\P $KL.<'O43VMQ'")GAD6(G;N*X&?2CV-'M^/_!#VM3O_7W'0?\
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MB+_GC;_]_A1]9H_S(/85?Y6<K79?#W_CZU/_ *X)_P"A57_X5WXB_P">-O\
M]_A73^"O"NIZ)>7DE_'$$EB55VR!N0<USXK$4I49*,DV;8>C451-HH:P1\W-
M<+?,///(_.O=VL(W^];Q-]5!J(Z/9MUL;4_6)?\ "N"CCE37PG75PCGU."\
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ML'\/G4;O7I&L$M"(K-!=1%$GDVCSY%10=ORYQQP6H][N&O<Q3\3?%XZZV_\
MWZ3_  H_X6;XPSC^VGS_ -<D_P *NP^?H-EXJL8Y;:5;**.2RE:&-R0\JX8$
M@DY0U?CMT:\ME2TL&\)M9AI[@HF<[,NQ?[PE#YP/H,8H][N&O<Q/^%F>,/\
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MV-"YGU#7N<O_ ,+.\7_]!MO^_2?X4O\ PLSQA_T&G_[])_A5Z#4+NT@\4+*
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M<<CWDK0A)3#M1-Q+#KWZ"I?[++1P2)<1LLB*Y7.'"EMN<>G2E[278.9GGO\
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M&L:62!!]\%7.\8((Z\<'MBG?VE,>&L(F12A12K80H,*1S_.G==PT'[-8NXY
MZ%ED5I29 H.,#)&>1GCTS4=NFJQE%BA8_N\JC*K KG(.#UY.12?VA,5 >R1R
M00[,K9<$8ZYX_"G6VJW=K.\R6X+,$'*MQM&!T_E1=7W8:#9+/4Y9+<M&\CLG
MFQD$'@G.3^/K1;&>:626XGCC2 E9!*2N=Y.5X!(R<TZWU2ZM@ EL/]6(V(#
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M&-HR,[2IS\I[<_04?;(L#_6\$[>GR]>?<T^>7\X<S_F'_P!O:A_SV3_OVO\
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:SKZFC[.OJ: *]2P=33_LZ^IIR1A#P30!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %G C8# 2(  A$! Q$!_\0
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M ( O\C^[G_A]9_P3;_Z+_+_X:GXS_P#SNZ/^'UG_  3;_P"B_P O_AJ?C/\
M_.[K^$:BC_4#*_\ G[5_\&+_ .0#_B ?!_\ T,N)/_ 4?W<_\/K/^";?_1?Y
M?_#4_&?_ .=W1_P^L_X)M_\ 1?Y?_#4_&?\ ^=W7\(U%'^H&5_\ /VK_ .#%
M_P#(!_Q /@__ *&7$G_@*/[N?^'UG_!-O_HO\O\ X:GXS_\ SNZ/^'UG_!-O
M_HO\O_AJ?C/_ /.[K^$:BC_4#*_^?M7_ ,&+_P"0#_B ?!__ $,N(_\ P%']
MW/\ P^L_X)M_]%_E_P##4_&?_P"=W1_P^L_X)M_]%_E_\-3\9_\ YW=?PC44
M?Z@97_S]J_\ @:_^0#_B ?!__0SXC_\  8G]W/\ P^L_X)M_]%_E_P##4_&?
M_P"=W1_P^L_X)M_]%_E_\-3\9_\ YW=?PC44?Z@97_S]J_\ @Q?_ " ?\0#X
M/_Z&7$?_ ("C^[G_ (?6?\$V_P#HO\O_ (:GXS__ #NZ/^'UG_!-O_HO\O\
MX:GXS_\ SNZ_A&HH_P!0,K_Y^U?_  -?_(!_Q /@_P#Z&7$G_@"/[N?^'UG_
M  3;_P"B_P O_AJ?C/\ _.[H_P"'UG_!-O\ Z+_+_P"&I^,__P [NOX1J*/]
M0,K_ .?E7_P/_P"T#_B ?!__ $,N)/\ P%']W/\ P^L_X)M_]%_E_P##4_&?
M_P"=W1_P^L_X)M_]%_E_\-3\9_\ YW=?PC44?Z@97_S]J_\ @Q?_ " ?\0#X
M/_Z&7$?_ ("C^[G_ (?6?\$V_P#HO\O_ (:GXS__ #NZ/^'UG_!-O_HO\O\
MX:GXS_\ SNZ_A&HH_P"(?Y7_ ,_*O_@?_P!S#_B ?!__ $,N)/\ P!']W/\
MP^L_X)M_]%_E_P##4_&?_P"=W1_P^L_X)M_]%_E_\-3\9_\ YW=?PC44?Z@9
M7_S]J_\ @Q?_ " ?\0#X/_Z&7$G_ ("C^[G_ (?6?\$V_P#HO\O_ (:GXS__
M #NZ/^'UG_!-O_HO\O\ X:GXS_\ SNZ_A&HH_P!0,K_Y^U?_  8O_D _X@'P
M?_T,N)/_  !']W/_  ^L_P"";?\ T7^7_P -3\9__G=T?\/K/^";?_1?Y?\
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M\(U%'^H&5_\ /VK_ .#%_P#(!_Q /@__ *&7$G_@*/[N?^'UG_!-O_HO\O\
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M(_\ P%']W/\ P^L_X)M_]%_E_P##4_&?_P"=W1_P^L_X)M_]%_E_\-3\9_\
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MW#K.C:$J^)-"'A/^VCED9@/XBH(KY+\2> ]=\*_$;6/AE??\C!I?C#_A"_\
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M4*"< _#7QDU;QMXA^*?Q&UGXL2ZU/\1I_%WB=/'2^*@%U%-276@%76E PJJ
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MMAX3_MD'P%HVA'OX<;PT=".>IZG)KI?CC^VA<?%#X=6'P?\ A[\"O@Y^S?\
M"JV\1Z;XRO-!^%VE)J/B77?$NAONT'6-;\9:Q'!K^4)VB7R3.RX5YG %>K1_
M\%'9_&&@^&;']IO]EC]G_P#:A\7^#[73M(TGXE^/++4?#OC=M.T4@Z(^N:UH
M\$XUT[LN1'L1I&>1U=W9FZ;8OZW]=_LB-G&W)[ME9\UUIR7=[/I[JM<]'DSI
MYPL\60IITO8_5U/#WIWJ<T7&;C[!.3?)4C>W[NFXRFTXKOO^";E[X%UCX:_\
M% ;?XX:[XX'PQMOV/]-L?$-UX=WZCXDT/P)_PDU[N'@K1->!7'E[V D&PNJ
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M*6+>.?!HT)I"TB_$_7R1<,&\XK$9=@,L2/TO[7'QHO/VBX/^"2GQEU/2-/\
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MX33:C;_$ZV\1>&!X%70 #J1\3'6MNAJ5(P5(X(.01VY-?T*?MZVWAZP^%O\
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MF^-P+M*,;QTE+EUC>7)&\I*"<IN,5>2@XK5F_J_P2_X)=>!M3G^&WC;]K/\
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MQ^+_ ((;0/$MCI0 (UO1==T&&'PR/#V>"H##@'=DX'Z%?%GXF_M2_!O]H?\
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M[K&N7/A+X?Z7I/B3Q[\4?&I./^$'^&O@S24UC5M5#-PK2SR1Q*6.T-XB!8@
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MJG'W;2E'G4I6Y%)Q^>/V:?V=_P!F+Q/^S-\3/VDOVE?B'\7O!FA^!_C)X?\
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M &0#\&O%NBZAKOB?X8_&'P5X=U72->UFT5M5L?'4>EOK6L>$=;9204N(U69
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MPD?SAU"R&2/?L7B?A%^S1^R1^TQ^UK\(O@+\"_BA\<!\-O&'AOQ9>^+O%'Q
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MI14:<8QC*+;4HQC",8R3;:E&,9)MM23;;L033PR6\\$__'KQ9\_\@_\ S_\
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MW)X2FN5*<H4Y37*UR6DX2DE&24HKF7*]4DSOM8^*7Q$U[P!H'PNU3Q1J.H^
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M^=34_AS_ ,$__2)F5?\ @5_^O%;_ -,UC_4"T'_D#:1_V"-,_P#25**-!_Y
MVD?]@C3/_25**_F2I_$G_CG_ .ES/\V:_P#'K_\ 7^M_Z>K'\:O_  <&1W5Q
M^VC\/3':SRX_9O\ "ZA5M?,&T?$_Q\!R0,]".G09/6OPQ\BX_P"?&Y_\ O\
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MSXW/_@%_]E1Y%Q_SXW/_ (!?_95_I[?V;8?] ^U_\!8^V/;MM_3ZX/[-L/\
MH'VO_@+'VQ[=MOZ?7!_Q$>7_ $*H?^!Q_P @_P")AU_T2<O_  _5/_E9_F$^
M1<?\^-S_ . 7_P!E1Y%Q_P ^-S_X!?\ V5?Z>W]FV'_0/M?_  %C[8]NVW]/
MK@_LVP_Z!]K_ . L?;'MVV_I]<'_ !$>7_0JA_X''_(/^)AU_P!$G+_P_5/_
M )6?YA/D7'_/C<_^ 7_V5'D7'_/C<_\ @%_]E7^GM_9MA_T#[7_P%C[8]NVW
M]/K@_LVP_P"@?:_^ L?;'MVV_I]<'_$1Y?\ 0JA_X''_ "#_ (F'7_1*2_\
M#]4_^5G^83Y%Q_SXW/\ X!?_ &5'D7'_ #XW/_@%_P#95_I[?V;8?] ^U_\
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M'VQ[=MOZ?7!_Q$>6W]E0M_CC_D'_ !,.O^B4E_X?JG_RL_S"?(N/^?&Y_P#
M+_[*CR+C_GQN?_ +_P"RK_3V_LVP_P"@?:_^ L?;'MVV_I]<']FV'_0/M?\
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M_94>1<?\^-S_ . 7_P!E7^GM_9MA_P! ^U_\!8^V/;MM_3ZX/[-L/^@?:_\
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MT^N#^S;#_H'VO_@+'VQ[=MOZ?7!_Q$>7_0JA_P"!Q_R#_B8=?]$G+_P_5/\
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M\/:(?$6L:AJRQ0$"VBT+;,LID=CN( =< >K>(/CG\*O#?P]\+?%34_%VF_\
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M9*[7TUH?_!1']C'7]0LK&Q^/?A,IK&CG6;/5=2DU32?#MRSCRVT>/7];BM]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%&1ZT7MOIZ
M@%%%&1ZCGI[T!<**,@]#FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^9^P_P#$$>!_^A74?G_K))7\[<NE][=-NA_8)_Q$6?LN?]$2_:$_\%_PU_\
MGET?\1%G[+@Z?!+]H0?]P_X:_P#SRZ_C[HH_U'X<[3_\&5/\P_X@CP/_ -"N
MI_XDDO\ Y$_L$_XB+/V7/^B)?M"?^"_X:_\ SRZ3_B(L_9<_Z(C^T'_X+OAK
M_P#/+K^/RBC_ %'X<[3TNOXE39[VUZ]>_6X?\00X'_Z%<_\ Q))?_(G]@G_$
M1;^RY_T1+]H3_P %_P -O_GET?\ $1;^RY_T1+]H3_P7_#;_ .>77\?=%'^H
M_#G:?_@<_P#,/^((\#_]"NI_XDDO_D3^P3_B(M_9<_Z(E^T)_P""_P"&W_SR
MZ/\ B(M_9<_Z(E^T)_X+_AM_\\NOX^Z*/]1^'.T__ ZG^8?\01X'_P"A74_\
M227_ ,B?V"?\1%O[+G_1$OVA/_!?\-O_ )Y=!_X.+/V72#_Q9+]H3_P7_#7_
M .>77\?=%-<#<.76D]U_R\J=_4/^((\#]<KJ)=7_ *R2=EU=N76W;KMU/] G
M]A7_ (*#_#/]O2P^)6J_#;P7X_\ "$'PPU?P[I.LCQ_9Z%!/JDOB#2]3U2%]
M%7PYXE\3PR10KICK*7F0X:/8DCL-GZ"H@ =@3AN,G/'([<_RK^8__@V]&?#G
M[61[#Q3\*@?HVB>-A]>W:OZ<PH7"#/4;CZ__ *NQ[_E7Y;Q%EV&RK.,SP>#N
MHPFK7;=THIWUO9)NV]W;[OY6X]R?!9!Q?G&3Y2O^$O#55"GS-RDDZ=.>[]YZ
MS:O?6R>FB)QT'>BCZT5XRV/D HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D;H?H?Y4M(W0_0_R
MH ^._P!O3_DR?]K?_LW+XOG\?^$$U_GZU_G6?\LO\_W:_P!%/]O3_DR?]K?_
M +-R^+__ *@FOU_G6?\ ++_/]VOUKPY_W7-O1?D?U1]'G_DG.*/^RBPZ^7L8
MZ>GEMY!1117Z-9=E]R_R/Z(LNR^Y?Y!11119=E]R_P @LNR^Y?Y!11119=E]
MR_R"R[+[E_D%%%%%EV7W+_(++LON7^04444679?<O\@LNR^Y?Y!11119=E]R
M_P @LNR^Y?Y']4'_  ;>?\BU^UK[>*?A2?RT3QQ7].0_A_WL?EC_ !-?S&_\
M&WO_ "+7[6O_ &-'PJ_],?CBOZ<A_#_O?_$U^!\7?\E#FG_7Q?DS^#O%?3Q#
MS]+;ZQ'1;?P*7R)1T'T%+2+T'T'\J6OFSX **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#H?C3XH:SXAN?#D'A[PS<!FD$]N?$LP(4& ;VVYO[77[1'Q3^'?BS]GSX(?
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M0?0?RI:1>@^@_E2U\V? !1110 4444 %&!Z444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C=#]#_*EI&Z'Z'^5
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M%#C-'_!_"]_NL[]K.]K.Q_P/QV^_IWZ7.IHHHH **** "BBB@ HHHH ****
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M7Q/'/X]U>7Q+XYAFUWX<?$GPKXDUC0_$NM>2]WX?>Z>SER&MH8O,45G:O.6
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M -/^OO.CHKG/^$I\._\ 09T[_OO_ .RH_P"$I\._]!G3O^^__LJ .CHKG/\
MA*?#O_09T[_OO_[*C_A*?#O_ $&=._[[_P#LJ/Z_"_Y:^FNVH'1T5SG_  E/
MAW_H,Z=_WW_]E1_PE/AW_H,Z=_WW_P#94 ='17.?\)3X=_Z#.G?]]_\ V5'_
M  E/AW_H,Z=_WW_]E0!T=%<Y_P )3X=_Z#.G?]]__94?\)3X=_Z#.G?]]_\
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M,>'?V<?V-_'?Q4\4_%OX">)OCM=:5XT^(FB_!A_ %CX(\;_\(!KOA+6/[?\
M"\SZT[Z_+Y7@^:'RXO%D+22H+5 [J^:6_-+_ ,"E_P#)%<JVY5]R_P C]EOL
M]O\ \\8/R7_XFC[/;_\ /&#\E_\ B:_%P_\ !1CXY_$SXK_\$ZO^&?/@1HNN
M_!;]L/P+\7O%'CJ/QMXVT3PWXV\(:I\/SX;?6M'6/8T;R>$FU7661D0GQ<5
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M_#FO>(6&S?<S %F!8QEV6N1\ ?\ !,C]F?X8?%OP-\6/#5[\8FO?AEXP\?\
MQ ^%?P^U/XN^,-2^$?PS\2_%7^WAXZG\#^ 'F3P]H<7B,^(-7$\:JS%IE$9&
M2#^C@5>"!_/O^-#. <=?7MC]*TO?IH^G37R_X!-?_:%J^J_"RMT['Y]^#/\
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M&[4?A+J/PI^%_C[]H;XB>+?B[_PKOPP(GG\/>!=!'B&20Z!X M_$GV>[/AN
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M.MZ3X<72='DE*:$Z0Z]J_G.@=Y)&WAHR.?QHUW_@I#^VKI?QI^+'@'PU\(/
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M TJ/1=)1F' 9DB16(R=VY1Q@GTZBGW\]_/U[_.X=O+;R].WRL%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %A CH# 2(  A$! Q$!_\0
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M *Z\86O_ *U\46[_ .L2M]_+;\3]%?\ A[+_ ,% ?^B_'_PU_P '/_G<4?\
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MD/\ ]J?HK_P]E_X* _\ 1?C_ .&O^#G_ ,[BC_A[+_P4!_Z+\?\ PU_P<_\
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MH#_T7X_^&O\ @Y_\[BC_ (>R_P#!0'_HOQ_\-?\ !S_YW%?G510_##P]L_\
MC#^$WH]%PTTWH]$^?1O9/H[/H'^NO&'_ $5?%'SXA37S7+JNZZJZZGZW?L\?
M\%,/VW?'G[0'P,\$^*OC;)J?AKQ=\9?AMX9\0:<WP_\ A'IT]WX8\0>+M'\/
M:_I,5QH'P_2>*79-*JSQW$4T:N=DT7RL/ZY/.7T_G_@:_@P_9'/_ !E;^S(3
MS_Q?_P"#Y/O_ ,7*T#-?WE@ @<#H.U?Q9])SA/AK),]X2PV4\.4,GH5>'*N(
MJT*4(TE5KO-<53=>7+9RDX1C"\G*5E%7LC^D?!C/\]S+),?4S//'FM:&*@H5
MI7DX1<9ODNT]6]79)-IOJ?RH?\%T/^3N_A]_V;MX7_\ 5C_%:OQ@K]G_ /@N
MA_R=W\/O^S=O"_\ ZL?XK5^,%?UMX'_\FHX3_P"R=Q'_ *FXT_#/$IO_ %\X
MLU?3J_Y(>84445^IKGLOAV7?LC\]LNR^Y?Y!1111[_\ =_$++LON7^04444>
M_P#W?Q"R[+[E_D%%%%)N:3;L[)NRO=V3=EYNUEYM%12<HJRUE%:I6UDEKIMK
MKY7#R/?]?_K45_2#)X2_;CTOX7?LQS_\$]-.\/>'_@;KOP7\#7WB2S&C_"'0
M?$.J_$IV8>,];\=?\+9C'B35UEC0,7\-!7>3>HDD54Q^>7[=GP=F\7_MMZ;\
M(_A#X#L!\5/%'AKX:6_CKPMX/TE_#7@F]^+NO:3)XA\:ZWX.$T%M+%H*0'0/
M$\OB6:,2P,/%/C2:29XWF?\ (.&O%BAFN=U,#7HT:-*5'B2M0;XH<ZW#\.'9
MUJ?-Q-AIX>E#(X5'2;HNC7Q,:J?LY>\[O[[-_#[%99@XXR#E4<N122C=M\0Q
M@[<.\KE)N',N;F@K7;5D]?S+HK]:/BKX?D\"? CXI_LR_LRW.A>(="^#EAI?
MC']M;XPPS_V9/\1/'$NK?V+H_@SP.'B$NL> OA?XA55N("QVI;PJV'\Q?&7U
M/^Q[9?$ZX^%_['%C\&M/\%ZA^S-J3_$L?MI'5K;X<7^GO>CQ;K$FO_\ "Y&U
MHE\GP'_9*^%%C4S-&D8O$:T-L&G,O%:6%R9YVLGI17UJ4(QQ&*EA_P#9Z>2_
MVVZ]>I*E4^K3XDC&<N&\DJT_>4\-*LZ<ZTJ$#+^!/K6:?V1+-)7]DG?D7OSD
MFHQIR;BI_P!A2:6>24G=\W+S))O^?"NOF^'WC^S\)V_C^;P=XDMO!%S>#1K3
MQ!=Z/_Q+!J9.@X)'7!_MO1,'N=>/<$5^P_Q"_94^,WP&_9P\?_#[X$?";QEX
MI\5_$O4?^$D_:"\;:5ICIJO@GX/LIUGP3\ ]'1BGB3Q'XB;P^^B>(OC''X36
M4%1_PA\<OC4W$2P_+7C+_@H?XY\9?L@:#^R9?> ?#L&E:9I7AWPZOBFU\1>+
M5O[WPWX,_P"$?&B2JD?B!%$R^(-#UZ)9P!X4>*7PZG@KP=X4'A) GIY1Q]F'
M$LUB>#LEIYUD\.*U0Q4*G$OL\1AN'%3AS\0U<*TJM%NLZL:5.<8N5*G&K[/D
MK4[98OA?!Y0YX;B/-7DS7#,G3<:;E"=2,Y<J4[.-VE!MWYHN?)O%GYW45^A7
M[*&@>!OAA\$/C/\ MA^.O!NB_$K5?AEK/AOX;?!SP9XJL#J?@M_B1XT"J?%O
MC'2 0NL2>&-!EAWRD.XMUN$@6.=H[FWFM_\ @IM^TMK4FH:3\5)/AU\9/A[J
MEFUG>?"SQY\,?"2^")&90C/I::!X=\)^(M+?PDH!!O/%L^UU610' 8>EBN*^
M(,=FF<9?PKP]'/J'#M6-/%5JW%#P\N:5.G5G'"T_J]18ATHU81G.M4H4>=NG
M"4G"I*/EX7(,FP>"RK&9QFS3SU/V25-M-*\8N3O'E4K*RBF[:VLTG^=]%?HC
M^VNH7X'_ + A'\?[-2N<>H\4ZLGY_(*F_9DC#?L-_P#!21^\>F_LGD?\"^,/
MB53_ #K27&M1<*0S[^R(>UEQ;3X6E#VVD%/B?_5N513Y6Y.$;U$N5*4E[/G2
M]\7^K4?[8>31=X\KE%VW7^K[S^*WZZ1O>^M[=#\Z**_?+Q9\*_A3^T5^R?\
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MEUS_ "S17[U?'CXE?\%/_AQJ/B?7=0\(> ?BE^S'?+JI\.>'/"7P^^&_Q/\
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M3JS24^6/=B.",DE_:?U/..)&\F<?<7#T)2:J4X5.916<<TJ?+42<E%]>VO\
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M1> :7]DY[HO^1A2Z+_GW/R/Y3O\ @NA_R=W\/O\ LW;PO_ZL?XK5^,%?L_\
M\%T/^3N_A]_V;MX7_P#5C_%:OQ@K^E/ _P#Y-1PG_P!D[B/_ %-QI^/^)?\
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MH?PQ/PYU'QU_;7B_0F!\<^#IO,*Z_P !R\A=4R6 *_+7I,O@SX0_!&;]KO\
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M[T?^SO%GB8:GHV-&&C:](AUS,GEJWA@B0.K-"T965F3S/QU^WW\?/&G@W7_
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M%%'O_P!W7??4 HHHH]_^[^(!1111[_\ =_$ HHHH]_\ N_B 4444>_\ W?Q
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M_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\
M"P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<
M?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^
MA\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K
M_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?
M\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<
M?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?
M^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W
M7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$
M> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8
M?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+
M9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T
M/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\
M]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\
MAQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G
M_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(
M?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?Q
MO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9
MY_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F
M?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+O
MVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?Q
MO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL
M?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N
M?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^
M@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_
M .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F
M'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[/
M/_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#
MW_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^
MUQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/
MBO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SF
MZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K
M_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\
M"P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<
M?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^
MA\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K
M_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?
M\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<
M?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?
M^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W
M7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$
M> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8
M?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+
M9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T
M/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\
M]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\
MAQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G
M_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(
M?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?Q
MO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9
MY_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F
M?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+O
MVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?Q
MO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL
M?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N
M?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^
M@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_
M .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F
M'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[/
M/_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/BO\ ]!W#
MW_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SFZ/\ AQ=^
MUQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K_D<G_$R/
MBO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\ "P^(?_SF
MZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<?_?QO\?K
M_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^A\_9Y_\
M"P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K_D<F?^F<
M?_?QO\?K_D<G_$R/BO\ ]!W#W_B+9=_F'_$$> O^@;$?^'RL?RA?\.+OVN/^
MA\_9Y_\ "P^(?_SFZ/\ AQ=^UQ_T/G[//_A8?$/_ .<W7]7N?^F<?_?QO\?K
M_D<F3VCCSV^<]>/4X]>O].3_ (F0\5_^@[A[Y<+Y<G\G?3R?31] _P"((<!/
M3ZMB==/^1Y6>_EU].NW4_F,^"/\ P1P_:<^&WQG^$'Q&UGQQ\![[0_AY\3?
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ME7/C&.0O;^7*V3UGAK]O#X)>*O'?AGP)/I/QJ\(2^/\ 4U\.?#KQ=\1O@?\
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M?Y"8'H/R%&!Z#\A2T47?=_>_\PLNR^Y?Y!1112&%%%% !1110 4444 %%%%
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M+OXS_"NWO(]+\#^*?^"?_P "_P!F7PA\5+J;2Y'OO'7PLU3Q1(9-8T2/7_\
MA)ET-U.BR2$@JPUV\B1I'1FJ_P#"']G_ .+OBCQ_\&K/XS_L]?&31+/X6^(=
M#\9WOC;QS^W'KOQ*^&MIXX\#Z3/+H>K?#+P,WBGQ-XGU[S_$ N(8?^$U\)>"
M$@\+N_F^8\C6[?L>0I[8. <$X].,]B../0^^0JA1]T=#P/SZ?7/Z<],UO[7W
MGHKR5F[:_#FD/3;-I7V^SO8Q;<GNK7VTT;_LR]M]7_9D=^\[64I7_&E?V;/C
MQXH\ ?MK_LGZW\/#H'@O]H3XD?'?XE>!/VA;7Q[X)U/PX&\>ZGHGB70M"U_P
M/'.?B.)$U^-_#GC24>$Y8'B60P/(L\<E6/A)^S]\7_$_CWX,V?QI_9Z^,VAV
M7PL\1:)XSO/&WCK]N77/B7\-;/QOX'TF:30]5^&/@5O%/B;Q1KK3^(!<0P'Q
MKX2\$I#X7D/F+*[M;O\ J%J'Q,\%:/\ $+PK\+M3URVMO'OCK1O$GB;PUH1M
MKSSM8TKP2VAQ>(-1B*H4"V/]NZ,K;Y,$2,D32%2"SXG_ !1\%_!_X?\ B;XE
M?$+7?^$;\%^$=-&I>(=9.D:QJG]FZ<A ,@TW0(+G7"02H B@<KDL(]A^6,+4
M5&]EI/E:;5T_[(A_9/-%N^DK^]HO>WU+Q%\0KNR>E[=UJKKY?,^5_P!JOX8_
M%G4_B/\ L[?M"_!?POIGQ*\2_L_:M\0!JGPPU7Q%IW@UO%OA?XHZ!9^'M:;0
M]?UR6/P]I'B/P[_9,=Q"VO 1.OFQM)'."'\BT?X6?'KXK_%+XZ_M"?$;X7V?
MP8O=:_9:UC]G3X8_"UO''@WQGXVU_P#MW5]9\3/KWC77=!=?#6BE_$=Y%H'A
M/0X/%MQ;0J+J2\FMW.1^HEC>6^HVD5[:2+-!=0+<6S@8$BE04.?4[PI!Z$D?
M2\<%>!CD_P")_IU[=.E8U,,XT505M%G*4KOG:SF7,TVY-6@TU!\J:3>JT<2A
M7YOWUEJFGHK;6;77;[_+4^9/V0_ &O\ PO\ V7?V>_AIXQT/_A'?%O@7X/\
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M:S\4_!>OQ_\ "T'U_P *O+JYE'A/PEXSC\7;$9A%ND+_ -" 3!SG\.GY^O\
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M6AZ_H_B71](\0Z%J5KJ^BZWIFG:OH^I6<PDL=0TO5UCN=+U")B%WK<0E)(R
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M;QEX@N?&7Q#\1^)?$WA/609=9TG7->\1^(KKQ!K=S(ZCR_$MQ<-XK^4,EXK
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M,/!<FKK\?M'\,^&_BTY\3>+K*;Q5HW@N,Q^']/\ -TGQ%;GP^MI&[(6\+?\
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M6"YU[6+@W'D+<*\D:[V4DCSS4_V7/@9J6E>*="O? J3:5XX^,&E?'/Q99_\
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MZGH^@KX=T?4BFL7$MMI/DZ)I<-MY/A^&W1=I<^;M$]3?"?X6^!/@_P""-/\
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M%-WXN\3'1?A?XBT_7+%_[&\&Z63I^KZ]H&L^/HFUK0_#:>*-<;Q4=%UCR_\
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MFFV@?U^-_P ]?77?4**** "BBB@ HHHH ,#T%&!Z?Y'2BB@ HHHH **** #
M'08HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH A!]!@].H(Z^_3USG\!VC)?/"J1GUQWSV_P#K8K&UW7;/P]HV
MI:U?K(MEI&G:CJ=SY"EB+/28I)Y5 ./G\E"P (S@@X K\8'_ ."^/["A^[;?
M&7KDY\ V0/OT\3'W_2NW!Y=C,9S/!X&I5:TDH*+L]6KV::OUOV/6R?AWB#/N
M99-E5?.7&W.J$'-QNFU>THI7LVK]C]NB1_>0>W/'7C\./R/KP9']]?U_SZ?Y
M/'XD_P##_/\ 83_YX?&C_P -_IW_ ,TM'_#_ #_82_YX?&C_ ,-_IW_S2UU_
MZO\ $'_0GK_^ 'M?\0YXX_Z)/B+Y8:7X>^?MF2AZD'ZKGU]_I^OM7XB^,/\
M@F+^T+!H?[6'P:^"7[87@OX<_LQ?MH_$?XO_ !)^*7@7QQ^RK#\6OB[X.U/X
M[,1\5]'^%WQ4;XX>#_"46A>)UN-8;PM_PLSX.>.'\&++#'"U]LB1;'_#_/\
M82_YX?&G_P (#3O?_J9?I^OKP?\ #_/]A+_GA\:?_" T[W_ZF7Z?KZ\8OAC-
MVTWE-:Z>_([[KKS7Z+KT79#7 /'*37^JG$UM-(X6<=KVNE/7NG;3IO<F^-G_
M  0N_80^*/P5^*W@+P]\/[GP%\4OB/\ !A?A,OQTE\5?%#Q'XAL;W0OA8/A/
MX(\:^(/!^A_$7PGX8\?:[X2\.Z)I#0Z%/'96UR]N(B8 ^Y_IVU_8)\!:9^SS
M\%/V3/!_B.;0_P!GGP%XFT35?BYX#DL=>UR_^..F:%Y^O2>#-<\0>(/'<MWH
M/@'Q9\16T?Q)X]\-,GB^U\8>#X)/AQBV\&^)+XR_+?\ P_S_ &$O^>'QI_\
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M^Z R>3N)ZGGOQ_C]*FPP/'([ ]OY=,?KW.:_%#0_^"[_ .Q'KFLZ7H=G:_&
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ML2<?KO[>GCC4])CC^'OPC\/77BY_'GP<T7[#J7Q)EUWPM?>%?BEXZ7P3 O\
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M$OA+H?PJ^'/[+7P^\1:EXO\ B_J7BGX8_#C4M-M/@0OC23Q B?&KQIXB\/\
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M,_X5R/\ @HA_P@/_  O'XN?\(6?!@_:,_P"$-/@;_A+]>_L/_A"_[  \-_\
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M\K%]:Q7_ $%8G_PIQ'_S0%%%%'LH?\^J'_@JG_\ *Q_6\7_T%8K_ ,*L3_\
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M^'O_ "/G@?\ ['#PQ_Z>:_T*8_N+_P!<J_SUOA[_ ,CYX'_['#PQ_P"GFO\
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M7SW$U_\ 5S-NUC\]\36_]0N+-7O'J_\ G]1\S^SNBBBOP _A$**** "BBB@
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M=.\7I)/1ZK6U]TT['Z4>#/VE_P!G"QT/XK>()U^-/PS^.OQK\6^--9\7^//
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MKW3^9_60O08Z8'\J6@< 45_GZMEZ+\D?L7KOY;!1113 **** "BBB@ HHHH
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MK]]?]P_^@M7XJ?\ !=;_ )-0^&7_ &<-X9_]5M\6J^^\)?\ DY?!?_958/\
M]*J'Q/B-_P D1Q/_ -@=3_VP_E-HHHK_ %1M.^T=^S[^A_ KW?J_S85Z+\-/
M!>B>.?$-QI?B'XA>%?AGH%MI&IZUK'BKQ2=6&G8T,\Z-H>AZ'X>\5^)?$'B%
M1R?"V[) .U6. ?.J]B^ 7PJT7XP?$O0O!?B+XD>!?A7X9N0+WQ%XR\>>(M&\
M.V%IINAG"IH(\0D)K_B(L>?#,C)&@)>1T12P\W.<4L#EF=8]SE15.E.?M84?
M;3I*,;N<*/L:ZJ226E-4*O,Y**IS;47T8-<V-A&R?-)))M)-MQ5FVTDM=[JV
M]TKGL-Q^Q_J?B&]^#;?!GXB^%/BSX6^-'CC5? ?A_P 5KHNM^#GT'QSH0T(Z
M[HWC70-<#OH3?\(YK+>)PD:F1F&%0EES%KW[+.B7GA/Q?XI^#WQN\)_&*X^'
M.K^%]%\>>']*\-^,?!.I6!\=:U_8.AZQHG]O^'"?$'A[_A(^?[N,X.17U[<Z
MOX.\&_'7]FVWUGQ?\(O!G[+OPE\=ZO8^!=+^&OQZ\*?$#QQ9>)UTE]:_X69\
M3S\*?$"^(S_PE?B+0=%/C/Q07:/P?X+*^#2?*G\Q[/Q1^)FM7?P-_:(TWXY^
M./V7;:Y\:W?A7Q+\,+/]F#Q/\/CXT\6?$S0/&DS+K6L1_"=O+UWX?GP_)K@9
MOBB@D= BRY\<Q1;/Q2'''%$\5DOU-SFJW*HI8=J<_:<32I*G*V15*=6M0R"4
M/K2HU,GC2?-552K%._Z5'AS)+9G)RBDE"7QQM;^P,TDW\::3SJ_+NVN563L?
M%/BG]DS7-.UC1O#G@#QAHOQ'U>Z^(^I_!CQ':Z3H^L^'/^$2\>:'G7M= _MX
MDGP\,:YGQ2./^)#XGY/-?.'BK3-*T'Q'X@T/1-<MO%FCZ9K&J65GXAM+,:;I
MFNY_YC.A\D?7!/3@\U^DOP\_:#MYK#P%I'Q@\;^ ?$6O_%B]\47GB2\M;/P?
MX;\->$O#&O:&-#_XNCK?@$>$@?B#\5O$6BZ$/&OBGQ5GQC_PID,N ?%AS\C?
MM(VWA:WU?P/)H5O\.M,\6WO@0-\4-(^$&J:1K_PVL/$K:OKIT(:-K&A>(?%?
MAQ&'P[_X0G_A.%\+^+1X-' 8=A]EPQQ!Q)+.*>39U%RE459\T*;]G>C*:G/G
M=*%J?-'V<&K)SFHM2LJDO"S++<H6"^MY0U=**:<E>_*KJSDWO=Z+97\CYTHH
MHK]*:GKI'KT?GY'Q+V?S_4*_:#_@AE_R=SXY_P"S<_%/_JQ_A37XOU^T'_!#
M+_D[GQS_ -FY^*?_ %8_PIK\M\;E_P :IXLT_P":=PW3_J-P7D?H7AK_ ,EY
MPI_V]_Z34/ZR****_P PELO1?DC^[PHHHI@%%%% !1110 4444 %%%% !111
M0 445Q&F>._!FN:_KGA71_%_A;5_$OAPQ_V_X?TKQ-HVI^(M#) 7&MZ)%.\^
MCG) (N(HRYY"Y.:/^!^.B^_IWZ7#^ON.WHKC](\7^%=>U37="T7Q/X>UK6/"
M]TEGXBTS2M;TV_U70K\*"R:WI,<C3:-("=RI,J-(69@N0Q&AI>NZ1J]LUUI>
MJ:=J$"W-Y:&XTVX2]0:AILDL>J0!DWKOA>,QLH)8$@\ATR =!1110 4444 %
M%%% !1110 4444 %%%% !115.XG@M(O-GFAMX!U-P0H!/;)8<_G0!<HK*_MW
M1O\ H*6'_@5#_P#%T?V[HW_04L/_  *A_P#BZ -6CI65_;NC?]!2P_\  J'_
M .+H.N:,01_:EAS_ -/4/_Q=)[/T?Y,#EOB$,> _'+?W_"7B#\ -(G_J*_SU
M:_T'/'FJ:9/X'\;PP:E832KX1\0E0+J,CY=(E+ [7; ^92<9/.1U)'\"?_"N
M/B/_ -"#XV_\)O6?\*_L'Z*^-P."P_%SQTX4[RX=4>><8:1E4U]Z<+I:7M?N
M['\T?2$P>,QF)X5]E3G-*4V^6$I=;[QC*UUIK;[CCZ*[#_A7'Q'_ .A!\;?^
M$WK/^%'_  KCXC_]"#XV_P#";UG_  K^O_[6RS_H=4?_  =2[7_Y^=M?37;4
M_G%X+,+O_A'J[O7DJ=W_ '#CZ*[#_A7'Q'_Z$'QM_P"$WK/^%'_"N/B/_P!"
M#XV_\)O6?\*/[6RS_H=4/_!U+_Y8+ZEF'_0GJ_\ @%3_ .0./HKL/^%<?$?_
M *$'QM_X3>L_X4?\*X^(_P#T(/C;_P )O6?\*/[6RS_H=4/_  =2_P#E@_J.
M8_\ 0FK?^"ZO_P K./HKL/\ A7'Q'_Z$'QM_X3>L_P"%'_"N/B/_ -"#XV_\
M)O6?\*/[6RS_ *'5'_P=2\_^GGD_N?9V7U+,/^A/5_\  *G_ ,@<?178?\*X
M^(__ $(/C;_PF]9_PH_X5Q\1_P#H0?&W_A-ZS_A36;99=?\ "U0W6GMJ7=:?
MQ!_4LPO_ ,B>K_X!4_\ D ^'O_(^>!_^QP\,?^GFO]"F+[D3DYQ#CTY(Q@_H
M1_+O7\ W@/X>>/X?&_@^>?P/XMMK?_A,/"__ #+>M?\ 0:_+\/U]/[Z$UG2
MD:'4[$8C _X^H>HYP3OQD=.V:_C+Z5.,P6.S'A&6 G"<8T^(5-PG&:UQ.'WY
M93M=*;U:NDVM(MK^E_H^8/%X/!\3JK3G!NM3E%2C*.RG_/&-TKI76B^9OCD
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M_P"%'_"N/B/_ -"#XV_\)O6?\*3S;+&FGG5!KLZU%K[G4:_ ?U',?^A/6_\
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M?#;!8^''?"LITZD8KFNY4ZD4M)[R=-)6VU:W/ZLAR ?4"EK*_MW1O^@I8?\
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MZ9IY/8?98?\ XC((YZ\#I0=$TC:"-+L.^?\ 18?7C^"OQ2^)7_!9;X:^ /\
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M^,/&NE^&_"7Q+M?@QXI\%ZQ\'?B[I7QLLOC'=7.B0Z/\&[?X#W7@./XW:_\
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MHGQ/_9VT?Q?X!^,_P"_:"^$7CB[^!7QR^-GAWX4#XQ^ O!?Q!^''A#QEX_\
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MG6%'AGP=-XFGSH'BATD'_"(^+5MO<])_;Q^ VN_"$_&?PG:_'3QCI%GX^O\
MX2:WX+\%_LS_ +0OB;XO>%_B;H6%UGP1XS^#&C_#.X^)OP_USPZEN?MI\7^$
MO#GALBYC<W87Q#8M*K.WUF[TT\[Z/_VZ/_@4?YHW77ZMKM_GY_W9?^ R_E=O
MM;^PM&_Z!=A_X"P__$5/!I]C9#_0[.VMO3R+:-3_ ..*N*^"[W_@HY^R_:>
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M7]"\-_M$?"/Q(GQE^%3%]!G^*?A7QIX6\(>.%>23QM\$YBT<:_NA157Z_/\
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M^$22D]==/^$YWU]Y7U:9[WXF_P"">C:O\(/CW\+A\6#$OQU_;>\.?ME2:^?
MH,WA-?#_ ,9/A%\6D^'":4WBAXM?$H^%2^&SXFN)(0T7B"2=_" -OY<OD'[>
MW[#WQ$^(WPN_X*">+?A+K.I^+?'G[6GPO_9E^'?AKP'I6E:98ZEX5?X(^,_$
M4LFNZ/K?B'Q"_AG5MVC^-KOQ#]GF\*1_9SX;CA(\6R306HR?'O[0OQ/\5>,O
M^"97[0?A[X[Z5X=\&?'SX_>(OA%\4/A7\#_BOX/^,_[*?BWPOHWP3_:9\;R:
MOH/Q.\3?!?X5?$?Q!KO_  D7@3067Q+"?!T"#1# _@B22*663R+]G3_@L?\
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M4 %%%% "8'H/RI<#T''3VHHH 3 ]!^7^?04M%% !1110 F!Z#\J,#T'Y4M%
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M$D>BZOK,N@Z$++PSHFC640T"WMDF6)FO/.G8RGV2BC_@?AM]UE;M96M96/\
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C 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "Z G # 2(  A$! Q$!_\0
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M_>% #Z*9YB?WA1YB?WA0 ^BF;QZ']/\ &GT %%%% !1110 4457FB\Z,#O\
MS&>?\XH _GD_X.$?$_Q&\:?LD?$#]G3X#_$2U\#_ !4MO .I_M,ZK<K9'4-5
MUWPQ\#-=T37]%\&Z(1E?[?\ %GB/1$\M=N4_L%\<-@?"O_!4#]MKQK^V1_P;
MM_!O]JKX,^+/#?A^?XQ>*/V9M%^-.D7MH+];SQ/_ ,++T+P]XV\%YBV@+%\2
M-&5O%L;C=/X-AN$8.N6D_I4T']E7P+H'Q5^-WQA@UOXD7_BCX_:/I.B^.K'Q
M#XOD\0>&K'3-#T1]$T=? NA:Z&3P.R1DD)%YBM(A'RD!E^#='_X(9_L(:+^S
MKXO_ &2M,T?XS6OP ^('Q2T[XS^(/ *_%[QD-/3XA:%K$6O:;JVB*UPLFA1#
M7O(U^3P]"WE>;H]OYEML0QL ?C)\%/B=\2_^">W_  4:_:P^'.BZC\/M/_8_
M_84_X)Z:Q^UEXO\ @YH&D^+-577M8^-!T#Q]\5=<\#:SK[M_PC_B3Q3\2(A)
M'MW>$%\'%=T<3Q2B/Z*^(G_!9?\ ;J\#_L-_%O\ :]G_ &;_  :/!ND_LR?
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M,_LT?LL _P#7G\2_YGQ6O]:3_B-0_;Y_Z-F_98_\!?B9_P#-57/?M"?M1?\
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MG_VWIL;LBZL4_P"%:LL;.$WA5^5D92SY/&+_ ,1P7A3_ *1^>)?_  _6D_\
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MZUV%G^RC\6YI;B>Q\*ZW]H_Z\Q^N.#_^KW- ']I!_P"#W?PW$#_QK\\2>O\
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MJ6H:9R!K&BG:QU]22 S*NY1\WW0:^+?^"GO_  ;;?LZ_M">"_%_Q+_98T?\
MX5-\5K71=3O1\-K(X\"^+I,$L-C8_P"$?\0;=K(Z/("=Z/L* N ?Y9LMI.(Q
M^XQC'(ZX_'^78>M9U?7/QR^!WBOX2>,]8\+>*M)U+1-0TJ\U31;RTO+,:=]@
MP1G@C!]2""#W%?*]W$/-_<] /I_G]>* ,ZM"SA\Z7R#G_/\ 7G].M5YH?*_S
M_/WZ=ZT+2'_GN/IG_#\N/K[T ?UW?\&?D-P/^"G7B!I^H_9B\?$>N1K'@/\
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M $+_ $2T_P _XU_81^R+_P $ ?@?\)=+T?Q5^T)XCN?&VL?8_MO_  A&D_\
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M'ZSINIV'UZ_R]_6OB?X2ZQ_P;\_&#5(/#GC'^V_ 'VH?Z'J^K:QK.FZ98?\
MZS],_P OY</VJ/'?[-?B3QE<3_LR^'/B1HG@?H;3XG:SHVI:EU_ZE_&,=\G
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ME9W?V/\ XF=__86B_4_F>A%>+_!G_@G[\';WX2_$_P ??$;Q'XCN=7T'1_\
MBF[2T']FZ;_:A]^I]LD@=N]'A7X8WT-AI^E?VY;7/V7-E9_9+,_YZ9[^] '7
MV=G\.=>O[CR/"NB?9_\ G\N]'^G7KC_&O2=!^#_P=UB:WG@\*Z;;7'''V/\
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M'VS[%9^WKGU_+]30!YA#'"?/![# ]OI_];\*]G^#X_XKSP_;C_EUUC2^??\
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MM2T_PO\ \5/>6GV/_./I_6O%OV\/&/QBO/V6OV9]*T/PKHFI?!?_ (4GI?\
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MIO[^#5;FY^U\?9/MG_,4Z'O^7X\'% &QH]G!J5U;Z3?3W.F=_P#CS_QQ]?\
M]5?='[.OPK\5:#\0? _Q&@@T3QMX7\&^)/MM[I/VS_B9GJ/_ *_3CVK\[_\
M3O\ 1[?_ (F0N/\ I[_^OCOZ5]X?L<>,+[3=9N/#E]_:7V:Z_P"/.[^V?_6Y
MXQ^- 'J&O?!^?4OB_P#\+&_X73X)MM'NO&']M?VM=^)-9TWQS8?\3K^WO[%_
ML,^_3DUR_P"T)>:5\8/BUXP\8^'-#U'1-'U[6/\ 0[O['_9OV[2Q_P QK/\
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M+LOLGV,?VF>OIV_S[']\/%7A6Q^#/P;T_P#MRQUSQ)J'V/[%]D[V&J>_^>:
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M/<$^W3\OI7Z ?!_^RM8L+?2>-2_Z=-)LQGUSZ8QZUYOXJT&?3?%&L00>'/\
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MTOM^J?VU[_YXQ7^C!_P2[^%>N?#;]CSP?!!H=U;?VI9_;=8N^W^>?RK^(_\
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M#T_R/;]./$F@Z5>_Z=!8_P!FZA=8Y]?7KZ]J\/N_#>JF7]Q!_HX[VGT[?SH
M^/\ 0?B=XC^!FO:/X5\5:Y<W/A?5+PV6C:M=WG_'ASSDG_\ 5BOMC]_J7V>^
MG^S7/VH_;?M?].W_ -?FO+_&O[&7PY^)]K<7WCC^TM;M[JS_ -#_ .8:-/\
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M</V+-0\8V%_J.B^(/ ?AS3+R\(Y_L\@E2..X(PW<,"#@B@#_ #H/^"SVL?\
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M\^GMV]*V)KRP^RV]]]A_M+_3/^/NT_XEOV#''^01[&L_^WOL<O\ H,]U<_\
M/Y]JL_\ 'ZT =AY,^FVN?L-S]GNO^G/^GYGIGKUKA]2O;&REN)Y_M.F?\^=W
M=5H:QXDGLK"Y@@@M?]*L\6?^F?T_3MCM7S?9Z]XJ\2:S<:5JMC;?V?:]+3[9
MP?RQZ_C0!Z!KWBK2KRU_<:YIMS[_ &P?Y_R>:\?AFOH;JX_TZV_[>[3./7Z
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M!GANK>Q@@N;FYNO^?3^>?_K>OX_3_P *K."\B\803^'+;1+BZ_T+J?[,]/\
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M6'_!NE_P44F^ 7QCT_X.:[? ^'O&?%G]LO/^/ 8YSVQCZ\9ZYK^]7]IWX$>
MOVZ?V;]6\-65Y:FXU;2C>>#_ !$#C^SO$H0G<0>I+*$XSRX(XKG.@_SVM.O/
M['NK?S['4K:WNA_Q.+2[O/\ C_\ \@?S]:KP^"8-8O[B^\*WW_'KB]^R7?\
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M_#BP^'GB;Q#\.K32;3PII?C#4OA[X3.E-_Q+UTWP6XAU3:J@X\V4LH9OERA
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M<=3T_P ]L5_+1_P6,_;K\#_'[2O"'P<\ ?:=2T_X=>)!>ZSXL_YAFNZJ"?\
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MQ'#8^)/B-_96E?9KFW-G]BL[32=8S_G_ #]:]9\$_ W5='U3S]<U8VUO:_\
M/I_R_P#?/Y&L_P"&/PEOM-T&X\<>(_#ES<Z?I=X/L=W]M_LWK_D__6XKC]3U
M+Q'-KUQ>SWVM_:./]$M/^09_];CU/\Z /I#QC^U%XXT&+_A!_#E[<Z;;Z79_
M8O\ 2[+_ (_^@^O.>1Z5X_#J6A^/(=/GOM*.F>*+J]_TR[M+S'V__//J/YUH
M:]X;@U[0?#\^N?\ (0Y_T3[8.O3_ #P/7BN/O=-TK1Y;>""#_CU_TTVGM[?Y
MQTSQ@4 >L6>@CPW=:??:Y_;?V>ZLS]C^R7G^?;_ZU5_C]\3I_A7\/M'\5:'J
MO]B8O/L6CW?_ #%/[4UWUZ]\\?GWKH/!5Y8ZE%<0>*M;_LWP_I?^FWFK:M_Q
M+=,L-+_'OZ__ *Z_'?\ :B^/T_Q^^*UQ8^#OM-K\-_!MX;+PY:=?M_'_ "&O
M\\_RH _T8O\ @AS\>_A7\5OV _A#X6\#ZUIEQXQ^'.BZCHGQ(T/[8#JY\4C6
MY0-9UH-D(?$Y<.'(;.]EV\<_L[%*"/UX_P _F/Q%?YYO_!(?]FS]M?4/B!X'
M\<_LB^*[C3 ='%YX\\;WEY_9O@;0],/ T/6QR?$3'H% +-G !-?V,>*/$_[;
MNA:*+"71-#MO[+M-EWXKTBS'B,WS* 3J^TX*L%Y*$!E&<J,4 ?I!O'H?T_QJ
M+S_;]/\ Z]?C)X/_ &GOVD--UT6^E+K/Q9MKEM]WI%GHPU'4]/T[^\. =QSR
MP&3D@YK/_P""E?[47[:_P9_9<@^*7P6^'-OX<@U.T%KXPU:]LGU/Q-\,],;*
MG6]9T5LCID%4/R[@, ,-P!_%#_P6[\>:+>?\%%_VE]<\+WP\G_A8XLK6[&2/
M[5T+1= SC(R5],_C7RQ^RO\ &'0O"OQ@\#^,O%7]I6VL6NL:7]LU:T_Y?_\
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M '3 UK']/7WY-<YT'X47GGY/D9S^O;&?Z_I7\S_[>TT__#1GCC_GW^V:7_\
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M6?VV\_M;\>O7C\?_ *P!7^-GQR\'?LQ_"#QA\3?$<]K]GT'1]4O+,GMJF?\
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MJ01U.>/R8^#/[*_[.?PEUG4-<@^!UMJ7BBUUC[;9^(?&_P#Q4FI]O\G'3UH
M_#?3?V=/VMO^"@45O8P:':_ 'X+VO_'G:>(1G4]>Q_+U_P#UU](?&;_@C_H?
M[-7[-.L>(_ ^JVWC;X@?;-+_ +8U;_G_ -+Q_P P/0_\]<8Q7]$$/Q"TK1[K
M]QX4TVZMQ_RZ?8\"P'Y?B.37J&O3>%?B=8:/!??\4W<6MY]N_P")39^_T)_S
MTZB@#\[?^""NB_M>? GX?^)]+GTK1;CX<^)M8;6A\*?%5I_PC?B@:H1@ZSH>
MM_=8'KM8,I94;&54C^FWX:?&#1?B8=8\.SV-SX2\8Z$1_P )#X3U:[9=2L-.
M*LJZQI#+N.PLV0P4!<?-N."WRIX)\8> --T;.NWVFZ;_ &79_8K.ZM/^);_Q
M-,_G_CQUKG_$OAJ?XA_&CX7^*?AEKEK;ZOX8\2:7>GQ!:_\ $M_M#PO_ ,Q[
M12",>( 1VR!^>* /L?X;_!_X9_L]V'B?5M#N-2M;;5;LWNL:KXAU<ZD<G&,'
MC&!D8(!.1TQS\D_MN_M%>*_#?[,/Q<UCP=^S[JGQ0M]0\.:MHXTCQ7?:1IVF
MZCICZ)(&U>31W9F:(;E94 3#Q(P(50B^^_M-?;Q+X!N+BX%MX0MM8U.]U<8Q
M]MU3:/[#7(QGYLD$C^+'2OF'XM?%KX2>*M!U#P=I6N:;XDU#^QQ>ZQX>^V?\
M>'?_ ) ?\C^- '^?/\/?V8]*_:0\6ZAX.U70O$GA+Q!:V?VW^UO['/\ H'XX
MQ_GL.*L?&#_@BI^TUX/M+C7/AS!;?%#P_:_Z;_Q*;/\ LW4\?]@3/0Y_,U_9
M!H.F_#+PK=:??:5X T3^T+7_ ) ]Y:6?_$SYQGKZ<?\ UZ](A^,%]H,OGSZ'
MHFFZ?=8_XE/V/W[_ )_C0!_G3^#YOC3^R[\3-.\1P:5XD\ >,/"UY]MLSJUG
M_9NIGO\ Y]N>]?U(?LQ_\'%!L]!\/Z'\</A7K>I:O;6?V*\\6>$]8T;_ $\_
MY].IY]:_3CXG?#WPK\9K76(-<^&/@GQM;ZIC_D8?#>C?VG8=O^0YW[_X5]6_
ML[?\$P?^"7&N_#K1X/$?[-G@"[\7WEFH\1W7B%=9&J+JA)W-HI+C(Z#"@,,$
M_-D8 /D+P3_P7R_8TUB*W/B.W^)'AOI_Q]Z/^O88_P ],UZQIO\ P6D_X)^:
MQ:W$_P#PG.I:;]E_Y^_#>L_VI?X'^/<5].^+O^"#/_!,?QL+B:T^#VH^$[JY
MM.3X'\=:SI:V(P#E5\R0CKCYF).#@ 8-<OH?_!"#_@E_\,H(=5\7>%-:UJ#2
M\WJW?Q$^(Y;3!SC+*6C) YX##([DT >%7G_!9[]@NSM#!8_$;7-;N#_S";3P
MWK.I?;_?I_\ 7-6/ ?[;'B/X_P!U;WWP6_9)^,FI>%OMG^F?$+QOHY\$^&;#
M_P *#/\ PD/..O\ 2MSXC?M@?\$6/V";&_M_ 7PX^#6M^+] 'V.STKP-X#T;
MQ'JG]JY^ZWC7Q"&  '4K*Q)'8&OY\OV]O^#C_P"*GQ3L-0\'? \V_P +_!_%
ME::5X?L_^)I?G&,_VV, 9QDA0!GD#.30!_23\0OVH?@[\!_"]QKGQ;\<:);:
MC]C^VWFDZ3>_S[__ *Z_G/\ VV/^"]G@XV&H^'/@]_;=M_RY67]DWG_$S_LO
MM_/^GK7\O_Q@_:$^-/QFU2XU3Q5XK\2:E<77;[9_G_/3BO+_  K\#?BI\6=0
M_L/P=X.\6^+=8NLV7V3P]H^L>)-3Z_U_R*#G.H_:$_;&^)OQSNM8@GU6YTW1
M[J\^VW>DB\SJ=_JGKKF/^1@_/KZ5\3WGGS?:)_\ 1KFXM<]^O?'Z_P!3TK^@
MCX/_ /!NO_P4M^+^EZ?XCG^!_P#PK?P_=6?VW_A(?BOXPT?X;Z98:7_W'\_Y
MZ5[Q/_P1/_8[^ 4OG_ME_P#!33]GCP!<?\QCP1\'/[9^+7B?\/\ A'^W//\
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MNO\ CSU;2?\ D&7_ %_IGZ'OS5>\\-^3+<0?VK;6UQGW]1CV_EFO\]_]F_\
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M;:V^RG[;K&/^)E_8.EC\OQ_QK^D?_@DO^S3\%OV:?BWXV^+?[0GBK4M;\/>
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M7=G_ &EXG_X1C7>-")X'_(I@#GKQ@>M 'Z0Z]\2?AE\,;6XMYX+;3;>TL_\
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M_*_BT'7/-_<07/\ HMYCK^><_ACIZ?6S#9^*O-MX()[GG_I\Z\<Y/^>37^F
M/^" _P#P2;\-YU75?"NI?9[7_3;RTU;XJ_\ $L_/C^GOZU\W?$?3?^"!'[&D
MDY\+?!SP#\1OB#H0S:66EV>L>-FT_5.N#_;[,N5[XW GH<<D&?Q4?L]?\$_?
MVQ/VG-4T^Q^'/PX\2:EH]U@GQ#J_]LZ;X9]O^)YP./Y9ZU^R'P\_X)%_"3]C
M_1O^%C?ML^.?#6MZAI>;ZS\)Z3K&/^)IU_Y >?\ BH#['.3QUKH/VEO^#@3Q
M5IL.L>#O@#H?AOX2^'Q>?8M'_LG1]%U+4[#2Q_U Q_/_ !K^>?XY?MU?'#XP
M:]J'B2_\5:WJ6L:K_P Q;5KS^TM3_3(\/=,^_-!SGZ\?M._\%8O#GPWT:X^'
M/P!TK_A5VCVEG]BL[O\ L?\ XF=_I8[_ -A?A]._KC^=?XG?M"?$WXG76H3^
M(_$>MZE;ZI>?;KR[N[P?VG?^_'^1^E</K-GKFOZK]NU6?4M;U"ZQ>WEW=\&_
M_P _Y]O</AC^QG^TG\<KJWL/A7\'?B1XVN.W_"/>#]:U'C/_ $'/P]OK70+Z
MPO+^OF?&][_TPY^U8]^N>GKT_P#U\5G#SX>L'^?3GOQ]??T_H!\$_P#!OK^W
MYJ5A;ZY\3? 'A+X%>%_^AA^,?CSP;X)^P=Q_Q(^P[UZA-_P2I_X)S_!^PU"?
M]J'_ (*:?#:Y\06MG]MO/!'P&T;6?&VI_P#8%.N$'K]/7Z$&?S3^3!Y7^?3Z
MX]__ *W-;&G?ZVWG_P!)N?6ZZ=_K_D8S7I/Q5T?X?Z;X\\46'PJOM2U/X?6N
MKZI_PA^K>(K,Z;JFH:9WP#T_+\^M>?6>?LH^SP?\3 WF?^/P_P"/OC_"@#]\
M/^"+7[2W[/7P27]J7P3\=_B+;?#C3_C9\(/%'P_\-^(?['UCQ)I=AJFN_P#0
M<]<\]/RYKD/'G[-_[)'P^MK#Q7\)/VVO"?QL\8?VQIA_X0C2?AOK/AO[?GH/
M[<\0<_C7XC0S3PRB^@GN3<?Y)_S[XKZ(^">I7UYXWT?S_P#2<ZQI?_'W_+_'
MO@=,5S@?LQX\_P"/FX_'^8KYO^(5G/-X<\003\V_V/U//'^?\?7TCXG>,+[3
M;^X\B#_P+],__KX[G]/G?Q)XVUR\T;4()_LWV>ZL_P##GZ^O3T YH.@\?\-_
ML3^/_%7P,\/_ !^@\1^&[;P?XH^,!^$ATK[9_P 5-8:IWUK7!C_D7?US]*^Q
MX?\ @C/\3KSQ=;Z'H?QB^&^I:/\ 8]+O=7\0VEGK.FC0=4UW_D Z+K>A_P#,
MOYKZY_9IA\?Z;_P3[^&^J^'/BI;?#?3[7]K3_B<:MXA_X0W4?#.@Z7W\:'0_
M^1G_ %!'K7ZH:QX5\.:;\<[>^TK]JC1/$EMJGP'TO6]8\.^$[S1M-U/Q[_;N
MM?\ $]UKIT\)\>*/;%!SG\C^C_L3_%36/VK[C]D+S]$MOBA:^,-4\,?\?G]I
M:9_:NA:(/KS]._UKUF'_ ()>?'B<>+["'5=$N?&_@S6?#&C>)/ ]H3J7B6PT
MS7M:&@Z'K>#Q_P (Z0!G Z #H*^E_ACH_@>S_P""G5OI5C\:?$@\#VGQ3\4?
M8_C?]L_LWQ-_R!>-:_MS_P"O7ZH:;^SW\#]'M;?XFZ%^WKXDMM8NKSQ1X+UC
MQ#=WG_$SU[_A.M:_L'0^?3PG]: /Y5_&UGXC^#/Q"\4?#G^W--\27'@/6-4\
M,#5M)_Y!E_JA_P"@'KF?Y^O2OKCX#_\ !3[]L3]FZZMY_A)^T+\4?!/V7_F$
MZ3XD_M+3+_W_ +#[CZ^U>#_M(?!__A6_Q?\ '/@[PYXC_P"$_P!'\+^,-5T6
MT\;VEI_Q+/%O7_B=#/Y\^^*^;[S1KZS^S_;K'[-_R^_:^3W]?S]?KS70!_21
MH/\ P<:?M0_$+2[?PK^TI\.?V9OVF?"__'EK%I\6/@_HQ\37_/\ T'/#_P!>
MW_UJ[CPW^U%_P0_^/$WG_'?]ACXI? 'Q#JG_ !^^(?V9?BI_:/AG_P (?Q :
M_EO\G][<3P?\>]KG_)_R<_SV+.\OH+OR()_IV_ ?C_.@#^M_3O\ @F1_P2;_
M &B?/G_9!_X*?Z=X!\0%OMEIX(_:D\.+X;VC!)T=M<9E.WC&%#-DC"D9(X#Q
M5_P0V_X*(_#&*X\1_!V#X;_M#^%[7_CSU;X#?%31O&VIW_\ W _^1G]N,].U
M?S'Z;XPU6SBMY_/^T_:LX]\G].A_R,5[Q\,?VKOBI\,;K3]5\'>,O&WA+4+7
M_F+>$_$FL^&_L'/_ %+_ /GO3^KOS_KY"^L+R_KYG[8:;\?O^"J_['$IL9]*
M_:0^&_\ 9F/]$\0^#_&7]F?_ %S[=/RKH-2_X+P?\%&;/]Q??'#6_P#KTN[/
M_/&.<_EQ7EOP4_X.#O\ @HM\);6'2I_CMJ/Q'\,0#YO#_P 8=(T?XC:<=+QM
M&C%M>(;<   00P &T^GV%_P_?_9S^,UJ(?VK_P#@F9^R]\6I[G/_ !4'@?'P
MW\2G..6R"<CJ,$#DY!QQS6.BZ[K[U_F?(^I?\%POVQ+S5/[5UW7+;6_LO_+I
M=_C_ )]/;/0F_P""VWQBU*+'BK0[FY[_ .B7G/\ G\>O/2O=[SXM_P#! WXY
M2V\&N?LV?M1?LNW%UQ>:M\//'FC?$CPS8#J/^)'X@_+\N?70T[_@G]_P1;^+
M(N)_AS_P5)\2_"_[59&^L_#OQM^"8TTV/<#7-<T @ \<9(&>X!- SSC0?^"V
M&N?:M/\ [5@\;:;;:7Q>?9+S1M2_K]<>O'M7VAX5_P""]GPRTZP_T_0_'YU#
M['G[7_8^C=/S'^?;KY/-_P &]_P6\;9_X4M_P50_8Y\;:A=6?VW1])U>\_X1
MO5+\^_\ Q4GK_/\ +8L_^#83X[Z]83WWA;]J_P#9+\6_93C[)X=\>''?_F.>
MG'4_3K0!ZAXV_P""S_[.?Q5\.:?I7BK5OCKX;N+6\%[>#P19:-INJ?\ U_KZ
MU]\?LR_\%V?V&/A!9Z1;7^M_&+Q>-"NS>6EUXMT;1O[2P1C!UOT/<?7%?D+9
M_P#!KS_P4#U*4&QUS]GK4OLW ^R?%[2-2Q]>,K_P+'I4&I?\&Q/_  4[TW$$
M'A;X;ZE]E_Z!/Q(T8'_'^7T)- '[K?M/_P#!QA^Q9X_\+V&E>%-%^*9N;?6%
MO;2[MM*TJPU+CC*B1W*Y[X.2>6)/-?@CKW_!7KX+^#_BUXP^+?@#P=\4;GQ1
MXHL_L6L7>K:QHW]F?V6.W]AY -0?\0RO_!4F[_U_@#P3UP/M?Q(T;\_PS^.:
MW9_^#6'_ (*+"V6]OYO@KHD#=#JOQ1TG3QCU+!64=^I'K[T >1:Q_P %MIYM
M9_X2/2M#\;6VL70_Z#&C?V9S]/;G_"O!_'G_  6 \?\ C"_^W7W_  G_ -HM
M?^/*TM/$G]F^^?Z>GM7V-IO_  :\_MB>;Y_CCXM?LO>"=&^R8O/$.K?%[2-2
MTRP.><C&<9[D8]\<UU,7_!NCX'\'6D'_  N+_@IW^QAX*N+J[)L[.S\2?\)(
M2>>!D@<^Y SCH!0<]\7??3]#X@A_X+,?&+3;2W@\.>&[JV^RV?\ Q^7?B3_C
M_P#SQSZ=^/SL:;_P6\_;+L_^05XDMK;TN^-2^P9_SQ_C7V./^"6W_!(7X9">
M?XC_ /!7GPYXC-K=BSO-(^&?P?UC4]4!(SM."PR.^"0.H)KD+VS_ .#>SX,\
M00?MG_M5ZAI?'^E_V-\-_#-__P!07'Z\4'0>/_\ #]3_ (*!ZD+>"#XMZEHG
M_3I:6GM^HZ=\9KE]2_; _P""FG[44MQI5C<?'[XD#5/^73PGX;UG4M,Z?_J_
M'I7UAHW_  6&_P""<_P!.?V9?^"3?P<M=8M?]-L_%?QN\>#XD:GU')^F..W/
M?C'BWQ9_X.7?V[O%5A<:5\.?%7PV_9Y\/C_F7O@EX#T;PX?3_D.<G/;GMGTH
M T?A[_P1;_X*=_'ZU@\1^,?AE_PISPQ=?Z;>>+/CSXPT;X;Z;8=?^8%X@_3'
M//K7O$'_  1G_8*^ /\ Q-?VV?\ @J3\'-,N+7_3=8\$? ?_ (N1JG_8%_MS
MU]N>XK^>?XP?MZ_M"_&R_P!0OOB;\8OB1\2-0_Y?/^$L\8:SJ6F7_8>O^0?I
M7R/J7Q"US4KK/VZVMNAX]/?W_P ]JZ#G/ZH/$GQX_P"#?K]F_P#<?"3]EWXZ
M_M:>(-+Q_P 5#\;O'O\ PA/@;^U,?] /^0S^!ZCS_6/^#CKXQ?#>UN-#_9)^
M!'[+O[*GA^U_X\_^$(^&^B^)/$W]E_\ 8<\0?_K^M?RWWNI7TQ$]]/<_Z5C_
M (^S^1S^F0..?K6?--^Z_P"GC[9T]OSY''&/IF@#]4/VE?\ @L!^V_\ M-R:
M@/BU\?OB1XMT^Y'&DC6/^$:\,<< #0O#_;CH.WX"OS?UCXJ>([R[M_/GN;:W
MNO\ EZ'Y?D.^?_KCAH?WT6?^/G\^/Q_^O@?6H)8?..)_LO3_ )_,<_Y[_2@#
M0U+6+Z\D_P!?]I_48_\ U\_YQ7/_ /'W+]HG@^S?YZ<9]/\ ZPJP(9_.\CS^
MW2[_ ,.?_P!1SG.:L>3Y,MOY\']?ZT :'_++_4?Z-]..GT_7]*V--A_TJW\C
MMQTSU/MU_P \9K'^QSS1?Z^V^S_G_D_S[UV&CV<\L7_3SV[>WT_SB@#^O7_@
MTV_Y2':O_P!FX>.O_3UH%?IG_P '/DV/V@OV9QZ_!/Q1W]?&G7MC]?TK\UO^
M#4*+_C83K\X_Z-P\=@?^#G01_GO^M??'_!U-K%[H_P ??V7_ "(/M./@GXI'
M(_ZG7T^O?\*YSH/Y<-8_UP_SVKYGT#]G;QQ^TM\?=8\ >![[1+;Q!_8^J>)O
M^*AO/[-TS^R]"T4?_K_&NXO/'FJP_P#+O;<>OT_7_#I[_3'_  3EFU74OVP[
MB^L-<_X1NXNO ?B@_P!K?\2;_0/^)+_U,'_ZOPXH ^;_ (;_ /!.KXF_%3X:
M?\)_H7BKPE;7']L?V+9>$[N\_LWQ-KVJ>FA\]OZ].QX?]I;]@_XJ?LKV'@_Q
M'XQN-$U+POX\L]4LM'U;P]>?\>&J:%_R'=%US\N?ZU^]'PWLX->_95UB?QQ^
MUAX)\-^(/"_CO2[*STFTT?1M-U/X:?\ %:?\3W/_ $,'B/W_ ,>/C?\ X*Q6
M?AS_ (M?/8_$W6_&WBBZ_M3^V/"=W>'4_#/]E_\ ,"\:Z'_V-G]!1]9\_P"O
MO.;ZNO+^OD?!^F_\$VOCC>VOPPU6>^\)>'/#_P 4-'TO6O!^K:M>?V;IE_\
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M;_U]A_7ZUY/#_P %C-#\26WD0:K\+O#>H=1=ZM_;/ICZ?Y^E?+^C_P#!*/\
M81^*G[_X._\ !6;X.?VA=#_0])^+'@/6?!.IG5.!W_SUYZU8U+_@W=^-.O1?
M;O@[^U1^R7\6K>ZS_P (W_9'Q4T;3=4\6YYS_+WX].*!GV1X5_X+&>')HKB#
MQ5XC^#ES<6I_T*[M+S6?_K8[?CTQ7J&F_P#!5SX<WG]H0'XT_!SPW<75F?\
MB;?\5E_D^O/%?D?J7_!N[_P4FL]4N(-#^'/@GQ;;VMG_ ,A;PG\2/!NI:98<
M>PQW_P#K\US^I?\ !OK_ ,%2=-TO^U8/V>M2UNW_ .?32?$FC:EZ^A.1U[_2
M@#]</!__  4.\'>%K^WOM<_;N^%WC_3[K_F$ZMX/UG3<_P#<<XQTQ[XKZP^'
MW_!3[]A'0O#?C"R\5_$;P1XD\4:]9ZI_Q4-Y_;(^P?K^7^-?S/P_\$/?^"G?
MF#_C$GXD=_\ EST8GGW]??UZUH?\.-_^"H4T1_XQ*^)''_3GHO7G_)Q^!XH
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M#_K;B?\ TG\L#^7I^?6OI#X#GR?&^C\_\OFE]?P_ST]NM>#V>F_O;CR(._\
M3\L?3G%?1'P'AGF\;^'YH/\ H,:7_C^O\L4 ?IA\5(?^)I<8_P G^9_J?3FO
MF[6(3_9>H0<?\>>>HX'K^/\ 3\OI;XJ@?:[;@=^U>$:FB?9KCY%[?PCT/M7.
M=!^M7P>\-_!W7OAS^Q/^TU8:'XMU+3_A?K&E_"36/A[I/@_1M2TSXE_%#_D/
M<_Y/U]?JC]H7X\>#OA]XC\+>*OCA\#]2^ '@[QY_H7AKXA>"+/1O&WB;_B1:
MT/[=T70]<_ZFSPY_7Z5Y=_P3]L;(?L:? 2\%G:B[7]N7PMMNA;Q"Y7_B2_PS
MA/-'X-5'_@K;^\T_X:Z(_P ^C0^/?'GE:0_S:9%_Q)3_ *NP.;1/^ Q"@#\]
MO%7[-/CB\^)?BC]KWP!X \2#]E?2_%__  L'1[OQ9_8VI>.;#P&2/^)UKG@?
MW[^_!-?J1X#^/$'Q.^$O[1&N?LO? _7/BUK&J'P'\/M'\;_V/HWAK3/"6J:[
MQ_Q(]#[_ .?>O1_%W[C_ ()F_# P?N3-^QYJB3&+]V94_MH?)(4QO7_9;(]J
M\5_X)"33:=\$?CA_9\LMA_Q=7P'_ ,><C6O_ #!/^F!2@#H_&'AOXC? WX57
M'BKQC^RA_P 3#X7^ _"^M>,-)U:S\&ZEX&L-4_MK_B>_$[^V^?\ A(/$7BSK
M_P (MSGZ&OP/_;J^.7PR^.7B/P?I/P/\#GP3\+_ >CZI9:/9W>CC3-3O]4UW
M_B?:[K6N'/;Z#ITK^NS]O&:8_LQ?M QF60Q_\*3'[LR,4ZC^ G;^E?Q,:E96
M?EV_^B6O3_GWB]!_L4'-B-OE^C/FJ\TV?R?/S_QZWGK_ )QZ$]/SH$,_F_Z@
M7/\ IGZCD_3'?K_*O;I[*R\NX_T2U[_\N\7J?]BF7FEZ9]A_Y!UCU'_+I;^W
M_3.N@\_V[_E7WGBGDP>;Y /VFX_Y?,?_ *_7^O6B&SN(93!<07/_ .O_ ">W
MUZ&O43ING>5<_P"@67_'X/\ EU@_^-U=-G:?:;?_ $6W^[G_ %$77(Y^[70=
M)YSY,T/^O_Y_/MO^EXSC],#\?PJQ/>:KYO!_T>UY^U\Y_#G]?K7J$UC9?8/^
M/.U_\!XO[P_V*P=3M+7[7;?Z-;_]^8__ (F@Y[ON_O?^9PL.O:K#+;_O_P#E
M\_X\[3V__7W'6N@A\;:Y#%B">Y_[>_0_X\=NE7I[&RX_T.U[?\N\7O\ [%'V
M&R\O_CSM?^//_GWB]?\ <HL=!:L_B1KAE_<3W-M_UZ>_7V_SUKL--^/'C+08
MKBQL=<\26UM=#K::QK.F_A_3^><UR(TS3?)N/^)=8_\ @);^I_Z9U2L;.T,H
MS:VQZ_\ +"+_ &?]FN3D7G^'^1T'O>@_M:?&/PW*)]#^)OC;1+CK>_V3X\UG
M3/\ #I^/2NX_X;V_:3F^T?\ %]_C']G]1\2/&7T_Z&3I_GWKY%^PV7DZ/_H=
MK_Q^?\^\7M_L5LZ-8V0EML6=J/\ 1!TMXAV'^Q5G-[=_RK\3Z9F_;V_::A_?
MS_'?XQ_9^_V3XD>,OSS_ ,))TY]^>E<OKW[<GQ_UZP_LK5?C3\4=2T^Z_P"/
MRTU;QYXRU+V]_P ^M>&:O96?V73_ /1+7_C['_+O%Z'_ &*P!8V7G7'^AVO_
M (#Q>_\ L4![=_RK[SLM2_:+\?ZE%Y$^N>+;G3\]+OQ)K)-_G_/_ .NN/_X6
MIKEY+Q/<_P"B_P#+W=WF#GC]1]??I6;]ALOLUM_H=K_#_P N\7I_N58L[&R\
MFX_T.U_YA?\ R[Q>H_V*#I,F\\>:[>?:+>QZ6O\ ^O'<?6L>;Q)KEY_Q_7WK
M_P#J_E_^NNVGL;+[2/\ 0[7_ (\Q_P N\7J?]BLB\L;+,_\ H=KT/_+O%Z#_
M &*#G.(^V3S?N//N3<<_Y]^W7/US6/YW[KR/L%S_ .!G&?7'7K^/;':O:;C3
M=.\JX_T"R_X\Q_RZP>__ $SKE(+&R^TG_0[7_CS/_+O%ZC_8H.@X'SKC'^C\
M_:OP_P \U7FS#%;_ +GIGG_'Z\=>G->KV5C9>5;?Z':]1_R[Q>K?[%3BQLO.
MN/\ 0[7_ ,!XO?\ V* /*)OWW^H_X^/L?_'I_P#7_P#KT[R?)_<?\O/_ .KK
M_3\.AYKTVXL;+SKG_0[7_CS'_+O%[?['N:DAL+'_ )\[3_C[/_+O#V/'\% '
MEO[_ ,JWGZ]^GH<?F>?ITK/,/G?O_(N?M&<?R_K],UZM=V-E^_\ ]#M?^87_
M ,N\7M_L57FL;+_1_P#0[7O_ ,N\7_Q% ' P^?YMO#/!_P!NG\O\\'./I5B&
M'SC^_)_T6S'^F=\C]/\ /->F16%C]HN?]"M/^/+_ )]H?_B*Z2&QLMMS_H=K
M_P >9_Y=XO4_[% 'C\-G/-=?88(!<X_SU]?Z?C7<:#IDUG-_R\VW^>,]??M^
MM=\MC9?;S_H=KQ9G'^CQ>O\ N5U&CV-EY)_T.U_\!XO7_<H.<_J/_P"#4N$P
M_P#!037O._Z-R\=$_3^V] W?^.YK[+_X.N/^3@OV9\]?^%*^*?\ U-!7RU_P
M:PJH_;Z\3851_P 8_>.>@ _YC.@>@K]"?^#E_2],U/XY_LS_ -I:=8ZA_P 6
M?\4?\?UI;W?_ #.A_P">\<E<YZ!_%%-_KC]1_.OLG]A73?!WQ(E_:!_9Z\1V
M.I?VQ\6O!_VWPWXL\/#1O[3T#2_ O_$^UW_D8/;']*NW'@[PC]ON?^*6\.=O
M^8'IGM_TZU]P?\$S? G@?_AL>P;_ (0WPIN_X0_QUS_PCND9_P"0+Z_8\T >
MY^ _&'B.']EKP_8^!_V<]-\2>#_A?X.U2]O/$/BS^QO^$F\>>%M"UH_V[K7]
MA_\ ,P?Y_#\__B=H/A7_ (*!:9X/TK]FS0_%MMXX\!ZQJE[\2/%GQ-U@Z;X9
ML-+UWG0O!>A_A^''0\5^R[:5I<'[&VF>1IMA#M\'?%"U7RK.WCVVW]MZ]_HX
MV1KB#_IB/W?^S7A'_!.3PIX7TW4_V@K/3O#>@6%G-X&\,>;:V6CZ=:VTN-;.
M/,@@MHXG_P"!*: /D?\ 97^)UC\*_&_PO_9)USX<ZEXD^/'@/XD&RUCPG=6>
MC:;X9O\ 5-#'3^W/^9@_.OJC1_A+^U#XJUGX@?$;Q_\  ?3=-T_Q1X\TNR\-
M_P#")ZQH_P#PDV@Z7H6M?\B6?3P[XL_YG?\ &O)? OAGPW_P\2T74/\ A'M#
M^W_\+(U3_3O[)L/MG_@3]G\[_P ?K]7"[_\ "#6\F]O,_P"%D?ZS<=__ "&Q
M_%G=^M '\WO[9O[6ECH_ASXL? C5?@[X2\$_&#^V-3^'WC#Q#X>_L;4O#-CX
M#T+6L_V+H?/?/2OPOO-'S=>?Y X_#Z>W_P"OZ5_0=^VAX$\$7'[1WQIDG\&^
M%9I/^$D_UDOA[2)'_P"0,?XGLV;]:^3)O /@3[-I_P#Q17A+M_S+FC^A_P"G
M/V%=!YF)V7I^I^2DVFYEMY_^?K_(_E_,8JOYQ_TC_CVX_P @=NN?K7ZE3^ ?
M ODV_P#Q1?A+J/\ F7-']/\ KSK(@\ ^!/MY_P"**\)?\?FE_P#,N:/[?].=
M!D?G79PW'^O_ -&Q_P N?^'Z=?Q]ZL6?GPW7D>?]I_Y\_P#ZW^?PK](+/P%X
M%P?^*+\)]!_S+FC^@_Z<Z3_A O OFP_\47X3[?\ ,N:/_P#(= 'YX_VE?_\
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M[_3\/ITK]*[SP#X$Y_XHKPE_#_S+FC__ "'6QH/P]\ _8;;_ (H?PA_Q^?\
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MHCX&V?D^+='S_P ?%K>:7_GKT[YQQBOMJ7P#X%QG_A"O"6?M;<_\(YH_H/\
IISKVGX>?#WP#;^+='\CP/X0@_P!,TS_4^&M%C[?[%DM 4-G\_P!#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'H G # 2(  A$! Q$!_\0
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M^._^AY\7_P#A2:[_ /)-'_"P?'?_ $//B_\ \*37?_DFN.HH_M',/^AQF/\
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M'.C85HW =,@NJ@KNO:KHNJ:)+9PZM92V,NH:98ZQ9I*8RT^FZE%YUE=+Y;N
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M2;:E*_*M(NS;2=FDV]#4_P"%@^._^AY\7_\ A2:[_P#)-'_"P?'?_0\^+_\
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MG5YK-=;>6XHSS*</:1JS<%%SYKS2Y4[.5G).R>E[;Z7N+_PL'QW_ -#SXO\
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M*37?_DFN.HH_M',/^AQF/_@;_P#D@^N8K_H*?_@53_,['_A8/CO_ *'GQ?\
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M'%TY1C35%U9U'*K&4KRE%U&Y24HMQ6CE[IROA-!_PJOXU'9L"K\/-L1P0O\
MQ4D\BM\HV!E*"2/R?W*>8VP'<V-"RM8O'WPX\*^"M#UO2-*USPOJWB6[U+PM
MK6H6^A0^*Y-9N+>?2]<T^_N&@TN^U+2+>UFL?L-]*ODPW/F^:DBJ#F>&[JR'
MPW^,\,12U^VR^!6T_3IIHS=+;KXAOKI;2- Q-P^GVCQQ7#0*ZQA-[,<EVR]*
M^'FJ>)M*AOO#NH:%KU[*KV^J>&&U.STKQ!IUTEPWV</9ZM);6]_:74*(\4FG
M71PY1IE5R0.GFK4(Y5'#PIXITLGJX*JXXNG[>3JYM5Q_M5.LW4<XT_<_>7G*
MJE)WAH4IU:,L+1P\(XR$<-*G*-.7)4Y>:=VI2;:G9Z:;VNK;8^O>%_&'@Q5T
MSQ%HVJZ!;ZA*+E(IED72=3E@4^7-;S0M+IMW<6RR%A/;SDLDN5# DU7\*G_B
MJ_"@/*_\)5X;)!Y _P")W8<X]3QGZ 'T/JPTW5_!'P]\;Z+X\O[:,^(X=/M?
M"7@R36;+6-0L_$2ZB+J\\316EA+=V_AV*VL6>T>8S12W2.(AO52*\G\,.D?B
MKPL[LJ1Q^*/#\CL[ )'!%K=D_F/(2%&V)'DED; 51O8X!QYV(P_U;,<JJO$X
MAQK8JBY4,3*G4=).;3E4E3]U\J]Y<O*^K2NK\M2BL+CLLDE*"Q%>DI4JS52>
M'4IVYJDH^ZU%>]HHMIZI.S?M.C1J?VK%P,%/BQXC:-CSY3_;=2E\V,8(64R'
M<Q Y_GR7Q"CA\66-K\4+&"-+S4=1N/#_ (XLH5")8^,K4!$U9T0!;6R\5V$:
M:A]I8M$NHK-&#O<HG4:3>V2?M1?VD]S;IIO_  M+Q!>_;6FB6S^QO<Z@T=R+
MDMY/V:12OES!_+8,I5CNY\X\&^(=*T34]<T[Q)!<W_@KQ3!>Z/XET^R :^6T
MCNY+S3M4TL/F$ZII]WMELI)000TL!8132 ]\Z^%J8:>5XNK36'QF:9Q4=2"<
M9TJU)T'A<0I=(/GGS6UE%.S?*D_2J5:=2G/#3K4:5/$9CF$7)Q;Y51=/DJ^Z
MW95.>23L_=4F[M)/U_X&*G@C7_AWXAN(U_X2/XC>+=-T'PQ;RQJ;C3?!L>KV
MUGXG\0302!A$=<97TC3VQY@LC-/"V9MPY7X3.3\6M:(;&[2OB[(,ML^5] \3
M2_(K#R4 )R$B1-JHI()W$UO#?BH^(?CAX'U^Z6'3-,M?%_AVSTJR,ZI9Z#X7
MTRZ@@T>P25F$4<5I9Q.U[.2C2WAN;B<E&B<K\)[^/3OBU?:D9[>W:"P^)LL%
MU</ L2SR:)KL=JJFXW6]R+B62*,0RJR2L\<8#^8$;T,#B,.Y\/X6EBI0P^'S
M;&4W4I^S2E*.6TJM2J^9<R]K*E*3<G?WHWV:3HUJ,8Y/3H2A]6P^:8R6JM4:
MJ83ZK*3=TE&56;JQYO\ EVHPO=67A5E-"D=M+:R"&81P&WFM)76]22-4),;6
M$J7:2(XW1- #(C -$I;:*^CO&CW(^('P8DUE''C4Z!\/Y_%XD4?V@FJ0ZPZV
M#:IY+.6U4Z0MDM\DK&8AQ-/AY-B\+!\9/B.UO"\6LV=I,T"J+FP\,>&+"YMF
M$6&$<]MI,4L2_P!UH9$8=8W5@I'.>'[R>X\:Z!J6I7LUW<7'BG2+V]O[JYD:
M\N9Y=1MY+FYN+F23"*@0,\DLGRJN6. ,>+A<;A<._J7U[$XV.(Q^$J.O*-)T
MJ$*->G)J=*I)2J6Y+)J<%:VIPTZV'P\WA</B/K+KXVA4E6C'D]@J4FI-*;F^
M9-64E:*C?>]B7XA?8A\0_B 6,+,OC#Q"7$K1DY_M2;(R&21)5( 1@-X/W6'.
M?1K_ $_4];^&WPHT_P 03RKK.M_$+5-"\,W%^3)J0\%WZZ=;R.SR%KN;3['7
M9#<:;]IE 66*XCC9D9 LGBWXK>,K+QSXL.G7_AJ2WMO%FJ2Z?)-X2\+W4%U
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M'_\ TTVE?@8.H_X%_P"@-7[Y_"'_ ))?\/?^Q,\/_P#IIM*_>? +_D;<0?\
M8)2_].1/T[PPM]>S>VWU2CUO]N1X+^VU_P D9D_[&/1?_0KBOR&K]>?VVO\
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MH4\;#"132=5<U"=9J4FGHO9O91>VNE@6%3I5\1'^'2Q5/#0GK[3FE2G4?O\
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MT/8^^,]^@'OCIZU\;IC_ ,+(UC+*"-'\%@\KV\,Z/[?W<>YZ<'%86O>/M?\
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M1:%I%I9;XA*]WJAM%M[02(IL=,N(V95,C5XXY!.1P"J@#*D@!0,'  XQG&"
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M%W_=^]_Y!1111==U]Z"[_N_>_P#(****+KNOO07?]W[W_D%%%%%UW7WH+O\
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M]"9%_P"#+5?_ ),[?_KS1_Q [BG_ *&66_\ @2_^4!_Q#;._^AK@_P#P4_\
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M@A_T)D?_ (,M4_\ DS\/_K\T?\0-XI_Z&66_^!+_ .4!_P 0VSO_ *&N#_\
M!3_^5GX@9'J/S%&1ZC\Q7[@?\,N?!#_H3(O_  9:K_\ )E'_  RY\$/^A,B_
M\&6J_P#R9V__ %YH_P"('<4_]#++?_ E_P#* _XAMG?_ $-<'_X*?_RH_#_(
M]1^8HR/4?F*_<#_AESX(?]"9%_X,M5_^3*/^&7/@A_T)D7_@RU7_ .3/Q_\
MK<4?\0.XI_Z&66_^!+_Y0'_$-L[_ .AK@_\ P4__ )4?A_D>H_,49'J/S%?M
M_P#\,N?!#_H3(_\ P9:I_P#)G?\ _5BE_P"&7/@A_P!"9%_X,M5_^3.__P"K
M%'_$#>*?^AEEO_@2_P#E ?\ $-L[_P"AK@__  4__E9^'^1ZC\Q1D>H_,5^X
M'_#+GP0_Z$R+_P &6J__ "92?\,N?!#_ *$R/_P9:I_\F?A_]?FC_B!O%/\
MT,LM_P# E_\ * _XAMG?_0UP?_@I_P#RL_$#(]1^8HR/4?F*_<#_ (9<^"'_
M $)D7_@RU7_Y,[?_ *\TG_#+GP0_Z$R/_P &6J?_ "9V_P#UYH_X@=Q3_P!#
M++?_  )?_* _XAMG?_0UP?\ X*?_ ,J/Q R/4?F*,CU'YBOW _X9<^"'_0F1
M?^#+5?\ Y,H_X9<^"'_0F1?^#+5?_DS\?_K<4?\ $#N*?^AEEO\ X$O_ )0'
M_$-L[_Z&N#_\%/\ ^5'X?Y'J/S%&1ZC\Q7[?_P##+GP0_P"A,C_\&6J?_)G?
M_P#5BE_X9<^"'_0F1?\ @RU7_P"3._\ ^K%'_$#N*?\ H99;_P"!+_Y0'_$-
ML[_Z&N#_ /!3_P#E1^'^1ZC\Q1D>H_,5^W__  RY\$/^A,C_ /!EJG_R9^'_
M -?FC_AESX(?]"9'_P"#+5/_ ),_#_Z_-'_$#>*O^AEEO_@2_P#E ?\ $-L[
M_P"AK@__  4__E9^(&1ZC\Q1D>H_,5^X'_#+GP0_Z$R+_P &6J__ "9V_P#U
MYI/^&7/@A_T)D?\ X,M4_P#DSM_^O-'_ ! [BG_H99;_ .!+_P"4!_Q#;._^
MAK@__!3_ /E1^(&1ZC\Q1D>H_,5^X'_#+GP0_P"A,B_\&6J__)GX_P#UN*/^
M&7/@A_T)D7_@RU7_ .3*/^('<4_]#++?_ E_\H#_ (AMG?\ T-<'_P""G_\
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M(?\ 0F1?^#+5?_DSO_\ JQ1_PRY\$/\ H3(O_!EJO_R91_Q [BG_ *&66_\
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M$O\ Y0'_ !#;._\ H:X/_P %/_Y4?B!D>H_,49'J/S%?N!_PRY\$/^A,B_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/OP!5\,R>8K_ !5\-JV[85^613\R\#!P1Q7UW0 4444 %%%% !1110 4444
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M_P#B+\2?VMM1TSQMXOU;PGX#\(?$KXL?!3X@^%M?\*ZU\#-,^-'@KQYXXL?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPKX$TSQWX7U;Q1KW]M^'+B^T_4[MO#.F:C/:21  ]Z_;._Y)CX*_[+_^S_\
M^K6\,U];U^=/[8_BCXL-8^'O#\GPELF^'\?QU^ LFG_$5OB'HQN+V5?B'X4N
M(H%\')81ZE UQJ$LNDI/+?NL,<9U-HUC9(D_1:@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDDX R2>:^O* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO3+:2ZN6CMM-LFU![.Q@B'W6RJZE6&58$$>H/!'%(J*@PH"CT'08X  Z  =
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MTI(]C95FV;<;#@J#Q\P)&X="2-Q!+,3S4M%=!H%<#\5O$>I>#OA=\2?%VC+
M^L>%? /C'Q'I*7,7G6S:EH?AW4=3L5N(=\?FP-=6L0EB\R/S(RR[USN'?5C>
M(]"TOQ3X>UWPSKEL;S1?$>C:IH6KV@DEB-UI>KV,^GZA;"6!EFC,]I<31"2%
MEE3=NC8. : /PX_9Q_;&_:L^/W@KP59^ ?BO\*_COX\^*G[,7A_XX:S-\'/
M&F^%H_V=_']SK/@^"3X;:\GQ"UVYT!K+Q5IVN:\-$TWXA7&D>/4NO".L:A:V
MD^D3120=3\6_B/\ &;2-=^%?@O\ :W^.GQ _9G\%S_ _XP^.G^)'@W5?!_@V
M^\8_'30O%FC6O@SP5J7B3P1#KGA6ZFTOP!<7_B3P[\-M.N7O/B'J+R6TT&JS
MZ0-.E_8#P'X!\)?#?POX>\$^"M!M- \,^%=!T+PUHFGVB?):Z)X:TNVT;0K%
M[AP;R[_LW3+2ULH)=0EFN%AA56D9BY/5W6GV%[&D-[96EW#'-'<I%=6\-PB7
M$1S#.BS(ZI-$>8Y5 DC.-C+0!^%MS^U'XO\ B5IW[)G@K]H7XVZS^S?H\_PB
MU/6/VMO%O@#6K;X;^)_!O[0LW@3P5XZ^$WP_\=^)+BRO;3X72>._!>L>(OB1
MIGA\M"WBC5M,C\) 74:QZ3>^%)^TU^TSJGP]\2>+/C-\9?B9\'OCIX,^!WPE
M\6?LB?#C1-*_X1RW_:F\3>(]8\2:9#KWBKX=3Z(UQ\2/$OCF[LO"&@^*_AY
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M=-74?+^V+ITEU%%<R6(F%J]Q&DS1&1%8:"PQJ00@! (!Y) .TD G. 2JGCN
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M&>:^LY%1D97 *-\K \ [B!CJ.I(&!R>@R3BOSY_;&\<^-YM'\.^&Q\(_$/\
MPBMI\=?@-):_$!/$/A9])U)D^(GA:\C%MI*Z@=9CCDO"VF&6YMH-DJ_: CPL
MF[]!I%9U(5MK94AB-P!5@W(R,@XP>>] 'X8_"K]OCX\>._'#Z5:>-/@7XTU;
M7OVK/VB?V8K+]GKP+X2U1?C)X#\+?#*Z\;6?A/XN:_?ZSXNBM+PZ;)X6TF7Q
MG%JVAZ#\/KC3]=TQ=,\517\HB;O/B+\4_P!K'1O"'PMT;]H?Q%KWP'\&^/\
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M9I:]HZTTTFMF%%%% Q,9ZCOZYX]<>O;UI:** (9G*@;<%B1UZ;2RA\]N$W$
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MR:?3K>]G0@YRL]ZEQ*K9YR'!SSG-=[!I]E:Q)!;6T,$4:A42"-80JCHH$03
M]NGM5RBO1I83"T?X.'HTO\%.,>W9>2^XVA0HT[^SI4X75GRPC&Z^2(Q$@(.#
MD9(.3G)R,]<=_2E\M?3/N>?Y_P"?QR:?16[2:L]5VU7Y./YFJTVT]$E^A R
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M&IU)8;$2Y+TTU%<DIINRM;G2W6]M;-H] _X0SPG/\]QX:T*9]J*'FTG3Y)
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MU/"_] U#_P %0_R/&)/V?OA*P^7PHL1&[+PZOKD+X*L""T6HJQ!W=,D9^;J
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M8$#?\F1@;2B-\O )4,S#+?-D')JS5>V5E0[E56+<E,@/A$7?@@;<[< !5&T
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M"74I8F]TSPQ9Z)J WDEMM_HRV%RG))79(NPX*G(!KE/^&#?@/8,LOA*3XH^
M)U<R"7P5\9?B7I0\PGY2L-SXCU""%8QCRXH8T@&!F(X%?9]%8QXBSZ/(EG.9
MR5/X(U<;B:\%I:WLL35Q5)JR2Y94I1LDN716VED>32=_[+P,);\]+#QH5$[M
M\RJ4)4:D97;]Z,XRU>NI\;']D_Q;I44J>#_VM?VF-#9P!$-=\5>'?'T$&#E2
ML?BWPS?2M@?+AKC!7@Y;+F%O@]^UYHP T#]K'P]XBV#:D/Q ^!F@S%D'(\^[
M\)>(/#TTTC?QNL48Y)$8QS]GU$?E<G\?0\C_ #^56^(LTD[UW@,8N5Q<<9D^
M3XF+33UURW#RYM7[_.Y:[F7^K^67YH1QE&2=TZ.9YI#6^S3Q]:%O+D7KT/BM
MS^WKH,00P?LL?$%8QN8BX^)?P^GF ZQI&T'B^WC<]5:29DW8! !W"6+XS?M9
M:'\OB#]D&VUM(X]TU[X#^.?A"]B8@?<M=*\3:7H-](6_@WR1EC@,$')^RGCB
M< '=QG SEL9&?F;)Y[_-SP,@<4+$JDG##@#E0?3KDD$ ] >,]CUK+^VJ',_;
MY!D,Z<G%SC&ACLMDY)^]R1RO%1HVDK)S<.?31)6*_LJI%7I9GC</--\BGR8S
MW?LW>*IRDTND>:RM>S;9_/G_ ,%3?VX/B7I?PET/X4Q_!;QY\&[WXG7,A\0Z
MK\1K7PQ=0W&@^&[JRU.6R\*7^@:_K%C=ZE_:264LSW1MI(XDCB2%S=#'T?\
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M3C)=[2A%KJE9I?0)<8X_4$?IC_"F-(0>XSG:."6P,\9[GIC/:N&TGXC>!M>
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MEE;GC>UDUAVKN/,K<Q;Q&;T$_:8'"XO:_L*SA?I\-2,4FOBLI-.UKL^RB_R
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M.[96O+_0=%O[QD4QH;F\TNVN)S&@9]BF65V559@H(7)ZG\M?VW?V]/V;KO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK0!\J_\ #7G@'_HGW[07_AA/B7_\H:/^&O/ /_1/OV@O_#"?$O\ ^4-?55%
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MW_#7G@'_ *)]^T%_X83XE_\ RAH_X:\\ _\ 1/OV@O\ PPGQ+_\ E#7U2""
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6^_X)X?![X!_MP?M)^$OAG\5;+]N70/BM\=K_P +?!ZZ^,GQ2TGX%2^$=/\
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MASA58!=ZJJAV57;)  GHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOA]J7AQK*TC>RTJ[TU_4?V(_'W[<7CGXJ>-(OCAXP_L;6H/!_CE_B!\(=?\
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M=X7/)(ZG / /&>#Z?2O#K/XOZQ);Q2GX1?%%_-CCF#1Z5H7EYE0,P/F>((I
M58G*LBG!7@9KY*_:<_:$^(^DW'AO2_"^F^*_ARLPEU.\EUBSTVTU'5'M;B*&
M"VM9[:\OTBMK=7,\ZLS++N"R*R_(,<YXVR/),HKYSB)XNMAJ$,/+V>'P>*]O
M5^L2@H1I*OAL/3<DIJ4DZB:C&32E8QQ_$.79=@GCJ\JSHJ,)6A0JN;4W%15I
M0C&_O7LY+9];)_I5368KCC()()STXXXP2Q)X 4$Y-?+_ ,.OCEXFUKP1X9U?
M5OAE\0]5U&^TFVEN]0TC2]!.EWLRJ5:[M!)KT$HCN_\ 6\H$' 1$&*\^_:#^
M/_C?0? Q/AOP;XS\$W^I:A;:?_;_ (@L=*@@MHY [O#:FVU346^V7(7RHRR1
M; 2\<GF "ML7Q=D^"R>6=U98AX2."I8[DAAZCK.E6C&48J+@H>T7.HR3FHJ2
M=I-6OI4S[+J6">/E4J>P5%5VE0K<ZC*$9J+3IJ*E:27Q<O7F:LW]Q*P89&1Z
M@C!'?!';@U6>>19-@@=U.[#J#@8!VJ3@@,6!SN*J%92"6RM?(/['WQ1\8_$3
MPEX@@\67-UJ<_AS4[2UL]7NTB6YO+:]BN&>WN"@!DEL);8@RN6E=)5#,0 *^
M)/VK_@=\6OC!^VKXSB\._!>Q^(?A^X_8Q\/:)X(\>^-_BCXU^&O@OX5?$^]^
M)/Q#MSXE\,3>%]#UQM7\8Z9:WFAZUJUII3Z%XACTS3]+6VU:,SV[1^AD6=X3
MB#*<-G."A7AA,71C6HK$05.K*$G**;A%R2U@^IVY;CJ&:X##YCA')X?$TO:T
M_:1Y)\O-.&L;NSYH2Z]N]C]E8K^WGFG@AGMI)+-Q'?1+/&T]I(Z++$LT*,[P
MF6%A-&LPB9XBLBJ48&K'G ;B0  2,97=QC+'YMH'(/7/(R*_G0\;6/[5G[/K
M_';1-#O/C/JOBWQ+XV^ /A_6_P!H[P_H/B9[7Q3KOPX_9$\/:/?^+K_3/#7@
MKXA^(M>M/B)\2]+?0;>&QTVUTR+Q1-);>)M9MX2AG^@O@A\8/VJ_&7BSX.W/
M[26L?M!_"WQAXA^'7[.>I_#;P)\//A%N^&OQ%\3ZWX(@O_CM;_'*]E\%^)V\
M(7VE>-Q=Z7KUAJGB'P0O@;PY#I^K:4VHMJ%PU>P=A^T=WJ5M8QF6\FM[.'>L
M0FN[FWMXB\C(L8,DTL:9=G550,78LH0,S!:MB7.#@%2IR5.[# XQP,XZ\A>O
MM7\N7Q(\0_\ !0+XN_LX_M&Z=\4-7^(-UX]MM"\&:SX\^!G@GX)?$'Q#XQ\!
M^/\ 1_VB? M]HM]\$-9U3PQI/@+7;#PWX0TS6=0?PYH/B'QQ#XSTN;2==AN[
M4K<P7'U<?B_^T@?$US;P?$+]J^;]AP?$62#4OV@Y_A,\?[2FGWJ?#B:[E\*Z
M7H$7PQ37Y?A0OQ*B_LVX\</\*I=3M-6D'AJ&[/AX+K+ '[PJ^X^Q!((Y!' R
M"!CJ2"#SWQUI]?-/[(.O_&7Q-^SO\,]:^/UA=:=\5;_2=3;7X=2TZTT;6[G3
MH/$6KV_@_5?$FB6)-GHOBK6_!*>'=7\4Z3:".UT_7[S4+6WM[6.(6T7TM0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M ",,JPQG((P3@'(Z$CD9]17RF_[&/[.<GQU7]I5_AGIK?%Q7%W_;IGN7MVU=
M;86T>O-I#/\ 8&UR"%/*AU H)%#-*/WQ#@HKKPF88_ .O]1QN*P:Q6'GA<4L
M+B*U!8G#U/CH5G1J4W4I2N^:G+FB[O17=^>OA,)BG2>)PN'Q#H58UJ+KT:=;
MV56/PU*?M(2Y9+36-GI]WTZELR#"EAPJX9$/W!@<@9 8Y8YS@D]N*^5?BS^Q
M'^S;\;_B9X=^+/Q)^&6G>(?&_AM+**WU-[J\M+74H].F2XTR/7M-MI$L]<CT
MZ6-&M!>HXB \HAH\@%%/ 9EF.55OK&69ACLOKNE4HNO@<9B\)B72K:5(?6L-
MB:&)Y)*R<76<;)*UDDIQ>"PF/I*CC,+A<3352-50K8;#U(J<7=-1E3:O?KOY
MVT/J^.%8XHXHXQ'&D01(E141%10D<:H@"HJHH4(HV*O PH%?+7QY_8V^ '[3
M&I^%]<^,OP]M/$VK>$&(TF^CNKK3[S['YZW,FD7MQ8RPRZCHL\JAGTRX+0_-
M(N09"244L'F&.R[$1Q> Q5?!XF#ER8C#U)TJ\5.,HU(JK&2G^\4Y<[<G)W=V
MVVR<7E^"S##RPN.PM+%X:<X3E1K1<J?[NW+'DOR\JY8V5M'%-;'TGH.AZ9H&
MCZ=HNC6%OI>DZ58VFG:;IUM;K;6UE8V4$=O:6EO;KE88+:&-(H8E)$:*%YP#
M6X!@8//_ .O/^?SHHKCDG.M4KSE.I6K2<JE2<Y2E)MN3;NWJVVVW>3;;<FVV
M^FG3IT:<*5&$:5*G%1ITX)*,(K1):;)))?DNBT444RPP/04F >H''3CI110
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21110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>tara-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 08 08:29:56 UTC 2023 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://www.Protaratherapeutics.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:tara="http://www.Protaratherapeutics.com/20221231" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="tara-20221231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="tara-20221231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="tara-20221231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="tara-20221231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet" id="tara_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals" id="tara_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement" id="tara_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement_Parentheticals" id="tara_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3" id="tara_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Consolidated Statements of Changes in Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow" id="tara_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/OrganizationandNatureoftheBusiness" id="tara_r_OrganizationandNatureoftheBusiness">
        <link:definition>007 - Disclosure - Organization and Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPolicies" id="tara_r_SummaryofSignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/FairValueofFinancialInstruments" id="tara_r_FairValueofFinancialInstruments">
        <link:definition>009 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/MarketableDebtSecurities" id="tara_r_MarketableDebtSecurities">
        <link:definition>010 - Disclosure - Marketable Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssets" id="tara_r_PrepaidExpensesandOtherCurrentAssets">
        <link:definition>011 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/PropertyandEquipmentnet" id="tara_r_PropertyandEquipmentnet">
        <link:definition>012 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/AccruedExpenses" id="tara_r_AccruedExpenses">
        <link:definition>013 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/Leases" id="tara_r_Leases">
        <link:definition>014 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/CommitmentsandContingencies" id="tara_r_CommitmentsandContingencies">
        <link:definition>015 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/StockholdersEquity" id="tara_r_StockholdersEquity">
        <link:definition>016 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/StockBasedCompensation" id="tara_r_StockBasedCompensation">
        <link:definition>017 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/IncomeTaxes" id="tara_r_IncomeTaxes">
        <link:definition>018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/EmployeeBenefitPlan" id="tara_r_EmployeeBenefitPlan">
        <link:definition>019 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/NetLossPerCommonShare" id="tara_r_NetLossPerCommonShare">
        <link:definition>020 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy" id="tara_r_AccountingPoliciesByPolicy">
        <link:definition>021 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" id="tara_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>022 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsTables" id="tara_r_FairValueofFinancialInstrumentsTables">
        <link:definition>023 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesTables" id="tara_r_MarketableDebtSecuritiesTables">
        <link:definition>024 - Disclosure - Marketable Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssetsTables" id="tara_r_PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>025 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetTables" id="tara_r_PropertyandEquipmentnetTables">
        <link:definition>026 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/AccruedExpensesTables" id="tara_r_AccruedExpensesTables">
        <link:definition>027 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/LeasesTables" id="tara_r_LeasesTables">
        <link:definition>028 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/StockBasedCompensationTables" id="tara_r_StockBasedCompensationTables">
        <link:definition>029 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/IncomeTaxesTables" id="tara_r_IncomeTaxesTables">
        <link:definition>030 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/NetLossPerCommonShareTables" id="tara_r_NetLossPerCommonShareTables">
        <link:definition>031 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" id="tara_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>032 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable" id="tara_r_ScheduleofcashcashequivalentsandrestrictedcashTable">
        <link:definition>033 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents, and restricted cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable" id="tara_r_ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable">
        <link:definition>034 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable" id="tara_r_ScheduleofgoodwillandaccumulatedimpairmentlossesTable">
        <link:definition>035 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of goodwill and accumulated impairment losses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsDetails" id="tara_r_FairValueofFinancialInstrumentsDetails">
        <link:definition>036 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable" id="tara_r_ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable">
        <link:definition>037 - Disclosure - Fair Value of Financial Instruments (Details) - Schedule of financial assets and liabilities that are measured and carried at fair value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesDetails" id="tara_r_MarketableDebtSecuritiesDetails">
        <link:definition>038 - Disclosure - Marketable Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable" id="tara_r_ScheduleofmarketabledebtsecuritiesTable">
        <link:definition>039 - Disclosure - Marketable Debt Securities (Details) - Schedule of marketable debt securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofinterestandinvestmentincomeTable" id="tara_r_ScheduleofinterestandinvestmentincomeTable">
        <link:definition>040 - Disclosure - Marketable Debt Securities (Details) - Schedule of interest and investment income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable" id="tara_r_ScheduleofprepaidexpensesandothercurrentassetsTable">
        <link:definition>041 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails" id="tara_r_PropertyandEquipmentnetDetails">
        <link:definition>042 - Disclosure - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable" id="tara_r_ScheduleofpropertyandequipmentnetTable">
        <link:definition>043 - Disclosure - Property and Equipment, net (Details) - Schedule of property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofaccruedexpensesTable" id="tara_r_ScheduleofaccruedexpensesTable">
        <link:definition>044 - Disclosure - Accrued Expenses (Details) - Schedule of accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/LeasesDetails" id="tara_r_LeasesDetails">
        <link:definition>045 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofleaseexpenseTable" id="tara_r_ScheduleofleaseexpenseTable">
        <link:definition>046 - Disclosure - Leases (Details) - Schedule of lease expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraERpGibwnKDuAJiNyIYG2H8s4SQ1D2uYlD5jFc0teK32BeW1Fr2o1Ni9NHX7+JbcT6d9/LlbyRbJSUzPIQg0nOkdo5WNEqHQXf9xzR45imSnjrybOQNzpPFlStmTd3tNMP/V17WoireM4++Z8KBdOTup6WP0OPJ7JL5pzC5fEliqx4tW2skLfFbEtpya7tUtv6utPlPNxxar1bCN3JJg1PSvnX5o+6sjk=] CSR-->
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofweightedaverageremainingleasetermandtheweightedaveragediscountrateforoperatingleasesTable" id="tara_r_ScheduleofweightedaverageremainingleasetermandtheweightedaveragediscountrateforoperatingleasesTable">
        <link:definition>047 - Disclosure - Leases (Details) - Schedule of weighted average remaining lease term and the weighted average discount rate for operating leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable" id="tara_r_ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable">
        <link:definition>048 - Disclosure - Leases (Details) - Schedule of operating lease payments included in the measurement of lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails" id="tara_r_CommitmentsandContingenciesDetails">
        <link:definition>049 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/StockholdersEquityDetails" id="tara_r_StockholdersEquityDetails">
        <link:definition>050 - Disclosure - Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails" id="tara_r_StockBasedCompensationDetails">
        <link:definition>051 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable" id="tara_r_ScheduleofrestrictedstockunitactivityTable">
        <link:definition>052 - Disclosure - Stock-Based Compensation (Details) - Schedule of restricted stock unit activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable" id="tara_r_ScheduleofthefairvalueofstockoptionsgrantedTable">
        <link:definition>053 - Disclosure - Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable" id="tara_r_ScheduleofstockoptionactivitiesTable">
        <link:definition>054 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock option activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleoftotalstockbasedcompensationcostsTable" id="tara_r_ScheduleoftotalstockbasedcompensationcostsTable">
        <link:definition>055 - Disclosure - Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofstockbasedcompensationexpenseTable" id="tara_r_ScheduleofstockbasedcompensationexpenseTable">
        <link:definition>056 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock-based compensation expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/IncomeTaxesDetails" id="tara_r_IncomeTaxesDetails">
        <link:definition>057 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable" id="tara_r_ScheduleoffederalandstateincometaxexpenseTable">
        <link:definition>058 - Disclosure - Income Taxes (Details) - Schedule of federal and state income tax expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" id="tara_r_ScheduleofdeferredtaxassetsandliabilitiesTable">
        <link:definition>059 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable" id="tara_r_ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable">
        <link:definition>060 - Disclosure - Income Taxes (Details) - Schedule of federal income tax to income before provision for income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/EmployeeBenefitPlanDetails" id="tara_r_EmployeeBenefitPlanDetails">
        <link:definition>061 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable" id="tara_r_ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable">
        <link:definition>062 - Disclosure - Net Loss Per Common Share (Details) - Schedule of net loss per share attributable to common stockholders, basic and diluted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable_Parentheticals" id="tara_r_ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable_Parentheticals">
        <link:definition>063 - Disclosure - Net Loss Per Common Share (Details) - Schedule of net loss per share attributable to common stockholders, basic and diluted (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/ScheduleofweightedaveragedilutivecommonsharesTable" id="tara_r_ScheduleofweightedaveragedilutivecommonsharesTable">
        <link:definition>064 - Disclosure - Net Loss Per Common Share (Details) - Schedule of weighted average dilutive common shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfGoodwillAndAccumulatedImpairmentLossesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfGoodwillAndAccumulatedImpairmentLossesAbstract"/>
  <xs:element name="ScheduleOfFinancialAssetsAndLiabilitiesThatAreMeasuredAndCarriedAtFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfFinancialAssetsAndLiabilitiesThatAreMeasuredAndCarriedAtFairValueAbstract"/>
  <xs:element name="MarketableDebtSecuritiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_MarketableDebtSecuritiesAbstract"/>
  <xs:element name="ScheduleOfMarketableDebtSecuritiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfMarketableDebtSecuritiesAbstract"/>
  <xs:element name="ScheduleOfInterestAndInvestmentIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfInterestAndInvestmentIncomeAbstract"/>
  <xs:element name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfAccruedExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfAccruedExpensesAbstract"/>
  <xs:element name="ScheduleOfLeaseExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfLeaseExpenseAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract"/>
  <xs:element name="ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfRestrictedStockUnitActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfRestrictedStockUnitActivityAbstract"/>
  <xs:element name="ScheduleOfTheFairValueOfStockOptionsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfTheFairValueOfStockOptionsGrantedAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfStockOptionActivitiesAbstract"/>
  <xs:element name="ScheduleOfTotalStockBasedCompensationCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfTotalStockBasedCompensationCostsAbstract"/>
  <xs:element name="ScheduleOfStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfStockBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfFederalAndStateIncomeTaxExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfFederalAndStateIncomeTaxExpenseAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract"/>
  <xs:element name="ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageDilutiveCommonSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract"/>
  <xs:element name="PreferredStock0001ParValueAuthorized10000000SharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_PreferredStock0001ParValueAuthorized10000000SharesAbstract"/>
  <xs:element name="CommonStock0001ParValueAuthorized100000000SharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_CommonStock0001ParValueAuthorized100000000SharesAbstract"/>
  <xs:element name="OtherIncomeExpenseNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_OtherIncomeExpenseNetAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_UnlabeledAbstract3"/>
  <xs:element name="CashPaidForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_CashPaidForAbstract"/>
  <xs:element name="CashEquivalentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_CashEquivalentsAbstract"/>
  <xs:element name="RestrictedCashNonCurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_RestrictedCashNonCurrentAbstract"/>
  <xs:element name="MarketableDebtSecuritiesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_MarketableDebtSecuritiesAbstract0"/>
  <xs:element name="CashEquivalentsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_CashEquivalentsAbstract0"/>
  <xs:element name="RestrictedCashNonCurrentAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_RestrictedCashNonCurrentAbstract0"/>
  <xs:element name="MarketableDebtSecuritiesAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_MarketableDebtSecuritiesAbstract1"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_UnlabeledAbstract4"/>
  <xs:element name="CurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_CurrentAbstract"/>
  <xs:element name="DeferredAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_DeferredAbstract"/>
  <xs:element name="NumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_NumeratorAbstract"/>
  <xs:element name="DenominatorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_DenominatorAbstract"/>
  <xs:element name="SettlementOfRestrictedStockUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tara_SettlementOfRestrictedStockUnits"/>
  <xs:element name="SettlementOfRestrictedStockUnitinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_SettlementOfRestrictedStockUnitinShares"/>
  <xs:element name="AmortizationOfDiscountsAndPremiumsInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_AmortizationOfDiscountsAndPremiumsInvestments"/>
  <xs:element name="ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities"/>
  <xs:element name="OrganizationandNatureoftheBusinessTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tara_OrganizationandNatureoftheBusinessTable"/>
  <xs:element name="OrganizationandNatureoftheBusinessLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_OrganizationandNatureoftheBusinessLineItems"/>
  <xs:element name="MarketableDebtSecuritiesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_MarketableDebtSecuritiesTextBlock"/>
  <xs:element name="MarketableDebtSecuritiesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_MarketableDebtSecuritiesPolicyTextBlock"/>
  <xs:element name="PatentCostsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_PatentCostsPolicyTextBlock"/>
  <xs:element name="RecentAccountingPronouncementsNotYetAdopted" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_RecentAccountingPronouncementsNotYetAdopted"/>
  <xs:element name="ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock"/>
  <xs:element name="ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock"/>
  <xs:element name="ScheduleOfInterestAndInvestmentIncomeTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock"/>
  <xs:element name="ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock"/>
  <xs:element name="ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock"/>
  <xs:element name="IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock"/>
  <xs:element name="ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems"/>
  <xs:element name="ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems"/>
  <xs:element name="FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"/>
  <xs:element name="FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems"/>
  <xs:element name="UnrealizedGains" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tara_UnrealizedGains"/>
  <xs:element name="UnrealizedLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_UnrealizedLoss"/>
  <xs:element name="EstimatedFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_EstimatedFairValue"/>
  <xs:element name="PrepaidSoftware" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_PrepaidSoftware"/>
  <xs:element name="AccruedInterestOnMarketableDebtSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_AccruedInterestOnMarketableDebtSecurities"/>
  <xs:element name="AccruedEmployeeRelatedCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tara_AccruedEmployeeRelatedCurrent"/>
  <xs:element name="AccruedResearchAndDevelopmentCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tara_AccruedResearchAndDevelopmentCurrent"/>
  <xs:element name="OperatingLeasesFutureMinimumPaymentDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tara_OperatingLeasesFutureMinimumPaymentDue"/>
  <xs:element name="PresentValueOfFutureMinimumLeasePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tara_PresentValueOfFutureMinimumLeasePayments"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2"/>
  <xs:element name="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod"/>
  <xs:element name="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised"/>
  <xs:element name="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue"/>
  <xs:element name="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable"/>
  <xs:element name="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems"/>
  <xs:element name="DeferredTaxAssetsOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_DeferredTaxAssetsOperatingLeaseLiability"/>
  <xs:element name="DeferredTaxAssetsRestrictedStockUnitsExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_DeferredTaxAssetsRestrictedStockUnitsExpense"/>
  <xs:element name="DeferredTaxLiabilitiesOperatingRightofuseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tara_DeferredTaxLiabilitiesOperatingRightofuseAsset"/>
  <xs:element name="EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost"/>
  <xs:element name="StockOptionsIssuedAndOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_StockOptionsIssuedAndOutstanding"/>
  <xs:element name="RestrictedStockUnitsIssuedAndOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_RestrictedStockUnitsIssuedAndOutstanding"/>
  <xs:element name="ConversionOfSeries1ConvertiblePreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_ConversionOfSeries1ConvertiblePreferredStock"/>
  <xs:element name="TotalPotentiallyDilutiveShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_TotalPotentiallyDilutiveShares"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tara_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="OperatingSegmentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_OperatingSegmentDescription"/>
  <xs:element name="MarketCapitalizationsPercentageChange" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_MarketCapitalizationsPercentageChange"/>
  <xs:element name="MicrocapCompaniesMarketCapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tara_MicrocapCompaniesMarketCapitalization"/>
  <xs:element name="VestingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_VestingPeriod"/>
  <xs:element name="StockOptionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_StockOptionPeriod"/>
  <xs:element name="PercentageOfLargestAmountOfBenefit" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_PercentageOfLargestAmountOfBenefit"/>
  <xs:element name="UnrealizedLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_UnrealizedLosses"/>
  <xs:element name="PropertyandEquipmentnetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tara_PropertyandEquipmentnetDetailsTable"/>
  <xs:element name="PropertyandEquipmentnetDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_PropertyandEquipmentnetDetailsLineItems"/>
  <xs:element name="TotalPropertyAndEquipmentNet" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_TotalPropertyAndEquipmentNet"/>
  <xs:element name="RestrictedCashNoncurrents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_RestrictedCashNoncurrents"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tara_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_CommitmentsandContingenciesDetailsLineItems"/>
  <xs:element name="DescriptionOfAgreements" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_DescriptionOfAgreements"/>
  <xs:element name="ResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_ResearchAndDevelopmentExpenses"/>
  <xs:element name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tara_StockholdersEquityDetailsTable"/>
  <xs:element name="StockholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_StockholdersEquityDetailsLineItems"/>
  <xs:element name="CommonStockIssuanceAndOutstandingPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_CommonStockIssuanceAndOutstandingPercentage"/>
  <xs:element name="IncreaseOrDecreaseEquityPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_IncreaseOrDecreaseEquityPercentage"/>
  <xs:element name="AggregateOfSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tara_AggregateOfSharesOfCommonStock"/>
  <xs:element name="NetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_NetProceeds"/>
  <xs:element name="GrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_GrossProceeds"/>
  <xs:element name="StockBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tara_StockBasedCompensationDetailsTable"/>
  <xs:element name="StockBasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_StockBasedCompensationDetailsLineItems"/>
  <xs:element name="StocksIssuedDuringPeriodValueNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_StocksIssuedDuringPeriodValueNewIssues"/>
  <xs:element name="SharesAvailableForIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tara_SharesAvailableForIssuance"/>
  <xs:element name="NumberSharesAuthorized" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_NumberSharesAuthorized"/>
  <xs:element name="NumberOfShareAuthorizedIncreased" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tara_NumberOfShareAuthorizedIncreased"/>
  <xs:element name="UnamortizedValueOfRsus" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_UnamortizedValueOfRsus"/>
  <xs:element name="WeightedAverageRemainingAmortizationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_WeightedAverageRemainingAmortizationPeriod"/>
  <xs:element name="NumberOfSharesRestrictedStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_NumberOfSharesRestrictedStock"/>
  <xs:element name="ConnectionWithTheNetShareSettlement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_ConnectionWithTheNetShareSettlement"/>
  <xs:element name="ShareBasedCompensationUnrecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tara_ShareBasedCompensationUnrecognized"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tara_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_IncomeTaxesDetailsLineItems"/>
  <xs:element name="EffectiveTaxRateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_EffectiveTaxRateDescription"/>
  <xs:element name="IncomeTaxCarriedForwardTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_IncomeTaxCarriedForwardTerms"/>
  <xs:element name="EmployeeContributions" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_EmployeeContributions"/>
  <xs:element name="EmployeeCompensation" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_EmployeeCompensation"/>
  <xs:element name="BoardOfDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_BoardOfDirectorsMember"/>
  <xs:element name="CholineLicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_CholineLicenseAgreementMember"/>
  <xs:element name="FederalNOLMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_FederalNOLMember"/>
  <xs:element name="FeinsteinAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_FeinsteinAgreementMember"/>
  <xs:element name="IowaAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_IowaAgreementMember"/>
  <xs:element name="LaboratoryEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_LaboratoryEquipmentMember"/>
  <xs:element name="PropertyAndEquipmentNotYetPlacedIntoServiceMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember"/>
  <xs:element name="Series1PreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_Series1PreferredStockMember"/>
  <xs:element name="SeriesOneConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_SeriesOneConvertiblePreferredStockMember"/>
  <xs:element name="StateIncomeTaxMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_StateIncomeTaxMember"/>
  <xs:element name="TwentyFourteenEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_TwentyFourteenEquityIncentivePlanMember"/>
  <xs:element name="TwentySeventeenEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_TwentySeventeenEquityIncentivePlanMember"/>
  <xs:element name="TwentyTwentyInducementPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_TwentyTwentyInducementPlanMember"/>
  <xs:element name="TwoThousandFourteenEmployeeStockPurchasePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
  <xs:element name="USFederalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_USFederalMember"/>
  <xs:element name="UnderwrittenPublicOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_UnderwrittenPublicOfferingMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tara_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>tara-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 08 08:29:56 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ConsolidatedBalanceSheet" roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ConsolidatedIncomeStatement" roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ConsolidatedCashFlow" roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraERpGibwnKDuAJiNyIYG2H8s4SQ1D2uYlD5jFc0teK32BeW1Fr2o1Ni9NHX7+JbcT6d9/LlbyRbJSUzPIQg0nOkdo5WNEqHQXf9xzR45imSnjrybOQNzpPFlStmTd3tNMP/V17WoireM4++Z8KBdOTup6WP0OPJ7JL5pzC5fEliqx4tW2skLfFbEtpya7tUtv6utPlPNxxau6lKwDYfP1pK6gS6VnA1wE=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GoodwillImpairmentLoss" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GoodwillImpairmentLoss" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="tara_AmortizationOfDiscountsAndPremiumsInvestments" xlink:href="tara-20221231.xsd#tara_AmortizationOfDiscountsAndPremiumsInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tara_AmortizationOfDiscountsAndPremiumsInvestments" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities" xlink:href="tara-20221231.xsd#tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>tara-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 08 08:29:56 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ConsolidatedBalanceSheet" roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ConsolidatedIncomeStatement" roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ShareholdersEquityType2or3" roleURI="http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ConsolidatedCashFlow" roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_OrganizationandNatureoftheBusiness" roleURI="http://www.Protaratherapeutics.com/role/OrganizationandNatureoftheBusiness"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_FairValueofFinancialInstruments" roleURI="http://www.Protaratherapeutics.com/role/FairValueofFinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_MarketableDebtSecurities" roleURI="http://www.Protaratherapeutics.com/role/MarketableDebtSecurities"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_PropertyandEquipmentnet" roleURI="http://www.Protaratherapeutics.com/role/PropertyandEquipmentnet"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_AccruedExpenses" roleURI="http://www.Protaratherapeutics.com/role/AccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_Leases" roleURI="http://www.Protaratherapeutics.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_CommitmentsandContingencies" roleURI="http://www.Protaratherapeutics.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_StockholdersEquity" roleURI="http://www.Protaratherapeutics.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_StockBasedCompensation" roleURI="http://www.Protaratherapeutics.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_IncomeTaxes" roleURI="http://www.Protaratherapeutics.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_EmployeeBenefitPlan" roleURI="http://www.Protaratherapeutics.com/role/EmployeeBenefitPlan"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_NetLossPerCommonShare" roleURI="http://www.Protaratherapeutics.com/role/NetLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_AccountingPoliciesByPolicy" roleURI="http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_FairValueofFinancialInstrumentsTables" roleURI="http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_MarketableDebtSecuritiesTables" roleURI="http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_PropertyandEquipmentnetTables" roleURI="http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_AccruedExpensesTables" roleURI="http://www.Protaratherapeutics.com/role/AccruedExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_LeasesTables" roleURI="http://www.Protaratherapeutics.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_StockBasedCompensationTables" roleURI="http://www.Protaratherapeutics.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_IncomeTaxesTables" roleURI="http://www.Protaratherapeutics.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_NetLossPerCommonShareTables" roleURI="http://www.Protaratherapeutics.com/role/NetLossPerCommonShareTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofcashcashequivalentsandrestrictedcashTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofgoodwillandaccumulatedimpairmentlossesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofmarketabledebtsecuritiesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofinterestandinvestmentincomeTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofinterestandinvestmentincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofpropertyandequipmentnetTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofaccruedexpensesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofaccruedexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofleaseexpenseTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofleaseexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofweightedaverageremainingleasetermandtheweightedaveragediscountrateforoperatingleasesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofweightedaverageremainingleasetermandtheweightedaveragediscountrateforoperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofrestrictedstockunitactivityTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofthefairvalueofstockoptionsgrantedTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofstockoptionactivitiesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleoftotalstockbasedcompensationcostsTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleoftotalstockbasedcompensationcostsTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofstockbasedcompensationexpenseTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofstockbasedcompensationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleoffederalandstateincometaxexpenseTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable_Parentheticals" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofweightedaveragedilutivecommonsharesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofweightedaveragedilutivecommonsharesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_FairValueofFinancialInstrumentsDetails" roleURI="http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_MarketableDebtSecuritiesDetails" roleURI="http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_PropertyandEquipmentnetDetails" roleURI="http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_LeasesDetails" roleURI="http://www.Protaratherapeutics.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_CommitmentsandContingenciesDetails" roleURI="http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_StockholdersEquityDetails" roleURI="http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_StockBasedCompensationDetails" roleURI="http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_IncomeTaxesDetails" roleURI="http://www.Protaratherapeutics.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_EmployeeBenefitPlanDetails" roleURI="http://www.Protaratherapeutics.com/role/EmployeeBenefitPlanDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#DocumentAndEntityInformation" roleURI="http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_Assets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_Liabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_Series1PreferredStockMember" xlink:href="tara-20221231.xsd#tara_Series1PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tara_Series1PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_OtherIncomeExpenseNetAbstract" xlink:href="tara-20221231.xsd#tara_OtherIncomeExpenseNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="tara_OtherIncomeExpenseNetAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_OtherIncomeExpenseNetAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_OtherIncomeExpenseNetAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_Series1PreferredStockMember" xlink:href="tara-20221231.xsd#tara_Series1PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tara_Series1PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_SeriesOneConvertiblePreferredStockMember" xlink:href="tara-20221231.xsd#tara_SeriesOneConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tara_SeriesOneConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_SettlementOfRestrictedStockUnits" xlink:href="tara-20221231.xsd#tara_SettlementOfRestrictedStockUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tara_SettlementOfRestrictedStockUnits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_SettlementOfRestrictedStockUnitinShares" xlink:href="tara-20221231.xsd#tara_SettlementOfRestrictedStockUnitinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tara_SettlementOfRestrictedStockUnitinShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTax" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_AmortizationOfDiscountsAndPremiumsInvestments" xlink:href="tara-20221231.xsd#tara_AmortizationOfDiscountsAndPremiumsInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tara_AmortizationOfDiscountsAndPremiumsInvestments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities" xlink:href="tara-20221231.xsd#tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_CashPaidForAbstract" xlink:href="tara-20221231.xsd#tara_CashPaidForAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="tara_CashPaidForAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_CashPaidForAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_CashPaidForAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/OrganizationandNatureoftheBusiness">
    <loc xlink:type="locator" xlink:label="tara_OrganizationandNatureoftheBusinessLineItems" xlink:href="tara-20221231.xsd#tara_OrganizationandNatureoftheBusinessLineItems"/>
    <loc xlink:type="locator" xlink:label="tara_OrganizationandNatureoftheBusinessTable" xlink:href="tara-20221231.xsd#tara_OrganizationandNatureoftheBusinessTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tara_OrganizationandNatureoftheBusinessLineItems" xlink:to="tara_OrganizationandNatureoftheBusinessTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_OrganizationandNatureoftheBusinessLineItems" xlink:to="us-gaap_NatureOfOperations" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/FairValueofFinancialInstruments">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/MarketableDebtSecurities">
    <loc xlink:type="locator" xlink:label="tara_MarketableDebtSecuritiesAbstract" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="tara_MarketableDebtSecuritiesTextBlock" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_MarketableDebtSecuritiesAbstract" xlink:to="tara_MarketableDebtSecuritiesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/PropertyandEquipmentnet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/AccruedExpenses">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/EmployeeBenefitPlan">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/NetLossPerCommonShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_MarketableDebtSecuritiesPolicyTextBlock" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tara_MarketableDebtSecuritiesPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_PatentCostsPolicyTextBlock" xlink:href="tara-20221231.xsd#tara_PatentCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tara_PatentCostsPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_RecentAccountingPronouncementsNotYetAdopted" xlink:href="tara-20221231.xsd#tara_RecentAccountingPronouncementsNotYetAdopted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tara_RecentAccountingPronouncementsNotYetAdopted" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesTables">
    <loc xlink:type="locator" xlink:label="tara_MarketableDebtSecuritiesAbstract" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_MarketableDebtSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_MarketableDebtSecuritiesAbstract" xlink:to="tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/AccruedExpensesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" xlink:href="tara-20221231.xsd#tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/NetLossPerCommonShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems" xlink:to="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_LaboratoryEquipmentMember" xlink:href="tara-20221231.xsd#tara_LaboratoryEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tara_LaboratoryEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm" xlink:href="tara-20221231.xsd#tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems" xlink:to="tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable">
    <loc xlink:type="locator" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems"/>
    <loc xlink:type="locator" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:to="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_GoodwillMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:to="us-gaap_GoodwillGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:to="us-gaap_Goodwill" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable">
    <loc xlink:type="locator" xlink:label="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems" xlink:href="tara-20221231.xsd#tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems"/>
    <loc xlink:type="locator" xlink:label="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable" xlink:href="tara-20221231.xsd#tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems" xlink:to="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_CashEquivalentsAbstract" xlink:href="tara-20221231.xsd#tara_CashEquivalentsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems" xlink:to="tara_CashEquivalentsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_CashEquivalentsAbstract" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_CashEquivalentsAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_RestrictedCashNonCurrentAbstract" xlink:href="tara-20221231.xsd#tara_RestrictedCashNonCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems" xlink:to="tara_RestrictedCashNonCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_RestrictedCashNonCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_MarketableDebtSecuritiesAbstract0" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems" xlink:to="tara_MarketableDebtSecuritiesAbstract0" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_MarketableDebtSecuritiesAbstract0" xlink:to="us-gaap_MarketableSecurities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_MarketableDebtSecuritiesAbstract0" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllOtherCorporateBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherCorporateBondsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AllOtherCorporateBondsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_UnrealizedGains" xlink:href="tara-20221231.xsd#tara_UnrealizedGains"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tara_UnrealizedGains" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_UnrealizedLoss" xlink:href="tara-20221231.xsd#tara_UnrealizedLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tara_UnrealizedLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_EstimatedFairValue" xlink:href="tara-20221231.xsd#tara_EstimatedFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tara_EstimatedFairValue" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofinterestandinvestmentincomeTable">
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfInterestAndInvestmentIncomeAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfInterestAndInvestmentIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfInterestAndInvestmentIncomeAbstract" xlink:to="us-gaap_InterestIncomeOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfInterestAndInvestmentIncomeAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfInterestAndInvestmentIncomeAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfInterestAndInvestmentIncomeAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_PrepaidSoftware" xlink:href="tara-20221231.xsd#tara_PrepaidSoftware"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="tara_PrepaidSoftware" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_AccruedInterestOnMarketableDebtSecurities" xlink:href="tara-20221231.xsd#tara_AccruedInterestOnMarketableDebtSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="tara_AccruedInterestOnMarketableDebtSecurities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_LaboratoryEquipmentMember" xlink:href="tara-20221231.xsd#tara_LaboratoryEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tara_LaboratoryEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember" xlink:href="tara-20221231.xsd#tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofaccruedexpensesTable">
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfAccruedExpensesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfAccruedExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="tara_AccruedEmployeeRelatedCurrent" xlink:href="tara-20221231.xsd#tara_AccruedEmployeeRelatedCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfAccruedExpensesAbstract" xlink:to="tara_AccruedEmployeeRelatedCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_AccruedResearchAndDevelopmentCurrent" xlink:href="tara-20221231.xsd#tara_AccruedResearchAndDevelopmentCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfAccruedExpensesAbstract" xlink:to="tara_AccruedResearchAndDevelopmentCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_OtherExpenses" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofleaseexpenseTable">
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfLeaseExpenseAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfLeaseExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfLeaseExpenseAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfLeaseExpenseAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfLeaseExpenseAbstract" xlink:to="us-gaap_LeaseCost" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofweightedaverageremainingleasetermandtheweightedaveragediscountrateforoperatingleasesTable">
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraERpGibwnKDuAJiNyIYG2H8s4SQ1D2uYlD5jFc0teK32BeW1Fr2o1Ni9NHX7+JbcT6d9/LlbyRbJSUzPIQg0nOkdo5WNEqHQXf9xzR45imSnjrybOQNzpPFlStmTd3tNMP/V17WoireM4++Z8KBdOTup6WP0OPJ7JL5pzC5fEliqx4tW2skLfFbEtpya7tUtv6utPlPNxxamteGGT4mKjrNLqbl4ZW/EY=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_OperatingLeasesFutureMinimumPaymentDue" xlink:href="tara-20221231.xsd#tara_OperatingLeasesFutureMinimumPaymentDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="tara_OperatingLeasesFutureMinimumPaymentDue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_PresentValueOfFutureMinimumLeasePayments" xlink:href="tara-20221231.xsd#tara_PresentValueOfFutureMinimumLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="tara_PresentValueOfFutureMinimumLeasePayments" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable">
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems"/>
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable">
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems"/>
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" xlink:to="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable">
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" order="30" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleoftotalstockbasedcompensationcostsTable">
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems"/>
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems" xlink:to="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofstockbasedcompensationexpenseTable">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable">
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfFederalAndStateIncomeTaxExpenseAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfFederalAndStateIncomeTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="tara_CurrentAbstract" xlink:href="tara-20221231.xsd#tara_CurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfFederalAndStateIncomeTaxExpenseAbstract" xlink:to="tara_CurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_CurrentAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_CurrentAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_DeferredAbstract" xlink:href="tara-20221231.xsd#tara_DeferredAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfFederalAndStateIncomeTaxExpenseAbstract" xlink:to="tara_DeferredAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_DeferredAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_DeferredAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfFederalAndStateIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfFederalAndStateIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="tara-20221231.xsd#tara_DeferredTaxAssetsOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="tara_DeferredTaxAssetsOperatingLeaseLiability" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_DeferredTaxAssetsRestrictedStockUnitsExpense" xlink:href="tara-20221231.xsd#tara_DeferredTaxAssetsRestrictedStockUnitsExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="tara_DeferredTaxAssetsRestrictedStockUnitsExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_DeferredTaxLiabilitiesOperatingRightofuseAsset" xlink:href="tara-20221231.xsd#tara_DeferredTaxLiabilitiesOperatingRightofuseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="tara_DeferredTaxLiabilitiesOperatingRightofuseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable">
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost" xlink:href="tara-20221231.xsd#tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable">
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract"/>
    <loc xlink:type="locator" xlink:label="tara_NumeratorAbstract" xlink:href="tara-20221231.xsd#tara_NumeratorAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="tara_NumeratorAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_DenominatorAbstract" xlink:href="tara-20221231.xsd#tara_DenominatorAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="tara_DenominatorAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_DenominatorAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofweightedaveragedilutivecommonsharesTable">
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="tara_StockOptionsIssuedAndOutstanding" xlink:href="tara-20221231.xsd#tara_StockOptionsIssuedAndOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract" xlink:to="tara_StockOptionsIssuedAndOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_RestrictedStockUnitsIssuedAndOutstanding" xlink:href="tara-20221231.xsd#tara_RestrictedStockUnitsIssuedAndOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract" xlink:to="tara_RestrictedStockUnitsIssuedAndOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ConversionOfSeries1ConvertiblePreferredStock" xlink:href="tara-20221231.xsd#tara_ConversionOfSeries1ConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract" xlink:to="tara_ConversionOfSeries1ConvertiblePreferredStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_TotalPotentiallyDilutiveShares" xlink:href="tara-20221231.xsd#tara_TotalPotentiallyDilutiveShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract" xlink:to="tara_TotalPotentiallyDilutiveShares" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tara_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_GoodwillMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_OperatingSegmentDescription" xlink:href="tara-20221231.xsd#tara_OperatingSegmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tara_OperatingSegmentDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_Goodwill" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_MarketCapitalizationsPercentageChange" xlink:href="tara-20221231.xsd#tara_MarketCapitalizationsPercentageChange"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tara_MarketCapitalizationsPercentageChange" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_MicrocapCompaniesMarketCapitalization" xlink:href="tara-20221231.xsd#tara_MicrocapCompaniesMarketCapitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tara_MicrocapCompaniesMarketCapitalization" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_VestingPeriod" xlink:href="tara-20221231.xsd#tara_VestingPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tara_VestingPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_StockOptionPeriod" xlink:href="tara-20221231.xsd#tara_StockOptionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tara_StockOptionPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_PercentageOfLargestAmountOfBenefit" xlink:href="tara-20221231.xsd#tara_PercentageOfLargestAmountOfBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tara_PercentageOfLargestAmountOfBenefit" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesDetails">
    <loc xlink:type="locator" xlink:label="tara_MarketableDebtSecuritiesAbstract" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_MarketableDebtSecuritiesAbstract" xlink:to="us-gaap_NetInvestmentIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_UnrealizedLosses" xlink:href="tara-20221231.xsd#tara_UnrealizedLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_MarketableDebtSecuritiesAbstract" xlink:to="tara_UnrealizedLosses" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails">
    <loc xlink:type="locator" xlink:label="tara_PropertyandEquipmentnetDetailsLineItems" xlink:href="tara-20221231.xsd#tara_PropertyandEquipmentnetDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tara_PropertyandEquipmentnetDetailsTable" xlink:href="tara-20221231.xsd#tara_PropertyandEquipmentnetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tara_PropertyandEquipmentnetDetailsLineItems" xlink:to="tara_PropertyandEquipmentnetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_PropertyandEquipmentnetDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_PropertyandEquipmentnetDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_PropertyandEquipmentnetDetailsLineItems" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_TotalPropertyAndEquipmentNet" xlink:href="tara-20221231.xsd#tara_TotalPropertyAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_PropertyandEquipmentnetDetailsLineItems" xlink:to="tara_TotalPropertyAndEquipmentNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_RestrictedCashNoncurrents" xlink:href="tara-20221231.xsd#tara_RestrictedCashNoncurrents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="tara_RestrictedCashNoncurrents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="tara_CommitmentsandContingenciesDetailsLineItems" xlink:href="tara-20221231.xsd#tara_CommitmentsandContingenciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tara_CommitmentsandContingenciesDetailsTable" xlink:href="tara-20221231.xsd#tara_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tara_CommitmentsandContingenciesDetailsLineItems" xlink:to="tara_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_CholineLicenseAgreementMember" xlink:href="tara-20221231.xsd#tara_CholineLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="tara_CholineLicenseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_IowaAgreementMember" xlink:href="tara-20221231.xsd#tara_IowaAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="tara_IowaAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_FeinsteinAgreementMember" xlink:href="tara-20221231.xsd#tara_FeinsteinAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="tara_FeinsteinAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_DescriptionOfAgreements" xlink:href="tara-20221231.xsd#tara_DescriptionOfAgreements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_CommitmentsandContingenciesDetailsLineItems" xlink:to="tara_DescriptionOfAgreements" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ResearchAndDevelopmentExpenses" xlink:href="tara-20221231.xsd#tara_ResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_CommitmentsandContingenciesDetailsLineItems" xlink:to="tara_ResearchAndDevelopmentExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BroadcastersLicenseAgreementCommitmentsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="tara_StockholdersEquityDetailsLineItems" xlink:href="tara-20221231.xsd#tara_StockholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tara_StockholdersEquityDetailsTable" xlink:href="tara-20221231.xsd#tara_StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="tara_StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_UnderwrittenPublicOfferingMember" xlink:href="tara-20221231.xsd#tara_UnderwrittenPublicOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tara_UnderwrittenPublicOfferingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_SeriesOneConvertiblePreferredStockMember" xlink:href="tara-20221231.xsd#tara_SeriesOneConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tara_SeriesOneConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_CommonStockIssuanceAndOutstandingPercentage" xlink:href="tara-20221231.xsd#tara_CommonStockIssuanceAndOutstandingPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="tara_CommonStockIssuanceAndOutstandingPercentage" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_IncreaseOrDecreaseEquityPercentage" xlink:href="tara-20221231.xsd#tara_IncreaseOrDecreaseEquityPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="tara_IncreaseOrDecreaseEquityPercentage" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_AggregateOfSharesOfCommonStock" xlink:href="tara-20221231.xsd#tara_AggregateOfSharesOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="tara_AggregateOfSharesOfCommonStock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_NetProceeds" xlink:href="tara-20221231.xsd#tara_NetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="tara_NetProceeds" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_GrossProceeds" xlink:href="tara-20221231.xsd#tara_GrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="tara_GrossProceeds" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsLineItems" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsTable" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="tara_StockBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_StockBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_StockBasedCompensationDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_StockBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_StockBasedCompensationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_TwentyTwentyInducementPlanMember" xlink:href="tara-20221231.xsd#tara_TwentyTwentyInducementPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tara_TwentyTwentyInducementPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_TwentySeventeenEquityIncentivePlanMember" xlink:href="tara-20221231.xsd#tara_TwentySeventeenEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tara_TwentySeventeenEquityIncentivePlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_TwentyFourteenEquityIncentivePlanMember" xlink:href="tara-20221231.xsd#tara_TwentyFourteenEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tara_TwentyFourteenEquityIncentivePlanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:href="tara-20221231.xsd#tara_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tara_TwoThousandFourteenEmployeeStockPurchasePlanMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_BoardOfDirectorsMember" xlink:href="tara-20221231.xsd#tara_BoardOfDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tara_BoardOfDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_StocksIssuedDuringPeriodValueNewIssues" xlink:href="tara-20221231.xsd#tara_StocksIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="tara_StocksIssuedDuringPeriodValueNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_SharesAvailableForIssuance" xlink:href="tara-20221231.xsd#tara_SharesAvailableForIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="tara_SharesAvailableForIssuance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_NumberSharesAuthorized" xlink:href="tara-20221231.xsd#tara_NumberSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="tara_NumberSharesAuthorized" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_NumberOfShareAuthorizedIncreased" xlink:href="tara-20221231.xsd#tara_NumberOfShareAuthorizedIncreased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="tara_NumberOfShareAuthorizedIncreased" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_UnamortizedValueOfRsus" xlink:href="tara-20221231.xsd#tara_UnamortizedValueOfRsus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="tara_UnamortizedValueOfRsus" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_WeightedAverageRemainingAmortizationPeriod" xlink:href="tara-20221231.xsd#tara_WeightedAverageRemainingAmortizationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="tara_WeightedAverageRemainingAmortizationPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_NumberOfSharesRestrictedStock" xlink:href="tara-20221231.xsd#tara_NumberOfSharesRestrictedStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="tara_NumberOfSharesRestrictedStock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ConnectionWithTheNetShareSettlement" xlink:href="tara-20221231.xsd#tara_ConnectionWithTheNetShareSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="tara_ConnectionWithTheNetShareSettlement" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_ShareBasedCompensationUnrecognized" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationUnrecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="tara_ShareBasedCompensationUnrecognized" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="tara_IncomeTaxesDetailsLineItems" xlink:href="tara-20221231.xsd#tara_IncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tara_IncomeTaxesDetailsTable" xlink:href="tara-20221231.xsd#tara_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tara_IncomeTaxesDetailsLineItems" xlink:to="tara_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tara_IncomeTaxesDetailsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_FederalNOLMember" xlink:href="tara-20221231.xsd#tara_FederalNOLMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="tara_FederalNOLMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_USFederalMember" xlink:href="tara-20221231.xsd#tara_USFederalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="tara_USFederalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_StateIncomeTaxMember" xlink:href="tara-20221231.xsd#tara_StateIncomeTaxMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="tara_StateIncomeTaxMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_EffectiveTaxRateDescription" xlink:href="tara-20221231.xsd#tara_EffectiveTaxRateDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_IncomeTaxesDetailsLineItems" xlink:to="tara_EffectiveTaxRateDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_IncomeTaxCarriedForwardTerms" xlink:href="tara-20221231.xsd#tara_IncomeTaxCarriedForwardTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_IncomeTaxesDetailsLineItems" xlink:to="tara_IncomeTaxCarriedForwardTerms" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tara_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/EmployeeBenefitPlanDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="tara_EmployeeContributions" xlink:href="tara-20221231.xsd#tara_EmployeeContributions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="tara_EmployeeContributions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tara_EmployeeCompensation" xlink:href="tara-20221231.xsd#tara_EmployeeCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="tara_EmployeeCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_OtherLaborRelatedExpenses" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>tara-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 08 08:29:56 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in)/provided by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash (used in)/provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease)/increase in cash and cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash - beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents and restricted cash - end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract_lbl" xml:lang="en-US">Schedule Of Cash Cash Equivalents And Restricted Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_lbl0" xml:lang="en-US">Goodwill at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl1" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value of Financial Instruments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfFinancialAssetsAndLiabilitiesThatAreMeasuredAndCarriedAtFairValueAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfFinancialAssetsAndLiabilitiesThatAreMeasuredAndCarriedAtFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfFinancialAssetsAndLiabilitiesThatAreMeasuredAndCarriedAtFairValueAbstract_lbl" xml:lang="en-US">Schedule of financial assets and liabilities that are measured and carried at fair value [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfFinancialAssetsAndLiabilitiesThatAreMeasuredAndCarriedAtFairValueAbstract" xlink:to="tara_ScheduleOfFinancialAssetsAndLiabilitiesThatAreMeasuredAndCarriedAtFairValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_MarketableDebtSecuritiesAbstract" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_MarketableDebtSecuritiesAbstract_lbl" xml:lang="en-US">Marketable Debt Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MarketableDebtSecuritiesAbstract" xlink:to="tara_MarketableDebtSecuritiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment, net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accrued Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfAccruedExpensesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfAccruedExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfAccruedExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Accrued Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfAccruedExpensesAbstract" xlink:to="tara_ScheduleOfAccruedExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock-Based Compensation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Restricted Stock Units, Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Restricted Stock Units, Balance at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant Date Fair Value, Balance at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Options, ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl" xml:lang="en-US">Aggregate Intrinsic Value, ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Employee Benefit Plan [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss Per Common Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract_lbl" xml:lang="en-US">Schedule of Net Loss Per Share Attributable to Common Stockholders Basic and Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract_lbl" xml:lang="en-US">Schedule of Weighted Average Dilutive Common Shares [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract" xlink:to="tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable debt securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US">Marketable debt securities, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Total property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 9)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_PreferredStock0001ParValueAuthorized10000000SharesAbstract" xlink:href="tara-20221231.xsd#tara_PreferredStock0001ParValueAuthorized10000000SharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_PreferredStock0001ParValueAuthorized10000000SharesAbstract_lbl" xml:lang="en-US">Preferred stock, $0.001 par value, authorized 10,000,000 shares:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PreferredStock0001ParValueAuthorized10000000SharesAbstract" xlink:to="tara_PreferredStock0001ParValueAuthorized10000000SharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value, authorized 10,000,000 shares: Series 1 convertible preferred stock, 8,028 shares authorized at December 31, 2022 and 2021, respectively 8,027 shares issued and outstanding as of December 31, 2022 and 2021, respectively.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred shares of par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_CommonStock0001ParValueAuthorized100000000SharesAbstract" xlink:href="tara-20221231.xsd#tara_CommonStock0001ParValueAuthorized100000000SharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_CommonStock0001ParValueAuthorized100000000SharesAbstract_lbl" xml:lang="en-US">Common stock, $0.001 par value, authorized 100,000,000 shares:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CommonStock0001ParValueAuthorized100000000SharesAbstract" xlink:to="tara_CommonStock0001ParValueAuthorized100000000SharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value, authorized 100,000,000 shares: Common stock, 11,267,389 and 11,235,731 shares issued and outstanding as of December 31, 2022 and 2021, respectively.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common shares of par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common stock authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common stock shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Loss on impairment of goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl0" xml:lang="en-US">Loss on impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl1" xml:lang="en-US">Impairment of goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl2" xml:lang="en-US">Goodwill impairment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl2"/>
    <loc xlink:type="locator" xlink:label="tara_OtherIncomeExpenseNetAbstract" xlink:href="tara-20221231.xsd#tara_OtherIncomeExpenseNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_OtherIncomeExpenseNetAbstract_lbl" xml:lang="en-US">Other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_OtherIncomeExpenseNetAbstract" xlink:to="tara_OtherIncomeExpenseNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest and investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_UnlabeledAbstract" xlink:href="tara-20221231.xsd#tara_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnlabeledAbstract" xlink:to="tara_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders, basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders, diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares outstanding, basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted average shares outstanding, diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US">Weighted-average common shares outstanding &#8211; basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl2" xml:lang="en-US">Weighted-average common shares outstanding &#8211; diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Net unrealized (loss) gain on marketable debt securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SettlementOfRestrictedStockUnits" xlink:href="tara-20221231.xsd#tara_SettlementOfRestrictedStockUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_SettlementOfRestrictedStockUnits_lbl" xml:lang="en-US">Settlement of restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SettlementOfRestrictedStockUnits" xlink:to="tara_SettlementOfRestrictedStockUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SettlementOfRestrictedStockUnitinShares" xlink:href="tara-20221231.xsd#tara_SettlementOfRestrictedStockUnitinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_SettlementOfRestrictedStockUnitinShares_lbl" xml:lang="en-US">Settlement of restricted stock units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SettlementOfRestrictedStockUnitinShares" xlink:to="tara_SettlementOfRestrictedStockUnitinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation - restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation - stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax_lbl" xml:lang="en-US">Other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Total stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_AmortizationOfDiscountsAndPremiumsInvestments" xlink:href="tara-20221231.xsd#tara_AmortizationOfDiscountsAndPremiumsInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_AmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Amortization of premium on marketable debt securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_AmortizationOfDiscountsAndPremiumsInvestments" xlink:to="tara_AmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_UnlabeledAbstract0" xlink:href="tara-20221231.xsd#tara_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnlabeledAbstract0" xlink:to="tara_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities" xlink:href="tara-20221231.xsd#tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities_lbl" xml:lang="en-US">Proceeds from maturity and redemption of marketable debt securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities" xlink:to="tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_UnlabeledAbstract1" xlink:href="tara-20221231.xsd#tara_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnlabeledAbstract1" xlink:to="tara_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_UnlabeledAbstract2" xlink:href="tara-20221231.xsd#tara_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnlabeledAbstract2" xlink:to="tara_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_UnlabeledAbstract3" xlink:href="tara-20221231.xsd#tara_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnlabeledAbstract3" xlink:to="tara_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_CashPaidForAbstract" xlink:href="tara-20221231.xsd#tara_CashPaidForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_CashPaidForAbstract_lbl" xml:lang="en-US">Cash paid for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CashPaidForAbstract" xlink:to="tara_CashPaidForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Purchase of marketable debt securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Repurchase of shares in connection with settlement of RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_Series1PreferredStockMember" xlink:href="tara-20221231.xsd#tara_Series1PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_Series1PreferredStockMember_lbl" xml:lang="en-US">Series 1 Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_Series1PreferredStockMember" xlink:to="tara_Series1PreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tara_Series1PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_Series1PreferredStockMember" xlink:to="tara_Series1PreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_SeriesOneConvertiblePreferredStockMember" xlink:href="tara-20221231.xsd#tara_SeriesOneConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_SeriesOneConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series 1 Convertible</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SeriesOneConvertiblePreferredStockMember" xlink:to="tara_SeriesOneConvertiblePreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tara_SeriesOneConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series 1 Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SeriesOneConvertiblePreferredStockMember" xlink:to="tara_SeriesOneConvertiblePreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Organization and Nature of the Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of cash, cash equivalents, and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US">Restricted cash, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated useful lives for significant property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock" xlink:to="tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm" xlink:href="tara-20221231.xsd#tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm_lbl" xml:lang="en-US">Shorter of the useful life of asset or the lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm" xlink:to="tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock_lbl" xml:lang="en-US">Schedule of goodwill and accumulated impairment losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock" xlink:to="tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillGross_lbl" xml:lang="en-US">Goodwill, gross amount as of December 31, 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillGross" xlink:to="us-gaap_GoodwillGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_lbl" xml:lang="en-US">Accumulated impairment loss, as of December 31, 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xml:lang="en-US">Additions to goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of financial assets and liabilities that are measured and carried at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_CashEquivalentsAbstract" xlink:href="tara-20221231.xsd#tara_CashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_CashEquivalentsAbstract_lbl" xml:lang="en-US">Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CashEquivalentsAbstract" xlink:to="tara_CashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Money market funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US">Corporate bonds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_RestrictedCashNonCurrentAbstract" xlink:href="tara-20221231.xsd#tara_RestrictedCashNonCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_RestrictedCashNonCurrentAbstract_lbl" xml:lang="en-US">Restricted cash, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_RestrictedCashNonCurrentAbstract" xlink:to="tara_RestrictedCashNonCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndInvestments_lbl" xml:lang="en-US">Money market funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestments" xlink:to="us-gaap_RestrictedCashAndInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_MarketableDebtSecuritiesAbstract0" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_MarketableDebtSecuritiesAbstract0_lbl" xml:lang="en-US">Marketable debt securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MarketableDebtSecuritiesAbstract0" xlink:to="tara_MarketableDebtSecuritiesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US">Corporate bonds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_CashEquivalentsAbstract0" xlink:href="tara-20221231.xsd#tara_CashEquivalentsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_CashEquivalentsAbstract0_lbl" xml:lang="en-US">Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CashEquivalentsAbstract0" xlink:to="tara_CashEquivalentsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_RestrictedCashNonCurrentAbstract0" xlink:href="tara-20221231.xsd#tara_RestrictedCashNonCurrentAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_RestrictedCashNonCurrentAbstract0_lbl" xml:lang="en-US">Restricted cash, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_RestrictedCashNonCurrentAbstract0" xlink:to="tara_RestrictedCashNonCurrentAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_MarketableDebtSecuritiesAbstract1" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_MarketableDebtSecuritiesAbstract1_lbl" xml:lang="en-US">Marketable debt securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MarketableDebtSecuritiesAbstract1" xlink:to="tara_MarketableDebtSecuritiesAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_MarketableDebtSecuritiesTextBlock" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_MarketableDebtSecuritiesTextBlock_lbl" xml:lang="en-US">Marketable Debt Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MarketableDebtSecuritiesTextBlock" xlink:to="tara_MarketableDebtSecuritiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xml:lang="en-US">Schedule of marketable debt securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Amortized Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_UnrealizedGains" xlink:href="tara-20221231.xsd#tara_UnrealizedGains"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_UnrealizedGains_lbl" xml:lang="en-US">Unrealized Gains</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnrealizedGains" xlink:to="tara_UnrealizedGains_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_UnrealizedLoss" xlink:href="tara-20221231.xsd#tara_UnrealizedLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_UnrealizedLoss_lbl" xml:lang="en-US">Unrealized Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnrealizedLoss" xlink:to="tara_UnrealizedLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_EstimatedFairValue" xlink:href="tara-20221231.xsd#tara_EstimatedFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_EstimatedFairValue_lbl" xml:lang="en-US">Estimated Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_EstimatedFairValue" xlink:to="tara_EstimatedFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock_lbl" xml:lang="en-US">Schedule of interest and investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock" xlink:to="tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xml:lang="en-US">Accretion/(amortization) of discount/premium, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xml:lang="en-US">Realized gain/(loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US">Total interest and investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Prepaid research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_PrepaidSoftware" xlink:href="tara-20221231.xsd#tara_PrepaidSoftware"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_PrepaidSoftware_lbl" xml:lang="en-US">Prepaid software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PrepaidSoftware" xlink:to="tara_PrepaidSoftware_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_AccruedInterestOnMarketableDebtSecurities" xlink:href="tara-20221231.xsd#tara_AccruedInterestOnMarketableDebtSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_AccruedInterestOnMarketableDebtSecurities_lbl" xml:lang="en-US">Accrued interest on marketable debt securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_AccruedInterestOnMarketableDebtSecurities" xlink:to="tara_AccruedInterestOnMarketableDebtSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_AccruedEmployeeRelatedCurrent" xlink:href="tara-20221231.xsd#tara_AccruedEmployeeRelatedCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_AccruedEmployeeRelatedCurrent_lbl" xml:lang="en-US">Employee Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_AccruedEmployeeRelatedCurrent" xlink:to="tara_AccruedEmployeeRelatedCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_AccruedResearchAndDevelopmentCurrent" xlink:href="tara-20221231.xsd#tara_AccruedResearchAndDevelopmentCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US">Research and development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_AccruedResearchAndDevelopmentCurrent" xlink:to="tara_AccruedResearchAndDevelopmentCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average remaining lease term and the weighted average discount rate for operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:to="tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term &#8211; operating lease (in months)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of operating lease payments included in the measurement of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:to="tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_OperatingLeasesFutureMinimumPaymentDue" xlink:href="tara-20221231.xsd#tara_OperatingLeasesFutureMinimumPaymentDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_OperatingLeasesFutureMinimumPaymentDue_lbl" xml:lang="en-US">Total future operating lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_OperatingLeasesFutureMinimumPaymentDue" xlink:to="tara_OperatingLeasesFutureMinimumPaymentDue_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_PresentValueOfFutureMinimumLeasePayments" xlink:href="tara-20221231.xsd#tara_PresentValueOfFutureMinimumLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_PresentValueOfFutureMinimumLeasePayments_lbl" xml:lang="en-US">Present value of future minimum lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PresentValueOfFutureMinimumLeasePayments" xlink:to="tara_PresentValueOfFutureMinimumLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of restricted stock unit activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Restricted Stock Units, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Granted option to purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of the fair value of stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod_lbl" xml:lang="en-US">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_UnlabeledAbstract4" xlink:href="tara-20221231.xsd#tara_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnlabeledAbstract4" xlink:to="tara_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Vested or expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested or expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Vested or expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested or expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" xlink:to="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:to="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" xlink:href="tara-20221231.xsd#tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock_lbl" xml:lang="en-US">Schedule of total stock-based compensation costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" xlink:to="tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of federal and state income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_CurrentAbstract" xlink:href="tara-20221231.xsd#tara_CurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_CurrentAbstract_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CurrentAbstract" xlink:to="tara_CurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_DeferredAbstract" xlink:href="tara-20221231.xsd#tara_DeferredAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_DeferredAbstract_lbl" xml:lang="en-US">Deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DeferredAbstract" xlink:to="tara_DeferredAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total income tax expense (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Capitalized research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock option expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="tara-20221231.xsd#tara_DeferredTaxAssetsOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="tara_DeferredTaxAssetsOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_DeferredTaxAssetsRestrictedStockUnitsExpense" xlink:href="tara-20221231.xsd#tara_DeferredTaxAssetsRestrictedStockUnitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_DeferredTaxAssetsRestrictedStockUnitsExpense_lbl" xml:lang="en-US">RSU expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DeferredTaxAssetsRestrictedStockUnitsExpense" xlink:to="tara_DeferredTaxAssetsRestrictedStockUnitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net of valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax assets, net of valuation allowance and deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of federal income tax to income before provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">True-up to prior years return</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">State rate change</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost" xlink:href="tara-20221231.xsd#tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost" xlink:to="tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl" xml:lang="en-US">Goodwill impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Employee Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of net loss per share attributable to common stockholders, basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_NumeratorAbstract" xlink:href="tara-20221231.xsd#tara_NumeratorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_NumeratorAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_NumeratorAbstract" xlink:to="tara_NumeratorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_DenominatorAbstract" xlink:href="tara-20221231.xsd#tara_DenominatorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_DenominatorAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DenominatorAbstract" xlink:to="tara_DenominatorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Net loss per share attributable to common stockholders, basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average dilutive common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock" xlink:to="tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StockOptionsIssuedAndOutstanding" xlink:href="tara-20221231.xsd#tara_StockOptionsIssuedAndOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_StockOptionsIssuedAndOutstanding_lbl" xml:lang="en-US">Stock options issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockOptionsIssuedAndOutstanding" xlink:to="tara_StockOptionsIssuedAndOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_RestrictedStockUnitsIssuedAndOutstanding" xlink:href="tara-20221231.xsd#tara_RestrictedStockUnitsIssuedAndOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_RestrictedStockUnitsIssuedAndOutstanding_lbl" xml:lang="en-US">Restricted stock units issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_RestrictedStockUnitsIssuedAndOutstanding" xlink:to="tara_RestrictedStockUnitsIssuedAndOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ConversionOfSeries1ConvertiblePreferredStock" xlink:href="tara-20221231.xsd#tara_ConversionOfSeries1ConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ConversionOfSeries1ConvertiblePreferredStock_lbl" xml:lang="en-US">Conversion of Series 1 Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ConversionOfSeries1ConvertiblePreferredStock" xlink:to="tara_ConversionOfSeries1ConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_TotalPotentiallyDilutiveShares" xlink:href="tara-20221231.xsd#tara_TotalPotentiallyDilutiveShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_TotalPotentiallyDilutiveShares_lbl" xml:lang="en-US">Total potentially dilutive shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_TotalPotentiallyDilutiveShares" xlink:to="tara_TotalPotentiallyDilutiveShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Restricted Stock Units, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Number of Options, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Restricted Stock Units, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_DeferredTaxLiabilitiesOperatingRightofuseAsset" xlink:href="tara-20221231.xsd#tara_DeferredTaxLiabilitiesOperatingRightofuseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tara_DeferredTaxLiabilitiesOperatingRightofuseAsset_lbl" xml:lang="en-US">Operating right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DeferredTaxLiabilitiesOperatingRightofuseAsset" xlink:to="tara_DeferredTaxLiabilitiesOperatingRightofuseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture, Fixtures and Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture, fixtures and other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_LaboratoryEquipmentMember" xlink:href="tara-20221231.xsd#tara_LaboratoryEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_LaboratoryEquipmentMember" xlink:to="tara_LaboratoryEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tara_LaboratoryEquipmentMember_lbl0" xml:lang="en-US">Laboratory equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_LaboratoryEquipmentMember" xlink:to="tara_LaboratoryEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillMember_lbl" xml:lang="en-US">Goodwill [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillMember" xlink:to="us-gaap_GoodwillMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xml:lang="en-US">Corporate bonds - presented in marketable debt securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllOtherCorporateBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherCorporateBondsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllOtherCorporateBondsMember_lbl" xml:lang="en-US">Corporate bonds - presented in marketable debt securities, non-current [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherCorporateBondsMember" xlink:to="us-gaap_AllOtherCorporateBondsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember" xlink:href="tara-20221231.xsd#tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember_lbl" xml:lang="en-US">Property and equipment not yet placed into service [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember" xlink:to="tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted stock unit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_OperatingSegmentDescription" xlink:href="tara-20221231.xsd#tara_OperatingSegmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_OperatingSegmentDescription_lbl" xml:lang="en-US">Operating segment description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_OperatingSegmentDescription" xlink:to="tara_OperatingSegmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_MarketCapitalizationsPercentageChange" xlink:href="tara-20221231.xsd#tara_MarketCapitalizationsPercentageChange"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_MarketCapitalizationsPercentageChange_lbl" xml:lang="en-US">Market capitalizations percentage change</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MarketCapitalizationsPercentageChange" xlink:to="tara_MarketCapitalizationsPercentageChange_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_MicrocapCompaniesMarketCapitalization" xlink:href="tara-20221231.xsd#tara_MicrocapCompaniesMarketCapitalization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_MicrocapCompaniesMarketCapitalization_lbl" xml:lang="en-US">Market capitalization of microcap companies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MicrocapCompaniesMarketCapitalization" xlink:to="tara_MicrocapCompaniesMarketCapitalization_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_VestingPeriod" xlink:href="tara-20221231.xsd#tara_VestingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_VestingPeriod_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_VestingPeriod" xlink:to="tara_VestingPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StockOptionPeriod" xlink:href="tara-20221231.xsd#tara_StockOptionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_StockOptionPeriod_lbl" xml:lang="en-US">Stock option period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockOptionPeriod" xlink:to="tara_StockOptionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_PercentageOfLargestAmountOfBenefit" xlink:href="tara-20221231.xsd#tara_PercentageOfLargestAmountOfBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_PercentageOfLargestAmountOfBenefit_lbl" xml:lang="en-US">Percentage of largest amount of benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PercentageOfLargestAmountOfBenefit" xlink:to="tara_PercentageOfLargestAmountOfBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetInvestmentIncome_lbl" xml:lang="en-US">Investment income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetInvestmentIncome" xlink:to="us-gaap_NetInvestmentIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_UnrealizedLosses" xlink:href="tara-20221231.xsd#tara_UnrealizedLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_UnrealizedLosses_lbl" xml:lang="en-US">Unrealized loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnrealizedLosses" xlink:to="tara_UnrealizedLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_TotalPropertyAndEquipmentNet" xlink:href="tara-20221231.xsd#tara_TotalPropertyAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_TotalPropertyAndEquipmentNet_lbl" xml:lang="en-US">Total property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_TotalPropertyAndEquipmentNet" xlink:to="tara_TotalPropertyAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lease, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_RestrictedCashNoncurrents" xlink:href="tara-20221231.xsd#tara_RestrictedCashNoncurrents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_RestrictedCashNoncurrents_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_RestrictedCashNoncurrents" xlink:to="tara_RestrictedCashNoncurrents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilities_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use asset obtained in exchange for operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_DescriptionOfAgreements" xlink:href="tara-20221231.xsd#tara_DescriptionOfAgreements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_DescriptionOfAgreements_lbl" xml:lang="en-US">Description of license agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DescriptionOfAgreements" xlink:to="tara_DescriptionOfAgreements_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ResearchAndDevelopmentExpenses" xlink:href="tara-20221231.xsd#tara_ResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ResearchAndDevelopmentExpenses" xlink:to="tara_ResearchAndDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BroadcastersLicenseAgreementCommitmentsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription_lbl" xml:lang="en-US">Description of sponsored research and license agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:to="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Conversion price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_CommonStockIssuanceAndOutstandingPercentage" xlink:href="tara-20221231.xsd#tara_CommonStockIssuanceAndOutstandingPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_CommonStockIssuanceAndOutstandingPercentage_lbl" xml:lang="en-US">Common stock issuance and outstanding, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CommonStockIssuanceAndOutstandingPercentage" xlink:to="tara_CommonStockIssuanceAndOutstandingPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_IncreaseOrDecreaseEquityPercentage" xlink:href="tara-20221231.xsd#tara_IncreaseOrDecreaseEquityPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_IncreaseOrDecreaseEquityPercentage_lbl" xml:lang="en-US">Convertible preferred stock, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_IncreaseOrDecreaseEquityPercentage" xlink:to="tara_IncreaseOrDecreaseEquityPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Preferred stock, liquidation preference per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_AggregateOfSharesOfCommonStock" xlink:href="tara-20221231.xsd#tara_AggregateOfSharesOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_AggregateOfSharesOfCommonStock_lbl" xml:lang="en-US">Aggregate of shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_AggregateOfSharesOfCommonStock" xlink:to="tara_AggregateOfSharesOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Offering price, per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_NetProceeds" xlink:href="tara-20221231.xsd#tara_NetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_NetProceeds_lbl" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_NetProceeds" xlink:to="tara_NetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_GrossProceeds" xlink:href="tara-20221231.xsd#tara_GrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_GrossProceeds_lbl" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_GrossProceeds" xlink:to="tara_GrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StocksIssuedDuringPeriodValueNewIssues" xlink:href="tara-20221231.xsd#tara_StocksIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_StocksIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StocksIssuedDuringPeriodValueNewIssues" xlink:to="tara_StocksIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SharesAvailableForIssuance" xlink:href="tara-20221231.xsd#tara_SharesAvailableForIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_SharesAvailableForIssuance_lbl" xml:lang="en-US">Shares available for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharesAvailableForIssuance" xlink:to="tara_SharesAvailableForIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_NumberSharesAuthorized" xlink:href="tara-20221231.xsd#tara_NumberSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_NumberSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_NumberSharesAuthorized" xlink:to="tara_NumberSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_NumberOfShareAuthorizedIncreased" xlink:href="tara-20221231.xsd#tara_NumberOfShareAuthorizedIncreased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_NumberOfShareAuthorizedIncreased_lbl" xml:lang="en-US">Number of share authorized increased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_NumberOfShareAuthorizedIncreased" xlink:to="tara_NumberOfShareAuthorizedIncreased_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_UnamortizedValueOfRsus" xlink:href="tara-20221231.xsd#tara_UnamortizedValueOfRsus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_UnamortizedValueOfRsus_lbl" xml:lang="en-US">Unamortized value of RSUs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnamortizedValueOfRsus" xlink:to="tara_UnamortizedValueOfRsus_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_WeightedAverageRemainingAmortizationPeriod" xlink:href="tara-20221231.xsd#tara_WeightedAverageRemainingAmortizationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_WeightedAverageRemainingAmortizationPeriod_lbl" xml:lang="en-US">Weighted average remaining amortization period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_WeightedAverageRemainingAmortizationPeriod" xlink:to="tara_WeightedAverageRemainingAmortizationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_NumberOfSharesRestrictedStock" xlink:href="tara-20221231.xsd#tara_NumberOfSharesRestrictedStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_NumberOfSharesRestrictedStock_lbl" xml:lang="en-US">Number of RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_NumberOfSharesRestrictedStock" xlink:to="tara_NumberOfSharesRestrictedStock_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ConnectionWithTheNetShareSettlement" xlink:href="tara-20221231.xsd#tara_ConnectionWithTheNetShareSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ConnectionWithTheNetShareSettlement_lbl" xml:lang="en-US">Net share settlement (in Dollars)</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraERpGibwnKDuAJiNyIYG2H8s4SQ1D2uYlD5jFc0teK32BeW1Fr2o1Ni9NHX7+JbcT6d9/LlbyRbJSUzPIQg0nOkdo5WNEqHQXf9xzR45imSnjrybOQNzpPFlStmTd3tNMP/V17WoireM4++Z8KBdOTup6WP0OPJ7JL5pzC5fEliqx4tW2skLfFbEtpya7tUtv6utPlPNxxakxtpgcmb7U5pw5KchHfpic=] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ConnectionWithTheNetShareSettlement" xlink:to="tara_ConnectionWithTheNetShareSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value options exercised (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ShareBasedCompensationUnrecognized" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationUnrecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_ShareBasedCompensationUnrecognized_lbl" xml:lang="en-US">Unrecognized share-based compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationUnrecognized" xlink:to="tara_ShareBasedCompensationUnrecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1_lbl" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1" xlink:to="us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_EffectiveTaxRateDescription" xlink:href="tara-20221231.xsd#tara_EffectiveTaxRateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_EffectiveTaxRateDescription_lbl" xml:lang="en-US">Effective tax rate description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_EffectiveTaxRateDescription" xlink:to="tara_EffectiveTaxRateDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Net operating losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_IncomeTaxCarriedForwardTerms" xlink:href="tara-20221231.xsd#tara_IncomeTaxCarriedForwardTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_IncomeTaxCarriedForwardTerms_lbl" xml:lang="en-US">Carried forward tax year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_IncomeTaxCarriedForwardTerms" xlink:to="tara_IncomeTaxCarriedForwardTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_lbl" xml:lang="en-US">Carried forward tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_EmployeeContributions" xlink:href="tara-20221231.xsd#tara_EmployeeContributions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_EmployeeContributions_lbl" xml:lang="en-US">Employee contributions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_EmployeeContributions" xlink:to="tara_EmployeeContributions_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_EmployeeCompensation" xlink:href="tara-20221231.xsd#tara_EmployeeCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_EmployeeCompensation_lbl" xml:lang="en-US">Employee compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_EmployeeCompensation" xlink:to="tara_EmployeeCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLaborRelatedExpenses_lbl" xml:lang="en-US">Other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLaborRelatedExpenses" xlink:to="us-gaap_OtherLaborRelatedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_MarketableDebtSecuritiesPolicyTextBlock" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_MarketableDebtSecuritiesPolicyTextBlock_lbl" xml:lang="en-US">Marketable Debt Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MarketableDebtSecuritiesPolicyTextBlock" xlink:to="tara_MarketableDebtSecuritiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_PatentCostsPolicyTextBlock" xlink:href="tara-20221231.xsd#tara_PatentCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US">Patent Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PatentCostsPolicyTextBlock" xlink:to="tara_PatentCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Interest and Investment Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share Attributable to Common Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_RecentAccountingPronouncementsNotYetAdopted" xlink:href="tara-20221231.xsd#tara_RecentAccountingPronouncementsNotYetAdopted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_RecentAccountingPronouncementsNotYetAdopted_lbl" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_RecentAccountingPronouncementsNotYetAdopted" xlink:to="tara_RecentAccountingPronouncementsNotYetAdopted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_CholineLicenseAgreementMember" xlink:href="tara-20221231.xsd#tara_CholineLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_CholineLicenseAgreementMember_lbl" xml:lang="en-US">Choline License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CholineLicenseAgreementMember" xlink:to="tara_CholineLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_IowaAgreementMember" xlink:href="tara-20221231.xsd#tara_IowaAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_IowaAgreementMember_lbl" xml:lang="en-US">Lowa Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_IowaAgreementMember" xlink:to="tara_IowaAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xml:lang="en-US">License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_FeinsteinAgreementMember" xlink:href="tara-20221231.xsd#tara_FeinsteinAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_FeinsteinAgreementMember_lbl" xml:lang="en-US">Feinstein Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_FeinsteinAgreementMember" xlink:to="tara_FeinsteinAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US">Sponsored Research and License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_UnderwrittenPublicOfferingMember" xlink:href="tara-20221231.xsd#tara_UnderwrittenPublicOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US">Underwritten Public Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnderwrittenPublicOfferingMember" xlink:to="tara_UnderwrittenPublicOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_TwentyTwentyInducementPlanMember" xlink:href="tara-20221231.xsd#tara_TwentyTwentyInducementPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_TwentyTwentyInducementPlanMember_lbl" xml:lang="en-US">2020 Inducement Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_TwentyTwentyInducementPlanMember" xlink:to="tara_TwentyTwentyInducementPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_TwentySeventeenEquityIncentivePlanMember" xlink:href="tara-20221231.xsd#tara_TwentySeventeenEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_TwentySeventeenEquityIncentivePlanMember_lbl" xml:lang="en-US">2017 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_TwentySeventeenEquityIncentivePlanMember" xlink:to="tara_TwentySeventeenEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_TwentyFourteenEquityIncentivePlanMember" xlink:href="tara-20221231.xsd#tara_TwentyFourteenEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_TwentyFourteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2014 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_TwentyFourteenEquityIncentivePlanMember" xlink:to="tara_TwentyFourteenEquityIncentivePlanMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tara_TwentyFourteenEquityIncentivePlanMember_lbl0" xml:lang="en-US">Twenty Fourteen Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_TwentyFourteenEquityIncentivePlanMember" xlink:to="tara_TwentyFourteenEquityIncentivePlanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:href="tara-20221231.xsd#tara_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">2014 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:to="tara_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="tara_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl0" xml:lang="en-US">2014 Employee Stock Purchase Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:to="tara_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_BoardOfDirectorsMember" xlink:href="tara-20221231.xsd#tara_BoardOfDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_BoardOfDirectorsMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_BoardOfDirectorsMember" xlink:to="tara_BoardOfDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_USFederalMember" xlink:href="tara-20221231.xsd#tara_USFederalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_USFederalMember_lbl" xml:lang="en-US">U.S. federal [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_USFederalMember" xlink:to="tara_USFederalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StateIncomeTaxMember" xlink:href="tara-20221231.xsd#tara_StateIncomeTaxMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_StateIncomeTaxMember_lbl" xml:lang="en-US">State income tax [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StateIncomeTaxMember" xlink:to="tara_StateIncomeTaxMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_FederalNOLMember" xlink:href="tara-20221231.xsd#tara_FederalNOLMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tara_FederalNOLMember_lbl" xml:lang="en-US">Federal NOL [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_FederalNOLMember" xlink:to="tara_FederalNOLMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_OrganizationandNatureoftheBusinessTable" xlink:href="tara-20221231.xsd#tara_OrganizationandNatureoftheBusinessTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_OrganizationandNatureoftheBusinessTable_lbl" xml:lang="en-US">Organization and Nature of the Business [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_OrganizationandNatureoftheBusinessTable" xlink:to="tara_OrganizationandNatureoftheBusinessTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_OrganizationandNatureoftheBusinessLineItems" xlink:href="tara-20221231.xsd#tara_OrganizationandNatureoftheBusinessLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_OrganizationandNatureoftheBusinessLineItems_lbl" xml:lang="en-US">Organization and Nature of the Business [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_OrganizationandNatureoftheBusinessLineItems" xlink:to="tara_OrganizationandNatureoftheBusinessLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable" xlink:to="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems" xlink:to="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of goodwill and accumulated impairment losses [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable" xlink:to="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of goodwill and accumulated impairment losses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:to="tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable" xlink:href="tara-20221231.xsd#tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable_lbl" xml:lang="en-US">Fair Value of Financial Instruments (Details) - Schedule of financial assets and liabilities that are measured and carried at fair value [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable" xlink:to="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems" xlink:href="tara-20221231.xsd#tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems_lbl" xml:lang="en-US">Fair Value of Financial Instruments (Details) - Schedule of financial assets and liabilities that are measured and carried at fair value [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems" xlink:to="tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xml:lang="en-US">Marketable Securities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xml:lang="en-US">Marketable Securities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of restricted stock unit activity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable" xlink:to="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of restricted stock unit activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable" xlink:to="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" xlink:to="tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of stock option activities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable" xlink:to="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of stock option activities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable" xlink:to="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems" xlink:to="tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="tara_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tara_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_PropertyandEquipmentnetDetailsTable" xlink:href="tara-20221231.xsd#tara_PropertyandEquipmentnetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_PropertyandEquipmentnetDetailsTable_lbl" xml:lang="en-US">Property and Equipment, net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PropertyandEquipmentnetDetailsTable" xlink:to="tara_PropertyandEquipmentnetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_PropertyandEquipmentnetDetailsLineItems" xlink:href="tara-20221231.xsd#tara_PropertyandEquipmentnetDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_PropertyandEquipmentnetDetailsLineItems_lbl" xml:lang="en-US">Property and Equipment, net (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PropertyandEquipmentnetDetailsLineItems" xlink:to="tara_PropertyandEquipmentnetDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_CommitmentsandContingenciesDetailsTable" xlink:href="tara-20221231.xsd#tara_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CommitmentsandContingenciesDetailsTable" xlink:to="tara_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_CommitmentsandContingenciesDetailsLineItems" xlink:href="tara-20221231.xsd#tara_CommitmentsandContingenciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_CommitmentsandContingenciesDetailsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CommitmentsandContingenciesDetailsLineItems" xlink:to="tara_CommitmentsandContingenciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StockholdersEquityDetailsTable" xlink:href="tara-20221231.xsd#tara_StockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StockholdersEquityDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockholdersEquityDetailsTable" xlink:to="tara_StockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StockholdersEquityDetailsLineItems" xlink:href="tara-20221231.xsd#tara_StockholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StockholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockholdersEquityDetailsLineItems" xlink:to="tara_StockholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsTable" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StockBasedCompensationDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockBasedCompensationDetailsTable" xlink:to="tara_StockBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_StockBasedCompensationDetailsLineItems" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StockBasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Stock-Based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockBasedCompensationDetailsLineItems" xlink:to="tara_StockBasedCompensationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_IncomeTaxesDetailsTable" xlink:href="tara-20221231.xsd#tara_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_IncomeTaxesDetailsTable" xlink:to="tara_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_IncomeTaxesDetailsLineItems" xlink:href="tara-20221231.xsd#tara_IncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_IncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_IncomeTaxesDetailsLineItems" xlink:to="tara_IncomeTaxesDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_AccruedEmployeeRelatedCurrent_lbl0" xml:lang="en-US">Amount of accrued employee related current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_AccruedEmployeeRelatedCurrent" xlink:to="tara_AccruedEmployeeRelatedCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_AccruedInterestOnMarketableDebtSecurities_lbl0" xml:lang="en-US">Amount of accrued interest on marketable debt securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_AccruedInterestOnMarketableDebtSecurities" xlink:to="tara_AccruedInterestOnMarketableDebtSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_AccruedResearchAndDevelopmentCurrent_lbl0" xml:lang="en-US">Amount of accrued research and development current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_AccruedResearchAndDevelopmentCurrent" xlink:to="tara_AccruedResearchAndDevelopmentCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_AggregateOfSharesOfCommonStock_lbl0" xml:lang="en-US">Aggregate of shares of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_AggregateOfSharesOfCommonStock" xlink:to="tara_AggregateOfSharesOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_AmortizationOfDiscountsAndPremiumsInvestments_lbl0" xml:lang="en-US">Amortization of discounts and premiums investments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_AmortizationOfDiscountsAndPremiumsInvestments" xlink:to="tara_AmortizationOfDiscountsAndPremiumsInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_CommonStockIssuanceAndOutstandingPercentage_lbl0" xml:lang="en-US">Common stock issuance and outstanding percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CommonStockIssuanceAndOutstandingPercentage" xlink:to="tara_CommonStockIssuanceAndOutstandingPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_DeferredTaxAssetsOperatingLeaseLiability_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process operating lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="tara_DeferredTaxAssetsOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_DeferredTaxAssetsRestrictedStockUnitsExpense_lbl0" xml:lang="en-US">Amount of restricted stock unit deferred tax assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DeferredTaxAssetsRestrictedStockUnitsExpense" xlink:to="tara_DeferredTaxAssetsRestrictedStockUnitsExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_DeferredTaxLiabilitiesOperatingRightofuseAsset_lbl0" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from operating right of use asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DeferredTaxLiabilitiesOperatingRightofuseAsset" xlink:to="tara_DeferredTaxLiabilitiesOperatingRightofuseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_DescriptionOfAgreements_lbl0" xml:lang="en-US">Description of agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DescriptionOfAgreements" xlink:to="tara_DescriptionOfAgreements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost_lbl0" xml:lang="en-US">Percentage of the difference between effective income tax rate reconciliation stock based compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost" xlink:to="tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_EffectiveTaxRateDescription_lbl0" xml:lang="en-US">Description of effective tax rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_EffectiveTaxRateDescription" xlink:to="tara_EffectiveTaxRateDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_EmployeeCompensation_lbl0" xml:lang="en-US">Employee compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_EmployeeCompensation" xlink:to="tara_EmployeeCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_EmployeeContributions_lbl0" xml:lang="en-US">Employee contributions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_EmployeeContributions" xlink:to="tara_EmployeeContributions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_EstimatedFairValue_lbl0" xml:lang="en-US">Estimated Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_EstimatedFairValue" xlink:to="tara_EstimatedFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_GrossProceeds_lbl0" xml:lang="en-US">Gross Proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_GrossProceeds" xlink:to="tara_GrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_IncomeTaxCarriedForwardTerms_lbl0" xml:lang="en-US">Income tax carried forward terms.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_IncomeTaxCarriedForwardTerms" xlink:to="tara_IncomeTaxCarriedForwardTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_MarketCapitalizationsPercentageChange_lbl0" xml:lang="en-US">Market capitalizations percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MarketCapitalizationsPercentageChange" xlink:to="tara_MarketCapitalizationsPercentageChange_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_MarketableDebtSecuritiesPolicyTextBlock_lbl0" xml:lang="en-US">Marketable Debt Securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MarketableDebtSecuritiesPolicyTextBlock" xlink:to="tara_MarketableDebtSecuritiesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_MicrocapCompaniesMarketCapitalization_lbl0" xml:lang="en-US">The amount of microcap companies market capitalization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MicrocapCompaniesMarketCapitalization" xlink:to="tara_MicrocapCompaniesMarketCapitalization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_NetProceeds_lbl0" xml:lang="en-US">Amount of net proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_NetProceeds" xlink:to="tara_NetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_NumberOfShareAuthorizedIncreased_lbl0" xml:lang="en-US">Number of share authorized increased.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_NumberOfShareAuthorizedIncreased" xlink:to="tara_NumberOfShareAuthorizedIncreased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_NumberSharesAuthorized_lbl0" xml:lang="en-US">Number shares authorized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_NumberSharesAuthorized" xlink:to="tara_NumberSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_OperatingLeasesFutureMinimumPaymentDue_lbl0" xml:lang="en-US">Operating Leases Future Minimum Payments Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_OperatingLeasesFutureMinimumPaymentDue" xlink:to="tara_OperatingLeasesFutureMinimumPaymentDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_PatentCostsPolicyTextBlock_lbl0" xml:lang="en-US">Patent Costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PatentCostsPolicyTextBlock" xlink:to="tara_PatentCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_PercentageOfLargestAmountOfBenefit_lbl0" xml:lang="en-US">Percentage of largest amount of benefit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PercentageOfLargestAmountOfBenefit" xlink:to="tara_PercentageOfLargestAmountOfBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_PrepaidSoftware_lbl0" xml:lang="en-US">The amount of development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PrepaidSoftware" xlink:to="tara_PrepaidSoftware_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_PresentValueOfFutureMinimumLeasePayments_lbl0" xml:lang="en-US">Present value of future minimum lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PresentValueOfFutureMinimumLeasePayments" xlink:to="tara_PresentValueOfFutureMinimumLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities_lbl0" xml:lang="en-US">The cash inflow associated with the proceeds from maturity and redemption of marketable debt securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities" xlink:to="tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_ResearchAndDevelopmentExpenses_lbl0" xml:lang="en-US">The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity&apos;s use, during the reporting period charged to research and development projects.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ResearchAndDevelopmentExpenses" xlink:to="tara_ResearchAndDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_RestrictedCashNoncurrents_lbl0" xml:lang="en-US">Restricted cash, non-current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_RestrictedCashNoncurrents" xlink:to="tara_RestrictedCashNoncurrents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of other information.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:to="tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock_lbl0" xml:lang="en-US">Schedule of weighted average dilutive common share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock" xlink:to="tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_SettlementOfRestrictedStockUnitinShares_lbl0" xml:lang="en-US">Settlement of restricted stock units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SettlementOfRestrictedStockUnitinShares" xlink:to="tara_SettlementOfRestrictedStockUnitinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_SettlementOfRestrictedStockUnits_lbl0" xml:lang="en-US">Settlement of restricted stock units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SettlementOfRestrictedStockUnits" xlink:to="tara_SettlementOfRestrictedStockUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod_lbl0" xml:lang="en-US">The number of shares under options that were exercised during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_lbl0" xml:lang="en-US">Amount of accumulated difference between fair value of underlying shares on dates of exercise and expired price on options expired (or share units converted) into shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_lbl0" xml:lang="en-US">Amount of accumulated difference between fair value of underlying shares on dates of exercise and forfeited price on options exercised (or share units converted) into shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_lbl0" xml:lang="en-US">Amount of accumulated difference between fair value of underlying shares on dates of granted and granted price on options exercised (or share units converted) into shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_ShareBasedCompensationUnrecognized_lbl0" xml:lang="en-US">Share Based Compensation Unrecognized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationUnrecognized" xlink:to="tara_ShareBasedCompensationUnrecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable_lbl0" xml:lang="en-US">Weighted average remaining contractual term of exercisable stock options, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised_lbl0" xml:lang="en-US">Weighted average remaining contractual term of exercised stock options, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired_lbl0" xml:lang="en-US">Weighted average remaining contractual term of Expired stock options, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares_lbl0" xml:lang="en-US">Weighted average remaining contractual term of forfeited stock options, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted_lbl0" xml:lang="en-US">Weighted average remaining contractual term of granded stock options, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm_lbl0" xml:lang="en-US">Shorter of the useful life of asset or the lease term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm" xlink:to="tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_TotalPropertyAndEquipmentNet_lbl0" xml:lang="en-US">The percentage is total property and equipment, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_TotalPropertyAndEquipmentNet" xlink:to="tara_TotalPropertyAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_UnrealizedLoss_lbl0" xml:lang="en-US">The amount of unrealized losses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnrealizedLoss" xlink:to="tara_UnrealizedLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tara_UnrealizedLosses_lbl0" xml:lang="en-US">Unrealized Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnrealizedLosses" xlink:to="tara_UnrealizedLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ResearchAndDevelopmentExpenses_lbl1" xml:lang="en-US">Research And Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ResearchAndDevelopmentExpenses" xlink:to="tara_ResearchAndDevelopmentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_PrepaidSoftware_lbl1" xml:lang="en-US">Prepaid Software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PrepaidSoftware" xlink:to="tara_PrepaidSoftware_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ConversionOfSeries1ConvertiblePreferredStock_lbl0" xml:lang="en-US">Conversion Of Series1 Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ConversionOfSeries1ConvertiblePreferredStock" xlink:to="tara_ConversionOfSeries1ConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_PreferredStock0001ParValueAuthorized10000000SharesAbstract_lbl0" xml:lang="en-US">Preferred Stock0001 Par Value Authorized10000000 Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PreferredStock0001ParValueAuthorized10000000SharesAbstract" xlink:to="tara_PreferredStock0001ParValueAuthorized10000000SharesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_EstimatedFairValue_lbl1" xml:lang="en-US">Estimated Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_EstimatedFairValue" xlink:to="tara_EstimatedFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl0" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ShareBasedCompensationUnrecognized_lbl1" xml:lang="en-US">Share Based Compensation Unrecognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationUnrecognized" xlink:to="tara_ShareBasedCompensationUnrecognized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl0" xml:lang="en-US">Marketable Securities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfInterestAndInvestmentIncomeAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfInterestAndInvestmentIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfInterestAndInvestmentIncomeAbstract_lbl" xml:lang="en-US">Schedule Of Interest And Investment Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfInterestAndInvestmentIncomeAbstract" xlink:to="tara_ScheduleOfInterestAndInvestmentIncomeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_NumberSharesAuthorized_lbl1" xml:lang="en-US">Number Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_NumberSharesAuthorized" xlink:to="tara_NumberSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_TotalPropertyAndEquipmentNet_lbl1" xml:lang="en-US">Total Property And Equipment Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_TotalPropertyAndEquipmentNet" xlink:to="tara_TotalPropertyAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl0" xml:lang="en-US">Lessee, Operating Lease, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl0" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription_lbl0" xml:lang="en-US">Broadcasters License Agreement Commitments, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:to="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl0" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_WeightedAverageRemainingAmortizationPeriod_lbl0" xml:lang="en-US">Weighted Average Remaining Amortization Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_WeightedAverageRemainingAmortizationPeriod" xlink:to="tara_WeightedAverageRemainingAmortizationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_NumberOfShareAuthorizedIncreased_lbl1" xml:lang="en-US">Number Of Share Authorized Increased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_NumberOfShareAuthorizedIncreased" xlink:to="tara_NumberOfShareAuthorizedIncreased_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_DeferredTaxLiabilitiesOperatingRightofuseAsset_lbl1" xml:lang="en-US">Deferred Tax Liabilities Operating Rightofuse Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DeferredTaxLiabilitiesOperatingRightofuseAsset" xlink:to="tara_DeferredTaxLiabilitiesOperatingRightofuseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_FeinsteinAgreementMember_lbl0" xml:lang="en-US">Feinstein Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_FeinsteinAgreementMember" xlink:to="tara_FeinsteinAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_IncomeTaxCarriedForwardTerms_lbl1" xml:lang="en-US">Income Tax Carried Forward Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_IncomeTaxCarriedForwardTerms" xlink:to="tara_IncomeTaxCarriedForwardTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_PatentCostsPolicyTextBlock_lbl1" xml:lang="en-US">Patent Costs Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PatentCostsPolicyTextBlock" xlink:to="tara_PatentCostsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_UnrealizedGains_lbl0" xml:lang="en-US">Unrealized Gains</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnrealizedGains" xlink:to="tara_UnrealizedGains_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfLeaseExpenseAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfLeaseExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfLeaseExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Lease Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfLeaseExpenseAbstract" xlink:to="tara_ScheduleOfLeaseExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_AccruedInterestOnMarketableDebtSecurities_lbl1" xml:lang="en-US">Accrued Interest On Marketable Debt Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_AccruedInterestOnMarketableDebtSecurities" xlink:to="tara_AccruedInterestOnMarketableDebtSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecurities_lbl0" xml:lang="en-US">Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_OperatingLeasesFutureMinimumPaymentDue_lbl1" xml:lang="en-US">Operating Leases Future Minimum Payment Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_OperatingLeasesFutureMinimumPaymentDue" xlink:to="tara_OperatingLeasesFutureMinimumPaymentDue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_DenominatorAbstract_lbl0" xml:lang="en-US">Denominator Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DenominatorAbstract" xlink:to="tara_DenominatorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfStockBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfStockBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Stock Based Compensation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="tara_ScheduleOfStockBasedCompensationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_UnrealizedLosses_lbl1" xml:lang="en-US">Unrealized Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnrealizedLosses" xlink:to="tara_UnrealizedLosses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SharesAvailableForIssuance_lbl0" xml:lang="en-US">Shares Available For Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharesAvailableForIssuance" xlink:to="tara_SharesAvailableForIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl3" xml:lang="en-US">Goodwill, Impairment Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_lbl0" xml:lang="en-US">Goodwill, Acquired During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_EmployeeContributions_lbl1" xml:lang="en-US">Employee Contributions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_EmployeeContributions" xlink:to="tara_EmployeeContributions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_USFederalMember_lbl0" xml:lang="en-US">USFederal Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_USFederalMember" xlink:to="tara_USFederalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl1" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl0" xml:lang="en-US">Realized Investment Gains (Losses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Total Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetInvestmentIncome_lbl0" xml:lang="en-US">Net Investment Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetInvestmentIncome" xlink:to="us-gaap_NetInvestmentIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfRestrictedStockUnitActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfRestrictedStockUnitActivityAbstract_lbl" xml:lang="en-US">Schedule Of Restricted Stock Unit Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="tara_ScheduleOfRestrictedStockUnitActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl1" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_Series1PreferredStockMember_lbl1" xml:lang="en-US">Series1 Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_Series1PreferredStockMember" xlink:to="tara_Series1PreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_CashPaidForAbstract_lbl0" xml:lang="en-US">Cash Paid For Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CashPaidForAbstract" xlink:to="tara_CashPaidForAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities_lbl1" xml:lang="en-US">Proceeds From Maturity And Redemption Of Marketable Debt Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities" xlink:to="tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StockOptionsIssuedAndOutstanding_lbl0" xml:lang="en-US">Stock Options Issued And Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockOptionsIssuedAndOutstanding" xlink:to="tara_StockOptionsIssuedAndOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_lbl0" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:to="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_AggregateOfSharesOfCommonStock_lbl1" xml:lang="en-US">Aggregate Of Shares Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_AggregateOfSharesOfCommonStock" xlink:to="tara_AggregateOfSharesOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired_lbl1" xml:lang="en-US">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Termyears Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_AccruedEmployeeRelatedCurrent_lbl1" xml:lang="en-US">Accrued Employee Related Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_AccruedEmployeeRelatedCurrent" xlink:to="tara_AccruedEmployeeRelatedCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl0" xml:lang="en-US">Payments for Repurchase of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl2" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SettlementOfRestrictedStockUnitinShares_lbl1" xml:lang="en-US">Settlement Of Restricted Stock Unitin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SettlementOfRestrictedStockUnitinShares" xlink:to="tara_SettlementOfRestrictedStockUnitinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StocksIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stocks Issued During Period Value New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StocksIssuedDuringPeriodValueNewIssues" xlink:to="tara_StocksIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl0" xml:lang="en-US">Prepaid Insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl0" xml:lang="en-US">In Process Research and Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation Share Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost" xlink:to="tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_TotalPotentiallyDilutiveShares_lbl0" xml:lang="en-US">Total Potentially Dilutive Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_TotalPotentiallyDilutiveShares" xlink:to="tara_TotalPotentiallyDilutiveShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Goodwill And Accumulated Impairment Lossses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock" xlink:to="tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl1" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_RestrictedCashNonCurrentAbstract_lbl0" xml:lang="en-US">Restricted Cash Non Current Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_RestrictedCashNonCurrentAbstract" xlink:to="tara_RestrictedCashNonCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnlabeledAbstract2" xlink:to="tara_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnlabeledAbstract1" xlink:to="tara_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillGross_lbl0" xml:lang="en-US">Goodwill, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillGross" xlink:to="us-gaap_GoodwillGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnlabeledAbstract4" xlink:to="tara_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_CommonStockIssuanceAndOutstandingPercentage_lbl1" xml:lang="en-US">Common Stock Issuance And Outstanding Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CommonStockIssuanceAndOutstandingPercentage" xlink:to="tara_CommonStockIssuanceAndOutstandingPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnlabeledAbstract3" xlink:to="tara_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StockOptionPeriod_lbl0" xml:lang="en-US">Stock Option Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StockOptionPeriod" xlink:to="tara_StockOptionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_MarketableDebtSecuritiesTextBlock_lbl0" xml:lang="en-US">Marketable Debt Securities Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MarketableDebtSecuritiesTextBlock" xlink:to="tara_MarketableDebtSecuritiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnlabeledAbstract0" xlink:to="tara_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_TwentyFourteenEquityIncentivePlanMember_lbl1" xml:lang="en-US">Twenty Fourteen Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_TwentyFourteenEquityIncentivePlanMember" xlink:to="tara_TwentyFourteenEquityIncentivePlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Future Minimum Rental Payment For Operating Leases Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:to="tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_UnamortizedValueOfRsus_lbl0" xml:lang="en-US">Unamortized Value Of Rsus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnamortizedValueOfRsus" xlink:to="tara_UnamortizedValueOfRsus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl0" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Total Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_DeferredAbstract_lbl0" xml:lang="en-US">Deferred Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DeferredAbstract" xlink:to="tara_DeferredAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock_lbl0" xml:lang="en-US">Issuance Of Stock Options And Restricted Stock Units To Employees And Directors Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" xlink:to="tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnlabeledAbstract" xlink:to="tara_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl0" xml:lang="en-US">Money Market Funds, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_lbl0" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl0" xml:lang="en-US">Marketable Securities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember_lbl0" xml:lang="en-US">Property And Equipment Not Yet Placed Into Service Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember" xlink:to="tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl0" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_CashEquivalentsAbstract_lbl0" xml:lang="en-US">Cash Equivalents Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CashEquivalentsAbstract" xlink:to="tara_CashEquivalentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl0" xml:lang="en-US">Corporate Bond Securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfStockOptionActivitiesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfStockOptionActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfStockOptionActivitiesAbstract_lbl" xml:lang="en-US">Schedule Of Stock Option Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfStockOptionActivitiesAbstract" xlink:to="tara_ScheduleOfStockOptionActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfGoodwillAndAccumulatedImpairmentLossesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfGoodwillAndAccumulatedImpairmentLossesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfGoodwillAndAccumulatedImpairmentLossesAbstract_lbl" xml:lang="en-US">Schedule Of Goodwill And Accumulated Impairment Losses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfGoodwillAndAccumulatedImpairmentLossesAbstract" xlink:to="tara_ScheduleOfGoodwillAndAccumulatedImpairmentLossesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remainning Period Term2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl0" xml:lang="en-US">Investment Income, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_CholineLicenseAgreementMember_lbl0" xml:lang="en-US">Choline License Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CholineLicenseAgreementMember" xlink:to="tara_CholineLicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_IowaAgreementMember_lbl0" xml:lang="en-US">Iowa Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_IowaAgreementMember" xlink:to="tara_IowaAgreementMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_GrossProceeds_lbl1" xml:lang="en-US">Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_GrossProceeds" xlink:to="tara_GrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl0" xml:lang="en-US">Preferred Stock, Liquidation Preference Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Total Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_OtherIncomeExpenseNetAbstract_lbl0" xml:lang="en-US">Other Income Expense Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_OtherIncomeExpenseNetAbstract" xlink:to="tara_OtherIncomeExpenseNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_NumeratorAbstract_lbl0" xml:lang="en-US">Numerator Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_NumeratorAbstract" xlink:to="tara_NumeratorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl0" xml:lang="en-US">License Agreement Terms [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl0" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares_lbl1" xml:lang="en-US">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Termyears Forfeitedin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_RestrictedCashNoncurrents_lbl1" xml:lang="en-US">Restricted Cash Noncurrents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_RestrictedCashNoncurrents" xlink:to="tara_RestrictedCashNoncurrents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Estimated Useful Lives For Significant Property And Equipment Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock" xlink:to="tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ConnectionWithTheNetShareSettlement_lbl0" xml:lang="en-US">Connection With The Net Share Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ConnectionWithTheNetShareSettlement" xlink:to="tara_ConnectionWithTheNetShareSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllOtherCorporateBondsMember_lbl0" xml:lang="en-US">Other Corporate Bonds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherCorporateBondsMember" xlink:to="us-gaap_AllOtherCorporateBondsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl0" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfTheFairValueOfStockOptionsGrantedAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfTheFairValueOfStockOptionsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfTheFairValueOfStockOptionsGrantedAbstract_lbl" xml:lang="en-US">Schedule Of The Fair Value Of Stock Options Granted Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfTheFairValueOfStockOptionsGrantedAbstract" xlink:to="tara_ScheduleOfTheFairValueOfStockOptionsGrantedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl0" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Other Information Related To Leases Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:to="tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_MarketCapitalizationsPercentageChange_lbl1" xml:lang="en-US">Market Capitalizations Percentage Change</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MarketCapitalizationsPercentageChange" xlink:to="tara_MarketCapitalizationsPercentageChange_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_VestingPeriod_lbl0" xml:lang="en-US">Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_VestingPeriod" xlink:to="tara_VestingPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_RestrictedCashNonCurrentAbstract0_lbl0" xml:lang="en-US">Restricted Cash Non Current Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_RestrictedCashNonCurrentAbstract0" xlink:to="tara_RestrictedCashNonCurrentAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_LaboratoryEquipmentMember_lbl1" xml:lang="en-US">Laboratory Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_LaboratoryEquipmentMember" xlink:to="tara_LaboratoryEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Estimated Useful Lives For Significant Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentAbstract" xlink:to="tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_FederalNOLMember_lbl0" xml:lang="en-US">Federal NOLMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_FederalNOLMember" xlink:to="tara_FederalNOLMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Deferred Tax Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="tara_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted_lbl1" xml:lang="en-US">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Termyears Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_RecentAccountingPronouncementsNotYetAdopted_lbl0" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_RecentAccountingPronouncementsNotYetAdopted" xlink:to="tara_RecentAccountingPronouncementsNotYetAdopted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_NumberOfSharesRestrictedStock_lbl0" xml:lang="en-US">Number Of Shares Restricted Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_NumberOfSharesRestrictedStock" xlink:to="tara_NumberOfSharesRestrictedStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SeriesOneConvertiblePreferredStockMember_lbl1" xml:lang="en-US">Series One Convertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SeriesOneConvertiblePreferredStockMember" xlink:to="tara_SeriesOneConvertiblePreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_EffectiveTaxRateDescription_lbl1" xml:lang="en-US">Effective Tax Rate Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_EffectiveTaxRateDescription" xlink:to="tara_EffectiveTaxRateDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable_lbl1" xml:lang="en-US">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Termyears Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Weighted Average Dilutive Common Share Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock" xlink:to="tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1_lbl0" xml:lang="en-US">Net Amount at Risk by Product and Guarantee, Weighted Average Period Remaining</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1" xlink:to="us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_UnderwrittenPublicOfferingMember_lbl0" xml:lang="en-US">Underwritten Public Offering Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnderwrittenPublicOfferingMember" xlink:to="tara_UnderwrittenPublicOfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_CashEquivalentsAbstract0_lbl0" xml:lang="en-US">Cash Equivalents Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CashEquivalentsAbstract0" xlink:to="tara_CashEquivalentsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_DeferredTaxAssetsRestrictedStockUnitsExpense_lbl1" xml:lang="en-US">Deferred Tax Assets Restricted Stock Units Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DeferredTaxAssetsRestrictedStockUnitsExpense" xlink:to="tara_DeferredTaxAssetsRestrictedStockUnitsExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_CurrentAbstract_lbl0" xml:lang="en-US">Current Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CurrentAbstract" xlink:to="tara_CurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_PercentageOfLargestAmountOfBenefit_lbl1" xml:lang="en-US">Percentage Of Largest Amount Of Benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PercentageOfLargestAmountOfBenefit" xlink:to="tara_PercentageOfLargestAmountOfBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_DeferredTaxAssetsOperatingLeaseLiability_lbl1" xml:lang="en-US">Deferred Tax Assets Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="tara_DeferredTaxAssetsOperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl1" xml:lang="en-US">Two Thousand Fourteen Employee Stock Purchase Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:to="tara_TwoThousandFourteenEmployeeStockPurchasePlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_StateIncomeTaxMember_lbl0" xml:lang="en-US">State Income Tax Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_StateIncomeTaxMember" xlink:to="tara_StateIncomeTaxMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl0" xml:lang="en-US">Short-Term Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_AccruedResearchAndDevelopmentCurrent_lbl1" xml:lang="en-US">Accrued Research And Development Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_AccruedResearchAndDevelopmentCurrent" xlink:to="tara_AccruedResearchAndDevelopmentCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_RestrictedStockUnitsIssuedAndOutstanding_lbl0" xml:lang="en-US">Restricted Stock Units Issued And Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_RestrictedStockUnitsIssuedAndOutstanding" xlink:to="tara_RestrictedStockUnitsIssuedAndOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl1" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_AmortizationOfDiscountsAndPremiumsInvestments_lbl1" xml:lang="en-US">Amortization Of Discounts And Premiums Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_AmortizationOfDiscountsAndPremiumsInvestments" xlink:to="tara_AmortizationOfDiscountsAndPremiumsInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillMember_lbl0" xml:lang="en-US">Goodwill [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillMember" xlink:to="us-gaap_GoodwillMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_CommonStock0001ParValueAuthorized100000000SharesAbstract_lbl0" xml:lang="en-US">Common Stock0001 Par Value Authorized100000000 Shares Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_CommonStock0001ParValueAuthorized100000000SharesAbstract" xlink:to="tara_CommonStock0001ParValueAuthorized100000000SharesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised_lbl1" xml:lang="en-US">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Termyears Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised" xlink:to="tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_TwentyTwentyInducementPlanMember_lbl0" xml:lang="en-US">Twenty Twenty Inducement Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_TwentyTwentyInducementPlanMember" xlink:to="tara_TwentyTwentyInducementPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_IncreaseOrDecreaseEquityPercentage_lbl0" xml:lang="en-US">Increase Or Decrease Equity Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_IncreaseOrDecreaseEquityPercentage" xlink:to="tara_IncreaseOrDecreaseEquityPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfFederalAndStateIncomeTaxExpenseAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfFederalAndStateIncomeTaxExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfFederalAndStateIncomeTaxExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Federal And State Income Tax Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfFederalAndStateIncomeTaxExpenseAbstract" xlink:to="tara_ScheduleOfFederalAndStateIncomeTaxExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_MarketableDebtSecuritiesPolicyTextBlock_lbl1" xml:lang="en-US">Marketable Debt Securities Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MarketableDebtSecuritiesPolicyTextBlock" xlink:to="tara_MarketableDebtSecuritiesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLaborRelatedExpenses_lbl0" xml:lang="en-US">Other Labor-related Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLaborRelatedExpenses" xlink:to="us-gaap_OtherLaborRelatedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfMarketableDebtSecuritiesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfMarketableDebtSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfMarketableDebtSecuritiesAbstract_lbl" xml:lang="en-US">Schedule Of Marketable Debt Securities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfMarketableDebtSecuritiesAbstract" xlink:to="tara_ScheduleOfMarketableDebtSecuritiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_EmployeeCompensation_lbl1" xml:lang="en-US">Employee Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_EmployeeCompensation" xlink:to="tara_EmployeeCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm_lbl0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remainning Period Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm" xlink:to="tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl0" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_DescriptionOfAgreements_lbl1" xml:lang="en-US">Description Of Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_DescriptionOfAgreements" xlink:to="tara_DescriptionOfAgreements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_PresentValueOfFutureMinimumLeasePayments_lbl1" xml:lang="en-US">Present Value Of Future Minimum Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_PresentValueOfFutureMinimumLeasePayments" xlink:to="tara_PresentValueOfFutureMinimumLeasePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_BoardOfDirectorsMember_lbl0" xml:lang="en-US">Board Of Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_BoardOfDirectorsMember" xlink:to="tara_BoardOfDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Interest And Investment Income Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock" xlink:to="tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_TwentySeventeenEquityIncentivePlanMember_lbl0" xml:lang="en-US">Twenty Seventeen Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_TwentySeventeenEquityIncentivePlanMember" xlink:to="tara_TwentySeventeenEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_OperatingSegmentDescription_lbl0" xml:lang="en-US">Operating Segment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_OperatingSegmentDescription" xlink:to="tara_OperatingSegmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="tara_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl0" xml:lang="en-US">Marketable Securities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Term And The Weighted Average Discount Rate For Operating Leases Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract" xlink:to="tara_ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl0" xml:lang="en-US">Interest Income, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfTotalStockBasedCompensationCostsAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfTotalStockBasedCompensationCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfTotalStockBasedCompensationCostsAbstract_lbl" xml:lang="en-US">Schedule Of Total Stock Based Compensation Costs Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfTotalStockBasedCompensationCostsAbstract" xlink:to="tara_ScheduleOfTotalStockBasedCompensationCostsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm_lbl1" xml:lang="en-US">Shorter Of The Useful Life Of Asset Or The Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm" xlink:to="tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_MarketableDebtSecuritiesAbstract1_lbl0" xml:lang="en-US">Marketable Debt Securities Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MarketableDebtSecuritiesAbstract1" xlink:to="tara_MarketableDebtSecuritiesAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_MarketableDebtSecuritiesAbstract0_lbl0" xml:lang="en-US">Marketable Debt Securities Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MarketableDebtSecuritiesAbstract0" xlink:to="tara_MarketableDebtSecuritiesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract_lbl" xml:lang="en-US">Schedule Of Federal Income Tax To Income Before Provision For Income Taxes Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl0" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Other Tax Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_UnrealizedLoss_lbl1" xml:lang="en-US">Unrealized Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_UnrealizedLoss" xlink:to="tara_UnrealizedLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_lbl0" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" xlink:to="tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_NetProceeds_lbl1" xml:lang="en-US">Net Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_NetProceeds" xlink:to="tara_NetProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndInvestments_lbl0" xml:lang="en-US">Restricted Cash and Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestments" xlink:to="us-gaap_RestrictedCashAndInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Operating Lease Payments Included In The Measurement Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_SettlementOfRestrictedStockUnits_lbl1" xml:lang="en-US">Settlement Of Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_SettlementOfRestrictedStockUnits" xlink:to="tara_SettlementOfRestrictedStockUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tara_MicrocapCompaniesMarketCapitalization_lbl1" xml:lang="en-US">Microcap Companies Market Capitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tara_MicrocapCompaniesMarketCapitalization" xlink:to="tara_MicrocapCompaniesMarketCapitalization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>tara-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 08 08:29:56 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ConsolidatedBalanceSheet" roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ConsolidatedIncomeStatement" roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ShareholdersEquityType2or3" roleURI="http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ConsolidatedCashFlow" roleURI="http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_OrganizationandNatureoftheBusiness" roleURI="http://www.Protaratherapeutics.com/role/OrganizationandNatureoftheBusiness"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_FairValueofFinancialInstruments" roleURI="http://www.Protaratherapeutics.com/role/FairValueofFinancialInstruments"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_MarketableDebtSecurities" roleURI="http://www.Protaratherapeutics.com/role/MarketableDebtSecurities"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_PropertyandEquipmentnet" roleURI="http://www.Protaratherapeutics.com/role/PropertyandEquipmentnet"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_AccruedExpenses" roleURI="http://www.Protaratherapeutics.com/role/AccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_Leases" roleURI="http://www.Protaratherapeutics.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_CommitmentsandContingencies" roleURI="http://www.Protaratherapeutics.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_StockholdersEquity" roleURI="http://www.Protaratherapeutics.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_StockBasedCompensation" roleURI="http://www.Protaratherapeutics.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_IncomeTaxes" roleURI="http://www.Protaratherapeutics.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_EmployeeBenefitPlan" roleURI="http://www.Protaratherapeutics.com/role/EmployeeBenefitPlan"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_NetLossPerCommonShare" roleURI="http://www.Protaratherapeutics.com/role/NetLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_AccountingPoliciesByPolicy" roleURI="http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_FairValueofFinancialInstrumentsTables" roleURI="http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_MarketableDebtSecuritiesTables" roleURI="http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_PropertyandEquipmentnetTables" roleURI="http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_AccruedExpensesTables" roleURI="http://www.Protaratherapeutics.com/role/AccruedExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_LeasesTables" roleURI="http://www.Protaratherapeutics.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_StockBasedCompensationTables" roleURI="http://www.Protaratherapeutics.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_IncomeTaxesTables" roleURI="http://www.Protaratherapeutics.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_NetLossPerCommonShareTables" roleURI="http://www.Protaratherapeutics.com/role/NetLossPerCommonShareTables"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofcashcashequivalentsandrestrictedcashTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofgoodwillandaccumulatedimpairmentlossesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofmarketabledebtsecuritiesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofinterestandinvestmentincomeTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofinterestandinvestmentincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofpropertyandequipmentnetTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofaccruedexpensesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofaccruedexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofleaseexpenseTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofleaseexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofweightedaverageremainingleasetermandtheweightedaveragediscountrateforoperatingleasesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofweightedaverageremainingleasetermandtheweightedaveragediscountrateforoperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofrestrictedstockunitactivityTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofthefairvalueofstockoptionsgrantedTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofstockoptionactivitiesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleoftotalstockbasedcompensationcostsTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleoftotalstockbasedcompensationcostsTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofstockbasedcompensationexpenseTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofstockbasedcompensationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleoffederalandstateincometaxexpenseTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable_Parentheticals" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_ScheduleofweightedaveragedilutivecommonsharesTable" roleURI="http://www.Protaratherapeutics.com/role/ScheduleofweightedaveragedilutivecommonsharesTable"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_FairValueofFinancialInstrumentsDetails" roleURI="http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_MarketableDebtSecuritiesDetails" roleURI="http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_PropertyandEquipmentnetDetails" roleURI="http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_LeasesDetails" roleURI="http://www.Protaratherapeutics.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_CommitmentsandContingenciesDetails" roleURI="http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_StockholdersEquityDetails" roleURI="http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_StockBasedCompensationDetails" roleURI="http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_IncomeTaxesDetails" roleURI="http://www.Protaratherapeutics.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#tara_r_EmployeeBenefitPlanDetails" roleURI="http://www.Protaratherapeutics.com/role/EmployeeBenefitPlanDetails"/>
  <roleRef xlink:type="simple" xlink:href="tara-20221231.xsd#DocumentAndEntityInformation" roleURI="http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_Assets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_Liabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="Series1PreferredStockMember" xlink:href="tara-20221231.xsd#tara_Series1PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="Series1PreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeExpenseNetAbstract" xlink:href="tara-20221231.xsd#tara_OtherIncomeExpenseNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="OtherIncomeExpenseNetAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseNetAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseNetAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SeriesOneConvertiblePreferredStockMember" xlink:href="tara-20221231.xsd#tara_SeriesOneConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesOneConvertiblePreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="Series1PreferredStockMember" xlink:href="tara-20221231.xsd#tara_Series1PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="Series1PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="5.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="SettlementOfRestrictedStockUnits" xlink:href="tara-20221231.xsd#tara_SettlementOfRestrictedStockUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="SettlementOfRestrictedStockUnits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SettlementOfRestrictedStockUnitinShares" xlink:href="tara-20221231.xsd#tara_SettlementOfRestrictedStockUnitinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="SettlementOfRestrictedStockUnitinShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTax" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmortizationOfDiscountsAndPremiumsInvestments" xlink:href="tara-20221231.xsd#tara_AmortizationOfDiscountsAndPremiumsInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDiscountsAndPremiumsInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities" xlink:href="tara-20221231.xsd#tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAbstract" xlink:href="tara-20221231.xsd#tara_CashPaidForAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="CashPaidForAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/OrganizationandNatureoftheBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandNatureoftheBusinessTable" xlink:href="tara-20221231.xsd#tara_OrganizationandNatureoftheBusinessTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationandNatureoftheBusinessLineItems" xlink:href="tara-20221231.xsd#tara_OrganizationandNatureoftheBusinessLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrganizationandNatureoftheBusinessTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureoftheBusinessTable" xlink:to="OrganizationandNatureoftheBusinessLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureoftheBusinessLineItems" xlink:to="us-gaap_NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/FairValueofFinancialInstruments">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/MarketableDebtSecurities">
    <loc xlink:type="locator" xlink:label="MarketableDebtSecuritiesAbstract" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="MarketableDebtSecuritiesTextBlock" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableDebtSecuritiesAbstract" xlink:to="MarketableDebtSecuritiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/PropertyandEquipmentnet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/AccruedExpenses">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/EmployeeBenefitPlan">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/NetLossPerCommonShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketableDebtSecuritiesPolicyTextBlock" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="MarketableDebtSecuritiesPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatentCostsPolicyTextBlock" xlink:href="tara-20221231.xsd#tara_PatentCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PatentCostsPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecentAccountingPronouncementsNotYetAdopted" xlink:href="tara-20221231.xsd#tara_RecentAccountingPronouncementsNotYetAdopted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RecentAccountingPronouncementsNotYetAdopted" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesTables">
    <loc xlink:type="locator" xlink:label="MarketableDebtSecuritiesAbstract" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableDebtSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfInterestAndInvestmentIncomeTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableDebtSecuritiesAbstract" xlink:to="ScheduleOfInterestAndInvestmentIncomeTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/AccruedExpensesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOfOtherInformationRelatedToLeasesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" xlink:href="tara-20221231.xsd#tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/NetLossPerCommonShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock" xlink:href="tara-20221231.xsd#tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentMember" xlink:href="tara-20221231.xsd#tara_LaboratoryEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LaboratoryEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm" xlink:href="tara-20221231.xsd#tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems" xlink:to="ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfGoodwillAndAccumulatedImpairmentLossesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfGoodwillAndAccumulatedImpairmentLossesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGoodwillAndAccumulatedImpairmentLossesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_GoodwillMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:to="us-gaap_GoodwillGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:to="us-gaap_Goodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems" xlink:to="us-gaap_Goodwill_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsAndLiabilitiesThatAreMeasuredAndCarriedAtFairValueAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfFinancialAssetsAndLiabilitiesThatAreMeasuredAndCarriedAtFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable" xlink:href="tara-20221231.xsd#tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"/>
    <loc xlink:type="locator" xlink:label="FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems" xlink:href="tara-20221231.xsd#tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndLiabilitiesThatAreMeasuredAndCarriedAtFairValueAbstract" xlink:to="FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable" xlink:to="FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CashEquivalentsAbstract" xlink:href="tara-20221231.xsd#tara_CashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems" xlink:to="CashEquivalentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashEquivalentsAbstract" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashEquivalentsAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedCashNonCurrentAbstract" xlink:href="tara-20221231.xsd#tara_RestrictedCashNonCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems" xlink:to="RestrictedCashNonCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedCashNonCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketableDebtSecuritiesAbstract0" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems" xlink:to="MarketableDebtSecuritiesAbstract0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableDebtSecuritiesAbstract0" xlink:to="us-gaap_MarketableSecurities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableDebtSecuritiesAbstract0" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMarketableDebtSecuritiesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfMarketableDebtSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMarketableDebtSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllOtherCorporateBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllOtherCorporateBondsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_AllOtherCorporateBondsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrealizedGains" xlink:href="tara-20221231.xsd#tara_UnrealizedGains"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="UnrealizedGains" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrealizedLoss" xlink:href="tara-20221231.xsd#tara_UnrealizedLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="UnrealizedLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EstimatedFairValue" xlink:href="tara-20221231.xsd#tara_EstimatedFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="EstimatedFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofinterestandinvestmentincomeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInterestAndInvestmentIncomeAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfInterestAndInvestmentIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInterestAndInvestmentIncomeAbstract" xlink:to="us-gaap_InterestIncomeOther" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInterestAndInvestmentIncomeAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInterestAndInvestmentIncomeAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInterestAndInvestmentIncomeAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidSoftware" xlink:href="tara-20221231.xsd#tara_PrepaidSoftware"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="PrepaidSoftware" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedInterestOnMarketableDebtSecurities" xlink:href="tara-20221231.xsd#tara_AccruedInterestOnMarketableDebtSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="AccruedInterestOnMarketableDebtSecurities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentMember" xlink:href="tara-20221231.xsd#tara_LaboratoryEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LaboratoryEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyAndEquipmentNotYetPlacedIntoServiceMember" xlink:href="tara-20221231.xsd#tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyAndEquipmentNotYetPlacedIntoServiceMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofaccruedexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccruedExpensesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfAccruedExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedEmployeeRelatedCurrent" xlink:href="tara-20221231.xsd#tara_AccruedEmployeeRelatedCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="AccruedEmployeeRelatedCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedResearchAndDevelopmentCurrent" xlink:href="tara-20221231.xsd#tara_AccruedResearchAndDevelopmentCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="AccruedResearchAndDevelopmentCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAbstract" xlink:to="us-gaap_OtherExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofleaseexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseExpenseAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfLeaseExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAbstract" xlink:to="us-gaap_LeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofweightedaverageremainingleasetermandtheweightedaveragediscountrateforoperatingleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraERpGibwnKDuAJiNyIYG2H8s4SQ1D2uYlD5jFc0teK32BeW1Fr2o1Ni9NHX7+JbcT6d9/LlbyRbJSUzPIQg0nOkdo5WNEqHQXf9xzR45imSnjrybOQNzpPFlStmTd3tNMP/V17WoireM4++Z8KBdOTup6WP0OPJ7JL5pzC5fEliqx4tW2skLfFbEtpya7tUtv6utPlPNxxahnsNjcdbN76nOVtSX0ye7E=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesFutureMinimumPaymentDue" xlink:href="tara-20221231.xsd#tara_OperatingLeasesFutureMinimumPaymentDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="OperatingLeasesFutureMinimumPaymentDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="PresentValueOfFutureMinimumLeasePayments" xlink:href="tara-20221231.xsd#tara_PresentValueOfFutureMinimumLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="PresentValueOfFutureMinimumLeasePayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfRestrictedStockUnitActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedStockUnitActivityAbstract" xlink:to="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable" xlink:to="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheFairValueOfStockOptionsGrantedAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfTheFairValueOfStockOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheFairValueOfStockOptionsGrantedAbstract" xlink:to="StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable" xlink:to="StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivitiesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable" xlink:to="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="24.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="28.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired" xlink:href="tara-20221231.xsd#tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleoftotalstockbasedcompensationcostsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTotalStockBasedCompensationCostsAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfTotalStockBasedCompensationCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTotalStockBasedCompensationCostsAbstract" xlink:to="StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable" xlink:to="StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofstockbasedcompensationexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockBasedCompensationExpenseAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFederalAndStateIncomeTaxExpenseAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfFederalAndStateIncomeTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="CurrentAbstract" xlink:href="tara-20221231.xsd#tara_CurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFederalAndStateIncomeTaxExpenseAbstract" xlink:to="CurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredAbstract" xlink:href="tara-20221231.xsd#tara_DeferredAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFederalAndStateIncomeTaxExpenseAbstract" xlink:to="DeferredAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFederalAndStateIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFederalAndStateIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsOperatingLeaseLiability" xlink:href="tara-20221231.xsd#tara_DeferredTaxAssetsOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsOperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsRestrictedStockUnitsExpense" xlink:href="tara-20221231.xsd#tara_DeferredTaxAssetsRestrictedStockUnitsExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsRestrictedStockUnitsExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxLiabilitiesOperatingRightofuseAsset" xlink:href="tara-20221231.xsd#tara_DeferredTaxLiabilitiesOperatingRightofuseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesOperatingRightofuseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost" xlink:href="tara-20221231.xsd#tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract"/>
    <loc xlink:type="locator" xlink:label="NumeratorAbstract" xlink:href="tara-20221231.xsd#tara_NumeratorAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="NumeratorAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DenominatorAbstract" xlink:href="tara-20221231.xsd#tara_DenominatorAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="DenominatorAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DenominatorAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable_Parentheticals">
    <loc xlink:type="locator" xlink:label="ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/ScheduleofweightedaveragedilutivecommonsharesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageDilutiveCommonSharesAbstract" xlink:href="tara-20221231.xsd#tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="StockOptionsIssuedAndOutstanding" xlink:href="tara-20221231.xsd#tara_StockOptionsIssuedAndOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageDilutiveCommonSharesAbstract" xlink:to="StockOptionsIssuedAndOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockUnitsIssuedAndOutstanding" xlink:href="tara-20221231.xsd#tara_RestrictedStockUnitsIssuedAndOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageDilutiveCommonSharesAbstract" xlink:to="RestrictedStockUnitsIssuedAndOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfSeries1ConvertiblePreferredStock" xlink:href="tara-20221231.xsd#tara_ConversionOfSeries1ConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageDilutiveCommonSharesAbstract" xlink:to="ConversionOfSeries1ConvertiblePreferredStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalPotentiallyDilutiveShares" xlink:href="tara-20221231.xsd#tara_TotalPotentiallyDilutiveShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageDilutiveCommonSharesAbstract" xlink:to="TotalPotentiallyDilutiveShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="tara-20221231.xsd#tara_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_GoodwillMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OperatingSegmentDescription" xlink:href="tara-20221231.xsd#tara_OperatingSegmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="OperatingSegmentDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_Goodwill" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketCapitalizationsPercentageChange" xlink:href="tara-20221231.xsd#tara_MarketCapitalizationsPercentageChange"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="MarketCapitalizationsPercentageChange" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MicrocapCompaniesMarketCapitalization" xlink:href="tara-20221231.xsd#tara_MicrocapCompaniesMarketCapitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="MicrocapCompaniesMarketCapitalization" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="VestingPeriod" xlink:href="tara-20221231.xsd#tara_VestingPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="VestingPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionPeriod" xlink:href="tara-20221231.xsd#tara_StockOptionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="StockOptionPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfLargestAmountOfBenefit" xlink:href="tara-20221231.xsd#tara_PercentageOfLargestAmountOfBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="PercentageOfLargestAmountOfBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesDetails">
    <loc xlink:type="locator" xlink:label="MarketableDebtSecuritiesAbstract" xlink:href="tara-20221231.xsd#tara_MarketableDebtSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableDebtSecuritiesAbstract" xlink:to="us-gaap_NetInvestmentIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrealizedLosses" xlink:href="tara-20221231.xsd#tara_UnrealizedLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketableDebtSecuritiesAbstract" xlink:to="UnrealizedLosses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentnetDetailsTable" xlink:href="tara-20221231.xsd#tara_PropertyandEquipmentnetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentnetDetailsLineItems" xlink:href="tara-20221231.xsd#tara_PropertyandEquipmentnetDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="PropertyandEquipmentnetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentnetDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentnetDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentnetDetailsTable" xlink:to="PropertyandEquipmentnetDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentnetDetailsLineItems" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalPropertyAndEquipmentNet" xlink:href="tara-20221231.xsd#tara_TotalPropertyAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentnetDetailsLineItems" xlink:to="TotalPropertyAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedCashNoncurrents" xlink:href="tara-20221231.xsd#tara_RestrictedCashNoncurrents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="RestrictedCashNoncurrents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="tara-20221231.xsd#tara_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsLineItems" xlink:href="tara-20221231.xsd#tara_CommitmentsandContingenciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CholineLicenseAgreementMember" xlink:href="tara-20221231.xsd#tara_CholineLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="CholineLicenseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IowaAgreementMember" xlink:href="tara-20221231.xsd#tara_IowaAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="IowaAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FeinsteinAgreementMember" xlink:href="tara-20221231.xsd#tara_FeinsteinAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FeinsteinAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_LicenseAgreementTermsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="CommitmentsandContingenciesDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAgreements" xlink:href="tara-20221231.xsd#tara_DescriptionOfAgreements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="DescriptionOfAgreements" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenses" xlink:href="tara-20221231.xsd#tara_ResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="ResearchAndDevelopmentExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BroadcastersLicenseAgreementCommitmentsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsTable" xlink:href="tara-20221231.xsd#tara_StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsLineItems" xlink:href="tara-20221231.xsd#tara_StockholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesOneConvertiblePreferredStockMember" xlink:href="tara-20221231.xsd#tara_SeriesOneConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesOneConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UnderwrittenPublicOfferingMember" xlink:href="tara-20221231.xsd#tara_UnderwrittenPublicOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="UnderwrittenPublicOfferingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="StockholdersEquityDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuanceAndOutstandingPercentage" xlink:href="tara-20221231.xsd#tara_CommonStockIssuanceAndOutstandingPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="CommonStockIssuanceAndOutstandingPercentage" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseOrDecreaseEquityPercentage" xlink:href="tara-20221231.xsd#tara_IncreaseOrDecreaseEquityPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="IncreaseOrDecreaseEquityPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateOfSharesOfCommonStock" xlink:href="tara-20221231.xsd#tara_AggregateOfSharesOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="AggregateOfSharesOfCommonStock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceeds" xlink:href="tara-20221231.xsd#tara_NetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="NetProceeds" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="17.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProceeds" xlink:href="tara-20221231.xsd#tara_GrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="GrossProceeds" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsTable" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsLineItems" xlink:href="tara-20221231.xsd#tara_StockBasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="StockBasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BoardOfDirectorsMember" xlink:href="tara-20221231.xsd#tara_BoardOfDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="BoardOfDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwentyTwentyInducementPlanMember" xlink:href="tara-20221231.xsd#tara_TwentyTwentyInducementPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwentyTwentyInducementPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwentySeventeenEquityIncentivePlanMember" xlink:href="tara-20221231.xsd#tara_TwentySeventeenEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwentySeventeenEquityIncentivePlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwentyFourteenEquityIncentivePlanMember" xlink:href="tara-20221231.xsd#tara_TwentyFourteenEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwentyFourteenEquityIncentivePlanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:href="tara-20221231.xsd#tara_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandFourteenEmployeeStockPurchasePlanMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="StockBasedCompensationDetailsLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StocksIssuedDuringPeriodValueNewIssues" xlink:href="tara-20221231.xsd#tara_StocksIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="StocksIssuedDuringPeriodValueNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesAvailableForIssuance" xlink:href="tara-20221231.xsd#tara_SharesAvailableForIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="SharesAvailableForIssuance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberSharesAuthorized" xlink:href="tara-20221231.xsd#tara_NumberSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="NumberSharesAuthorized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareAuthorizedIncreased" xlink:href="tara-20221231.xsd#tara_NumberOfShareAuthorizedIncreased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="NumberOfShareAuthorizedIncreased" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnamortizedValueOfRsus" xlink:href="tara-20221231.xsd#tara_UnamortizedValueOfRsus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="UnamortizedValueOfRsus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingAmortizationPeriod" xlink:href="tara-20221231.xsd#tara_WeightedAverageRemainingAmortizationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="WeightedAverageRemainingAmortizationPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesRestrictedStock" xlink:href="tara-20221231.xsd#tara_NumberOfSharesRestrictedStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="NumberOfSharesRestrictedStock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConnectionWithTheNetShareSettlement" xlink:href="tara-20221231.xsd#tara_ConnectionWithTheNetShareSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="ConnectionWithTheNetShareSettlement" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationUnrecognized" xlink:href="tara-20221231.xsd#tara_ShareBasedCompensationUnrecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="ShareBasedCompensationUnrecognized" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="tara-20221231.xsd#tara_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsLineItems" xlink:href="tara-20221231.xsd#tara_IncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="USFederalMember" xlink:href="tara-20221231.xsd#tara_USFederalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="USFederalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StateIncomeTaxMember" xlink:href="tara-20221231.xsd#tara_StateIncomeTaxMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="StateIncomeTaxMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FederalNOLMember" xlink:href="tara-20221231.xsd#tara_FederalNOLMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="FederalNOLMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="IncomeTaxesDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EffectiveTaxRateDescription" xlink:href="tara-20221231.xsd#tara_EffectiveTaxRateDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="EffectiveTaxRateDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxCarriedForwardTerms" xlink:href="tara-20221231.xsd#tara_IncomeTaxCarriedForwardTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="IncomeTaxCarriedForwardTerms" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/EmployeeBenefitPlanDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeContributions" xlink:href="tara-20221231.xsd#tara_EmployeeContributions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="EmployeeContributions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeCompensation" xlink:href="tara-20221231.xsd#tara_EmployeeCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="EmployeeCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_OtherLaborRelatedExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="tara-20221231.xsd#tara_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105506853088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 03, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protara Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TARA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,306,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001359931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-4580525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">345 Park Avenue South<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">3rd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">844-0337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York, New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105504441328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 24,127<span></span>
</td>
<td class="nump">$ 35,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable debt securities</a></td>
<td class="nump">60,243<span></span>
</td>
<td class="nump">55,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,776<span></span>
</td>
<td class="nump">1,883<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">86,146<span></span>
</td>
<td class="nump">93,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable debt securities, non-current</a></td>
<td class="nump">17,886<span></span>
</td>
<td class="nump">39,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,592<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">6,277<span></span>
</td>
<td class="nump">7,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">29,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">644<span></span>
</td>
<td class="nump">865<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">113,290<span></span>
</td>
<td class="nump">172,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,586<span></span>
</td>
<td class="nump">954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,237<span></span>
</td>
<td class="nump">2,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">917<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,740<span></span>
</td>
<td class="nump">4,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current</a></td>
<td class="nump">5,467<span></span>
</td>
<td class="nump">6,384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,207<span></span>
</td>
<td class="nump">10,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, authorized 10,000,000 shares: Series 1 convertible preferred stock, 8,028 shares authorized at December 31, 2022 and 2021, respectively 8,027 shares issued and outstanding as of December 31, 2022 and 2021, respectively.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, authorized 100,000,000 shares: Common stock, 11,267,389 and 11,235,731 shares issued and outstanding as of December 31, 2022 and 2021, respectively.</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">262,724<span></span>
</td>
<td class="nump">256,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(159,964)<span></span>
</td>
<td class="num">(94,012)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(688)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">102,083<span></span>
</td>
<td class="nump">161,914<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 113,290<span></span>
</td>
<td class="nump">$ 172,596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105504458848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">11,267,389<span></span>
</td>
<td class="nump">11,235,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">11,267,389<span></span>
</td>
<td class="nump">11,235,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tara_Series1PreferredStockMember', window );">Series 1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">8,028<span></span>
</td>
<td class="nump">8,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">8,027<span></span>
</td>
<td class="nump">8,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">8,027<span></span>
</td>
<td class="nump">8,027<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tara_Series1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tara_Series1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105504706240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 16,808<span></span>
</td>
<td class="nump">$ 21,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">20,737<span></span>
</td>
<td class="nump">26,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Loss on impairment of goodwill</a></td>
<td class="nump">29,517<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">67,062<span></span>
</td>
<td class="nump">47,489<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(67,062)<span></span>
</td>
<td class="num">(47,489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_OtherIncomeExpenseNetAbstract', window );"><strong>Other income (expense), net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest and investment income</a></td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (65,952)<span></span>
</td>
<td class="num">$ (47,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic (in Dollars per share)</a></td>
<td class="num">$ (5.86)<span></span>
</td>
<td class="num">$ (4.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, basic (in Shares)</a></td>
<td class="nump">11,259,615<span></span>
</td>
<td class="nump">11,232,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized (loss) gain on marketable debt securities</a></td>
<td class="num">$ (477)<span></span>
</td>
<td class="num">$ (211)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(477)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss</a></td>
<td class="num">$ (66,429)<span></span>
</td>
<td class="num">$ (47,463)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_OtherIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_OtherIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105509619248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (5.86)<span></span>
</td>
<td class="num">$ (4.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">11,259,615<span></span>
</td>
<td class="nump">11,232,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105507007056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Series 1 Convertible </div>
<div>Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 245,992<span></span>
</td>
<td class="num">$ (46,760)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 199,243<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">8,027<span></span>
</td>
<td class="nump">11,211,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SettlementOfRestrictedStockUnits', window );">Settlement of restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(228)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SettlementOfRestrictedStockUnitinShares', window );">Settlement of restricted stock units (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation - restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation - stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,842<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(211)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(47,252)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(47,252)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">256,126<span></span>
</td>
<td class="num">(94,012)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
<td class="nump">161,914<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">8,027<span></span>
</td>
<td class="nump">11,235,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SettlementOfRestrictedStockUnits', window );">Settlement of restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SettlementOfRestrictedStockUnitinShares', window );">Settlement of restricted stock units (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation - restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,273<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation - stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(477)<span></span>
</td>
<td class="num">(477)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(65,952)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(65,952)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 262,724<span></span>
</td>
<td class="num">$ (159,964)<span></span>
</td>
<td class="num">$ (688)<span></span>
</td>
<td class="nump">$ 102,083<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">8,027<span></span>
</td>
<td class="nump">11,267,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_SettlementOfRestrictedStockUnitinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_SettlementOfRestrictedStockUnitinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_SettlementOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_SettlementOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33775-111570<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105504385808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (65,952)<span></span>
</td>
<td class="num">$ (47,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Loss on impairment of goodwill</a></td>
<td class="nump">29,517<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">6,688<span></span>
</td>
<td class="nump">10,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating lease right-of-use asset</a></td>
<td class="nump">1,366<span></span>
</td>
<td class="nump">1,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_AmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium on marketable debt securities</a></td>
<td class="nump">1,137<span></span>
</td>
<td class="nump">1,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">265<span></span>
</td>
<td class="num">(418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">631<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">748<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(1,327)<span></span>
</td>
<td class="num">(1,009)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(26,457)<span></span>
</td>
<td class="num">(34,502)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable debt securities</a></td>
<td class="num">(43,550)<span></span>
</td>
<td class="num">(124,748)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities', window );">Proceeds from maturity and redemption of marketable debt securities</a></td>
<td class="nump">58,620<span></span>
</td>
<td class="nump">27,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(596)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in)/provided by investing activities</a></td>
<td class="nump">14,950<span></span>
</td>
<td class="num">(98,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of shares in connection with settlement of RSUs</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in)/provided by financing activities</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease)/increase in cash and cash equivalents and restricted cash</a></td>
<td class="num">(11,597)<span></span>
</td>
<td class="num">(132,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash - beginning of year</a></td>
<td class="nump">36,469<span></span>
</td>
<td class="nump">169,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash - end of period</a></td>
<td class="nump">24,872<span></span>
</td>
<td class="nump">36,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_CashPaidForAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income Taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_AmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of discounts and premiums investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_AmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_CashPaidForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_CashPaidForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the proceeds from maturity and redemption of marketable debt securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105506817984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_OrganizationandNatureoftheBusinessLineItems', window );"><strong>Organization and Nature of the Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Nature of the Business</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. Organization and Nature of the Business </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Overview</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Protara Therapeutics, Inc., and its consolidated
subsidiaries (&#8220;Protara&#8221; or the &#8220;Company&#8221;), is a clinical-stage biopharmaceutical company committed to advancing
transformative therapies for the treatment of cancer and rare diseases. Protara&#8217;s portfolio includes two development programs utilizing
TARA-002, an investigational cell therapy in development for the treatment of lymphatic malformations, or LMs and non-muscle invasive
bladder cancer, or NMIBC. The third program in the portfolio is Intravenous, or IV Choline Chloride, an investigational phospholipid
substrate replacement therapy initially in development for patients receiving parenteral nutrition, or PN who have intestinal failure
associated liver disease, or IFALD.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2020, privately-held ArTara Subsidiary,
Inc. (&#8220;Private ArTara&#8221;) and Protara Therapeutics, Inc. (formerly ArTara Therapeutics, Inc., formerly Proteon Therapeutics,
Inc.) completed the merger and reorganization (the &#8220;Merger&#8221;), in accordance with the terms of the Agreement and Plan of Merger
and Reorganization, dated September 23, 2019, (the &#8220;Merger Agreement&#8221;) by and among Protara Therapeutics, Inc., Private ArTara
and REM 1 Acquisition, Inc., a wholly owned subsidiary of Protara Therapeutics, Inc (&#8220;Merger Sub&#8221;). Thereupon, Merger Sub
merged with and into Private ArTara, with Private ArTara surviving as a wholly owned subsidiary of Protara Therapeutics, Inc. The Merger
was structured as a reverse merger and Private ArTara was determined to be the accounting acquirer based on the terms of the Merger and
other factors, and the post-merger company retained the name ArTara Therapeutics, Inc., which on May 11, 2020 was changed to Protara
Therapeutics, Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">In addition, concurrently with the execution of the Merger Agreement,
Protara issued a private placement, whereby all of the outstanding shares of Protara Therapeutics, Inc.&#8217;s Series A Preferred Stock
were converted into shares of Protara Therapeutics, Inc.&#8217;s common stock. Shares of the Company&#8217;s common stock commenced trading
on The Nasdaq Capital Market under the new name and ticker symbol &#8220;TARA&#8221; as of market open on January 10, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Liquidity, Capital Resources and Management Plans</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is in the business of developing
biopharmaceuticals and has no current or near-term revenues. The Company has incurred substantial clinical and other costs in its drug
development efforts. The Company will need to raise additional capital in order to fully realize management&#8217;s plans.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that its current financial
resources are sufficient to satisfy the Company&#8217;s estimated liquidity needs for at least twelve months from the date of issuance
of these consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Impact of the COVID-19
Pandemic</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the impacts of the COVID-19 pandemic,
the Company has experienced delays and may experience additional future delays that impact the business, research and development activities,
the healthcare systems in which the Company operates and the global economy as a whole. Due to the continued impact of the&#160;COVID-19&#160;pandemic,
the Company is not able to estimate the ongoing effects on the Company&#8217;s results of operations, financial condition, or liquidity.
The Company will continue to monitor the impact of the COVID-19 pandemic and its related macroeconomic effects closely including whether
the effects would have a material impact on the Company&#8217;s operations, liquidity and capital resources.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_OrganizationandNatureoftheBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_OrganizationandNatureoftheBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105505374592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. Summary of Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;
or &#8220;GAAP&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Principles of Consolidation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in the
accompanying consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses,
and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Significant items subject
to such estimates include but are not limited to income taxes, the valuation of deferred tax assets, recoverability of goodwill, and
contingencies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On an ongoing basis, the Company&#8217;s management
evaluates its estimates based on historical and anticipated results, trends, and various other assumptions believed to be reasonable.&#160;Actual
results could differ from those estimates. The results of any changes in accounting estimates are reflected in the financial statements
of the period in which the change becomes evident.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Reclassification</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in prior periods related to the classification of accrued
expenses and income taxes have been reclassified to conform to current period presentation. These reclassifications to adjust prior period
presentation had no impact on consolidated statements of operations and comprehensive loss or consolidated statements of cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Cash, Cash Equivalents
and Restricted Cash</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid instruments
with an original maturity of three months or less when acquired to be cash equivalents. Cash and cash equivalents are held in depository
and money market accounts and are reported at fair value. The Company&#8217;s restricted cash balances consist of cash deposits to collateralize
letter of credit obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides a reconciliation
of cash, cash equivalents, and restricted cash in the consolidated balance sheets to the total amount shown in the consolidated statements
of cash flows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,127</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">35,724</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Restricted cash, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">24,872</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">36,469</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Fair Value Measurements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 820 &#8220;Fair Value Measurements&#8221; provides the framework for measuring fair value and establishes a fair value hierarchy
that prioritizes the inputs used in pricing the asset or liability. The hierarchy gives the highest priority to unadjusted quoted prices
in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3
measurements).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value is defined as the exchange price,
or an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly
transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, the three-tier
fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 Quoted prices in
    active markets for identical assets or liabilities.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 Quoted prices for
    similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are
    not active, or other inputs that are observable, either directly or indirectly.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 Significant unobservable
    inputs that cannot be corroborated by market data.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of cash and cash equivalents,
prepaid expenses and accounts payable approximate their fair values due to the short-term nature of these instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Marketable Debt Securities</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies investments in marketable
debt securities with remaining maturities when purchased of greater than three months as available-for-sale. Investments with a remaining
maturity date greater than one year are classified as non-current.&#160;The cost of securities sold is based on the specific identification
method. Interest and dividends earned on securities are classified as available-for-sale are included in investment income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records investments at fair value
with unrealized gains and losses recorded as a component of other comprehensive loss in the consolidated statements of operations and
comprehensive loss until realized. Realized gains and losses are reflected in interest and investment income in the consolidated statements
of operations and comprehensive loss and are determined using the specific identification method with transactions recorded on a settlement
date basis. Fair value is determined based on quoted market rates when observable or utilizing data points that are observable, such
as quoted prices, interest rates and yield curves. To determine whether an other-than-temporary impairment exists, the Company considers
whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability
of the cost of the investment outweighs evidence to the contrary. The Company has the ability to hold such securities with an unrealized
loss until its forecasted recovery. The Company determined that there was no material change in the credit risk of these investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Concentrations of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, which potentially subject
the Company to concentrations of credit risk, consists principally of cash, cash equivalents, restricted cash, and marketable debt securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company currently invests its excess cash
primarily in money market funds and high quality, investment grade marketable debt securities of corporations. The Company has adopted
an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Property and Equipment,
net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment, including leasehold improvements,
are recorded at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the
estimated useful life of the asset. Depreciation begins at the time the asset is placed in service. Leasehold improvements are amortized
using the straight-line method over the shorter of the lease term or estimated useful life of the asset.&#160;Repairs and maintenance
costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimated useful lives for significant property
and equipment categories are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Asset
    Classification</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
    Useful Life</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture,
    fixtures and other</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory
    equipment</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shorter of the useful life of asset or the lease term </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company enters into contracts in the normal
course of business and assesses whether any such contracts contain a lease. The Company determines if an arrangement is a lease at inception
if it conveys the right to control the identified asset for a period of time in exchange for consideration. Under ASC 842, lease expense
is recognized as a single lease cost on a straight-line basis over the lease term. The lease term consists of non-cancelable periods
and may include options to extend or terminate the lease term, when it is reasonably certain such options will be exercised.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases classified as operating leases are included
in operating lease right-of-use (&#8220;ROU&#8221;) assets, current operating lease liabilities and noncurrent operating lease liabilities
in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations, in our consolidated
balance sheet. ROU assets represent the right to use an underlying asset for the lease term. Lease liabilities represent the present
value of future lease payments, net of lease incentives, discounted using an incremental borrowing rate, which is a management estimate
based on the information available at the commencement date of a lease arrangement. ROU assets and lease liabilities are recognized at
the lease commencement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has elected to account for the lease
and non-lease components for leases as a single component for classes of all underlying assets and allocate all the contract consideration
to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included
in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating
expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes costs associated with
lease arrangements having an initial term of 12 months or less (&#8220;short-term leases&#8221;) on a straight-line basis over the lease
term; such short-term leases are not recorded on the balance sheet.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Impairment of Long-Lived Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be recoverable or that
the useful life is shorter than originally estimated. When such events occur, the Company compares the carrying amounts of the asset
or asset group to the undiscounted expected future cash flows. If this comparison indicates that the asset or asset group is impaired,
the amount of impairment is measured as the difference between the carrying value and fair value of the asset or asset group. If the
useful life is shorter than originally estimated, the Company will amortize the remaining carrying value over the new shorter useful
life. To date, no such impairment loss has been recognized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Segment Information</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company identifies its operating segments
in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 280, Segment Reporting (&#8220;ASC 280&#8221;). Operating segments
are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief
operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#8217;s
chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes
of allocating resources. Accordingly, the Company has determined it operates and manages its business in a single reportable operating
segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Goodwill</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2020, in connection with the Merger,
the Company separately valued the assets and liabilities acquired, and then determined goodwill as the residual of the purchase price
less identified net assets, resulting in the initial recording of $29.5 million in goodwill.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill represents the excess of purchase price
over the fair value of identifiable net assets acquired in a business combination. Goodwill has an indefinite useful life. Goodwill is
assessed annually for impairment as of&#160;December 31, or more frequently if an event occurs or circumstances change that would indicate
that it is more likely than not that the fair value of a reporting unit or the fair value of an indefinite-lived intangible asset has
declined below its carrying value. In performing its annual goodwill impairment assessment, the Company has the option under GAAP to
qualitatively assess whether it is more likely than not that the fair value of a reporting unit is less than its carrying value; if the
conclusion of the qualitative assessment is that there are no indicators of impairment, the Company does not perform a quantitative assessment.
Otherwise, a quantitative assessment is performed and the fair value of the reporting unit is determined.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill is evaluated for impairment at the reporting
unit level, which is defined as an operating segment, or one level below an operating segment. The Company has determined that it operates
as one reporting unit and has selected December 31 as the date to perform its annual impairment test.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022 and 2021, the Company elected to forego the
qualitative screen and performed a quantitative annual goodwill impairment test for the reporting unit.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Company&#8217;s stock price and market
capitalization declined 60% from December 31, 2021, which reflects the overall decline of similar companies with less than $250 million
in market capitalizations, or microcap companies. The life sciences sector, which includes pre-commercialization and therefore net operating
loss generating companies, relies heavily on the capital markets to finance their operations and fund pre-clinical and clinical trials
for their existing development programs. As a result of a shift in risk appetite in the overall financial markets, the availability of
capital for life science sector companies decreased significantly in 2022. The challenging financing conditions had a negative impact
on stock prices and respective market capitalizations, particularly for microcap companies. The Company considered the heightened financing
risk that impacted the life sciences sector during 2022 to be one of the key macroeconomic factors that led to a sustained decrease in
the Company&#8217;s stock price and market capitalization leading up to its annual goodwill impairment assessment date in late 2022. Based
upon the results of our 2022 annual goodwill impairment test, the Company recorded a loss on impairment of goodwill of $29.5 million during
the year ended December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table provides a roll forward of the Company&#8217;s
goodwill and accumulated impairment losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Goodwill, gross amount as of December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,517</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Accumulated impairment loss, as of December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,517</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -8.15pt; padding-left: 17.15pt">Additions to goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -8.15pt; padding-left: 17.15pt">Loss on impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,517</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Goodwill as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based upon the results of our annual goodwill impairment test, no adjustments
to the carrying value of goodwill were necessary during the year ended December 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Research and Development</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses consist primarily
of third-party costs incurred to develop drug candidates, employee-related expenses, including salaries, benefits, travel and stock-based
compensation expense, depreciation and other allocated overhead costs, which include rent and maintenance of facilities and other supplies.
Research and development costs are expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before a compound receives regulatory approval,
the Company records upfront and milestone payments made to third parties under licensing arrangements as expense provided that there
is no alternative future use of the rights in other research and development projects.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nonrefundable advance payments to vendors for
goods or services that will be used or received in future research and development activities are deferred and recognized as expense
in the period in which the related goods are delivered or services are performed. Where milestone payments are due to third parties under
research and development collaboration arrangements or other contractual agreements, the milestone payment obligations are expensed when
the milestone conditions are met and the amount of payment is reasonably estimable.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once a compound receives regulatory approval,
the Company records any milestone payments in&#160;identifiable intangible assets, less accumulated amortization&#160;and, unless the
asset is determined to have an indefinite life, the Company amortizes the payments on a straight-line basis over the remaining agreement
term or the expected product life cycle, whichever is shorter.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain third-party costs are included as a component
of research and development expense. These expenses include fees paid to contract research organizations (&#8220;CROs&#8221;) and other
clinical trial costs, contractual services costs and costs for supply of its drug candidates. Depending upon the timing of payments to
the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses
are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved and experience with similar
contracts. The Company monitors each of these factors and adjusts estimates accordingly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Patent Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All patent-related costs incurred in connection
with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure.
Amounts incurred are classified as general and administrative expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Interest and Investment Income</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investment income consists primarily of interest
income, accretion income earned and amortization expense incurred and realized gains or losses&#160;related to our marketable debt securities
and interest income related to cash, cash equivalents and restricted cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Stock-Based Compensation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s stock-based compensation
programs include stock options, restricted stock units (&#8220;RSUs&#8221;), and an employee stock purchase program (&#8220;ESPP&#8221;).
The Company accounts for stock-based compensation using the fair value method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures all stock options and other
stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense
of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes
forfeitures at the time forfeitures occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of each option is estimated on
the date of grant using the Black-Scholes option-pricing model. Expected volatility for the Company&#8217;s common stock is determined
based on an average of the historical volatility of the Company and the historical volatility of a peer-group of similar public companies.
The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual
term of the option and the weighted-average vesting period of the option. The assumed dividend yield is based upon the Company&#8217;s
expectation of not paying dividends in the foreseeable future. The risk-free interest rate is based upon the U.S. Treasury yield curve
commensurate with the expected term at the time of grant or remeasurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The stock-based compensation expense associated
with purchase rights under the ESPP is measured at fair-value using a Black-Scholes option-pricing model at commencement of each offering
period and recognized over that offering period. The Black-Scholes option pricing assumptions are similar to those used for stock options
with the exception of the expected term of purchase rights for the ESPP which is based on the duration of an offering period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair values of RSUs are based on the fair
market value of the Company&#8217;s common stock on the date of the grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The RSUs are granted to directors pursuant to
the Company&#8217;s equity plan. Settlement for the RSUs is deferred until the earliest to occur of (i) the director&#8217;s termination
of service, (ii) death, (iii) disability or (iv) a change in control of the Company. In the event of a change in control of the Company,
the RSUs will vest in full.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of all stock-based awards is recognized
as stock-based compensation expense on a straight-line basis over the vesting period, which is typically one to four years for RSUs and
four years for stock options.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies stock-based compensation
expense in its statement of operations and comprehensive loss in the same way the payroll costs or service payments are classified for
the related stock-based award recipients.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Income Taxes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax assets and liabilities are recognized
for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets
and liabilities and their respective tax basis, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are
measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.
The measurement of net deferred tax assets is reduced by the amount of any tax benefit that, based on available evidence, is not expected
to be realized, and a corresponding valuation allowance is established. In making such a determination, the Company considers all available
positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,
tax-planning strategies, and results of recent operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tax benefits are recognized only for tax positions
that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount
of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for unrecognized tax benefits is recorded
for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and measurement standards. The Company&#8217;s
policy is to record interest and penalties on uncertain tax positions as a component of income tax expense in the consolidated statement
of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Net Loss Per Share Attributable to Common
Stockholders</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per share is computed by dividing
the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period.
Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares
of common stock outstanding during the period plus the common equivalent shares for the period including any dilutive effect from unvested
restricted common stock, outstanding stock options and potential shares issuable under the ESPP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Recently Adopted Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2018, the Financial Accounting Standards
Board, or the FASB, issued ASU&#160;No.&#160;2018-15,&#160;<i>Intangibles &#8211; Goodwill and Other &#8211;&#160;Internal-Use&#160;Software
(Subtopic&#160;350-40):&#160;Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a
Service Contract</i>&#160;(&#8220;ASU&#160;2018-15&#8221;).&#160;This ASU is designed to reduce complexity for accounting for costs of
implementing a cloud computing service arrangement. This standard aligns the accounting for implementation costs of hosting arrangements,
regardless of whether they convey a license to the hosted software. The standard became effective for the first interim period within
annual reporting periods beginning after December&#160;15, 2020. On January 1, 2021, the Company adopted ASU 2018-15. The adoption of
this standard did not have a material effect on the Company&#8217;s financial position, results of operations, or cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12,
<i>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </i>(&#8220;ASU 2019-12&#8221;). The amendments in ASU 2019-12
remove certain exceptions to the general principles in Topic 740. The amendments also clarify and amend existing guidance to improve
consistent application. The amendments became effective for annual reporting periods beginning after December 15, 2020. On January 1,
2021, the Company adopted ASU 2019-12. The adoption of this standard did not have a material effect on the Company&#8217;s financial
position, results of operations, or cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Recent Accounting Pronouncements
Not Yet Adopted</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the Financial Accounting Standards
Board, or the FASB issued ASU 2016-13, <i>Measurement of Credit Losses on Financial Statements</i>. The new standard requires that expected
credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through
an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to
the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value
increases. In November 2019, the FASB issued ASU 2019-10, <i>Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and
Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the effective date for certain companies. The standard
is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December
15, 2022. Early adoption is available. The Company has evaluated the impact of the adoption of ASU 2016-13, and related updates, and
has determined that the impact will not be material to its consolidated financial statements and disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated other recently issued
accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material
impact on the Company&#8217;s financial position or results of operations upon adoption.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Subsequent Events</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the financial statements were available to be issued. Other than as described
in Note 11 and, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial
statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105590858016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>3. Fair Value of Financial Instruments</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tables below present information about the
Company&#8217;s financial instruments that are measured at fair value on a recurring basis as of December 31, 2022 and 2021 and indicates
the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, as described under <i>Note 2,
Summary of Significant Accounting Policies.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables present the Company&#8217;s
financial assets and liabilities that are measured and carried at fair value and indicate the level within the fair value hierarchy of
the valuation techniques it utilizes to determine such fair value:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash Equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds<sup>(a)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,284</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,284</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate bonds<sup>(a)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,523</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,523</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted cash, non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds<sup>(b)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">745</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate bonds<sup>(c)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78,129</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78,129</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,029</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">80,652</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">94,681</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash Equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds<sup>(a)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,323</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,323</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted cash, non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds<sup>(b)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">745</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate bonds<sup>(c)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">94,972</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">94,972</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,068</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">94,972</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">122,040</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0in">&#160;</td> <td style="width: 0.25in; padding-right: 0pt; padding-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds and corporate debt securities with original maturities of 90 days or less are included within Cash and cash equivalents in the Consolidated Balance Sheets.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="padding-right: 0pt; padding-left: 0pt; text-align: justify">&#160;</td> <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="padding-right: 0pt; padding-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Money market funds are included within Restricted Cash, non-current in the Consolidated Balance Sheets.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="padding-right: 0pt; padding-left: 0pt; text-align: justify">&#160;</td> <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="padding-right: 0pt; padding-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td> <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate debt securities with original maturities greater than 90 days are included within Marketable securities in the Consolidated Balance Sheets and classified as current or noncurrent based upon whether the maturity of the financial asset is less than or greater than 12 months.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Money market funds are classified as Level&#160;1
within the fair value hierarchy, because they are valued using quoted prices in active markets. Corporate debt securities classified
as Level&#160;2 within the fair value hierarchy are valued on the basis of prices from an orderly transaction between market participants
provided by reputable dealers or pricing services. Prices of these securities are obtained through independent, third-party pricing services
and include market quotations that may include both observable and unobservable inputs. In determining the value of a particular investment,
pricing services may use certain information with respect to transactions in such investments, quotations from dealers, pricing matrices
and market transactions in comparable investments and various relationships between investments. There were no transfers of financial
instruments among Level&#160;1, Level&#160;2, and Level&#160;3 during the period presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash equivalents, prepaid expenses and other
current assets, accounts payable and accrued expenses at December 31, 2022 and 2021 are carried at amounts that approximate fair value
due to their short-term maturities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Non-Recurring Fair Value Measurements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify"><b><i>&#160;</i></b></p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">During the fourth quarter of 2022, the Company recorded a goodwill
impairment loss of $29.5 million, refer to Note 2 for additional details on the impairment of goodwill. The fair value of our reporting
unit was determined using an income approach based on discounted cash flows, or DCF. Determining fair value using a DCF analysis requires
the exercise of significant judgment with respect to several assumptions and estimates, including the amount and timing of expected future
cash flows and appropriate discount rate to be applied. The expected cash flows used in the DCF analysis are based on our most recent
internal long-range forecast and budget and, for years beyond the budget, our estimates, which are based, in part, on industry benchmarks
and forecasted growth rates. The discount rate used in the DCF analysis is intended to reflect the risks inherent in the expected future
cash flows of the respective programs within our portfolio. The inputs to the DCF model are Level 3 valuation inputs.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105509460592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Debt Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_MarketableDebtSecuritiesAbstract', window );"><strong>Marketable Debt Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_MarketableDebtSecuritiesTextBlock', window );">Marketable Debt Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. Marketable Debt Securities</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marketable debt securities, all of which were
classified as available-for-sale, consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortized<br/> Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unrealized<br/> Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unrealized<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Estimated<br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Corporate bonds - presented in marketable debt securities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">60,790</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(547</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">60,243</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Corporate bonds - presented in marketable debt securities, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,027</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(141</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,886</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">78,817</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(688</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">78,129</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized<br/> Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated<br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Corporate bonds - presented in marketable debt securities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55,548</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(43</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55,505</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Corporate bonds - presented in marketable debt securities, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,635</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(168</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,467</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">95,183</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(211</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">94,972</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.05pt">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount of realized gains and losses reclassified
into earnings for the year ended December 31, 2022 was $17 included in investment income within the consolidated statements of operations
and comprehensive loss. There were no sales of securities in the periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The contractual maturities of all securities
held at December 31, 2022 was 16 months or less. Of the 34 securities in a loss position held by the Company, there were 16 securities
in a continuous unrealized loss position for greater than twelve months at December 31, 2022. The total unrealized loss related to these
securities was $358 and was not material. The Company has the ability to hold such securities with an unrealized loss until its forecasted
recovery. The Company determined that there was no material change in the credit risk of the above investments. No other than temporary&#160;impairment
loss has been recorded on the securities as of December 31, 2022, as the Company believes that any decrease in fair value of these securities
is temporary and the Company expects to recover at least up to the initial cost of the investment for these securities.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Interest and Investment Income</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interest and investment income consists of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,230</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,974</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accretion/(amortization) of discount/premium, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,137</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,737</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Realized gain/(loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total interest and investment income</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,110</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">237</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_MarketableDebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_MarketableDebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_MarketableDebtSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_MarketableDebtSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105505374592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. Prepaid Expenses and Other Current Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">Prepaid expenses and
other current assets consist of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">288</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">279</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">569</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">684</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued interest on marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">634</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">173</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">127</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,776</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,883</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105508448384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. Property and Equipment, net</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">Property and equipment,
net consists of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Computer equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">205</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">175</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture, fixtures and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">352</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">352</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">591</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">553</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property and equipment not yet placed into service</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">99</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">613</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,955</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(483</td><td style="padding-bottom: 1.5px; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(236</td><td style="padding-bottom: 1.5px; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,592</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,719</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was $247 and $117 for the
years ended December 31, 2022 and 2021, respectively. During the year ended December 31, 2022, $137 and $110 was included in research
and development expense and general and administrative expense, respectively, within the consolidated statements of operations and comprehensive
loss. During the year ended December 31, 2021, $36 and $81 was included in research and development expense and general and administrative
expense, respectively, within the consolidated statements of operations and comprehensive loss. As of December 31, 2022 and 2021, 100%
of the Company&#8217;s total property and equipment, net was attributable to the United States.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105608427552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>7. Accrued Expenses</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">Accrued expenses consist
of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employee Costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,543</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,801</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">512</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">437</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">182</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">251</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,237</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,489</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105509433872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>8. Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Operating leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, the Company entered into an
agreement to lease approximately 10.3 square feet of office space in New York, New York (&#8220;Office Lease&#8221;), which commenced
in April 2021. Annual rent is approximately $1,117. The Office Lease has a term of approximately seven years and contains provisions
for a free-rent period, annual rent increases and an allowance for tenant improvements. The Company has an option to extend the term
by five years, however, the Company determined at the lease commencement date that it was not reasonably certain to exercise the renewal
option and such renewal was excluded from the operating lease right-of-use, or ROU, asset and operating lease liability recorded for
this lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is responsible for real estate taxes,
maintenance and other operating expenses applicable to the leased premises which are recognized as variable lease expense in the period
when incurred. In conjunction with the Office Lease, the Company established a letter of credit of approximately $745 secured by cash
balances included in restricted cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2021, the Company amended the existing
agreement with its contract development and manufacturing organization, or CDMO, establishing a term of eight-years from the amendment
date. Prior to the amendment, the leased spaces met the short-term lease exception under a quarter-to quarter arrangement and were not
included in measurement of lease liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases classified as operating leases are included
in operating lease right-of-use, or ROU, assets, operating lease liabilities and operating lease liabilities, non-current, in the Company&#8217;s
consolidated balance sheets. The Office Lease and the CDMO leased spaces are included in operating lease ROU assets and operating lease
liabilities. Cash paid for operating lease liabilities was $1,327 and $1,009 during the years ended December 31, 2022 and 2021, respectively,
which is included in operating cash flows. The ROU asset obtained in exchange for operating lease liabilities related to the Office Lease
was $6,549.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The components of lease expense were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><b>Lease expense</b></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Operating lease expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,366</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,050</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Short-term lease expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">102</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,369</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,152</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Variable lease expense for the years ended December
31, 2022 and 2021, respectively were not material.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-align: justify; text-indent: -20.05pt">The weighted
average remaining lease term and the weighted average discount rate for operating leases were:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-indent: -20.05pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Weighted-average discount rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Weighted-average remaining lease term &#8211; operating lease (in months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total remaining operating lease payments
included in the measurement of lease liabilities on the Company&#8217;s consolidated balance sheet as of December&#160;31, 2022, was
as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">For the year ending December 31:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Lease Payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,327</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,327</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,395</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,429</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">805</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,712</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,328</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Present value of future minimum lease payments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,384</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105509314848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>9. Commitments and Contingencies </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Employment Agreements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Executive Employment Agreements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&#8217;s executive officers have entered into at-will employment
agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Collaborations and License Agreements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Choline License Agreement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 27, 2017, the Company entered into
a license agreement (the &#8220;Choline License Agreement&#8221;) with Alan L. Buchman (&#8220;Dr. Buchman&#8221;). Pursuant to the Choline
License Agreement, the Company received from Dr. Buchman the license rights in and to the &#8220;Licensed Orphan Designations&#8221;,
the &#8220;Licensed IND&#8221;, &#8220;Existing Study Data&#8221; and the &#8220;Licensed Know-How&#8221; for one or more of the licensed
indications.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2022 and
2021, the Company recorded research and development expense of $2 and $0, in connection with the Choline License Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">License Agreement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the Company entered into
an agreement (the &#8220;Feinstein Agreement&#8221;) with The Feinstein Institute for Medical Research (the &#8220;Feinstein Institute&#8221;),
a not-for-profit corporation with 50 research labs and 2,500 clinical research studies. Pursuant to the Feinstein Agreement, the Company
acquired an exclusive license relating to treatment of fatty liver diseases in humans for which Choline may be an effective therapeutic.
In consideration for the rights and license granted, the Feinstein Institute would receive a royalty of one percent (1%) of the first
one hundred million dollars ($100,000) of net sales of IV Choline Chloride and a royalty of one and one-half percent (1.5%) of all net
sales thereafter. In addition, the Company would pay the Feinstein Institute twelve and one-half percent (12.5%) of net proceeds resulting
from agreements entered within 2 years from the effective date, and seven and one-half percent (7.5%) of net proceeds resulting from
agreements entered into thereafter. Pursuant to the Feinstein Agreement additional payments would be due to the Feinstein Institute for
license maintenance payments and for meeting milestone events. Pursuant to the Feinstein Agreement, upon the achievement of certain future
new drug application milestones, the Company would be obligated to remit an aggregate of $275.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2022 and
2021, the Company recorded research and development expense of $17 and $15, respectively, in connection with the Feinstein Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Sponsored Research and License Agreement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 28, 2018, the Company entered into a sponsored research
and license agreement (the &#8220;Iowa Agreement&#8221;) with the University of Iowa. Pursuant to the Iowa Agreement, the University of
Iowa, which is engaged in clinical research to improve the diagnosis and treatment of lymphangioma using a pharmaceutical product (OK-432),
would assist the Company in collecting case reports, forms, source data, and safety data available to the University of Iowa in support
of the development of the Company&#8217;s proprietary <i>Streptococcus Pyogenes</i> investigational product, TARA-002 for the LMs indication.
During the term of the services, the Company would generally pay the University of Iowa thirty thousand dollars ($30) per year to fund
the project, plus additional amounts upon the realization of certain milestones. More specifically, upon forty-five (45) days of an approval
of TARA-002 by the FDA, the Company would pay up to $1,750 to the University of Iowa for meeting these milestones. Furthermore, the Company
would pay the University of Iowa royalties of up to 1.75% for net sales ranging from $0 - $25,000, 2.25% for net sales ranging from $25,000
to $50,000, and 2.50% for net sales in excess of $50,000. Pursuant to the Iowa Agreement, the University of Iowa would be entitled to
additional payments for the Company achieving annual net sales of product according to the milestones. For annual net sales of product
up to $25,000: $62; for annual net sales of product of up to $50,000: $62; and for annual net sales of product of up to $100,000: $125.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Iowa Agreement there were no
research and development expenses recognized during the years ended December 31, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Chugai Agreement</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2019, the Company entered into
an agreement (the &#8220;Chugai Pharmaceutical Agreement&#8221;) with Chugai Pharmaceutical Co., LTD (&#8220;Chugai&#8221;), a drug
manufacturing firm with offices and operations in Japan. Pursuant to the Chugai Pharmaceutical Agreement, Chugai would help the
Company in its goals to develop and commercialize a therapeutic product (the &#8220;New Product&#8221;) which is comparable to the
Chugai existing therapeutic product (the &#8220;Existing Product&#8221;). In addition, the Company would be entitled to the use of
Chugai materials and technical support as necessary. On July 14, 2020, the Company and Chugai entered into an amendment (the
&#8220;Chugai Amendment&#8221;) to the Chugai Pharmaceutical Agreement, with an effective date of June 30, 2020. The Chugai
Amendment extended the date through which Chugai will exclusively provide the Existing Product and materials to the Company from
June 30, 2020 to June 30, 2021, extended the date through which Chugai will not provide materials or technical support to any
third-party for the purpose of development and commercialization in a given area from the fifth anniversary to the eleventh
anniversary of the original effective date, and provides for further such extensions on the occurrence of certain events and
milestones. The amendment further provides that, in addition to the designated fee provided upon the initial indication approval in
the Chugai Pharmaceutical Agreement, the Company will pay Chugai a designated fee for each additional indication approval. The
Company is obligated to Chugai for certain payments upon the completion of agreed upon milestones. As consideration for
Chugai&#8217;s performance under the Chugai Pharmaceutical Agreement, the Company agreed to pay Chugai a payment in the low,
single-digit millions related to such initial indication approval, which payment will be made in two installments with an initial
payment in July 2020, and the remaining majority of the payment payable upon FDA approval of the New Product.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the agreement there were no research
and development expenses recognized during the years ended December 31, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Contingencies</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may be subject
to various legal proceedings and claims that arise in the ordinary course of its business activities. Management is of the opinion that
the ultimate outcome of these matters would not have a material adverse impact on the financial position of the Company or the results
of its operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, the Company
enters into contracts in which it makes representations and warranties regarding the performance of its services and that its services
will not infringe on third-party intellectual rights. There have been no significant events related to such representations and warranties
in which the Company believes the outcome could result in losses or penalties in the future.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105509305088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. Stockholders&#8217; Equity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Company had 100,000,000
shares of common stock authorized for issuance, $0.001 par value per share, of which 11,267,389 and 11,235,731 shares were issued and
outstanding as of December 31, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of the Company&#8217;s common stock
are entitled to one vote per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Preferred Offering (defined
below) on September 22, 2020, the Company filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights and
Limitations of Series 1 Convertible Preferred Stock of the Company (the &#8220;Amendment&#8221;) with the State of Delaware to increase
the authorized number of shares of the Company&#8217;s Series 1 Convertible Preferred Stock that may be issued from 3,880 to 8,028. The
Amendment was approved by a committee of the Company&#8217;s Board of Directors and the requisite holders of outstanding shares of Series
1 Convertible Preferred Stock. No approval of the holders of the Company&#8217;s common stock was required to effectuate the Amendment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022 and 2021, the Company
had 10,000,000 shares of preferred stock authorized for issuance, $0.001 par value per share of which 8,028 shares of Series 1 Convertible
Preferred Stock are authorized for issuance and 8,027 shares were issued and outstanding, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Description of Series 1 Convertible Preferred
Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of Series 1 Convertible Preferred
Stock is convertible into 1,000 shares of the Company&#8217;s common stock, at a conversion price initially equal to approximately $7.01
per common share, subject to adjustment for any stock splits, stock dividends and similar events, at any time at the option of the holder,
provided that any conversion of Series 1 Convertible Preferred Stock by a holder into shares of the Company&#8217;s common stock would
be prohibited if, as a result of such conversion, the holder, together with its affiliates and any other person or entity whose beneficial
ownership of the Company&#8217;s common stock would be aggregated with such holder&#8217;s for purposes of Section 13(d) of the Securities
Exchange Act of 1934, as amended, would beneficially own more than 9.99% of the total number of shares of the Company&#8217;s common
stock issued and outstanding after giving effect to such conversion. Upon written notice to the Company, the holder may from time to
time increase or decrease such limitation to any other percentage not in excess of 19.99% specified in such notice. In addition, upon
the occurrence of certain transactions that involve the merger or consolidation of the Company, an exchange or tender offer, a sale of
all or substantially all of the assets of the Company or a reclassification of its Common Stock, each share of Series 1 Convertible Preferred
Stock will be convertible into the kind and amount of securities, cash and/or other property that the holder of a number of shares of
Common Stock issuable upon conversion of one share of Series 1 Convertible Preferred Stock would receive in connection with such transaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The terms of the Series 1 Convertible Preferred
Stock provide that, in the event of a fundamental transaction (as such term is described in the certificate of designation of preferences,
rights and limitations of series 1 convertible non-voting preferred stock), each share of Series 1 Convertible Preferred Stock outstanding
will thereafter be convertible into the kind and amount of securities, cash and/or other property which a holder of the number of shares
of Common Stock of the Company issuable upon conversion of one share of Series 1 Convertible Preferred Stock immediately prior to such
fundamental transaction would have been entitled to receive pursuant to such fundamental transaction, provided that, if the value of
the aggregate of such securities, cash and/or other property the which the holder of one share of Series 1 Convertible Preferred Stock
would be entitled to upon conversion thereof would be less than the stated value, then each outstanding share of Series 1 Convertible
Preferred Stock will instead be convertible into such kind of securities, cash and/or other property with an aggregate value equal to
the stated value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of Series 1 Convertible Preferred
Stock is entitled to a preference of $10.00 per share upon liquidation of the Company, and thereafter will share ratably in any distributions
or payments on an as-converted basis with the holders of Common Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of Series 1 Convertible Preferred
Stock are not entitled to vote.<b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Underwritten Public Offering</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 24, 2020, pursuant to an underwriting
agreement dated September 22, 2020, the Company issued and sold in an underwritten public offering (the &#8220;Common Offering&#8221;)
an aggregate of 4,600,000 shares of its common stock at an offering price of $16.87 per share, for gross and net proceeds of approximately
$77.6 million and $73.6 million, respectively. The underwriters were granted an option to purchase up to 690,000 additional shares of
the Company&#8217;s common stock at the public offering price, less the underwriting discount. On October 6, 2020, the underwriters exercised
their overallotment option in full, purchasing an additional 690,000 shares, resulting in the receipt of gross and net proceeds of $11.6
million and $11.1 million, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 24, 2020, pursuant to an underwriting
agreement (dated September 22, 2020), the Company issued and sold in an underwritten public offering (the &#8220;Preferred Offering&#8221;)
an aggregate of 4,148 shares of its Series 1 Convertible Preferred Stock at an offering price of $16,873.54 per share, for gross and
net proceeds of approximately $70.0 million and $66.3 million, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105508455856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>11. Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>2020 Inducement Plan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 26, 2020, the Compensation Committee
of the Board of Directors (the &#8220;Compensation Committee&#8221;) approved the ArTara Therapeutics, Inc. Inducement Plan (the &#8220;2020
Inducement Plan&#8221;) in order to award nonstatutory stock options, restricted stock awards, restricted stock unit awards and other
stock-based awards to persons not previously an employee or director of the Company, or following a bona fide period of non-employment,
as an inducement material to such persons entering into employment with the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2020 Inducement Plan provides for a total
of 600,000 shares for the issuance of the Company&#8217;s common stock. The Compensation Committee also adopted a form of stock option
grant notice and stock option agreement and forms of restricted stock unit grant notice and restricted stock unit agreement for use with
the Inducement Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, 446,639 shares remain
available to be issued under the 2020 Inducement Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>2017 Equity Incentive
Plan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2017, Private ArTara, (a predecessor
of the Company), its Board of Directors and its stockholders approved the ArTara Therapeutics, Inc. 2017 Equity Incentive Plan to enable
Private ArTara and its affiliates to recruit and retain highly qualified personnel and to incentivize personnel for productivity and
growth.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2017 Equity Incentive Plan provided for the
grant of a total of 2,000,000 shares for the issuance of stock options, stock appreciation rights, restricted stock and restricted stock
units to among others, members of the Board of Directors, employees, consultants and service providers to the Company and its affiliates.
As of January 9, 2020, in connection with the Merger, no additional awards will be made under the 2017 Equity Incentive Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>2014 Equity Incentive Plan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 3, 2014, the stockholders approved
the 2014 Equity Incentive Plan. On June 20, 2017, the Company&#8217;s Board of Directors amended the 2014 Equity Incentive Plan, or the
Amended and Restated 2014 Plan. On July 31, 2017, the stockholders approved this amendment. On January 1, 2020, Protara Therapeutics,
Inc. amended its Amended and Restated 2014 Equity Incentive Plan to increase the number of shares of stock available for issuance under
the 2014 Equity Incentive Plan to 1,048,300 shares and made conforming changes and updates pursuant to Section 162(m) of the Code.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Amended and Restated 2014 Plan provides for
the grant of incentive and non-statutory stock options, stock appreciation rights, restricted stock and stock unit awards, performance
units, stock grants and qualified performance-based awards. The Amended and Restated 2014 Plan provides that the number of shares reserved
and available for issuance will automatically increase each January 1, by four percent of the Company&#8217;s common stock on the immediately
preceding December 31, adjusted for the number of shares of the Company&#8217;s common stock issuable upon conversion of any security
that the Company may issue that is convertible into or exchangeable for the Company&#8217;s common stock, or such lesser number of shares
as determined by the Company&#8217;s Board of Directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Terms of the stock awards, including vesting
requirements, are determined by the Board of Directors, subject to the provisions of the plans. Certain awards provide for accelerated
vesting if there is a change in control as defined in the plans.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2022, pursuant to the Amended 2014
Plan&#8217;s annual evergreen feature, the number of shares authorized under the Amended 2014 Plan was increased by 840,181 shares to
1,238,785 shares. As of December 31, 2022, 603,218 shares remain available to be issued under the Amended 2014 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2023, pursuant to the Amended 2014
Plan&#8217;s annual evergreen feature, the number of shares authorized under the Amended 2014 Plan was increased by 861,933 shares to
1,465,151 shares available to be issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>2014 Employee Stock
Purchase Plan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 3, 2014, the stockholders approved
the 2014 Employee Stock Purchase Plan (the &#8220;2014 ESPP&#8221;). The 2014 ESPP initially authorized the issuance of up to 3,513 shares
of the Company&#8217;s common stock. The number of shares increases each January 1, commencing on January 1, 2015 and ending on (and
including) January 1, 2024, by an amount equal to the lesser of one percent of the outstanding shares as of the end of the immediately
preceding fiscal year, 7,025 shares or any lower amount determined by the Company&#8217;s Board of Directors prior to each such January
1st.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2022, pursuant to the increase
per the 2014 ESPP, the number of shares authorized under the 2014 ESPP was increased by 7,025 shares to 32,062 shares. As of December
31, 2022, the authorized number of shares under the 2014 ESPP is 32,062 and the number of shares available for issuance is 32,062. During
the years ended December 31, 2022 and 2021, no shares were issued under the 2014 ESPP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 1, 2023, pursuant to the increase
per the 2014 ESPP, the number of shares authorized under the 2014 ESPP was increased by 7,025 shares to 39,087 shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Restricted Stock Units</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes restricted stock unit activity:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restricted<br/> Stock Units</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average Grant<br/> Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Non-vested 12/31/2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">96,201</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">28.87</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,425</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,400</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.01</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,388</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21.67</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Non-vested 12/31/2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">196,838</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12.49</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of RSUs is amortized on a straight-line
basis over the requisite service period of the respective awards. As of December 31, 2022, the unamortized value of RSUs was $1,412.
As of December 31, 2022, the weighted average remaining amortization period was 1.53 years. As of December 31, 2022 and 2021, 289,500
and 286,918 RSUs, respectively, have vested that have not yet been settled into shares of the Company&#8217;s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2022, the Company issued 31,658
shares of the Company&#8217;s common stock from the net settlement of 48,806 RSUs. The Company paid $90 in connection with the net share
settlement of these RSUs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Stock Options</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determined the fair value of stock
options granted based upon the assumptions as provided below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">$ 2.77 - $ 6.90</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">$ 6.56 - $ 19.82</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 66%; text-align: left">Dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92.00% - 99.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89.00% - 98.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46% - 4.23</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.45% - 1.33</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.27 - 6.08</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.27 - 6.08</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes stock option activities
for the year ended December 31, 2022:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term&#160;(years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding 12/31/2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,356,639</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20.51</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.59</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(246,977</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(125,733</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">25.40</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,828,329</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">14.23</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">8.16</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Vested or expected to vest at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,828,329</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable as of December, 31 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">755,234</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18.71</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate&#160;intrinsic
value&#160;represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31,
2022. The&#160;intrinsic value&#160;of options exercised during the years ended December&#160;31, 2022 and 2021 was $0 as no options
were exercised.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average grant date fair value per
share of the options granted during the years ended December 31, 2022 and 2021 was $4.80 and $12.60, respectively. As of December 31,
2022, there was approximately $8,333 of unrecognized share-based compensation for unvested stock option grants which is expected to be
recognized over a weighted average period of 2.50 years. The total unrecognized share-based compensation cost will be adjusted for actual
forfeitures as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Summary of Stock-Based Compensation Expense</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following tables summarize total stock-based compensation costs
recognized:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">RSUs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,272</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,520</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,416</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,842</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,688</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,362</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock-based compensation expense was reflected within the consolidated
statements of operations and comprehensive loss as:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,511</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,409</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,953</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,688</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,362</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105509212048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Federal and State income tax expense is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Current</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in">Total current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Federal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,954</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(8,918</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,068</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,294</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in">Total deferred</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,022</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,624</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,624</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total income tax expense (benefit)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income taxes, if applicable, are provided
for the differences between the basis of assets and liabilities for financial reporting and income tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tax effects of temporary differences that
give rise to significant portions of the deferred tax assets are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net operating loss carry forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,768</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,350</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,418</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Stock option expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,477</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">920</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,710</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,551</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,481</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,564</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">RSU expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,199</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,960</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">408</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,461</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,352</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(38,983</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,803</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Deferred tax assets, net of valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,478</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,549</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Operating right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,456</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,549</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,478</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,549</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Deferred tax assets, net of valuation allowance and deferred tax liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the provision for income
taxes with the amounts computed by applying the statutory Federal income tax to income before provision for income taxes is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">U.S. federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.8</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">True-up to prior years return</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State rate change</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2021, the Company&#8217;s effective
tax rate was 0%, which consisted principally of a federal rate of 21%, and the Company&#8217;s estimate of state taxes, net of federal
benefit, of 0.6%, offset by a valuation allowance 12.9% and true-up to the prior year&#8217;s tax return of 8.2%. For the year ended December
31, 2022, the Company&#8217;s effective tax rate was 0%, which consisted principally of a federal rate of 21%, the Company&#8217;s estimate
of state taxes, net of federal benefit, of 2.2%, research and development credits of 3.3% and a true-up to the prior year&#8217;s tax
return of 0.7%, offset by goodwill impairment of 10.4% and a valuation allowance 17.0%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022 and 2021 for U.S. federal
and state income tax reporting purposes, the Company has approximately $114,800 and $100,200, respectively, of unused net operating losses
(&#8220;NOLs&#8221;) available for carry forward to future years. As a result of the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;),
for U.S. income tax purposes, NOLs generated in tax years beginning before January 1, 2018 can still be carried forward for up to 20 years,
but net operating losses generated for tax years beginning after December 31, 2017 carryforward indefinitely and can be used to offset
taxable income. Of the total Federal NOL, $600 can be carried forward until 2037; and $114,200 can be carried forward indefinitely. The
New York state and city NOLs may be carried forward through the year 2042 and may be applied against future taxable income. Further, the
benefit from utilization of NOL carry forwards could be subject to limitations due to material ownership changes that could occur as the
Company continues to issue additional shares of common stock pursuant to its capital raising plans. Based on such limitations, the Company
has significant NOLs for which realization of tax benefits is uncertain. The Company has not performed a study to determine whether or
not there is such a limitation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company remains subject to examination by
tax authorities for all tax years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on a history of cumulative losses at the Company and the results
of operations for the years ended December 31, 2022 and 2021, the Company determined that it is more likely than not that it will not
realize benefits from the net deferred tax assets. The Company will not record income tax benefits in the financial statements until it
is determined that it is more likely than not that the Company will generate sufficient taxable income to realize the deferred income
tax assets. As a result of the analysis, the Company determined that a full valuation allowance against the deferred tax assets, net,
was required. As of December 31, 2022 and 2021, the Company has recorded a valuation allowance of $39.0 million and $27.8 million, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022 and 2021, management
does not believe that the Company has any material uncertain tax positions that would require it to measure and reflect the potential
lack of sustainability of a position on audit in its consolidated financial statements. The Company will continue to evaluate its uncertain
tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does
not believe there will be any material changes in its unrecognized tax positions over the next year.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105504346592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Employee Benefit Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>13. Employee Benefit Plan</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains a defined contribution
benefit plan under section 401(k) of the Internal Revenue Code covering substantially all qualified employees of the Company (the &#8220;401(k)
Plan&#8221;). Under the 401(k) Plan, the Company matches 100% of employee contributions up to 4% of employee compensation. For the years
ended December 31, 2022 and 2021, the Company recorded expense of $223 and $215, respectively, representing employer contributions under
the 401(k) Plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105505405712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>14. Net Loss per Common Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the computation
of the net loss per share attributable to common stockholders, basic and diluted:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Net loss attributable to common stockholders</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">65,952</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">47,252</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-110; -sec-ix-hidden: hidden-fact-109">Weighted-average common shares outstanding &#8211; basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11,259,615</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11,232,576</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-112; -sec-ix-hidden: hidden-fact-111">Net loss per share attributable to common stockholders, basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5.86</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4.21</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the Company was in a net loss position
for all periods presented, net loss per share attributable to common stockholders was the same on a basic and diluted basis, as the inclusion
of all potential common equivalent shares outstanding would have been anti-dilutive. The Company excluded the following potential common
shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to
common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Stock options issued and outstanding</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,828,329</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,356,639</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted stock units issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">486,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">383,119</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Conversion of Series 1 Convertible Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,029,039</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,029,039</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total potentially dilutive shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,343,706</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,768,797</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105504615664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;
or &#8220;GAAP&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Principles of Consolidation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in the
accompanying consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses,
and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Significant items subject
to such estimates include but are not limited to income taxes, the valuation of deferred tax assets, recoverability of goodwill, and
contingencies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On an ongoing basis, the Company&#8217;s management
evaluates its estimates based on historical and anticipated results, trends, and various other assumptions believed to be reasonable.&#160;Actual
results could differ from those estimates. The results of any changes in accounting estimates are reflected in the financial statements
of the period in which the change becomes evident.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Reclassification</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in prior periods related to the classification of accrued
expenses and income taxes have been reclassified to conform to current period presentation. These reclassifications to adjust prior period
presentation had no impact on consolidated statements of operations and comprehensive loss or consolidated statements of cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Cash, Cash Equivalents
and Restricted Cash</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid instruments
with an original maturity of three months or less when acquired to be cash equivalents. Cash and cash equivalents are held in depository
and money market accounts and are reported at fair value. The Company&#8217;s restricted cash balances consist of cash deposits to collateralize
letter of credit obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides a reconciliation
of cash, cash equivalents, and restricted cash in the consolidated balance sheets to the total amount shown in the consolidated statements
of cash flows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,127</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">35,724</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Restricted cash, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">24,872</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">36,469</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Fair Value Measurements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 820 &#8220;Fair Value Measurements&#8221; provides the framework for measuring fair value and establishes a fair value hierarchy
that prioritizes the inputs used in pricing the asset or liability. The hierarchy gives the highest priority to unadjusted quoted prices
in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3
measurements).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value is defined as the exchange price,
or an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly
transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, the three-tier
fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 Quoted prices in
    active markets for identical assets or liabilities.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 Quoted prices for
    similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are
    not active, or other inputs that are observable, either directly or indirectly.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Wingdings; font-size: 10pt">&#216;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 Significant unobservable
    inputs that cannot be corroborated by market data.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of cash and cash equivalents,
prepaid expenses and accounts payable approximate their fair values due to the short-term nature of these instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_MarketableDebtSecuritiesPolicyTextBlock', window );">Marketable Debt Securities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Marketable Debt Securities</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies investments in marketable
debt securities with remaining maturities when purchased of greater than three months as available-for-sale. Investments with a remaining
maturity date greater than one year are classified as non-current.&#160;The cost of securities sold is based on the specific identification
method. Interest and dividends earned on securities are classified as available-for-sale are included in investment income.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records investments at fair value
with unrealized gains and losses recorded as a component of other comprehensive loss in the consolidated statements of operations and
comprehensive loss until realized. Realized gains and losses are reflected in interest and investment income in the consolidated statements
of operations and comprehensive loss and are determined using the specific identification method with transactions recorded on a settlement
date basis. Fair value is determined based on quoted market rates when observable or utilizing data points that are observable, such
as quoted prices, interest rates and yield curves. To determine whether an other-than-temporary impairment exists, the Company considers
whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability
of the cost of the investment outweighs evidence to the contrary. The Company has the ability to hold such securities with an unrealized
loss until its forecasted recovery. The Company determined that there was no material change in the credit risk of these investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Concentrations of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, which potentially subject
the Company to concentrations of credit risk, consists principally of cash, cash equivalents, restricted cash, and marketable debt securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company currently invests its excess cash
primarily in money market funds and high quality, investment grade marketable debt securities of corporations. The Company has adopted
an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Property and Equipment,
net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment, including leasehold improvements,
are recorded at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the
estimated useful life of the asset. Depreciation begins at the time the asset is placed in service. Leasehold improvements are amortized
using the straight-line method over the shorter of the lease term or estimated useful life of the asset.&#160;Repairs and maintenance
costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimated useful lives for significant property
and equipment categories are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Asset
    Classification</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
    Useful Life</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture,
    fixtures and other</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory
    equipment</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shorter of the useful life of asset or the lease term </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company enters into contracts in the normal
course of business and assesses whether any such contracts contain a lease. The Company determines if an arrangement is a lease at inception
if it conveys the right to control the identified asset for a period of time in exchange for consideration. Under ASC 842, lease expense
is recognized as a single lease cost on a straight-line basis over the lease term. The lease term consists of non-cancelable periods
and may include options to extend or terminate the lease term, when it is reasonably certain such options will be exercised.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leases classified as operating leases are included
in operating lease right-of-use (&#8220;ROU&#8221;) assets, current operating lease liabilities and noncurrent operating lease liabilities
in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations, in our consolidated
balance sheet. ROU assets represent the right to use an underlying asset for the lease term. Lease liabilities represent the present
value of future lease payments, net of lease incentives, discounted using an incremental borrowing rate, which is a management estimate
based on the information available at the commencement date of a lease arrangement. ROU assets and lease liabilities are recognized at
the lease commencement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has elected to account for the lease
and non-lease components for leases as a single component for classes of all underlying assets and allocate all the contract consideration
to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included
in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating
expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes costs associated with
lease arrangements having an initial term of 12 months or less (&#8220;short-term leases&#8221;) on a straight-line basis over the lease
term; such short-term leases are not recorded on the balance sheet.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Impairment of Long-Lived Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be recoverable or that
the useful life is shorter than originally estimated. When such events occur, the Company compares the carrying amounts of the asset
or asset group to the undiscounted expected future cash flows. If this comparison indicates that the asset or asset group is impaired,
the amount of impairment is measured as the difference between the carrying value and fair value of the asset or asset group. If the
useful life is shorter than originally estimated, the Company will amortize the remaining carrying value over the new shorter useful
life. To date, no such impairment loss has been recognized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Segment Information</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company identifies its operating segments
in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 280, Segment Reporting (&#8220;ASC 280&#8221;). Operating segments
are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief
operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#8217;s
chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes
of allocating resources. Accordingly, the Company has determined it operates and manages its business in a single reportable operating
segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Goodwill</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2020, in connection with the Merger,
the Company separately valued the assets and liabilities acquired, and then determined goodwill as the residual of the purchase price
less identified net assets, resulting in the initial recording of $29.5 million in goodwill.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill represents the excess of purchase price
over the fair value of identifiable net assets acquired in a business combination. Goodwill has an indefinite useful life. Goodwill is
assessed annually for impairment as of&#160;December 31, or more frequently if an event occurs or circumstances change that would indicate
that it is more likely than not that the fair value of a reporting unit or the fair value of an indefinite-lived intangible asset has
declined below its carrying value. In performing its annual goodwill impairment assessment, the Company has the option under GAAP to
qualitatively assess whether it is more likely than not that the fair value of a reporting unit is less than its carrying value; if the
conclusion of the qualitative assessment is that there are no indicators of impairment, the Company does not perform a quantitative assessment.
Otherwise, a quantitative assessment is performed and the fair value of the reporting unit is determined.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill is evaluated for impairment at the reporting
unit level, which is defined as an operating segment, or one level below an operating segment. The Company has determined that it operates
as one reporting unit and has selected December 31 as the date to perform its annual impairment test.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022 and 2021, the Company elected to forego the
qualitative screen and performed a quantitative annual goodwill impairment test for the reporting unit.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Company&#8217;s stock price and market
capitalization declined 60% from December 31, 2021, which reflects the overall decline of similar companies with less than $250 million
in market capitalizations, or microcap companies. The life sciences sector, which includes pre-commercialization and therefore net operating
loss generating companies, relies heavily on the capital markets to finance their operations and fund pre-clinical and clinical trials
for their existing development programs. As a result of a shift in risk appetite in the overall financial markets, the availability of
capital for life science sector companies decreased significantly in 2022. The challenging financing conditions had a negative impact
on stock prices and respective market capitalizations, particularly for microcap companies. The Company considered the heightened financing
risk that impacted the life sciences sector during 2022 to be one of the key macroeconomic factors that led to a sustained decrease in
the Company&#8217;s stock price and market capitalization leading up to its annual goodwill impairment assessment date in late 2022. Based
upon the results of our 2022 annual goodwill impairment test, the Company recorded a loss on impairment of goodwill of $29.5 million during
the year ended December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table provides a roll forward of the Company&#8217;s
goodwill and accumulated impairment losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Goodwill, gross amount as of December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,517</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Accumulated impairment loss, as of December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,517</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -8.15pt; padding-left: 17.15pt">Additions to goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -8.15pt; padding-left: 17.15pt">Loss on impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,517</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Goodwill as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based upon the results of our annual goodwill impairment test, no adjustments
to the carrying value of goodwill were necessary during the year ended December 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Research and Development</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses consist primarily
of third-party costs incurred to develop drug candidates, employee-related expenses, including salaries, benefits, travel and stock-based
compensation expense, depreciation and other allocated overhead costs, which include rent and maintenance of facilities and other supplies.
Research and development costs are expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before a compound receives regulatory approval,
the Company records upfront and milestone payments made to third parties under licensing arrangements as expense provided that there
is no alternative future use of the rights in other research and development projects.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nonrefundable advance payments to vendors for
goods or services that will be used or received in future research and development activities are deferred and recognized as expense
in the period in which the related goods are delivered or services are performed. Where milestone payments are due to third parties under
research and development collaboration arrangements or other contractual agreements, the milestone payment obligations are expensed when
the milestone conditions are met and the amount of payment is reasonably estimable.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once a compound receives regulatory approval,
the Company records any milestone payments in&#160;identifiable intangible assets, less accumulated amortization&#160;and, unless the
asset is determined to have an indefinite life, the Company amortizes the payments on a straight-line basis over the remaining agreement
term or the expected product life cycle, whichever is shorter.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain third-party costs are included as a component
of research and development expense. These expenses include fees paid to contract research organizations (&#8220;CROs&#8221;) and other
clinical trial costs, contractual services costs and costs for supply of its drug candidates. Depending upon the timing of payments to
the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses
are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved and experience with similar
contracts. The Company monitors each of these factors and adjusts estimates accordingly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Patent Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All patent-related costs incurred in connection
with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure.
Amounts incurred are classified as general and administrative expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Interest and Investment Income</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Interest and Investment Income</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investment income consists primarily of interest
income, accretion income earned and amortization expense incurred and realized gains or losses&#160;related to our marketable debt securities
and interest income related to cash, cash equivalents and restricted cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Stock-Based Compensation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s stock-based compensation
programs include stock options, restricted stock units (&#8220;RSUs&#8221;), and an employee stock purchase program (&#8220;ESPP&#8221;).
The Company accounts for stock-based compensation using the fair value method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures all stock options and other
stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense
of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes
forfeitures at the time forfeitures occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of each option is estimated on
the date of grant using the Black-Scholes option-pricing model. Expected volatility for the Company&#8217;s common stock is determined
based on an average of the historical volatility of the Company and the historical volatility of a peer-group of similar public companies.
The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual
term of the option and the weighted-average vesting period of the option. The assumed dividend yield is based upon the Company&#8217;s
expectation of not paying dividends in the foreseeable future. The risk-free interest rate is based upon the U.S. Treasury yield curve
commensurate with the expected term at the time of grant or remeasurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The stock-based compensation expense associated
with purchase rights under the ESPP is measured at fair-value using a Black-Scholes option-pricing model at commencement of each offering
period and recognized over that offering period. The Black-Scholes option pricing assumptions are similar to those used for stock options
with the exception of the expected term of purchase rights for the ESPP which is based on the duration of an offering period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair values of RSUs are based on the fair
market value of the Company&#8217;s common stock on the date of the grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The RSUs are granted to directors pursuant to
the Company&#8217;s equity plan. Settlement for the RSUs is deferred until the earliest to occur of (i) the director&#8217;s termination
of service, (ii) death, (iii) disability or (iv) a change in control of the Company. In the event of a change in control of the Company,
the RSUs will vest in full.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of all stock-based awards is recognized
as stock-based compensation expense on a straight-line basis over the vesting period, which is typically one to four years for RSUs and
four years for stock options.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies stock-based compensation
expense in its statement of operations and comprehensive loss in the same way the payroll costs or service payments are classified for
the related stock-based award recipients.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Income Taxes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax assets and liabilities are recognized
for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets
and liabilities and their respective tax basis, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are
measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.
The measurement of net deferred tax assets is reduced by the amount of any tax benefit that, based on available evidence, is not expected
to be realized, and a corresponding valuation allowance is established. In making such a determination, the Company considers all available
positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,
tax-planning strategies, and results of recent operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tax benefits are recognized only for tax positions
that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount
of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for unrecognized tax benefits is recorded
for any tax benefits claimed in the Company&#8217;s tax returns that do not meet these recognition and measurement standards. The Company&#8217;s
policy is to record interest and penalties on uncertain tax positions as a component of income tax expense in the consolidated statement
of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Net Loss Per Share Attributable to Common
Stockholders</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per share is computed by dividing
the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period.
Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares
of common stock outstanding during the period plus the common equivalent shares for the period including any dilutive effect from unvested
restricted common stock, outstanding stock options and potential shares issuable under the ESPP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Recently Adopted Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2018, the Financial Accounting Standards
Board, or the FASB, issued ASU&#160;No.&#160;2018-15,&#160;<i>Intangibles &#8211; Goodwill and Other &#8211;&#160;Internal-Use&#160;Software
(Subtopic&#160;350-40):&#160;Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a
Service Contract</i>&#160;(&#8220;ASU&#160;2018-15&#8221;).&#160;This ASU is designed to reduce complexity for accounting for costs of
implementing a cloud computing service arrangement. This standard aligns the accounting for implementation costs of hosting arrangements,
regardless of whether they convey a license to the hosted software. The standard became effective for the first interim period within
annual reporting periods beginning after December&#160;15, 2020. On January 1, 2021, the Company adopted ASU 2018-15. The adoption of
this standard did not have a material effect on the Company&#8217;s financial position, results of operations, or cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12,
<i>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes </i>(&#8220;ASU 2019-12&#8221;). The amendments in ASU 2019-12
remove certain exceptions to the general principles in Topic 740. The amendments also clarify and amend existing guidance to improve
consistent application. The amendments became effective for annual reporting periods beginning after December 15, 2020. On January 1,
2021, the Company adopted ASU 2019-12. The adoption of this standard did not have a material effect on the Company&#8217;s financial
position, results of operations, or cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_RecentAccountingPronouncementsNotYetAdopted', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Recent Accounting Pronouncements
Not Yet Adopted</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the Financial Accounting Standards
Board, or the FASB issued ASU 2016-13, <i>Measurement of Credit Losses on Financial Statements</i>. The new standard requires that expected
credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through
an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to
the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value
increases. In November 2019, the FASB issued ASU 2019-10, <i>Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and
Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the effective date for certain companies. The standard
is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December
15, 2022. Early adoption is available. The Company has evaluated the impact of the adoption of ASU 2016-13, and related updates, and
has determined that the impact will not be material to its consolidated financial statements and disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated other recently issued
accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material
impact on the Company&#8217;s financial position or results of operations upon adoption.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><b><i>Subsequent Events</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the financial statements were available to be issued. Other than as described
in Note 11 and, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial
statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_MarketableDebtSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable Debt Securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_MarketableDebtSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent Costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_RecentAccountingPronouncementsNotYetAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_RecentAccountingPronouncementsNotYetAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105501915600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of cash, cash equivalents, and restricted cash</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,127</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">35,724</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Restricted cash, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">745</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">24,872</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">36,469</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock', window );">Schedule of estimated useful lives for significant property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Asset
    Classification</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
    Useful Life</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    equipment</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture,
    fixtures and other</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory
    equipment</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shorter of the useful life of asset or the lease term </span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock', window );">Schedule of goodwill and accumulated impairment losses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Goodwill, gross amount as of December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,517</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Accumulated impairment loss, as of December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,517</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -8.15pt; padding-left: 17.15pt">Additions to goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -8.15pt; padding-left: 17.15pt">Loss on impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,517</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Goodwill as of December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105505346752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of financial assets and liabilities that are measured and carried at fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash Equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds<sup>(a)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,284</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,284</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate bonds<sup>(a)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,523</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,523</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted cash, non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds<sup>(b)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">745</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate bonds<sup>(c)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78,129</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78,129</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,029</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">80,652</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">94,681</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash Equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds<sup>(a)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,323</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,323</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted cash, non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds<sup>(b)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">745</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate bonds<sup>(c)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">94,972</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">94,972</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,068</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">94,972</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">122,040</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0in">&#160;</td> <td style="width: 0.25in; padding-right: 0pt; padding-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds and corporate debt securities with original maturities of 90 days or less are included within Cash and cash equivalents in the Consolidated Balance Sheets.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="padding-right: 0pt; padding-left: 0pt; text-align: justify">&#160;</td> <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="padding-right: 0pt; padding-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td> <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Money market funds are included within Restricted Cash, non-current in the Consolidated Balance Sheets.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="padding-right: 0pt; padding-left: 0pt; text-align: justify">&#160;</td> <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="padding-right: 0pt; padding-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td> <td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate debt securities with original maturities greater than 90 days are included within Marketable securities in the Consolidated Balance Sheets and classified as current or noncurrent based upon whether the maturity of the financial asset is less than or greater than 12 months.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105509934368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_MarketableDebtSecuritiesAbstract', window );"><strong>Marketable Debt Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of marketable debt securities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortized<br/> Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unrealized<br/> Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unrealized<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Estimated<br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Corporate bonds - presented in marketable debt securities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">60,790</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(547</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">60,243</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Corporate bonds - presented in marketable debt securities, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,027</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(141</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,886</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">78,817</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(688</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">78,129</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortized<br/> Cost</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Gains</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unrealized<br/> Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated<br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Corporate bonds - presented in marketable debt securities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55,548</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(43</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55,505</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Corporate bonds - presented in marketable debt securities, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,635</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(168</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,467</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">95,183</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(211</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">94,972</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.05pt">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock', window );">Schedule of interest and investment income</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,230</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,974</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accretion/(amortization) of discount/premium, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,137</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,737</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Realized gain/(loss)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total interest and investment income</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,110</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">237</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_MarketableDebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_MarketableDebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105509379936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid insurance</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">288</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">279</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">569</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">684</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued interest on marketable debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">486</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">634</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">173</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">127</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,776</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,883</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105509367984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Computer equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">205</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">175</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Furniture, fixtures and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">352</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">352</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">591</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">553</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Property and equipment not yet placed into service</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">99</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">613</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,955</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(483</td><td style="padding-bottom: 1.5px; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(236</td><td style="padding-bottom: 1.5px; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Total property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,592</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,719</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><b>&#160;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105509269808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employee Costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,543</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,801</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">512</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">437</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">182</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">251</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,237</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,489</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105504740176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><b>Lease expense</b></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Operating lease expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,366</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,050</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Short-term lease expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">102</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,369</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,152</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock', window );">Schedule of weighted average remaining lease term and the weighted average discount rate for operating leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Weighted-average discount rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Weighted-average remaining lease term &#8211; operating lease (in months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock', window );">Schedule of operating lease payments included in the measurement of lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">For the year ending December 31:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Lease Payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,327</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,327</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,395</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">1,429</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">805</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total future operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,712</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,328</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Present value of future minimum lease payments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,384</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105505561712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of restricted stock unit activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restricted<br/> Stock Units</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> Average Grant<br/> Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Non-vested 12/31/2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">96,201</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">28.87</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178,425</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,400</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.01</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,388</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21.67</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Non-vested 12/31/2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">196,838</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12.49</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of the fair value of stock options granted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">$ 2.77 - $ 6.90</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">$ 6.56 - $ 19.82</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 66%; text-align: left">Dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">0.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92.00% - 99.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89.00% - 98.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46% - 4.23</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.45% - 1.33</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.27 - 6.08</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.27 - 6.08</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term&#160;(years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value (1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding 12/31/2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,356,639</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">20.51</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.59</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(246,977</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(125,733</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">25.40</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,828,329</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">14.23</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">8.16</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Vested or expected to vest at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,828,329</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable as of December, 31 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">755,234</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18.71</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate&#160;intrinsic
value&#160;represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31,
2022. The&#160;intrinsic value&#160;of options exercised during the years ended December&#160;31, 2022 and 2021 was $0 as no options
were exercised.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock', window );">Schedule of total stock-based compensation costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">RSUs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,272</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,520</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,416</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,842</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,688</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,362</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,511</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,409</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,953</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,688</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,362</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105508558816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of federal and state income tax expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Current</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in">Total current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Federal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,954</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(8,918</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,068</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,294</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in">Total deferred</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,022</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,624</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,624</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total income tax expense (benefit)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net operating loss carry forwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,768</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,350</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,418</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Stock option expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,477</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">920</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,710</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,551</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,481</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,564</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">RSU expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,199</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,960</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">408</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,461</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,352</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(38,983</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,803</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Deferred tax assets, net of valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,478</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,549</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Operating right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,456</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,549</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,478</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,549</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Deferred tax assets, net of valuation allowance and deferred tax liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of federal income tax to income before provision for income taxes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">U.S. federal statutory rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.8</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">True-up to prior years return</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State rate change</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Effective tax rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105509383984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Net loss attributable to common stockholders</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">65,952</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">47,252</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-110; -sec-ix-hidden: hidden-fact-109">Weighted-average common shares outstanding &#8211; basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11,259,615</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11,232,576</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt"><div style="-sec-ix-hidden: hidden-fact-112; -sec-ix-hidden: hidden-fact-111">Net loss per share attributable to common stockholders, basic and diluted</div></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5.86</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4.21</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock', window );">Schedule of weighted average dilutive common shares</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Stock options issued and outstanding</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,828,329</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,356,639</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Restricted stock units issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">486,338</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">383,119</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Conversion of Series 1 Convertible Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,029,039</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,029,039</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total potentially dilutive shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">10,343,706</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,768,797</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of weighted average dilutive common share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105500020464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 09, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_OperatingSegmentDescription', window );">Operating segment description</a></td>
<td class="text">the Company has determined it operates and manages its business in a single reportable operating
segment<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 29,517<span></span>
</td>
<td class="nump">$ 29,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_MarketCapitalizationsPercentageChange', window );">Market capitalizations percentage change</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_MicrocapCompaniesMarketCapitalization', window );">Market capitalization of microcap companies</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">$ 29,517<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockOptionPeriod', window );">Stock option period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_PercentageOfLargestAmountOfBenefit', window );">Percentage of largest amount of benefit</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_GoodwillMember', window );">Goodwill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 29,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">$ 29,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_VestingPeriod', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_VestingPeriod', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_MarketCapitalizationsPercentageChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market capitalizations percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_MarketCapitalizationsPercentageChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_MicrocapCompaniesMarketCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of microcap companies market capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_MicrocapCompaniesMarketCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_OperatingSegmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_OperatingSegmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_PercentageOfLargestAmountOfBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of largest amount of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_PercentageOfLargestAmountOfBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_StockOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_StockOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_VestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_VestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105509967872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents, and restricted cash - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Schedule Of Cash Cash Equivalents And Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 24,127<span></span>
</td>
<td class="nump">$ 35,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="nump">$ 24,872<span></span>
</td>
<td class="nump">$ 36,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105500008704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, Fixtures and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tara_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm', window );">Shorter of the useful life of asset or the lease term</a></td>
<td class="text">Shorter of the useful life of asset or the lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shorter of the useful life of asset or the lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tara_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tara_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105504627600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of goodwill and accumulated impairment losses - Goodwill [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of goodwill and accumulated impairment losses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross amount as of December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment loss, as of December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill at beginning</a></td>
<td class="nump">$ 29,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions to goodwill</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Loss on impairment</a></td>
<td class="num">(29,517)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill at ending</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 29,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105505355984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="nump">$ 29,517<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105500344560">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - Schedule of financial assets and liabilities that are measured and carried at fair value - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_CashEquivalentsAbstract', window );"><strong>Cash Equivalents</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 13,284<span></span>
</td>
<td class="nump">$ 26,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Corporate bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_RestrictedCashNonCurrentAbstract', window );"><strong>Restricted cash, non-current</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">745<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_MarketableDebtSecuritiesAbstract0', window );"><strong>Marketable debt securities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Corporate bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">78,129<span></span>
</td>
<td class="nump">94,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">94,681<span></span>
</td>
<td class="nump">122,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_CashEquivalentsAbstract', window );"><strong>Cash Equivalents</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">13,284<span></span>
</td>
<td class="nump">26,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Corporate bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_RestrictedCashNonCurrentAbstract', window );"><strong>Restricted cash, non-current</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">745<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_MarketableDebtSecuritiesAbstract0', window );"><strong>Marketable debt securities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Corporate bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,029<span></span>
</td>
<td class="nump">27,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_CashEquivalentsAbstract', window );"><strong>Cash Equivalents</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Corporate bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_RestrictedCashNonCurrentAbstract', window );"><strong>Restricted cash, non-current</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_MarketableDebtSecuritiesAbstract0', window );"><strong>Marketable debt securities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Corporate bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">78,129<span></span>
</td>
<td class="nump">94,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80,652<span></span>
</td>
<td class="nump">94,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_CashEquivalentsAbstract', window );"><strong>Cash Equivalents</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Corporate bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_RestrictedCashNonCurrentAbstract', window );"><strong>Restricted cash, non-current</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_MarketableDebtSecuritiesAbstract0', window );"><strong>Marketable debt securities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Corporate bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds and corporate debt securities with original maturities of 90 days or less are included within Cash and cash equivalents in the Consolidated Balance Sheets.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Money market funds are included within Restricted Cash, non-current in the Consolidated Balance Sheets.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate debt securities with original maturities greater than 90 days are included within Marketable securities in the Consolidated Balance Sheets and classified as current or noncurrent based upon whether the maturity of the financial asset is less than or greater than 12 months.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_CashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_CashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_MarketableDebtSecuritiesAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_MarketableDebtSecuritiesAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_RestrictedCashNonCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_RestrictedCashNonCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105505375120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Debt Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_MarketableDebtSecuritiesAbstract', window );"><strong>Marketable Debt Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Investment income</a></td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_UnrealizedLosses', window );">Unrealized loss</a></td>
<td class="nump">$ 358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_MarketableDebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_MarketableDebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_UnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized Losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_UnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105500552704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Debt Securities (Details) - Schedule of marketable debt securities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 78,817<span></span>
</td>
<td class="nump">$ 95,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_UnrealizedGains', window );">Unrealized Gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_UnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="num">(688)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_EstimatedFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">78,129<span></span>
</td>
<td class="nump">94,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds - presented in marketable debt securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">60,790<span></span>
</td>
<td class="nump">55,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_UnrealizedGains', window );">Unrealized Gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_UnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="num">(547)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_EstimatedFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">60,243<span></span>
</td>
<td class="nump">55,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AllOtherCorporateBondsMember', window );">Corporate bonds - presented in marketable debt securities, non-current [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">18,027<span></span>
</td>
<td class="nump">39,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_UnrealizedGains', window );">Unrealized Gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_UnrealizedLoss', window );">Unrealized Losses</a></td>
<td class="num">(141)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_EstimatedFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">$ 17,886<span></span>
</td>
<td class="nump">$ 39,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_EstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_EstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_UnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_UnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_UnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_UnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AllOtherCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AllOtherCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105500172240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Debt Securities (Details) - Schedule of interest and investment income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfInterestAndInvestmentIncomeAbstract', window );"><strong>Schedule Of Interest And Investment Income Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">$ 2,230<span></span>
</td>
<td class="nump">$ 1,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Accretion/(amortization) of discount/premium, net</a></td>
<td class="num">(1,137)<span></span>
</td>
<td class="num">(1,737)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized gain/(loss)</a></td>
<td class="nump">17<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Total interest and investment income</a></td>
<td class="nump">$ 1,110<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfInterestAndInvestmentIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfInterestAndInvestmentIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105506968176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Schedule of prepaid expenses and other current assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Prepaid research and development</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_PrepaidSoftware', window );">Prepaid software</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_AccruedInterestOnMarketableDebtSecurities', window );">Accrued interest on marketable debt securities</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 1,776<span></span>
</td>
<td class="nump">$ 1,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_AccruedInterestOnMarketableDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest on marketable debt securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_AccruedInterestOnMarketableDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_PrepaidSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_PrepaidSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105504668848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_PropertyandEquipmentnetDetailsLineItems', window );"><strong>Property and Equipment, net (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_TotalPropertyAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_PropertyandEquipmentnetDetailsLineItems', window );"><strong>Property and Equipment, net (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_PropertyandEquipmentnetDetailsLineItems', window );"><strong>Property and Equipment, net (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_PropertyandEquipmentnetDetailsLineItems', window );"><strong>Property and Equipment, net (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_PropertyandEquipmentnetDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_PropertyandEquipmentnetDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_TotalPropertyAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage is total property and equipment, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_TotalPropertyAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105499893296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net (Details) - Schedule of property and equipment, net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 2,075<span></span>
</td>
<td class="nump">$ 1,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(483)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">1,592<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tara_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">866<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember', window );">Property and equipment not yet placed into service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tara_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tara_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105500141456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Details) - Schedule of accrued expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfAccruedExpensesAbstract', window );"><strong>Schedule Of Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_AccruedEmployeeRelatedCurrent', window );">Employee Costs</a></td>
<td class="nump">$ 2,543<span></span>
</td>
<td class="nump">$ 1,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_AccruedResearchAndDevelopmentCurrent', window );">Research and development costs</a></td>
<td class="nump">512<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Total</a></td>
<td class="nump">$ 3,237<span></span>
</td>
<td class="nump">$ 2,489<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_AccruedEmployeeRelatedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued employee related current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_AccruedEmployeeRelatedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued research and development current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfAccruedExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfAccruedExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105506871600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company entered into an
agreement to lease approximately 10.3 square feet of office space in New York, New York (&#8220;Office Lease&#8221;), which commenced
in April 2021. Annual rent is approximately $1,117.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_RestrictedCashNoncurrents', window );">Restricted cash</a></td>
<td class="nump">$ 745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilities', window );">Operating leases</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use asset obtained in exchange for operating lease liabilities</a></td>
<td class="nump">$ 6,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_RestrictedCashNoncurrents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted cash, non-current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_RestrictedCashNoncurrents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities that result from activities that generate operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105501887264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of lease expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfLeaseExpenseAbstract', window );"><strong>Schedule Of Lease Expense Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 1,366<span></span>
</td>
<td class="nump">$ 1,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">$ 1,369<span></span>
</td>
<td class="nump">$ 1,152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfLeaseExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfLeaseExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105500201408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of weighted average remaining lease term and the weighted average discount rate for operating leases<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract', window );"><strong>Schedule Of Weighted Average Remaining Lease Term And The Weighted Average Discount Rate For Operating Leases Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term &#8211; operating lease (in months)</a></td>
<td class="text">67 months<span></span>
</td>
<td class="text">79 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105505501008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of operating lease payments included in the measurement of lease liabilities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Schedule Of Operating Lease Payments Included In The Measurement Of Lease Liabilities Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">1,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">1,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_OperatingLeasesFutureMinimumPaymentDue', window );">Total future operating lease payments</a></td>
<td class="nump">7,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_PresentValueOfFutureMinimumLeasePayments', window );">Present value of future minimum lease payments</a></td>
<td class="nump">$ 6,384<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_OperatingLeasesFutureMinimumPaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Future Minimum Payments Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_OperatingLeasesFutureMinimumPaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_PresentValueOfFutureMinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of future minimum lease payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_PresentValueOfFutureMinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105500207328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 28, 2018</div></th>
<th class="th"><div>Dec. 22, 2017</div></th>
<th class="th"><div>Sep. 27, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_DescriptionOfAgreements', window );">Description of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company entered into
an agreement (the &#8220;Feinstein Agreement&#8221;) with The Feinstein Institute for Medical Research (the &#8220;Feinstein Institute&#8221;),
a not-for-profit corporation with 50 research labs and 2,500 clinical research studies. Pursuant to the Feinstein Agreement, the Company
acquired an exclusive license relating to treatment of fatty liver diseases in humans for which Choline may be an effective therapeutic.
In consideration for the rights and license granted, the Feinstein Institute would receive a royalty of one percent (1%) of the first
one hundred million dollars ($100,000) of net sales of IV Choline Chloride and a royalty of one and one-half percent (1.5%) of all net
sales thereafter. In addition, the Company would pay the Feinstein Institute twelve and one-half percent (12.5%) of net proceeds resulting
from agreements entered within 2 years from the effective date, and seven and one-half percent (7.5%) of net proceeds resulting from
agreements entered into thereafter. Pursuant to the Feinstein Agreement additional payments would be due to the Feinstein Institute for
license maintenance payments and for meeting milestone events. Pursuant to the Feinstein Agreement, upon the achievement of certain future
new drug application milestones, the Company would be obligated to remit an aggregate of $275.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tara_CholineLicenseAgreementMember', window );">Choline License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_DescriptionOfAgreements', window );">Description of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company entered into
a license agreement (the &#8220;Choline License Agreement&#8221;) with Alan L. Buchman (&#8220;Dr. Buchman&#8221;). Pursuant to the Choline
License Agreement, the Company received from Dr. Buchman the license rights in and to the &#8220;Licensed Orphan Designations&#8221;,
the &#8220;Licensed IND&#8221;, &#8220;Existing Study Data&#8221; and the &#8220;Licensed Know-How&#8221; for one or more of the licensed
indications.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tara_IowaAgreementMember', window );">Lowa Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ResearchAndDevelopmentExpenses', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tara_FeinsteinAgreementMember', window );">Feinstein Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ResearchAndDevelopmentExpenses', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Sponsored Research and License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BroadcastersLicenseAgreementCommitmentsDescription', window );">Description of sponsored research and license agreement</a></td>
<td class="text">the Company entered into a sponsored research
and license agreement (the &#8220;Iowa Agreement&#8221;) with the University of Iowa. Pursuant to the Iowa Agreement, the University of
Iowa, which is engaged in clinical research to improve the diagnosis and treatment of lymphangioma using a pharmaceutical product (OK-432),
would assist the Company in collecting case reports, forms, source data, and safety data available to the University of Iowa in support
of the development of the Company&#8217;s proprietary Streptococcus Pyogenes investigational product, TARA-002 for the LMs indication.
During the term of the services, the Company would generally pay the University of Iowa thirty thousand dollars ($30) per year to fund
the project, plus additional amounts upon the realization of certain milestones. More specifically, upon forty-five (45) days of an approval
of TARA-002 by the FDA, the Company would pay up to $1,750 to the University of Iowa for meeting these milestones. Furthermore, the Company
would pay the University of Iowa royalties of up to 1.75% for net sales ranging from $0 - $25,000, 2.25% for net sales ranging from $25,000
to $50,000, and 2.50% for net sales in excess of $50,000. Pursuant to the Iowa Agreement, the University of Iowa would be entitled to
additional payments for the Company achieving annual net sales of product according to the milestones. For annual net sales of product
up to $25,000: $62; for annual net sales of product of up to $50,000: $62; and for annual net sales of product of up to $100,000: $125.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_DescriptionOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_DescriptionOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BroadcastersLicenseAgreementCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the commitments for license agreements that have been executed but were not reported because they do not meet the conditions for recording a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472701&amp;loc=d3e49107-107924<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BroadcastersLicenseAgreementCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tara_CholineLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tara_CholineLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tara_IowaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tara_IowaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tara_FeinsteinAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=tara_FeinsteinAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105501017168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 06, 2020</div></th>
<th class="th"><div>Sep. 24, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 22, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares of par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,267,389<span></span>
</td>
<td class="nump">11,235,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,267,389<span></span>
</td>
<td class="nump">11,235,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares of par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_CommonStockIssuanceAndOutstandingPercentage', window );">Common stock issuance and outstanding, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tara_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_AggregateOfSharesOfCommonStock', window );">Aggregate of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_NetProceeds', window );">Net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_NetProceeds', window );">Net proceeds (in Dollars)</a></td>
<td class="nump">$ 11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted option to purchase</a></td>
<td class="nump">690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_GrossProceeds', window );">Gross proceeds (in Dollars)</a></td>
<td class="nump">$ 11.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares of par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,267,389<span></span>
</td>
<td class="nump">11,235,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,267,389<span></span>
</td>
<td class="nump">11,235,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tara_SeriesOneConvertiblePreferredStockMember', window );">Series 1 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_IncreaseOrDecreaseEquityPercentage', window );">Convertible preferred stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tara_SeriesOneConvertiblePreferredStockMember', window );">Series 1 Convertible Preferred Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tara_SeriesOneConvertiblePreferredStockMember', window );">Series 1 Convertible Preferred Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tara_SeriesOneConvertiblePreferredStockMember', window );">Series 1 Convertible Preferred Stock [Member] | Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_AggregateOfSharesOfCommonStock', window );">Aggregate of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,873.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_NetProceeds', window );">Net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_GrossProceeds', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_AggregateOfSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate of shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_AggregateOfSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_CommonStockIssuanceAndOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issuance and outstanding percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_CommonStockIssuanceAndOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_IncreaseOrDecreaseEquityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_IncreaseOrDecreaseEquityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_NetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_NetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_StockholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_StockholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tara_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tara_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tara_SeriesOneConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tara_SeriesOneConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105499740656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Oct. 03, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StocksIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SharesAvailableForIssuance', window );">Shares available for issuance</a></td>
<td class="nump">32,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">11,267,389<span></span>
</td>
<td class="nump">11,235,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares</a></td>
<td class="nump">11,267,389<span></span>
</td>
<td class="nump">11,235,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value options exercised (in Dollars)</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 12.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ShareBasedCompensationUnrecognized', window );">Unrecognized share-based compensation (in Dollars)</a></td>
<td class="nump">$ 8,333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1', window );">Weighted average period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares</a></td>
<td class="nump">48,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tara_TwentyTwentyInducementPlanMember', window );">2020 Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SharesAvailableForIssuance', window );">Shares available for issuance</a></td>
<td class="nump">446,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tara_TwentySeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SharesAvailableForIssuance', window );">Shares available for issuance</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tara_TwentyFourteenEquityIncentivePlanMember', window );">Twenty Fourteen Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SharesAvailableForIssuance', window );">Shares available for issuance</a></td>
<td class="nump">603,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,048,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tara_TwoThousandFourteenEmployeeStockPurchasePlanMember', window );">2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_NumberSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="nump">32,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Twenty Fourteen Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | 2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_NumberOfShareAuthorizedIncreased', window );">Number of share authorized increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Twenty Fourteen Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SharesAvailableForIssuance', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_NumberOfShareAuthorizedIncreased', window );">Number of share authorized increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Minimum [Member] | Twenty Fourteen Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">861,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Maximum [Member] | Twenty Fourteen Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SharesAvailableForIssuance', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,465,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_UnamortizedValueOfRsus', window );">Unamortized value of RSUs (in Dollars)</a></td>
<td class="nump">$ 1,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_WeightedAverageRemainingAmortizationPeriod', window );">Weighted average remaining amortization period</a></td>
<td class="text">1 year 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_NumberOfSharesRestrictedStock', window );">Number of RSUs</a></td>
<td class="nump">289,500<span></span>
</td>
<td class="nump">286,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">31,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ConnectionWithTheNetShareSettlement', window );">Net share settlement (in Dollars)</a></td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=tara_BoardOfDirectorsMember', window );">Board of Directors [Member] | Minimum [Member] | 2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsLineItems', window );"><strong>Stock-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ConnectionWithTheNetShareSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ConnectionWithTheNetShareSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_NumberOfShareAuthorizedIncreased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share authorized increased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_NumberOfShareAuthorizedIncreased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_NumberOfSharesRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_NumberOfSharesRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_NumberSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_NumberSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ShareBasedCompensationUnrecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Unrecognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ShareBasedCompensationUnrecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_SharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_SharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_StockBasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_StockBasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_StocksIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_StocksIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_UnamortizedValueOfRsus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_UnamortizedValueOfRsus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_WeightedAverageRemainingAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_WeightedAverageRemainingAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average period until annuitization or benefit payment is expected to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124504833&amp;loc=d3e7104-158389<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tara_TwentyTwentyInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tara_TwentyTwentyInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tara_TwentySeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tara_TwentySeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tara_TwentyFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tara_TwentyFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tara_TwoThousandFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tara_TwoThousandFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=tara_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=tara_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105506942832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of restricted stock unit activity - Restricted stock unit [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2014 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of restricted stock unit activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Restricted Stock Units, Balance at beginning | shares</a></td>
<td class="nump">96,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Balance at beginning | $ / shares</a></td>
<td class="nump">$ 28.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Restricted Stock Units, Granted | shares</a></td>
<td class="nump">178,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">$ 6.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Restricted Stock Units, Forfeited | shares</a></td>
<td class="num">(26,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">$ 11.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted Stock Units, Vested | shares</a></td>
<td class="num">(51,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">$ 21.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Restricted Stock Units, Balance at ending | shares</a></td>
<td class="nump">196,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Balance at ending | $ / shares</a></td>
<td class="nump">$ 12.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105500307792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 2.77<span></span>
</td>
<td class="nump">$ 6.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.46%<span></span>
</td>
<td class="nump">0.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 6.9<span></span>
</td>
<td class="nump">$ 19.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.23%<span></span>
</td>
<td class="nump">1.33%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105499720192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of stock option activities - Equity Option [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of stock option activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Balance at beginning | shares</a></td>
<td class="nump">1,356,639<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Balance at beginning | $ / shares</a></td>
<td class="nump">$ 20.51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2', window );">Weighted Average Remaining Contractual Term (years), Balance at beginning</a></td>
<td class="text">8 years 7 months 2 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Balance at beginning | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, ending | shares</a></td>
<td class="nump">1,828,329<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, ending | $ / shares</a></td>
<td class="nump">$ 14.23<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm', window );">Weighted Average Remaining Contractual Term (years), ending</a></td>
<td class="text">8 years 1 month 28 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate Intrinsic Value, ending | $</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested or expected to vest | shares</a></td>
<td class="nump">1,828,329<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested or expected to vest | $ / shares</a></td>
<td class="nump">$ 14.23<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (years), Vested or expected to vest</a></td>
<td class="text">8 years 1 month 28 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested or expected to vest | $</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable | shares</a></td>
<td class="nump">755,234<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable', window );">Weighted Average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 18.71<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable', window );">Weighted Average Remaining Contractual Term (years), Exercisable</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted | shares</a></td>
<td class="nump">844,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 6.13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted', window );">Weighted Average Remaining Contractual Term (years), Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Granted | $</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod', window );">Number of Options, Exercised | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised', window );">Weighted Average Remaining Contractual Term (years), Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised | $</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited | shares</a></td>
<td class="num">(246,977)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="nump">$ 15.35<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares', window );">Weighted Average Remaining Contractual Term (years), Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Forfeited | $</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options, Expired | shares</a></td>
<td class="num">(125,733)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired | $ / shares</a></td>
<td class="nump">$ 25.4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired', window );">Weighted Average Remaining Contractual Term (years), Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Expired | $</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate&#160;intrinsic
value&#160;represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31,
2022. The&#160;intrinsic value&#160;of options exercised during the years ended December&#160;31, 2022 and 2021 was $0 as no options
were exercised.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were exercised during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and expired price on options expired (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and forfeited price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of granted and granted price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercised stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of Expired stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of forfeited stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of granded stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105500180768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 6,688<span></span>
</td>
<td class="nump">$ 10,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="nump">4,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems', window );"><strong>Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 5,416<span></span>
</td>
<td class="nump">$ 5,842<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105500137520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 6,688<span></span>
</td>
<td class="nump">$ 10,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">1,511<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation</a></td>
<td class="nump">$ 5,177<span></span>
</td>
<td class="nump">$ 8,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105506772208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_EffectiveTaxRateDescription', window );">Effective tax rate description</a></td>
<td class="text">For the year ended December
31, 2022, the Company&#8217;s effective tax rate was 0%, which consisted principally of a federal rate of 21%, the Company&#8217;s estimate
of state taxes, net of federal benefit, of 2.2%, research and development credits of 3.3% and a true-up to the prior year&#8217;s tax
return of 0.7%, offset by goodwill impairment of 10.4% and a valuation allowance 17.0%.<span></span>
</td>
<td class="text">For the year ended December 31, 2021, the Company&#8217;s effective
tax rate was 0%, which consisted principally of a federal rate of 21%, and the Company&#8217;s estimate of state taxes, net of federal
benefit, of 0.6%, offset by a valuation allowance 12.9% and true-up to the prior year&#8217;s tax return of 8.2%.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_IncomeTaxCarriedForwardTerms', window );">Carried forward tax year</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards', window );">Carried forward tax</a></td>
<td class="nump">$ 114,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">38,983<span></span>
</td>
<td class="nump">$ 27,803<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=tara_FederalNOLMember', window );">Federal NOL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards', window );">Carried forward tax</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=tara_USFederalMember', window );">U.S. federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating losses</a></td>
<td class="nump">$ 114,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=tara_StateIncomeTaxMember', window );">State income tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_EffectiveTaxRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_EffectiveTaxRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_IncomeTaxCarriedForwardTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax carried forward terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_IncomeTaxCarriedForwardTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherTaxCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=tara_FederalNOLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=tara_FederalNOLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=tara_USFederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=tara_USFederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=tara_StateIncomeTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=tara_StateIncomeTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105499959296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of federal and state income tax expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_CurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_DeferredAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(7,954)<span></span>
</td>
<td class="num">(8,918)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1,068)<span></span>
</td>
<td class="nump">4,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(9,022)<span></span>
</td>
<td class="num">(4,624)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">9,022<span></span>
</td>
<td class="nump">4,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_CurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_CurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_DeferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_DeferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105506772704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 26,768<span></span>
</td>
<td class="nump">$ 23,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Capitalized research and development</a></td>
<td class="nump">3,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock option expense</a></td>
<td class="nump">2,477<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">3,710<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">1,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_DeferredTaxAssetsRestrictedStockUnitsExpense', window );">RSU expense</a></td>
<td class="nump">2,199<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">408<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">40,461<span></span>
</td>
<td class="nump">29,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(38,983)<span></span>
</td>
<td class="num">(27,803)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="nump">1,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_DeferredTaxLiabilitiesOperatingRightofuseAsset', window );">Operating right-of-use asset</a></td>
<td class="num">(1,456)<span></span>
</td>
<td class="num">(1,549)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,478)<span></span>
</td>
<td class="num">(1,549)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net of valuation allowance and deferred tax liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_DeferredTaxAssetsRestrictedStockUnitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted stock unit deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_DeferredTaxAssetsRestrictedStockUnitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_DeferredTaxLiabilitiesOperatingRightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from operating right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_DeferredTaxLiabilitiesOperatingRightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105500296896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of federal income tax to income before provision for income taxes<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract', window );"><strong>Schedule Of Federal Income Tax To Income Before Provision For Income Taxes Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(2.20%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(3.30%)<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">True-up to prior years return</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">State rate change</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Goodwill impairment</a></td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">12.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between effective income tax rate reconciliation stock based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105501941328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_EmployeeContributions', window );">Employee contributions</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_EmployeeCompensation', window );">Employee compensation</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLaborRelatedExpenses', window );">Other expenses</a></td>
<td class="nump">$ 223<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_EmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_EmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_EmployeeContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee contributions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_EmployeeContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLaborRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of labor-related expenses classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLaborRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105504613376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details) - Schedule of net loss per share attributable to common stockholders, basic and diluted - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="nump">$ 65,952<span></span>
</td>
<td class="nump">$ 47,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding &#8211; basic</a></td>
<td class="nump">11,259,615<span></span>
</td>
<td class="nump">11,232,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (5.86)<span></span>
</td>
<td class="num">$ (4.21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105506857904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details) - Schedule of net loss per share attributable to common stockholders, basic and diluted (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract', window );"><strong>Schedule of Net Loss Per Share Attributable to Common Stockholders Basic and Diluted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding &#8211; diluted</a></td>
<td class="nump">11,259,615<span></span>
</td>
<td class="nump">11,232,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (5.86)<span></span>
</td>
<td class="num">$ (4.21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140105508447616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details) - Schedule of weighted average dilutive common shares - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract', window );"><strong>Schedule of Weighted Average Dilutive Common Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_StockOptionsIssuedAndOutstanding', window );">Stock options issued and outstanding</a></td>
<td class="nump">1,828,329<span></span>
</td>
<td class="nump">1,356,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_RestrictedStockUnitsIssuedAndOutstanding', window );">Restricted stock units issued and outstanding</a></td>
<td class="nump">486,338<span></span>
</td>
<td class="nump">383,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_ConversionOfSeries1ConvertiblePreferredStock', window );">Conversion of Series 1 Convertible Preferred Stock</a></td>
<td class="nump">8,029,039<span></span>
</td>
<td class="nump">8,029,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tara_TotalPotentiallyDilutiveShares', window );">Total potentially dilutive shares</a></td>
<td class="nump">10,343,706<span></span>
</td>
<td class="nump">9,768,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ConversionOfSeries1ConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ConversionOfSeries1ConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_RestrictedStockUnitsIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_RestrictedStockUnitsIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_StockOptionsIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_StockOptionsIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tara_TotalPotentiallyDilutiveShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tara_TotalPotentiallyDilutiveShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tara_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>f10k2022_protarathera_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:tara="http://www.Protaratherapeutics.com/20221231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tara-20221231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
        </entity>
        <period>
            <instant>2023-03-03</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:Series1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:Series1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tara:Series1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tara:Series1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tara:Series1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tara:Series1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tara:Series1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
        </entity>
        <period>
            <instant>2020-01-09</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tara:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tara:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tara:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tara:PropertyAndEquipmentNotYetPlacedIntoServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tara:PropertyAndEquipmentNotYetPlacedIntoServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tara:CholineLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-27</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tara:IowaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tara:IowaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-22</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tara:FeinsteinAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">tara:FeinsteinAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-28</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-22</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-22</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tara:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tara:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-24</startDate>
            <endDate>2020-09-24</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-06</startDate>
            <endDate>2020-10-06</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tara:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tara:SeriesOneConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tara:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-24</startDate>
            <endDate>2020-09-24</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentyTwentyInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentySeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwentyFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-10-03</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tara:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-10-03</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tara:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-12-31</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tara:USFederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tara:StateIncomeTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001359931</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">tara:FederalNOLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">001-36694</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">Protara Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0">20-4580525</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0">345 Park Avenue South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0">3rd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">10010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">844-0337</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">TARA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="-5" unitRef="usd">19600000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">11306753</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="c0">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c0">Ernst&#160;&amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0">New York, New York</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">24127000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" unitRef="usd">35724000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c3" decimals="-3" unitRef="usd">60243000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c4" decimals="-3" unitRef="usd">55505000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">1776000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="-3" unitRef="usd">1883000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">86146000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="-3" unitRef="usd">93112000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c3" decimals="-3" unitRef="usd">745000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c4" decimals="-3" unitRef="usd">745000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c3" decimals="-3" unitRef="usd">17886000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c4" decimals="-3" unitRef="usd">39467000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">1592000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" unitRef="usd">1719000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">6277000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" unitRef="usd">7171000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="c4" decimals="-3" unitRef="usd">29517000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">644000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c4" decimals="-3" unitRef="usd">865000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c3" decimals="-3" unitRef="usd">113290000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="-3" unitRef="usd">172596000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="-3" unitRef="usd">1586000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c4" decimals="-3" unitRef="usd">954000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">3237000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c4" decimals="-3" unitRef="usd">2489000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">917000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="-3" unitRef="usd">855000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">5740000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="-3" unitRef="usd">4298000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" unitRef="usd">5467000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="-3" unitRef="usd">6384000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" unitRef="usd">11207000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="-3" unitRef="usd">10682000</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c5" decimals="0" unitRef="shares">8028</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c6" decimals="0" unitRef="shares">8028</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c5" decimals="0" unitRef="shares">8027</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c6" decimals="0" unitRef="shares">8027</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c5" decimals="0" unitRef="shares">8027</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c6" decimals="0" unitRef="shares">8027</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">11267389</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">11267389</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c4" decimals="0" unitRef="shares">11235731</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c4" decimals="0" unitRef="shares">11235731</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" unitRef="usd">11000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="-3" unitRef="usd">11000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" unitRef="usd">262724000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="-3" unitRef="usd">256126000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" unitRef="usd">-159964000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="-3" unitRef="usd">-94012000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="-3" unitRef="usd">-688000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c4" decimals="-3" unitRef="usd">-211000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">102083000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" unitRef="usd">161914000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">113290000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="-3" unitRef="usd">172596000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">16808000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" unitRef="usd">21088000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">20737000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" unitRef="usd">26401000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GoodwillImpairmentLoss contextRef="c0" decimals="-3" unitRef="usd">29517000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" unitRef="usd">67062000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c7" decimals="-3" unitRef="usd">47489000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-67062000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="-3" unitRef="usd">-47489000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="-3" unitRef="usd">1110000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c7" decimals="-3" unitRef="usd">237000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">1110000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c7" decimals="-3" unitRef="usd">237000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-65952000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" unitRef="usd">-47252000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-5.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c7" decimals="2" unitRef="usdPershares">-4.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c0" decimals="0" unitRef="shares">11259615</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c7" decimals="0" unitRef="shares">11232576</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c0" decimals="-3" unitRef="usd">-477000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c7" decimals="-3" unitRef="usd">-211000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c0" decimals="-3" unitRef="usd">-477000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c7" decimals="-3" unitRef="usd">-211000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="-3" unitRef="usd">-66429000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c7" decimals="-3" unitRef="usd">-47463000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding contextRef="c8" decimals="0" unitRef="shares">8027</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="c9" decimals="0" unitRef="shares">11211840</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" unitRef="usd">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" unitRef="usd">245992000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="-3" unitRef="usd">-46760000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="-3" unitRef="usd">199243000</us-gaap:StockholdersEquity>
    <tara:SettlementOfRestrictedStockUnitinShares contextRef="c15" decimals="0" unitRef="shares">23891</tara:SettlementOfRestrictedStockUnitinShares>
    <tara:SettlementOfRestrictedStockUnits contextRef="c16" decimals="-3" unitRef="usd">-228000</tara:SettlementOfRestrictedStockUnits>
    <tara:SettlementOfRestrictedStockUnits contextRef="c7" decimals="-3" unitRef="usd">-228000</tara:SettlementOfRestrictedStockUnits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c16" decimals="-3" unitRef="usd">4520000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c7" decimals="-3" unitRef="usd">4520000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c16" decimals="-3" unitRef="usd">5842000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c7" decimals="-3" unitRef="usd">5842000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="c18" decimals="-3" unitRef="usd">-211000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="c7" decimals="-3" unitRef="usd">-211000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:NetIncomeLoss contextRef="c17" decimals="-3" unitRef="usd">-47252000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" unitRef="usd">-47252000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c19" decimals="0" unitRef="shares">8027</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="c20" decimals="0" unitRef="shares">11235731</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" unitRef="usd">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" unitRef="usd">256126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" unitRef="usd">-94012000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="-3" unitRef="usd">-211000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" unitRef="usd">161914000</us-gaap:StockholdersEquity>
    <tara:SettlementOfRestrictedStockUnitinShares contextRef="c25" decimals="0" unitRef="shares">31658</tara:SettlementOfRestrictedStockUnitinShares>
    <tara:SettlementOfRestrictedStockUnits contextRef="c26" decimals="-3" unitRef="usd">-90000</tara:SettlementOfRestrictedStockUnits>
    <tara:SettlementOfRestrictedStockUnits contextRef="c0" decimals="-3" unitRef="usd">-90000</tara:SettlementOfRestrictedStockUnits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c26" decimals="-3" unitRef="usd">1273000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c0" decimals="-3" unitRef="usd">1273000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c26" decimals="-3" unitRef="usd">5415000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">5415000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="c28" decimals="-3" unitRef="usd">-477000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax contextRef="c0" decimals="-3" unitRef="usd">-477000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:NetIncomeLoss contextRef="c27" decimals="-3" unitRef="usd">-65952000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-65952000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c29" decimals="0" unitRef="shares">8027</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="c30" decimals="0" unitRef="shares">11267389</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="-3" unitRef="usd">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c31" decimals="-3" unitRef="usd">262724000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="-3" unitRef="usd">-159964000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="-3" unitRef="usd">-688000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">102083000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-65952000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" unitRef="usd">-47252000</us-gaap:NetIncomeLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c0" decimals="-3" unitRef="usd">29517000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">6688000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="-3" unitRef="usd">10362000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="-3" unitRef="usd">1366000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c7" decimals="-3" unitRef="usd">1050000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" unitRef="usd">248000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c7" decimals="-3" unitRef="usd">117000</us-gaap:Depreciation>
    <tara:AmortizationOfDiscountsAndPremiumsInvestments contextRef="c0" decimals="-3" unitRef="usd">1137000</tara:AmortizationOfDiscountsAndPremiumsInvestments>
    <tara:AmortizationOfDiscountsAndPremiumsInvestments contextRef="c7" decimals="-3" unitRef="usd">1737000</tara:AmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" unitRef="usd">-265000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c7" decimals="-3" unitRef="usd">418000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c0" decimals="-3" unitRef="usd">-222000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c7" decimals="-3" unitRef="usd">-295000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="-3" unitRef="usd">631000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c7" decimals="-3" unitRef="usd">40000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c0" decimals="-3" unitRef="usd">748000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c7" decimals="-3" unitRef="usd">576000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c0" decimals="-3" unitRef="usd">-1327000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c7" decimals="-3" unitRef="usd">-1009000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">-26457000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="-3" unitRef="usd">-34502000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c0" decimals="-3" unitRef="usd">43550000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c7" decimals="-3" unitRef="usd">124748000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <tara:ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities contextRef="c0" decimals="-3" unitRef="usd">58620000</tara:ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities>
    <tara:ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities contextRef="c7" decimals="-3" unitRef="usd">27150000</tara:ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" unitRef="usd">120000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c7" decimals="-3" unitRef="usd">596000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" unitRef="usd">14950000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c7" decimals="-3" unitRef="usd">-98194000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c0" decimals="-3" unitRef="usd">90000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c7" decimals="-3" unitRef="usd">228000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" unitRef="usd">-90000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c7" decimals="-3" unitRef="usd">-228000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" unitRef="usd">-11597000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c7" decimals="-3" unitRef="usd">-132924000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" unitRef="usd">36469000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c13" decimals="-3" unitRef="usd">169393000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">24872000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" unitRef="usd">36469000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;1. Organization and Nature of the Business &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Overview&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Protara Therapeutics, Inc., and its consolidated
subsidiaries (&#x201c;Protara&#x201d; or the &#x201c;Company&#x201d;), is a clinical-stage biopharmaceutical company committed to advancing
transformative therapies for the treatment of cancer and rare diseases. Protara&#x2019;s portfolio includes two development programs utilizing
TARA-002, an investigational cell therapy in development for the treatment of lymphatic malformations, or LMs and non-muscle invasive
bladder cancer, or NMIBC. The third program in the portfolio is Intravenous, or IV Choline Chloride, an investigational phospholipid
substrate replacement therapy initially in development for patients receiving parenteral nutrition, or PN who have intestinal failure
associated liver disease, or IFALD.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 9, 2020, privately-held ArTara Subsidiary,
Inc. (&#x201c;Private ArTara&#x201d;) and Protara Therapeutics, Inc. (formerly ArTara Therapeutics, Inc., formerly Proteon Therapeutics,
Inc.) completed the merger and reorganization (the &#x201c;Merger&#x201d;), in accordance with the terms of the Agreement and Plan of Merger
and Reorganization, dated September 23, 2019, (the &#x201c;Merger Agreement&#x201d;) by and among Protara Therapeutics, Inc., Private ArTara
and REM 1 Acquisition, Inc., a wholly owned subsidiary of Protara Therapeutics, Inc (&#x201c;Merger Sub&#x201d;). Thereupon, Merger Sub
merged with and into Private ArTara, with Private ArTara surviving as a wholly owned subsidiary of Protara Therapeutics, Inc. The Merger
was structured as a reverse merger and Private ArTara was determined to be the accounting acquirer based on the terms of the Merger and
other factors, and the post-merger company retained the name ArTara Therapeutics, Inc., which on May 11, 2020 was changed to Protara
Therapeutics, Inc.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;In addition, concurrently with the execution of the Merger Agreement,
Protara issued a private placement, whereby all of the outstanding shares of Protara Therapeutics, Inc.&#x2019;s Series A Preferred Stock
were converted into shares of Protara Therapeutics, Inc.&#x2019;s common stock. Shares of the Company&#x2019;s common stock commenced trading
on The Nasdaq Capital Market under the new name and ticker symbol &#x201c;TARA&#x201d; as of market open on January 10, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Liquidity, Capital Resources and Management Plans&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is in the business of developing
biopharmaceuticals and has no current or near-term revenues. The Company has incurred substantial clinical and other costs in its drug
development efforts. The Company will need to raise additional capital in order to fully realize management&#x2019;s plans.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company believes that its current financial
resources are sufficient to satisfy the Company&#x2019;s estimated liquidity needs for at least twelve months from the date of issuance
of these consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Impact of the COVID-19
Pandemic&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a result of the impacts of the COVID-19 pandemic,
the Company has experienced delays and may experience additional future delays that impact the business, research and development activities,
the healthcare systems in which the Company operates and the global economy as a whole. Due to the continued impact of the&#160;COVID-19&#160;pandemic,
the Company is not able to estimate the ongoing effects on the Company&#x2019;s results of operations, financial condition, or liquidity.
The Company will continue to monitor the impact of the COVID-19 pandemic and its related macroeconomic effects closely including whether
the effects would have a material impact on the Company&#x2019;s operations, liquidity and capital resources.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;2. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;
or &#x201c;GAAP&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements include
the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in the
accompanying consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses,
and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Significant items subject
to such estimates include but are not limited to income taxes, the valuation of deferred tax assets, recoverability of goodwill, and
contingencies.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On an ongoing basis, the Company&#x2019;s management
evaluates its estimates based on historical and anticipated results, trends, and various other assumptions believed to be reasonable.&#160;Actual
results could differ from those estimates. The results of any changes in accounting estimates are reflected in the financial statements
of the period in which the change becomes evident.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Reclassification&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain amounts in prior periods related to the classification of accrued
expenses and income taxes have been reclassified to conform to current period presentation. These reclassifications to adjust prior period
presentation had no impact on consolidated statements of operations and comprehensive loss or consolidated statements of cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Cash, Cash Equivalents
and Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers all highly liquid instruments
with an original maturity of three months or less when acquired to be cash equivalents. Cash and cash equivalents are held in depository
and money market accounts and are reported at fair value. The Company&#x2019;s restricted cash balances consist of cash deposits to collateralize
letter of credit obligations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table provides a reconciliation
of cash, cash equivalents, and restricted cash in the consolidated balance sheets to the total amount shown in the consolidated statements
of cash flows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;24,127&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35,724&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Restricted cash, non-current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;24,872&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;36,469&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounting Standards Codification (&#x201c;ASC&#x201d;)
Topic 820 &#x201c;Fair Value Measurements&#x201d; provides the framework for measuring fair value and establishes a fair value hierarchy
that prioritizes the inputs used in pricing the asset or liability. The hierarchy gives the highest priority to unadjusted quoted prices
in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3
measurements).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Fair value is defined as the exchange price,
or an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly
transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, the three-tier
fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Wingdings; font-size: 10pt"&gt;&#xd8;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 Quoted prices in
    active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Wingdings; font-size: 10pt"&gt;&#xd8;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 Quoted prices for
    similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are
    not active, or other inputs that are observable, either directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Wingdings; font-size: 10pt"&gt;&#xd8;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 Significant unobservable
    inputs that cannot be corroborated by market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying amounts of cash and cash equivalents,
prepaid expenses and accounts payable approximate their fair values due to the short-term nature of these instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Marketable Debt Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies investments in marketable
debt securities with remaining maturities when purchased of greater than three months as available-for-sale. Investments with a remaining
maturity date greater than one year are classified as non-current.&#160;The cost of securities sold is based on the specific identification
method. Interest and dividends earned on securities are classified as available-for-sale are included in investment income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company records investments at fair value
with unrealized gains and losses recorded as a component of other comprehensive loss in the consolidated statements of operations and
comprehensive loss until realized. Realized gains and losses are reflected in interest and investment income in the consolidated statements
of operations and comprehensive loss and are determined using the specific identification method with transactions recorded on a settlement
date basis. Fair value is determined based on quoted market rates when observable or utilizing data points that are observable, such
as quoted prices, interest rates and yield curves. To determine whether an other-than-temporary impairment exists, the Company considers
whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability
of the cost of the investment outweighs evidence to the contrary. The Company has the ability to hold such securities with an unrealized
loss until its forecasted recovery. The Company determined that there was no material change in the credit risk of these investments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments, which potentially subject
the Company to concentrations of credit risk, consists principally of cash, cash equivalents, restricted cash, and marketable debt securities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company currently invests its excess cash
primarily in money market funds and high quality, investment grade marketable debt securities of corporations. The Company has adopted
an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment,
net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment, including leasehold improvements,
are recorded at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the
estimated useful life of the asset. Depreciation begins at the time the asset is placed in service. Leasehold improvements are amortized
using the straight-line method over the shorter of the lease term or estimated useful life of the asset.&#160;Repairs and maintenance
costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The estimated useful lives for significant property
and equipment categories are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 49%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Asset
    Classification&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 49%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated
    Useful Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture,
    fixtures and other&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Laboratory
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shorter of the useful life of asset or the lease term &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company enters into contracts in the normal
course of business and assesses whether any such contracts contain a lease. The Company determines if an arrangement is a lease at inception
if it conveys the right to control the identified asset for a period of time in exchange for consideration. Under ASC 842, lease expense
is recognized as a single lease cost on a straight-line basis over the lease term. The lease term consists of non-cancelable periods
and may include options to extend or terminate the lease term, when it is reasonably certain such options will be exercised.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Leases classified as operating leases are included
in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, current operating lease liabilities and noncurrent operating lease liabilities
in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations, in our consolidated
balance sheet. ROU assets represent the right to use an underlying asset for the lease term. Lease liabilities represent the present
value of future lease payments, net of lease incentives, discounted using an incremental borrowing rate, which is a management estimate
based on the information available at the commencement date of a lease arrangement. ROU assets and lease liabilities are recognized at
the lease commencement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has elected to account for the lease
and non-lease components for leases as a single component for classes of all underlying assets and allocate all the contract consideration
to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included
in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating
expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes costs associated with
lease arrangements having an initial term of 12 months or less (&#x201c;short-term leases&#x201d;) on a straight-line basis over the lease
term; such short-term leases are not recorded on the balance sheet.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Long-lived assets are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be recoverable or that
the useful life is shorter than originally estimated. When such events occur, the Company compares the carrying amounts of the asset
or asset group to the undiscounted expected future cash flows. If this comparison indicates that the asset or asset group is impaired,
the amount of impairment is measured as the difference between the carrying value and fair value of the asset or asset group. If the
useful life is shorter than originally estimated, the Company will amortize the remaining carrying value over the new shorter useful
life. To date, no such impairment loss has been recognized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company identifies its operating segments
in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 280, Segment Reporting (&#x201c;ASC 280&#x201d;). Operating segments
are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief
operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#x2019;s
chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes
of allocating resources. Accordingly, the Company has determined it operates and manages its business in a single reportable operating
segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 9, 2020, in connection with the Merger,
the Company separately valued the assets and liabilities acquired, and then determined goodwill as the residual of the purchase price
less identified net assets, resulting in the initial recording of $29.5 million in goodwill.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Goodwill represents the excess of purchase price
over the fair value of identifiable net assets acquired in a business combination. Goodwill has an indefinite useful life. Goodwill is
assessed annually for impairment as of&#160;December 31, or more frequently if an event occurs or circumstances change that would indicate
that it is more likely than not that the fair value of a reporting unit or the fair value of an indefinite-lived intangible asset has
declined below its carrying value. In performing its annual goodwill impairment assessment, the Company has the option under GAAP to
qualitatively assess whether it is more likely than not that the fair value of a reporting unit is less than its carrying value; if the
conclusion of the qualitative assessment is that there are no indicators of impairment, the Company does not perform a quantitative assessment.
Otherwise, a quantitative assessment is performed and the fair value of the reporting unit is determined.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Goodwill is evaluated for impairment at the reporting
unit level, which is defined as an operating segment, or one level below an operating segment. The Company has determined that it operates
as one reporting unit and has selected December 31 as the date to perform its annual impairment test.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022 and 2021, the Company elected to forego the
qualitative screen and performed a quantitative annual goodwill impairment test for the reporting unit.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022, the Company&#x2019;s stock price and market
capitalization declined 60% from December 31, 2021, which reflects the overall decline of similar companies with less than $250 million
in market capitalizations, or microcap companies. The life sciences sector, which includes pre-commercialization and therefore net operating
loss generating companies, relies heavily on the capital markets to finance their operations and fund pre-clinical and clinical trials
for their existing development programs. As a result of a shift in risk appetite in the overall financial markets, the availability of
capital for life science sector companies decreased significantly in 2022. The challenging financing conditions had a negative impact
on stock prices and respective market capitalizations, particularly for microcap companies. The Company considered the heightened financing
risk that impacted the life sciences sector during 2022 to be one of the key macroeconomic factors that led to a sustained decrease in
the Company&#x2019;s stock price and market capitalization leading up to its annual goodwill impairment assessment date in late 2022. Based
upon the results of our 2022 annual goodwill impairment test, the Company recorded a loss on impairment of goodwill of $29.5 million during
the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table provides a roll forward of the Company&#x2019;s
goodwill and accumulated impairment losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Goodwill, gross amount as of December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,517&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Accumulated impairment loss, as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Goodwill as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -8.15pt; padding-left: 17.15pt"&gt;Additions to goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; text-indent: -8.15pt; padding-left: 17.15pt"&gt;Loss on impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29,517&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Goodwill as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Based upon the results of our annual goodwill impairment test, no adjustments
to the carrying value of goodwill were necessary during the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development expenses consist primarily
of third-party costs incurred to develop drug candidates, employee-related expenses, including salaries, benefits, travel and stock-based
compensation expense, depreciation and other allocated overhead costs, which include rent and maintenance of facilities and other supplies.
Research and development costs are expensed as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Before a compound receives regulatory approval,
the Company records upfront and milestone payments made to third parties under licensing arrangements as expense provided that there
is no alternative future use of the rights in other research and development projects.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Nonrefundable advance payments to vendors for
goods or services that will be used or received in future research and development activities are deferred and recognized as expense
in the period in which the related goods are delivered or services are performed. Where milestone payments are due to third parties under
research and development collaboration arrangements or other contractual agreements, the milestone payment obligations are expensed when
the milestone conditions are met and the amount of payment is reasonably estimable.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Once a compound receives regulatory approval,
the Company records any milestone payments in&#160;identifiable intangible assets, less accumulated amortization&#160;and, unless the
asset is determined to have an indefinite life, the Company amortizes the payments on a straight-line basis over the remaining agreement
term or the expected product life cycle, whichever is shorter.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain third-party costs are included as a component
of research and development expense. These expenses include fees paid to contract research organizations (&#x201c;CROs&#x201d;) and other
clinical trial costs, contractual services costs and costs for supply of its drug candidates. Depending upon the timing of payments to
the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses
are based on management&#x2019;s estimates of the work performed under service agreements, milestones achieved and experience with similar
contracts. The Company monitors each of these factors and adjusts estimates accordingly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Patent Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All patent-related costs incurred in connection
with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure.
Amounts incurred are classified as general and administrative expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Interest and Investment Income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Investment income consists primarily of interest
income, accretion income earned and amortization expense incurred and realized gains or losses&#160;related to our marketable debt securities
and interest income related to cash, cash equivalents and restricted cash.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s stock-based compensation
programs include stock options, restricted stock units (&#x201c;RSUs&#x201d;), and an employee stock purchase program (&#x201c;ESPP&#x201d;).
The Company accounts for stock-based compensation using the fair value method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company measures all stock options and other
stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense
of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes
forfeitures at the time forfeitures occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of each option is estimated on
the date of grant using the Black-Scholes option-pricing model. Expected volatility for the Company&#x2019;s common stock is determined
based on an average of the historical volatility of the Company and the historical volatility of a peer-group of similar public companies.
The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual
term of the option and the weighted-average vesting period of the option. The assumed dividend yield is based upon the Company&#x2019;s
expectation of not paying dividends in the foreseeable future. The risk-free interest rate is based upon the U.S. Treasury yield curve
commensurate with the expected term at the time of grant or remeasurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The stock-based compensation expense associated
with purchase rights under the ESPP is measured at fair-value using a Black-Scholes option-pricing model at commencement of each offering
period and recognized over that offering period. The Black-Scholes option pricing assumptions are similar to those used for stock options
with the exception of the expected term of purchase rights for the ESPP which is based on the duration of an offering period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair values of RSUs are based on the fair
market value of the Company&#x2019;s common stock on the date of the grant.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The RSUs are granted to directors pursuant to
the Company&#x2019;s equity plan. Settlement for the RSUs is deferred until the earliest to occur of (i) the director&#x2019;s termination
of service, (ii) death, (iii) disability or (iv) a change in control of the Company. In the event of a change in control of the Company,
the RSUs will vest in full.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of all stock-based awards is recognized
as stock-based compensation expense on a straight-line basis over the vesting period, which is typically one to four years for RSUs and
four years for stock options.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies stock-based compensation
expense in its statement of operations and comprehensive loss in the same way the payroll costs or service payments are classified for
the related stock-based award recipients.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred tax assets and liabilities are recognized
for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets
and liabilities and their respective tax basis, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are
measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.
The measurement of net deferred tax assets is reduced by the amount of any tax benefit that, based on available evidence, is not expected
to be realized, and a corresponding valuation allowance is established. In making such a determination, the Company considers all available
positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,
tax-planning strategies, and results of recent operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Tax benefits are recognized only for tax positions
that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount
of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for unrecognized tax benefits is recorded
for any tax benefits claimed in the Company&#x2019;s tax returns that do not meet these recognition and measurement standards. The Company&#x2019;s
policy is to record interest and penalties on uncertain tax positions as a component of income tax expense in the consolidated statement
of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share Attributable to Common
Stockholders&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic net loss per share is computed by dividing
the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period.
Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares
of common stock outstanding during the period plus the common equivalent shares for the period including any dilutive effect from unvested
restricted common stock, outstanding stock options and potential shares issuable under the ESPP.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In August 2018, the Financial Accounting Standards
Board, or the FASB, issued ASU&#160;No.&#160;2018-15,&#160;&lt;i&gt;Intangibles &#x2013; Goodwill and Other &#x2013;&#160;Internal-Use&#160;Software
(Subtopic&#160;350-40):&#160;Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a
Service Contract&lt;/i&gt;&#160;(&#x201c;ASU&#160;2018-15&#x201d;).&#160;This ASU is designed to reduce complexity for accounting for costs of
implementing a cloud computing service arrangement. This standard aligns the accounting for implementation costs of hosting arrangements,
regardless of whether they convey a license to the hosted software. The standard became effective for the first interim period within
annual reporting periods beginning after December&#160;15, 2020. On January 1, 2021, the Company adopted ASU 2018-15. The adoption of
this standard did not have a material effect on the Company&#x2019;s financial position, results of operations, or cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2019, the FASB issued ASU 2019-12,
&lt;i&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes &lt;/i&gt;(&#x201c;ASU 2019-12&#x201d;). The amendments in ASU 2019-12
remove certain exceptions to the general principles in Topic 740. The amendments also clarify and amend existing guidance to improve
consistent application. The amendments became effective for annual reporting periods beginning after December 15, 2020. On January 1,
2021, the Company adopted ASU 2019-12. The adoption of this standard did not have a material effect on the Company&#x2019;s financial
position, results of operations, or cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements
Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2016, the Financial Accounting Standards
Board, or the FASB issued ASU 2016-13, &lt;i&gt;Measurement of Credit Losses on Financial Statements&lt;/i&gt;. The new standard requires that expected
credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through
an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to
the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value
increases. In November 2019, the FASB issued ASU 2019-10, &lt;i&gt;Financial Instruments &#x2013; Credit Losses (Topic 326), Derivatives and
Hedging (Topic 815), and Leases (Topic 842): Effective Dates&lt;/i&gt;, which amended the effective date for certain companies. The standard
is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December
15, 2022. Early adoption is available. The Company has evaluated the impact of the adoption of ASU 2016-13, and related updates, and
has determined that the impact will not be material to its consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has evaluated other recently issued
accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material
impact on the Company&#x2019;s financial position or results of operations upon adoption.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the financial statements were available to be issued. Other than as described
in Note 11 and, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial
statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;
or &#x201c;GAAP&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The consolidated financial statements include
the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in the
accompanying consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses,
and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Significant items subject
to such estimates include but are not limited to income taxes, the valuation of deferred tax assets, recoverability of goodwill, and
contingencies.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On an ongoing basis, the Company&#x2019;s management
evaluates its estimates based on historical and anticipated results, trends, and various other assumptions believed to be reasonable.&#160;Actual
results could differ from those estimates. The results of any changes in accounting estimates are reflected in the financial statements
of the period in which the change becomes evident.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Reclassification&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain amounts in prior periods related to the classification of accrued
expenses and income taxes have been reclassified to conform to current period presentation. These reclassifications to adjust prior period
presentation had no impact on consolidated statements of operations and comprehensive loss or consolidated statements of cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Cash, Cash Equivalents
and Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers all highly liquid instruments
with an original maturity of three months or less when acquired to be cash equivalents. Cash and cash equivalents are held in depository
and money market accounts and are reported at fair value. The Company&#x2019;s restricted cash balances consist of cash deposits to collateralize
letter of credit obligations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table provides a reconciliation
of cash, cash equivalents, and restricted cash in the consolidated balance sheets to the total amount shown in the consolidated statements
of cash flows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;24,127&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35,724&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Restricted cash, non-current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;24,872&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;36,469&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;24,127&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;35,724&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Restricted cash, non-current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;745&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;24,872&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;36,469&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">24127000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" unitRef="usd">35724000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">745000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c4" decimals="-3" unitRef="usd">745000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">24872000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c4" decimals="-3" unitRef="usd">36469000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounting Standards Codification (&#x201c;ASC&#x201d;)
Topic 820 &#x201c;Fair Value Measurements&#x201d; provides the framework for measuring fair value and establishes a fair value hierarchy
that prioritizes the inputs used in pricing the asset or liability. The hierarchy gives the highest priority to unadjusted quoted prices
in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3
measurements).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Fair value is defined as the exchange price,
or an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly
transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, the three-tier
fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Wingdings; font-size: 10pt"&gt;&#xd8;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 Quoted prices in
    active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Wingdings; font-size: 10pt"&gt;&#xd8;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 Quoted prices for
    similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are
    not active, or other inputs that are observable, either directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Wingdings; font-size: 10pt"&gt;&#xd8;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 Significant unobservable
    inputs that cannot be corroborated by market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying amounts of cash and cash equivalents,
prepaid expenses and accounts payable approximate their fair values due to the short-term nature of these instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <tara:MarketableDebtSecuritiesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Marketable Debt Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies investments in marketable
debt securities with remaining maturities when purchased of greater than three months as available-for-sale. Investments with a remaining
maturity date greater than one year are classified as non-current.&#160;The cost of securities sold is based on the specific identification
method. Interest and dividends earned on securities are classified as available-for-sale are included in investment income.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company records investments at fair value
with unrealized gains and losses recorded as a component of other comprehensive loss in the consolidated statements of operations and
comprehensive loss until realized. Realized gains and losses are reflected in interest and investment income in the consolidated statements
of operations and comprehensive loss and are determined using the specific identification method with transactions recorded on a settlement
date basis. Fair value is determined based on quoted market rates when observable or utilizing data points that are observable, such
as quoted prices, interest rates and yield curves. To determine whether an other-than-temporary impairment exists, the Company considers
whether it has the ability and intent to hold the investment until a market price recovery, and whether evidence indicating the recoverability
of the cost of the investment outweighs evidence to the contrary. The Company has the ability to hold such securities with an unrealized
loss until its forecasted recovery. The Company determined that there was no material change in the credit risk of these investments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</tara:MarketableDebtSecuritiesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments, which potentially subject
the Company to concentrations of credit risk, consists principally of cash, cash equivalents, restricted cash, and marketable debt securities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company currently invests its excess cash
primarily in money market funds and high quality, investment grade marketable debt securities of corporations. The Company has adopted
an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment,
net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment, including leasehold improvements,
are recorded at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the
estimated useful life of the asset. Depreciation begins at the time the asset is placed in service. Leasehold improvements are amortized
using the straight-line method over the shorter of the lease term or estimated useful life of the asset.&#160;Repairs and maintenance
costs are expensed as incurred, whereas major improvements are capitalized as additions to property and equipment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The estimated useful lives for significant property
and equipment categories are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 49%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Asset
    Classification&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 49%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated
    Useful Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture,
    fixtures and other&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Laboratory
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shorter of the useful life of asset or the lease term &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <tara:ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 49%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Asset
    Classification&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; width: 49%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated
    Useful Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture,
    fixtures and other&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Laboratory
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shorter of the useful life of asset or the lease term &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</tara:ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c38">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c39">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c40">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <tara:ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm contextRef="c41">Shorter of the useful life of asset or the lease term</tara:ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company enters into contracts in the normal
course of business and assesses whether any such contracts contain a lease. The Company determines if an arrangement is a lease at inception
if it conveys the right to control the identified asset for a period of time in exchange for consideration. Under ASC 842, lease expense
is recognized as a single lease cost on a straight-line basis over the lease term. The lease term consists of non-cancelable periods
and may include options to extend or terminate the lease term, when it is reasonably certain such options will be exercised.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Leases classified as operating leases are included
in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, current operating lease liabilities and noncurrent operating lease liabilities
in our consolidated balance sheet. Finance leases are included in property and equipment and finance lease obligations, in our consolidated
balance sheet. ROU assets represent the right to use an underlying asset for the lease term. Lease liabilities represent the present
value of future lease payments, net of lease incentives, discounted using an incremental borrowing rate, which is a management estimate
based on the information available at the commencement date of a lease arrangement. ROU assets and lease liabilities are recognized at
the lease commencement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has elected to account for the lease
and non-lease components for leases as a single component for classes of all underlying assets and allocate all the contract consideration
to the lease component only. Lease cost for operating leases is recognized on a straight-line basis over the lease term and is included
in operating expenses on the statements of operations and comprehensive loss. Variable lease payments are included in lease operating
expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes costs associated with
lease arrangements having an initial term of 12 months or less (&#x201c;short-term leases&#x201d;) on a straight-line basis over the lease
term; such short-term leases are not recorded on the balance sheet.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Long-lived assets are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of the asset or asset group may not be recoverable or that
the useful life is shorter than originally estimated. When such events occur, the Company compares the carrying amounts of the asset
or asset group to the undiscounted expected future cash flows. If this comparison indicates that the asset or asset group is impaired,
the amount of impairment is measured as the difference between the carrying value and fair value of the asset or asset group. If the
useful life is shorter than originally estimated, the Company will amortize the remaining carrying value over the new shorter useful
life. To date, no such impairment loss has been recognized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company identifies its operating segments
in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 280, Segment Reporting (&#x201c;ASC 280&#x201d;). Operating segments
are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief
operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company&#x2019;s
chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes
of allocating resources. Accordingly, the Company has determined it operates and manages its business in a single reportable operating
segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <tara:OperatingSegmentDescription contextRef="c0">the Company has determined it operates and manages its business in a single reportable operating
segment</tara:OperatingSegmentDescription>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 9, 2020, in connection with the Merger,
the Company separately valued the assets and liabilities acquired, and then determined goodwill as the residual of the purchase price
less identified net assets, resulting in the initial recording of $29.5 million in goodwill.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Goodwill represents the excess of purchase price
over the fair value of identifiable net assets acquired in a business combination. Goodwill has an indefinite useful life. Goodwill is
assessed annually for impairment as of&#160;December 31, or more frequently if an event occurs or circumstances change that would indicate
that it is more likely than not that the fair value of a reporting unit or the fair value of an indefinite-lived intangible asset has
declined below its carrying value. In performing its annual goodwill impairment assessment, the Company has the option under GAAP to
qualitatively assess whether it is more likely than not that the fair value of a reporting unit is less than its carrying value; if the
conclusion of the qualitative assessment is that there are no indicators of impairment, the Company does not perform a quantitative assessment.
Otherwise, a quantitative assessment is performed and the fair value of the reporting unit is determined.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Goodwill is evaluated for impairment at the reporting
unit level, which is defined as an operating segment, or one level below an operating segment. The Company has determined that it operates
as one reporting unit and has selected December 31 as the date to perform its annual impairment test.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022 and 2021, the Company elected to forego the
qualitative screen and performed a quantitative annual goodwill impairment test for the reporting unit.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022, the Company&#x2019;s stock price and market
capitalization declined 60% from December 31, 2021, which reflects the overall decline of similar companies with less than $250 million
in market capitalizations, or microcap companies. The life sciences sector, which includes pre-commercialization and therefore net operating
loss generating companies, relies heavily on the capital markets to finance their operations and fund pre-clinical and clinical trials
for their existing development programs. As a result of a shift in risk appetite in the overall financial markets, the availability of
capital for life science sector companies decreased significantly in 2022. The challenging financing conditions had a negative impact
on stock prices and respective market capitalizations, particularly for microcap companies. The Company considered the heightened financing
risk that impacted the life sciences sector during 2022 to be one of the key macroeconomic factors that led to a sustained decrease in
the Company&#x2019;s stock price and market capitalization leading up to its annual goodwill impairment assessment date in late 2022. Based
upon the results of our 2022 annual goodwill impairment test, the Company recorded a loss on impairment of goodwill of $29.5 million during
the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table provides a roll forward of the Company&#x2019;s
goodwill and accumulated impairment losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Goodwill, gross amount as of December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,517&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Accumulated impairment loss, as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Goodwill as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -8.15pt; padding-left: 17.15pt"&gt;Additions to goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; text-indent: -8.15pt; padding-left: 17.15pt"&gt;Loss on impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29,517&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Goodwill as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Based upon the results of our annual goodwill impairment test, no adjustments
to the carrying value of goodwill were necessary during the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:Goodwill contextRef="c34" decimals="-5" unitRef="usd">29500000</us-gaap:Goodwill>
    <tara:MarketCapitalizationsPercentageChange contextRef="c0" decimals="2" unitRef="pure">0.60</tara:MarketCapitalizationsPercentageChange>
    <tara:MicrocapCompaniesMarketCapitalization contextRef="c0" decimals="-6" unitRef="usd">250000000</tara:MicrocapCompaniesMarketCapitalization>
    <us-gaap:GoodwillImpairmentLoss contextRef="c35" decimals="-5" unitRef="usd">29500000</us-gaap:GoodwillImpairmentLoss>
    <tara:ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Goodwill, gross amount as of December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,517&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Accumulated impairment loss, as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Goodwill as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -8.15pt; padding-left: 17.15pt"&gt;Additions to goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; text-indent: -8.15pt; padding-left: 17.15pt"&gt;Loss on impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29,517&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Goodwill as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</tara:ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock>
    <us-gaap:GoodwillGross contextRef="c42" decimals="-3" unitRef="usd">29517000</us-gaap:GoodwillGross>
    <us-gaap:Goodwill contextRef="c42" decimals="-3" unitRef="usd">29517000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c35" decimals="-3" unitRef="usd">29517000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development expenses consist primarily
of third-party costs incurred to develop drug candidates, employee-related expenses, including salaries, benefits, travel and stock-based
compensation expense, depreciation and other allocated overhead costs, which include rent and maintenance of facilities and other supplies.
Research and development costs are expensed as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Before a compound receives regulatory approval,
the Company records upfront and milestone payments made to third parties under licensing arrangements as expense provided that there
is no alternative future use of the rights in other research and development projects.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Nonrefundable advance payments to vendors for
goods or services that will be used or received in future research and development activities are deferred and recognized as expense
in the period in which the related goods are delivered or services are performed. Where milestone payments are due to third parties under
research and development collaboration arrangements or other contractual agreements, the milestone payment obligations are expensed when
the milestone conditions are met and the amount of payment is reasonably estimable.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Once a compound receives regulatory approval,
the Company records any milestone payments in&#160;identifiable intangible assets, less accumulated amortization&#160;and, unless the
asset is determined to have an indefinite life, the Company amortizes the payments on a straight-line basis over the remaining agreement
term or the expected product life cycle, whichever is shorter.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain third-party costs are included as a component
of research and development expense. These expenses include fees paid to contract research organizations (&#x201c;CROs&#x201d;) and other
clinical trial costs, contractual services costs and costs for supply of its drug candidates. Depending upon the timing of payments to
the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses
are based on management&#x2019;s estimates of the work performed under service agreements, milestones achieved and experience with similar
contracts. The Company monitors each of these factors and adjusts estimates accordingly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <tara:PatentCostsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Patent Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All patent-related costs incurred in connection
with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure.
Amounts incurred are classified as general and administrative expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</tara:PatentCostsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Interest and Investment Income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Investment income consists primarily of interest
income, accretion income earned and amortization expense incurred and realized gains or losses&#160;related to our marketable debt securities
and interest income related to cash, cash equivalents and restricted cash.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s stock-based compensation
programs include stock options, restricted stock units (&#x201c;RSUs&#x201d;), and an employee stock purchase program (&#x201c;ESPP&#x201d;).
The Company accounts for stock-based compensation using the fair value method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company measures all stock options and other
stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense
of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes
forfeitures at the time forfeitures occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of each option is estimated on
the date of grant using the Black-Scholes option-pricing model. Expected volatility for the Company&#x2019;s common stock is determined
based on an average of the historical volatility of the Company and the historical volatility of a peer-group of similar public companies.
The expected term of options granted to employees is calculated using the simplified method, which represents the average of the contractual
term of the option and the weighted-average vesting period of the option. The assumed dividend yield is based upon the Company&#x2019;s
expectation of not paying dividends in the foreseeable future. The risk-free interest rate is based upon the U.S. Treasury yield curve
commensurate with the expected term at the time of grant or remeasurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The stock-based compensation expense associated
with purchase rights under the ESPP is measured at fair-value using a Black-Scholes option-pricing model at commencement of each offering
period and recognized over that offering period. The Black-Scholes option pricing assumptions are similar to those used for stock options
with the exception of the expected term of purchase rights for the ESPP which is based on the duration of an offering period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair values of RSUs are based on the fair
market value of the Company&#x2019;s common stock on the date of the grant.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The RSUs are granted to directors pursuant to
the Company&#x2019;s equity plan. Settlement for the RSUs is deferred until the earliest to occur of (i) the director&#x2019;s termination
of service, (ii) death, (iii) disability or (iv) a change in control of the Company. In the event of a change in control of the Company,
the RSUs will vest in full.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of all stock-based awards is recognized
as stock-based compensation expense on a straight-line basis over the vesting period, which is typically one to four years for RSUs and
four years for stock options.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies stock-based compensation
expense in its statement of operations and comprehensive loss in the same way the payroll costs or service payments are classified for
the related stock-based award recipients.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <tara:VestingPeriod contextRef="c36">P1Y</tara:VestingPeriod>
    <tara:VestingPeriod contextRef="c37">P4Y</tara:VestingPeriod>
    <tara:StockOptionPeriod contextRef="c0">P4Y</tara:StockOptionPeriod>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred tax assets and liabilities are recognized
for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets
and liabilities and their respective tax basis, operating loss and tax credit carryforwards. Deferred tax assets and liabilities are
measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled.
The measurement of net deferred tax assets is reduced by the amount of any tax benefit that, based on available evidence, is not expected
to be realized, and a corresponding valuation allowance is established. In making such a determination, the Company considers all available
positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income,
tax-planning strategies, and results of recent operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Tax benefits are recognized only for tax positions
that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount
of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for unrecognized tax benefits is recorded
for any tax benefits claimed in the Company&#x2019;s tax returns that do not meet these recognition and measurement standards. The Company&#x2019;s
policy is to record interest and penalties on uncertain tax positions as a component of income tax expense in the consolidated statement
of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <tara:PercentageOfLargestAmountOfBenefit contextRef="c0" decimals="2" unitRef="pure">0.50</tara:PercentageOfLargestAmountOfBenefit>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share Attributable to Common
Stockholders&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic net loss per share is computed by dividing
the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period.
Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares
of common stock outstanding during the period plus the common equivalent shares for the period including any dilutive effect from unvested
restricted common stock, outstanding stock options and potential shares issuable under the ESPP.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In August 2018, the Financial Accounting Standards
Board, or the FASB, issued ASU&#160;No.&#160;2018-15,&#160;&lt;i&gt;Intangibles &#x2013; Goodwill and Other &#x2013;&#160;Internal-Use&#160;Software
(Subtopic&#160;350-40):&#160;Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a
Service Contract&lt;/i&gt;&#160;(&#x201c;ASU&#160;2018-15&#x201d;).&#160;This ASU is designed to reduce complexity for accounting for costs of
implementing a cloud computing service arrangement. This standard aligns the accounting for implementation costs of hosting arrangements,
regardless of whether they convey a license to the hosted software. The standard became effective for the first interim period within
annual reporting periods beginning after December&#160;15, 2020. On January 1, 2021, the Company adopted ASU 2018-15. The adoption of
this standard did not have a material effect on the Company&#x2019;s financial position, results of operations, or cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2019, the FASB issued ASU 2019-12,
&lt;i&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes &lt;/i&gt;(&#x201c;ASU 2019-12&#x201d;). The amendments in ASU 2019-12
remove certain exceptions to the general principles in Topic 740. The amendments also clarify and amend existing guidance to improve
consistent application. The amendments became effective for annual reporting periods beginning after December 15, 2020. On January 1,
2021, the Company adopted ASU 2019-12. The adoption of this standard did not have a material effect on the Company&#x2019;s financial
position, results of operations, or cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <tara:RecentAccountingPronouncementsNotYetAdopted contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements
Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2016, the Financial Accounting Standards
Board, or the FASB issued ASU 2016-13, &lt;i&gt;Measurement of Credit Losses on Financial Statements&lt;/i&gt;. The new standard requires that expected
credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through
an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to
the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value
increases. In November 2019, the FASB issued ASU 2019-10, &lt;i&gt;Financial Instruments &#x2013; Credit Losses (Topic 326), Derivatives and
Hedging (Topic 815), and Leases (Topic 842): Effective Dates&lt;/i&gt;, which amended the effective date for certain companies. The standard
is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December
15, 2022. Early adoption is available. The Company has evaluated the impact of the adoption of ASU 2016-13, and related updates, and
has determined that the impact will not be material to its consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has evaluated other recently issued
accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material
impact on the Company&#x2019;s financial position or results of operations upon adoption.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</tara:RecentAccountingPronouncementsNotYetAdopted>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Subsequent Events&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the financial statements were available to be issued. Other than as described
in Note 11 and, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial
statements.&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;3. Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The tables below present information about the
Company&#x2019;s financial instruments that are measured at fair value on a recurring basis as of December 31, 2022 and 2021 and indicates
the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, as described under &lt;i&gt;Note 2,
Summary of Significant Accounting Policies.&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following tables present the Company&#x2019;s
financial assets and liabilities that are measured and carried at fair value and indicate the level within the fair value hierarchy of
the valuation techniques it utilizes to determine such fair value:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Cash Equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Money market funds&lt;sup&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,284&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,284&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate bonds&lt;sup&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted cash, non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Money market funds&lt;sup&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Marketable debt securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate bonds&lt;sup&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78,129&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78,129&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.25in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,029&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;80,652&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;94,681&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Cash Equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Money market funds&lt;sup&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Restricted cash, non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Money market funds&lt;sup&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Marketable debt securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate bonds&lt;sup&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;94,972&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;94,972&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.25in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,068&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;94,972&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;122,040&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; padding-right: 0pt; padding-left: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Money market funds and corporate debt securities with original maturities of 90 days or less are included within Cash and cash equivalents in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="padding-right: 0pt; padding-left: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="padding-right: 0pt; padding-left: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted Money market funds are included within Restricted Cash, non-current in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="padding-right: 0pt; padding-left: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="padding-right: 0pt; padding-left: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate debt securities with original maturities greater than 90 days are included within Marketable securities in the Consolidated Balance Sheets and classified as current or noncurrent based upon whether the maturity of the financial asset is less than or greater than 12 months.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Money market funds are classified as Level&#160;1
within the fair value hierarchy, because they are valued using quoted prices in active markets. Corporate debt securities classified
as Level&#160;2 within the fair value hierarchy are valued on the basis of prices from an orderly transaction between market participants
provided by reputable dealers or pricing services. Prices of these securities are obtained through independent, third-party pricing services
and include market quotations that may include both observable and unobservable inputs. In determining the value of a particular investment,
pricing services may use certain information with respect to transactions in such investments, quotations from dealers, pricing matrices
and market transactions in comparable investments and various relationships between investments. There were no transfers of financial
instruments among Level&#160;1, Level&#160;2, and Level&#160;3 during the period presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash equivalents, prepaid expenses and other
current assets, accounts payable and accrued expenses at December 31, 2022 and 2021 are carried at amounts that approximate fair value
due to their short-term maturities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Non-Recurring Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;During the fourth quarter of 2022, the Company recorded a goodwill
impairment loss of $29.5 million, refer to Note 2 for additional details on the impairment of goodwill. The fair value of our reporting
unit was determined using an income approach based on discounted cash flows, or DCF. Determining fair value using a DCF analysis requires
the exercise of significant judgment with respect to several assumptions and estimates, including the amount and timing of expected future
cash flows and appropriate discount rate to be applied. The expected cash flows used in the DCF analysis are based on our most recent
internal long-range forecast and budget and, for years beyond the budget, our estimates, which are based, in part, on industry benchmarks
and forecasted growth rates. The discount rate used in the DCF analysis is intended to reflect the risks inherent in the expected future
cash flows of the respective programs within our portfolio. The inputs to the DCF model are Level 3 valuation inputs.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Cash Equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Money market funds&lt;sup&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,284&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,284&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate bonds&lt;sup&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted cash, non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Money market funds&lt;sup&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Marketable debt securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate bonds&lt;sup&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78,129&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;78,129&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.25in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;14,029&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;80,652&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;94,681&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Cash Equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Money market funds&lt;sup&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Restricted cash, non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Money market funds&lt;sup&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Marketable debt securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate bonds&lt;sup&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;94,972&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;94,972&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.25in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,068&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;94,972&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;122,040&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; padding-right: 0pt; padding-left: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Money market funds and corporate debt securities with original maturities of 90 days or less are included within Cash and cash equivalents in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="padding-right: 0pt; padding-left: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="padding-right: 0pt; padding-left: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted Money market funds are included within Restricted Cash, non-current in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="padding-right: 0pt; padding-left: 0pt; text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="padding-right: 0pt; padding-left: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(c)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 0pt; padding-left: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate debt securities with original maturities greater than 90 days are included within Marketable securities in the Consolidated Balance Sheets and classified as current or noncurrent based upon whether the maturity of the financial asset is less than or greater than 12 months.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c44" decimals="-3" id="ix_0_fact" unitRef="usd">13284000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c3" decimals="-3" id="ix_1_fact" unitRef="usd">13284000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c45" decimals="-3" id="ix_2_fact" unitRef="usd">2523000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c3" decimals="-3" id="ix_3_fact" unitRef="usd">2523000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:RestrictedCashAndInvestments contextRef="c44" decimals="-3" id="ix_6_fact" unitRef="usd">745000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments contextRef="c3" decimals="-3" id="ix_7_fact" unitRef="usd">745000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:MarketableSecurities
      contextRef="c45"
      decimals="-3"
      id="ix_10_fact"
      unitRef="usd">78129000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c3" decimals="-3" id="ix_11_fact" unitRef="usd">78129000</us-gaap:MarketableSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c44" decimals="-3" unitRef="usd">14029000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c45" decimals="-3" unitRef="usd">80652000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c3" decimals="-3" unitRef="usd">94681000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c47" decimals="-3" id="ix_4_fact" unitRef="usd">26323000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c4" decimals="-3" id="ix_5_fact" unitRef="usd">26323000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestments contextRef="c47" decimals="-3" id="ix_8_fact" unitRef="usd">745000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments contextRef="c4" decimals="-3" id="ix_9_fact" unitRef="usd">745000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:MarketableSecurities
      contextRef="c48"
      decimals="-3"
      id="ix_12_fact"
      unitRef="usd">94972000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c4" decimals="-3" id="ix_13_fact" unitRef="usd">94972000</us-gaap:MarketableSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c47" decimals="-3" unitRef="usd">27068000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c48" decimals="-3" unitRef="usd">94972000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c4" decimals="-3" unitRef="usd">122040000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:GoodwillImpairmentLoss contextRef="c0" decimals="-5" unitRef="usd">29500000</us-gaap:GoodwillImpairmentLoss>
    <tara:MarketableDebtSecuritiesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;4. Marketable Debt Securities&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Marketable debt securities, all of which were
classified as available-for-sale, consist of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amortized&lt;br/&gt; Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Unrealized&lt;br/&gt; Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Estimated&lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Corporate bonds - presented in marketable debt securities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;60,790&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(547&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;60,243&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Corporate bonds - presented in marketable debt securities, non-current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(141&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;78,817&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(688&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;78,129&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amortized&lt;br/&gt; Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized&lt;br/&gt; Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Estimated&lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Corporate bonds - presented in marketable debt securities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;55,548&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;55,505&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Corporate bonds - presented in marketable debt securities, non-current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,635&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(168&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,467&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;95,183&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(211&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;94,972&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.05pt"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The amount of realized gains and losses reclassified
into earnings for the year ended December 31, 2022 was $17 included in investment income within the consolidated statements of operations
and comprehensive loss. There were no sales of securities in the periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The contractual maturities of all securities
held at December 31, 2022 was 16 months or less. Of the 34 securities in a loss position held by the Company, there were 16 securities
in a continuous unrealized loss position for greater than twelve months at December 31, 2022. The total unrealized loss related to these
securities was $358 and was not material. The Company has the ability to hold such securities with an unrealized loss until its forecasted
recovery. The Company determined that there was no material change in the credit risk of the above investments. No other than temporary&#160;impairment
loss has been recorded on the securities as of December 31, 2022, as the Company believes that any decrease in fair value of these securities
is temporary and the Company expects to recover at least up to the initial cost of the investment for these securities.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Interest and Investment Income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Interest and investment income consists of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Interest income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,230&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,974&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accretion/(amortization) of discount/premium, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,137&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,737&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Realized gain/(loss)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total interest and investment income&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,110&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tara:MarketableDebtSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amortized&lt;br/&gt; Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Unrealized&lt;br/&gt; Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Estimated&lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Corporate bonds - presented in marketable debt securities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;60,790&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(547&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;60,243&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Corporate bonds - presented in marketable debt securities, non-current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(141&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,886&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;78,817&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(688&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;78,129&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amortized&lt;br/&gt; Cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized&lt;br/&gt; Gains&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Unrealized&lt;br/&gt; Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Estimated&lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Corporate bonds - presented in marketable debt securities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;55,548&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(43&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;55,505&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Corporate bonds - presented in marketable debt securities, non-current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,635&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(168&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,467&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;95,183&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(211&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;94,972&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.05pt"&gt;&#160;&#160;&lt;/p&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c50" decimals="-3" unitRef="usd">60790000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <tara:UnrealizedLoss contextRef="c50" decimals="-3" unitRef="usd">-547000</tara:UnrealizedLoss>
    <tara:EstimatedFairValue contextRef="c50" decimals="-3" unitRef="usd">60243000</tara:EstimatedFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c51" decimals="-3" unitRef="usd">18027000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <tara:UnrealizedLoss contextRef="c51" decimals="-3" unitRef="usd">-141000</tara:UnrealizedLoss>
    <tara:EstimatedFairValue contextRef="c51" decimals="-3" unitRef="usd">17886000</tara:EstimatedFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c3" decimals="-3" unitRef="usd">78817000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <tara:UnrealizedLoss contextRef="c3" decimals="-3" unitRef="usd">-688000</tara:UnrealizedLoss>
    <tara:EstimatedFairValue contextRef="c3" decimals="-3" unitRef="usd">78129000</tara:EstimatedFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c52" decimals="-3" unitRef="usd">55548000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <tara:UnrealizedLoss contextRef="c52" decimals="-3" unitRef="usd">-43000</tara:UnrealizedLoss>
    <tara:EstimatedFairValue contextRef="c52" decimals="-3" unitRef="usd">55505000</tara:EstimatedFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c53" decimals="-3" unitRef="usd">39635000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <tara:UnrealizedLoss contextRef="c53" decimals="-3" unitRef="usd">-168000</tara:UnrealizedLoss>
    <tara:EstimatedFairValue contextRef="c53" decimals="-3" unitRef="usd">39467000</tara:EstimatedFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c4" decimals="-3" unitRef="usd">95183000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <tara:UnrealizedLoss contextRef="c4" decimals="-3" unitRef="usd">-211000</tara:UnrealizedLoss>
    <tara:EstimatedFairValue contextRef="c4" decimals="-3" unitRef="usd">94972000</tara:EstimatedFairValue>
    <us-gaap:NetInvestmentIncome contextRef="c0" decimals="-3" unitRef="usd">17000</us-gaap:NetInvestmentIncome>
    <tara:UnrealizedLosses contextRef="c3" decimals="-3" unitRef="usd">358000</tara:UnrealizedLosses>
    <tara:ScheduleOfInterestAndInvestmentIncomeTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Interest income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,230&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,974&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accretion/(amortization) of discount/premium, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,137&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,737&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Realized gain/(loss)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total interest and investment income&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,110&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tara:ScheduleOfInterestAndInvestmentIncomeTableTextBlock>
    <us-gaap:InterestIncomeOther contextRef="c0" decimals="-3" unitRef="usd">2230000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c7" decimals="-3" unitRef="usd">1974000</us-gaap:InterestIncomeOther>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c0" decimals="-3" unitRef="usd">-1137000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c7" decimals="-3" unitRef="usd">-1737000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c0" decimals="-3" unitRef="usd">17000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:InvestmentIncomeNet contextRef="c0" decimals="-3" unitRef="usd">1110000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c7" decimals="-3" unitRef="usd">237000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;5. Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"&gt;Prepaid expenses and
other current assets consist of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;288&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;279&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;569&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;684&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued interest on marketable debt securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;173&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;127&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;34&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,776&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,883&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;288&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;279&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;569&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;684&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued interest on marketable debt securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;486&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;173&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;127&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;34&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,776&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,883&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance contextRef="c3" decimals="-3" unitRef="usd">288000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c4" decimals="-3" unitRef="usd">279000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">569000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c7" decimals="-3" unitRef="usd">684000</us-gaap:OtherResearchAndDevelopmentExpense>
    <tara:PrepaidSoftware contextRef="c0" decimals="-3" unitRef="usd">122000</tara:PrepaidSoftware>
    <tara:PrepaidSoftware contextRef="c7" decimals="-3" unitRef="usd">79000</tara:PrepaidSoftware>
    <tara:AccruedInterestOnMarketableDebtSecurities contextRef="c0" decimals="-3" unitRef="usd">486000</tara:AccruedInterestOnMarketableDebtSecurities>
    <tara:AccruedInterestOnMarketableDebtSecurities contextRef="c7" decimals="-3" unitRef="usd">634000</tara:AccruedInterestOnMarketableDebtSecurities>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c3" decimals="-3" unitRef="usd">184000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c4" decimals="-3" unitRef="usd">173000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">127000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c4" decimals="-3" unitRef="usd">34000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">1776000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="-3" unitRef="usd">1883000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;6. Property and Equipment, net&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"&gt;Property and equipment,
net consists of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;205&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;175&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Furniture, fixtures and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;352&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;352&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;553&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Property and equipment not yet placed into service&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;99&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;613&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,075&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(483&lt;/td&gt;&lt;td style="padding-bottom: 1.5px; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(236&lt;/td&gt;&lt;td style="padding-bottom: 1.5px; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,592&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,719&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation expense was $247 and $117 for the
years ended December 31, 2022 and 2021, respectively. During the year ended December 31, 2022, $137 and $110 was included in research
and development expense and general and administrative expense, respectively, within the consolidated statements of operations and comprehensive
loss. During the year ended December 31, 2021, $36 and $81 was included in research and development expense and general and administrative
expense, respectively, within the consolidated statements of operations and comprehensive loss. As of December 31, 2022 and 2021, 100%
of the Company&#x2019;s total property and equipment, net was attributable to the United States.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;205&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;175&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Furniture, fixtures and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;352&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;352&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;553&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Property and equipment not yet placed into service&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;99&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;613&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,075&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,955&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(483&lt;/td&gt;&lt;td style="padding-bottom: 1.5px; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(236&lt;/td&gt;&lt;td style="padding-bottom: 1.5px; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,592&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,719&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c60" decimals="-3" unitRef="usd">205000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c61" decimals="-3" unitRef="usd">175000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c62" decimals="-3" unitRef="usd">352000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c63" decimals="-3" unitRef="usd">352000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c64" decimals="-3" unitRef="usd">866000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c65" decimals="-3" unitRef="usd">591000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c66" decimals="-3" unitRef="usd">553000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c67" decimals="-3" unitRef="usd">224000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c68" decimals="-3" unitRef="usd">99000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c69" decimals="-3" unitRef="usd">613000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="-3" unitRef="usd">2075000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="-3" unitRef="usd">1955000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" unitRef="usd">483000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="-3" unitRef="usd">236000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">1592000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" unitRef="usd">1719000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c54" decimals="-3" unitRef="usd">247000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c55" decimals="-3" unitRef="usd">117000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c56" decimals="-3" unitRef="usd">137000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c57" decimals="-3" unitRef="usd">110000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c58" decimals="-3" unitRef="usd">36000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c59" decimals="-3" unitRef="usd">81000</us-gaap:Depreciation>
    <tara:TotalPropertyAndEquipmentNet contextRef="c0" decimals="2" unitRef="pure">1</tara:TotalPropertyAndEquipmentNet>
    <tara:TotalPropertyAndEquipmentNet contextRef="c7" decimals="2" unitRef="pure">1</tara:TotalPropertyAndEquipmentNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;7. Accrued Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"&gt;Accrued expenses consist
of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Employee Costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,543&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,801&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;512&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;437&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;182&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;251&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,237&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,489&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Employee Costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,543&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,801&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;512&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;437&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;182&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;251&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,237&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,489&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <tara:AccruedEmployeeRelatedCurrent contextRef="c3" decimals="-3" unitRef="usd">2543000</tara:AccruedEmployeeRelatedCurrent>
    <tara:AccruedEmployeeRelatedCurrent contextRef="c4" decimals="-3" unitRef="usd">1801000</tara:AccruedEmployeeRelatedCurrent>
    <tara:AccruedResearchAndDevelopmentCurrent contextRef="c3" decimals="-3" unitRef="usd">512000</tara:AccruedResearchAndDevelopmentCurrent>
    <tara:AccruedResearchAndDevelopmentCurrent contextRef="c4" decimals="-3" unitRef="usd">437000</tara:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">182000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c4" decimals="-3" unitRef="usd">251000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherExpenses contextRef="c0" decimals="-3" unitRef="usd">3237000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c7" decimals="-3" unitRef="usd">2489000</us-gaap:OtherExpenses>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;8. Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Operating leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2020, the Company entered into an
agreement to lease approximately 10.3 square feet of office space in New York, New York (&#x201c;Office Lease&#x201d;), which commenced
in April 2021. Annual rent is approximately $1,117. The Office Lease has a term of approximately seven years and contains provisions
for a free-rent period, annual rent increases and an allowance for tenant improvements. The Company has an option to extend the term
by five years, however, the Company determined at the lease commencement date that it was not reasonably certain to exercise the renewal
option and such renewal was excluded from the operating lease right-of-use, or ROU, asset and operating lease liability recorded for
this lease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is responsible for real estate taxes,
maintenance and other operating expenses applicable to the leased premises which are recognized as variable lease expense in the period
when incurred. In conjunction with the Office Lease, the Company established a letter of credit of approximately $745 secured by cash
balances included in restricted cash.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2021, the Company amended the existing
agreement with its contract development and manufacturing organization, or CDMO, establishing a term of eight-years from the amendment
date. Prior to the amendment, the leased spaces met the short-term lease exception under a quarter-to quarter arrangement and were not
included in measurement of lease liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Leases classified as operating leases are included
in operating lease right-of-use, or ROU, assets, operating lease liabilities and operating lease liabilities, non-current, in the Company&#x2019;s
consolidated balance sheets. The Office Lease and the CDMO leased spaces are included in operating lease ROU assets and operating lease
liabilities. Cash paid for operating lease liabilities was $1,327 and $1,009 during the years ended December 31, 2022 and 2021, respectively,
which is included in operating cash flows. The ROU asset obtained in exchange for operating lease liabilities related to the Office Lease
was $6,549.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The components of lease expense were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Lease expense&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,366&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,050&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Short-term lease expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;102&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,369&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,152&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Variable lease expense for the years ended December
31, 2022 and 2021, respectively were not material.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-align: justify; text-indent: -20.05pt"&gt;The weighted
average remaining lease term and the weighted average discount rate for operating leases were:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.05pt; text-indent: -20.05pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term &#x2013; operating lease (in months)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The total remaining operating lease payments
included in the measurement of lease liabilities on the Company&#x2019;s consolidated balance sheet as of December&#160;31, 2022, was
as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;For the year ending December 31:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating Lease Payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,327&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,327&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;1,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;805&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total future operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,712&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,328&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,384&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="c70">the Company entered into an
agreement to lease approximately 10.3 square feet of office space in New York, New York (&#x201c;Office Lease&#x201d;), which commenced
in April 2021. Annual rent is approximately $1,117.</us-gaap:LesseeOperatingLeaseDescription>
    <tara:RestrictedCashNoncurrents contextRef="c3" decimals="-3" unitRef="usd">745000</tara:RestrictedCashNoncurrents>
    <us-gaap:IncreaseDecreaseInOperatingLiabilities contextRef="c0" decimals="-3" unitRef="usd">1327000</us-gaap:IncreaseDecreaseInOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLiabilities contextRef="c7" decimals="-3" unitRef="usd">1009000</us-gaap:IncreaseDecreaseInOperatingLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" unitRef="usd">6549000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Lease expense&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Operating lease expense&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,366&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,050&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Short-term lease expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;102&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,369&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,152&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="-3" unitRef="usd">1366000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c7" decimals="-3" unitRef="usd">1050000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c0" decimals="-3" unitRef="usd">3000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c7" decimals="-3" unitRef="usd">102000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost contextRef="c0" decimals="-3" unitRef="usd">1369000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c7" decimals="-3" unitRef="usd">1152000</us-gaap:LeaseCost>
    <tara:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term &#x2013; operating lease (in months)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</tara:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="3" unitRef="pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c4" decimals="3" unitRef="pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3">P67M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4">P79M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <tara:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;For the year ending December 31:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating Lease Payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,327&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,327&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;1,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;805&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total future operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,712&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,328&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,384&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tara:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c3" decimals="-3" unitRef="usd">1327000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="-3" unitRef="usd">1327000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c3" decimals="-3" unitRef="usd">1395000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c3" decimals="-3" unitRef="usd">1429000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c3" decimals="-3" unitRef="usd">1429000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c3" decimals="-3" unitRef="usd">805000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <tara:OperatingLeasesFutureMinimumPaymentDue contextRef="c3" decimals="-3" unitRef="usd">7712000</tara:OperatingLeasesFutureMinimumPaymentDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c3" decimals="-3" unitRef="usd">1328000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <tara:PresentValueOfFutureMinimumLeasePayments contextRef="c3" decimals="-3" unitRef="usd">6384000</tara:PresentValueOfFutureMinimumLeasePayments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;9. Commitments and Contingencies &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Employment Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Executive Employment Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company&#x2019;s executive officers have entered into at-will employment
agreements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Collaborations and License Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Choline License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 27, 2017, the Company entered into
a license agreement (the &#x201c;Choline License Agreement&#x201d;) with Alan L. Buchman (&#x201c;Dr. Buchman&#x201d;). Pursuant to the Choline
License Agreement, the Company received from Dr. Buchman the license rights in and to the &#x201c;Licensed Orphan Designations&#x201d;,
the &#x201c;Licensed IND&#x201d;, &#x201c;Existing Study Data&#x201d; and the &#x201c;Licensed Know-How&#x201d; for one or more of the licensed
indications.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2022 and
2021, the Company recorded research and development expense of $2 and $0, in connection with the Choline License Agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 22, 2017, the Company entered into
an agreement (the &#x201c;Feinstein Agreement&#x201d;) with The Feinstein Institute for Medical Research (the &#x201c;Feinstein Institute&#x201d;),
a not-for-profit corporation with 50 research labs and 2,500 clinical research studies. Pursuant to the Feinstein Agreement, the Company
acquired an exclusive license relating to treatment of fatty liver diseases in humans for which Choline may be an effective therapeutic.
In consideration for the rights and license granted, the Feinstein Institute would receive a royalty of one percent (1%) of the first
one hundred million dollars ($100,000) of net sales of IV Choline Chloride and a royalty of one and one-half percent (1.5%) of all net
sales thereafter. In addition, the Company would pay the Feinstein Institute twelve and one-half percent (12.5%) of net proceeds resulting
from agreements entered within 2 years from the effective date, and seven and one-half percent (7.5%) of net proceeds resulting from
agreements entered into thereafter. Pursuant to the Feinstein Agreement additional payments would be due to the Feinstein Institute for
license maintenance payments and for meeting milestone events. Pursuant to the Feinstein Agreement, upon the achievement of certain future
new drug application milestones, the Company would be obligated to remit an aggregate of $275.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the years ended December 31, 2022 and
2021, the Company recorded research and development expense of $17 and $15, respectively, in connection with the Feinstein Agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Sponsored Research and License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 28, 2018, the Company entered into a sponsored research
and license agreement (the &#x201c;Iowa Agreement&#x201d;) with the University of Iowa. Pursuant to the Iowa Agreement, the University of
Iowa, which is engaged in clinical research to improve the diagnosis and treatment of lymphangioma using a pharmaceutical product (OK-432),
would assist the Company in collecting case reports, forms, source data, and safety data available to the University of Iowa in support
of the development of the Company&#x2019;s proprietary &lt;i&gt;Streptococcus Pyogenes&lt;/i&gt; investigational product, TARA-002 for the LMs indication.
During the term of the services, the Company would generally pay the University of Iowa thirty thousand dollars ($30) per year to fund
the project, plus additional amounts upon the realization of certain milestones. More specifically, upon forty-five (45) days of an approval
of TARA-002 by the FDA, the Company would pay up to $1,750 to the University of Iowa for meeting these milestones. Furthermore, the Company
would pay the University of Iowa royalties of up to 1.75% for net sales ranging from $0 - $25,000, 2.25% for net sales ranging from $25,000
to $50,000, and 2.50% for net sales in excess of $50,000. Pursuant to the Iowa Agreement, the University of Iowa would be entitled to
additional payments for the Company achieving annual net sales of product according to the milestones. For annual net sales of product
up to $25,000: $62; for annual net sales of product of up to $50,000: $62; and for annual net sales of product of up to $100,000: $125.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the Iowa Agreement there were no
research and development expenses recognized during the years ended December 31, 2022 and 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Chugai Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 17, 2019, the Company entered into
an agreement (the &#x201c;Chugai Pharmaceutical Agreement&#x201d;) with Chugai Pharmaceutical Co., LTD (&#x201c;Chugai&#x201d;), a drug
manufacturing firm with offices and operations in Japan. Pursuant to the Chugai Pharmaceutical Agreement, Chugai would help the
Company in its goals to develop and commercialize a therapeutic product (the &#x201c;New Product&#x201d;) which is comparable to the
Chugai existing therapeutic product (the &#x201c;Existing Product&#x201d;). In addition, the Company would be entitled to the use of
Chugai materials and technical support as necessary. On July 14, 2020, the Company and Chugai entered into an amendment (the
&#x201c;Chugai Amendment&#x201d;) to the Chugai Pharmaceutical Agreement, with an effective date of June 30, 2020. The Chugai
Amendment extended the date through which Chugai will exclusively provide the Existing Product and materials to the Company from
June 30, 2020 to June 30, 2021, extended the date through which Chugai will not provide materials or technical support to any
third-party for the purpose of development and commercialization in a given area from the fifth anniversary to the eleventh
anniversary of the original effective date, and provides for further such extensions on the occurrence of certain events and
milestones. The amendment further provides that, in addition to the designated fee provided upon the initial indication approval in
the Chugai Pharmaceutical Agreement, the Company will pay Chugai a designated fee for each additional indication approval. The
Company is obligated to Chugai for certain payments upon the completion of agreed upon milestones. As consideration for
Chugai&#x2019;s performance under the Chugai Pharmaceutical Agreement, the Company agreed to pay Chugai a payment in the low,
single-digit millions related to such initial indication approval, which payment will be made in two installments with an initial
payment in July 2020, and the remaining majority of the payment payable upon FDA approval of the New Product.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the agreement there were no research
and development expenses recognized during the years ended December 31, 2022 and 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Contingencies&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From time to time, the Company may be subject
to various legal proceedings and claims that arise in the ordinary course of its business activities. Management is of the opinion that
the ultimate outcome of these matters would not have a material adverse impact on the financial position of the Company or the results
of its operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the normal course of business, the Company
enters into contracts in which it makes representations and warranties regarding the performance of its services and that its services
will not infringe on third-party intellectual rights. There have been no significant events related to such representations and warranties
in which the Company believes the outcome could result in losses or penalties in the future.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <tara:DescriptionOfAgreements contextRef="c71">the Company entered into
a license agreement (the &#x201c;Choline License Agreement&#x201d;) with Alan L. Buchman (&#x201c;Dr. Buchman&#x201d;). Pursuant to the Choline
License Agreement, the Company received from Dr. Buchman the license rights in and to the &#x201c;Licensed Orphan Designations&#x201d;,
the &#x201c;Licensed IND&#x201d;, &#x201c;Existing Study Data&#x201d; and the &#x201c;Licensed Know-How&#x201d; for one or more of the licensed
indications.</tara:DescriptionOfAgreements>
    <tara:ResearchAndDevelopmentExpenses contextRef="c72" decimals="-3" unitRef="usd">2000</tara:ResearchAndDevelopmentExpenses>
    <tara:ResearchAndDevelopmentExpenses contextRef="c73" decimals="-3" unitRef="usd">0</tara:ResearchAndDevelopmentExpenses>
    <tara:DescriptionOfAgreements contextRef="c74">the Company entered into
an agreement (the &#x201c;Feinstein Agreement&#x201d;) with The Feinstein Institute for Medical Research (the &#x201c;Feinstein Institute&#x201d;),
a not-for-profit corporation with 50 research labs and 2,500 clinical research studies. Pursuant to the Feinstein Agreement, the Company
acquired an exclusive license relating to treatment of fatty liver diseases in humans for which Choline may be an effective therapeutic.
In consideration for the rights and license granted, the Feinstein Institute would receive a royalty of one percent (1%) of the first
one hundred million dollars ($100,000) of net sales of IV Choline Chloride and a royalty of one and one-half percent (1.5%) of all net
sales thereafter. In addition, the Company would pay the Feinstein Institute twelve and one-half percent (12.5%) of net proceeds resulting
from agreements entered within 2 years from the effective date, and seven and one-half percent (7.5%) of net proceeds resulting from
agreements entered into thereafter. Pursuant to the Feinstein Agreement additional payments would be due to the Feinstein Institute for
license maintenance payments and for meeting milestone events. Pursuant to the Feinstein Agreement, upon the achievement of certain future
new drug application milestones, the Company would be obligated to remit an aggregate of $275.</tara:DescriptionOfAgreements>
    <tara:ResearchAndDevelopmentExpenses contextRef="c75" decimals="-3" unitRef="usd">17000</tara:ResearchAndDevelopmentExpenses>
    <tara:ResearchAndDevelopmentExpenses contextRef="c76" decimals="-3" unitRef="usd">15000</tara:ResearchAndDevelopmentExpenses>
    <us-gaap:BroadcastersLicenseAgreementCommitmentsDescription contextRef="c77">the Company entered into a sponsored research
and license agreement (the &#x201c;Iowa Agreement&#x201d;) with the University of Iowa. Pursuant to the Iowa Agreement, the University of
Iowa, which is engaged in clinical research to improve the diagnosis and treatment of lymphangioma using a pharmaceutical product (OK-432),
would assist the Company in collecting case reports, forms, source data, and safety data available to the University of Iowa in support
of the development of the Company&#x2019;s proprietary Streptococcus Pyogenes investigational product, TARA-002 for the LMs indication.
During the term of the services, the Company would generally pay the University of Iowa thirty thousand dollars ($30) per year to fund
the project, plus additional amounts upon the realization of certain milestones. More specifically, upon forty-five (45) days of an approval
of TARA-002 by the FDA, the Company would pay up to $1,750 to the University of Iowa for meeting these milestones. Furthermore, the Company
would pay the University of Iowa royalties of up to 1.75% for net sales ranging from $0 - $25,000, 2.25% for net sales ranging from $25,000
to $50,000, and 2.50% for net sales in excess of $50,000. Pursuant to the Iowa Agreement, the University of Iowa would be entitled to
additional payments for the Company achieving annual net sales of product according to the milestones. For annual net sales of product
up to $25,000: $62; for annual net sales of product of up to $50,000: $62; and for annual net sales of product of up to $100,000: $125.</us-gaap:BroadcastersLicenseAgreementCommitmentsDescription>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;10. Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022, the Company had 100,000,000
shares of common stock authorized for issuance, $0.001 par value per share, of which 11,267,389 and 11,235,731 shares were issued and
outstanding as of December 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The holders of the Company&#x2019;s common stock
are entitled to one vote per share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the Preferred Offering (defined
below) on September 22, 2020, the Company filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights and
Limitations of Series 1 Convertible Preferred Stock of the Company (the &#x201c;Amendment&#x201d;) with the State of Delaware to increase
the authorized number of shares of the Company&#x2019;s Series 1 Convertible Preferred Stock that may be issued from 3,880 to 8,028. The
Amendment was approved by a committee of the Company&#x2019;s Board of Directors and the requisite holders of outstanding shares of Series
1 Convertible Preferred Stock. No approval of the holders of the Company&#x2019;s common stock was required to effectuate the Amendment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022 and 2021, the Company
had 10,000,000 shares of preferred stock authorized for issuance, $0.001 par value per share of which 8,028 shares of Series 1 Convertible
Preferred Stock are authorized for issuance and 8,027 shares were issued and outstanding, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Description of Series 1 Convertible Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Each share of Series 1 Convertible Preferred
Stock is convertible into 1,000 shares of the Company&#x2019;s common stock, at a conversion price initially equal to approximately $7.01
per common share, subject to adjustment for any stock splits, stock dividends and similar events, at any time at the option of the holder,
provided that any conversion of Series 1 Convertible Preferred Stock by a holder into shares of the Company&#x2019;s common stock would
be prohibited if, as a result of such conversion, the holder, together with its affiliates and any other person or entity whose beneficial
ownership of the Company&#x2019;s common stock would be aggregated with such holder&#x2019;s for purposes of Section 13(d) of the Securities
Exchange Act of 1934, as amended, would beneficially own more than 9.99% of the total number of shares of the Company&#x2019;s common
stock issued and outstanding after giving effect to such conversion. Upon written notice to the Company, the holder may from time to
time increase or decrease such limitation to any other percentage not in excess of 19.99% specified in such notice. In addition, upon
the occurrence of certain transactions that involve the merger or consolidation of the Company, an exchange or tender offer, a sale of
all or substantially all of the assets of the Company or a reclassification of its Common Stock, each share of Series 1 Convertible Preferred
Stock will be convertible into the kind and amount of securities, cash and/or other property that the holder of a number of shares of
Common Stock issuable upon conversion of one share of Series 1 Convertible Preferred Stock would receive in connection with such transaction.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The terms of the Series 1 Convertible Preferred
Stock provide that, in the event of a fundamental transaction (as such term is described in the certificate of designation of preferences,
rights and limitations of series 1 convertible non-voting preferred stock), each share of Series 1 Convertible Preferred Stock outstanding
will thereafter be convertible into the kind and amount of securities, cash and/or other property which a holder of the number of shares
of Common Stock of the Company issuable upon conversion of one share of Series 1 Convertible Preferred Stock immediately prior to such
fundamental transaction would have been entitled to receive pursuant to such fundamental transaction, provided that, if the value of
the aggregate of such securities, cash and/or other property the which the holder of one share of Series 1 Convertible Preferred Stock
would be entitled to upon conversion thereof would be less than the stated value, then each outstanding share of Series 1 Convertible
Preferred Stock will instead be convertible into such kind of securities, cash and/or other property with an aggregate value equal to
the stated value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Each share of Series 1 Convertible Preferred
Stock is entitled to a preference of $10.00 per share upon liquidation of the Company, and thereafter will share ratably in any distributions
or payments on an as-converted basis with the holders of Common Stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The holders of Series 1 Convertible Preferred
Stock are not entitled to vote.&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Underwritten Public Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 24, 2020, pursuant to an underwriting
agreement dated September 22, 2020, the Company issued and sold in an underwritten public offering (the &#x201c;Common Offering&#x201d;)
an aggregate of 4,600,000 shares of its common stock at an offering price of $16.87 per share, for gross and net proceeds of approximately
$77.6 million and $73.6 million, respectively. The underwriters were granted an option to purchase up to 690,000 additional shares of
the Company&#x2019;s common stock at the public offering price, less the underwriting discount. On October 6, 2020, the underwriters exercised
their overallotment option in full, purchasing an additional 690,000 shares, resulting in the receipt of gross and net proceeds of $11.6
million and $11.1 million, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 24, 2020, pursuant to an underwriting
agreement (dated September 22, 2020), the Company issued and sold in an underwritten public offering (the &#x201c;Preferred Offering&#x201d;)
an aggregate of 4,148 shares of its Series 1 Convertible Preferred Stock at an offering price of $16,873.54 per share, for gross and
net proceeds of approximately $70.0 million and $66.3 million, respectively.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c78" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c78" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c78" decimals="0" unitRef="shares">11267389</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c78" decimals="0" unitRef="shares">11267389</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c79" decimals="0" unitRef="shares">11235731</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c79" decimals="0" unitRef="shares">11235731</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c80" decimals="0" unitRef="shares">3880</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c81" decimals="0" unitRef="shares">8028</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c4" decimals="0" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c4" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c82" decimals="0" unitRef="shares">8028</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c82" decimals="0" unitRef="shares">8027</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c82" decimals="0" unitRef="shares">8027</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="c83" decimals="0" unitRef="shares">1000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockConvertibleConversionPrice contextRef="c82" decimals="2" unitRef="usdPershares">7.01</us-gaap:PreferredStockConvertibleConversionPrice>
    <tara:CommonStockIssuanceAndOutstandingPercentage contextRef="c0" decimals="4" unitRef="pure">0.0999</tara:CommonStockIssuanceAndOutstandingPercentage>
    <tara:IncreaseOrDecreaseEquityPercentage contextRef="c83" decimals="4" unitRef="pure">0.1999</tara:IncreaseOrDecreaseEquityPercentage>
    <us-gaap:PreferredStockLiquidationPreference contextRef="c82" decimals="INF" unitRef="usdPershares">10</us-gaap:PreferredStockLiquidationPreference>
    <tara:AggregateOfSharesOfCommonStock contextRef="c84" decimals="0" unitRef="shares">4600000</tara:AggregateOfSharesOfCommonStock>
    <us-gaap:SaleOfStockPricePerShare contextRef="c84" decimals="2" unitRef="usdPershares">16.87</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c85" decimals="-5" unitRef="usd">77600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <tara:NetProceeds contextRef="c85" decimals="-5" unitRef="usd">73600000</tara:NetProceeds>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c85" decimals="0" unitRef="shares">690000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c86" decimals="0" unitRef="shares">690000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <tara:GrossProceeds contextRef="c86" decimals="-5" unitRef="usd">11600000</tara:GrossProceeds>
    <tara:NetProceeds contextRef="c86" decimals="-5" unitRef="usd">11100000</tara:NetProceeds>
    <tara:AggregateOfSharesOfCommonStock contextRef="c87" decimals="0" unitRef="shares">4148</tara:AggregateOfSharesOfCommonStock>
    <us-gaap:SaleOfStockPricePerShare contextRef="c87" decimals="2" unitRef="usdPershares">16873.54</us-gaap:SaleOfStockPricePerShare>
    <tara:GrossProceeds contextRef="c88" decimals="-5" unitRef="usd">70000000</tara:GrossProceeds>
    <tara:NetProceeds contextRef="c88" decimals="-5" unitRef="usd">66300000</tara:NetProceeds>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;11. Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;2020 Inducement Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 26, 2020, the Compensation Committee
of the Board of Directors (the &#x201c;Compensation Committee&#x201d;) approved the ArTara Therapeutics, Inc. Inducement Plan (the &#x201c;2020
Inducement Plan&#x201d;) in order to award nonstatutory stock options, restricted stock awards, restricted stock unit awards and other
stock-based awards to persons not previously an employee or director of the Company, or following a bona fide period of non-employment,
as an inducement material to such persons entering into employment with the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The 2020 Inducement Plan provides for a total
of 600,000 shares for the issuance of the Company&#x2019;s common stock. The Compensation Committee also adopted a form of stock option
grant notice and stock option agreement and forms of restricted stock unit grant notice and restricted stock unit agreement for use with
the Inducement Plan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022, 446,639 shares remain
available to be issued under the 2020 Inducement Plan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;2017 Equity Incentive
Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 10, 2017, Private ArTara, (a predecessor
of the Company), its Board of Directors and its stockholders approved the ArTara Therapeutics, Inc. 2017 Equity Incentive Plan to enable
Private ArTara and its affiliates to recruit and retain highly qualified personnel and to incentivize personnel for productivity and
growth.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The 2017 Equity Incentive Plan provided for the
grant of a total of 2,000,000 shares for the issuance of stock options, stock appreciation rights, restricted stock and restricted stock
units to among others, members of the Board of Directors, employees, consultants and service providers to the Company and its affiliates.
As of January 9, 2020, in connection with the Merger, no additional awards will be made under the 2017 Equity Incentive Plan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;2014 Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 3, 2014, the stockholders approved
the 2014 Equity Incentive Plan. On June 20, 2017, the Company&#x2019;s Board of Directors amended the 2014 Equity Incentive Plan, or the
Amended and Restated 2014 Plan. On July 31, 2017, the stockholders approved this amendment. On January 1, 2020, Protara Therapeutics,
Inc. amended its Amended and Restated 2014 Equity Incentive Plan to increase the number of shares of stock available for issuance under
the 2014 Equity Incentive Plan to 1,048,300 shares and made conforming changes and updates pursuant to Section 162(m) of the Code.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Amended and Restated 2014 Plan provides for
the grant of incentive and non-statutory stock options, stock appreciation rights, restricted stock and stock unit awards, performance
units, stock grants and qualified performance-based awards. The Amended and Restated 2014 Plan provides that the number of shares reserved
and available for issuance will automatically increase each January 1, by four percent of the Company&#x2019;s common stock on the immediately
preceding December 31, adjusted for the number of shares of the Company&#x2019;s common stock issuable upon conversion of any security
that the Company may issue that is convertible into or exchangeable for the Company&#x2019;s common stock, or such lesser number of shares
as determined by the Company&#x2019;s Board of Directors.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Terms of the stock awards, including vesting
requirements, are determined by the Board of Directors, subject to the provisions of the plans. Certain awards provide for accelerated
vesting if there is a change in control as defined in the plans.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 1, 2022, pursuant to the Amended 2014
Plan&#x2019;s annual evergreen feature, the number of shares authorized under the Amended 2014 Plan was increased by 840,181 shares to
1,238,785 shares. As of December 31, 2022, 603,218 shares remain available to be issued under the Amended 2014 Plan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 1, 2023, pursuant to the Amended 2014
Plan&#x2019;s annual evergreen feature, the number of shares authorized under the Amended 2014 Plan was increased by 861,933 shares to
1,465,151 shares available to be issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;2014 Employee Stock
Purchase Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 3, 2014, the stockholders approved
the 2014 Employee Stock Purchase Plan (the &#x201c;2014 ESPP&#x201d;). The 2014 ESPP initially authorized the issuance of up to 3,513 shares
of the Company&#x2019;s common stock. The number of shares increases each January 1, commencing on January 1, 2015 and ending on (and
including) January 1, 2024, by an amount equal to the lesser of one percent of the outstanding shares as of the end of the immediately
preceding fiscal year, 7,025 shares or any lower amount determined by the Company&#x2019;s Board of Directors prior to each such January
1st.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 1, 2022, pursuant to the increase
per the 2014 ESPP, the number of shares authorized under the 2014 ESPP was increased by 7,025 shares to 32,062 shares. As of December
31, 2022, the authorized number of shares under the 2014 ESPP is 32,062 and the number of shares available for issuance is 32,062. During
the years ended December 31, 2022 and 2021, no shares were issued under the 2014 ESPP.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 1, 2023, pursuant to the increase
per the 2014 ESPP, the number of shares authorized under the 2014 ESPP was increased by 7,025 shares to 39,087 shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table summarizes restricted stock unit activity:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Restricted&lt;br/&gt; Stock Units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average Grant&lt;br/&gt; Date Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Non-vested 12/31/2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;96,201&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28.87&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178,425&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,400&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51,388&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21.67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Non-vested 12/31/2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;196,838&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12.49&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of RSUs is amortized on a straight-line
basis over the requisite service period of the respective awards. As of December 31, 2022, the unamortized value of RSUs was $1,412.
As of December 31, 2022, the weighted average remaining amortization period was 1.53 years. As of December 31, 2022 and 2021, 289,500
and 286,918 RSUs, respectively, have vested that have not yet been settled into shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2022, the Company issued 31,658
shares of the Company&#x2019;s common stock from the net settlement of 48,806 RSUs. The Company paid $90 in connection with the net share
settlement of these RSUs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company determined the fair value of stock
options granted based upon the assumptions as provided below.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;$ 2.77 - $ 6.90&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;$ 6.56 - $ 19.82&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;92.00% - 99.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;89.00% - 98.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.46% - 4.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.45% - 1.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.27 - 6.08&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.27 - 6.08&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes stock option activities
for the year ended December 31, 2022:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&#160;(years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value (1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding 12/31/2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,356,639&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20.51&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.59&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(246,977&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(125,733&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;25.40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,828,329&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;14.23&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.16&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Vested or expected to vest at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,828,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable as of December, 31 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;755,234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;18.71&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Aggregate&#160;intrinsic
value&#160;represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31,
2022. The&#160;intrinsic value&#160;of options exercised during the years ended December&#160;31, 2022 and 2021 was $0 as no options
were exercised.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The weighted average grant date fair value per
share of the options granted during the years ended December 31, 2022 and 2021 was $4.80 and $12.60, respectively. As of December 31,
2022, there was approximately $8,333 of unrecognized share-based compensation for unvested stock option grants which is expected to be
recognized over a weighted average period of 2.50 years. The total unrecognized share-based compensation cost will be adjusted for actual
forfeitures as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Summary of Stock-Based Compensation Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following tables summarize total stock-based compensation costs
recognized:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;RSUs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,272&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,520&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,416&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,842&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,688&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,362&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Stock-based compensation expense was reflected within the consolidated
statements of operations and comprehensive loss as:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,511&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,409&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,953&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,688&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,362&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <tara:StocksIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="0" unitRef="shares">600000</tara:StocksIssuedDuringPeriodValueNewIssues>
    <tara:SharesAvailableForIssuance contextRef="c89" decimals="0" unitRef="shares">446639</tara:SharesAvailableForIssuance>
    <tara:SharesAvailableForIssuance contextRef="c90" decimals="0" unitRef="shares">2000000</tara:SharesAvailableForIssuance>
    <tara:SharesAvailableForIssuance contextRef="c91" decimals="0" unitRef="shares">1048300</tara:SharesAvailableForIssuance>
    <us-gaap:CommonStockSharesAuthorized contextRef="c92" decimals="0" unitRef="shares">840181</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c93" decimals="0" unitRef="shares">1238785</us-gaap:CommonStockSharesAuthorized>
    <tara:SharesAvailableForIssuance contextRef="c94" decimals="0" unitRef="shares">603218</tara:SharesAvailableForIssuance>
    <us-gaap:CommonStockSharesAuthorized contextRef="c95" decimals="0" unitRef="shares">861933</us-gaap:CommonStockSharesAuthorized>
    <tara:SharesAvailableForIssuance contextRef="c96" decimals="0" unitRef="shares">1465151</tara:SharesAvailableForIssuance>
    <us-gaap:CommonStockSharesAuthorized contextRef="c97" decimals="0" unitRef="shares">3513</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c98" decimals="0" unitRef="shares">7025</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c99" decimals="0" unitRef="shares">7025</us-gaap:CommonStockSharesAuthorized>
    <tara:SharesAvailableForIssuance contextRef="c100" decimals="0" unitRef="shares">32062</tara:SharesAvailableForIssuance>
    <tara:NumberSharesAuthorized contextRef="c101" decimals="0" unitRef="shares">32062</tara:NumberSharesAuthorized>
    <tara:SharesAvailableForIssuance contextRef="c3" decimals="0" unitRef="shares">32062</tara:SharesAvailableForIssuance>
    <tara:NumberOfShareAuthorizedIncreased contextRef="c102" decimals="0" unitRef="shares">7025</tara:NumberOfShareAuthorizedIncreased>
    <tara:NumberOfShareAuthorizedIncreased contextRef="c103" decimals="0" unitRef="shares">39087</tara:NumberOfShareAuthorizedIncreased>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Restricted&lt;br/&gt; Stock Units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average Grant&lt;br/&gt; Date Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Non-vested 12/31/2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;96,201&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28.87&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178,425&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(26,400&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(51,388&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21.67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Non-vested 12/31/2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;196,838&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12.49&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c107" decimals="0" unitRef="shares">96201</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c107" decimals="2" unitRef="usdPershares">28.87</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c108" decimals="0" unitRef="shares">178425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c108" decimals="2" unitRef="usdPershares">6.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c108" decimals="0" unitRef="shares">26400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="c108" decimals="2" unitRef="usdPershares">11.01</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c108" decimals="0" unitRef="shares">51388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c108" decimals="2" unitRef="usdPershares">21.67</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="c109" decimals="0" unitRef="shares">196838</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c109" decimals="2" unitRef="usdPershares">12.49</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <tara:UnamortizedValueOfRsus contextRef="c104" decimals="-3" unitRef="usd">1412000</tara:UnamortizedValueOfRsus>
    <tara:WeightedAverageRemainingAmortizationPeriod contextRef="c104">P1Y6M10D</tara:WeightedAverageRemainingAmortizationPeriod>
    <tara:NumberOfSharesRestrictedStock contextRef="c104" decimals="0" unitRef="shares">289500</tara:NumberOfSharesRestrictedStock>
    <tara:NumberOfSharesRestrictedStock contextRef="c105" decimals="0" unitRef="shares">286918</tara:NumberOfSharesRestrictedStock>
    <us-gaap:CommonStockSharesIssued contextRef="c106" decimals="0" unitRef="shares">31658</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c30" decimals="0" unitRef="shares">48806</us-gaap:CommonStockSharesOutstanding>
    <tara:ConnectionWithTheNetShareSettlement contextRef="c104" decimals="-3" unitRef="usd">90000</tara:ConnectionWithTheNetShareSettlement>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;$ 2.77 - $ 6.90&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;$ 6.56 - $ 19.82&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;92.00% - 99.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;89.00% - 98.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.46% - 4.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.45% - 1.33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.27 - 6.08&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.27 - 6.08&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c110" decimals="2" unitRef="usdPershares">2.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c111" decimals="2" unitRef="usdPershares">6.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c112" decimals="2" unitRef="usdPershares">6.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c113" decimals="2" unitRef="usdPershares">19.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="4" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c7" decimals="4" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c114" decimals="4" unitRef="pure">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c115" decimals="4" unitRef="pure">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c116" decimals="4" unitRef="pure">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c117" decimals="4" unitRef="pure">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c114" decimals="4" unitRef="pure">0.0146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c115" decimals="4" unitRef="pure">0.0423</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c116" decimals="4" unitRef="pure">0.0045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c117" decimals="4" unitRef="pure">0.0133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c114">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c115">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c116">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c117">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&#160;(years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value (1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding 12/31/2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,356,639&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20.51&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8.59&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;844,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(246,977&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(125,733&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;25.40&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,828,329&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;14.23&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;8.16&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Vested or expected to vest at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,828,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;14.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable as of December, 31 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;755,234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;18.71&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Aggregate&#160;intrinsic
value&#160;represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31,
2022. The&#160;intrinsic value&#160;of options exercised during the years ended December&#160;31, 2022 and 2021 was $0 as no options
were exercised.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c118" decimals="0" unitRef="shares">1356639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c118" decimals="2" unitRef="usdPershares">20.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <tara:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2 contextRef="c119">P8Y7M2D</tara:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c118"
      decimals="-3"
      id="ix_14_fact"
      unitRef="usd">1000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c119" decimals="0" unitRef="shares">844400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="c119" decimals="2" unitRef="usdPershares">6.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c119" decimals="0" unitRef="shares">246977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="c119" decimals="2" unitRef="usdPershares">15.35</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c119" decimals="0" unitRef="shares">125733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c119" decimals="2" unitRef="usdPershares">25.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c120" decimals="0" unitRef="shares">1828329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c120" decimals="2" unitRef="usdPershares">14.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <tara:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm contextRef="c119">P8Y1M28D</tara:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c120" decimals="0" unitRef="shares">1828329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="c120" decimals="2" unitRef="usdPershares">14.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c119">P8Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c120" decimals="0" unitRef="shares">755234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <tara:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable contextRef="c120" decimals="2" unitRef="usdPershares">18.71</tara:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable>
    <tara:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable contextRef="c119">P7Y6M</tara:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c3" decimals="2" unitRef="usd">4.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c4" decimals="2" unitRef="usd">12.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <tara:ShareBasedCompensationUnrecognized contextRef="c0" decimals="-3" unitRef="usd">8333000</tara:ShareBasedCompensationUnrecognized>
    <us-gaap:NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1 contextRef="c0">P2Y6M</us-gaap:NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1>
    <tara:IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;RSUs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,272&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,520&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,416&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,842&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,688&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,362&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</tara:IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock>
    <us-gaap:ShareBasedCompensation contextRef="c104" decimals="-3" unitRef="usd">1272000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c105" decimals="-3" unitRef="usd">4520000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c121" decimals="-3" unitRef="usd">5416000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c122" decimals="-3" unitRef="usd">5842000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">6688000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="-3" unitRef="usd">10362000</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,511&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,409&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,953&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,688&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,362&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation contextRef="c56" decimals="-3" unitRef="usd">1511000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c58" decimals="-3" unitRef="usd">1409000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c57" decimals="-3" unitRef="usd">5177000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c59" decimals="-3" unitRef="usd">8953000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">6688000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="-3" unitRef="usd">10362000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;12. Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Federal and State income tax expense is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Total current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Deferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-left: 9pt"&gt;Federal&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,954&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(8,918&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,068&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,294&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Total deferred&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,624&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,624&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total income tax expense (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred income taxes, if applicable, are provided
for the differences between the basis of assets and liabilities for financial reporting and income tax purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The tax effects of temporary differences that
give rise to significant portions of the deferred tax assets are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Net operating loss carry forwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23,350&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Capitalized research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,418&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Stock option expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,710&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,551&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,481&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,564&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;RSU expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;408&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,352&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(38,983&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27,803&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Deferred tax assets, net of valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,478&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,549&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Operating right-of-use asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,456&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,549&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,478&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,549&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Deferred tax assets, net of valuation allowance and deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A reconciliation of the provision for income
taxes with the amounts computed by applying the statutory Federal income tax to income before provision for income taxes is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;U.S. federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.8&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;True-up to prior years return&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;State rate change&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12.9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the year ended December 31, 2021, the Company&#x2019;s effective
tax rate was 0%, which consisted principally of a federal rate of 21%, and the Company&#x2019;s estimate of state taxes, net of federal
benefit, of 0.6%, offset by a valuation allowance 12.9% and true-up to the prior year&#x2019;s tax return of 8.2%. For the year ended December
31, 2022, the Company&#x2019;s effective tax rate was 0%, which consisted principally of a federal rate of 21%, the Company&#x2019;s estimate
of state taxes, net of federal benefit, of 2.2%, research and development credits of 3.3% and a true-up to the prior year&#x2019;s tax
return of 0.7%, offset by goodwill impairment of 10.4% and a valuation allowance 17.0%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022 and 2021 for U.S. federal
and state income tax reporting purposes, the Company has approximately $114,800 and $100,200, respectively, of unused net operating losses
(&#x201c;NOLs&#x201d;) available for carry forward to future years. As a result of the Tax Cuts and Jobs Act of 2017 (&#x201c;TCJA&#x201d;),
for U.S. income tax purposes, NOLs generated in tax years beginning before January 1, 2018 can still be carried forward for up to 20 years,
but net operating losses generated for tax years beginning after December 31, 2017 carryforward indefinitely and can be used to offset
taxable income. Of the total Federal NOL, $600 can be carried forward until 2037; and $114,200 can be carried forward indefinitely. The
New York state and city NOLs may be carried forward through the year 2042 and may be applied against future taxable income. Further, the
benefit from utilization of NOL carry forwards could be subject to limitations due to material ownership changes that could occur as the
Company continues to issue additional shares of common stock pursuant to its capital raising plans. Based on such limitations, the Company
has significant NOLs for which realization of tax benefits is uncertain. The Company has not performed a study to determine whether or
not there is such a limitation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company remains subject to examination by
tax authorities for all tax years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Based on a history of cumulative losses at the Company and the results
of operations for the years ended December 31, 2022 and 2021, the Company determined that it is more likely than not that it will not
realize benefits from the net deferred tax assets. The Company will not record income tax benefits in the financial statements until it
is determined that it is more likely than not that the Company will generate sufficient taxable income to realize the deferred income
tax assets. As a result of the analysis, the Company determined that a full valuation allowance against the deferred tax assets, net,
was required. As of December 31, 2022 and 2021, the Company has recorded a valuation allowance of $39.0 million and $27.8 million, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2022 and 2021, management
does not believe that the Company has any material uncertain tax positions that would require it to measure and reflect the potential
lack of sustainability of a position on audit in its consolidated financial statements. The Company will continue to evaluate its uncertain
tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does
not believe there will be any material changes in its unrecognized tax positions over the next year.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Total current&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Deferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-left: 9pt"&gt;Federal&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,954&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(8,918&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,068&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,294&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Total deferred&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,624&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,624&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total income tax expense (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c0" decimals="-3" unitRef="usd">-7954000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c7" decimals="-3" unitRef="usd">-8918000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c0" decimals="-3" unitRef="usd">-1068000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c7" decimals="-3" unitRef="usd">4294000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c0" decimals="-3" unitRef="usd">-9022000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c7" decimals="-3" unitRef="usd">-4624000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="-3" unitRef="usd">9022000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c7" decimals="-3" unitRef="usd">4624000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Net operating loss carry forwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23,350&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Capitalized research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,418&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Stock option expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,710&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,551&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,481&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,564&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;RSU expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;408&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,352&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(38,983&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27,803&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Deferred tax assets, net of valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,478&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,549&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Operating right-of-use asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,456&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,549&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,478&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,549&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Deferred tax assets, net of valuation allowance and deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="-3" unitRef="usd">26768000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="-3" unitRef="usd">23350000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c3" decimals="-3" unitRef="usd">3418000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c3" decimals="-3" unitRef="usd">2477000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c4" decimals="-3" unitRef="usd">920000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c3" decimals="-3" unitRef="usd">3710000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c4" decimals="-3" unitRef="usd">1551000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <tara:DeferredTaxAssetsOperatingLeaseLiability contextRef="c3" decimals="-3" unitRef="usd">1481000</tara:DeferredTaxAssetsOperatingLeaseLiability>
    <tara:DeferredTaxAssetsOperatingLeaseLiability contextRef="c4" decimals="-3" unitRef="usd">1564000</tara:DeferredTaxAssetsOperatingLeaseLiability>
    <tara:DeferredTaxAssetsRestrictedStockUnitsExpense contextRef="c3" decimals="-3" unitRef="usd">2199000</tara:DeferredTaxAssetsRestrictedStockUnitsExpense>
    <tara:DeferredTaxAssetsRestrictedStockUnitsExpense contextRef="c4" decimals="-3" unitRef="usd">1960000</tara:DeferredTaxAssetsRestrictedStockUnitsExpense>
    <us-gaap:DeferredTaxAssetsOther contextRef="c3" decimals="-3" unitRef="usd">408000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c4" decimals="-3" unitRef="usd">7000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="-3" unitRef="usd">40461000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="-3" unitRef="usd">29352000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-3" unitRef="usd">38983000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="-3" unitRef="usd">27803000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c3" decimals="-3" unitRef="usd">1478000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c4" decimals="-3" unitRef="usd">1549000</us-gaap:DeferredTaxAssetsNet>
    <tara:DeferredTaxLiabilitiesOperatingRightofuseAsset contextRef="c3" decimals="-3" unitRef="usd">1456000</tara:DeferredTaxLiabilitiesOperatingRightofuseAsset>
    <tara:DeferredTaxLiabilitiesOperatingRightofuseAsset contextRef="c4" decimals="-3" unitRef="usd">1549000</tara:DeferredTaxLiabilitiesOperatingRightofuseAsset>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c3" decimals="-3" unitRef="usd">-22000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c3" decimals="-3" unitRef="usd">1478000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c4" decimals="-3" unitRef="usd">1549000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Years Ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;U.S. federal statutory rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.8&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;True-up to prior years return&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;State rate change&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12.9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="3" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="3" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="3" unitRef="pure">-0.022</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c7" decimals="3" unitRef="pure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c0" decimals="3" unitRef="pure">-0.033</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c7" decimals="3" unitRef="pure">-0.028</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="c0" decimals="3" unitRef="pure">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="c7" decimals="3" unitRef="pure">0.082</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c0" decimals="3" unitRef="pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c7" decimals="3" unitRef="pure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c7" decimals="3" unitRef="pure">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <tara:EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost contextRef="c0" decimals="3" unitRef="pure">0.001</tara:EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost>
    <tara:EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost contextRef="c7" decimals="3" unitRef="pure">0.012</tara:EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses contextRef="c0" decimals="3" unitRef="pure">0.104</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="3" unitRef="pure">0.17</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c7" decimals="3" unitRef="pure">0.129</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <tara:EffectiveTaxRateDescription contextRef="c7">For the year ended December 31, 2021, the Company&#x2019;s effective
tax rate was 0%, which consisted principally of a federal rate of 21%, and the Company&#x2019;s estimate of state taxes, net of federal
benefit, of 0.6%, offset by a valuation allowance 12.9% and true-up to the prior year&#x2019;s tax return of 8.2%.</tara:EffectiveTaxRateDescription>
    <tara:EffectiveTaxRateDescription contextRef="c0">For the year ended December
31, 2022, the Company&#x2019;s effective tax rate was 0%, which consisted principally of a federal rate of 21%, the Company&#x2019;s estimate
of state taxes, net of federal benefit, of 2.2%, research and development credits of 3.3% and a true-up to the prior year&#x2019;s tax
return of 0.7%, offset by goodwill impairment of 10.4% and a valuation allowance 17.0%.</tara:EffectiveTaxRateDescription>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c123" decimals="-3" unitRef="usd">114800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c124" decimals="-3" unitRef="usd">100200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <tara:IncomeTaxCarriedForwardTerms contextRef="c0">P20Y</tara:IncomeTaxCarriedForwardTerms>
    <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards contextRef="c125" decimals="-3" unitRef="usd">600000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards contextRef="c3" decimals="-3" unitRef="usd">114200000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-5" unitRef="usd">39000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="-5" unitRef="usd">27800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;13. Employee Benefit Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company maintains a defined contribution
benefit plan under section 401(k) of the Internal Revenue Code covering substantially all qualified employees of the Company (the &#x201c;401(k)
Plan&#x201d;). Under the 401(k) Plan, the Company matches 100% of employee contributions up to 4% of employee compensation. For the years
ended December 31, 2022 and 2021, the Company recorded expense of $223 and $215, respectively, representing employer contributions under
the 401(k) Plan.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <tara:EmployeeContributions contextRef="c0" decimals="2" unitRef="pure">1</tara:EmployeeContributions>
    <tara:EmployeeCompensation contextRef="c0" decimals="2" unitRef="pure">0.04</tara:EmployeeCompensation>
    <us-gaap:OtherLaborRelatedExpenses contextRef="c0" decimals="-3" unitRef="usd">223000</us-gaap:OtherLaborRelatedExpenses>
    <us-gaap:OtherLaborRelatedExpenses contextRef="c7" decimals="-3" unitRef="usd">215000</us-gaap:OtherLaborRelatedExpenses>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;14. Net Loss per Common Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table sets forth the computation
of the net loss per share attributable to common stockholders, basic and diluted:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;65,952&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;47,252&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110; -sec-ix-hidden: hidden-fact-109"&gt;Weighted-average common shares outstanding &#x2013; basic and diluted&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,259,615&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,232,576&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112; -sec-ix-hidden: hidden-fact-111"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5.86&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4.21&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Since the Company was in a net loss position
for all periods presented, net loss per share attributable to common stockholders was the same on a basic and diluted basis, as the inclusion
of all potential common equivalent shares outstanding would have been anti-dilutive. The Company excluded the following potential common
shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to
common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Stock options issued and outstanding&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,828,329&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,356,639&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units issued and outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;486,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;383,119&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Conversion of Series 1 Convertible Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,029,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,029,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total potentially dilutive shares&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,343,706&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,768,797&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;65,952&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;47,252&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110; -sec-ix-hidden: hidden-fact-109"&gt;Weighted-average common shares outstanding &#x2013; basic and diluted&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,259,615&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;11,232,576&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112; -sec-ix-hidden: hidden-fact-111"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5.86&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4.21&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c0" decimals="-3" unitRef="usd">65952000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c7" decimals="-3" unitRef="usd">47252000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c0" decimals="INF" unitRef="shares">11259615</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c7" decimals="INF" unitRef="shares">11232576</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare contextRef="c0" decimals="2" unitRef="usdPershares">-5.86</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare contextRef="c7" decimals="2" unitRef="usdPershares">-4.21</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <tara:ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Stock options issued and outstanding&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,828,329&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,356,639&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units issued and outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;486,338&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;383,119&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Conversion of Series 1 Convertible Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,029,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,029,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total potentially dilutive shares&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,343,706&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,768,797&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</tara:ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock>
    <tara:StockOptionsIssuedAndOutstanding contextRef="c0" decimals="INF" unitRef="shares">1828329</tara:StockOptionsIssuedAndOutstanding>
    <tara:StockOptionsIssuedAndOutstanding contextRef="c7" decimals="INF" unitRef="shares">1356639</tara:StockOptionsIssuedAndOutstanding>
    <tara:RestrictedStockUnitsIssuedAndOutstanding contextRef="c0" decimals="INF" unitRef="shares">486338</tara:RestrictedStockUnitsIssuedAndOutstanding>
    <tara:RestrictedStockUnitsIssuedAndOutstanding contextRef="c7" decimals="INF" unitRef="shares">383119</tara:RestrictedStockUnitsIssuedAndOutstanding>
    <tara:ConversionOfSeries1ConvertiblePreferredStock contextRef="c0" decimals="INF" unitRef="shares">8029039</tara:ConversionOfSeries1ConvertiblePreferredStock>
    <tara:ConversionOfSeries1ConvertiblePreferredStock contextRef="c7" decimals="INF" unitRef="shares">8029039</tara:ConversionOfSeries1ConvertiblePreferredStock>
    <tara:TotalPotentiallyDilutiveShares contextRef="c0" decimals="INF" unitRef="shares">10343706</tara:TotalPotentiallyDilutiveShares>
    <tara:TotalPotentiallyDilutiveShares contextRef="c7" decimals="INF" unitRef="shares">9768797</tara:TotalPotentiallyDilutiveShares>
    <us-gaap:Goodwill
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="hidden-fact-5"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c4"
      decimals="0"
      id="hidden-fact-6"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="hidden-fact-7"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="3"
      id="hidden-fact-8"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="hidden-fact-9"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="0"
      id="hidden-fact-10"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="hidden-fact-11"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="3"
      id="hidden-fact-12"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c7"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="hidden-fact-14"
      unitRef="usdPershares">-4.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-15"
      unitRef="usdPershares">-5.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="0"
      id="hidden-fact-16"
      unitRef="shares">11232576</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="hidden-fact-17"
      unitRef="shares">11259615</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c8"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c12"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:SettlementOfRestrictedStockUnits
      contextRef="c14"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:SettlementOfRestrictedStockUnits
      contextRef="c15"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:SettlementOfRestrictedStockUnits
      contextRef="c17"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:SettlementOfRestrictedStockUnits
      contextRef="c18"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c14"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c15"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c17"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c18"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="c14"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="c15"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="c16"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="c17"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c14"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c15"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c16"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c18"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c19"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:SettlementOfRestrictedStockUnits
      contextRef="c24"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:SettlementOfRestrictedStockUnits
      contextRef="c25"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:SettlementOfRestrictedStockUnits
      contextRef="c27"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:SettlementOfRestrictedStockUnits
      contextRef="c28"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c24"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c25"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c27"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c28"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="c24"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="c25"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="c26"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="c27"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c24"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c25"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c26"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c28"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c29"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c0"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c7"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="c42"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="c35"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="c43"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="c45"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="c46"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c44"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c46"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="c45"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="c46"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="c44"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="c46"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c46"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="c48"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="c49"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="c48"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="c49"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="c47"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecurities
      contextRef="c49"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c49"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:UnrealizedGains
      contextRef="c50"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:UnrealizedGains
      contextRef="c51"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:UnrealizedGains
      contextRef="c3"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:UnrealizedGains
      contextRef="c52"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:UnrealizedGains
      contextRef="c53"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:UnrealizedGains
      contextRef="c4"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="c7"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted contextRef="c119" id="hidden-fact-83" xsi:nil="true"/>
    <tara:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue
      contextRef="c119"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod
      contextRef="c119"
      id="hidden-fact-85"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c119"
      id="hidden-fact-86"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <tara:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised contextRef="c119" id="hidden-fact-87" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="c119"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares contextRef="c119" id="hidden-fact-89" xsi:nil="true"/>
    <tara:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue
      contextRef="c119"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired contextRef="c119" id="hidden-fact-91" xsi:nil="true"/>
    <tara:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue
      contextRef="c119"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="c120"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="c120"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <tara:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable
      contextRef="c120"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c3"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c4"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c0"
      id="hidden-fact-106"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c0"
      id="hidden-fact-107"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c7"
      id="hidden-fact-108"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="hidden-fact-109"
      unitRef="shares">11232576</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="hidden-fact-110"
      unitRef="shares">11259615</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="hidden-fact-111"
      unitRef="usdPershares">-4.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-112"
      unitRef="usdPershares">-5.86</us-gaap:EarningsPerShareDiluted>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001359931</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-69"
          xlink:label="hidden-fact-69"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-61"
          xlink:label="hidden-fact-61"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-70"
          xlink:label="hidden-fact-70"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-62"
          xlink:label="hidden-fact-62"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-63"
          xlink:label="hidden-fact-63"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-60"
          xlink:label="hidden-fact-60"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money market funds and corporate debt securities with original maturities of 90 days or less are included within Cash and cash equivalents in the Consolidated Balance Sheets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-69"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-61"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-70"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-62"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-63"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-60"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-64"
          xlink:label="hidden-fact-64"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-65"
          xlink:label="hidden-fact-65"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-72"
          xlink:label="hidden-fact-72"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-71"
          xlink:label="hidden-fact-71"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Money market funds are included within Restricted Cash, non-current in the Consolidated Balance Sheets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-64"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-65"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-72"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-71"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-67"
          xlink:label="hidden-fact-67"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-73"
          xlink:label="hidden-fact-73"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-66"
          xlink:label="hidden-fact-66"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-74"
          xlink:label="hidden-fact-74"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate debt securities with original maturities greater than 90 days are included within Marketable securities in the Consolidated Balance Sheets and classified as current or noncurrent based upon whether the maturity of the financial asset is less than or greater than 12 months.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-67"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-73"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-66"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-74"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-90"
          xlink:label="hidden-fact-90"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-95"
          xlink:label="hidden-fact-95"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-88"
          xlink:label="hidden-fact-88"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-94"
          xlink:label="hidden-fact-94"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-92"
          xlink:label="hidden-fact-92"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-84"
          xlink:label="hidden-fact-84"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-93"
          xlink:label="hidden-fact-93"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate&#160;intrinsic
value&#160;represents the difference between the exercise price of the option and the closing market price of our common stock on December&#160;31,
2022. The&#160;intrinsic value&#160;of options exercised during the years ended December&#160;31, 2022 and 2021 was $0 as no options
were exercised.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-90"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-95"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-88"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-94"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-92"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-84"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-93"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>85
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M ;PQ@.^7 O3)?F"NRP__'IG]#5!+ P04    " "-0FA6"?UF+N\"  #)"@
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M8[V21'5.4]THOBZ/.N9<*9Z7ERN@*0ACH']?<*Y>;LP+ZM.RZ;]02P,$%
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M+X[X2M6+\N'YK%R>+9=?&.]A6/U#'N_A'UY]^3\7UW8P)$3_>XP1,LVCX]-
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MNAL)AM9)HHO%/T =W\OCI?2H(*)1HVIK!^R2'FP*UENQMZ(,,2V<50HG"TX
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M=O1D]LV"?J.@X04TO]3:[3M\0/>K9_XW4$L#!!0    ( (U":%8U K=KM (
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MLZ2?%C1L0/,;K=VQPPOTOT&KOP%02P,$%     @ C4)H5CY5/K%L @  : 4
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MJEE/-3N'_J9VG$4XS6\\)/\]PL$ !T.A4&K&!JHBM@92*8Z*;>1Z&F!#0*Q
MNZ8$KBFN,TEP+5JNG@'(I3+6D/>$#D99BFLRF,1)<(_9F2YJPF2)0MGB &A1
MSA83.?<1_CA9.@Z^8C+]PB*9(/HH";XIRSABI0.:CCUV-OE(3CUQ=/3W"]!K
MKW%7SD;:3@B]M1\CBTX]+^[=#+IE>MU(0SA4&!H/QZ.0Z$[7W<&JUFMII2PJ
MTV]K'(6@G0/>5TK9P\$EZ(=K_A=02P,$%     @ C4)H5H^IHO"]!@  F!
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M;ZX 5I86X/W"&-_>$(/N^^7%?P%02P,$%     @ C4)H5MD ([\F"0  @!L
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M-2G"PPT =W-("6SQ!%KDTLDTU'].)5UN3+X)5:!0=D4>IZPOG<EU)ONYV'E
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ME-FV-2UE2,B52]-H%I]NGN\Z7*XL1#P<E+U.RBKW,*%[?6DJ]?NC).:ID'!
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M>+8(CQUYL"A2P=L7B#'T="O/UN1'NQ?<DS[H(N8@D>U9D-M"VET>H0%C N]
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M] +&EU5ENAM:H/^QTYO_ %!+ P04    " "-0FA6YU;K9*4)   +&0  &0
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MBT1N;3"</&U^S"DUT!R\Y30EYY%;-\\G<43SD%5_UQJ[WV[R7_?JX OUV/
M;L\&$TS))8S&6U2;LQ&F_V9EOY-_#X02IEFP3Z/<J)#"4X4R2W/>0V?Q/(&_
MV_*WK06A]QJG0U(PY9J+8&,/"@HJG+BQ4\TF %;-"\YEFK^,!P2PC I)'PHP
M_=6.&+=7>QXC6P&<PW5.<5:%>@BAIM!YZ+,'XO5 \+>%F&M),+=B9ENEHGVE
M(*OI.,A^;7*W7]GTO-6.A\&@X<R@S#+D!NG!9$*V5/"1<QA!]I&23Z)]GU#!
M7#>3R9XSV@[42*JK1OR7)E1WFI@[99M2<>^Y<O4/?0T][7R@+I5=\&=X[I&5
M#]^JMZO;+_TWX0/W[GCX-\'OTBZH?A=J#E(,TV>]\#6C??%FQ9^[I\9[4_+C
M4DG,*W0 ^W.#"&E>2,#V_Q_7_P-02P,$%     @ C4)H5OR<9+3F @  D@8
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M3Z[H0')^'XOYN<-1Y\5_E,,=]X6+IY)M;9XR8 :0Y66O(F!-\FV5K)XW!5"
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ML*17%BJ[@;YO)4743ZR#X=VV^@902P,$%     @ C4)H5IX=AHSG(0  OFX
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MJ0B$E24&7* ?4HZIY,C9B.?O^D9:U[ GBZIL79C).#@.("@5M8<NL@M_FX:
M.YZQDFNCY*A (K2EUOV;(.[3AQ1FRI?30^7)+%@88H,?<2II]-B^8[A\>I7X
M$YF&BN<19!( E8B R?BI&8FIXFHEOR<S;,/.;^^$!9J3\4N&MS"YXJ;+O&[
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M^T,_8D^D,O@ ?+]N@5SR"R[@_V3=Z_\#4$L#!!0    ( (U":%:44$C]H@,
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M!7W4H'83:#Q7RIXZ#J#[3%K_ U!+ P04    " "-0FA6^'[MT,$#  "U"0
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M&1O RWK96<#+_KWL3\N5=0:[Y==SPCO8_#RLOT'7=L=KF$=X12R89X@6/_Y
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M]*K$4IMNR'6.T[LP6%;:X9@*YA;_%X#Q ;B_UMJ=''] _T]C\0=02P,$%
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M+W=O<FMS:&5E=',O<VAE970R-RYX;6R=5=MNVS ,?<]7$-XPM$!07Q+GML1
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M.FKG0/LKI>Q^X@YH_R.2OU!+ P04    " "-0FA6QRTGW&@"   ^!0  &0
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MU6:C88,(3?[:6V-%4\IF<\H4;/$D#=)HX<H9TH21G"9NPWK6Y''LZ9%2%B%
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M##K1> G/I/E$FW+N$"8G:ZEX7@G#"G+*RF_\6!&Q)7 :O"(050+1"X&P_XI
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M+;1I=K?-S3A&:2^8\TP(O3-L@&[ Q[\!4$L#!!0    ( (U":%;9K[M 6@8
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M.D"98G]@W]\HOBG.O NN\ 1=7*Z!Q2!T #Y?<:Z>;O0QNOK;9/(_4$L#!!0
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MBQ:O'F-Q"P,J#<3[-2%\/Y +-/>ZX"]02P,$%     @ C4)H5J:D=Y]5 P
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M3:XNMOX1$>Q/W .V'4$C/.EF.ZS8#HULYRS)<@F\YHB^?X9D";QS AC!SIT
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MX#I W5\Q)I]/]#Y3M:\8_ =02P,$%     @ C4)H5MEA4B/( @  EP<  !D
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M#A/LG"!- .XOA=#;B?E TXO#/U!+ P04    " "-0FA6CAP,K&\#  #?"@
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MD##H#[!Z5E0!6=EW0Z[P;\52(,Y F]0?L!Q_Q7+<:T;D]-7+\R@*+C_66YW
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M2T8YHN% 81 WPE*@@RY"N)[==79*'M:N"%E64-&F_NM%@4:15'%]5R)YEA&
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M^&(FCLT-E!9 :8SVS?7<M>QYY]T#'-JK0-'T1"B=2\TZ=V#..O(\V]S1Z*!
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M\Q%?+W%H'"J+/RCLY-$S,J$\</YH!E^2F>,91L @5@:"Z)\M+($Q@Z1Y_-V
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MJ/O7>J!X6;6 #USIAK)ZS'3/#\(8Z/<IY^IY8!9H_XLP_P=02P,$%     @
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MO_^&!]T_/$'VJB![/NNC?Y9F]0WZ@@]ZS2]9PK(0$%-H K,XR^)LAOYSYK7
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MZ^%Y+<=.S =TIDZ.-R!LX+A5:[)W,[MA50/+O78/6!PKP>2)36X]@(9">+H
M;P=AI92\0/M;!>:,Q>OP@%BL!).#N]ZMI7"B]IK>IUZ>TA(3J^1D[Z;X'1=3
MB!M5X7%C?$QZ@Y,@V/'8M:),GM@:UP$VU(.C/>ZW:=\-D5HEI2_0'E>PG1\
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MCI;S9+G@)%<CV8IP,>"IQTC,X$!E@'B_)H3O%_* >JKW_P)02P,$%     @
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M0- B[Z0,ZJ.R!MNL#6EI>(XJ/*ZK\-@9_@F3DE.$Z&!?,YE8*\9L4_VYD:+
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M&RP0*?@GL !;N6"R8X$!W:FT8,9P!@2Z ,0Y%AR@*@,%08^D(()(WP5XV-Z
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MP^\8D&8!OD^%T(>!V:#_,EK\!U!+ P04    " "-0FA6F??9?I0"   R!P
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MI*DA0C=^E9Q.M:4!UL<[]L]6.VI94 43D;ZP6"=#Y]8A,2QIGNHGL?T"I9[
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M[01Z^V2SFT!O1[V=0&]'O9U ;T>]G4!O1[V=0&]'O9U [T"]@T#O0+V#0.]
MO8- [T"]@T#O0+V#0.^8_*PDT#M0[R#0.U#O(- [4.\@T#M0[R#0.Z/>F4#O
MC'IG KTSZIT)],ZH=R;0.Z/>F4#OC'KG[]2[CI^'4J\]7VM\_G=2/9[O+=?'
M7Y9?)R<OU 7G=%M1G_\"4$L#!!0    ( (U":%;2-&04[ $   <F   3
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MC4)H5D^+>>/M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ C4)H5IE<G",0!@  G"<  !,
M ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "-0FA6=K5J
MQIP'   8,@  &               @($,"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ C4)H5B,$8ROX!0  *AD  !@
M ("!W@\  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( (U"
M:%8)_68N[P(  ,D*   8              " @0P6  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    " "-0FA6@!I+.(4$  !,$   &
M        @($Q&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ C4)H5D[QWU+  @  LP8  !@              ("![!T  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( (U":%:W6KX5H04  "PF   8
M              " @>(@  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    " "-0FA6\V7NC#<&   Y&P  &               @(&Y)@  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ C4)H5IPQ^L# !P
M"Q,  !@              ("!)BT  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( (U":%9@>R ;'B   &IA   8              " @1PU
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "-0FA6CKL[
MU>\'  "%%   &0              @(%P50  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( (U":%9;#:3M0@4   $-   9
M  " @99=  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
MC4)H5C4"MVNT @  608  !D              ("!#V,  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    " "-0FA6"*[NP+4#   2"0  &0
M            @('Z90  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( (U":%8^53ZQ; (  &@%   9              " @>9I  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ C4)H5H^IHO"]!@
MF!   !D              ("!B6P  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    " "-0FA6U90&3SP*  #+'   &0              @(%]
M<P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( (U":%;9
M "._)@D  ( ;   9              " @?!]  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ C4)H5LDI--2[#   ^"0  !D
M     ("!38<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (U":%:44$C]H@,  #()   9              "
M@9O'  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ C4)H
M5OA^[=#! P  M0D  !D              ("!=,L  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    " "-0FA6'G.T_D8#  !U"   &0
M        @(%LSP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( (U":%837V:-K0(  /T%   9              " @>G2  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ C4)H5N4?$8?) @  +P8
M !D              ("!S=4  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    " "-0FA6QRTGW&@"   ^!0  &0              @('-V
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( (U":%82:SY<
M30,  )@(   9              " @6S;  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ C4)H5IKMT*D !0  [0P  !D
M ("!\-X  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "-
M0FA6CI4J/X@$  !L"P  &0              @($GY   >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( (U":%8,A,834 ,  .\'   9
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M970S-BYX;6Q02P$"% ,4    " "-0FA6FX:Y V "  #L!0  &0
M    @($H^P  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M (U":%;9K[M 6@8   4H   9              " @;_]  !X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ C4)H5H?]??A% @  )P4  !D
M             ("!4 0! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    " "-0FA6@')X(<T#  !"$0  &0              @(',!@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( (U":%8%#3!W] (
M !H(   9              " @= * 0!X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ C4)H5MG/M(D\ P  XPD  !D              ("!
M^PT! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "-0FA6
MIJ1WGU4#  "6#@  &0              @(%N$0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( (U":%9>QQ6Q\P,  &,4   9
M      " @?H4 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ C4)H5MEA4B/( @  EP<  !D              ("!)!D! 'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " "-0FA6CAP,K&\#  #?"@
M&0              @($C' $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    ( (U":%8E (Z5E (  .T&   9              " @<D? 0!X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ C4)H5N\H'UR'
M @  S08  !D              ("!E"(! 'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    " "-0FA6NR%+H^X"  !@"   &0
M@(%2)0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( (U"
M:%:?I="49PD  .HN   9              " @7<H 0!X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ C4)H5L9 PFCG"   \%H  !D
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M=#4U+GAM;%!+ 0(4 Q0    ( (U":%;:%J-;\@(  .$+   9
M  " @9-3 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
MC4)H5CZNWH\P P  P@L  !D              ("!O%8! 'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6Q02P$"% ,4    " "-0FA6EI>,Q(0$   H$P  &0
M            @($C6@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4
M Q0    ( (U":%9&.\FQ)0,   $,   9              " @=Y> 0!X;"]W
M;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ C4)H5D-]JDCM P
M< \  !D              ("!.F(! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX
M;6Q02P$"% ,4    " "-0FA6A@<:AL<#   E#0  &0              @(%>
M9@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( (U":%:9
M]]E^E (  #('   9              " @5QJ 0!X;"]W;W)K<VAE971S+W-H
M965T-C(N>&UL4$L! A0#%     @ C4)H5A0'73 % P  GP@  !D
M     ("!)VT! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
M" "-0FA6U#H^G=@"  !$!P  &0              @(%C< $ >&PO=V]R:W-H
M965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( (U":%8[@B."$ ,  #X(   9
M              " @7)S 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L!
M A0#%     @ C4)H5GU*Z9<T P  2!,   T              ( !N78! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " "-0FA6EXJ[',     3 @  "P
M        @ $8>@$ 7W)E;',O+G)E;'-02P$"% ,4    " "-0FA6_ Z%,?$$
M  !'*P  #P              @ $!>P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ C4)H5K5Q8'P6 @  JB8  !H              ( !'X ! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ C4)H5M(T9!3L 0
M!R8  !,              ( !;8(! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $D 20#V$P  BH0!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>126</ContextCount>
  <ElementCount>335</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Changes in Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Organization and Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/OrganizationandNatureoftheBusiness</Role>
      <ShortName>Organization and Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Marketable Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/MarketableDebtSecurities</Role>
      <ShortName>Marketable Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/PropertyandEquipmentnet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Marketable Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesTables</Role>
      <ShortName>Marketable Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/MarketableDebtSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/PropertyandEquipmentnet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/AccruedExpenses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/Leases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/StockBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/NetLossPerCommonShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents, and restricted cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents, and restricted cash</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of goodwill and accumulated impairment losses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of goodwill and accumulated impairment losses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Fair Value of Financial Instruments (Details) - Schedule of financial assets and liabilities that are measured and carried at fair value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable</Role>
      <ShortName>Fair Value of Financial Instruments (Details) - Schedule of financial assets and liabilities that are measured and carried at fair value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Marketable Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesDetails</Role>
      <ShortName>Marketable Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Marketable Debt Securities (Details) - Schedule of marketable debt securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable</Role>
      <ShortName>Marketable Debt Securities (Details) - Schedule of marketable debt securities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Marketable Debt Securities (Details) - Schedule of interest and investment income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofinterestandinvestmentincomeTable</Role>
      <ShortName>Marketable Debt Securities (Details) - Schedule of interest and investment income</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails</Role>
      <ShortName>Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Property and Equipment, net (Details) - Schedule of property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable</Role>
      <ShortName>Property and Equipment, net (Details) - Schedule of property and equipment, net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Accrued Expenses (Details) - Schedule of accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofaccruedexpensesTable</Role>
      <ShortName>Accrued Expenses (Details) - Schedule of accrued expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/AccruedExpensesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/LeasesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Leases (Details) - Schedule of lease expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofleaseexpenseTable</Role>
      <ShortName>Leases (Details) - Schedule of lease expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/LeasesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Leases (Details) - Schedule of weighted average remaining lease term and the weighted average discount rate for operating leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofweightedaverageremainingleasetermandtheweightedaveragediscountrateforoperatingleasesTable</Role>
      <ShortName>Leases (Details) - Schedule of weighted average remaining lease term and the weighted average discount rate for operating leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/LeasesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Leases (Details) - Schedule of operating lease payments included in the measurement of lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of operating lease payments included in the measurement of lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/LeasesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/StockholdersEquity</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/StockBasedCompensationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Stock-Based Compensation (Details) - Schedule of restricted stock unit activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of restricted stock unit activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/StockBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/StockBasedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock option activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of stock option activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/StockBasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleoftotalstockbasedcompensationcostsTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/StockBasedCompensationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock-based compensation expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofstockbasedcompensationexpenseTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of stock-based compensation expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/StockBasedCompensationTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/IncomeTaxesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Income Taxes (Details) - Schedule of federal and state income tax expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of federal and state income tax expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/IncomeTaxesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/IncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Income Taxes (Details) - Schedule of federal income tax to income before provision for income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of federal income tax to income before provision for income taxes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/IncomeTaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Net Loss Per Common Share (Details) - Schedule of net loss per share attributable to common stockholders, basic and diluted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable</Role>
      <ShortName>Net Loss Per Common Share (Details) - Schedule of net loss per share attributable to common stockholders, basic and diluted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Net Loss Per Common Share (Details) - Schedule of net loss per share attributable to common stockholders, basic and diluted (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable_Parentheticals</Role>
      <ShortName>Net Loss Per Common Share (Details) - Schedule of net loss per share attributable to common stockholders, basic and diluted (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="f10k2022_protarathera.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Net Loss Per Common Share (Details) - Schedule of weighted average dilutive common shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.Protaratherapeutics.com/role/ScheduleofweightedaveragedilutivecommonsharesTable</Role>
      <ShortName>Net Loss Per Common Share (Details) - Schedule of weighted average dilutive common shares</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.Protaratherapeutics.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 16 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:EarningsPerShareDiluted, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  f10k2022_protarathera.htm 11203, 11204, 11205, 11206, 11207, 11208, 11209, 11210, 11212, 11213, 11214, 11215, 11307, 11308, 11309, 11310</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="f10k2022_protarathera.htm">f10k2022_protarathera.htm</File>
    <File>f10k2022ex10-17_protarathera.htm</File>
    <File>f10k2022ex21-1_protarathera.htm</File>
    <File>f10k2022ex23-1_protarathera.htm</File>
    <File>f10k2022ex3-6_protarathera.htm</File>
    <File>f10k2022ex31-1_protarathera.htm</File>
    <File>f10k2022ex31-2_protarathera.htm</File>
    <File>f10k2022ex32-1_protarathera.htm</File>
    <File>tara-20221231.xsd</File>
    <File>tara-20221231_cal.xml</File>
    <File>tara-20221231_def.xml</File>
    <File>tara-20221231_lab.xml</File>
    <File>tara-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="540">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f10k2022_protarathera.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 540,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 126,
   "dts": {
    "calculationLink": {
     "local": [
      "tara-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tara-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f10k2022_protarathera.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tara-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tara-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tara-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 511,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 90,
    "http://www.Protaratherapeutics.com/20221231": 23,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 116
   },
   "keyCustom": 75,
   "keyStandard": 260,
   "memberCustom": 16,
   "memberStandard": 25,
   "nsprefix": "tara",
   "nsuri": "http://www.Protaratherapeutics.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Fair Value of Financial Instruments",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.Protaratherapeutics.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tara:MarketableDebtSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Marketable Debt Securities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.Protaratherapeutics.com/role/MarketableDebtSecurities",
     "shortName": "Marketable Debt Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tara:MarketableDebtSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Prepaid Expenses and Other Current Assets",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Property and Equipment, net",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnet",
     "shortName": "Property and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.Protaratherapeutics.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.Protaratherapeutics.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.Protaratherapeutics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Stockholders\u2019 Equity",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.Protaratherapeutics.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.Protaratherapeutics.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.Protaratherapeutics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Employee Benefit Plan",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.Protaratherapeutics.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Net Loss Per Common Share",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.Protaratherapeutics.com/role/NetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Accounting Policies, by Policy (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Marketable Debt Securities (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesTables",
     "shortName": "Marketable Debt Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Property and Equipment, net (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetTables",
     "shortName": "Property and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.Protaratherapeutics.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.Protaratherapeutics.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c5",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.Protaratherapeutics.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.Protaratherapeutics.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Net Loss Per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.Protaratherapeutics.com/role/NetLossPerCommonShareTables",
     "shortName": "Net Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tara:OperatingSegmentDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tara:OperatingSegmentDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents, and restricted cash",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of cash, cash equivalents, and restricted cash",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "tara:ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c38",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "tara:ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c38",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "tara:ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c42",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of goodwill and accumulated impairment losses",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of goodwill and accumulated impairment losses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "tara:ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c42",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Fair Value of Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Fair Value of Financial Instruments (Details) - Schedule of financial assets and liabilities that are measured and carried at fair value",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable",
     "shortName": "Fair Value of Financial Instruments (Details) - Schedule of financial assets and liabilities that are measured and carried at fair value",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetInvestmentIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Marketable Debt Securities (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesDetails",
     "shortName": "Marketable Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetInvestmentIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Marketable Debt Securities (Details) - Schedule of marketable debt securities",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable",
     "shortName": "Marketable Debt Securities (Details) - Schedule of marketable debt securities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "tara:ScheduleOfInterestAndInvestmentIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestIncomeOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Marketable Debt Securities (Details) - Schedule of interest and investment income",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofinterestandinvestmentincomeTable",
     "shortName": "Marketable Debt Securities (Details) - Schedule of interest and investment income",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "tara:ScheduleOfInterestAndInvestmentIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestIncomeOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable",
     "shortName": "Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Property and Equipment, net (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails",
     "shortName": "Property and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "2",
      "lang": null,
      "name": "tara:TotalPropertyAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Property and Equipment, net (Details) - Schedule of property and equipment, net",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable",
     "shortName": "Property and Equipment, net (Details) - Schedule of property and equipment, net",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "tara:AccruedEmployeeRelatedCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Accrued Expenses (Details) - Schedule of accrued expenses",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofaccruedexpensesTable",
     "shortName": "Accrued Expenses (Details) - Schedule of accrued expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "tara:AccruedEmployeeRelatedCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c70",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.Protaratherapeutics.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c70",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Leases (Details) - Schedule of lease expense",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofleaseexpenseTable",
     "shortName": "Leases (Details) - Schedule of lease expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "tara:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Leases (Details) - Schedule of weighted average remaining lease term and the weighted average discount rate for operating leases",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofweightedaverageremainingleasetermandtheweightedaveragediscountrateforoperatingleasesTable",
     "shortName": "Leases (Details) - Schedule of weighted average remaining lease term and the weighted average discount rate for operating leases",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "tara:ScheduleOfOtherInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "tara:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Leases (Details) - Schedule of operating lease payments included in the measurement of lease liabilities",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable",
     "shortName": "Leases (Details) - Schedule of operating lease payments included in the measurement of lease liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "tara:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c74",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tara:DescriptionOfAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c74",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tara:DescriptionOfAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Stockholders\u2019 Equity (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders\u2019 Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "4",
      "lang": null,
      "name": "tara:CommonStockIssuanceAndOutstandingPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "tara:StocksIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "tara:StocksIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c107",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Stock-Based Compensation (Details) - Schedule of restricted stock unit activity",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of restricted stock unit activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c107",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c118",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock option activities",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of stock option activities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c118",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleoftotalstockbasedcompensationcostsTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "tara:IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c104",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Stock-Based Compensation (Details) - Schedule of stock-based compensation expense",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofstockbasedcompensationexpenseTable",
     "shortName": "Stock-Based Compensation (Details) - Schedule of stock-based compensation expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c56",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tara:EffectiveTaxRateDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.Protaratherapeutics.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tara:EffectiveTaxRateDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Income Taxes (Details) - Schedule of federal and state income tax expense",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable",
     "shortName": "Income Taxes (Details) - Schedule of federal and state income tax expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3",
     "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable",
     "shortName": "Income Taxes (Details) - Schedule of deferred tax assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Income Taxes (Details) - Schedule of federal income tax to income before provision for income taxes",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable",
     "shortName": "Income Taxes (Details) - Schedule of federal income tax to income before provision for income taxes",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "tara:EmployeeContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Employee Benefit Plan (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.Protaratherapeutics.com/role/EmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "tara:EmployeeContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Net Loss Per Common Share (Details) - Schedule of net loss per share attributable to common stockholders, basic and diluted",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable",
     "shortName": "Net Loss Per Common Share (Details) - Schedule of net loss per share attributable to common stockholders, basic and diluted",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "063 - Disclosure - Net Loss Per Common Share (Details) - Schedule of net loss per share attributable to common stockholders, basic and diluted (Parentheticals)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable_Parentheticals",
     "shortName": "Net Loss Per Common Share (Details) - Schedule of net loss per share attributable to common stockholders, basic and diluted (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "tara:ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tara:StockOptionsIssuedAndOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "064 - Disclosure - Net Loss Per Common Share (Details) - Schedule of weighted average dilutive common shares",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.Protaratherapeutics.com/role/ScheduleofweightedaveragedilutivecommonsharesTable",
     "shortName": "Net Loss Per Common Share (Details) - Schedule of weighted average dilutive common shares",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "tara:ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tara:StockOptionsIssuedAndOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Organization and Nature of the Business",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.Protaratherapeutics.com/role/OrganizationandNatureoftheBusiness",
     "shortName": "Organization and Nature of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10k2022_protarathera.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 43,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r293",
      "r426",
      "r441",
      "r455",
      "r456",
      "r470",
      "r474",
      "r478",
      "r518",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable",
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails",
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r293",
      "r426",
      "r441",
      "r455",
      "r456",
      "r470",
      "r474",
      "r478",
      "r518",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable",
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails",
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r286",
      "r293",
      "r321",
      "r322",
      "r323",
      "r402",
      "r426",
      "r441",
      "r455",
      "r456",
      "r470",
      "r474",
      "r478",
      "r514",
      "r518",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable",
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails",
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r286",
      "r293",
      "r321",
      "r322",
      "r323",
      "r402",
      "r426",
      "r441",
      "r455",
      "r456",
      "r470",
      "r474",
      "r478",
      "r514",
      "r518",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable",
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails",
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r506",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_AccruedEmployeeRelatedCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued employee related current.",
        "label": "Accrued Employee Related Current",
        "terseLabel": "Employee Costs"
       }
      }
     },
     "localname": "AccruedEmployeeRelatedCurrent",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_AccruedInterestOnMarketableDebtSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued interest on marketable debt securities.",
        "label": "Accrued Interest On Marketable Debt Securities",
        "terseLabel": "Accrued interest on marketable debt securities"
       }
      }
     },
     "localname": "AccruedInterestOnMarketableDebtSecurities",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_AccruedResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued research and development current.",
        "label": "Accrued Research And Development Current",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_AggregateOfSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate of shares of common stock.",
        "label": "Aggregate Of Shares Of Common Stock",
        "terseLabel": "Aggregate of shares of common stock"
       }
      }
     },
     "localname": "AggregateOfSharesOfCommonStock",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tara_AmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of discounts and premiums investments.",
        "label": "Amortization Of Discounts And Premiums Investments",
        "terseLabel": "Amortization of premium on marketable debt securities"
       }
      }
     },
     "localname": "AmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_BoardOfDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board Of Directors Member",
        "terseLabel": "Board of Directors [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_CashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents Abstract",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_CashPaidForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid For Abstract",
        "terseLabel": "Cash paid for:"
       }
      }
     },
     "localname": "CashPaidForAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_CholineLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Choline License Agreement Member",
        "terseLabel": "Choline License Agreement [Member]"
       }
      }
     },
     "localname": "CholineLicenseAgreementMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_CommitmentsandContingenciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Line Items]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsLineItems",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_CommitmentsandContingenciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsTable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_CommonStockIssuanceAndOutstandingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issuance and outstanding percentage.",
        "label": "Common Stock Issuance And Outstanding Percentage",
        "terseLabel": "Common stock issuance and outstanding, percentage"
       }
      }
     },
     "localname": "CommonStockIssuanceAndOutstandingPercentage",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tara_ConnectionWithTheNetShareSettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Connection With The Net Share Settlement",
        "terseLabel": "Net share settlement (in Dollars)"
       }
      }
     },
     "localname": "ConnectionWithTheNetShareSettlement",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_ConversionOfSeries1ConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Of Series1 Convertible Preferred Stock",
        "terseLabel": "Conversion of Series 1 Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConversionOfSeries1ConvertiblePreferredStock",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofweightedaveragedilutivecommonsharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "tara_CurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Abstract",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_DeferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Abstract",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process operating lease liability.",
        "label": "Deferred Tax Assets Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_DeferredTaxAssetsRestrictedStockUnitsExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restricted stock unit deferred tax assets.",
        "label": "Deferred Tax Assets Restricted Stock Units Expense",
        "terseLabel": "RSU expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsRestrictedStockUnitsExpense",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_DeferredTaxLiabilitiesOperatingRightofuseAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from operating right of use asset.",
        "label": "Deferred Tax Liabilities Operating Rightofuse Asset",
        "negatedLabel": "Operating right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingRightofuseAsset",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator Abstract",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_DescriptionOfAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of agreements.",
        "label": "Description Of Agreements",
        "terseLabel": "Description of license agreement"
       }
      }
     },
     "localname": "DescriptionOfAgreements",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between effective income tax rate reconciliation stock based compensation.",
        "label": "Effective Income Tax Rate Reconciliation Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationCost",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "tara_EffectiveTaxRateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of effective tax rate.",
        "label": "Effective Tax Rate Description",
        "terseLabel": "Effective tax rate description"
       }
      }
     },
     "localname": "EffectiveTaxRateDescription",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_EmployeeCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee compensation.",
        "label": "Employee Compensation",
        "terseLabel": "Employee compensation"
       }
      }
     },
     "localname": "EmployeeCompensation",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tara_EmployeeContributions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee contributions.",
        "label": "Employee Contributions",
        "terseLabel": "Employee contributions"
       }
      }
     },
     "localname": "EmployeeContributions",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tara_EstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Fair Value",
        "label": "Estimated Fair Value",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "EstimatedFairValue",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments (Details) - Schedule of financial assets and liabilities that are measured and carried at fair value [Line Items]"
       }
      }
     },
     "localname": "FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueLineItems",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments (Details) - Schedule of financial assets and liabilities that are measured and carried at fair value [Table]"
       }
      }
     },
     "localname": "FairValueofFinancialInstrumentsDetailsScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_FederalNOLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal NOLMember",
        "terseLabel": "Federal NOL [Member]"
       }
      }
     },
     "localname": "FederalNOLMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_FeinsteinAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Feinstein Agreement Member",
        "terseLabel": "Feinstein Agreement [Member]"
       }
      }
     },
     "localname": "FeinsteinAgreementMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_GrossProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Proceeds.",
        "label": "Gross Proceeds",
        "terseLabel": "Gross proceeds (in Dollars)"
       }
      }
     },
     "localname": "GrossProceeds",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_IncomeTaxCarriedForwardTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax carried forward terms.",
        "label": "Income Tax Carried Forward Terms",
        "terseLabel": "Carried forward tax year"
       }
      }
     },
     "localname": "IncomeTaxCarriedForwardTerms",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tara_IncomeTaxesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsLineItems",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_IncomeTaxesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "localname": "IncomeTaxesDetailsTable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_IncreaseOrDecreaseEquityPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Or Decrease Equity Percentage",
        "terseLabel": "Convertible preferred stock, percentage"
       }
      }
     },
     "localname": "IncreaseOrDecreaseEquityPercentage",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tara_IowaAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Iowa Agreement Member",
        "terseLabel": "Lowa Agreement [Member]"
       }
      }
     },
     "localname": "IowaAgreementMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Stock Options And Restricted Stock Units To Employees And Directors Table Text Block",
        "terseLabel": "Schedule of total stock-based compensation costs"
       }
      }
     },
     "localname": "IssuanceOfStockOptionsAndRestrictedStockUnitsToEmployeesAndDirectorsTableTextBlock",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tara_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment Member",
        "terseLabel": "Laboratory Equipment [Member]",
        "verboseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable",
      "http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_MarketCapitalizationsPercentageChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market capitalizations percentage.",
        "label": "Market Capitalizations Percentage Change",
        "terseLabel": "Market capitalizations percentage change"
       }
      }
     },
     "localname": "MarketCapitalizationsPercentageChange",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tara_MarketableDebtSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Debt Securities [Abstract]"
       }
      }
     },
     "localname": "MarketableDebtSecuritiesAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_MarketableDebtSecuritiesAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Debt Securities Abstract0",
        "terseLabel": "Marketable debt securities"
       }
      }
     },
     "localname": "MarketableDebtSecuritiesAbstract0",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_MarketableDebtSecuritiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Debt Securities.",
        "label": "Marketable Debt Securities Policy Text Block",
        "terseLabel": "Marketable Debt Securities"
       }
      }
     },
     "localname": "MarketableDebtSecuritiesPolicyTextBlock",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tara_MarketableDebtSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Debt Securities Text Block",
        "terseLabel": "Marketable Debt Securities"
       }
      }
     },
     "localname": "MarketableDebtSecuritiesTextBlock",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/MarketableDebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tara_MicrocapCompaniesMarketCapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of microcap companies market capitalization.",
        "label": "Microcap Companies Market Capitalization",
        "terseLabel": "Market capitalization of microcap companies"
       }
      }
     },
     "localname": "MicrocapCompaniesMarketCapitalization",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_NetProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net proceeds.",
        "label": "Net Proceeds",
        "terseLabel": "Net proceeds (in Dollars)"
       }
      }
     },
     "localname": "NetProceeds",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_NumberOfShareAuthorizedIncreased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share authorized increased.",
        "label": "Number Of Share Authorized Increased",
        "terseLabel": "Number of share authorized increased"
       }
      }
     },
     "localname": "NumberOfShareAuthorizedIncreased",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tara_NumberOfSharesRestrictedStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Shares Restricted Stock",
        "terseLabel": "Number of RSUs"
       }
      }
     },
     "localname": "NumberOfSharesRestrictedStock",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tara_NumberSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number shares authorized.",
        "label": "Number Shares Authorized",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "NumberSharesAuthorized",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tara_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator Abstract",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_OperatingLeasesFutureMinimumPaymentDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases Future Minimum Payments Due",
        "label": "Operating Leases Future Minimum Payment Due",
        "terseLabel": "Total future operating lease payments"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentDue",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_OperatingSegmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segment Description",
        "terseLabel": "Operating segment description"
       }
      }
     },
     "localname": "OperatingSegmentDescription",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_OrganizationandNatureoftheBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Nature of the Business [Abstract]"
       }
      }
     },
     "localname": "OrganizationandNatureoftheBusinessLineItems",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/OrganizationandNatureoftheBusiness"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_OrganizationandNatureoftheBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Nature of the Business [Table]"
       }
      }
     },
     "localname": "OrganizationandNatureoftheBusinessTable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/OrganizationandNatureoftheBusiness"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_OtherIncomeExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income Expense Net Abstract",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNetAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_PatentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Costs.",
        "label": "Patent Costs Policy Text Block",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyTextBlock",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tara_PercentageOfLargestAmountOfBenefit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of largest amount of benefit.",
        "label": "Percentage Of Largest Amount Of Benefit",
        "terseLabel": "Percentage of largest amount of benefit"
       }
      }
     },
     "localname": "PercentageOfLargestAmountOfBenefit",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tara_PrepaidSoftware": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Prepaid Software",
        "terseLabel": "Prepaid software"
       }
      }
     },
     "localname": "PrepaidSoftware",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_PresentValueOfFutureMinimumLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of future minimum lease payments",
        "label": "Present Value Of Future Minimum Lease Payments",
        "terseLabel": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "PresentValueOfFutureMinimumLeasePayments",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the proceeds from maturity and redemption of marketable debt securities.",
        "label": "Proceeds From Maturity And Redemption Of Marketable Debt Securities",
        "terseLabel": "Proceeds from maturity and redemption of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromMaturityAndRedemptionOfMarketableDebtSecurities",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_PropertyAndEquipmentNotYetPlacedIntoServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property And Equipment Not Yet Placed Into Service Member",
        "terseLabel": "Property and equipment not yet placed into service [Member]"
       }
      }
     },
     "localname": "PropertyAndEquipmentNotYetPlacedIntoServiceMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_PropertyandEquipmentnetDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, net (Details) [Line Items]"
       }
      }
     },
     "localname": "PropertyandEquipmentnetDetailsLineItems",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_PropertyandEquipmentnetDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, net (Details) [Table]"
       }
      }
     },
     "localname": "PropertyandEquipmentnetDetailsTable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_RecentAccountingPronouncementsNotYetAdopted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements Not Yet Adopted",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "RecentAccountingPronouncementsNotYetAdopted",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tara_ResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects.",
        "label": "Research And Development Expenses",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenses",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_RestrictedCashNonCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash Non Current Abstract",
        "terseLabel": "Restricted cash, non-current"
       }
      }
     },
     "localname": "RestrictedCashNonCurrentAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_RestrictedCashNoncurrents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash, non-current.",
        "label": "Restricted Cash Noncurrents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrents",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_RestrictedStockUnitsIssuedAndOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units Issued And Outstanding",
        "terseLabel": "Restricted stock units issued and outstanding"
       }
      }
     },
     "localname": "RestrictedStockUnitsIssuedAndOutstanding",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofweightedaveragedilutivecommonsharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "tara_ScheduleOfAccruedExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Accrued Expenses [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAccruedExpensesAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash Cash Equivalents And Restricted Cash [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Deferred Tax Assets And Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Useful Lives For Significant Property And Equipment Abstract"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Useful Lives For Significant Property And Equipment Table Text Block",
        "terseLabel": "Schedule of estimated useful lives for significant property and equipment"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesForSignificantPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tara_ScheduleOfFederalAndStateIncomeTaxExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Federal And State Income Tax Expense Abstract"
       }
      }
     },
     "localname": "ScheduleOfFederalAndStateIncomeTaxExpenseAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Federal Income Tax To Income Before Provision For Income Taxes Abstract"
       }
      }
     },
     "localname": "ScheduleOfFederalIncomeTaxToIncomeBeforeProvisionForIncomeTaxesAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfFinancialAssetsAndLiabilitiesThatAreMeasuredAndCarriedAtFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of financial assets and liabilities that are measured and carried at fair value [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFinancialAssetsAndLiabilitiesThatAreMeasuredAndCarriedAtFairValueAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Future Minimum Rental Payment For Operating Leases Table Text Block",
        "terseLabel": "Schedule of operating lease payments included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tara_ScheduleOfGoodwillAndAccumulatedImpairmentLossesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Goodwill And Accumulated Impairment Losses Abstract"
       }
      }
     },
     "localname": "ScheduleOfGoodwillAndAccumulatedImpairmentLossesAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Goodwill And Accumulated Impairment Lossses Table Text Block",
        "terseLabel": "Schedule of goodwill and accumulated impairment losses"
       }
      }
     },
     "localname": "ScheduleOfGoodwillAndAccumulatedImpairmentLosssesTableTextBlock",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tara_ScheduleOfInterestAndInvestmentIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Interest And Investment Income Abstract"
       }
      }
     },
     "localname": "ScheduleOfInterestAndInvestmentIncomeAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfInterestAndInvestmentIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Interest And Investment Income Table Text Block",
        "terseLabel": "Schedule of interest and investment income"
       }
      }
     },
     "localname": "ScheduleOfInterestAndInvestmentIncomeTableTextBlock",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tara_ScheduleOfLeaseExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Lease Expense Abstract"
       }
      }
     },
     "localname": "ScheduleOfLeaseExpenseAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfMarketableDebtSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Marketable Debt Securities Abstract"
       }
      }
     },
     "localname": "ScheduleOfMarketableDebtSecuritiesAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Net Loss Per Share Attributable to Common Stockholders Basic and Diluted [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfNetLossPerShareAttributableToCommonStockholdersBasicAndDilutedAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Operating Lease Payments Included In The Measurement Of Lease Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasePaymentsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfOtherInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other information.",
        "label": "Schedule Of Other Information Related To Leases Table Text Block",
        "terseLabel": "Schedule of weighted average remaining lease term and the weighted average discount rate for operating leases"
       }
      }
     },
     "localname": "ScheduleOfOtherInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tara_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of prepaid expenses and other current assets [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Abstract"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfRestrictedStockUnitActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Restricted Stock Unit Activity Abstract"
       }
      }
     },
     "localname": "ScheduleOfRestrictedStockUnitActivityAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfStockBasedCompensationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Based Compensation Expense Abstract"
       }
      }
     },
     "localname": "ScheduleOfStockBasedCompensationExpenseAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfStockOptionActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Option Activities Abstract"
       }
      }
     },
     "localname": "ScheduleOfStockOptionActivitiesAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfTheFairValueOfStockOptionsGrantedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of The Fair Value Of Stock Options Granted Abstract"
       }
      }
     },
     "localname": "ScheduleOfTheFairValueOfStockOptionsGrantedAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfTotalStockBasedCompensationCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Total Stock Based Compensation Costs Abstract"
       }
      }
     },
     "localname": "ScheduleOfTotalStockBasedCompensationCostsAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of weighted average dilutive common share.",
        "label": "Schedule Of Weighted Average Dilutive Common Share Table Text Block",
        "terseLabel": "Schedule of weighted average dilutive common shares"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageDilutiveCommonShareTableTextBlock",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tara_ScheduleOfWeightedAverageDilutiveCommonSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted Average Dilutive Common Shares [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageDilutiveCommonSharesAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Remaining Lease Term And The Weighted Average Discount Rate For Operating Leases Abstract"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermAndTheWeightedAverageDiscountRateForOperatingLeasesAbstract",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "tara_Series1PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series1 Preferred Stock Member",
        "terseLabel": "Series 1 Convertible Preferred Stock",
        "verboseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "Series1PreferredStockMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_SeriesOneConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series One Convertible Preferred Stock Member",
        "terseLabel": "Series 1 Convertible",
        "verboseLabel": "Series 1 Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesOneConvertiblePreferredStockMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_SettlementOfRestrictedStockUnitinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of restricted stock units.",
        "label": "Settlement Of Restricted Stock Unitin Shares",
        "terseLabel": "Settlement of restricted stock units (in Shares)"
       }
      }
     },
     "localname": "SettlementOfRestrictedStockUnitinShares",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "tara_SettlementOfRestrictedStockUnits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of restricted stock units.",
        "label": "Settlement Of Restricted Stock Units",
        "terseLabel": "Settlement of restricted stock units"
       }
      }
     },
     "localname": "SettlementOfRestrictedStockUnits",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were exercised during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period",
        "terseLabel": "Number of Options, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and expired price on options expired (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Total Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and forfeited price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Total Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of granted and granted price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Total Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remainning Period Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (years), ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "tara_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remainning Period Term2",
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Balance at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainningPeriodTerm2",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "tara_ShareBasedCompensationUnrecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Unrecognized.",
        "label": "Share Based Compensation Unrecognized",
        "terseLabel": "Unrecognized share-based compensation (in Dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationUnrecognized",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercisable",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercisable",
        "terseLabel": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Termyears Exercisable",
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercisable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercised stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Termyears Exercised",
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Exercised"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExercised",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of Expired stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Termyears Expired",
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Expired"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsExpired",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of forfeited stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Termyears Forfeitedin Shares",
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsForfeitedinShares",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "tara_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of granded stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Termyears Granted",
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Granted"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTermyearsGranted",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "tara_SharesAvailableForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Available For Issuance",
        "terseLabel": "Shares available for issuance"
       }
      }
     },
     "localname": "SharesAvailableForIssuance",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tara_ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shorter of the useful life of asset or the lease term.",
        "label": "Shorter Of The Useful Life Of Asset Or The Lease Term",
        "terseLabel": "Shorter of the useful life of asset or the lease term"
       }
      }
     },
     "localname": "ShorterOfTheUsefulLifeOfAssetOrTheLeaseTerm",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_StateIncomeTaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "State Income Tax Member",
        "terseLabel": "State income tax [Member]"
       }
      }
     },
     "localname": "StateIncomeTaxMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_StockBasedCompensationDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsLineItems",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of restricted stock unit activity [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityLineItems",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of restricted stock unit activity [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofrestrictedstockunitactivityTable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of stock option activities [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofstockoptionactivitiesLineItems",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of stock option activities [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofstockoptionactivitiesTable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedLineItems",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of the fair value of stock options granted [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleofthefairvalueofstockoptionsgrantedTable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsLineItems",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoftotalstockbasedcompensationcostsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of total stock-based compensation costs [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsScheduleoftotalstockbasedcompensationcostsTable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoftotalstockbasedcompensationcostsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_StockBasedCompensationDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsTable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_StockOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Period",
        "terseLabel": "Stock option period"
       }
      }
     },
     "localname": "StockOptionPeriod",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tara_StockOptionsIssuedAndOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Issued And Outstanding",
        "terseLabel": "Stock options issued and outstanding"
       }
      }
     },
     "localname": "StockOptionsIssuedAndOutstanding",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofweightedaveragedilutivecommonsharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "tara_StockholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsLineItems",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_StockholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsTable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_StocksIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stocks Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StocksIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tara_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentLineItems",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of estimated useful lives for significant property and equipment [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of goodwill and accumulated impairment losses [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesLineItems",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of goodwill and accumulated impairment losses [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofgoodwillandaccumulatedimpairmentlossesTable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tara_TotalPotentiallyDilutiveShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Potentially Dilutive Shares",
        "terseLabel": "Total potentially dilutive shares"
       }
      }
     },
     "localname": "TotalPotentiallyDilutiveShares",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofweightedaveragedilutivecommonsharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "tara_TotalPropertyAndEquipmentNet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage is total property and equipment, net.",
        "label": "Total Property And Equipment Net",
        "terseLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "TotalPropertyAndEquipmentNet",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tara_TwentyFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Fourteen Equity Incentive Plan Member",
        "terseLabel": "2014 Equity Incentive Plan [Member]",
        "verboseLabel": "Twenty Fourteen Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwentyFourteenEquityIncentivePlanMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_TwentySeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Seventeen Equity Incentive Plan Member",
        "terseLabel": "2017 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwentySeventeenEquityIncentivePlanMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_TwentyTwentyInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Twenty Inducement Plan Member",
        "terseLabel": "2020 Inducement Plan [Member]"
       }
      }
     },
     "localname": "TwentyTwentyInducementPlanMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_TwoThousandFourteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Fourteen Employee Stock Purchase Plan Member",
        "terseLabel": "2014 Equity Incentive Plan [Member]",
        "verboseLabel": "2014 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandFourteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_USFederalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "USFederal Member",
        "terseLabel": "U.S. federal [Member]"
       }
      }
     },
     "localname": "USFederalMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_UnamortizedValueOfRsus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized Value Of Rsus",
        "terseLabel": "Unamortized value of RSUs (in Dollars)"
       }
      }
     },
     "localname": "UnamortizedValueOfRsus",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwritten Public Offering Member",
        "terseLabel": "Underwritten Public Offering [Member]"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tara_UnrealizedGains": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gains",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "UnrealizedGains",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_UnrealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unrealized losses.",
        "label": "Unrealized Loss",
        "terseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "UnrealizedLoss",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_UnrealizedLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Losses",
        "label": "Unrealized Losses",
        "terseLabel": "Unrealized loss"
       }
      }
     },
     "localname": "UnrealizedLosses",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tara_VestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "VestingPeriod",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tara_WeightedAverageRemainingAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Amortization Period",
        "terseLabel": "Weighted average remaining amortization period"
       }
      }
     },
     "localname": "WeightedAverageRemainingAmortizationPeriod",
     "nsuri": "http://www.Protaratherapeutics.com/20221231",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r9",
      "r477"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r62",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r147",
      "r154",
      "r364",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r142",
      "r435",
      "r446",
      "r447"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r4",
      "r477"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r328",
      "r329",
      "r330",
      "r501",
      "r502",
      "r503",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r83",
      "r84",
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation - restricted stock units"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherCorporateBondsMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in corporate fixed maturity debt securities classified as other.",
        "label": "Other Corporate Bonds [Member]",
        "terseLabel": "Corporate bonds - presented in marketable debt securities, non-current [Member]"
       }
      }
     },
     "localname": "AllOtherCorporateBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r107",
      "r118",
      "r138",
      "r167",
      "r210",
      "r218",
      "r220",
      "r227",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r360",
      "r362",
      "r373",
      "r477",
      "r516",
      "r517",
      "r557"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r131",
      "r144",
      "r167",
      "r227",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r360",
      "r362",
      "r373",
      "r477",
      "r516",
      "r517",
      "r557"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r223",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable",
      "http://www.Protaratherapeutics.com/role/ScheduleoftotalstockbasedcompensationcostsTable",
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails",
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BroadcastersLicenseAgreementCommitmentsDescription": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the commitments for license agreements that have been executed but were not reported because they do not meet the conditions for recording a liability.",
        "label": "Broadcasters License Agreement Commitments, Description",
        "terseLabel": "Description of sponsored research and license agreement"
       }
      }
     },
     "localname": "BroadcastersLicenseAgreementCommitmentsDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r39",
      "r133",
      "r458"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet",
      "http://www.Protaratherapeutics.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r40",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r34",
      "r39",
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash - end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash - beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r34",
      "r104"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net (decrease)/increase in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r167",
      "r186",
      "r187",
      "r190",
      "r192",
      "r199",
      "r200",
      "r227",
      "r258",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r269",
      "r270",
      "r273",
      "r277",
      "r284",
      "r373",
      "r457",
      "r488",
      "r498",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r110",
      "r123"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r66",
      "r252",
      "r253",
      "r451",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r501",
      "r502",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3",
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "verboseLabel": "Common shares of par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Common stock authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Common stock shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r477"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, authorized 100,000,000 shares: Common stock, 11,267,389 and 11,235,731 shares issued and outstanding as of December 31, 2022 and 2021, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r19",
      "r150",
      "r152",
      "r158",
      "r432",
      "r438"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment [Member]",
        "verboseLabel": "Computer equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable",
      "http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r115",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of stock shares"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds - presented in marketable debt securities [Member]"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r500",
      "r549",
      "r551"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r345",
      "r353",
      "r500"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r500",
      "r549",
      "r551"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r500",
      "r550",
      "r551"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r37",
      "r95",
      "r346",
      "r352",
      "r353",
      "r500"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r108",
      "r117",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r500",
      "r550",
      "r551"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net of valuation allowance and deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r93",
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r93",
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOtherTaxCarryforwards": {
     "auth_ref": [
      "r93",
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.",
        "label": "Deferred Tax Assets, Other Tax Carryforwards",
        "terseLabel": "Carried forward tax"
       }
      }
     },
     "localname": "DeferredTaxAssetsOtherTaxCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r92",
      "r93",
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r93",
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock option expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesDetails",
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [
      "r93",
      "r548"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r93",
      "r548"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r37",
      "r60"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow",
      "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r295",
      "r325",
      "r326",
      "r327",
      "r332",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plan [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockSupplementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r159",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r183",
      "r186",
      "r190",
      "r191",
      "r192",
      "r196",
      "r368",
      "r369",
      "r433",
      "r439",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r159",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r186",
      "r190",
      "r191",
      "r192",
      "r196",
      "r368",
      "r369",
      "r433",
      "r439",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/NetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r168",
      "r336",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "U.S. federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r546",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r546",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r546",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r546",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "State rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r546",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "terseLabel": "True-up to prior years return"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r546",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r546",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalincometaxtoincomebeforeprovisionforincometaxesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoftotalstockbasedcompensationcostsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r67",
      "r129",
      "r154",
      "r155",
      "r156",
      "r170",
      "r171",
      "r172",
      "r174",
      "r180",
      "r182",
      "r198",
      "r228",
      "r285",
      "r328",
      "r329",
      "r330",
      "r348",
      "r349",
      "r367",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r394",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3",
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails",
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r101",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails",
      "http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable",
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r267",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r371",
      "r399",
      "r400",
      "r401",
      "r468",
      "r469",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r267",
      "r287",
      "r292",
      "r371",
      "r399",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r267",
      "r287",
      "r292",
      "r371",
      "r400",
      "r468",
      "r469",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r267",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r371",
      "r401",
      "r468",
      "r469",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r267",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r399",
      "r400",
      "r401",
      "r468",
      "r469",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r237",
      "r268",
      "r282",
      "r365",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r465",
      "r507",
      "r508",
      "r509",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r57",
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture, Fixtures and Other [Member]",
        "verboseLabel": "Furniture, fixtures and other [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable",
      "http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative [Member]",
        "verboseLabel": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails",
      "http://www.Protaratherapeutics.com/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r136",
      "r238",
      "r430",
      "r467",
      "r477",
      "r512",
      "r513"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill at ending",
        "periodStartLabel": "Goodwill at beginning",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet",
      "http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable",
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r241",
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Additions to goodwill"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r244",
      "r245",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r240",
      "r243",
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "terseLabel": "Goodwill, gross amount as of December 31, 2021"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r240",
      "r243",
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated impairment loss, as of December 31, 2021"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r37",
      "r239",
      "r242",
      "r244",
      "r467"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Loss on impairment",
        "netLabel": "Goodwill impairment loss",
        "terseLabel": "Loss on impairment of goodwill",
        "verboseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow",
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement",
      "http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable",
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill [Member]",
        "terseLabel": "Goodwill [Member]"
       }
      }
     },
     "localname": "GoodwillMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofgoodwillandaccumulatedimpairmentlossesTable",
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "Sponsored Research and License Agreement [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r21",
      "r112",
      "r113",
      "r124",
      "r159",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r186",
      "r190",
      "r191",
      "r369",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Net loss per share attributable to common stockholders, basic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails",
      "http://www.Protaratherapeutics.com/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails",
      "http://www.Protaratherapeutics.com/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r168",
      "r337",
      "r338",
      "r344",
      "r350",
      "r355",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r169",
      "r181",
      "r182",
      "r209",
      "r335",
      "r351",
      "r356",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Total income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r153",
      "r333",
      "r334",
      "r338",
      "r339",
      "r343",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffederalandstateincometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilities": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities that result from activities that generate operating income.",
        "label": "Increase (Decrease) in Operating Liabilities",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofinterestandinvestmentincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r161",
      "r163",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r27",
      "r208"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest and investment income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r26",
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Total interest and investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofinterestandinvestmentincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "terseLabel": "Accretion/(amortization) of discount/premium, net"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofinterestandinvestmentincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r226",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Interest and Investment Income"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r391",
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of lease expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable",
      "http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Lease, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofoperatingleasepaymentsincludedinthemeasurementofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r167",
      "r227",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r361",
      "r362",
      "r363",
      "r373",
      "r463",
      "r516",
      "r557",
      "r558"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r109",
      "r121",
      "r477",
      "r499",
      "r510",
      "r554"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r132",
      "r167",
      "r227",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r361",
      "r362",
      "r363",
      "r373",
      "r477",
      "r516",
      "r557",
      "r558"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable debt securities, non-current"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r201",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Nature of the Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/OrganizationandNatureoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average period until annuitization or benefit payment is expected to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Net Amount at Risk by Product and Guarantee, Weighted Average Period Remaining",
        "terseLabel": "Weighted average period"
       }
      }
     },
     "localname": "NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r162"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in)/provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r162"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in)/provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r34",
      "r35",
      "r38"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r38",
      "r114",
      "r125",
      "r130",
      "r148",
      "r151",
      "r156",
      "r167",
      "r173",
      "r175",
      "r176",
      "r177",
      "r178",
      "r181",
      "r182",
      "r188",
      "r210",
      "r217",
      "r219",
      "r221",
      "r227",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r369",
      "r373",
      "r464",
      "r516"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow",
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement",
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r178",
      "r183",
      "r184",
      "r189",
      "r192",
      "r210",
      "r217",
      "r219",
      "r221",
      "r464"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentIncome": {
     "auth_ref": [
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.",
        "label": "Net Investment Income",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "NetInvestmentIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/MarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r210",
      "r217",
      "r219",
      "r221",
      "r464"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r386",
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r382"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r390",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofweightedaverageremainingleasetermandtheweightedaveragediscountrateforoperatingleasesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r389",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term \u2013 operating lease (in months)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofweightedaverageremainingleasetermandtheweightedaveragediscountrateforoperatingleasesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r143",
      "r477"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r56",
      "r157",
      "r374",
      "r379",
      "r380",
      "r431",
      "r436",
      "r493",
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r67",
      "r149",
      "r152",
      "r157",
      "r374",
      "r379",
      "r380",
      "r431",
      "r436",
      "r493",
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r145",
      "r146"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized (loss) gain on marketable debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r25",
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofaccruedexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLaborRelatedExpenses": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of labor-related expenses classified as other.",
        "label": "Other Labor-related Expenses",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherLaborRelatedExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r491",
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Other Research and Development Expense",
        "terseLabel": "Prepaid research and development"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of shares in connection with settlement of RSUs"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r30",
      "r53",
      "r160"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchase of marketable debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share conversion price of preferred stock.",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "terseLabel": "Conversion price per share (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "auth_ref": [
      "r2",
      "r68",
      "r69",
      "r498",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.",
        "label": "Preferred Stock, Liquidation Preference Per Share",
        "terseLabel": "Preferred stock, liquidation preference per share (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "verboseLabel": "Preferred shares of par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r2",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r2",
      "r477"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, authorized 10,000,000 shares: Series 1 convertible preferred stock, 8,028 shares authorized at December 31, 2022 and 2021, respectively 8,027 shares issued and outstanding as of December 31, 2022 and 2021, respectively."
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet",
      "http://www.Protaratherapeutics.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r459",
      "r466",
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from Issuance of Common Stock (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, net [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable",
      "http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r61",
      "r134"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Property, Plant and Equipment [Member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r63",
      "r122",
      "r434",
      "r477"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "verboseLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet",
      "http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofestimatedusefullivesforsignificantpropertyandequipmentTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized gain/(loss)"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofinterestandinvestmentincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r86",
      "r128",
      "r565"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development [Member]",
        "verboseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/PropertyandEquipmentnetDetails",
      "http://www.Protaratherapeutics.com/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r39",
      "r45",
      "r106",
      "r119",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r39",
      "r45",
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash, non-current"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestments": {
     "auth_ref": [
      "r448",
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.",
        "label": "Restricted Cash and Investments",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "RestrictedCashAndInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoffinancialassetsandliabilitiesthataremeasuredandcarriedatfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r449",
      "r490",
      "r497"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash, non-current"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "netLabel": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock unit [Member]",
        "verboseLabel": "RSUs [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable",
      "http://www.Protaratherapeutics.com/role/ScheduleoftotalstockbasedcompensationcostsTable",
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails",
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r70",
      "r120",
      "r445",
      "r447",
      "r477"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r129",
      "r170",
      "r171",
      "r172",
      "r174",
      "r180",
      "r182",
      "r228",
      "r328",
      "r329",
      "r330",
      "r348",
      "r349",
      "r367",
      "r442",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r388",
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use asset obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price, per share (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of federal and state income tax expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of net loss per share attributable to common stockholders, basic and diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of federal income tax to income before provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r80",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockbasedcompensationexpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial assets and liabilities that are measured and carried at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses and other current assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofpropertyandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r75",
      "r76",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activities"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of the fair value of stock options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock unit activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock based compensation",
        "verboseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedCashFlow",
      "http://www.Protaratherapeutics.com/role/ScheduleofstockbasedcompensationexpenseTable",
      "http://www.Protaratherapeutics.com/role/ScheduleoftotalstockbasedcompensationcostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Restricted Stock Units, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of Options, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Restricted Stock Units, Forfeited",
        "negatedTerseLabel": "Number of Options, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable",
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "netLabel": "Granted option to purchase",
        "terseLabel": "Restricted Stock Units, Granted",
        "verboseLabel": "Number of Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable",
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "verboseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable",
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Intrinsic value options exercised (in Dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, ending",
        "periodStartLabel": "Number of Options, Balance at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, ending",
        "periodStartLabel": "Weighted Average Exercise Price, Balance at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Options, Vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleoftotalstockbasedcompensationcostsTable",
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails",
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r299",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "periodEndLabel": "Aggregate Intrinsic Value, ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodStartLabel": "Aggregate Intrinsic Value, Balance at beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofthefairvalueofstockoptionsgrantedTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Restricted Stock Units, Balance at ending",
        "periodStartLabel": "Restricted Stock Units, Balance at beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited",
        "verboseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable",
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Balance at ending",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Balance at beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Vested or expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofrestrictedstockunitactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r387",
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease expense"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofleaseexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r46",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r167",
      "r186",
      "r187",
      "r190",
      "r192",
      "r199",
      "r200",
      "r227",
      "r258",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r269",
      "r270",
      "r273",
      "r277",
      "r284",
      "r373",
      "r457",
      "r488",
      "r498",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3",
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r15",
      "r67",
      "r129",
      "r154",
      "r155",
      "r156",
      "r170",
      "r171",
      "r172",
      "r174",
      "r180",
      "r182",
      "r198",
      "r228",
      "r285",
      "r328",
      "r329",
      "r330",
      "r348",
      "r349",
      "r367",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r394",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3",
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r198",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r2",
      "r3",
      "r70",
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation - stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofstockoptionactivitiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r52",
      "r477",
      "r499",
      "r510",
      "r554"
     ],
     "calculation": {
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet",
      "http://www.Protaratherapeutics.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r166",
      "r270",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r285",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r381",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r381",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r381",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r268",
      "r282",
      "r365",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r507",
      "r508",
      "r509",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ScheduleofmarketabledebtsecuritiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r202",
      "r203",
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r185",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted-average common shares outstanding \u2013 diluted",
        "netLabel": "Weighted-average common shares outstanding \u2013 basic",
        "terseLabel": "Weighted average shares outstanding, basic (in Shares)",
        "verboseLabel": "Weighted average shares outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement",
      "http://www.Protaratherapeutics.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable",
      "http://www.Protaratherapeutics.com/role/ScheduleofnetlosspershareattributabletocommonstockholdersbasicanddilutedTable_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=6472701&loc=d3e49107-107924",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124504833&loc=d3e7104-158389",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r481": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r482": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r483": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r484": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r485": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r486": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r487": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001213900-23-018373-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-018373-xbrl.zip
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MTP:6PXC%B8HSX5=P8M!7[.*SH[O';OF7LHE8"2=BI9GG>$-2$FT7H!([!2W
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MD-+V[H'4[I>\-M=V3\+LJ_\A&.9)^L=([(>0U=82NGJ 5//NR5'-UMKNEQA
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MDY#N_I@VE1[5,S+8M#3]43(L\(/*"9;S2VV,,BE2"^5(8]J46-ZF$J.6/N?
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MHJ%L$O$V<=#(5 K(]O1KE"%+$R()X6@[3TP2V:4MKBF;5&'T^C[7MD%G:P/
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M"7H2XE)'R"_Z='+8/G[_X4.KDKUB,,C(PC'=@X639C3%5#2,CZ?V%O(U8MW
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M+ 5P7V9)*?8@[I-+\?0YM#]C:R0E9=CV(&'GFAB[=4ZC$Q'DFMC^1C6S3$[
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MJ^<38=A911@>/7&?->GZ-\W0CV#PB>0?-SN?KC!1.OX>2\!+!T6SEF'MF6
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MJ&RR8I0E6":/?!WI5.-NUCY#?A;S%+#4](E)32<<,=I'#+X? BV@^@:Z2)#
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MH3P-).L9>F:73N%E215"O<\;##E<A[P&89@EM'WX1:>="!WO)D;1@?7V0*,
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M9(W0;>A7?5<CY504?J.-DL2WE\@M -0:_BZ7KSLG+F[:@*?YTYGJ&NWG[Q)
MOP ,(D?R:N=:"81\2UGZKX/IC2T)#.0<BPC.NA*][MSL .P:_\VWVT8BVW[8
MT*,JA4'2A"M=O2(MD"GC,MGA!F*'@BIJ*V6[$%',A-AU++>T]]:L.WW_-?FI
M*KSR16:5%JJ\N%9.W7I1BPJ2\4_CA7RQQ<ETH>-A@=F9ZFN%2?%#=.\XN\M&
M)DIA9BR89M8E8R/@=R^M"%0-=>:<,/1)"W("M!%]QXR)-021S!#"02%F*+(0
MBJ)DX#TJ)QM%+T29"0=X._!26'9++*$D)-U;RI#VQ!V())MO!99L;DD@I&98
ML8+5ER&[R3M0\=%3C%\N:9U=[*5+Y[R(XP/'U\*=PCKYQB5> ^3$[<S-H5MC
MW;JV'!PVKD.*..WOR-QF[@6\:3R8&)D57@QB'G%[')23ETK8_ZS"Y!;2J"_(
MK?KH%@!CPST86#7&R,+'G=3<^H%,4VUP%#@+>2FRRQS(JO@"692A2]'X\:&9
M*H!9(1^/7 5:\I@0&YUL@_COANHJ4>*&AU=HS52?3A[,5V.RQ,^9KL*:3Y24
M<63(1T3ANT);SNX/M.7+([3E-[^XO[&&R8V#OZ2Q#%,O]CF@'Y$RPMI*#8K
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MO.9"-\EHCMGA9*EJ-\M#V&6K\;RA>#FQR F;$VMJ.#[K-:_B#'.8[%RRF>"
M47\9]LH,Q!,Z;;XCTM-PN9_$[2>0T'<_[5E/BY:0'@@GR(B.XE$,!_RL&B#N
M)%'',9(+!(PA_.F57WPCTNI\EJKL#1+WY>*&&PX<\327MGJO.PIO4Z8SLT#'
M,6.SBZCK+Q\+(86G9S@3#(VD%,X>:/!!;V S &$%JV%. J9?],'Z>0WV'[E>
MANNEKPN?__?'I;B#_/SS0R-SQAV,Z:-A[;_\_/ P'^NIR!'_H:I6/%KV3H9"
MJ]S/E!TSNVS7FVI;:V"9Q&_?XLWO"JN DR]H49$C(BR#-XO-O^\S8=C>^F#,
MMOQ',!),:SSHO]1I#>>$/S)IT%UU+?I,B"]IP0=O&&YD>%D_$-4Z&@>>,<<,
MR\T,VQ6XX,,Z;^8UT*5ZT.F1GXD7QA [RJD-1)2.^)K)OJUO.7&KK;",.UE6
M22A<@^\V2&?VC8@"L;R]CN,T6!KOVU*%QK_8FTIR%CYW%T_.Q#79OW9"\>UV
MU&=\:!P,YY-$W>-F*4=S3''%L/[\[FP=%Z$2_LPI[U)K-XR9@$].GXKY.#D/
MU>.,OO*$]_N& 7.,ZD[MGBW?;!?M*JT.>O7MT.][B<I(C=.]Y\?9=S90W)NI
MZV579DYWZWRW(2Q+9(^@#5C; \0&%WCO;HA9PHL4C%EPMPQXH>6SY5O-AT@9
M:;K9.M4.$=5&)O1,I(QVP?M_U;2WS=N] -X<CG%8YN 6FH]D?;M8R!V+9?%G
M7#TW:R?ESU!^UC)O9!_ ZD*"D;\5ZY:0A&-\$]/,<Q 04XEPI+F&*,LP5E&S
M,0#!1+4DM9Z '%A<T?P2G@^&HB"H6'/O.,N6R+U@F# "K[*"V]!:HY7BAF,\
M[(G>7W*_6'K6;%*4@\RGY]1/:0Y+99,3,P)<DW]O:9I?B6@=89T0B5^V73=L
MJ)U?LB&TVN\E\?J=LY(!%"+9P.\NGUT0X*V]KF<UUNF.LT(.B=<ZH\017KEC
M_!M1H/#?NESD3O_%@>_.! ?E,Z+3@1.)"+YOJ(Y<))$>W9+_57#/RLXXXELH
MPD'S0?&W.:LLD*=M@C8F5,=H.5 TBU &)X)V=(PSE3M+^:GJI=Y(6&J]MF09
M?)J>+<*!2:%/&_8+!4;]1P2LO)3)9M/6!A_U"ELYZNC<@OZY#QZ9]/&7'<L7
M1;.5)@=!)09Y0;B&1&L[<-3CG$,^'^F'(\F]6=N^TB.4^'!%5"A<92!PR8HE
M,Y=EW:%M"#$F\>#D2.6I-V3:36'"NU+5<31#!3_:)*'(^:@7?%)RW,+H#.*Z
MYAR=#*UL,I-.$4)^O$E<;.4?5%2$E"3'W\U58N]1IEKM8DQ-A\-?DSKWTA8^
M'I.L\V9'$J;(]IT)(@YPO7!5<U-WK0)>70*,J?__%3Y&WJDXUO-JCW3@:=A0
M&UV4+Z*.KZ3FR!BC;O>\DD+7)<5J'<4I_,'G7*+9&2 2:=?V=3W/7]A=M8#/
MB#\'E$HLD&PT#@[PH.S$T">S@81[@M^[6!E]?MTC?4J[3]UP[0LA6TSZ=$9S
MWY6+NBTY Q%G@QUF922Y)>^Z-P#; GQ;@'/%S9H]7HY^Y%PD!#(J>QJY?^P5
MY2P"T?;>5C,0=_)5W5:Y04"(U$IY@\IUJ0C7!/"\I+F$ASJC*N)-1#8*<?BZ
M!+T8ZYHQ X18YTBQFBXIO 9^K>764)<+=P&NXN J\#/)U6>D7KS=/F(O??E1
MQSUXAB2V4A"DEVONA.U-5:"$/V,$NLO8:[ZGEO5G =!]<G\ =.=' -UO9W&K
MV\"0M>@Q]/?29?@[FW-XZJZ+HB$-TG""9.(J%"X5L6KGT7>@N6-U";1,K*F"
M2662GDLOU&LBSBO[):129XFKI)Y?'/0_BFQ9H[1/QYKZP<7>L1V//2H=.<K'
MJ?,0Q\0:L*X0!"3B3BR^-XHXZ.DR.[]B\; '.3D\<M]2<H\."^RG;[G%K^KO
MW0:Z0&!H!1H!VYT7A/6_+A?Y^:?:_U@QN2HGX=IU\*0H[3NL5B?;,)3X*92)
M)J^9GST$\#8L6/LT7Z9JKL"/S0589M&C4J63A7?Z:RQS<?[F:UG8[ZY3<(>P
M0H2K0A5EDL\XMHU,%-#"-\HYY3T1$U^C1M]))-#G^U6(?H"ZS1W3(;,Y\0QD
MH_:2"1DG$Z@ TE3ZQ33/$"_#?2J46V2=1V*R;7;!)JQ64GN<A26C37 D3H#T
MZ*3#;-'^5=LN,@/PL&5)1G_O#(>!8#G\8Z#,DW+>M5H-IG!/SHY?U+CL>;NU
M34?]ODS:'3G.?;0P[6^%%JV3&?.G+8YER,EM-JPC1YI/UP3"N>((7BLG@.OI
M)6Y:^BGZBBC^*JPQR??*Z6\R:6V44.Q C\#?J_UN.Y7)OKVNX(YQWZ4-7P (
MXP@PO5V\1Y&MZG\.]4)D$@G 6[/ CE@9!ROJ:A,7YL>_+EFFCG*M(=XO!ZX
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M USJ9=553GSYK\]_--2,W@8=E-N*09\P*4!V2:&*7@"W]^FEVF8EQLQS8PJ
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M[*BK53MC^F/-_N"TE8^QB@UXP6FE="075BGEBBTD<7@IER1)JZ1DH[)XU)R
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MCRA)A;3$!_2]+,RP;<LE$8JSNHG6J(E;WM;*".\%H=#'9(C^3FFUJJ?2@)_
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MA#_J)9R7:N^U>.Y2UKU?2?=1++1?=7PV$^3\T@';S_I(27U=6<MCE.:!/GC
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M(V(RVP.+$40?;(UOO/K^N][H  EDTA"H#&C*Z\MVI]9VU6ZW3+G./[.H#YG
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M5RLV!M'&6 LZFX3G,>#(A8(<!%-="&UDB&\?=C&*V<(>I'CM#^I)QTG@O@I
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M*\S8AGJ(+GW-.:LMH^KOOAOP*@3M3IUGS@1E[@1#8EP]?>'6%WLH5:;A,@M
MF'@YU,%%![)"6'+0JYS#NL!L+"WPFZ_B57V5OZCORDIRN70>U411GNX;LBTT
M.K9/8FT?TAE^7]3EGQX/ZO(/3ZC+7]J9O/7 A9ECSB&M=074ND0%C<,M<31S
M=V]$T >3GU2R)4(S3F3"LA5D+^ASPE%B!H,-$OU6S[=H[)409F2!?4!A<D%T
M[*^4"2/#W@/SWEUIRU"USN $FC^55R_L%P9 PE/@MYN:'@.][$VU-<J3#,5_
MY]$""V%Y),Z(M6! ?;^R Y!1ERP[DM]\^\;'KN)Y@EDE#M=B=KC0T0MX2;E!
MXUAGKRA.J-K?N:!8/*!]VU"O?<V:8$#P$[4=6_K2]\"4:S0ST;_R-U@(BW"6
M3;1C9(27')T8G;H)KA1B2BX*GS%=XAO?QQ_^A>_@(QWU"OQ9BMI#6RQ4&Z6O
MG(5(U*=Z4(?4?6S#:Q>**]W.EGKP.CK,B6GA+ ['A0LF#^QWG8XBI3L?3H=S
M>)S+F_O6T^!N1#T9LGV6[RR[5VU6B;:].-'@0:5OZXX9.Y.+^SB3Y/#QV+@W
M*)@"1$$F*JI#%X8O;.095!\N",1+4M#Q$D<Z>7KF*P6A:8J&!*]H_?FGT@"L
M(JW[J(^S$W_>8X-DP<\M ?2XEVWDIAKGD+PT_U >LA@@\";'LS 9*;QX +\N
MAP/$7K%)AT,FBWY):,WH64_UGUIMV+FN%OF+ AOM^5><+%%(BP%'AU\K."FV
MU2)AZM$Y1)#8'.#OE%4AL(XA.?&!JW8[[&0AR6!QG_WDL=%WN1$"(^F"& ]^
MFX!+BV79USU'OAXB"$@A.*?'YLX1865&,\^Z;,NA86%>K(K$9I+)]:%A#33L
M2C:0!'=+P@AW!^F!UJA;!/QR-H&0*W;^5"I]'ZLUSA"E+L *@L@\D1*\U?=@
M'"4U!U9\X(D*#/6TNO!PE/BREKI"<G!%$#_R8BCC8CY4"MB>/LEX]PG/KDJ7
M"I=.<NGT.('/-DZIT#IE8@YD$;HX')P&<C4I/R[9 "B"4!-\M?M=_)!ZCL17
M%'>U8.A!\K($-=J*UOT/U< II6.N01OF&W/A9]\A]AV!U\>;GR<(."+R%8'H
MGCL%0WX*;KB3@I82N(,&DP:8- /0P2,;W&=%V"MUPN.0MK;!*G@VA<5)/F6<
M%UG5D(<A/C-FG12GDR[V@C_$7'AUXJ:;(7;*5Z:?MHV=L,)_D\9!S-6V90WF
MFPC>"#5=\S<ND$JNF;6?:!?JU0#B&*B)[8R.Q<_N;(DIM"J*94YUSYG R>T=
M 8)J,7RT-NY$+\BR,IXQ:P*)8PKF,'A2!VKP0E1&K5O1.P!36D[4/B%YE?9Y
MNH&C51&3M[J,=_M8.+,TT_]NZOQIHS52O=+X&#3/>])N"M4)%B2A84<[(7E0
MYJ:^^O+;[](W>LE:N^_Q7G:993L/),.\6;Q[^?W+LV?/7G"M*(\Y)HEM"103
MB;"Z/(52B4X_/,F\!W?7$>6]\0"J(@T$DMK]OEH_OIJ-%#7@H$0#!?6I)E@3
M_TS1C'T%<?R%-LI<>OEK<G?&GW-&WI?PL_MPK2?Z!6%<I>-#C7/GEKQQQ=4L
MCT,+%P===,(W=+(AX,S2\9-ZC5LUHIG"'CTMIWPLYK9?@2AP:QUSHG?N>F1,
M;P;PB//%MZ>O*9?JAQZ,F,+8JP.V)>5YR=Y 340E[HOD\&A2AVG): H@"!F]
MKU+;@C.>.><I14=IW7;I$^1'=5T+"1Y0&O4'HAZFV)DCW@*T1KHQDR4!]P_)
M_':D(+E2*KS<ZE",:YV-*8:3L3]??$5^&WC,)RC;!L*P(9^;%(:=DG1P=]'G
M3UV7&Y.<U,0"UH;P"ADGD$3\%$LB11?BR=2U2W2.7]4=AVAZ_KL9XL;0>#7(
M2B8QK]S_$?8BL]PB9NL^A*2;9$66E,J);N$Z< 08=^"!:4)%@Y2.TF@TF*H)
M-% 7*;C<56ON?1VM),^2Q#K,$]N=AM8/1YB0!#>>9VD2,/I.\7IC;;CKBE+.
MT#@2Q:-1^"$Z*WP 9,G7^/4PQR.=]Z$1J13G*$!6_\VW;PJ[.;?,17_EB[^^
M3*+3K%[&T3MG4U;*#K-JNX[3E]R%+OF+,$K<=)J*HNNR2Y[_F16J^ORM'I3C
M>,]ZVF?/'D\][8]/];2'$,$<3 0$!W4H^[Y=L=(SMBP2QI*;'46Q4P]WE*KC
M;YD9*D:RR,A-DDWJ!C)7B6,P6J#H!.SZ@"=0PA5<[6S8%_:;:'=@=24E0-Z4
MG<LDBHA[Y-:2+=^V/2S<X<XH"DY<"/5VK46GKKP.EF"7 YK9<R=EGD56YK%(
M0!*5)^%3.@<P\6,N@?%!0&.2@Q=]L(3P9,P<0ZGUK W'\W)(-$_'@*MWS;$@
M%*XF$>K#:3@(/5-5'::85,WD.0D^SN5*].MJ87J-]%$9/E:HTI MQ_"-\M5:
M/SD-6IE9O3G$3V JQ0P^5SOD$:"'9244=Q1V>84;SC$UZA)8O-_<)8VLR6-R
MDG*61F+.XZTA&>7%6_8LP["/I^R)J$;W34V%07--<4%2$I;L1=F_3V2+B(FO
M*Y^X.Z92/.@:*[HFI<!\)3L<'"/C82J<.F:@<ZQ*FOY37SF^47)B"RM#="[G
M#RK(5IW8^B#5&W!BTJ#48%&QCUK]G58_;WM>;>888Y$])$?DQIS*:]@K!5F5
M!YY)]A<E Z'DH2$% ^^K8P(0W(ZAF@5"WP2H&J'9<=-KREO:4@D91S-A*A]9
MVN*[/ 6DW%MU U=;XF;^+=-_QXT_$MQ*JHW*@#C%-<ZL"+EV@I+P$ND0\PEU
M8S0?1=A!CC+^$D3PGC[,I;5L34T!*7*C"2[%\=DBLV"W]-=X![E@3EH -J)U
MF8SIG9947&E7]7J@ 3&6ZFH-EE.*]AC!>"4BJJ?83485Z'V]KTB7ME!+)X1G
M^,R6B!G6TS#R'G0T4S:S"7L<25^3_H-$\9Z FRCI2BGFCZDND\![5KR=[+8%
M6PZ*M^\\OFPI0  ?SXG@/!74O?NA9L_#%;W[:>DH$88E2*_C<9:\)BWU$="%
MUI7=7?VDX!8YFI2QQL>+VQ;;C/W+Y3LU'V7*)'V5MJ&HMLZ@L +[OQE3:C''
MI<H/D#CJ'OY1=)=0!$@^.()E?PB;>+-C57;]3+F)!&=2'I>DI=>5<&W'>1J:
M*B[P]LAHC$0XV"C1 :BL,[L)FBFQ6*Z+)/@#+B6 QEF]RUI9P'EE,==0CD')
M5P([[HH+%(=N7J3,/+,8FNF:<^]7-5=UQS(,8XE9$H2%XF&9?PP1A"LG7;?=
M>Q2*?<IH9#+&6R;<OF4^E/[KB:7U2PHM0/8WYUIG #ZXS<MM6-<]Y)XI[)52
MG\_#QD"-&D7B61[/.QQ+_-<E:EQG.ZI&:Y#,V5):&\A;U_V.2Q2EY-<DJ>FH
MXG6)!2>M,6=DL?05+Z5/3(I0+6AEZ(3H+1Y0),069<\#!3E#KPI#?<5*VGJ1
M1^C&M60.$.1K/3_N:+K5_Q=W7['0?^'(+6V@*"MR#5PSP978T1AH%B[+U7ND
M5"QJ9^^E70&&MU:,%7X;?]2Y&%CK%+3:-#$)#!* #%"5''G>@J_#X!6HT6BS
MBV]E*FP-(JNX!_H@1;3]L2<1JF+Q^EWZ=QZ9*DUJ@-\DQM1=3&%\]O565G>*
M&F2%4U+:+>OZ8' PBW>YN#-&-A(T@D764%E@T(G9_VQK;'CLG*)]7GL8B9X)
MDBX>6&5CMC4U-^8.IJ:-J.#TMV^_>/T*CY%YD1SA&AYD<CQFO*"N)SE>\>_O
M.\(&:S_/"+-!O_IJH/H9/O"RK\ND!(.G3U'V145*0-% 58S:WK=;61L4\T$G
MTC(9O3&=UM+=Q6_@ZSKFA_=##ZQ8_LXAR=N-X#55T[7;K1U$\: 2B2D02K!4
M*+F26*)\WU07MS5#$,ZJ32_!1M>/)&LR4:!@'QH:$AY)JU\DC9A;H+EH\;6V
MV6Q)MW99':ZKJEE\/\155N)993:85E5"F)+RW3M^!:) 1G.Y+&')C)BPR%HR
MD5*+3FY]><)<CQ5*';9L%G-VRN@CPQA484M-?XS'Q#WY\<"1E.!@]-6@L-5?
MCBJ5F/E>G1=5 "@6&2GL3)8UZY DS1??XSJ3Q<O@&?$#K_^Q>'794@ 7_[N-
M)R>%@_\YN#-PXH_\/QQT#\=QOV\QZ_GC*6;]Z:F8]0$7(O[WC^>??$:CDGE4
M9_Q;.'G?PS1^7S'\)!HC<K->Q5T?M_K;0[MZ__,X?G=[N _@@=[Y01(JFQ7$
MXM!PCP-!V):6@KN"3.*V>F3..0,.P1_%@Z(XW,NR\[[""3W'S99\X%(DT[YU
M%Q)2!A(),ZQ++I*3 KX85%><XUQ5?5)S")<U <3(V1"2@?@D52.BC?% [-R\
M">K;/2?7;M=EC:",WJTG(N(Y45["U'!!)0T!CM"V";QB3+%3?-V_Q,.7JC[/
MB\6+9R]>T/V^K%85>)$_T5]2H@8"-6L-!;>4Y]@L_NO%^:>?<$,>+3_\ZO?G
M?WIVOG@KXL8"%*(^&B9N@?H$1(T.\U.VD"FC5*/,BLFD%Z=TTC_$OOR/\A5/
MY$^_3O(G<5:U0"M^O[*&^9+_I,Q\JQ]J5Q@%?@GFF*1CFZ.UM%HO%--,T8;+
M4I5 %:JSK7HJV/42)VDTE?\N)373[Y3?RA2N^0%CX+8G;4:Z%QY"*R-2!9(4
M?U*%'8TBZ_O%*WTXZKX3^;R/?SN>2F1^1'MT'D(_XJC5>++/8#O%[+Z\B3&P
M$% #-EB[08Y*=F;O[L[) KWGTSI_6N<_.8^JY1#I*4Z<,#>OY*R-!#Q6K$ S
ME>+X< N8__?\L[IY6LH?]U)FD)P) FM7')[$.N,$5BFXDF&YC;]CI7HJ4_3U
MT\I\6ID_Z1,D+"K*+K)(V848@:9O<^]O)!Y^\@B>%NM__ 2,?U\PMM,U'*I+
MP,BE&6Y#)32P-L'B/W")G];RTUK^B5R"Y@"2A4,KG;&=-N_QBN9PB\HL,;I:
M.@&WZ$,0*BDC ['D"?W%N;3R)??AIP7\M(!_F@5<DZ*OUJ$+X^S"D[A*-YGL
M@LO7M$I[_3RYN@0[N"BMH1F.;[EB@ 6QF#?,]H(LWZ:2#"+!4[<D9C]P8]6^
M I\YZ_K:1]F+N2BI:]I0K:>_MI$>KJ?M\;0]_O,G( (50KF:<@'XDNKM0-!<
M/ NAA^+R$SA&<_$4VSTMP9_679YUA97#2U0[ -Y[,GE/Z^VG-GE+[X5*EDO=
MU\[Z%%KV9JGEQ_NL1CEJM<+XJ^C ]KW&>8!1H<>8/ D/7M"NSJPO*6=5UX!Q
M5>[K X!PNUU]>'*.G[;"3_0$CH^YVM8K FQ7)56;-P/O!8:?E-$.'WM:LG&L
M"<_&%$W7S05Q\QF1#']X>=3/_P(:<!__JGQX2G ':135=  W4%4?,D.5',G'
M8+@>WA)971).#2E3I8!W;$K*$*]4 _]IB?7S#RHMB/_]]-GY'Y^ 9K_.Q<==
M\QGL,AUE@S!'U@T5GM@I)(0JEAY37M!'B8K\@RK]_<1 QU_H<>[7\_#BT?0\
M?/;LJ>?AU[[D[_,,B7<03 XP+@RBAC#$117CS5)(L7UOO6]S%*BY$%^R31)V
M$31[$=R[W1R(>YQ@ZM0?9]T9=-?4.B7RSLP+OG'\$<' []RAJEV:=J.^NJ#H
M$^0??;58=FVI7",9&!]-<^6V;R>MV'@4HO2> -X90/Z@FK;NR;:@] I%/(.V
MV_9:YJ)NUR!1R2=X#F=?2G?"47H$>]?A4&0'D;#(8SE07:$^#)"ZW99]+W4+
MWQV1JALA%2):(=; @CA?O"7L9/H@<&KITDIXG%H+_=H%7:>TLM-ZD(Y SV-P
MT-91D@?5EN0^9P<](0@1/;Q-;>QSW(BZ'YCL:M2PRHVH<R\N@P5VBZ8?JG4H
M-]1]2>0F3!^VJR#?8N4?^1EP<<<,(\VRQ\F(T8#%'3,0/XHGBUF,R&*,A>+!
M;P77!%4WJZ'SZP T7_UBV+<Y!5:BDP&RGR#L@,FKP.!BCF]5C LV%*/1TL)]
M7!U5T/+,Q@"RH@'V ), FCRP5! 5B2=9P9_S)*402Y%4)7'29GQ2=% U?=[R
M+A,\@F3ESQ-2!T*ZV-NO7F6$A:!@80(_.D;N]N3S=U^U7;P?X6J8A!?GGK]7
M$=(+9*2)0[,65IRO?N00=?%R=>!#_&W9+<NX3<^^^W%;'>GW[FV\I%EU4?=;
M,9EQ=5_'F([^VPT4=5C;>+0W2V9'II&@*_VM[-?E_SY\(W"[7 VUH0S"7!9F
MXG[EE!SM[.DRR(66M%,?1A4+687OK*_<^$F380(YT/LJ]-0*EX@/6"SJ$-_]
MC,A+AUW25>WC8<1J*]6/\60!IQ$S>'2>5R;Q#V5*8R,IU!;P+WN-0'<4IE'0
M*69DE-.]KH3S-TD$CHVG>G,V!YEE)28F;$$:%:+TX&U/+YFH.H1X_^<^OGZU
M;O\\V:.13 DM/@VMR;P%0GE$8[151<E^(E&A)*HE\<I Z"C1NA#9R"GZ-FN;
M55K41W8&"GF7:\;E3C<Y=4)FXP7G?F<#GUFK;*?$*XG-!C?BS/?EQKV0,0>1
M5+XD5(6P_8#I4Y:-K170^&_;'@V-LEJ4^"*&B6AR8E:9?$DQJUM:-38$S-07
M!U%CP<#D/NFB,4RHKLHMQW/\XB(F+>':G>^%%A8*=[R[#U8S^@#+DE7I71O1
MP9B[1W_Z)A(2OVP: DU];]?^.KY<7&UG_Q._M57F;(PT\=OA1)99 0_-VXIC
MHT^??:J\EM-Y%,$GF'$EU]')8S\WHR>*T4E\)X 9%IMJ.E5T\AQ:)?F!#3!W
M*Z03BRAHFE6B(=8[PAYGL9$?:*%*Y@EG*B%58+'V5,2;VE3*G))I8/UF@6JY
ML?82R>;#(EFYIQ&!-H,(:,21+M\S(620M29;!AD4F<RT,CDJ-*_YU*YU+'$I
M<BX-H4AZ:&;J=>?934(Z!=C_N/N>9!>D-98R1B.".8[XR<!F)\R-\<=-5P[K
M\\5+NRZ_>D&<Z3N*W+M 9(=P;=<5K431I!&_@+(#96,*?FV#-F35_"R8PV[9
MM]L!(C\Y"[LJAJ3[6O:CA8&/1H,W(_%I[*JX/;^HF*M =G#=$/ZB$>H!L=8T
MSMOMZ,H]7LD9/H2@,G7^%?1IQP_KYZL/PE2*T41%BL8QC3WXXHQ-S3^-=!"P
MH5"Y6:+G3A> LM0!Y(8?[1YD=TJ)(YSF,TEO64)@?)P[&[XX:<.!\ZTW4Z75
M&YVVZ8E4A'EA:O7=Q%B*.3CMQHGZ-DPZ S(NH]M>-<5L(G!<J0JJGK/:*L,<
M>.-GZ%-*/4- <*P:/?B-"T!OT2, WO_XT82H+D]%B\'$&2CB*==7\4BE@@8)
M4K"P4W#^& ADY_,*H_BUW\4MCB%5*VRA;)[F3"?!M")9T?>VY)X)IW+-9' \
ME6WWV/)=_Q1^RLV1PV$9Y# >Y*-+YK#[KJ;AJU?Q9'-?G<S/T5@D;UT8WE'/
M,TQ*4Z@EE9XR/TQ,G+(&0!LV/1\]Z5(::O M9JS'J=OJ$J(=S>YO?QY>T4MU
MFG">/OC<MY1SFU%>Y6'HL]&>#AE,HF8,+DNHQ*M,KRU5,(,35$RT"4Y+;J1W
M=JH;_S3]S^C$K(GF$14)N3B?DBSW/=Y%X_WCWLX+YK(K'*=GMY=$2;31R NE
MN]SI!IXD715G3 ^;/RL;60IC6E*3$<NNK4&"YQ*3BR%'951BZO)/5VL6#KL7
M= 8+<W/#_+)"F9W."VBM=K?L(M@X63_,U,C"U)2HTFRO)K0VV[8\A(OH)AY8
MK:Q9_->+SYY%#VN[U;H.LVM?@:32SKMH+=@]NNGQ:SY#2PX7X0.3PX6S=UE1
ML/I?SY_9S523?>8):3@Q@_R$?TA?>E#'XGVA&)\\'BC&\R<HQJ^.?I)]-:'>
MI3S+JMZ39[TOCYPTH<"= C4J,2HS_U3#_G&Y2N\<0S*77KCB7_>62Y*4%DNB
M#P:AK$I(5XK,K21!/7>VD\62Z"1)*;ST9Y]V,A#!3;6J#4D0<$#$[QX=EV &
M*]>@ES_0QDEDB !]BB +S)M#5U&IL]D)_U67)&8O]1^NP-<;[>!3=F>#Y^L&
MPGG67Z8/M'ID1L>U[>SO0[,IK]I.%&2FGR62Z>%@D$FC;!<O1A4^QLX+DIGB
M^$3G9=CI22[A[&/9IG\\__UGND^GCF"8.((0;]UL!X:*2?#N)GFM$R-^TJE5
MH-.KLS>1HSA??)5_-]AWD5*F5F4L),Y[($%FM[&>D9FT12'"U023H?,>@=3X
M>X"2S:#(PFU)$7$1*U%G8*YVAMC-#X7=LS!;:&I[((3T6560JLLP!+$X] $3
M9=G7C20:08*ZEG.HMOVBTM\G'C_?!/!8&^#:X>6?FLU@;3ENGU&JAS**DM/Q
M^QBM9S$PZ(Z\D_ERK/%XA]M%_ZMD!>PTRP/&@XJ@O97M85UX,<;W&WK)*W7;
M8R%0H/E@Q\8 E7P-(6@DAZZ1OTJN=V15XHX9&144V-6B/!S7_.Z$W&,^[N^N
MJ8WQLMZ'MZH6@J7YC:6K?BZK^HMD[UYI:F6"@V0!!*VK!]O'W0A1:.;4TC1<
MW2"=G^6N/LC8VE+3FT"31%@E'\MI)3[-R4&G4>XA B:\%60T4_;+%RMYB">.
MXSM1MX/YI*U;]T:WP:= .<%D]G6,ODE]B81*&>=:!.TNDJF+]J&A>&'KQ":T
MLD^](.EJ*G<Z9@T6D!=K_S'$IEF4%Q==!;E[*A_!$C)FB%,7Q6?/GA7/GCT[
M#R]'R:"^RD:OX#7KARBMRVP4=>1PO&LAVG20E\?)0OU0_N\ONE#UYB]C6'A&
MN2^,&?R27BM_.&=BD$&5RW6[&G:F\L59XB^C(;VFS%;\CYPR2&;2-.<BD)FC
MB_G.M7W)>]$:*TW7;L\]Y^.I"8R((%5&/HAWI->2"OF/S*R\F4X7]:M!1KL*
M*+DKK%/Q*<LCP&THVH]U1<?SAN8&QOMD"KPCM/A2ZLB2YDSW9 4Q7256'^ Z
M4'+&W:)S=<D7SS[1)*RMLV^D ^25>ZF_EM>H4G[YS:N_JN<3KWA9+TE2.5L\
MT><3$$SUHTHY/__L_]';D%K50?2OKEKF#D^Z F1#1?4K^EY+9AN'51O,"KLW
MH0'>=-0/ L2?#3*R+C<M\<7L$H_/UUA:P@%7(+?W'F]U&&\L:#O,7SGLH()@
MY9UE6W;0!EM'XPA! W,BR0GM]Z1$CPP!G^%$H*[<Z.Y2V4;\2/RE[_)=M9CL
M*HGEHFU2',:K.*=(>;^Z)/>Q,WDIB)_1#[:BZU[DJ,"DQ6C18<<:[W)^K>N>
M!/5ZD^=RL6=^(F+&I,@-$,?D,ZJ:-4,ELTC1S@_#ND89*3V,/82L>,U6N/5B
M8%X]^H.UL#\RLWS;D@FZ9!;_P9)!<@^PBYFU@]1N?(NKD@MK*S7H %559.*"
M-MF(FO6RNBRW0N,FGR?733H0E+>0T#7U>HBK@^2ZA[B$VFNVY**B=MNB2+P&
MM/@X")ZNY!,/L=J6]<Y(X&@?$(TRVEFZ?B@9,4G?S8\4G"$X'MK;9D:>AD_)
M0AF<[_(HF,HX-^/3S; PY28&^QVE$U>'#IIZ2#5?MI+9X-FS)X>8#._BTH^.
MP;K<'EYV_J&PFT=[F)_N@$)L[[;ZK*%)>SS<?3J=)C'# 0=D.B1M=4VBVGTV
M=6+"YJ[NNF?,A(37W-E'^T3!/R@K'VX:122;2,%0$TLWVW+3"TR0%$+O-T)<
MB)(OY)!E2;"2>'D40&OBXSK19$,=>]LK%E^F_!"O*Y.Y_&&(ZYEJ]*BC/Z0C
M]+Z5T4\?3V7TQ5-E],,NQ!G=O=>>*_2-<H5^CYS+S^B7Z$M^\*C^G[-H2W;U
M"@-O!B@8,R7KQ;9=@E_XX+-1:N5OY%H5=/95U6F?\8A)1AHC1%2N5K^GA!1(
M<#+TM-37A%=M+28]7-8Q,H&:7"4"T<(V1R>>'2>/T,,4=1,[6*A4'2QY-YD#
M%&K6%75!0%N:AK10YV\F'D!61D&^O"I$-5V.K&AK+J?*SNA.'(DV%S*AT7NZ
MXA+$ :67G@H6J:'PABDG,>\XX8B_&WW#?;PV2C*\#AG<[Q+8*O)^8D!8;+P1
MO.Z_2)6[\S>BE 9\./\T/(#]N'.?_GQR+$,VEE=Q@AGV[YP*&6%R:%M%#ERW
MW?;C!:VCJ,?+RO-625=5P<V4[YOVFMQNMP![H$ !A^A=DZ4JMZ6VTT+QW>IH
MFNRU 3;B7>/7M86#?Z+ ))G.D(#JU1XYK$TM89<^2X66A*:BQY;Z(#5W=&Y:
M_1M"Z+MT?1WP%'GIC;N&I/LB<-%4%=#-=MIMSA>O$7I@S%0BWM J6C"4U[>7
MMNAF,AIMEP:C$(1H66\!H!9)/GDSO$#)4%/VIJ^8GX(&<5V9SQT?@!M-QG"8
MJ02V:R9FGX?"%HIY6U(+/0!R*39J:I88CKI#:-7AVUH[4+E""5%MO]&O_>RX
M8]-F.-NN""3*(#-$RZWN\1C6:;&L^@.'?55_F*G8))H;*>0:=RIM$K(O%>IL
MG*/%>*&R'"T'W8<VQ;9:7U1%V%71=JWY+>C79]1?Q-D::<=JN_=L4E)=1]Z<
MEP=R1?2^]"),4J(V4%*]+TT='>7C0WS>2IMGN7,VC*R>NA0^L45_&@V]M8ML
MCSYV%!R!@AF4_4.S%#<)GX?43.6TSS]:$_HEX[&Y9Q^9Z[);]\*-VUS01M%=
MBKDI^.S!O^SL26PPG#R("V>/G:K3A(6$' LQR92K:@ AGMOJDX[LB9_IMH]=
MMR;B"$T]< O758R-JUX$.7_T9 0E>YXQ=.IYF\+=80*#<M41;:89R+AD5S&F
MIQP7K2QQ4E&Q0O*]^K'F%EU]$C&#^B-%]#428VQEDC4TXW"CLTM@$/F<PGP&
M\=*2JQN<T5)(Q\RU*)U%K:EKR@'%Q5#63<*C,!5R@JRK-ZP6A<Y%Y5ZVW%^?
M4Y$$)C""+[3L2+@L>H<@VJI7?'+&-SV+._D,XTLEPGP9..JCK"AT;6T'%T,9
M+WRHY$3R0VV9XAOC"QQ C,QAA6:Z0L5U&D=@R8?!I,:=6??H3G!F+DWJFO.0
MYXNOXGH.]6;R<#<'/\P80P\'_S$]ZPU#P&K6<;?UR;*Z TG<9[D!HJ3.@)V7
M,2P7'S)%;U@3DF]$A@Q]\LCOQJ?_01JB[8VN:P()Z47'BY2&UY75_4J];879
MU>E)TQHE!7#J%15?:H#[3'111]FU1R$Q,N%&N[UTC&K[X('DPC^"XM(IF$CF
M"S \E_(P*.7N=H,796]6_ ,->;G'=I35N$(W")N,%**4.QIJ6/:N)I-'X5]B
M](&R.Q*CTKA1BFV/_N0!.7D$<(TT!A?!>U"S;FZB=.%&D+QW2N\KQ :OD26G
MKN3O;@]'+80*<R&4AFCQRM>7E7!'<%V4^IM7KI*&4#07N^>"M R0,#*,/L9)
MXN0 !T,ZVA?1522X8>:8<[5EL1:3 Y;B"&L[6J%A+5?=F7M>;LNE454FAJE7
MG.'6T>B*S,%FV.*B2]'.5FPXFT+Z(5T.*.CT/4*!L9'+PV.BP>'6=HUD6T!(
MHODD% %=[Z0/0M5J=3Z0'1^-4Z:F.?H;A3G7_J@N0O(H/=D>@0/D.]PDVI1=
M1R4LV@MX-&R=>"$8VBSS+\W'E:6I4%^/2^J" ?UNQ,6F&EN5>TZJXN TII)5
ME65O%J>S-\17H\-(SZIT"&L:"(JT$M^3Y,BVVW+9LB<<M*##Y$D(*(#%A:&8
M9"U\3,84T<*L,?]L#\H:W[=.\=GCJ5-\\E2G^)6Z!>^4S[&5QEH:XOB]D-4+
MK4]%_+F;<_:M #EW%*.KY[P>%"EF_D>6W"WD' ;*7^P-<R;&I<+Q095S[!@:
MJ>:.:>#+(/-IQSE^4-M)_V:]-V6.<Y$>VV*KGLJKU,W\>,!<7[M'XV^-G\C?
M&8=WY=Q8:K_BM@1859>RR+\WY%%"L.%.#Y<7=T>]/]:OG;%1.)8^"KK(\+O1
M$& !UYNWQP=EAN\)<K1,?U8W"(Q$Y;.U<ADPD!!0+A0A1KVCC@H!AXR:[K8Q
M_*4@2;N6"0A+*.UJWTN;CE40IB6+=.M@MU[2*CVP/T=2H)2<VG#2M.1,BPEW
M:L+0^4^%D5Y--VX6AN774-Q$$1R8P@$SD-V13 ORXUL:#DE^KJ]JS@9SPSW1
M]RS1JS[B[%G6LB?]S:7W9UD)/@BN4U _TS*F4(_2L%1\4:QS3O:IH"_Q,:SA
MPHBOQQ?U88I&LY+R%Y (M=U(O]VVKB"TRFB\VR8NK9E$-^1B6,IU<A&"G@$9
MR0/G9B68X7=+<+AX".G =E4*F*XJ;A$$ML2G>#51*TF)/!W,_F;^]-WI*Q1I
M6"<L.UI8J^HN#)(-%UH?)5.[4"=[]. G7GPZK+\#4F8RL@:1T8>BD"IN&8!1
M*6$'=&O=YR'>.'=\#5M\5;=#CX/@A[BT'U9Q[#XMV_-,2;3]P_BHF:G&(^]#
M38J^BOB8JN-?@XZE2.5"=B5"<BPLIFQ.!5SK-OY/GKMSZY&Q>QF)#-FL+-TN
M&0=R 9+QU8IX@,5?<7.?!F5,O6%I["R?>CCA [K"8/+_<&C=P?\+WO^+/A]N
M,._X.<?CFK#HB$!WG**^H '2DGDRR^^!-72E!!1DR2R_!QW,1@\(4)K[9&\R
M$R./QXP_&WJNF:[BE&RSJI6#N9XO7E&'%04SA^UQ8HQR"QEFH =[L-/ ZU1:
MGF;$C:<30$D>\KQG01'HKV7IIO@2E[PFI9Y*B?1$^!_\DHP/2F>\)8\2OPIG
MP23;4S=&DDCY5'KKE$JD%];FSPR&4X^\4IK:SEAF H[#I< G9])**9O ';N4
M@DEBCZV^!"4G]D?WEY(@*)OH#UQ2$53X-L%$:F=OPF$$2S#3FJVZCMX)O-;^
M66<>;QDMH%M@"Z!6#-WARLPUGW'BA%!:/+MRHV6T_CQ8FP<_$3TZ']B2R'$S
M)WZ7KWC>K:+@EF=BU*-44RH>Y6?Z;@2+>E#'XKWT8;+ <S$./(,//..HQKV]
M&X5X"Q95T&/@QGDX%;JQ[9>J*_-AHGS!-CXXU%-FXPUE/6/K"[7= &:S\^-7
M;FY";UI#:?V/CABN\VEM&#8O*^2-R/64E"SO)N(48G_@'9^;W%%UOU4F"]K"
M(E'!H#W;/93)KUOFA;:O3V!=*OM#[/%OS*SG<O)VW]OF+MQ#?H6C!V$&YEC)
MU%>PX;2_U= O.4"!;[4?^#H9OC*&KO2H/;@<. \]RCXCN(][G'[D%+708TZN
M-0$7Z75I/5%VV+!0\D!=>]6^KSCP#'K4'5KI;M#"I(-6+IQ'2F:GQ&F+ ,V
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M213L]IRF$F#EV-JNIG =&1PJIM97.BC3,:77!*JGW-)IB=(Y'<5UI^0Y3%6
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MDY6]U<JR>*^$,0[9,&]-E-%E,ZYV,$%7K?IV*69BR6YC5EB,!;VYF.AT,;>
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M-'2*JN*P**0CI\PER"IL/3T!S(,UK;(JX(EQW-7#)E1:UU-I7<3T@R4.T%S
MXB]\B_/*P13[1+1Z8+D2AL:=F23D!%"=D%1?&$;QROV2-%Y4GF1WS 4EMBO9
MZ+YMH[,A)(C;M&@UC&76MSP"I1 5YUP/5EY+-; S<UV=D9X&8[7XZV'!4F_;
MCHH;K(IR\8RY.PI% #RVX" [ES;A*=H30(+IB2?\,V'"FU2?-"=-<6B<;5MM
MX+VPX\9C%\E+<94@KK#<_GU'OJIL?_):U'2L4O[*FY:_\DOIJV")[!4&<G&(
M4,BH]W#2(!/H\D).9F%:'B/HP+^>(^S+!4,4;<PYC0[<EMXJ!"["GW8_2PL?
MCF@TL$)C82236ST%K)S58TS47\XNCHXV:YY.'EO1H8I6/2?D)%@83-5VR?RD
M5] 3<.G9]IM7FD]S!X<>,9*,0*I\L\(_W!8ZZ5=%8K8G)3LKL#03B-A*0][
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M7K.Q;9YMMN2X*F7%\"".HT?E#<+'YC1IR/46AXW+0E&*>L2RM\F":GL0V8:
M=VRL-/TENXQ&1FF[*]1(6^HKF:#<<-'1)'(T#X<!,1DGY,L*]0&7<69? '>K
M9AEOUOP3&2+I#2.L.XAS-6X&!V4-8LYVW'T8;'$JF(2,2P]HZ"+R5\GN#MMY
MQ)-D"6N:L)>T^/0,[H@M&0+'#.,2*QE=0$X !WST,5=9.GH@)ZI8<N,D4J:9
MZP18-AT"!QV!R"1XU9,3"F$P;(SYX'$Z',8Y025UTRA7M>OD5MMB.DQ,F?$
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MWQFV6=<U3_:7>-Q?HC]KCY_M3N+HZ3=-H-P1[W?Z<?1-53^(Y1&7QNL&,UC
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M&_-$@F"(,G17<0=FX@2<:#M.)"+(@4"&W;LF4AKG[/82LS!SD,5$@Q7M;2A
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M)![^&0,\6-?#Q39 T<""[(]4'@10".7+C>U*1U*Z)5Z9RA:0H#9A&E^':8[
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MWK"'&WXEX(HJ78]OB Z-QAZQ^C7Q2U4:IR*56@&X%;V[];^R)U\N 6X 70S
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M(1G<C\2?CUF_I%A.G4Y8FT_^?G;W@OKNO,[LLZ72[;U@>__@I9]" WAUK_7
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MCM/A,,YS.IUKY!MLJ"*W* _C[HS##CSKH.FW[$$5M[B7;DJ_&T49S1,DRB%
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MNV.XN\]/[E<E5_]&'XSR'2U'>A%\]C ?+N#I4NAX6_!*78<=[;F02_IL&TX
M:NT[N:I/;*-".[S9]KH_OD-1E5;C[LUQW@GW4?:GS0RJQ <"M]UI.^19]L?+
M]M'*/N+"ON#;[J??P;##16WPBNF]\;;2[?CXOB*QQGIWW#W\JZ#(08@K(IO=
M024EJ@T*6-OZT9Y9)LSOM<;_;6/I2KOSXDU;)&*<..M)PF\([=SHP^[N-(Y=
MN%;)M73QGN9)I=@!5T0S'0WR8U,7;VE=-T:YO;D>Y1O-#7M'FPFJ# J=>]6I
M6NS4#ZKP%7Q),]T0;+I"4>A28^S&2[M!R>[V]=Y-IS07K532E3G?1[D+VWN#
M-SE+>F 8EH]*%=B%;6[HG.2X@D81=9GX:!D$QBD1(=?W56E8X\I_<(?J7Y7)
M-"N::]QRF=AFQUN_.;OMLKG[\E?<2HRNA;%$WV4URJS(X)U>=&()G_D*"H26
MASMW3V]-H*WNH)($NAGFZ_V'I42687<O9'$*SK$ZX\0ZE+LU=U=!V^N?GR.N
M J%Z^N#ZL+S/6WM'4DYI>2\OTXLZ+7.\/F^W9)]EONPLX%B[^$P:\;(7WZ3K
MX8DX3RHEGRE:^;%>?V7$^5 ?#_*]'*=V[Y6A$/#<S?5Y7'B9B3FG*5@;N/V*
M.*:'A;)9+E=@LU=@H?".WK]N*,"S[R!"47FA7H\9U^)ILEM-%^^FR(+>ZUQD
MP#[N^@V;TM%'U_D):#NOJ*C3[4PM">*N 4A@>(0Y$XP]O"2$YIM7!Y*0THW'
M/*2LE(*S[VTS^Z.)8UQ"57N+9A2LIQ2=1JGIJ:[]K7/5Z701FIE#+.J:$08S
MU[/^ \^  .QTZ/\<!>@2DCHZ+SY7UXK*J.M?M$T?CS=_/-K\\1"D _/P7NGB
M/4.$P4*019HG-][Z0_76[Y2MKN0O(B'UE3CZ-N+V2 _H*'H 9_L<162TERE=
MZYU>E@LB]0=Q<M5CK;3HS>JQ+#IA\L[$N]R+#[X?'M ^;#N=FJES'P:R;^+!
MD*CHG)!7LZR;TG^0W&S1WG T@'@.!1J(J\Q]E=3$]JP?]@\NW;K@Q <5)[X3
MA0<-'-<IJ.U<U)WS4G>ZO<T:2[>;\WEG\^<W:?XK[F0J)YOY6VJ\N^J<2]%+
M GU@H['>S\PD2-\#*-&+>X?V3,TZYU*&F@B6U<\JCCJ!6[4Q#+B8X#E09-UM
MR\Z.+T2Z0^+L*[E3], P;(V IRQ'-LXX5H:.5_09%O3!N>/+V9#,->H5PM@[
M->8N3ZCA2._VMLV+/3@=2DG\#.>AZ(#&IM;$:KH0^V6#0#2!@3T/WQD>]JWS
ME;6]Y4M3MQE[U, K5F3:\$:_&54Y&$U'4#83;CMLFAH(=S/0.Y6 FUX=8J:,
M>BX$%&&B.:7EP.],>XE-*E^EUWAT(=CFSJ1"1ZKDO%.I^(&(^!%(^(D%]]-O
MQH\"?#:ZSL_)6MF [%CMJ6_<E@GB-6]<KX"Z6&[CCB6=YB;.IO$S0J<L$3H]
M6EYL3(:HX68>9MZ4SM'3.TTA9)[JYFPC)TIMSJBKWW3WGENWF_)[.U7?6_WD
M'V5Q>$W9=+>.68K#+L7[NTVL*[L_S9?U-](4-'[5;CI]?65,,R83WJD2W;..
M&_!VN1.U%5G4]K?E!_"'>=PL_$A67[83XO49=4+L7SHA;M,)L5]K)T3Z;T:[
M]./JB=C,*A+=$;]&@@CC2:(, QYHH0Z4,"(UM!_WM,ZF&BFV+HT4-^G>!]#X
MKX%&BO]DAN=K[\ N,!,!U()FS:6IXJ6IXJ6IXE93C^M:)8!)X:Z!^U_'7CL
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M%EYZ#1O9K)TX:%3$,*QMGFH+$N]YU!A4X<K!&F!^3L<5J,128Q1AQP/DQMY
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M<7/PO,A[K]OA9^98C\(H_R@,=VC;?;1 *L+96.K1[GUAOAMZ$P'D_X?A@-E
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M6]R(171%ZL DS=AG%@FZJ];*I2B7@U,!86<%PC%I99ZH:.,C)[$'^X82#U0
MS^6D@T_E_#'-C9'33U2:H$V"ESA11#[U[(:VR5UZ!B+/ 9?@;2QFD$T"==VQ
M(.>IT_PVCRZ(JR*'LHG8S%YC][TSBMV/+['[O>?07(+SYQF<_PIKM$#W1L2V
MR+WY&8@.VKC_#;[WF^U._BP:L"\V6EU!_-Z5]C6<SX5+6'FW%K]<DV\_BC!^
MR=V0H?W2FUB.1WXS?,N_GWY&'<X):-ZWCEDOYVSSCAU:*C1-[AF-)]IL*H/*
M5_49AR5WKU^-TWHOUIA(-;%4H^Z,1$IIKG^@10KP V,.]F[& +B9%5I48D@+
M#_1J:V'#7!^9@\%R4+7A<PP:FM)S]QUT>G+6DZT#C'=+K&!$8;GO5U^OM-]O
M;S\+AW<++ #QD?+75_MS7^R-9P?5>+9?4CK&2@K,F(9=EI9^F\;8H73['',D
M<%IB4GOPP1R$X!M68Z+!.L%7D%L:%6RYLDPF4;64J'<ZJ!>Y$+*C]!:&"&YM
MF[)\/!G=?C!L%(7":8.Y8+R"T]=BZ<EL:PYSBF5@JYP@;E32P2&17&J].32!
M-ZK&J\.2 N\[HL*]$WZOPKF\R6_M4*A]YS".T:MW(<GR+82],<FX&I.,,@1:
M(;:0-LI:KFE4U'%5S)#)&&N$':X$\\VL8-DB+0TU)\UCE./C*^%#<K,:?[+(
M[<LEF>'[(6^2(%S@!KE&25S"!%Q*K9"^ Y@&[]6MJPTG]2BRJD>=6_463V7C
M+MI4V3'1_I$\Z#0:3409$&-A:L@K*"+XKQ)6M$7>=Q#I_X;%M# P%TYFRM+%
M+:$]A %%\= OCL);9/U:O+XOP/H^G=[_9-AAM!>F3$2!!R**>&SB/C&/KX+,
M^D?7-='536E3K6C9R*5GJ-->5SN]XW7JR-I#VV36*69/BDC) ]J!>F:((#YU
M+<89!UDN\!4&C)+O9I8?N%Z4:(#)!Z#'$IN+8(N.N=KDK<,'GD!!<4-?9"2H
MQU?$KF7:'P)MN0X&>ZXX0]Q.@I"'KRF$,Z'8AVG!>?=DF-GU%?G $QF4B \E
MQU-VGB_M0V$/*C+%PZ],;391+,%,HU,<;(X@DPR4\9? (O 4 M40N=$)SO#,
MW%0[,]<EU2(PGER/([5]81,;F(I>1JX-$TF$._865"3/(EXKJCB5'7>'JE5Z
M/N=J)'8[U5CL9IU8WH*7&B/\'?,P-5E38B +G*80/G$L64;:$],FT<>[D;>D
M?B.2PV,M0;$"O6C9?$2AH=&/(IE("+V%XD,D:>LSY=O\[3ZO0L*U)";=4K\,
M;\<"'25RG="7%(TQ$;CG46NXO#PV@V5A61.H:3Y&[C=\/X*-.4<MIMNM&+CH
ME/7-<:2I/"2J--PFN64*^^ZV>,<.936^']-R@>V4:8CBE0B8[HYP;L]4BE<-
MIW5S;>-:^%!.KR:FWDDJ*$I T#L]GZH89M;CS%Z*A!^0_%B;P_5842L$0M-Z
MI(K J(,E:;@>BW(Y,2$*,YF?0=C*,ARIK:=A%Z^T#8B,'N::V2:O:%RX/N9.
M+>D\P)O84I8,1.Y/,BP\U: /L&[1(ZN6)1*6U4RO!.1CY/\DNOA!=!.(&0C0
M$ALO4H]REULV"^!G>A 6:L%7'FQ1PWDD5T=3/K92^53],\JGNK[D4U5@\DN2
MU27):ENVJ5<?J9ATT<W*NFA '^G7J8\TZ''$BWD*=ZK[C%XVWOI:M._A*?,P
M@8EE6T2HEKB1]16-0<\$<1;.N82E)VYYX%7&^)5.Q<$NIC5SYH:/W&<G\\M)
MYUYL)K[>18GB_G3OBLD:W?QLC8WYBI,9,T,;NURM A9C0M(,5+UOS)OSAI6\
MW2TRD)J=D1WGK^>$O?F5\RN"D0@,Q;^_0#,7?O<7QD3^7IHKA/I"NN;"AVM>
M_O2+]FR9P0Q'Z?STHA!NY&9,2"G:LR%&<<;M9X:PASB<;:YI]) -GPV3!BHX
M?W\QBDB0#ZF?\<JL^;YE$X[=T._J!9'J5T:NAL-Y /3LU4_/7J?7JX>.1[+:
M[FZYIAIZJSCLX]%/JPCII6"3LXSL- &D9/EI(QA^]%0AV'OQ]$WJZ5TT)UB5
MW[?!G>%YF*=$QN;&)@3=7GX'I(VDR#X2!T;C;9L(;$'C_E ?%VAP5)C&A]&1
MDD[<EZ06JA.NF(B+G'9_FVW.;)[V]2E"<UG/5./!\-*0:%<"X* W;-_]SXJU
M)B)Q\8U,SVRS-M.J+6*>)J.8)]D!ITEA<VE0M-<&1=6WI_D>1!*4?P?.GL,(
MO%8LLN@.2J8#O#<LCY3&/YB!B;0HQ[C+I6+=3N$!=QCHQSGQ6)>FS&H?4%N'
MP5P5JR*ZPUPO>GEVDB'\*HS8''!,G(+Z%<$%#<_TM3O7C'.W9*WA[=<[64_8
M^N8NX+Q=]SJRVG -WTD<OLCC3KFL'ARC9]?[DU";YO0XOC^.IY-: C(:)*'E
MS\A1KWPXLYB':#++%J7;4TJ7%5C_$<-;SB($!27T>?8L?#PAUS]6,V&B.4=5
M$4GF/'(?C:@]6D]B&$Q78'XT_!(]^:'#T\A@Y+]"%__!T9G?HEQ> K7FB0,<
MD(IR;GE>,L_25]Y,4-PV0N%H74$#3K)7$:8-:%:K$W ??.8]D5M8+%2,TF\E
M1CF.[(!Z#WO%ZI9N?GE+^2/;KWS8&PR&O8\/D84PMU,"FS5\ 5PJDL:)IW4L
M)38<^*L5B+]@\@O/F(S.$X]GT3'D0$"4-8] X# N0@/38S[H4CS[/3Z!"V,I
M:VHX+#RFXL?GDK+C!:2?O6PIU8+PBN 9DT1%BL["\'B^/Z7\$ X6U170"909
M2#CAU><3N?_P0D7&J&>)5RA0'E(;SJW7RI)%2% 2.;"@6"*I @E>D"WK?!&@
MK"G*=UQGMF)-2S>KJ&7;,SNH?&8;C-65",@%[F*MCU]V*<YW"\LG?\7P2"+6
M,C7FEKU\K?TO+ 87Z(OPA0^<SA>#X_>Z(Q@?O_PFMRE:G,^U]F4YY%F9P$=Q
MI_X_]8*&PT?3*'])7ZE+V8>1EG$LFS^5%:MFNM<-G,IAY5,YN)S*PSJ5O=2I
MA/-'\_ M&-7PUJC)*\JUGM2^4\<8?LD=3PH 7J_K,9H%(3O2BPAYD9<'BLM;
M/JC%^K>N,8L>,2U0>1 #'J?AR-_.4G#T*M9"=;.*H;85'*/*@F-X$1R')3CZ
MB=)TU0JFZ:B'%)[ @XP% :[GN0^NQ]/RHIQ^3!AM^G!F0T <R!FM6'_5ZZQ+
M=ZMR-)O%N!$Y BKLPF1=GHK>(IP(R]02I8E1Z0=8JB0*C,7"<W]$>+^6IQAQ
M8$S'*,,^Y@URP'Q'[2KH,[7J92==)_9FU_4JEE/URL(3\@8AN$%OV4/PE4VP
M< B&+NG3Q[3\UP7'VJ$[/YZ1AE/2XCF=JT>_5Q6,,#\OOBPK218OSX*[J;Z3
M)=2^:/X7 =[,HPFW3.0J/YHRARD$"6Y8#O>9!=$G6'*W"+W)C.-N3+5'['](
M;7D,)UFFA_#K3P:HX/"*-FCG;?0 7FE*'K7 0XQ?U8IJ_@BS)C&VZS!MR5"?
M]^+*<NZX5%*?!$8'QSCCU77*PGP7J_W\9,LN?\$FR$/">I AC]:<!3/7Q G#
M'- '3[CU%H%HF+X&4W'X(,H+5N>V2@)Z2 #G4' BWAA1"G^&;OM>Q>S_7G^=
M/E+^(._D0&*M"4;7U-.8*"/EA;"A(SK7F-HCG V![>3ZJ)CP(60W.\0=@+/!
M&Y#*_CHK4 3YB3Q).(-6QABX%[;LJ ,'X\O:&:Z@UUCJ&5KA]P)5,/E@"[(X
M5^G;AZTG'C>=<8V?<=&W304CC&B,G:'AA >!S8&(2#!1;.%*2T=2HA='\D6X
M*(31P;M5D Q5(GBN%_>C);M$6[B6L\[=@ !<+=CXA/-#CPD<=\188C4E0F4\
M$0:1&T]0]G"@X K^T$8)"\HJ<)*'6-J(?V%YO!O3#\N7T8^5DNZ6',@*J'<(
MA8-$[$:T?13AG1E*7AX'B3:?\Y,1Q61P*1+^:\EKK>3X'+IHPLBU@GLG]C4)
M%M:*0,[\N %*_#XW#"C'WH^'4UJ"X,)76UJI*Y++( RT]'4)I(S/;$LY+Q9W
M,3.P.#@8%5]?\E5JL\D9AVV#?7_F7;BBAAHB-"=/"R\&]RS_3]6VB,3*<=PB
M!U$:/CBCTO";2VGXI33\4AI^[*7AO8H9D[VR&9/  4A_KGU]@<OFCNX=_*D$
MMOFZ(78)?Z3.@L.;\QL4YW&VGI2*N9&]_-S((HP3 1H58K+F4J(BP:;X9F5S
M[86+2JQ%O1DB)%Q%=^/0="G64I0S74+]^++? PVU 67 2]=V\09\D1<PY:\Y
M#D6O7K:MF.77R\KR*\R!.W(1Q/W$N38O,&_AB@.C AFB!7P$@UKT1!*K:AJB
M;XI:^(*E U:B85,S9L4,>O0,DVU@)XXM[:$IR"&F5HPBPW2Q04G+2/BN%N18
M$0T@N7O+UQY#L+1L[ #)P2'17,<#PX]'-#W@$# G8[N<,WSD=J1T.H9&,(O/
MD("[EIT1S_ 05$R;ZXU+X]JB^R588L/NX-8QL4AF$<?W2M=,%!UOIWU/^)2(
MJ:+YZ"V'!6>K&E3,_^KEYW^59BBI)U3@Q,;V+,$R+&(9I54J-J)FY#*RYEC\
M(#*)6]P]*IVX ?=7$:2A,9F$\U"@_6.B]<2*!2*8/EY@_<?@,+=OU8\MGURB
M89#T>L)UAD5T;13 TM>)WB?JJ1+WT0Y]-@UMD*73J$\ )4VE7O+ 'LG/R[L*
MP)>94D]A44/U"7?WHJ2V)NQ*^YA) 7)JBM7 -5)PPCRDSH$0J3("Q]8HPNYZ
M6H'5\$/V!</\GFQJ3!Y*Z@/.F]+CS$0& /G794M[5 890L'#=_Z-*5[IY8BF
MM>0/IRN2M^\5=U<6IYSAC=6OF!G6R\\,*RT9^E5%2L-:8 8C/XGT1E])?Y(\
MU4KP%+!AP!Y=3\8BS[JLH%\QQZF?CS&]-GLDAA.3+37,[[2-'W$7W[N>,A?)
M>2K3%8,6J\#LN\AEW( I5BG-,>5%?UB%HA O'Z1Q:1K(000]\1:O$9KD7:KI
M 6J'Z[,CQ2Q[FP%Y#FVU$0/31#D7:Q_A5DTO-P,'8Q7OXK_N[MZ]>_]^=9,S
M.*'QU=UQ78GGG4?",VL+-VW8.K"/[,EO$"C]ZP1P01ML\==FZ&&V2V'324J9
M*:N34,.()FFK)+GO![&K[T//L3#54J?93(&4H2>"X13FWM\&WQS[!A_)P?YH
M4*HWPK@?QM$>= YUY\?'=+0C.Y)G^BO&5[,[6]]]NHE'NDD5DINY]U.P!N*M
MOY^2]G'OP5^)&HA)^^+-UZ1-G+)]HT+KI+V<WG*MT4*(JC9# 2=8\R9$Q0SV
M?MD,]H\,MHIO;-FL=2D_-@RQ0T<J?_^Y^DS[%1/3^_F)Z44X1')K,6[:23"+
M4C?0C\;#I &"947IJ [>C'8+Z./Q%KT/Z MD,IL3<TE]GC$ITA67//DN'@A_
MHI9D7+RMR:J#%W+@"<_###J>>NK++VD\8,4( Z(%3UKHDG6>V)+G_Q$0F2;G
M[]H\KU DDC)32%ETT!BR(QF*8XLGMD:(&BH4A?#A?H<3Y&FW7^^TZT%/%[,1
M[L>6Q;-0@8^D3U%#1ZDM)3G/<J3TU(3;E -?1%[36.QSXBANTR@N#=.E''IT
MA-H<'9]W=./-<(QEU.C5741>3=AYAIJUIW$JBY(HY04ZSW6UB-A1'\VE-A%]
MY&@OY8C8X14+]M@/YDTLGYGGZ!^MF 7?S\J"+R\^^B7$1X->4/[B5!V%2 "7
M414_446!T$NI!_BI;;O3-NA$$7S5E_OO$KXJ:C@LFPFF!TAT4G:P+Z!3X%&:
M2IAJ_)=H!W$E\NA8UDHX6%56N(!^FZK?5/M 8=AIY;VMU'MA];(:/D+Q24HX
MI!5E,A/B#A5/1L(M+4P^KE I.:CXN<43Y+'U=DAUD'P, ?T#$W<8)6OS/UN4
MA8&^4IW:72/K1S$MRC>8\-)2PT9GH\<[>F#2NTS7(;FN].N6_O16HNC'<KA5
M1K$U6:(C0UL3=S['I%CZONR>'5T6\1V2H"AE(ZPRC@CU22G.4X>D $^]YAPE
M7L4TQOZ@%HDW*"'Q^KM1F##!AHG*&6Q9RHF1/($M(8_:$2/Q$B >)I)B1=$8
MXB(ATD)L4JV(J^'239]VH7W9L'KD?7PD+I*8!$DEIB5**%(S@7-F+Z6,($T%
M7[PBQ),Z3AEEAM>7^&NN@*B(6];XE>O<>J7]P_ L$@E):;4BJX4@EB^.&MN>
MXU&NF$K:STHE+7PJ![LKVR,N]361*.#[+B9&,%X]UEJY'*B5<71K69A *I(5
MIEJWE^YE*144!3: 'Y%(72EX.%KXW5]$C5)Z,&)?!,90R]OPJTE%X0QYMV(^
M:7]4TL_S(:JLN_?>6O["]0W[?OK1=1XQ0&R2CZ^J ZC*V#OT#,73PR. TVK3
MO#0^L5I=1@?J':J8L-G/PCFD@;9DI^9,.-Q=FW97JA2D"#]9[!G^-N495&+J
M6$7JL"<J\^17M"=*'<E1-+&\23B'&]SA&'Y4 ,JB.LDTSDLBYPN'XC]@T&I!
MK@P!#!25CO(27!RNE7:A@W2526<<@T#T)K:7<9K.E?:_Z.0@@2OG/P%#,5TR
M"_]Z E4X"YDFFG(K-66A7X&2%IM#J&60@BA,*J65O/8!QQ+Y@*#$^,@J@F9^
M3+1,ZJ Z1;O"3+VE0+O"])2*8'A* *-&J+&F-9TRC^H()3!K8ITQGK,">;IA
MG\0J6*OL9B2)3BXEF6<HZH4EJ$5J;M$EZ@#;R]?PM[?P[;R FLQ,Q^6;K9"$
MRGU1<7_ I<<:;;WP/@=3<UNVO'9X1N6UW<ZEOG;S=7PII;V4TI;@D'HUL(HU
M#?WKDGK^5_:(>_J%+?#V$4-7[3%2:+ =:O)B/G":(B?J&6CO@XK)Z_VLY'4^
M4$DFV8FG(PIL\K+#V*?F\]F*/A?H/R"7 :&?5&H@HO6N.SA-SDP1%=1'\1'Y
M^)5VOSH7CO@3M3!0/*&\U0")NP6HP0CCXH:!"!+X#'1CM")0J?88_#!52H#C
MT("E 'B1U<)07>2?/2RYDCNSV+05DPF[3?F$+63\R3P"$99_:L.?\!'2<2EB
M@Y]0J=#,?29OKW2Z@JG@AMY$A)XL1P3#\5%X$TW0F23#W4BG[O@7OT4STM;/
M"+?UCIYY]X--0JK)O)_"3N&'/'+BJWJT'%CUFY(W*A7CDOT6*/@3>F",,L)N
M$HNB0(U<UA6QC(=KMY>ZEB-;E>RHB <$W[P%P>E9%$-^\29(^=$56!U+1NV8
M+/WAZT1B1%D'E$@@7.8>\2,W#R/WKN"[M% Z0X_9H&)QQ2"_N"(YK]]=UT1#
M[M8Q/S@@6QXMV!+NV) ?I7JFY]RFA0?<X8TJ7]Q\WM2F64A.4^9P.+=OQ4R\
M03<W4%B>P^1<JO!F8W+BWM'^QX 5>DOM1M=ZG5Z'KAAXK<-XTQP.<S?#[ES>
M(PC[!(R%O!+M)7>)F+%W1@2WU;#VY*^0W$2R3Y6CRMI'L7;I'@*I;YDAHO)/
MY>5  *(<\JU% 1 EGPH3 F1R!GPUM.GJL&3@GH=2> 0#/X!!_[:YAV>R2^2P
M5)=(N8]1-\C12K/.FZO5_K+:'+Y#&H03D>,<;XF*^9"#_'S(\F>O7_G4-ICL
M)-\8)\]$C;CP6 !SITY+Y*E,NE+E^2&%)3Y!T4GENDVDZ8"B_( I>Y2&&,V!
MP#W(7XPJM14DO.'*<Q8HWCPY$[1N!_8'G;!)IS[E;$TY5[YE$S9_@&GWNZ0/
MSUT/&P"2:XQ@3KBJ_D2A(?2=\Q! PN\ODBB5+F/2J\T; /(D0QK9MOY$*49.
M8G3V1T[O),4,H>*A#,$3+?/D4T^IY! A#2OB&N&T!KJU0'[8'/R3V:#,HUZ9
M]#$CDK!4WDF@D5Q%XL4",T$_)#"'%$CKM?@[SYODR1O:[[>WG\%^:'% %0-5
M>J  'T)30#JW)1%\GZ0U?7%UB;_@5J+?'D[-Q [)Z! R7YF9LC0<4 &\Y.%I
MN;.NYR=##TE"F"[S:?*"IC!;> D<@I6W7+7N<?QGL +U]4\1A $?BMC:S" (
MO\W2)(FOOG,4\15S5@?Y.:OE!?6@LHAO,+M+$9O2?[ 2 Y6IAQ%SM8BYJ*NG
MDMFHN#H,9]4WPUL6.8Q_3TBBK =7,9W2"+2*O8QPPSAHBO$)9 H^\F6VFB+F
MH\ @16K=Z(@J,D]9.[SC')-.!A5S'P?YN8_E^7]8^>0TF(%U2Q= 0GT NZ9'
MK <_=),7@I(UB<&S1PJ<JU>BAKX^YLBHAI3TJ0MA_96,?!IYN)*GH4'V7;'8
MDTV?#HRG*R8!#O+Q),MSYJ@R3P]WSM,)5HX\KGX 1!+(Z#$(9"L"&^)TBE3/
MC69P1[6">X6,8*4ASEWBE?YGYF$HT7AD=Z281^9QNZ?8QV"ZL!=O1IT5\_@G
M4/_=^0H5NO*J$\T#A*:+:3IP$L4RJ:>'Z.U'22Y.!,(>ZZ:;/0()4K1')6AA
M33P7J'\GWYM%G VN@N$J*:2GH!7U9-&2V^MSFTF\.5ZR*.?"U!@?#A5923X0
MS?4BA4&B,()EV:9J P\C'))MA(KK4:H!+\.('-V4T?+('*DW1&]%EXR-!)\Q
MXPD1*%V9ZT-SCILJNE&Q"N^3E4JZ1J!*/B_84]YY%5.QY2\! M[[+2%LX>O4
MAX!',T"U<7E)S,)S'SUC+EL^<V<1-US\F37%LCZ.CV\L%BQ >U9XD21+Q5&?
MJ*LD>;UXS(?#_KM3>=YX=KU"<$%OA0V!:;#0#?M7Q *0XW3B*>=[!K:L;3,0
M0]@#FL^ 2.Q(S+"9@=>2PQ[YE817T"1H8:N96!YP,L*2,14L[HNYRCR\UW4(
MQT48Z>M8*=W>0;@ 9]@S(6 H7Z+)MHBJ7%&DR8EGL[A1,WFW:[JY@2T>&&F3
MPIKZD[!+84(,7NO"U,#BFI#I1Z/;H@I"\T%^&B3D)(FQG6]QF9FB"R9$D_>0
M9]@5ML6Y1HN)__@OW]+?<+];4:-SSH6\T"#TI,*R4:E(ZC$Q-"!/+$,O8B)W
M-AHFW_4YK,'U&2>9?H3I5'6$<BZ@':,V3LPQDS8#OP<OBI10B"IFI ^R$(ZW
M5:3&E16I.GH\\OP$CF-'2)&\0MESL8L+R7W7)MG\;'BFE"OIH'@<D^!M'2.8
MS50:9UVE.P?+5Q5ST ?YH,$%0/$4!KJ-]R I8& +<E'PMF7HZ\H,/6X.26\M
M>%ZIAL$\)W05CDE,-<X9Q739!"!=WL,"UH9Z* 7X(MO,!K2#>2.>#%D9V>!V
M*QF[&6-G)R[&D?(:9IP!<+4.'V@5^,I[?'C9ZPST7O]:[PV'K]:V:;Z^_BF>
MMX[9/PAPP5/KC4QKL)M>G=S_S0B"T5-)TMEL"AO]MS5CIL$$J18\.NO9:@4&
MXQ6UHE])K?C=4[6)_JHVH0^[XQ5]8BUELM9<;:L+GYW;]=>(7G1G\X]E#DYD
MQE':3(BJ(TG&4'+5$<ZL;?UHSRP3=*K7&O^WC1I\>PB2LBUNL&)GM:[]*W-4
M8^=\SGYMVI&B]-[+,=OZA#5WK-(CIQ3T]O55EQA#\@L^ ]PRIC_#\5,QMA]3
M]T)3^U64^Z_7<O\^V+SDR2NY$1]7K-2CEW(ORYC5U0[F&K.ZZC$M+%1?U7\?
M#G S<R1I+V_"@RH< 5_23#<$?;R0SE-JC+)'_J;PA3<H?MW5A<)8#^#B+@S4
MBB4Z@ZRV(Q6-O.MU!821)ZGR+I"S4%OG+,SU$SJN9I@X"U[^(/O7IHI9%1?A
M,R/?/B:386:H\,7F>.&ZI^T#&5:LY!G<E,Q=_\)\(/)D!ISW-@Y;O.,8,>6R
MU@L,M<-\=3D;\J8I\]D%[B?,0++5H26I#RL610P[N3ZN,JPDT]/+L5]C&Y9@
M%C5\%Z$T33@0I1;UM>.=O"W/;&/T:BDP=V0S'M3WQ3B:Z858S.^85(:$]:OS
MA>TN&6M3OSD!EH!O43LS^89M>!3-?& .FUH4^/,,3)K"25((J4V <2T,DL'W
M^9Z(L?35YDPN1R@5]5N\:]&,&2:?>BHBJWD2T$_I0$00><9$A1SD@_KA8H$A
MUZO66DIN;EYTAKE5PXKE(L/\<I$RIZI?X20VF&S^&P_U&[Q.,J3X\811?R&/
M/:(GRP4=P5A@;,6PD_4A/"KI@^HR]5S)O98-6@E&<R. M#DVER2U!$XOCSW#
MZ#Q+&9:)(&L(?*+B9"'@':>$#.J82E(PXN"BUF,'S'-X/%R@GH1^G).+JCK5
M[_$CXZT[*/ ";.!ZCOALPXJU&,/\6HPR[#VH<"0:3,[]Y#H>PV04#@!J/I$H
MCM@9./D)=&3,1X"C0U%$*DX0'>Y$EH+$+@X)8=23IXJ*+@2SKN5(-.>?8K!0
MDTT9W7$\NT/%?XZ H;GI(*"FX3=^MW!S@M]Y?)Y\/*Q9\/B\HEGC)U$&)"$8
MP1\R3C.-$*X[T*VUBZ+(U8/H()L\[9BA3&<4=Q:=&6CP&(\>$]T1:1TK4U&Q
M;I/W'()'M9+?43)I\-$Y"Z)T_AC12 Z<A*;F2$+ "E?*(3YT,=&4HET*Y&=T
M3B _W0O(3P4NOR#_7)!_MF6;>E6BBK5+P_S:I3+JS;""2M1@U<4]BK*M; 3\
M.4.;L!R^JXE:U70QI:^OMD)6.Q_S(8 ]=5!"1,(W:T5-B-4Z)A<A>%FJHA53
M5)/YEA(AD&>;1[/-!]R-T00C_:4E^Q'S&EX!TPBT,L-)P--C)\N)+='J"?4R
M!C8\1ZND8A'4,*L(JO0I:K#.XTXT.5EU8R4PQ FE/8(M0K_76J5:J+R4K!WW
MB8D@T+4IPU1_PS(UI==./)SK/1J.3 N/0);NOMS'&-.1SZF53,273BQ598]L
M";$H1[BZ>*=B=%DMJ7H7_I+RT5%;<3"J>/JU"(2 VBW '!3;BX2+>)'T#7C^
M:K:T0.9>>(R6'Z._>RA&O%#Q D8F$@^="'1Z7Q)5/@[?3(]&6%-1$XFXPT24
M>"Y12",\UV?7^U,I-.-.$+D<U>2)9"6*O9G%GH3]AZ_V>*4!U;>(LI>6W(=4
MXO[<!0F'IBHS<+^G8H$RH9XR7REXI,[5B'&8SE'\5*Q7&PY+AH(^ [&=X YY
MK20*(*70KO_Z#J,^?!(:S>)<.[P-*^;E#[/R\GDS[R*<T5PYHFV#Q,491 &3
M5+ E@2'4(CDTM6S>V8!4&Y] Y!"9CO.'@>&*29:O1HE)Q&XEQ+86'<&PYQ&A
M]''MB@"ZEU*:TB@F-?B]:MU&%HP8#M^3[!C%J]=$PK\)MXN%RAPYD,^X2\>P
M8O[_,#__/SFO#PZ8#,&FIO1Y[0S6#;#+G@5H,V/5-S)1/"'T)KAS=K8RL&**
MSG!MBDX19FF,Q,J^6K2O<6/$*"!-JJQ@AA9_2B=ED?%%\.^!HNT(U4TU6:/P
M5BRMR*S&:D1TUH/DXYU@J/Z([[BBIF)B$"]B)(/99 \!EE:&'F\XQP%"!9^*
MB2C?QMX .N\0@+WDP&;GGGU>/ KJ/5FH^/DN2^_R40</1%Z.*N8*#<OF"GU%
M1QMEA]TI&0?WA/)$F6NB,1ZV!_?+Y0Y5&'J7:-*4;,'SXM3YG:MT'55,(AKE
M)Q%MPV-10L56?+H+".MD)3A/X]'4-)Z6Q V(7">\9ERTHM55P<@_P8SLV&?R
MY>OWR&?"$3 1OD[D'<GZ\QBUC]X5??G=U\^?(TCKEFJ^BU9_PH.R9NZB%68*
MFFS.@IE[CGD^HXIY/J/\/)]M&+U?PV%I, \HX33BO7Q\ZO.8. >*.U#E1N.9
MT-V!J1VA8DC6Y]\P+8]QAU.BXZH*I.?$X&#"N*/1DCD/OI:5>L<S UUTU?%Y
M*-YX4&]\=/%''D/*D%#@TX1):'/D=M3Z!*"Z[-G-,[(EH@:](>EBBV>'V"13
M1N:H+]'; M@)3?T[H5F>X[&LF&LTRL\UVN9(#6HXE@VW@4WB37)'+D?ZM&*O
M+1ZJEGJ$^/&)KP9*EFA_G<Q<&[F0!F@C) H^,'=-9E]I[V1TZLD%8X%CW4AP
ML_1-BN!!$?Q,(LH6MU4VL),R'*_'Z%#/P(9R/0HC*.]( C1$F3EK'S;@@#*O
MS5N4*=A/B_#!)JU:@MC091K%W&2O32G,,N45]DDS[(D(,\;T@W<L;.Y)XE=K
M#$R50.E-+5B)C[3D^Q6L5KE47H_.S+;\>K8DXM_B\L?P_1!C"'!4,7IJ:DO,
MY<#Y/R0+2M*X%YP>_"#!N(27:E"MB!S*EZ!(F(SB,\9[75#6&G\W8OVTIQYC
ML9E)O3-67_[]ZBM\Q:,;92FF" +P"0%AL=<U_!F_&.&0)S=+%:(13U,VG;BC
M"+GR#(5IQ2R%47Z6PC:"<%B#,&VX>^]:)5HZ9.(NOMRQ'6GM(J&8A^R0*U%M
M3[8^#$A6M[FL%@WJ"PA>_&*B\WLDYK&'(D(D"2F02@ 5>HX11 \*<<$/:=:+
M-?EBDAY2J?-8)$+)_XZZ%"6N1F:'E)DMY:!B:I 5PSFOB-DTY>1-0G2+%+"$
M1FB&7B27$*0VM:PS/.@5<R%&^8"PVQS240T'O<%$BZ361,%W--"U1+A>6B M
M@0:70/3>J.VL,U;.D3\K!LM'^>"NV_#6N ;^K .G; -_1@RI:*&QG0RRTT<(
M8IGQDN9'-&Q!%U[ O*_@S4%@\YM#RE@:G:.#\]H!W!";RVG#P]*Q@.((:(PB
M#[^T7HFVO7P&T8NX4L]]9*AI<SM:AR_ -TQF!#/Z&7^Q_ @?TX._/;W"-";>
MHX$'C //M5,'C#H@T*R>Q,67_QV>8$@KI"J+)Q[E  7U+!NJC"JF'XSR80&W
M.3[7-1S!\2X-Z\C9E71J43&(5+D0]SY7@\S/$DT:=XHW*E@NT-RUEQO;W_5'
MZ4C1/_B GVF\-CP0!8$4%!)$JG@-&M8S)N0R)Y%,E!C@Q1O78>GH!XJ+C9,:
M5WW9U V][!CPVF6](:@"/Q^U@@0B%[6.V<J)OA6</D6G. .K2U"FE)Y 0H4^
M1Q%5,<-D-%[;)W4KR;03+WJ4>K0AZA1G 5!6K"_+/[B7*H&.C=_SV RK99\8
M1P$63AH?6%-[-I8R5YVP3WG&5ES@ERS@4]*BL(91K1-<$8$H_JR%A=\]#M8]
MB-JW\3G5OO4NM6^7VK=+[=NQU[Z-*B;QC:Y+)X)B2MHWXT?E/-#L[^\T#92R
MZF .K)'$]Z/KQCNNF!4WNLDU0W/9169\%."KQD[H6^EI"8P?:WOD>DPU)J6S
M)H[A"F0(' (33L5%BLD$@6<]A#S;DQQ%Z!GGGSVPX!E;6)$_,Y*FL2H9(<%)
M,8?1!=DZA4^TM3)1'I:T/#7W 6=%AJRN=(\C190>QSG#^BWQ1@&^3Z5=A2C3
MBN(H/'+"'-%$!+[%F[2#?&:P[DGLYB+ .@7N @,7L.R%ZQ&RG4(E670@VX$]
M1-4$$@<#?6@FCQ@KP46*D+(@=J0IBR#7@!E.L,/G,H4E@18 $8R#25&81H^=
MSZ*=C(V.+PRYHDO-XKTKY2Q;<I8\)UADE0%?>+@G+B^6X[T#*9*,O1 (J81G
M!<#@EC]#*(\/6)KV)V%<A5A#&(7JZ8O)TKF):/3"<W^B6;86KF^)7FAFW(5&
MF7N$HQ6!FP!I?<-.LAM0A+-PUA[I$HHG<1!$13"E5[?@]S;Z/*G"EFHWV"-A
M=HG<90F<B/7)3J"84,=AN=0KD"LFC8ZSDD:+B=<F\]/BLY26HW">1!LC/'"<
M4S%429%10GO)[&]+IRON(409"^R'(<\%'6D\ZR&(%9Y7+_(N^!E7WI^( ?,L
M$!N61$4B]#!ZSE5!0(EG<+ #'K]UFNG2%C=DNY]^Y//A-5+WT]_X9#:U:,OJ
M2[;@(T:T3 @H3D$_BD5<:;>1B.?;$SH*T0)U0X63%5L<T:V8DIX^.BRL.:\\
MRPJ'T!W!0&0X G[)=&F3YXP%HN15O#K*NE%E/':4-OEEE9$T#,(/V9W\LZZ8
M9YSWPBT#Q[#I'J/VRQ-9YZVR8ZJLFU>/D Z)CRF.()$U%)M(T57>*N(5.FV<
MUG'%Y-YQMZ2)\L[P\)+!KH;D:ZQHJ>0,LT.#Y1.<!$)EAZEH-!?M-J55WE&0
MNT7^[9EKHQI0JVESF,45XXJ)J>.LQ%0:J#CO- ?K"'KZA!174M 7B#) >V[Q
M'.HPX$HK9?S))FS1XVES0\U^$(PA-=Z5Q$6XD1 V&F/%^$)2QY+9$V% \I82
M#F/L:9'BTWIKV32YXG-O9MZM4O/6%G;H"]%-WXD+ZR0=I,T2@?1)C9DZU^.J
M2:46!@[V0@VI"A&N1+4J3YF2GIC3:J+^PL7B:[(&^10LWP^)-LDDMATHQP=Z
MFU1,HQSW2]XF0$%E7,]UW%#D^HG@5,7KI>RX.\4#1U41M,1;$W@2.#>>J):<
M:?-5?4?K4ZN8_3?.S_ZKS)%2 =N"I1LLV]9NPT?X3>MUNM?<LQ$'&!0&_"H5
M_M9O+ORC2WBN][=??]-)3"+#?OW.F>.3*Z _<=1V=Z@+GB$P (%4YFMD+G1_
MT7Y7VTK>$ZZI^(A_C0 $P%YH?_<9_\M7=QH\HP?LY=?P(7 7UH3_O3_LM >=
M5Z_Y;W>P+C 7XM0L93UXMWR8+[CAQ;>;T$,PSA-!=AC:G>V&O**6HW/<QBBL
M8/B V?0!+H[65Q$QOG-YZ0*>#3X%6; 84480)"I>Y'_]-H.;&I[A"6C8]9C[
MW+BSC.YPF_V05J&17(8(7$];EEP/3Z.>T-PGT=PCT*1X#6B]67YDS6G$'J(J
M(_D2*TDK^4YMY@JWJ )/J\/U^PC#$; <//,\8[2I\!_RESW!/X8 LH[P2W @
M--W$SG*[,IK8 YM@S)[?]01?+?AO:GF4RP8<8LVEIH IUY;3$HU /+9 &($H
M>P@=P' P..;<%#T*LG4'WPQ@5^S?T;G2[AWM?PP8PUMJ46_U1-F-%-2P<V)C
MA<?#=&6F-^B)*H5-RR0[FX/J:>C$)G PH<5D%Z H7FII'>N)KB>1B4OGDG *
MIK;[?)9.O(KYM>.L_-KMY':#SCV0VU&_&>"\&ST2QHHLID_:W9[>2H7?M)??
M4&9J8Y25VE=>I[64^GE:2JI?1,FFR#3YADB<"7\?<TR)5JE.!.3"W'W"KJ_<
MW1-51/A2"DB\H058"Q-K8?,81C3;E?$-VW?1U06$6PK($$:8;\)]_AA:)KGX
ML3_Y'-'OL(R*@$E2*$LK0V>*G-(B15LC35JYT@0)MB)-M%JE2>LB3?*D0L54
MX?&H=)<C5/[7R9E/;O!/%@B[H!#678GQ=F[BK#=L6C Q#68F3:!SA2\95TS_
M'&>E?V[/:'$OI"I,VN0E^#^APU!8CBJ:+JG;<M3N]G4-&/6/9#S[CH?I/Q*V
M%(K5["0LZPT7V ZL*I+1!*G@R2X74:Q:1/XY7!7/):4+V%64/1$UCT)EHD!<
M0"USD$&1*4]WGPP^M^&J:OO&*LZ5#.)[O#V,YX:/LY:AAL+)H%"G=J5]"/@U
M:UMS2Y9L1U'[Y#+B- $1LZ([,W]:HF9'#/NP%.D)J99\J"XPN&N5*@1:-DY.
MH7(<2J>:2OC%<D/?7JKS2D[;FBIC(C(95E_3TAWM$Z@,A=2L#C%.S!@?'!^D
M,M<EI*6;Y".AA?5[HU<Z* R>]41) CSS_K^9^8A+%P]==X<")N<CS2WZ^Z '
M*MR[2$EYBWD?R(FR1H(T&L9KYF-=ABKQ:*^%*A8C "0,+VP<E-2 TH@!&H-3
M:0GW,<:'Y\!,U#U(JDCQHXH&%0&N15;;>AVJ)70H4(?>&9Z]C!4B9'S)74F,
MD1GV>N&Y'F+QV 9R$LC**%6G2AQ^GA<AL P6HA\:;@B.J *CB^9*<EQR8* N
M!C2(]##4.@,_&9S,R#B2F"\^F.R$(W..FE;%5,KQ6CS$:C?=3BH=DMPIVVT)
M]R^7+"W% ;-(S)R8!4> &0L ]#0S1@D]T7!QQ%Z+LCR06Y>@;,4'/&+BE$'1
MDN,6=4]PR(D,DX+G/,C3=QQ\?A#E$=?G5![1OY1'7,HC+N41QUX><5TQPWU<
M&O<U?."IW\&[IZU#Q(4&VR6V:S0?C4_H^!M$5V&*Z[59MF5W?R<J7JS>^?'^
M$6:#R/[W#,?G::(B\9:@)2@C=AJ(7),'PR:KW)]A6B89;>%"^LKIUTCSRS0K
MJ'%]G#G/+32N$%Z)2"METY)IXT\\ZP$43PN-7ABZV]6H0Y3JHY8.9]%]:DFI
M.*L+Y T]W= VN28IK'/9.H6[53S%XHG@TR+7=+R*JY(JW/XD9V%Y]=ZP/-+F
MWL8V7VDYM7&0&IA<RI_^E8:OXNHG:O.9/HX]NVJK6JG%=D(Z0(ON6Z,2AI+U
MT%MBN\^:0%*$\\.3W"E96[;_:*TWU"S%.Q6G_:=PV6*H60/M29!.:(T*AR,9
M=E&8J\\#Y#V2;1C;$AX>$\-KS&^ET&MG%BB/WF06(5G&93D!F\P<ZZ]0^/*D
MY D1S/(_LF^]<,/P^IQX7#TAR432'J;RHCSKZ:VOX7QN\&XHRNV3B$>(^^<J
MTL;V89TVR\W]4MS<L$MDZJ+OF9<Z$5]+CLX"XEQQC:>KXC)8&7/^#>#<%;96
M&927H&"?.)$\DH9;5AFVM99AK4#RJ;^13U^?*&<-2G%6V9S0KY,9,T.;W4^C
M\6^)#6X=\V/,!")V8]X[7Z3,PN1N_QOR5WEKH,Z7PH)YJO6$V?;",#$-^>\O
M<*'PN[\P)O+WTHPAO#G4,WSAL]>:_.D78&@SF.$HG9]>H,_BU\"3XS\Q+T#X
M),E#W!?R0G@V G.]_R=FL\!\HSR),V[S5'$<SC9_T<0Z8T<+^I@2WX]>!Y,&
M*CA_?]$=1#3(\U/]HF6\,VO"*W=5>NZ9$\T8/KGVGP/O6*C:JY^H'TEF=NLA
MY?$LN";>.9X%]\]GP=_<P+!W*QM^T39+!YM-@1!WF(GU+NX_)>>82:&UHV1O
MA_H<H0\7>3!KP,MDCF RQ?GR 4X1=@UP3-0M7 ]>^_CPLM<9Z+W^M=X;#E^M
M<JY0.(:]GY('#.<1GW+\[;5V0T$7/,L)P3 UYI:]?)VG]="S/JC;7$EZ\>8/
MUV%+T>A-F\*L_5_]</'F)7K7\0?X+[SJ39I:4D7Z*5O:I)]:7=:+-W];,^9-
MZFFQ:QOKUP<#M8"]W<^I8$>5V_KQK\Z_L$EQ6G\EBOQ!!'F/]+@-[D16#>FR
M44%[7ZEG#WV08]V^WKL>K)2TKR5=%E&R>7,/U%9B@PA4V;9^M&>6:3)XA/_;
M1MJUL?U76]A#)[W.[I&O<]/IZ5<Y/-W#/CQU*A(-B^ [UT.DFH#!E/+D;T-7
M8N%CT%M[#/9TF6^^%H95.+N7R=FW,BCTWO6^ @^_90_!UR@A\W8R">>\H<_O
MGNO[WQV)6?*[83F_45[%-^/'>O[OZ<->/Y?]]T7DHNS1/RKVJ"3W^L?*'<VJ
ML*OO_I+L\ZMK,/4V!6R=X  U_,MDCF(R1W2OKS.M'G9[M==O-XTR16!\WM'M
M0@CILL.YOUZRC0?#H[_U!@=WZQ6=^?#@9E[[?3T^*&;=]27,33&*H*5*B Y0
MME\F<Q23:>8*3L4)=F]Q3S9[/$O$6@K'5XIN7+F1REX"H[67P)J]*3KMXR-9
M_<Z$[AHG<R278RMQP[USK7=[-[E7S]EM5U$.'U\XO#D_\!I'\,$P>+,J5WI*
M@]7+BQ<L% R3#ZKP#WQ),]T0B%TH5%!JC ;,R)3KC)+#,A+@-@0+!GJG KL,
MMCG:Q[DQY>ZLK3?FNJ./AKW+QI2ZG:X+WTZG2:?ZKJ2M^?=FH(^NNTWPK[R%
M?J8[\;BQ>8HE*P]+I3;GPXDVD\P<@;TWE"I]R5\^G/SEFI)N+_G+E_SETU_P
M)7_YDK]\;)[IRV0N^<O'F;\\KN)Z&]2;@MD;Z?T"64;'D>]:U/B^.?*\WH+K
M'!][GO;&TU/E\ P/^_#4JTA<<O$NDSDVI>) %(E#RM:KI"5<'U0"5'.4*WH3
MKJ_D.?29'UGQ115FO3DH9JWW$K[DXETF<RI7\"5;;T^Y3./U)5:77";U]KFN
ME,R47?M7+IGI9J#?C,LG09S\=A7E\,&%PQO3K[K9Y8N'P^#;J%R77+SR1N+6
M*3.]L=X975]2ONJ^D>K(9:IR2D]S8XK>/>L+XLZ#3O5=.-LG^?9Z>F?0.9UD
MO*;Z!A5+L!N52L=;V]NUJ2R\QO+DE&2X#4ES+]YL4CD"=T$/I,,X'50E%,;*
M>D1T*Y!<ZO',D4Z&:I+FV[BU0&VF- ^+1P;S.EL_ZFE?:-:<5::N&SB(&AV#
M:XF_O-!^S.W7MH$["(+V^]=FW?8<P#CR&:0[YR%:L>;"@BS'L+%?D_S G6HW
M'<TTECXB[5,K;H-P]D7+* %S3#DY'",9?F!Q<HY$Y$\T5_E-]"/XBOT($"-;
M$%\AV)M8)I7BP8TB)[6YVW#?FB&WX9>T+#[(===XZAYV=NJZNSEU2CPYZP!F
M'!OE&W?I"/3EY%Q.SIJ3,]G9R>GMYN3<E;^8'CUF!++QC+RBLLZ8$F!2QLT_
M7/PZLPW?MZ:$^N]K\F3"30@'5?[V8/C4Y!.4P><9$]UPF)QKU)HBU70 FX[2
M=4H+@!$3"^KVM#D0:5;@B!^@NGZPW0]OSJG[X>#2_?#2_?#,NQ\>9/O#8LZ&
M<2G7Q*BY]CIK=-GDU4CE,9P<W59.[QM=>V 3(_2I7<Z2!J,GX!+UL8//7Z&+
M3+@ S9C?U 9O*\RGX%]IZ]6%>%*MY*1ZN0UYE&F(_L2\0Q4U?Z>93#UWKM%E
M#3+?7JJ]]V!%P3-CCB33PD"MTX*;._!;"\]]LE C><#F\8M09KN A>R168WC
MX\)]YCWAFZZTS_R-7'7P$YH+SM-]P&[KU+'9<\/'&38@8@M&;1^QTY[EF6V<
MPG)EZ!9O5T0JDIPLTENT5:;&1W-C&3T"@AWTKP?\.LT:OQXZRA\L!Q;$>]S+
M/D74A4GT-J).;X:@1V@;'GQ!9BGIK?3LZ-7(&+*?O-J/C%1!8/X%FP34O%!I
M?8A<0LV1XM&!R96%T=X)DNL156!D+Z**H$9Z6.H[[XFU1H,3(9X,SP+)Q!N]
MX_,S:^%'K* \34WE8=^HD:(CICZEW9\JS0K5;FH@_F""ZK'2$_S,6\PK?^EK
M9NA)TH-4M%Q3-L%BYOXZ9#?KO[TN)23'S0G)NY3?"WF,+0S+A!L+#J;/.,=0
MC_:6M!QX]S'82=XXSH=CLHQ.&?S10V$4?S_8V"</17+<H$S>GKR3V0)$T \+
MV[ KLJ]EADPT 84_^3/7"]IX@!4K:P=LLT?FN2G%/-?-,0]OD/G)==I17$#M
ME2G"!O7WQZ3_#E83$%(3DUNDO'GKKKU%=VB-_13Y-E+D+4J(%V_>QL)RZH8>
M7"U_A7!)P=D"D8Q'*]FQUF,3O/;A;&F/KFL^6S:(:_C(\J@++:R 9/G?-L8*
M.XE8X;!4K/!W\=8/T4L_PCNC0.%H)0/AYFHUT5>;PPCP@P[KF:*OP>4]>GLX
M$PU=0O@8J/UPE1N6[4M-2%DI+%(2@&ZU1(?/J0:D1!T'9 E0MX53TIZIF:9H
M82AU/ /O1[A:&1=.!ES=W(\";\1^OBB]1%V.-K7=9]@XF.';N_=7( 1C-4-Y
MN1@7GX'1#7N)RIOH&,P;A[(?S)M8/LW3M^*^G?\.S4=:6UK#\.%V];C#)IPO
MN$:  A>N=1*F,"FN)TE.XE*7-V:VYOA7>!4*<'+Q3D.0JZP5KXG+>5P_*"2D
MSHJ5:Z3<\C[+\+EM8:/E;[0$,98R2(AD$YIM8O%X)41$Q8V9NWZ G QK!5T#
MJ(A;;;OH&C2<1SP(\*'A\P4\ %58P'LW(W<LF>&A<K-T<76H'M,#.HVL4.1Y
M9L%F1N]&$I'ZI^,L0$^%D^LM81QG,D.-B^M>\LTPUT?/?<9MP-'XHI-46;M<
M_!\LRC%Y=U?@<)OV$9[S+/]/_!25L-BSOF%CA,].\ (:'[!)CYXQ]Z4=@:M&
M-I^"T>SR>7)56/;5QKG-79/91 L!'Z#T^Q2*<Q%Q>L MJ&/O:A+<?U66KVF0
MB6Z0U[FCU-6'>G"E^H/Q9=I7I>#@Z/I.%R>_A/0ILV'-N136%GV ,FS;>/RX
M&$&#J97T-$1]Z-L@--H^W'XZ$@4D0!"YVF4SX.-KD%M\>_JE-[17LE%N5OYK
MX7.]*8E6/=:E$ER*P3N540./!+)( 8(J!-]2)#)Q:63;JY^HMW-4??_#S%\?
MO)_?@/G@!_60]1@6'W?PX:O'/C[^^2X?#31V1NM_)XP L?S8@[%;P=($6@_]
MQ2+_^FNM?;.FNB]5DZ>U8P<LVASSW%+7U&2V@1+9B%%2!4]DV-DFTWES)S I
M-%%<4D;L^@3H44<?W^3G/^\'OZ42T8MFX8^2+M-U_STH0)LJ!'E9/QN2D1F+
MYX3G#$9 9Q",E6:UX6"\'9^].A"*-D302-Y'SMR-Q[8W.% DH+4%W U+_4S
MH=,LRQQV#^+RZ%[KG5[^H3Z[BMJB5]"E94C!2ZH*NU>[I+J#\LCL:S=GY<(Z
MNGUI:%O*7'7=L7Y]/=IW(7AM;5N*78*G6SJ^5;.%VFZN\;5^W2U_<YUF/6[1
MZ^K,>XALOJ.J\'6U*VIT71L20NX%=:A[T<Q6E+F6*G83.]C"\2)=7!H-P U*
M!^#ZZ^K'BT;:&JL'O_1-N?1-V4>3B6,,E]6V^.,,ES6V_",)E]6V_DNX[(#"
M974B[P][!V$R#H?Z<)"O>1]'IX.B)M_-$0;)2M(BQ_58A?FJV77;QG.:"(_M
M_1R7MLOPF';R,;DOD;$3]4D?AG^Q?Z./^OE<>&YAGJ+WSO7Z3D+G1K*<ZVEW
M;L=N!0#6[GG&Q7;B@ 01,Q@U%'R_Q,6."_BTMGOK9JAWK_/UT+.(]Q2^K-8W
M^SD+.FV^H:KP=;4+JM<MG[K1.Z>X6.6M*',M-8<(7G=<C/[;&UUU%%UC1VC*
MQ6-<P])1L4%S=8;?XIIL=ZK)XZD]HJ.=BIQM\CEC370,'&0Y@:LQP\,"<Y]*
MG[&F$,N?-5Y<O(K"@27N94K_R]V6GU@0M_;Z0%7SF[*/5JO^(TA$2T6ED07X
M"C#21 4!\R/H+RKL7S"/@]RT.)3P'&SY&7-\+(Y&,J8Q;K RD[ZYBKK(T6G\
MPX:G.03 PIO..0$6#B^ A1? PC,'+#Q$O,+B5_FH].4_;/;RQW?@-1BNH-HC
MS$!\,[5F<(BS$;;P;N^.!!RO!,&_TNXYU$!_D+K?#(X%M'!]PM+1:."'I0HF
M1,A"\J:$H95IT ""^H@L%T8V16K8:1HQ.'AF-F(D\FEFK82#E 3HD%@9EQ#L
M.&X* 0ZV5 CF7.6F)I_>INY:_>&J,X^.$\[.<1&T$$@! H"O4L(VS0R? _-0
M"XXEKF_FPH805F :9AJHF*8+'&C+UJS 5Q!J6H@%]<2\9?)5"L01@:Z)/:;I
M1;/3)C-"VI'ZEL=,*R!X&HE=83S V$GL0+@>70$KC1O-YAA4\9;\,,?03"V:
M,:[X >$'(\0J@>&D0DC2"5AA$%T3U))+>F"VQ9Z81)&C1<*4#9\6D 1^2N-4
MMBP_GBI'1%)&YM [/L?I(6HBR]H,P8?"A830L8 %B&ANC.VAZ*]"-4^\]DH1
M<37)%>GCZUQ1D[1&,-&J"MQQ:8%;!U L_;<MF[BL)]('O!R9P).*31B-VS"U
M0MD=P5Y=E]ZK.O J7R1W8=7\$]@Y?D/@.;7AY)2DW74NV,U:-*JXFY,D7:*Y
M-N?>9,^F2V9NP3RZ4;.)N9><W.WI61\4T)&L=L>9W%LE7(Y'F0E D8RWQ-5Z
MT(E5VSA#Y4JY%+Y'O7A#&U8@Z*%BA=1)T&VZVY8B:%>_&0\.,U?MQ9O;"1@G
M.*&?T1>#(632'%ZA9B,Q1']>>&QNA7-=<UB46;9I#XMR1.DXXW:'(*F,?&+!
MK;+B^^E;L5Q07#[S!1=)F-&[_?S\C W!Q[W0<3O>;X:.XVWHV.P]4C#%$[O9
M*=&RGU^B<^'$TZ"V.9&26C%'435/GENK0DGWJ></%LYBZ=6;<MELWO0@2@8C
MD.KU]OA))G+4?-=MTD^ZW4::8Y_8AM1\:6[0P O<A#6DUA0M"#]\0'52P.]X
MY0/O(9Y5"+X1<GG#$'7AJ ^Q117O;_-.[6]#K];$NS7^\MI\O/1F26/%D5L'
MD'H1LDL(]6);5).;O1NYV)/<EDY [J*_^W-&SZ$6CQTE>PXUC)A>?N9U.HF+
M[645][ \8;&'..-=%\?PQ3&\?WI>',,7QW 0WPA@BX8>=K<^<$_F-M608JT?
MY%(W:*4%$*F.WRN\385."5J.\T&E]N00ELR/:<;8Y)545!,[,;F+N5)9W)#?
MLC&3F)2.+V)1MX[Y-EZ2T,8WE)N/\K<K;\W[H-<V%NLV]!I=Y\<[]EF;N)[K
M?7<:/!L>.S8NIQP,L8BO8@T;/#Z]_-J=4^'G<I0I()=W'9T+J09%N#_=(A _
M1\6T8HDRHGKOK$M76K]I@P+(P2?%SC70;-0_-A'-W63I#M'[W+]M]&Y:C1!+
MXCX5'I%-2/S;[ME^Z+2-3EV)3N/\XO9]QK6$<7Z?X6,\_DADHP>&>POS&>#2
MKV+')[3@QA2X=(X#RN2404IJ<"<)20UF8ZECJX_'Y7M G%\@N@8?5=4-NFX&
M-V;/H>FL(&GE8/1G#\O^@^5GVZ <N'=_A1:Y33 OSG;]T(LC746CTV7&K"M<
M/<)P-7\M^0"C=XHTT",(4%?:"AFQKKB/^PEA*_O$HGUJP3XU7:I4?K+9VUU/
M85FE/>MOL^';Q<37OO(2"[_$PB^Q\$LL?.^Q<"P^#Q$P(;I6#CR .]HF2+A6
M'O_NI>#I4O'<.L&H#Y>TVS0DK4K:[OA <;Y?O'D?>C!54 MT;0H4@!]X0B<E
M#^[3X3K:IIE"U8WJ#X\SJ#C:SM^Q+V+M.OSRT7A 6'K76ZY>!7O9MNV\(-6V
M[7ITG)'&T7 /Q!K>Y$.U[E)<?T00'D(RLN8+SWV2B&=[W);1/K9EN&UT;$_$
MVB:;J;)BUSNN,/E:ZR?;140H8$L6: LP<WB>B:OYS'NR5I->3ROB-;K> S?=
ME&\E>M9AR='-'C9IU"T?XMACL6RZ;X*VR#SIQYHG4UEPZYT"AN,AWG/[T&N[
M^LUP6VH=R$7WD?G^:^UV,@GG(<?G--G" W)1O.#HY67]_<FC_B(QR=XJ%(.?
M;0*( 792<3[6LMJF/,UJDO7':;87JK^EQNZVLM<OGZB1MY6-@TF4OC03@$<G
ME4+2R)6<@S(QO&FD8\B)[4PCUW_.SHR[Y0V3??5RJ2'7H$1F47[A?,64@\;P
M-%2!+[/D"\"1#[?A._6=&^Z,04:;%92W.3/;QG=9;&;=K 8P BF[A4UL_+5=
M;'#^&.G5L6 2\;FM)V8OK[2WH0>G);<+CIZW^&T\A 47GX$V4V1;MG''%=V6
M55@B8F6U-X^L4VVEZE0CWL>_/S*'>7#-X\^&.;<<RP^P,\\3DX\E]T\OW>!'
M6VGPT^(-?HHQ0C>7$;;Q5Q4C=X9*5X0/MO'1%)O8]6H<82T;I,N5"[)!JS$V
M$'V>;K/;!RCRHWAY7:]XI1AIM_**6J<1M'L*Q1=P896I6]O!9+J=+'BRU!]^
M:HD$1]$NX?_^UW6O._[%%\T[-BCXQ$M&$'C60\AS[40KA>\P#=AKZH[C7Q5)
M53P$#6??$RK5JZM[3KVZ1I=>7?6B7EW:>%W:>#7(466J/FXGA'GL?S:6>(6@
MAXT7:7^T>!\EB_E;%(!4'+ZN6I#QE2:A"-Y%A=>U%8"D<.SJJ/S8=CMD$<CV
MV[H/AI9[%4$:BB*0UC&TJ]E^Z^I!*5Q]ZP6E\%*9<0#TO%1F7"HS@&KOY@O;
M73(T>/U5X(@#*QVHW.U22&&YV"^\YV9NI7)/'P[R@\W'7Y)1Q6N_#5V[^G4G
M/ZMW3_487];Y "?J"3F6#"AUF[)Q^')W:]@]SI*,;;FZ(KD&E3K0'& .%$<6
M2D-D'6VB3,.80BMZ?@$@KO*9#&>=R+L]OE#Y3>H-\R^JG>?QGAF4T-: O=+;
MM"%JJ3?4+N7$MF)K+.#\K>CI@^N=)!+M'!ZH#@\Q)B8S=L]#Q<XC5:.5[U.S
M>93FTHI^?7AS?:7QU]7=@#S]K@;\P06)+]V^A?=J=WWAH\G ^>";4'\G^(Q-
M;PRJIR")^^5VI-?<"?C@Q.D;O4ZO$V5L9![_<:?(R7T+1]VS%I3^\D9)7M#(
M4R4+\@RG93QZC$)[&/XC!M",Q<)S?X"X#IB]A%5>]37_KQ"#:U/&J$F1.YU:
M$Z:A+YIA: Z7_T_7^U./?M)>8II$K_/+/7^4)D5_ZO[R2M>>9Q98TQ-W/L=
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M;$_(("5$_, (O#?J^'N0IQ&XH;[K13]KI&+JB!0#D<%#XK_2UT$ S! =3*S
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M>Q6>K51FE7BXCTXTL8,*VFR)@O!$Y1O2?GF'\CGOYP>>3XPS9!&N4"=!K&
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MCM9^E=019EOCEOO)(S&6,]&E:;S>*BZ0-12U2\M8^P1E[Y*3\"M0/-S5A;'
MA,QF"RB6L!Y03\/?[D*?B+\S4YSG\D\HJ^D+E[Q5Q+]^4)Y-PWN$M[2_>P49
MZ__P'/%^3/Z@AX70U2P3_A7/:_>,S=G_ 5-YQKO0DP#QQ3.!K")XW<SX0>'[
M#-+LH<(@\GM_.0HTQ8*%+:9$(G]"D<(/BF1)&;P!E?XQ=MZ\BRK*Z":D$$L6
MJA\2?L,G! HNH3?C U&PIR'[Z"/4 5[IIL-J38K!S!O/2<5XE(WIQAX<F]J$
MP,JV\U9Q'L:OM787[W>U7N_[.'-R_A[T*7M_@6E'!).L5.U-1WT#/LGZ)H1
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M\>%*Z:47QU^()WJR4(<-&[!,=(<>R-0 AR$<5>_7V"G@)L$_X&X$(CY3/'P
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M;\R7MQ1J>^E,B,O^?"2Z@;8"?90"\T[\[]@V5N_H9X_>?/;N_P-02P,$%
M  @ C4)H5NLTP9'),P  >/H  "    !F,3!K,C R,F5X,3 M,3=?<')O=&%R
M871H97)A+FAT;>U]:7/;1MK@=U;Q/V!=.RFJBI(E^8BO<95LRXFF?.BUY,FD
MWMH/(- D.P8!#@[)S*_?Y^H+ "G)=R+MSFXL"6AT/_W<YY-?3U^_>CH<//GU
M\. %_#?"__/D].CTU>'3)[?YO_#7V_+G)\_>OO@].CG]_=7A/V]-B[Q^%.WM
M+NOH5"]4%;U1Y]&[8A'G8_[%.#I1I9[>@A?AU6/S7JT^UMMQIF?YHZC4LWG]
M.%K$Y4SGVW6Q?!3MVA\G15T7"_C-K:=/GCT]_#C7$UW#!W?V?GYR^QGL[[BU
M\H7+_)1/JN7C[HN7/<KCR-]\HO):E:W=+^ONAY<UG>#XW=O3@W<'P\'IKX?O
M#HX/WY\>/3\91T=OGN_TG^?;;.OP/X?/82O_/HP.7Q^_>OO[Z\,WI]'!+^\.
M#_%?G[NS2^PBW/X?357KZ4I^J?-4X:?NW-OY^1YN^/.O\$OOZ/37HY.H#XC#
M@85B-*KGNHI^RM+_-L7C)^^?'LQ*I1:PT)/;[Y_^5-*OMR)XA"Y/I9'.ZR*:
MK*(X3Z.)JL^5RJ/CLJCC,HY.YZJ,EZJI=0+'.LJ3'5Q?><L_+Q;+.%_YBX^'
M USK.*Y+G7R(7L:3B2ZBD7OG\*-*8,DS%6QIE!19IA+\?;:*2C55)6X/-A=7
M4?C1X[BLM:J\UZ.BA(.D^DRG39QY[P\'O$#<>CW8,3Y03*-_Q7D3EZOHWCC:
MW]V_,R:05'-8#P"3% L5J>F4=Q@5>62/\5-9X3)5!,\ I!,"-RZH%LNL6.%/
MP\&YKN=T#(%8&Y"'=ND7<1U 9AR=SW4RISO[N(2'&"H393=\9Y=WO/.5L?5'
M) K@*[\!ESL\.$$& KCGPQ@OT%Y3E*I*EPIA1[C/F$_D8HD$_YBJJ<X5WI4N
MHT53 T*Q^*AHO;1!W(OH/DM5X87@6QUL& X '98JK^): [8P>>6P=EU=TWMZ
M\_8W^ I>ULNW[P[ENG0.9)-7.@5.0X "NL$K%, ORV*A*\6@3XHSE<=YC926
MUS'<4AH!AU*:P3L%)E# NV4T*XJ4?G469TT\R53XC3%]H52)T@ (>&XXJ)KI
M5"<:J'>%.[ 4A\LC<TP^Y,5YIM*92OGM)?,@>@!9#&(0\I$I<+'BO'IT':_X
MY5L00-XVMBO]I^*]W'JZMX/Z'3[R%-C="Z8BO*.3I%@J!/JA99?(_JX1D=S?
MO1A\HW@K<N [+BJ-F%RQK&5H$M2B@\J04"A2QAXG/-<@TRI5GA'*/I]K-8U>
M:B"M1 /-O452 "J29829[GCOLU L%>R_C*HFF0\'DZ8">JSX2H%JI_!OV&#,
MWX'U*N"W3#FJ!$H%:"9\ZQTQRAQVS#1;U<B6B=MVGUP*&.COO/QP(/L=X]',
M1N,*MC(!O6"")Z[@+EB(NB,!D7N'M5]@V+C'!#8[;6#"NI.X@D7CNF^=X6"N
M8A#GP#1429! G/J]*#^,HS>_[Z"BA7#1P+9Z01+7V_09IU%$#0$?OP5++N32
M UD&/_AJ%'-*0)BV.N7H+CJ%I0B-1/FXH<& !B<^#;Z=P'HD3YCRAH,73:GS
M&=->"-,.\0D1K,7^:!H#2D\;U&61HDA3 1Q35;T&0R8ZT_6*I1E](E5G1:UZ
M'L55(TNOH-,6I>@V-4#6?,J2_<N"T2QM0@F]X8@D#0'I\X)TH]AH]2J?Q3,5
MD;Q>B:QV*#V.BB1IEO*1DNB_R6H$*:V QT,9C^^FH,F!XB5J/_V[5(LF-UH$
M,H2BJ9DC+(&PX+4EL"50"%I\[6)21P D65S"]\>&FZ$!$$=POFW8T3;R.UU'
MDR(NB8!Y1T5I&!#"8:)0(V0M! B20<%TFG\"* !'KI&$O*2.L;_CT>=!O?T;
MT,%PT-(KHI-F\H=H[2<H( &VT<_CZ $;? _AID"#8RU/+$U1[^HY</<N/7E,
MN6/E&>$@W%;XN'#7X<![%;^]B$E"(4,':5RS.,%EB#!I<4 &@]M)W%0J:I:(
M[H"<("@1T0 YQY9,6/+A2WDA/_BBBV1(5<.G19%@PN6#YDH35G8/_$<Q":1X
M#NNCHEX0+,=B!Z>Q_#@I\@95>.$CF?Z@HBD\'@!JAOLI0=4GBYWHFDYP#B"Q
MF@JQP!B4 CK@HD@UD*BH]#%^4F@'2.DC@*.B/X!DUP!F>3 R1L(Y?&O<STLW
MV>U?F^C^XCXJNY?_L[T-*J7*TD= 1#/U&#[XWP:=(["O:'M;7,!/7AS]N\^I
MNK??LY?[^+M)40+.VM\]R\ TB_9VX.-1560ZA2VTW+0=7O;D-GRU9P,3() /
MVQ,%N 6[7-*N_4W=[]D3;O2JG_1 <QMAP^#X,>[O!\2HC1S_3F!5/O<\+C<V
MY 4VY+,8F>U)#)K-B@7C>OVU*].6P)<]A8^<G\[;A>RYRU>M)1B3L115]&V0
M<2!\(E#<R![\OW?OWAOO[NZBA(E6*B[)D&->#P*1!8?14_&_8G&ENDI*Y2NH
MSXPZ]L*J8Z'JU_;!T@N^ZW4X0#D*FB_HKJB"U;IN4"JC@$.!J\)/M9?#,SKX
MFD79VO/^:)6$9:S1'P^">M; '^"?()NS#&^A(D]9G"3 _DCFMN62!7*.4IGN
MIRSPGDI4&!'HH\KI/24P8XUJ*"XS+[(4[ATV=@ PT7F"B@)IZ?XF1W4Q4R@X
M/9D(_R\'40M&.N*-]_26*+Z!Y+X(,H0UTZ9N2M5GZ/JV+<%P.)AJT%Y(<\IB
M^ ><6;0PAF><(JV@QTY/09T!(%3PQ3$#8(K!!KC<T&E?6N4+$2DEG"0M"%0B
M=E_P-^%!^N0YF/!P]N$@C<EQ&!-AL"E_[;@/V<?OGY[ @P03O)B#/$<_[C/4
M 9G+G'H$R%B"( N<,3&85VJ;J+OBQ5B))/ZPS^RA16SR4?<A+QP%ZY,3V'J)
M= FFY.C.[A;<\&J-OXPW&BR+'A6/B @;R-V+3Y3*H%_A' ././8$O",E1Q4P
ME,T*9]>",)YM<E>?&?X<[*MK>K,&KZ?CP(!(+7\')?M<9?#X:&]_"YAK7L\K
M[RQ=:'A?*!7>2=51X<?,#KI>0KK>#BP9@-9=A^P&'1,[T1'P.7@O 1X1G Q#
M+:3ODT^D 1NH!-E6!<"B\$W:(&%GUM /OVM9'\?0<'LZQ4#$-*)#T+%ZG"8Z
M][AJ,E?)A['OF2&#HV:X(\-0B"PHYS)BUT TN*%S^.[$$YQMOQ#Z*HHSG2K+
MRT)O#!X)_:UVW0THW2=_E['X1^B4(H\[SLPXJXKA ("C )$U4@[&S.(2+3+X
M'Q&T$[<H')@Z6R39)GT;;B4<CZ,:6(V"FUH4#1P4K@4>A@^A.VJU/<7= !]-
MR H;W;WWCZW^0Q'2)4U9(K0\P;(3O=&YJE=FD6CT<'?=&IO5)MFG1ANYKDL]
M:20$:R[%MX4))6!']JM[^%7$A>!5%ZR^7:MXX2]A?1C(?P0X@LD,T>% J-Z@
MK)%WJ6+A15%]>@%,H@V:T55T&XI?HH=[C&MC] MHIC<*WH%&U^?O8[1C2D#R
M&;H-6.UC_NOCD'&/ (>+,7Z+,AA$.FHD5CK+73$^"O \S\J?JBS&XJDGQPF^
M$R=SK<YLU)XXJ/P9U*UE09HI+'([2#*(9@7029MVD&PX5<"0SE3<'L%))@J$
M+#$E .;^[O[=:*1WU,[XXK#R)<'K^*K -X M90ML]4!85^2K1%I'$.3 M5@K
MQ2_E!7IYMDMV3#%L0]6UA[8"'Y=U;%5M#Q6[:(79&=Z76C'\^9LD?K9VE]'G
M;1*X?Z(PE%P9*<4D*.[%Z,'U4P434@4/0=9RK@W8Z2>AZM3VQU^.*9%L+:8L
M>U&YRI$F&]'?%\@8-,N1GDO&M _23"7U0VW2O,:1\(?U<523' 0L*<X)X8#%
M+NG*8?UE4R9S%$AW=G=)987'2]4V0H-\$=#$0%4HD@]M6?IV:7P:+BU(#-]I
MC'DJ<?D!^![F.RBS[U0L:OPW;9!(23;1TF-Y?:&4,XHRG0&+G18-<XS*SVWP
M["!0(_.6M(Y&^RBLB3/P2KP=5.F)^8 & 8^7:(N%VTN%T3(#*]4BUL0C&:25
MMR1IK( CM$E.YC /LRH$ OPCJ$/WK7(K'\(#\2YP'7Q>;#6"C4#!72NNGV,6
MF6:E5#AS9<+%7NBU:XD#D]T%;=8BYQ)4MOY[C8[A3V%&&D!!,"DV1B^R,,[/
M\]1]D0!K/!JR?&\2(#KF,:!@LEW2(FG(U1#%J+WF5O;9))N)Y-6AN0STW V!
M^_HBVRNPPW,@:X(1([9<YAAAB1F"N#[_I<EU75G_/"J$%-#D]X&8JB9FA9AT
M+H 8/@PZ60G(PZ&TT!A F3^/S\B3P9E[7>^1.&,<ZUFC_C!*6 4+E\3-.M6*
MK=U9 [H[J?A"D!. U1S_#=@[5V$\I8]]K%B]#\]N+MEBFWV.'H@"SY#OGO&?
M!W:+,1"\'4)$/*V#'!LNHB5MA%?GUD-UQ]T\2/[P%!6IC>NH1>P*>2?P)H*<
M  @MNEK3WT2L7BYLLO]8^!,P8/B:Z!:/HW\CSX<_?ZNHRK=(%O? 8 #P.#I=
M+>&<!V4\T<GCZ$V\4 RD-P4>?3^(JYBW\"_7,.;S ^F#EPSDW/5#]QQ]4,!"
MGDG*[$4!BDZ"34L:4;IFHI>H88AMK.0C)BU71(JX$B3O!B5?/*W1QD0%0Y).
MPV0QY&@SA:DGF>6RG(R#D6SB^97*-46E98]MG0&-ZB1KT T_MO']3(,D\A)6
M.PKCK"R:9;10*3K%QA'"&_][ICGP#<))-C*&M:9X\*HI44:P]CS-U$>$SS;H
M-'G*N24)&4P$B=!3"](:??DL82D=&D^7X&H9A4E U059(EE*/D E(1 Y.-AN
MR/^GF .'3I"ZLK=0^9[*OPE?_X+D<<\GCV>2NX4J&$I)=0GRZ 3P0*-;3$"I
M\EV[[&>69$GE<L3J$M0HP"SBX4@#)EA2<$#()9/)?A"=&TH\]+V=AO*F38GO
M&7<%)WN N9>+N6P5F$NFBA*54IAH?.DPF>S4@8%5=!!VR0I5E:OI0&Z9M 5$
MT((,3.*J*A)-"C6G\J!Q091$T:1:;4?\(^N@HHNSD5=0,II3CK."TUF(D2R4
M0E.FBC:?'4VJ[F%O:*U-:_>#G()3+QX(_WNA8L[">F&YZTVFP069!M:!@CQ"
MG$$7!,& JJP?#H,]<)Y:0C_DF.V^;BYFS ^@H5^CK3S:NRLQ$7;?A:ERPT$W
MC&7T@S-Q"+N;OKGE#?G0?,L4X?1HAB73^V7!Z7Q^=!T99=HE)U^5@S]@W!__
MH_!A5%2(+5K3&7[2=49!E4?12&_U>:#]-(9Z#DK3C/FB*^>SKC*WO<>P&BP7
MJCL  9TW"G839[#O!#TEIJI+$A5.<3O1?YR"EY,%A6P?=M*D&)YX!T9SGL!I
M&1 '">'9WL,']RC9A5(9X4A>S>3SM\_>'?2Z_]8)-O)=>T4%Y!"S_K QI5EZ
M@4L;%B6_ZEFL,U8!5B"9S@D6 (Q0?F"%HY%M^#5V(WG2OO)OIR4EC3^']F'\
MY/?B28%!T0EHOWTKSF-V_:_(LZ)R;\''M/&1/MO"$(#1NL^,EE&Z:Q)_R ?
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M-O4L%",;AM@<E_H,6=I!>8I/T"</7T=[T4$"!@7WE.='D;F<SPM4@XISZ@2
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MWMJ]13^?'!\\-S_+5LYU6L]Q+[O_>!Q]:0(_?6<^<Z: VX$.9F )+ZX1WGB
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M'&&T6@\7-)>!GAWY_WW/3K#)[X\KMY^]??$[Y8'^>OKZU=/_#U!+ P04
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M,#(R97@R,RTQ7W!R;W1A<F%T:&5R82YH=&W55EMOVC 4?D?B/QPAK6HE+KE
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M%'O&L@4.44GL#53TPGI2C='J!%J-14%&0,3Y-1)KC%^ 9V8D[W=#"O:=L0E
MK'V!&2G>)0*? L[A/[ECVJ&IL\$!X&]N. ]YK^6["P,G?/Y6F,=-H02+J9B!
MT =35B6R.3M1$&KE/6=(R ? "0GTF[B.ADLWH$H33%P0-  +*3)O/QFQG7MQ
M\E$&Q#]/POW*SNVABU:#?8F*&N!WFH.=SQOFB(;XH*.:F)(]>#?ZB4Z-X4"@
M&5HR?\:SB>3=.K$QT08HB6C.R@ZRKN)B:C203GP,H%0N6A)R#_BV2H4K]'*/
MN(,W=#X&+Z0\+:#95)B;\^$0K!2^M\Z3E<>&UN?L9L:!>;]NM&<]E@.@K,-S
M\)UK<QR3CI**1"FN'+&>F#EH=(2,A@D?B_I9$%KL=W)H15!O\<3;,;QO3)8'
MS-,,9H4*3PT/PKI7,)XM3LY(-7P#[ =T"(T4 90TCQ3H-M8=N,T^::'OACQJ
M&2T+W+:RK,NGW>B/$"6X2/QIRE$32>NCV8',IAGN%4N__N/B.'%DV9\E,]+:
M"G2_C?2M7E42C_80H8.UAC7BS828HH*%&7)1PGZH])W3Q'"S283!4W\!_NB9
M3E.@?6AZT5K#8J)N=B.T>OSZ8_&BHA<8L!$$1!OV;#T=9U6\P'G-;S_%'?BM
M64DK?,$U]04)>)3-%\G2GAI).@:--)#$?;X\(1$\+1;E#2'6@::AQG=Y*7BC
M@%$P-( '_);4+&0Z%67^K8%0M$?O)B+\WR,ITS5D'9RL7I]HTX/N$\5J@:TY
MLQD@$:=3XSR'R/;!IGJ95;DG<;#!D%L F6%*9NCF)]$42!4@ABPDR:[$MUO8
MJR)UV2? ]6.#X5,+. <89QI+XD40A' KT._U"/3!,:H4[X#W@JDYQ4\3D EC
M%!0C=%^.16.647#$8"0%:D@HXN)'^""=8%JC2P3<>^QHFAGW6U8;.WSNDM:Z
M6F^,>]%WNR+@\">QIA7TA+ASEDZ*K H5_2U4<E"S5L/LFISTK3S&@"'U*D$4
MT1EKF75SPTT[U F(OW]('TT#?)MX4&W;$_-.$\Y[MAU4?]QWT4GLU@.5ER(7
M86?#G!F2;XHU'DH@L*@*%\BQ#-C<&5#P4 .0 8[P39SC(SPSV 82#.&N./"M
M:MM[VG>C4Q Z\O(0F96-+Q?^#+B=Z*8M():LMD1FVZW3!(]6<RUA:%56A3^K
M2U@[IJ6)+"?V,V;=T2DJ)@=IW6\N17_ ]FYNI-F'4;RJ!V1=F!0.L:H*=$.#
M1GR#4431W+/&;[F>*Y/6YU";&[7E-^CC=I.DGTL31=&+VQ9&YTD@1GOKJEGW
MME-;YYHU5NI)%JN"M2#.KTU6H9SGDT+,3K*]0'W(;C5%A*>LY+NU\V<)CGR^
M(&53=.37( $(*6+ XPS $<09<"BS:DI&0W4Y5;Q=9 ?VIY\$B18U.7<;CCX0
M)7!4)]&'DC4"/$Q,,6MSC7^@&A"BB#,Q1<2M9)E5)N)Z%J+S27GKS-IY3BFH
M6X9Q8.X5LBIG)=K"(D=0E*2P-C;@,59V>U@G4<VU6 %N/UPB1-R0*\SHMLPV
MRP9WC-<07M;AW=Z#+8/SH9>;28\U^84S[0@:,F_[5PL[ ]/ /))N$FID:_ 1
M4XAZST$<\DB,:<F<) .,"717#*B'FI[8^2GHQ<'W\;I*%YIE=Z9UL;7\U6CQ
M7YE1L4[P_]%!=$%GN/@5H1(4'T2_8SXY_/RY<@,^1TU1@ :+@(-HL%S .@]S
M-32C@^@<CATCZ3S#I3^J90?84?C+/<Q<Z"'/K_\@6,;QA.)'EY@4B86(S 6O
M%HDI.8AT.I_KL>'TNIHZ>V+Y$D$9;2D,STTX38F,&E(< JOZR78S?5_>&@4O
MW=RHSQOF\Z,,VM\! MIYL@=,G\>R$Z7 L2Y6[D10*QU#]#]DLF'@TOA%8KYH
ML,H.$)LK[^/6-^+=QQFH1K-<1EM/:C4L/;"1P[T+N.@#88M1F092HA*>1#S2
MUK5,R:6\-1()1T7&V>Z2@.NTCL#+1_$@MHW$_S:D?<<<"/+V;^W+*EN+7$4!
M0'V6[EP)!V5@^&*>KCVUTK<IRGW=1Q^RK!5']@XFQC9KA:3R>[6IWP*F%9YK
MZM)L^6'6ZC17BUG@;=K<('?3*I]E/=KGDF>'RU!WD#55J:@Q'AEQ'S;8/SS)
MF230/=F]0D<'WGPD5RXGP73Z?;MP;Z,]B=&5)S+*203T%Y34E$4W696, \]1
M(S]"14UXVQM2L'9<)8X_=(&SY;,L-S<D=VHZS?64+2?)J"?ML86B[4#/:R=O
MQ+<3(BG7JICY' B*##C'?FZ/Z43T[C!#?A6*YK!J V_P!CBFKLA9\A5Q;9QM
M;K2S3ML56O?=3RTUCR?*U<F%)A)91+F6>(!C&>W2"'HP],BL$$\?*@&8-&,V
M_7T6#G'X#Y8?-?'!!@]8PX4$WV2AEL[)>S$)$N)BCPRQ%HFO$C[@K">Z5S"F
M-2^X/(5!1ITGRQJ*;?5(>S>\M=DKO^#@K\DLX+D;33E9OD@GS->BPVR9&TQT
M.U=UV^(U"&P2X;*A.L  X7A8@-7 -94+>L6(V'#/9*N6Q.QX0FYPF<4Z?I0T
MJ.B!O(%^U<8]BYRB I%(#2BLFM;:(TR':7Y94'%%DH' +%A)"$> ^#-C=<T+
M (Z-^;5(7PW!LNV+4;M7$?<$-;$VCUL*D-M:)X#*/.:\3?*8PJ8/:^=6GB&7
M4A:61$7]*/P8#8]<YIA4A;E[Z.=%>5P6H!\@\Z8T+/;_=FQ,#\(Q"QGU"R/!
M6>#\V;L=0&N. 9)Q9[&O23<W7*:A>#(+3J%R%!6[.+O7J#!HO>:Y[PJ0U)Z7
M^C$)]0C6>W&[]M%P08Q^Q;>RN:1K'UYV5 VW4>1S<#D@)RPAB5M,!/7U4!50
M/=*;^5?@[^UF]=^%-PGOE[X-#^=C?63[C_\>S'@KK=<DI[.!%#[7*D6*FR+I
M1S8"@!HDM<;"1U[K? KG\=#RZ._TU\!R$T$AGA&_C&GW,YN:B>*<.!F,WUUJ
MZ?@D3N@Q69"*>-R57I2:V.BCQ]36\Y=8$K5:J>R7)Z^C_>AP]'=E"L-?89<^
MM%5<4ZBPMQ_Y+5"/2Y8[V4W*4;;" ._-G0._]@*$]3 ?=#<#['M-[-T7/C21
MZZ"I@PNZS+.Q"ZW83 -096$356*C5=^)D(C0NNB>VB9.K/-'OD;FHSLS_/<@
MZ^GN?A0R113U["N]<F%EINZ:6['N!4B0$.VQ:)ALUJ&%^6;5?.YB5^SD,M>H
MN<'!'S'!;TD%.G%;C%]9+VP/W]V6/ILU"'S29!0XZ+H(H0%LX)M%%TEG,<@5
MQP /91:NEVIW+>AOV1-W91V&GL35;V"MQT)J<Z5JANT0="2IYK)^S#Y#0;'I
M2[DW3MT+$71)%>&JM1%']0CZ<3TP^2;(O 5]C?-WD1+.PI#P;<CL\++VO]9B
M9#NT^F#E]A6V1J[S';%8F2#Q*1N2$PY6V"UDH(598(&'J2.P2?YH6R#$JK3E
M4C]C>;>EB-[5,476JO+3WC>YM@:WS$DN B,M?EZQA?%!6[U->4'.2 0I%U#.
M.=M<'S8A@,04N<9II93]T/]/C$/6P7%OE\.+"!N5G* L\/+C+8!CG!9DO\R+
M3M-\;--I@P1VL9%\VKI%^#HT'23'QUW9\3#/+[N__.OI#T"U:G$K5UR!4';Z
M._[0@/?#V%RK?P[SEIJ]UFHQX:7Q/D)>9'-=DH!S4Z&]SQEVHG^O8-B[<LR_
M"V\6WH^X !BU3.[YB$+TC>,T!]& N%)8*EI+C^$,R'09E"_:<(W;.)$Q\(()
M\-72)_@'-5KR9OZI8[XFC6YNU)@;U\_="L(T S)(Q5N1EGF62$C-+;AW:"-T
M*&<.%)DJ9X<2/TY)^$O+1,3!4U/T2T$H:S9#.G!I%MEY0/<8D2M*9(ASII1^
M(RQ*FLI,(UJ[!@N\=TKL>CDOC[^GMTAZR^-[D][RJ:CY,_9B/OW]HQJ+?\29
M^BJ;,0^:7GE?;PW&U$*C.A?I]R1Z1A_'"K\I.KDZ_?<][3]?;\]])/&+D1.J
MM<:INV'VE?+U:DE6H*K;R-TY?7,1'=%/U#W%V==M6]WU;Y#$EVH(6A$\!]HL
M-]QN&=LV$2VX:*%9S04KJW)3DLK-J>[[OSQ^S"$GSHR.^[*_?1V(L75(-"DH
M%6%QO,MS +./,!>=QI'\<<H>'OOI5!0R.YKC. !*JA7&J#F? _1U'\3R?6XQ
M>IO!OE"(# XKF16EFDYIW036SA+F82N53&&Y[&)+>A?:D!97?G876G&\_CWV
M$4CI^-?2]NT4)C74Z8/,IEJA"B47:2RLM)DP0>^:8#EB/S4G$HAEREJ37T&B
M;(M^OX ? _*SKT\1A7.MI4E['Y%)HUU;<UEWNWF:G1YTKO=V,'OA%.34 5W9
MSF1=0*U#\!\ >VH+D%O@@LZ?-Z%==7;7 W8W.BS9.]*>.9RA\\H+G[<0S!B[
M4#97\9#ES8DEB3 WCC>--)V6K A1<4.?V;V#H02,R0>8L"TH5\+JFX=X4.C=
MW&IAC1F"!#$91ZV^>",)'B(5YUKLWIG^'3 >&;LM/H<C+*E4:6D2KJ6X97M,
MZD/O)G=NE&(TT^-*,MP\)GV*(]=)-G-_]X,<Q^C*O">,.F!,;MF0X<XPF%5$
MG!'[$L'KE@YO@#;?O!@^A',@JS4:RQ 5VM0F':F%&AF\T"</G:WXMGEVK<@4
MKI.+2D"/'R^IHXW<)]2;&AS0J-]?^"<;<<#-A=7Z!0O9Y'J^2&B$O9YE%=ZL
M%*0RJX\KO.M;S)=6"[]P/_)+IHUF1(>+I^J=/BR[O+TULZ]&)D(.5(LVZVYR
M12GW(IK%<$F6)GSE#Z>,R 9C)E0^5[8/K.Z"K8P2K3"1BCQ9RYV)8<-@1'&D
MGY_^X)2W;@]GK7%!)P=O]3T6Q<.QZAKU9[EO:1=@1,KP7"=?RLI#RDSD%%$0
M1K5$;(T_HM=*^"QY["3'X]X2-_<)^UV-5#HR<B]/Y!KB,G53[ULDMU8C;/90
M4GV;W:>96= .7MLI[5ZW64W8V*8]1SU?B=MDNZIRJ[AVJ,TH]75^K?O?BU+F
MH?34K-*)(8KP\%(O)54(5;+0R&O!GK$I:A6:L94<_OS%F%*=5*):T.&V*0B$
MP*:2C;#8-;A23@&-3K:<9WN&@<S57]2UPM$Y)_<CP@)D8#C222V,?:&W=CJ+
MJ/4"G #L5@&*7%[-N=.,=$_'M-OV?/?VE' UU+FCMJ9Y?%4O'/]$XJ"+VB7Q
MGY7YH*W;;28N7[("=F)2%<#N/8%U#.KL[-<5+ATN=Q)UTZG$8QF);P2QXOBZ
M-5@K@G/ N<J P2]FH%)J'PRP& 7N@!.FY5=#L)_1E77R^\GY/75F#5;1NNU]
M %HZ779!^0:VX\^O5*J.[!?5XI@]1*PR+[1*>HU>(?2XV3'B0^[3 -N[J175
MA0*&<G'>#/#PCGDW)IEWP3A<(C@'WK'#EUATNG*XC4';LKMK:+@N?<S]MNJ-
MRUB(-94)3M*F:S6^B.:ZWAY](LVUW2RM@6E0@'I1W0'Y@6UYL!WV@6LW@9/@
M,Q#.S R-;PM7KPFU:6>V$:]K<>B#O4V*ISH'5QA)F*'&DMCOL<3+2[%W!O4[
M"*X1 3N=.UQH8N6YHK8:%/DEZLF#.VPPYP:;0J#RA:U>N3R0^VO,4;K%TN02
M)@';67=A*=1 R<NTHT:"?L (S%C:=HWHU0"ZHIY##@0Y2]WWM-9J'NGX(#;O
MCT0Z.?WMU>">2J25-XI,6,^FFM8/[ WL*F76[D(9!\F(WLE;\Z,2('*0'??)
MPGZ;'+8H@1NM>[^2M6!X#!DP9)N3TTYL<'$U9KY1ZDK+W7D>V;$ZLI%,/JBH
MP.9HV6 BS81:RN)C,B,?8LJR648W.:XJ=7T;@UH:GMJ.JBOVA.:/4NP=*V%K
MC3"-V2H\TN=:$OMMX"2XZ>%VK N"K=V(;+,,'$I!XLPM[1%KGL2P?Y(W/UW<
MH-'^SE<#1]BQT5UO70(_+I1UDH=(O=5)3FE]5C)2/RH\0-ANB80K<V3VYP2W
M:!>V4[<U.EP%F[SP&S!J[RR?Y\GW?![)YWER;_)YOBFMX?ST_*-2=[YAI:&9
MI8/ET_FUKM>2BQG@["^NH0^L@GK** :2E$]P[KV[3'BC=!5LM][.76=!EO_<
MPY4%&C4688&(F:TL\$AGK[%QFYD,HMDVMJ]9SZ:0%3M_48D*L[/:8&'PD.?T
ME+>J\B6YO=9:I.@ M5FE<2FZ0[G%.!(D'C@1I5X):GO!4 XZJ?WU6ZYDSW\2
M\Q7LS+:I;^]?E'00AH'0C:BU+6^X$W9H]S83>EP-!EF  3*:O71[C&AK-J.N
MX.SF>IZS1%(+;NJ\17I3/7?&E-S8D7-XREG8-;I?E<)K=JA+0$<#8)O*U'-)
M2FWEK/>Z6P5OO_</<'%EWB.; NJ*HQ,\G7%T#H. @VD*"I\D^!OE.O3W%.)
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MN?-DV]]9][4P35>!M9)>3&NF5-][;C] XDY(2P%]0).*,V*0" +FXTRY/D8
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MW7G"#QC[5A=7UEP*&6ZE1K>4#ZR1FI(<1SG?(8;^D06?_[%I(<;'-P0JSSY
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M&6[S%AP0#-F*MX/L4I1A(@^UUAU@W.AX/T.8(+JY5_W?;"$[(C+&*F(X]D5
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M[*))_@NP9&&[COTO4PJ7W[5K+D-O\K>2(!A]^V$?^8B;INYS+WW$,T(!,4_
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MV[9$D\+LSR8\&MKF9C/(<TZL)O60;,FM.PM;X,X!IT<U[)N>ELM[MN9"]Y&
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M4_I *8Z\N"5LT3V4V,39=:4OKC3N[I)M$@ZP 0O0[CQXK.3],M8(I3ZZ6%9
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MOH_#CM3M] 3H^A?!EI,QN6*]JF-%[B6R&]E@W7$1F;K1^N,WKU')WD^?<7T
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M.!$$K2/3Y_/3ZE.9,FX+!9[^\,/Q;A;KDD(R(@_:('0;,!%"0!T',O*!TFN
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M%O<:@?80&):TG[RZ%N$XR<KA@+P:UXB:%\>V>B')'!"H11KMO<QW6=:V Z/
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M@L_>\!@^G>3?=2[[<MYHB9%-]<N7):TGX<!Q<&RU*QA0BVK%@8%M07 =@.Z
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M^8"&@XV4DW]BLG4AXHC0QP6?TOV^?3]U0O,[V@<WM?&E$C5H *O57NGS-^:
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M814VP<E_WP^);2-J/_E)CVJ#'4#*5U4/KT647R,MY@@-YP1).P^PA'BR'U=
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MXPTT^.SP:DRX5:J?@CFQ%A$T..DEE&KC'<?4N8!X!CT#T9!#3F\UY"QUS2"
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M%^M@-K?V>C-/ZM*A,O6LMX\?'DTI2"-+5?RT=P#NWJZ(M^L,ZJ._+%^>(35
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MK_%=N0\^?ZN<D3JC,F3]J$QM;V?)@W*524XI-T20:4R?-&70V;H\)[XKN,)
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MGFAIE$)H\TQ:C2QTY7R>ZQ3.U>XM U7;J+OM=H^MI*!J@&S?.,;^H!/U/N\
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MV=0XTI43RY=$]#()-RBZ&EP@D) M*ZGFMBV32ZKY';._$>8QTZI-3Q0 ,N>
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M85L8"3I/4AT6&K!SU5&*A_2S0.F.A7(E_8N1EO_\S2%T);S:ZFP4' ]*L0_
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MTP);C\!"B2M?6[G$J0)&K<><<ESA0)CBE]B6:Y0M5FYC+-?>#:8#H9N/G0G
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M8H20B8VN+;L\$?YMY'I.MTG<5!BCR20N3DB*^7V\O[3[^URM5\Q"$RZFK&'
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M"LPD4<ZR@;\AN71['\$H^R2#]>^5P1@IBQOL8\FF<D+7OT\&$PG(%([DMCR
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M)9/]_>#+LL[&TH?:CZ[0C1[_?HX0$]@4M+\&C"ZF(JB\B>JN4Q"%?Q&W4FJ
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M,%$ 3T*N0IOXAZ@1H\"O3)$Z1!?:*3P)[978-NBMSC]8"RI-_IA^Q>;K[K1
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MR0P\/,%_)\A-)BJBL\&R5E4YB!['K2?:@#$L?+P,IDK7E7\7I3WY><Q>K:7
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MXS\_AI)6]T<OX5DHH\QM@U'1]5!NQ?1/E\(N7CXM6<0[BTHRZ!F-#\M(8CL
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MJ#$:J#P!'DQV#SA(P<E;]5]15L<+.[=L+E.^^F-;B*[6<[FGD$/R,(K2[<A
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M&Q4_6*/5.>E!5KW\B[.%S]4@!+5H:\A@Z<0 OCVBE83H#==>\ (1:='AQ@Z
M,"GADH[W8/0S5=O@%-OB/<Y6NU4WG(JH[VZZSG4:&Y8^W1Y<_D."&<=T5-9.
MB#+M=,6^TMX\7 LNH0"]5-!H#>"8Y/52?8DIE @:\3]"I?*H$R*62.K3?T[?
M">:N:K3BC4MW_K0[,;S]U!?P"'HM6<&W4[O^]'W!G[^^I  N\Z5 1UOF2B(<
MT@6MY@-ZMT',WYO'_6P1GX2P?.Q,=05!$R]/QXL$8)*[,KHS"/1(I$$,IC1
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MF8W&2=P_N5_)C=Z;VBN#Q+3HT<<!/48=&77Z1L]F]^'%3G&1R+["=:N\?.J
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M,P7G&*%M*(Y.:!#$X.,G\+$D.RR*2[;#\-NMATDK8/-0\:_9FJ;^HN?).YG
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M'- L2L[SZ%8[[F%[AO-.4\:GO/+\^'$(3#V;UM#W\G"ZFU$]G2Y]/W#4.=[
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M8L)COYD[%3M*\BR0^I-E':O2>@Z>6!2JM23&\.Q5.6X?4L_<P+ LA<M$?+4
M6]]HU<F"5I)A-U/ U0BUXRH'RG'*R FR+P_4J"-H,RX7#VD/=$SPE?&Q.[0J
M'9Z0$^S5V9I K9C=,(]W]2HZQW_%2T46]@UHE-?D,YL<=80JV8DH0(3)"#CR
M,;*[M%3VP%ZU,%"R WXP(FEH9BX*Y"HSC,0 'H[B>1.BX:<P563!. 'ZW$(V
M]2S:MWK#T5R=0N\>[CG"ZZ(IRO3H-ED+&B'X?O:9A)KJ3BUE7S$&#Z=(G8[
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M),-DM K20!\<YP_B<X72?%7@BQ-9MOK^I;\?3_PG03_T-T%_\)\$'6O&)>-
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MX__^LB?Z[@?JFP'4/HY"8W78B&HY%CIO2$]A=]0 D_6U9,](JX1ZQ[[Y3H9
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M W;=@(0"YR8W87(5XQD@12FAF2-W.FFI7NL5&:7SF:6=!V'R='R6>%Y>5I]
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M*:Y!#]?<#1:_=-G8YO+WK?OUS5[=M,195Z9T%*\;X(9Y)*#1&Z9\!O[$I>I
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M0K)BK4!#\Q35=;[H8A.Q0F&,W 57@S3&HL:%T%@<_]S,1U^O?2LRQ&:=)&4
MD:,S0>M7"< ;"F:B(U@B58T>2[C[;V/O6"LZ@*@H-ZXM^[?+O^+K6(X]W3%H
M!"^;]_VO/,S\--)FL3G[,7PE65V6S>0I:D=HN/[1J,.0Q3=9_?1J2RZV -V$
M\.$4]46DKX0= 5K?0WSEO#??&JBKNWABS!@':G.J%<_TKWZG;C0<!X-=@G;D
MU6Y/ZB+DS8P/M3/J7LZ[L_(Y%*NYL.-8]--;K>[Y1][V)A[I7%0Y_'KG;]4_
M?PSHOOF]^%YB52R]P+EF&%5>Y!^)Z&J)T?R&-=+G)8CTT1,"9+&J:*NF153-
M0,T\U4NT-^]6CN%"*FJ)2IYV&>(&:0L$,Y5$X\W%#K!7H:5D!NJ@:#W#A]U.
M7F]RW?<0M"A1&+_=I\8<<?]Q%)^-E ''-=/M=(0HFA'2H0J2%L6I_3M"I"P"
M8LRR == W"99CX_Z#$?U,D7>.@=U[&*Y(3+)")_)EP0R%6"$DF\)_@KOVU&4
MY+0 .A",_"9K"@3WJABI.L)#UGDX8H/VBI<[[H0=M+? 4["I8F X"\Y2R49\
M5?GT%*$51,U2YL0U>HSC:C#"Q;0QR9*#6==FHJO['9%\T!=>H'@,TS-O<)MX
M!@=3FVJSS2^/VZ@#D:I3\)#Z5VTQ=4WTB?.?ZD3-Q+-T0Y9C] F+QNV':P!;
MIN,&V/ZF;?)/VQ9>#HI?7_M^VXV#\J[J&X/;\IT-G1]OV=<5#1]G.$55OEP7
M_NIA5^SGRX*=05T+[QO>V%$7H\B..SC2AYG-I87T!;A1';6E.)EYR$8,8!]E
MF91A!,9U>)F?@FW6:_/=ULOYIJA+)W4A2NXLT1:B)^'++?<&2>8HI03<A>Q*
M@),5 ])=R!NUT!W*9CE#,3?ZS:&OHLR:,=J#D*^\*;A9RZ< ^M4 Q_@M^BL4
M/T[5PU?F+)*GANO:A398:W!0$V^:[XIZ#8!DR7&]JR\PE)] \I3O(1)G(?;6
MWI$K>87D28,VJ6+8*_PS\J1^FOGUQU>N9)-HSU)JCZH6G2^FV:T:CHX$RLN&
M/6J3ZS]W!+R3_2@N#N\.>^?\*>9P_L/:"\/<%F*OCYH$VY]7T'L!9>+I4;S@
M_) :%://1L$9R8-8??*T2Q!#+#(5FC)Q L0'0B6B!B\+B"W<]&(C) AF_)0G
MMI_>M0CFI8%!2KX!.1OG*1O>U+X_T4.6+9: )SI#>TY'B";VVA/[7)MEU:.9
MU$6@5R<[LC63?:\@'5UP$@YIXNFUYG:(Z?<+<G]%*I^QS,%I2(%2EL:: @UD
M@AM?,1F-CQ"Q"K"YUM1/@3][Y9#.$L=6;LFEA1V;F#;287;ZUJ?/4\9?'NNK
M=:Q=O^7<DW-E,7$!:VL3DM>%<P-(^\K(492#KRO@->9]DL6)!PO1Y34U]5$E
M/TQNLQO=T9B3"4IR:I;&WX4W3%>2>\.!Z "Z?"6RRAG=0[?;AQ[FJ/-A@[/5
MHEYK(&/S.ZHQ,T_U&SGS/?0)\:1D7WW@V-B&KM=X=61^0?&,G_XMUE+AV$!/
MY>"0)IK./D*>B_4\5TZ1;UL$!S-35!1I:]8%<$V>+XX:U]8*O#^PF[H8LWFF
M?4^7[A%XY9%3GE[Q)7W2F@V*?KTL',$H?3K"U,0ORW2$D9FA-P^)B/XGZ%TZ
MPA^ %2"_,C$N"6'T'J<9H7$/H(\EFLVL3I*!**JT3; +JMT!\\5VO%G8;'0A
MXF_9.)IE;]#.6L3TF&PT1A3LF\3F]4HDL)DZ>S4M07$N?PG-P(9GAJS!?SS]
M3!>.[?Y2ND$%=1'V/&E$E@G@EM^6U>&#F?+>_&8H2NV?VX6RY3Q<5&@L%:33
MF#W6SILEV L5TPW(G.^7O!8K189@F/WRR)J_%'!J2];;SZ[,\O&0HSK"?(TF
MF?0L[^@XRA75WD?+R?LCV)X891BX&U__*?:))\J](CI$/%<XT,#NP;4(HW'4
M&/6%&=(G!Q3C*?&T.=& B2 JV5M'R/3:N_R86<'>KA7N%6S)>,6*@['ER4J>
MV;OTV%?K!+Y*JRZ_D,&)I>7E07WOOC-V7PAJC_<[@3:;;=\4.7D'G\%S=LWH
M,"*KB1A^!W/4)VB6I"FU4O:,VE2V8CF;*,H0*4AS/QO_TGLGTDE),O2[:_XU
M+]Y(&;.MX4:6IMD):-$1S$7R/^C3P/!;K':6$[3UB9(X%?FFSH:Y38#ID'7N
M;5-F1R.;:*D8;R9S<$8"$V^ +M".YXI$: >K3>@$+<E1TG-B8Y0_@>$JO\#F
M'>3>V/=[17N.[SHU<5#S#3LEM4G?EG3A&(J[D-(49N+W/V2N#_N#/G3P7<:$
M[Y9O2O[-LK.X5^02>RJQZYF.D-/Z3)2K(T!;I\$#+:3JMU1'Y&ER*6JKO5?#
M/?V0;<>RC<2F72#/C1$98C,0<C#47P/5;D8ND;C*V*E 9FO<U185W<Q7_A3=
MQ9!'"G;)1V<&Q,8IF6"$@J@/1Z!S+26%P[(9J$\IUDXG>@6H=(04V6QW6D^K
M3S?5D_4BN$S*-XJA5PGSE&,PJ:F"2&\34#0;<5FS$ Q'=DK'K# G)*BYV +B
MY)J_SVN63?_H8ANC*=FT:P*?X8Z*FX(*9 ]:0()H_'3 4+!=0;/$_N+9@T2-
MUY )ZV6QOK:0Y?BID#\\<!U=#SEF@F3<GNV#E]3(V=;@:HB>)EP"+LY2$"6
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M/@?I]_?%U]XW<LS0IWSB+T!O8U%G,W2[B'#O^BO5M%B4?8_<DT,X;S&5(IU
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M>ARG3\G7JEMU 459AE.P@R$VVE_EF^K>MF^5D/CK\\E3H06\/%.A<:\X"XL
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M"$TG!"M' 1[[?[]LOI%/\7_/#?$2S^VP;!AOV;DDEL@P0S<"I4'9;(]JSVE
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MKXAY5E2(5_6,[<;"\9QZ^APV&;37)'='>+^6U!+Z#%8-]O 9_0GMI63)P3I
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ML)*I%P]XO7T+#W^EXBC:9/3_SL,G2?5K^/J;IGO%5 5SMMI("PA.+TP?OH/
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M-<\H8_6^D\"]MVXPBM0&"\G+*S53;92S-Z(8/MI]^E5$O=8'BN\@>U*3R=!
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MB3M^"(F',,#+WS&-6A*&P0SN%@]<$ZT@,DB(0\6DNI<J9UDKG*&H/II?DCY
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M[\&;#1*3P99.-Z"CN-1C??&#OZQ? 1E*2ZM5'YZ&FKS_,]+8Y$L7%3#"8/P
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MQ_4E$08 _TIB* A#<>#SC*?LB5;Z^(;W,Z[!#,CTOX]N6!'YM<FAVKU7_2$
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M"]X?V5I'6MNR/+IY0BU<)Q0K_\)"8SPI]P!8*TK'#C3\0/YAF6S)9O0]_2U
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MOC=])E %COIV(J.;1\#'P6U<ZP8!(K93LNNNR-'<\M:7JE 3PTE69W'[Z5M
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M),CRD< D.!LSS&-0%EU@\*C @.RA<4KV=3'=A'X6I.7RV#/9LAREZ;4U)DK
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MA^AB8!9RGIV9C@1_<6)_99Q5Z/C,5%T^!W]7!I5,^S3&N'5.B9/1]))4]'R
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M]%52MV"&3NCZU!M!B2,1ZYYY%&K=A;I/74CH:LI$F(<<U)=C'R(N@?XKV(#
M>ADA9\5!8:AI[RT8B"\\A.<JW3YJ%?QX!(\]BC%A\S/9=Z]IX]J!-S6.HF*#
M['%LKJ(:$P,3K;"#]>]^B<,XW[@P53I$Z>/?5D4H;52IRFR/O8U,IQ/$F:@H
M,US*F;-N 8X[UHB=-9$I#!;RFTWC<57D^% Y"$Y;E!_C6_=.JG1:</3F%WHX
MF P:L]8>A8"ZF$_Y7-X"PHM)R$#-4][*^98Z:^^#T&AWTJ&9&)^ +5/G-%>O
MUUR+$5+&W!8J*!>BOB_6X2SX!*L,P9$?[%=#Y V?71[WD<EL>%AP)E9!WM&<
M9>PTY+PR'TWRRH?H78CHD!RF!/-J253TB(5@1O!J<)EZB,UP^51QOC$I)!XK
M]_[EC(!C(3.6I'OJ$QPM29H-,_(2^7ON\(K3\K1'\Y;62FR%^K+AB9+V]1,6
M!U7&,NV6<2GF7U(Q*2+IWB6&V=P*1L;2T:)AP"Y)SXPSB^%,4)'$XF&XW:>2
M8[$>1%\E%W'U<**,DH;"Z 3DKY7X']<Y">H&^1FG"]K[UHU>/\X4L&-!'P+6
MX16!;E]N 5T#,Z)##\>OJ,GX%KIE%1O./0[?O?4P-3]/0-T"'H-'"G=GENFH
M/2U KR; [53CR)A"Z/(+)D'O@==-K&*H>5%SR9LG[XPW<NGD_>3ZSF%0R%_#
M<**73:T8OPA!M_GEF64YJ#EZ*T"&,U6)4>-C]L\#HP< G+O678V0=K_9/]N)
M)AX> S>6EFF<@N7I9VH#S8H.Y%!+G%Z3B)""3XA//I#AW$<U@B $\$6AQ'E.
MJ1A0;C^C]L?)YI/$$#+% 70;?"UQ/*U+D2ZS1W@WC5X8\RM49;,]0J"5OC44
M6\GR9%['CZ07:2L# '\?_VP[0/N&_)?5TV.K"G0:,LTH03VJ?#V5UD#CQ^\1
MJOKO>VP2@Y,"^?';@HN"OFN1;WQ&^$B\C":]K]V!U2W4]0JL#;7UT^LG=LF+
M2L4K:HCY?.2'+T.++PRI-BX*F648YQQMPH?JS'UL]*5;GVE(1\IHQ-K0GAH@
M:!%=&K.!0P?(^7%)3QL1\;>-I2DV-/J"R07^O>TNB$J0QGG<1MM"F]#BX9.9
M=DJPJ,K[8JQB[_Q9F9-4IIT3.I=B)W'[A?>PDL 5O4"H29KN0M9(@N02>[JQ
MI%-L2H4[0(LL*M"K(E#C^/O)6"%6-[C+!0TJ.0@;:)Z*FU?) U.G@M 4;<LE
MKM3+/]2CWW@/1\ZEO(JSDMYXG/B-]RLQX@D^[@, J4C6ZP\N&@(NAA$J+9@-
M*07MA(!2<Q<I7P3Q/=!P"Y&_ZQO\WI_6PKW.21;-WQXH0$@6FNX3R<+_"S7?
M'@_EOZX]?D@1RC''42K)J1Q2:*82DN24B)A*8DA3(9/&C$/.IZ(H8BJ$G,J9
MQ@QF4*F48XYC9BIRR/,4X\D<O-/:ZUU[[_5;Z[?>M=?>G_=]__C^X_/A>]_W
M==_7?5WSS,.ZT,]3VCI-V2AT!P.H+3B>=^R8K[9C54*QZ(*]:ZKVZV!21FJ?
MQ_,/;]#'JTL3J"[NH6\8<<76NXO,1CAF=[6+REP^96:^L-U3/NI7/#R#EZP!
M0REIZ32XPJLJ#RAA]L>8M-!HC1W!A./E96F6BKN_)4<EJ[XYU5*AUG"-S6'Q
M1KCLHI[I$=!\!@&W7H7==.E@/X<:J#*W6E=A?@%SWT\/'SN6<9/4NV354MU8
M?TIE[O4MG4S-W1CSZ8-J)^*$HS>E/:KYF#)%P80/- _6>5; K=Y7ZI\C'@5X
M';R)NT%;-S^I-<O]F7T2>#O@@TZ\4[I5;%M\N.N/ /<Y*2.)1.K9K_;,;6DQ
MCX[O=I#[_-:[-N3N#-.5=?+*\HSI0K!7C4=32N#9*TYEHJJ'3P<X7DYIN)EM
M&',)I1I2&Q98.CX326B_!VBI"F:P"YS:V[:W=U&?XM(JUK?O:SQWE\9'W,FV
M3US=P<Z(55AM2'X7@,CG3@(RLSD/1K83&:\N*7MI'NM?6,JU<XL3^[ZD=G3$
MW*[AA[O">>R6 P_S5<*.XO,J9CR,PVO-?%]&F;3LM)<]D= FDAA<_,HB[*#,
M&>'.D_X^%S07SI1.,FN+'YS=?)_Q/*N4D_*H]^3).M]#(9GV5MN<=F8X#>59
MO=(;7\Q"$ >!QG<G^G>=*&T.&#D1,G,(DWU^],[IRBK?*LL!LC*4[ )0J(2D
MYLI,O4+3I(G?8MZT]!GS3H[9Z)==_[*FIG^RJ?;"V<AJ8ZM;*8^<C4[G%X-N
M'2MU=[_D1=QXV!U8,FI2QZ0R#-:=LM-UYBW9Y089JMR[EW_RR'8;R^CRM1WG
M(<]?G\]<]"A75FV^7#]XML'KZ-")7EV3,O-'Y_B^S:_\2JR,K3*<>VDOGS(2
M1",G%ZMQ9\!(7QV_R2[7D]:^@$'<X8RR NU=L<]E/-Y8=*K$5*<6"&^=>I(5
M%)^%RCY[-I=E")U]]O&G@\31![R,NSC[HZ_U/Z!?XY8_3\Q/NPUI]U//ENAV
M5LK.?*_2[HU3>V?HGO2C;,>/$I,=K^RUK5?,RR08NY",4UR?W9&5S6%1AP_K
MSZVS.-H$2\E\T?AJZ]27[158Q$I/9[,N2H)D%2J?4FHR0*=B9.ACCU/A'B]L
MM-I'4D=OP:GXG=A!N^O5K\Z6-#?]YF;I?26H<N9:^+6&(L\W,E3:H8Y0K,+(
MN(+_XENK)9W#L4YRAT7'WDSN?%H8&"D&\SU[A)I2N>:W)>=".>UII_;FQ<X/
M+S64V_>-*\MT/Y![RMCE[M%H<7';#98V\^G3ZM*=-_KO7,H;\[R9?=QEKT])
M^Q.95SV22^% 9ZG6VY/$AJL->E5X;[>UH_=/7>U\[\9&I9XT;?9^/IEGZE*=
MZ]!?CMB$1?0X/B/R@O+&-M)UV;W/A,YG*$D8W(O<>OOZL<9MJ;YH,;[N5&I/
M,0TC_/TZ\KLPN [Q('3I$R>X$XJAK:S"DA;TZJ1E C(#E6,KB>@BJXC+"9DF
M=Y.J1VB<O0CG&NG=9+^M-:HY%5(-I9[^S?'Q9QX\N5LZ<]*LHU]BO?[6_L6/
MA=&]U[=>(6T9Z;80D:K8<B7J-G9N2%*W:U^GTQU>G*8.C>'?KJ?M_43A@8](
MUBI,(ETW#',W\)$K>,\M[>V5C2YWE1=]#F5D?,DK.BX^. BF&[1TA]1/VQ3F
M>8^X5/K[N,9-62HL?Y]I-AQ/-+Z"?)DMZS6ZTW;]]8^5\M&DV/5)M LMG@*/
MNJ&2&U3E/Z$"]L37&JA2F9*'NNSX'^QWCMJ#M3:.34D?)X9G/72O??>:&,&8
MYGL7B+2'1MLT9W_6\T8_PL9[ 1W?9SRDJH*+O)DG_.HW4P\B)#QZ5).WW5TJ
M@5TPSPUSO!+5J*V&6X4ID"X&?7M<0SSXH>A%0];$@BM CS/6D_7*UVZSO3-3
M/UAZ0^F66F_=B\*TPDC'![%WONS%&0\HWF?N./O4YWE=P!G?=:YMKBD#.B=*
MC[L57#=F/A 0*<6VE7EY$4T.J.-E:V8/C%Z2I&/\M%[GIF5_)G?[I(';<]>D
M,@TV3+.7)2(P3V:5T^YE%_A$-*OHE&HD,9(,,B;.;7E >Q<O\FW]*44_]R&]
MJHL6DA$B?.\7C#PS+_5O;Q_R7B7;]:_"ZD+V']07<K<JK<WWKV1B<DRK=Q=L
M9U<:+^V]6'FUX);<!J/8B\W9$;U[KX6AU<;O+;0B6]-;IS2GKP8O(>J^1%RW
M&F ;GF"89>2<>%S25N<1BGYU\.KWQGZG4L7S_;TE+5_NMX+&GZ9VAC2=W=?T
MO;&.75F9XU&V-7?H\+)Y =/_4Q]>8]S+[@LVM\N4S3;= XY:[&&S96:NSIH-
MS.Z25$6;C+>0=L7>#5/=>=E=75$RTGW/Y!Z9 T+M(;<OPWY2S[-2/F3V[ _G
M\/S+ \_=#0_1KF\JN6'WEA)^O+QI9@^_+\^FQS3LK<'U\1GYW89/<^Z.1ESX
M-#]T3:#+@W^9@5W_'WB!6W_T>%-8S&D5)G!A[Y4I./Z&5=@K TAP\SF_^%78
M8A\:U8(5(;*K-ASMN<O0/K5((*5[I?>1=CG,#M<$VMPLJ*PGD/+?YDMP@O;"
M18?=U;IH*YO>K5-ZTU6B 2.E3"E-^@ELUU8IP[VS&6)+^ZJF;3H1HD!7>DCZ
M'%(>W?T4G8]SVS+\.6=#3:M[UQ:2M%Q2-XDWJ*2JFC+5+3;7!%A28GRTFOB]
M Q&<B!KX5,X*90/.J =;A4A#1W6=*7%,DS*6VUET_-+CC/"N8?NKHU5[9GTF
MF)5275/#119X%7D[J5*&O&C/]E48-F^4'2"Y=X33LO0<BKH]@]QM;5/"[<!/
M$JCZ.$'6CPP-N$H!%.Y]VU78>L'%_)LO5V& [U/"=S_"*NRD#H/"7 ,Z\-97
MT[GK"-]CII!,%3_"HDG;*FRR>!7VNH>V/MWI9Y+A?ILO.LO"?*7@R7C>NMN$
MR6[75=@G@?_GESO_Y2*DX"(B]SY$6/I9P-<(DQ.4OEMO%=::O0K;(0W%#=-Y
MDI<)D/8J['L!**S9CS^7\NM/\P2B)^XT)(#OT'D49#A ^&F8#OGV1,,7MUNM
MPF+TW%9AF>:$E1\VW /?!+_[*,MS%19EP'>$@Y(UE!7E24$V+JNPSS8,_J^\
ME=0+?LAS"+_+%;,*\T83&-F(M83W]Q7YZ^M0_&-<PLJ8H$4VF"<1IGT%3#LI
M\-IWQ+B6%Q?X<8U(KB#^GTX0X0]*:L,UG&J37I'=L@IKRRH3=%B>P-F[_Z/<
M!1;_CY+/_-]%%@34?>+7XWX!6U>]A8/"V&)^W"D,7X3R\P"!MD=0_.G &,'-
M#JNPN\2$7XG+G0]/?^/V3>ROP[KSUX&/KL*&<I!,L2M_ 3YR%980) C__9#8
M*BR:N K;B93^+@!]Q\LE^+VJ,>F_1F3'?XX[ CG[ USA7/EG0(KZ"T@4 4:"
MROC"@6ZB"'+Z6/(J;(U'U2IL>]@J;.E<.A0U)OAE2]T&P3BCN __JD/3J=R_
MWZ&O'?X<N,VOP%U^?8]"FD\Q)M DF<05)5\*)".(2DC0 Z._7DRN%#"'*))_
M$J_QJY!.OY!'-?XN**>_COM/S>4O**!:!W+1L)L ;!.$)<S?7/_K;?'3<+XX
M@5O"1?XJ9,$OX"F7D?^Y#PO^*NB>KE5818< \,:_#S@\_N=? )]?A?T9<<U?
MB)?^[T8L^NO>,J*LPLKD_E'R\$]_D/S?FW;,'W1\S1].NY$ UBICXI\O2O]U
MD0#6[=<$T'_Y1]#_$3F]1OYKTTY?A?U5JH*?#"2A?L=-J["5Y_\:.3$$X_@E
M_>]V:M5_M5/_5,/?\<D[.I_TX1\5XH\V"23XLXU_W;2O_PDZ$=#/7R?[IRK:
M_6ZR?JVH'?_GDR48Q#^##A> [B  ';G"[?UW(/_"VP<F_@ MOS]DJ7];)<C_
M?(]@!&?_)8HF"AK?,^EWQ/"O;)(_3_OO<_]7.S7[]]#_!PGQ.^AU_GB3_-MN
M_]W&HDG] 4F=^ .2*N;A\4C4I1U_0U7\U_?(GY3.[XC?]U_B:*) B*)R?L<G
MO]I=Y>^V>_D?+9)_Z\*_L:_^ZQ+G3[->^.^U) AJB?S+(OECC/Z0F_Z\VO]&
M\O^]L_[/2IV_Q4V"#OT=-?G^@VG_#]C_O6G_G3;Y/UHES#5_1$Z_"%,;^?O"
M_$/"C]ZGN6GJLO.I ^<V#L?9P?84O[&=! JV,BDXLG0>78*L_FP:I_)P8Z>A
MU-W :+%'JDDLP2WXM8OJZ^.57IVD]#]0/0\+&Y=9LRE:2"C.:-9[M'!Z4'G[
MW>+IYHOV:_**A@\6#Q_P*MPU,FJ].1II>.A=^]X!)SN9RP7Y.HM5ZTF(MXU&
M*CG,8%5K]>8NQU@S?'N5F7/RBTOJ[U237ET<GZBW&032Q5E[;\BFT<X]-P8-
MY _)9=<$61V5O0JI:KXN[YT-N[9L(C".O!1.J\!;PA[?)TDUB?4I(88E,HQ&
MM]R]9W!!2ZF]5*O2?+TT+0D6*@_/N3_ZPV\OIR*%M??=+H=+ZZ8T2SIL#_SZ
M4NK_*V>MM"H(?;B=T=+:,QFN#$B/& ZQ/B^WHS;:<?8$\.7ZR+N_8GPJL!Y=
MG=1N(#VQ,^]RY@1DZ='_J"\T<'S-*.W:1%"*V4!];FCHV:NWC\B?0]_#F7(4
M\2.K,!6$&?=P/63%XMU@;Q["N4TBUUGCC=$H88I_ZHTNNAS)A#F.:)<T=[$E
M21A0@R2HU<.C4-N%#R3[ZX^P92Z])--PWVK.X4PKU>-"*Z]0>_A]J-IE*GTX
MF$'*WP^.#]1FKW0E&/<(<?<!!/838E' *FPC?QN495,'9$<;F[=X> 89CK!.
MD4YF<-S[]<_T6I@_'IEIYM<$"SK%ZR7E\,B;OL[S0:07HA_#)$FJLD,:&:2G
M,C#SRP?WJF\'W&)P?F=R,"DX;4:5PM=GIR/JU9 =RNJY3(FUEVA7:?J/:P:"
M+LTS&S?:&WN'7"DGGZ[>/E_9&HG'""1Z S&%K&L_6;4&_\Y,JY68C))U:",H
M<M'0\Y)AG.- )4(.NH 4QM;QX8*0UW.UF"UPJEMS<0+N[ U6682#U?.!)36=
M(Q\NUHZKHS9,6)IDE152D?)%A+;C=115W'Y0<5X3X#"L4Y%SW4 Y3K4&:KC!
M1,FB/G+=E:LZ]'3:PCLI\"@+I$_1:2S!L1[R]&7-KP\4.S50GMMIJK!2[JU(
MT%=16I(NS.6O&^;H#D/(=KXH$'\S="$N''63";+ST"4X73"N!>#0PHOC$-J!
M&5 \4SK:PI8I+>GE/H/8 H0EU5F*##5O+[ARN=[V;+'5$]OB+O1:[Y@3O%CD
MA0J[#F5]$EEZ8%%/ZU@\H]\LGDJ0Q&;3S.#M!&73-FB.";F&LGKBKRDZ88,[
M&E#2!7VU-(#;7%'X\O;7<.> C72K)^[;GHF@X+@(CC5.9^ BSO5Q $%,G[]I
MAKB!K(K=V7>XWT*'=8I[8[VZ*2B5R$C.+0TM@\MZ3F/T*KX5A950:X[$[9TK
MB%.Z/R5S;!7FOSY2:-]>)43Q4"G?;Q:UA3_LP]?#1 _I)2(07"$WJN'UI%68
M/&Y/Q8NSJ"PKI"&PZ[*-_-(X3,[)ZG_NN*BQ@[0VZ2IF1MN^=/7>G751ZL@F
MK0?,QPU-<9-VGWKD^,=Z1)YHG\M\??^W&JK6G3<R[M3*:7I@Y(G;<2*1[G]B
MGZ0*BXFCI+2OJDZ;KY]Z_?"$\+816_6]!:FP<V_>7.DYYBB:HUWR>KJRZ)27
MZ]T[<2=/PJ++UZTO5(U>)W)UG=P,3$!D@E/V-EC$T')])E5N2/3FQE>Z@5L[
M][^@.=64O78+__:=*C_6)'SYH82<L_Z1J?Y5&/)AU_M/:9\&/)-+@C8^:6J,
M&YDP7%\S9B>W@:8ZGWKJ4_OG>VGEI%M&+^6$+B7%*B6?S;4PW20>_#VO'''Q
MKLB&UQ\U\DDG^F%.5G+_\0BE,R7U3"HD/#[D![XX,6B<9WDT8\'AWBA]U*;$
MP_["\IXPB1_4T(N9M8/?*[WW.9T2.B/$+>/=)XMQW>$R?+F/V!=,U%QJ%6X/
M[]9H)WD-X$N?6_()(<KC@I@J%*E56/N>$9M.G1NY3;4$V+A_CM3#_,U@STW<
MOBME=DR"BET!E//-2_G=@/$RSQ5<D[]2'UN!=J*?_HIYBO:(>Y"3E[G3&UT1
M@=8KH=3Z;3[YY4TW^YY2@I/N4=M6$^XTOG5/OD3?*BQ0S9P1@E19A9V5B(5.
M,8DRV!@J68V72]8*\-:$:D"?3@0<0OH!/AT>78E<^>V916B^0A.YOB:WDRY[
MOGF(Y%LZP]=/&]0)S*JNS6=K2$_SZ3S'O3N/2VBKG#H^P,B$5#:]_K3T<C)R
MFY_5NR\PH0R' X9B6@\_I5&\[Y<$N5W<68 6;LZ:BLJPY+9FO1H9*VF=/",%
M9^IUI0:1E)CFE'@[QETP->].@_)N\(X'KR?>XN7YU&^C+M5 7<L7RE71G&-Z
M0;7=Z$O?]$7.R;^Y(T37*8"]?OWZNNB1,^'?U[Z<[1I*>Y+[A>8@E>(:_6##
MF_*/F\X8.GX7&D\)Z\##L2Y\\5/@ DT@O!";N%;IC&+J?D5'T*_#(=5;$2JH
M,(U%HN$RD!\;!U11);=(.E WXBX"V7$(.(I[&+K"6H7!T<M[PMO])W3Z:M]*
M''R_H%OUS<2N;3LXEZ_-HUB@BSVXMM"CR051[CZP:^XK('P"LF(0DR?V]G+/
M"L1.NPN3TY.4KPXH)EZR< 4<[-./-[T/=5@#.5A!=QG=T 70NA@3P9SV6-EO
M>,2O&E4;&>' N?!*"4)--D@5V70M#$-9/9N0\B1#L?W\F-MC;D.N/S]S?+QQ
MY[VT#M;S6R$L7E4ZC0X[3JP@;IA]#C6?LJ$1Q5^)C_MW'<FUCU&^OVML+2:/
M>!QQ3N/^&R=^W'LA*SG'_];C?0KL[@J/;U^()FY";/^Z)\LLK@R89831I-6^
M9BD31];D1I0(F#R<DG"Q? E>;2L_]/'2I9!IQ@N.\7,'=ECFJ]M;1ZC]L_'0
M_<G]!LQL*B$!OCZT.W=VORS3-)KD-FE_X8==QHY0<WNMCA6%1PR>]=3Q+*;$
MO2V4Z!ZG',]]6@WY<DU'1MQ]4XPO"D&Q@ %??#,''Z"L-2<,4M@9T$:.$>3)
M#N:1+0X"W8S!]$?<'2"1%A3((K1+JW+/ 9(+R7PXE-SA@DU[+2T*);<W?RDH
MH'^<"9>*%3$;BM6K\]HZ/K-2F(-_TLMN( (N#BF[^.]KN/"; C5K2#^0SBP!
M?OM)!)Q1ZP^"(5^EF=< SE&Z>#9C%-7%:H/=,HT2_=F2[.Y4S&MZ)2O=<($7
M@]CD /BP#2%5OA9(X6ZA/UM.P8M"=,:U0H/%CJ$ZGMND="P&MYEAAU$>6X7Y
M1F3\>OF]]D5G1*AQ]WY])O/SX:P&A3S>:X?A,C:N$33@;G=#"2'6.C '!P2>
M0".SXRI.&S"'[B^!NYJ5%]ASS2HSJ)'VV9!V7J4'=!3'"/O"[1>"0B<=$HBB
M C6<0ZFOXLK[=7H;@LLT VG^&Z(8Q9<P',-ZUU0(+3 ):7Q-JB\K'0X160;L
M?L3Z&*9T8FA442#9;% W!"XYC5?MK;QH/!R:G+K]]=J*BO&3.PG/%;ER!I,Z
M7,P0"<TYR.]'2I%<.&[XCTCQ.H-D;Q7(=9(^(L;H241(XM_!UUD(EZ)'_-H7
MA@VH:?G[4%(.X*QKO2"M;>K( ?N' R0_E@VH>^[[*-5;I<\2__(@1Y4K, AQ
M"1"#8SVK\!UJ0 E<&D!G2+>OPE0A@PZVLF(" IXJ-DDN9;;XM0]E*4L]*GS3
MY9KM"/KV+U?/*)H.3OBFY9JTE!MYE,?'Q_#7?>#H?%V%U2X+W$M A33#+9)K
MSL*(X+2&^++3^<KO^>I<BSZ+C7+*J[#DD/1-E-3.NX&,O=\F07YN1('E$S1"
MLZY?(Z?+DCQ0KF#J97U-8Q.J&CX/R]_'BUDT2+OF2$<UQ%L(@\)N.7IAM!QX
M4IV7C2-@0=[R0N=&%73#&Y3*W97CN>F#Y4RP5YMZ?]/&9[]15,E"?"KQ-Y(-
M9R-.CD>F!-)3X9L$Z'J@"<\QJ7P+W&F(,+F0C)(CRZ/-&CHPB?Q]0P(Y(1 F
M 0.AQ'B^&?"NJ QZ.FLSF,GHS'[XKJ*8ZH,N]OPZ2;IUF/B!'HN7Q;JU$<3G
MR3*/QP/RY>*IS938;PJ09]V71T6!VN$-H+>*^0ULI5:^RJN'!FJDH!TC7J=^
M(G,$'G:2F+\3G.+*-C"*Y[9QW"9F5N!Q9"F<59^%^5Y ,6DQU;F/E=UF$(U2
M. ^ZM;4@.QHP3\9;XN-(80POK38 =P"HMO2MW#KB.Y'3G%HK4W-,2.#-VE01
M:R#69-6< ; *<X1R(UA1S%58FO*00/[XM]A0U<W H63NC>M -I4N;R);Q36'
M['TJH8730Q:'LNC2^%]?Q] K"-CM'6#TFJ_E17#,">ICX+="M@(KG@OZ)2*#
MB#'TFK!$BV"..-<;F.KL2>;K0P9H!GW8DRG6Z:" <X<LR]#*\"23%JT.=5W0
M+X6D5<C5$C!T'$'\]#1"%R/BY>%0,!M^]U8?"M70NW !^<'WVWW?TJ]AX8A'
M@:*=>27NI]'9]8?EZ_,[9\;G+^D=?63M[MMPF[DS]FC!V2,:RMP$2.!?12Y!
M7D!!!P56IX(<\6$_!5%4AV%+YG.HF&.$$P'=4DC26NW$FRY[4IEY,*SSZU$K
M**( *N@(%ZW/9+X]VGVL">Q*M+"I^GK9(AE=%A-ZS0]6P3'"#PJD?<\\.FB2
M,F+#,&CM&7XZRM8#IVCV8=0)14%)4Q":6#Z531S$*T!AG<I=T=\0)GN*T$5>
MN-U]H@/\Y.M57XD2&+WS@UH?!G=L _=7/@K>X!"'6P?VL3^#\+EE01E;!RF!
MHU7#?:STUE589'C5?.IDA2GC7:Q!IX/$;.8$UGQR*@YG4XPS[C7A>+G9-/>2
MQ>D0P3FGR[GI67\!%"^68%#G6289=&Y/==57MV@!\=PEBT!H$-%'HZQ?A:%1
M(]V,J=99A\1F8B>6XD-?BW.M_4#PNX?0G%7F\G7ZO_0QG@/]<)D0HM ,8EM3
MTV 560Y-1C9 5Z[<",,ZQ U*9$=709G\=:' @@<8-I]>BB:H\I%8-T;Q?-=D
M3T*.06=Z9+AI D[3M!U+UL Y -YY@LITH%1PFN@RR, )1$2!RK/4\./YI3)0
MQE0[<N3DJU([1BE&V79,>(H>"P><U)"3\;%D':P1RR:2JP=T,59AK?2/BI/2
M\Q$<\^+84(>-,[.LA:CF=*J7*75""[#TAO(Y3@,&)+])>#)[#Q[65^A9EF=#
M4W9+L5"\CLN860Y^=05TZ^B!] VZD''J>S'1?*-L]F9(#!QBF+8;W/0VY3VT
MV,^QG$76RE?>9Q(2D0K<S8JT6F@?L(^LA/7L<$$/DD6 M$=%TWPM*)4U.IIK
M2PHL>87Q863WZF$NG>.%0)\%7=?"RT/Z[T7ZW$-H.+ \HSB*I['.<-&6K*:@
M /PVR*4]G!"W)9ZQW&FB'*B5@I,NF\V7 +*332+62VQZ FK%A\Q;KXG\^7PW
MN,!?U\U82(8K<JW 64;Z_&:.+?\54HZ_95H=#F1WJF'85T&WF[4MIBRQ>)Q6
M4' @HP.LBK<@3!+5L1$63@R>V<SLD0\D N.M.77"L.9#ZI.L$5I]O<*5=J$^
M?">\MJJ#,B+@>2G>HRV =(R%)$>7>PI2 ::Z"))ZF"6DO&E7A!'S27%)X&6N
M,^"7;JQF<^09T ZY4#,_>HQ #J@/XP9+'Z8"9(8]/1PPJH1T.N!,_&C3BI+$
M28)]S,-T600"=XI71;A4-9)]'$)S-G_-HL/)>W%FP%1[CSSWBKWB04%/Q-<2
M1"$M)B*;P;-L1XD8[]?L1"J:Z#G_L$Y3TKOHV[NT:7-MK!V_C[N5EX_8SMW+
M*Q3TDPT)ZF919+BR33PB7QRG#@4!!;2)72W@MKST))PP,J$0C._0.S&!KO\A
M*+&G[W7&./+DH!6_Z'K5F/M,<_UCW<^-T>)S9 W^ZWQQZ#[G*&X-[PG.LQ*;
M[31$N; @Q3W:A]^$57OR#/.;.T1DYL41'PN\KPD[9P77'-N36HXS0E]G5$G1
MJ266:]*+ L-'J(%;1U+2'L+O9Q%4*!CI=?P^Q,Y56/1E_DOU];P\KE,!_S6A
M.GN.PM(ACJBPR\"NCCP;QZ$J$EHZS6+'BE9BB(-HQ7*"A9W P'MQD1&7X++Z
MQ3Y2R<H!/LX- Y4F]HB]^+U0'0>%[T76]G0AH:U3*7Q9[B; +0X9Z"#*[Q7L
M9$?Z< TSK)V8@-I@<A,RFB0F$<7)&VTG%Q(1>BV@:=Q\3X+%=6"6"GH4IY*,
M"MW1S[#QKHK-EU*6S2Z4^N[_P!%<SI7U9&EUID/:8O,Z'(>O1'6^*?\U7PTD
MSK$X>W&Z4!#HP\9"B0QSATV!R]Z2@_AM 4@YBVW,A=^P/>WJ1L!XY^W? KT5
M&M^'OG6Q#+(YWJ_50@+&>7G=$_)+R(V"U:.$O/""'K\*JY&.(DF LNPH"%G"
M?T76%C@C+48#C1Z/VMC;QR37@/&L/?>"2!@0PU1,J7NKXIG;B3<8#$5C+ Z6
M6Y6.J E[O^@W,!X/M"&_+[37WR4M#B*Y\HKLNY"T6.<J+ I>JS7' :@T8GU8
M-"F(LPM2G+P;WY:NA,V@LF] ('(^G?DVK!6UUF26Y]F9%0P-,>ZFQW)M&02Y
M4=RQWKH;$>'?5/34]2RI5^E/2B\^6^1K0T6<P[CCH&(''=J^S)53;"4*A_#"
MV'=YM\DF."L(";JPSX**Z:BVE?KLR6V]%@:L!8G <#CM" O$Q'*#@843("4&
MY\2@*PS3$;>9F\ZG3L;;]1LGZA''%PV@K<0Y@:EN1Z7BA2 JBYXJT$>*M/01
MV=. =!)^.[\/)<.]KM;0Q0:1[1)U%$B['"O1H2[Q@6M0@--?A<4:E10$T*46
M%X0@@E7OXMMS/T[V5UU<DLA#N022+?EJRRQX)%^:]QB_!X>$FD J^SVOR>(4
M!X$=FBQNH\#Q Z@-N"T:P+68\I:.B=3)!<E1K&=[OCA@$$,RG- C'@.1J4OW
M<$C3)-R)',D['D^*KP4%!46*]:* 8PM)@M*P.,+XEW"!S0[;7L"25L ) 2+Y
M>@-^&CUE$/'(ATF _Z+LM?R]=:%>=D<;^Y]L3OBA?T\U$Q4Z])98K=B:#!^.
M8?OPB*LPOUSSNG[BY%"[@2@.01ZX?<K-;8!D7G!J.+"Y.?X(\4)5I4U)@'^G
M"5IT\ ML:>5XY*]7(O[CL<AD(5-QBI,]\>J:+5 4<R])DS%^802^QK:R.:!<
MSP2C\MK"Z+&-:HYK1<><\^D LZ)"I_&#&SE;JW6K+8X^.<P5"*#H<!QFP"$-
MH8P3:8*6.')<QSJ@.,I$6FHM7YK?LPI3(2OB[ :"N+N+:A7"V"L-2>LGI&KO
M>!3*8#/&ORG;'[7*8;[:DO-YD.))WH.]P.I 2I \BVU V2ZBN$6>F?TY@CK7
M-$(..W2@[GWWS%#--!VX-9VOV8O[>J8Z8YU/D/*,;<67G+T*^SXEG> ^X*4@
MM+B'^LFZV"VK,*8!C3@RZM1G$<3D>;;CA8%X6E4R7!2A 7FB@,HZP.@8]&&R
M2AW+[!(T-DFQQ-]CHHK!^=GZBV.YMI5HLD*_3W7\R8$Z[4M;-T3BZ6VI]\7=
MMOKMF_IT0-HB#2:R@133%=R%.P1(98):[>%5-TU2[3J43;+*V-9!GFUXK4&<
M&C,(P6QGJQWJ73@"JD>%^3[]VK#;ZZ#L?;UO\A>L_+5LSX2EOMAA>MWG2H\6
M^I66_][3F:\T+A]WWV-:2H5M?;D$SX/ASIK.;0:\2.8E$)Y*0ZDL*G%MR['I
M7N!R$FD_2&4BTED.B<M\G=[:MV(>F$3$MIHA&4['!]O'_LW6F6?5'Q[Y4&X\
M:Q>QZ:/NJ3V^O&C"!8-YHG2 ,B&J:E%-ELI&2>L^@6XP%N0AH@UTEOD<2),(
MQ,0V>%L DOFE\'A2T(W)'>7EBM1E;\U:RFUD32T#AXE-+4F>\WH='.<2E?ER
M\GQ*/E;II-+76Q&2^I];+Z:HGOETYEOGF'K\ODU=IU-"'TK?IEQ\.2!8#D;[
MKM+A@J;]D3TEN0J3<*.ZGUDCMZL'KF_TSE"HJK+L$V%T;SIT$K'N4S#G +ZG
M-;A?X!S6QPJ/9<#4>HZN,'_7O?^=1S/#Y.XUQ+7\AS*F4K&VJO-G+A_0-+:"
MW]F$"1L;3;RZ[A5,_8"JC(3/PW<#0H=*,I+^_"%@$DQ;R7(]_'3:E1@^0?@]
M:&<%,^I6>G=\<JWDS3&C+L>6>.'12G3'0>?BO9KH3S$I/B5M8FIM8HU%CR-U
MNB[=#AKI^?[@N[7*IXTI)4)7-[J&P39-9MA>V-XAYRCD=.]6QI%WMI>N4.5W
M'F%%'_R4<C[28=^;.XXB5VC/(Q4?2*UKT\AWCTE)G<I2Z@P7<OX;GY6>PV8Q
M5WJHS4L3V<7Z5:4CTR-YG;F%+T2\W!SC7J-U:P?/E?]&'RL_F7+T&:UKY[CT
MCV*!&.,U [%3\_=+N/:0K6 /:#&RJ7#9[40 XPX:>RM RVAF(QXI'?,!YPHM
MET R!HG*G_BB@&)[5;SRC#]19*&<NV^2MXUDR;QQZE$U*,].#Y(BPA=MF-VC
MN082V#1VEV/?8FYWD-C)QN<#H>A',79]55OZOFVMH?3[-6$K'E;7-V[HN;+M
MS2W:L\(X&U<E9!2EVJ9](1$OQ6OD*WL&$.7)!A"'%I[=7@M] +?\Z%B%U;_+
M!6W:,K"!@D4F)4M5U_[ A$0#F:,=]AZ$M,%E;QW +1&GP]B$4)_.E^C/=8AW
M3_KV>M0N07A%JGX5YOIJ;/3>D3%<K_;(% PF=2+Z(>SF127Q=>!"6O@JC&8@
M@3,$LY/(2FV,%W19K,^1%E#6'4JG3AB KBW\U(>CW@$>=?F9C![ATY[83$]0
M;R#OQ0A$.-9W2;*#__2#1Z'>UML5-U1%4PB[NK14SVS,W[569"=O0$Q+7,I]
M@T,.UQ%R>,1U!QC E[I*:(H:K>?<?>K9$%D=ZO$&X$G&%38.=POK\ZE>P.?/
M>;V/3FV-8PZRYO>$.;[8.CBW0_C[+$-L?H%S$'<-0+;?,!#H!&F^6 !<-70A
M&B\0YW@=M%EZ G_S-$6:)/D0TNIR\Q:+9\@WCWW5[!C!=):&-JD<!EO26L[D
M$*@5/O;]FP?*ZQ*(QQ2SC 6*AI# #9V$R^ %!EB*K("-H%QPB'7&P9]!#8I)
M2V^/]K%$OY2"/D> N)KRGDFU/>T3!$G[L\#K(:94I#YK* R9_B7^5#RUP>.J
MY_!I.B^PA-"&1%Z8I:_'AE%/-INF+*[C(I%IA<1.;R4HD:4FP31(/@,5APFH
MH6,_LBO?_/E )LW;\!F43@@,+,%62UYE?ZY<F-?#5&Q]_J(^VG^I#O/1CGUQ
M@.3V&%O WU"6NGW4.KEUW95)!^G9D2_Q0$V',TXK;BU"\30TQ2 32RP9*,4Q
M[&_FYFNY>U?>WF2NK6W9HE/4;*_EH-"J[L0YX\T-47:+FT]+!!KX\J>@64#-
M>-Q[E(;03N^Z.D9,F)"_@:KS+SZ<3OTJ'JBMJX@_^8SI9=[=V'#DR_:]!.O
M3ZA1O:,X?>!0#>8LR&'C11,D&@6N?Q 8/"XF_+6G22MS:>!_]KG(/WEP3IP0
M2)I&E\$+-\3C=@./6:R*1.@V0#D)#K7=,VD1ML(D"H G(5DZDIX=_(V-+\ +
M1478"]][O_4J9,P>':R3B#!U;:@/VC/])C,BQ^$=?!C.]@6SHRG^"^)0NHU
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M#JS"!&*L1\:*HS)-J4$F6$@70(-4=BKO\3Q>QY^_)YO=V%_W0J4D*/_UJ.V
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M&3_50J88+*R_D@S^76 NS"UKU6P</IQ;?N*02I.9QR>HM/N4 *%DLYY 5BL
M8_1]J-?*P)RF&Z_RT#!"=?Z]>[[(U/1*8B!6=:2U15>YW.31!5U=DZU)3<V_
M>_BZH?6I<L#F&DVDD"8Z?W@,-8:JZ.@* -[MF,^+E \F;W#9C?.&NQO?(-XG
MNGSM_VO?*9';UWYYH(PE>10JMH*3!"H=Z"K'KK)@_$+S:P2<(MU&[M!=I[]E
M=&AT3UM^;DR;SSB8+M*MXRAR\^$TD-BY_$5J:8OY9BBA5\7JRGB*O-C #\C?
M-%I&,N Z4PI7UU2REW7(+I<L5I#W"3A(?RT]Z?*YJ;TZ.BCK[2KZ)(0_P$.6
M5IJBC8[W8!ECN,XK.ZVW<U "C;N8TNT3#&&?H(^!@8;*96XK1+=EAXF[K'ZG
M<N3;'7ZXF(OH/E8@IANEOGDPU2S)RQE+^,8AF7#=_-<UE=Z_MT?<3SUS _?!
M^5<]>(]A3J&/I-&Y3XA#LE)E^%<40T5S'Y(R$\@S9G:UKB\B"(N=DPZU'/?^
MROZ556F;-$B(=IJ5'6[ "P%1[K0?+0_A6C#^95))7"6)0_[%C%]D1\H^ZN-#
M^6>9OM]VLP3_DXO+O#/3JL/+\@'<@YDB[/8?5D*@".4N!Q0+@*5AJ7@,1 GU
MS4,&(%=]IX5V2L#C"@]S&>C0*@#" 9$,&*!SN;<,2PSVN3QNP?((6@%QP46(
M';5VV2I_D::,%4$3N3,V??@71R#QAM0(,BSF"!2 3LOG@SY GQRB0:G@M'R*
M66PXC!W0.>B'GM%2%_&=P''3'(HI-FS&-0B'U4#U3E%1IAQMLR=0__<FY-RJ
MNGS#L'_]"JMUUBYK)XJ%EM6#Y@*BNB"<PX%:8&[ \=IPNW:!WV[BELMRG@1Q
MHR&0L^^/E.0@?GU&@SCQE2.<X\%G)T][/_'DC/$9OUW1VB+=)H>L1P2M"$7A
M\7;=TUG\4CWZ*E]6,_Y[DF9_POR'CL8P.SEP:,.,<@1*=(E8?S>/)8E2@^H/
M=)?_,LZ/[6!(TWTXT$3U\8>7WX5O4)EEHSFFX0214/I<HIH*-A B:D'%GUR3
M/@^\*D$@&U0IJ:XW,=U7W4UK5W1Q0OD-DQN:%4@CND(R1!/I#;RC15%+8R'L
M2'FZSWHBC?H?$4^6:CXL;[>B&'GU9M_7WTO"G;$IT";T8@2 Q3^#W1+@)*;T
MU4P;VGZ/:X:;A,?SK%NKQ^9YY 9"MVNW&74.G]R#DDG:Z]M/RZ\ 2I97'E]
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MK-GM)C/&1A4D"Y6?6IR]J-=/><1[]8ILF9S7E2%AU7,L\:>_&)EA)\>BPCZ
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M?(*]$)%HA=OW@41RP)>^IO369Q->:9;=),_,11)/.I9TPE E!W^MR"'\G&N
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M)JD["WLB))]$I)[T&[A*"MW9U0V WFC-(XUK;IE.AE@9/,L=DI7:%6H\ I'
MY ?O/@9(I&)2M:Q,=PDW<6T-G^(7_DUF77(U?.G:=U#X=_"BO91T!R\/DI]F
MO)M.EV_N&ZS$B\/\!@H01R 'FXV]5PY<5M)_9K]-^V5,_PHZR:9#FW:U:D/D
M/'Y<,NRX<"4V5<.M68^,;.-/*QQZ^T!;3UH"SF\#:'X4FWA_^U:'Q86"S8*E
M*&= +Y_O][_'7F_(I;?M_;TJ]/UOU15;B_ZVCL0_^5YIL,+[8"(+ZLK?/_X#
M+;MSJ#GT"%&:P#Z93\=J-@%X6NM]%1R4%G(RL,@2ZS><VWGB<=%H_V\+N=B&
MV"&]+Q*V#"L@7*F20,6?K/M\\C1=+35SZ"9KI)@@@<W'\!ZNXP%"CK2_R$[)
MZDOIMLNL"U2P1I3=4/NN?.-RE(%SX7)'A[A[?Y5J)5!82IW[MGFQYK)A^'RY
MFYE,"E)5]CU9T(/X+HU%@5-=LY,M_RJ'=HBZ$,(_>M;F18-BTTG5A=7]J WN
M1UP/6Q_ZL(MWRO'Q!.ZL:Y*J1'.J8P*.6_ T:@+CLHT[ @$*-A;_VT?'*;'*
M3^,BHM& PVMI+Q$=-$"8_9=YN\6N2S*!G-V@ON[ZQ_WJ$>C/=_'5*_UB2PJE
M9;*G:JY4". /3%2A*XO'[FJERMYGK^R?SK9HTT=BH^X1"*[^=W+!5_!E\-#P
M]AYU/]3#CE[I.FX(I0WV9R\F(_91Y26^NJ(ZHOX5_5QQV7,"=RL7XF9C8RXK
M4J\0BJK'>+:*DFSL_I:!N$,GFVQ*;6&74&-'($&&*AF:D(U_OF/P3GZRW:?8
M;6IY0J>L[FN73VSTMX-W(I+WNV#::1.O'L=F_ZVO&N7*_.WT#24K'M_MN7*1
ML*9]O]1*;U:-EC+6DN%GHO!X?>/C]]1>LB]9V:$RL?3&I>?YFMD.R#K;@]_W
MFR:Q]CN\^1?3OXX,_,N;%97;4WF6N,R.RFVU_Y9FM(_6_XN-SX,,X\X"CM:3
M#"/]H?OT'+]77YPWU -!28M$!&$F_?R'A<N\Q>XH![;]LP\WYN\OT0@ W;TE
M.A)1)2(I:,QO*9Q0?3WUAO9RR<?;@L4<_7YZ.BV%\FJ.#[ ^M34B'2JF$JF1
MFG;%M]]+^8@B!JZ8?H>4;Z.K";8FPJ2P_]O)10J*"8>=6ID5F,3TJJ*OT^9B
ML0W3N9+NXX86U4Z("(NT(5<+K0RV_?["X(#  -7Y;/.SD$B];'.B89L:6N4(
MY V;*C6FP0G*/$%'H-U%(.K@JB_DM&\)8$S+Z69* SX%B/KK.<: GQ<-8XZC
MYW60H8)KK5DI08;G:'@;C/%S/Q(X/E#]3U%^KSXC=#90>=^;GD->>@911&K2
MT3$X62"T:U:>%E]9 -,I]*1NL)K3H7&JV;.B+<WC.X%<'LTMQ$VO$34!(W>1
MU?,"KI>6Z5><1>E>N_\=9AH:T JI9NL)B+DZ]O5W!QK@^#QQ^EZ\H3K]V!W:
M)!KR5P.QN]4VP@C1V\I>M+4;M*'X;1C_"E.&;AWGI]"'%9U%+#Y1TRI75=52
MY7-S'0Q&GV7?K'+B>&K*<H45N*9'LC;_,O2091ATTJBVL8Y%TOI:_VF"<=ZE
MJ*64\#+5Q,LO[YQSO"L4*:61'MR0Z<!]W5L0XJ1G['"1=1%SG)Q9&6;T'C.(
M%!%U"2@E.[R*+EQK94]\& 8[S;A"C\M_L9W/1Y)/V0@])I!NE'PS<:?M]/BD
MQ?AV>GIGQN"97E%^C7Z\#@G=I0L17-&_+\U&FTQCRBW#6+7/0.</L7TR,3#X
ML+8,F&'? H@7(7R,:=+E%)C :J1AGA;QP;@6FAWA,DKA:4[8<8=,$D1<M*N+
MMR^;^AR8K4#&5NTC__Q@GX7V[:P,N?CYTIQ>=QKF06AG3]C4/&+9Z0,A7QUX
MO4>JTIS%(#Z$S:<LB;>,P8 +4_QL7'37-5*QF9B8F%WG_A^<V6%]\'$2Z>ER
M#<8 ON"GXOWZQRY\DC:Q3L6%YOW[\01;PT%P 2FU8V,)DH^;9<M5,=9/96PQ
M-LYG.DFL/-\&TQ"==V$*S5\D<#<./T)4 Y@G:)@TN9%B)WAU.(87B#+%_>>H
MPU.U8LJD4!P#F?<3%UH_W+^@<S8EP^-!:/:M@;IO0=Z)B[M.-[5=MFRM?@PG
M9_C)S>9N>(=-FU,)5%]O0,54DV^AW+98KYG'G8+U#E@K]'!_&-7<\T^\73_=
M2O9+CRO]?-#C!RA#J\K7#@I0)9JP*<A-'<2Y.4@GP-S0.]]1]YA?YZ3;G3 U
M"+M>'8@JO5<1+EU=5/.J:*!JM:E9-&M2%164IWC>O$KA\\OOPGV=J?=>95^X
M:PV>ZB' !,)5CT _YT[O&)A_S;^PU@<Y.[+]_'&_ET_]Z)P]+C4D9%#.=_44
MIR ,VB/E_B:8URKV^R6,C-UTU'\4&E"!R7[_S_V7[^>0C:__FB(+OPW\98CX
M99)K&XS:J8ZYBE'Z&8N/\F7K4W7%G:O'9O?7PJ+N/H#@;WW8CX8.%**,;.;9
M@4,#%'(R2;648.3&HE,\#^7LO77*U5(UH->15N\3G+:X&\"E]QC->^!VV9 J
MU ]X4I5W>2C@%&G-EMO6@"$TH!#A<N*2N?N$3I;NV9.=\D%<M8."&<^V93PJ
MU:/ SWKMX?^6)&Q'IOW3UNQKDCTPV/*=I+H),?W19.#^$J?57KN/O%S&IG!)
MQ3YLZGXK'_:=UJONI^___4CZP*L!4P(Q.(8>.@I6(V_33CT=DJZF0GFG!B32
M:6>LB:[%K/BIN^FN*;']<_)O=^W<OLFP0F0^/QBOTD8+W.Q9S.KS.#<9/DR(
MAWYNQ^L<@2[_:ZI2ZHAG%R8M,T_1TE[<\3OF?F:F+$MA^NB-VB039)IQ\:>W
M$'8UHN"TT9J\(<7A=^&;^9K-];5[]+>K1/<"ZO4XH=G=C+KQ,$?UM*RI0HMP
M^-QOAXY?]R8U5PJC]Z7. 72R8J>$2"Y57;@M6!*(ZB)MS#0\S].,#O;Q\A8S
M1&Y>N<I+,?\ _*4XE*211+L#3=GNW;"DX/E\21I:09?;C>^1.@C&&4*O^LYV
M.?0XUO^SG.(#7TV0@;59W;6W)HKZ&E)_@[BE#7@C46=6?S__ID38:TDO5/S<
MIR1TYU[.FW7LCQV/3:O O\&%'D4%%90WC<VU)>4W-EP=#HO'\P8\=A]#N9A&
M4T M1 U1RW#V'0EP22N9M#7C+@GPJ4^7#*MU5XIZ)9HOW![BZJ+B^]7A>J_Z
MVT['%72/JCIU'-NS>?KZ[%F:R4O,]4_\I  /J8F@1DO?YU=-X!'Z 3IK<B.]
MLKS3(:ZQ:8WC2$=B6"5>!"G3TCH:=E"9"<0&!BGD37#<OPQ-:/SWC:4X-=F4
M:"R%LX# W@F%GIP3>HA;D_+O<A*,J;AT*J28A?WL=O_E58X^5%2/%.<63H[R
MZT=)^%L+:JU0X>#U:A>AT=?GG+\&WR!6M+R^3VG<\TCZ\L\M.;[\]U0-/#53
M5^1W<N65LOYB\Y*9DH69JD7L8)2JU_?[A^,+_*Z,R#NL!Z'DL/9: <N/0#J[
M809&3=7ESJT.%EX+5CGN>7-/8)=%U@&XL\#]G#E OQYO]#A3(E:8#<WG<#9$
M:++62TQJS[#,*"0JKY,Z+<0;/)D'F9?!!ND=!FRKK[<&((/@%UJKN@MN1V]\
M;8C&E#B)R65-A(K"&W<&IFO:V]O"FP/!HG# 5P79#./H&HJ"BGC)[#$.[/[+
M;SC_R*P[(.V@B^[=!)V:^NWV9V>N19_JV4_=0#DQW1-*H(<>L4DZ_'LVI<VR
MRU EN)K-PP=^[+-. Q;H><-J][VFV/UL%X)D*KR^:F-/_[&AW89,@YCX@6[W
M8X)G.*5QJ,DJL3_2AYW]O?1KM!]JV*@=2L,?R[(,__ZQ^K ]/GRRBPWX.5OX
M%TJVJ.TP6T3A\MJ)SJ&POY>_H6G'$+!5 JVP8<;088 V>JN>BDT[YA2"*I2L
MGE(#W\9R_+RNXID6L,D5X-+87QGHHSIFZ]X0/+/2Y&UL<A:FH?#XJON[JUU8
M#/Y^H"5%@:% PN7,Y\QHG,9J64[M>%;WE*U*^+]UN=#<?LEYYJKCK6P+3KGT
MM]^ZY.4^/=;>_UOF/#U+&O)YPN;HL'?+$JXE>-Y"J-;\%/#;@L7!C*ITC6U'
M^._F^@H9#U[&B=*U)S#%4Z1?'LBK])G<WJ;ADYFN@;I]$JG%Q6U?UMW)=8G<
MM_I39.UO\]_A9.Q!YAG6ZJF? _2=\[3G/R$BMWH5[RDIC>6)?Y5JD!*ZC<A*
M*U9T$0@D>RE;7/WWGG .FS2T]>U^J(K;N81NBF!"8_KBF\W[5+&^OXIRVSA,
M5&40Y@32;OSZL6]%>HY5RWIW-=.RXAA&A1=GF/6Z^BGZ,P3V<^:^/T^<_O?L
M^S0Z!B7V;OH@RIE.2%QX)69UV$+9<-Y8$G?OJ]I>45'A$WPI:_[ZY#U0%];+
MI/.6Z >I5W$*8@JLI=)+H]FOU3B6MD"1H027@^6%EI#7T=7<UAJVD?;]%*5[
MVM/ORL<<\;"0'WMU/_<1Y$M_%._8"%$;:M7LO45+*M\5X6F"/[0V8X] W&$%
MJ3[S^6"55X<#I:/5FS[7>4/J9XM[*Z:6SG4-Z7V/^.2WZU K)S(QW"7D+RQP
M>H*O0O\B/UOG[LJ&XT6L::8@EQEP)5(+WV5]>6/JB?IGDM#%47S],?LX(#^E
M!.',4_Y[&AO[*IW7.B1$<_+,H2*R<7NH9>G?$2B?<"'?)(CH/V0_;?_O"O-!
MI57#M@7J.?=3=LY+IZ[,\YJ-BG]'1/3)$U)1I]3,P70!NL70M]#Y30$!S;G?
MMFF?6?/>_%G@M1"G2D4^J MJZ(#L+G;_V>J7S$E5VZC9'BA];B$?-]JY.V14
M+W##?)<X"'[[^6ZZ?A!G7T"R9,+^!KBBLEABS-]@]H>6/[$\H&V6.50)=Y]Z
MXV_=J'B[(Z>2\_TT-*18/Q4YKM,:Y/?B57#<00LHSWS(+3HZ<K23]4-Q09N;
MG5]#CN4;F*O:!&E.UK[ PC=SL(#S8D&RVN ?V *+B9"M]U3T(..IDIYCY"6]
MY4@IG]^R,M46-U\*%(&LS1="'-G/U;YJ8^,UP'B\?B^4X7!C]<:N^[U)^&6C
MO*R1E;EB_+'AX_Z-Q:D?@43F4CP4DV,L3ACI]AS<^?OR:I>1GIY1P,PM).Y]
M7JY&9)X9,G]I,OO;Z'8.C\IL+N0KE\X8O&0,GMI^3S,"K5\P%''9PSO/.TW[
MB:N:@S;;RP\\]BNC9Q KLY^W]BVYX@H3;!MG_%.+ ]V=!V&Z/YKK'Z^FE(W<
M\?OL2QU2-+FP(:QH[>"R][+-;"7M5Z17VB_JV@^_$FVC$-3G8_V(%OY)%?<?
MW:!;H%<TDQ@\F3EH6/071M'"_/V]SJ'1*RN3F-O1GW N?PD*Y52CCH[:[;4A
MK7W%LJ+TIN2 %H/H+739GR-0)?H5^.7;?J>4);:%D- 4+[$AZ-?7_;$I/H;>
M+;)RC\"V75= N^5^51S3ZZ9H HW9J*U5>B$]4&ZR3;3B]</)MM:V "NV:?_O
M%_)2G5VWEI&R!W<8IT<-O;$(XSZ'[-?9'O75:ZW@9VICG:/3YMD=OVJG_-5_
MUUF<['L[!PK_DJTG>]TLLV4_AXSI"90DYS_7RN?PB]N4_90XN[B[(M3Q>^9;
MO&M+DG=[ 5&P[NR-@KOW7V5_ 9J+5_73D5")H-R(,DF9I#RN<?5,XDP-3TV^
M5W#8GFXSB_USAZ;IPB<^2#F8L@C[J8YG9JPI@@/SO#9N5'PU,L_QI3<")4M1
M^2'&:=M'D<W 5GV-R[$;#+ 46/YA:XLBU:70U7(B*@HJ0@:*$)_=*M5[%A&_
MPB7X][\C;MM5K*PVEBU\5#@CB991R5W'!JRYKNN\DYON#65V4[=.8#Y-'8&&
M&J![&^CN:EO8G;);%O*F;S+G6DN.0%=T@;R>Y](U_&WC!Y6,I)+^;SN-S0JU
MEWJ=P%=O"";9?'(Z?C2W^1 XQI/$RC"[72WTTG=UAK#E$>@-NQPT'0IP'H'.
ME_Y402_]F&8RS(Y O6,VQ7YI$9#\^]^',QN?)1*L7330+L,%&"\S)O)_FP?=
MP?^[U?%>FA:[DP);?#?DSQ0;;DQ5ODV$APTJJNP82.9P%8D,*P9$E66+7V_.
MVFHB&+A6?&(+49X_ L7(U#O$?6"XT*LW%@OV^Q)Z9AR^#EF,_E$A:K7E.XX4
MC)]OZW@0$>_=&$,/]+(5!ZN<?W VQ7$Y[.W%SO?<TC;_-HGM,/+OZEXT'U/7
M4KM]Q#B"DL]C5%37NR+\[1( O=$<T?SX5EW?F=Z0[N_B]RWLAW.[XI UT3U3
M#WQR'OU0X'_VT:&&_<Q;ZUQ89?^-=&=[/^+K7WYE?<9"'QTR<BRGY0I^*WQA
M('L4.RGT=P\NX"1R+3QK!18ZM,8<Y4IRZAI;B#/PP(<D(U8FWQ#'T-]?B(#K
M[W8+$G(L1A=>@CX$JDPLY):F7=D^40!/F#T9\HW)2VO3] G5B2T6F%I+#]0(
MG;O0^OO/Y92PO2,0="(79J'">\KJJY.44-'&$TOVV/<Y=8ZOB^/>%ZV_F7Z=
M_VY5!2(]NR&!;'Z\)QJQ@'.\H@<18>B^X0Y!"':KI*:4TW8S?IR6+?Y@R =V
M*53O&HJS \D!T60!H87 X8:%)29KD"8P66Q[>VN]97F+P;73Y2G#7&/M)N=M
M*T*=3/+\CL,]@OST^30V)DSLP\,,-I$ .*_-[?-/^Y_6_GYQRVDKM,];MU/]
M.<__EGWF*I*]K-H*;?R/G/AC ?%'>.39@L:GNY'\'ETF-KL/7$?5N\SP%T3!
M7/NM8>7-?X-F!$3':/AM'N,CT$EC!D8L8Q<%W.CY32OH-5UOU\>U<,U7GN R
M*:ODBP@;$/_7^C2 #"=-SVM/)I2.MKO/YPILP;E=_6S@V-.;ZN%Z85E-+[]F
M1<C>:FUID0@?NZ[LGIFB\XM5N086?&@3E']X-TK&(]^%#L<PD)) 8O.A#T,V
M0D[X8%[E4_HU&1W0 /4#VRXVB_)#X*OFMRR9V/+K8CY0;P67.%V)5[L1_K_J
M_/HG%Y&M\&BPNNZ7NO5!UA<]X\4WDM[HN11?N?A=6UPKP\K=P&5ZK:0<]AU]
M?RY!^BP035OU15JQ.OOKSV)#JW(5WU_Z]*P@AF2X<:]<GGA=+?NL=9^2&/LL
M^WCMTN\CD-$UPO+).Z,C+OW?XMRTJ]M$2+P4SVOI42\UV'^/:D>;$D]ISEV9
M#QYE4*NC6D2<XP?J4GB=8W-OO.SQI(V-K>K\EK=^<T5/-R!J0-=[SKA9N7-T
ML.[7A5,Y(:4)A3?X,H#W7J>W6OP/_V#_3($+DI2G#+J3+GXX<7R 58&Y>0P/
MPP(PH$,[4>JTF:$40TT*]@208S;1KNQ=/KL\F7>^KI48]#Q;NZ2R9 @>7?IK
ME4VU0?3QJ-S+P?/X;Q\JT1 TS7HF=/[^7,-Q])IUHJ>2R:5Q3&' JT=?9OU?
M =)16AX8HN"3)-"$MZC3U^@&U(@$AG8H=:H&J>HSCXF/#,2]H>7T-V<^=H&_
MV#0,EI]I?+/]V _M"=YFI6M2T=WHV,(>8\I<+_P40Z>17O/94)?L;M,?^1V?
MT%#M"$.@IN#%)I6KMUW]'N]M=:<%GN_H:$C?(O_G\*H]QW:5 9U@7,,"E93_
M="$B(V%S++[9^ 1YP)%ZYGR4Y$_#B)(UIL!H(UQP+=FH*NLB9( 25;DA]4OA
M)9Q2;[&83OT6<1?LT7"[]I,>FZ4"&PLF9],KG1N_EA^J-R?+UV5N7V_;6RS*
M+DY]"F+E+/Q 3>>@IKP'Z=]YS2)$\(_O.GM)_NHOI]!7:<#!3W&H.DL:"R!#
M@6V,?&08T9M[)6&  T2-+MH->Y:G1--]RC1">M=/A"FK:I()R:BSQT$%A;P)
M]"8;-!V!GL?VZTA+U])]XK7!4OXD8U<3\J&!>W,V<=(MG72H@MM_Q?WBSF7C
MJ:=LL:N:^_LI24 L!;JN.&_S8A9"Q[P(:H^B;H#)2WU8?D"V'WH&PKG\U]=B
M'I:,4@)"I9-EXG:B[ZTNF>7T9HN2"FF3\56, !_RC$?W)$$"EK#]7=/9."@+
MZ@>BHA_BDR:A]VF$GE%:)86<1*!B.RU+Z/L(ERZFU,Q;YGD$S$YG5W]Y$C+W
M_UA[[ZBFOFYM- B*!42DUZA4Z=)!("(" C]ZDQJ1#M);@$"0WD&J4J5W(KV'
M#@)"I$N0DB"])4B)$,+'^]YSOCO.N.=^][OCWC_F'WOL/?98>ZTUG_D\>\RY
MIL?S3"+R!4K.P8<ST"_MYA^S8[6ZQDW"'S!G\(+&.D$$Z[=D+3Q\!5BX\.=3
M>4DPQO;S_C71,JA,]EJ<CCW?2)V5J$7:VQ\% 3^YP*VIS&>\+ZG49DZZ+-$N
MWDOL4X=&W>W)]</.MF6+&AX^/D*_4EGI1P3B17J;C\B7@0E@BFZWI ^P9O*!
M2^M5+F045 G= 8SSVC$&4G::!<KGCNX$)(78YFLJRL?K1DT>^&@$B6Z<:1GG
MK0L]$7MQ-+#'?PH<4F#_BG.+E%-"6YC8IOZ#8X^I<C -?;GNRCYF^#6O;_VM
MQ^BHRX'MSVL$4<#]=<;:GT*O]_\K)!H4C]T!/0CFO (X0H!H,TBD,,7P:M6^
M<S_[LQDWJ*Z/1R7$6;]S]KU]2W;_U):LRX;0>,<OB?VCKW%CC7;(.?<##331
MXR-.F5V\*JXL.L_"--%,/2775L_PJ?I]0FJ2^*RVW65<N@)$RI&'09KH-^0#
MJ93)I+(2%1!BH<F8K3(UZ1N8H"[AH^0=3>)<XUYZH^6HR3/"Y9OW$58-;+#O
M=6% )V97.F$MD14[J)HE8J;$R0 _S6#9MNSX>K6O3E]QFHE]BY08:\M$OR-?
MYZ51]9TU-_= /])D_TTFMJ#;=%AP!,P.')O'-IFQAD;N:^,Z^K3I"VJ4R:."
M'_>BW6+;^5YES96_S=C#%ZF$#:1<ELX,"N%/\$7O% U)XHRUPDXQ6(<D!E #
M<NBY^+N"@P(<K,^->FDHQ.7NH]0A4Y+VY),GSYUM71&FME7KHD)T(T?5#7<R
M;62:*5>W ]VJ= :'$"9&U+FJ_$;G<VQ3:=FN4X9F:L^;#LH.;)M*TM^6HRV5
MHGMUPW)RY3@B%=)8-\>?ZB>RJ^MLNHST9YPYFG &E?SZ@_>XWG?PY5C\8+<C
M/$Z!S@Y( [,!QYN:\Q9LS"*8P1!]S%PZ<]B?;^\F)5R>F_.2+%-[&^4[O'TW
MFNSC#5M,/77N;DO2GB/X"_?76"U\;'2+76;!"?<['_N81]CA7--+31[V5,>^
MZT@3MQ'A>=*5=!(HXQ'_]:\/U)N+@7>,W]OK>?'EYM[1.;X2U]#U%SNSN,0=
M((+TK% P_=04D?_&NL*H9T0!N6O@J'_L42/A[-0,-I\T]XLD!%[S(R;3FL-P
MJ"$ZGV91A$S[RVZ['?S^E%B^F'9[FXZ((G# ZTRQ-M<^.869VYQ=M(PL("R'
M]<(XU8B.URLPP,=!'<C*KU>C7NW3E,N<9F5ZMKV7O:+)8IDN.U.EFI?PVB@R
M":57H57\,%!*>M;YSQ)]96<*2?(P>3+)$(M P0MYT8'5I\]CR$GG7FXR,2(]
MB*S7PL[I[[W3D>Z9]PKT>->U?Q"==9^)DH2'H2;O#X0$2YW]$=SX@.=5=BE+
M'\>[OM]<S1-5[]3Z]I=L\WW'K8;WPS<S7E86XM+-'QMV>(Z*[\S&Z?KFY0W^
MX;F](.$WN1D_<*E-J4^[NGG7R,N19[2$BP5U8:D&MFT[/BA#CTN9=/PXE."W
MS5OK;_\R)YY2+UHMM>OFX]!"MI9Z&M@V;\6B)$7WHW"?47KW0Z*";A]%0$0/
M2#U2AN1FV^'0G=^ITU_D[@^'J#K!LH*H,&6@ M!$J_FV7L[,+\<)S\U,R92*
M@R&^(G7!I2$^88VR6^TLBD.Z^DG"W8=J@\M"VH%==*=39]R%667NY.?4A.W9
M2L?BZ7:G[=W*X I0UY/K %M*HDRV2K,EILOPV.2K:*M<RJWGYT>W@A&%J;[&
M#0$E-K6+ 9S).2E.@@N-RQTFIF>!_&#X%F<Y^&W/(Q'KO)P'0?+=ESZC>(T^
M9EC8GIN >+_G#\M=T^4NWK:T[V.!\!VQ';\1%CJ6MV95G_^A_A#^\E90P#U-
M]8GSP)^"KONNMM-E]"V39N.T]29+C$6?%BT*G\O1_!53DHY55A$99PVA<W<B
MREY< ?).:$ISUIY.0H_G6W^GI.BI[2W-SM8$S69-+O4GR*9$O)IIDTDS-W7<
M=>0O<YG-;7:L.2#]<G[7E+>&\L9_D(C_'2/K.0:F"_[70]9OB'"]9AQAM9<F
M>"#7QY_ID_LIQ5NI]0*%!5/_B Q3^ ,^SJ38_->SEDF_<<RU4;%!U%>&V>GF
MY9[Z>7G8.\(=C[;/I"1+%";)/$5E4JB?U&=^MQ)YS6+2504OYL\K)N:C=7F?
M/AU<JOSHD;)MS\!P5CI)$^ZD/&0F3]SH-E)R9OCH1L%1K%MM/1/.HBAW7TO4
M_5GJ,)W\(T;&DK+;Y2]%DOIOE\-?%V>N?E3C3#'C3#E6'SNZ'DVYU7\6,?"O
M 2DA9@-$UEGQ)'J\O0K.-\S#A7\% K.8%)!3+7-28_Y,\= !E<-@Y(=\9/'Q
M!;;.]VVTP5<.'/Q4"+O9VQT/I%/@WLUON +T7P%0*Z=<;J$@1F'O(+/>#'IV
M/CP,RX-ICBJ12)O:0@WW)?VKM:HB]H_6O!LG(L<YRS[4&TR!#_MG.E-S1O!$
M&O4W'62J((S7'EX6P<-J'<"4P3Q+!'9<==VB!1Z&H6N):-1F'BY<-EFJ652N
M@&@,L'CO>ZEV1RCT5_QDR9;YW9!B;0NS@F2<Z4+5BJ"BEQT2;&[JV)9HT'NW
MA;*^<VL+$TC_H''^K2N W>?&_-AET*1N0<-,4V3<$(B>8()>H1C$J.W?RO?#
M=("IG MY?5';+<ZR/5LDY[I.>[BZMR]6CFS>NO F'&'OZ'SO%_QCPYK58+B?
MGGY_W?#=K[1O5.'**Z&W?NWWD!BX "( ,_MG9EM!'3HW?@<D/LL?+MM$Q>*!
MI^F7;= [6!I#/*AHJWGY+N[D<+";!K+6-X<ZJ,*%]0&I$&QXE8N>+*Z\EEHE
M#!*X8X3:R"YUTE,.="MSS!*?%/Q]]GYKS#5Z6H@J >8FS],;,)_@:H96C2&H
M8>&KB#KL='\^.U$0 AM 42Y'8%<&0;3_:K?@A+++_N*P!VLD<FXKT$U#;=$6
M^D/+3R87-5NF&FM\IXXFIHT>K/3:D>RN-'L L=50NF]K:U> O6LG"X -SF''
M@URU2$";Y\:;VOM1.*&3QB7R'ABV*IA/CA[$2B310LBR,T^O8^GF4W$<?:C0
M.$$KB>*VMA1CT$(ELJSOT8S?@4'D,_[@N"F_AH:&K0ORVO*:1UO?O?+ZG[_F
M).W84CCL\C"E*_G%SH-K^M4\I7IS]B"!*SQ14>,#?1R9%-4#GG5=H76K9 V?
M/7Y$85T>>ZY:G^>F7MC&F0TF)Z71+'9RL:'K_"/OJ)9@Z]'@\M->R1:4YI);
MNT7L]Y@EPXFUD9MUZ2A5^6A.]I\\<VG*S/N7/UD3BJ1)?P&D]_.)+?2\-;8L
M%R.J*(<<E)OR G?-V7E:V]_L32?AO>$E,S/+*X!GG9;+8JI3SBV9H6FDUCTZ
M^439LVV3+$1,J?-<C6W5MJP1W.8*L"LH$7C/0GWI$CH66%X:D98H6?]Q_H<1
MD;R$SDE/2U"*G+Z$::K"-,&0JS*EZF43\T=G,^F9.%/G IHRI,_3461A N?I
M+LA69HRXW.U2#?V, ?Z</[7!2<QDSH-N0;D*G&RS7I_ R(*J>ICKU5)>=;M@
M729BGJ5KN%%LF(N0.]:Z@A943;&+G-WW0(Y)*&"/,_.WMU--2-KM%5J")./'
M)-%^#'MJK9,PLXMAXC*ETX(O!2\@%>S\-H!J-*-+UG_#2W.82/?L4[2B9Z5)
M6$&6XM $'PA;$CDTHLS/-<;;6%C#526WF;*>DBG:8R7RIR-X^B;S3_5,OP[7
M=,C@2 OW8EA'6F[3-.;T!\CE"G#[*7$$_P'+OT99_ ;,/Z1 C9/JIPQ ,U .
ME:#E-090CSN2W]X*HI_X2?\\-&(\6. *T&L,<H*CBI0Z\(;8E@$$?=AJ>8H-
M_H,@,AQJ;;7&#Z9U4F">V[?!7N[)?IX2W_;^UOF\&J54*93I<Z_I5R2-ITTL
M2+"[S(DP>TUE4PBD>%M<'#HI5+C3'UU7X61*/B0<R:R55(5:&BM;06VSR^":
MH]#PA]LJ.[<>CEM7;)\)G\89]PGVF2#9V1_.GE-%FJNE64$6'^53_S9QE;JI
M3PV^)]MJ?J,DMDC.DHI&)8\G(]>M:@;B=V="!.+DEVO/.R%$K3J((RI_FD6_
MG[]@D1A\BV-THF(".D>G5<PD,GO;[W&C]#W*U^UFJM-\]/3MA/?&KP W2;#P
M&,1-*!^.9R@.%"/+$-<$)D>9XY/ VN'!TFW8R(X*E'@S0T!S$GPK2ZBB=-PV
M^ ?73J/"*SN[5E05/0>X3!R\*'5J,6\IWH!'KVJ8V$DG4KJ9@BDM7,%=+-?\
M75[4QH>3W$C91IKL1E_7G[Y@^A\$RH(MQ -L::IC(<2^/\NB-JE@V\@C>O^]
M^.YMCI:FIAB_A_2\1<]S%XH__QSC%\O@;HF&DJ\>T@[-+7-ADR*:+NRY\@3=
M^L\EX312;%;=]6W7*Q;WE*?\T0<PR^<-J&#"=S$*+2#WA.AW(7ZVA 'TTQ_?
MM^;*5"G!#-$5445[3NOPU)\ZN;).?+[!2 WE@?/W]/=BOD+DV)@7:L'Q51KW
M5')?#PN>.A6C;S*I&QH):4YH"7]NY3Y.;<Q6Z@2M'9+A2Y=<Y:360'=WL2,=
M-NT\T8U!)I*1?&;?&SIRS2B'1%^#GOYFWOM 1MK*>OPH7FIZ'@M/E^C^V7)J
MAJ/K[9I1((4^CSWN$%W>RJ)58&Z/J3OJE+)D=Q%U^'EL3:V4<Q0P+]G]]3I,
M+?%X+Y/CHH9AD9FO#DV@#+B.X1':FVI/6>F9B35P1T<JJX<FP^PB)1[F(F7]
M)RD&#7*CJ5TE)]6UN89L=+_*(@:G<]K,SMH<2J>@=9K%/A?04R"]R8<:VRN
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M^NP-U)4^&$D34<4\P[W&5#X36\$XTN?8Y\B7>F:3U:%90ST>UV>%^^F$_\=
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M/_Q>]#BF+K++4O)[<2AB7T/$.52"@S8+7UT\W52+K(\CA*RKRI/&DQSTY/?
MDCNBR 5'MO/NR /.\\AAPW2X#]/=KDED;9+G+3W 1%EO6^-O,^)7 %HH$&=>
M5Z86O&#OL:9-H>WQJ.=9')LLF9Q_B/[P_C5/[<L7'H0M@->THZ8$!,Z'^UN/
MJ>)E;_?J3 /QRA*W.U4IVP%3#;_POD^BRYYG/XGZ^*ZX0(Z=GW]HR#/-FI7=
M*C*#V\5,_9.<Z@S.^]U25T[IYL3Z&-WW7/2F^-/&ND]RP=0GZ5"Y.79!,U.?
MBD ??AY_"Z$W51WL#1<ZD,-KU=YMGQ\/HR;PGFYCM$D)<CA03*-*1XC%(LQA
M6]9F7K(/,UOR08A#]$EDS$:,&8? ,\LBM,7+37TL,JKI>;-19_</;[.+(>5G
M!6V=4_NU/,^^V/\L-;%(-_S$^]@S('\,O.AW>GR977L%L!5.L 1.0RT"_3&'
M#! E ZQD^JJ%ZLLYPE/,@H\P]>!EQA^%)$R-F :"V36#.R5(7R<4A6&!K"VP
MYKW_*'TN?'KSLHKP_,(4>OLKSC*SP!QB;(ZU'>\.(5B@Q^(:N\THP6K3 IUQ
M8QJ#!F*.[36IRO[VFT^0S W]8J]Q3"R+ ^Z17I&K30--]>K'7PT@>6\HC*Q,
M4T/+]!!FX67A14]E)+=G!I2H[VKQ&2Q!1BRD)@BQ<AH9[Z1K_34IABE-F]Z'
MTO2CT89M6DT"P7R(QRK9\0R-)6'>55JX^*[XPK]9YE4'MB.D\K#SX\9OWVS(
M[%E/&.4>RL*$G8*@YA9K##:UJ?4+_H+T^5Q;07&3BRTGFW\C:'4-_N?!^N'$
M'RMW,?@%+&RH^QX/O@XGMIK;DE#]9%*(R 5EPZGDK\*BS^D:YT5BION( C.-
MET9L]!?Z"=D:##],) CN2Q,"7"WM#J[O\/.GKRY3B?3!HPKB37@E;,=I%SYJ
M#8@W1G$=%-02)YBO +$(\A7+;X@G#^CP'W$LZMCA#]YNL<QY317+C7YK0\$\
ML[7PDP3U4Y:$E^='3&1JQYO[MMB6H14Z!+5D)G:#ZNZ.@CPV,Y$()!AB,R/E
MO,J=F.T_0.UKH%(XWTS,&/@6OM]PJO'RW17@GTG"B_/ GX@2EQ(G'BT$O3'2
M5L[HZ#'AUV5VMTT2 Q$)8B#>AAK@40HT2A?:P5.P1OB^%"YS+3\!2GV_IFIG
M_CP_"4I5I;8*6_C3%RS4B3U)[*J%/L/[K";<4S7LQ'&B%))<_%:_K:C_F-LU
M(0,$KYH5)(JR,-G;/_:DTV!-KE2[^SRWU>C=!/EWM;RJ1=<C Y$A!1VQ')(0
ME?V*9!9W\G<)7]Y2_Q$3%DJ9HW\WLBG[6O"MXVJH1D4??>+RK5;OZ#$.0%7G
M'EGH;U[N$,%)\&>&%:P^D-3$#*^MU8I7PXGV8X#Q_VY61.>,W33'4?4!*78"
MW.*(-TU1*Y"YH\T!Q!/\AS*\T-KKMOI9\>P$DCV?Q4L-P\#?+19"3._RQ(^[
MF8E+B!M8AGB)%<I=XEU\&I$!'U@)E<>N#%/%MOMF?[& 4*VZQ2OPF&YELM-C
M6Q+<C,TU-0P[%#&"=V&T3L'WIR3&@7T9LL0$_RK+Q<4E@2^D39<-W;\_X?F)
M8__.9;\"5)GU2YQT!7L2?ZXP0V7G$"QX"^$H(F=+M/AAX@J)*] <>%_N#8(\
M]?IA:BA_E70+KCK #.^),1%D^M+RP748Y?/"N\?(A0C>FOV__1?Q_ZNQDRBD
MZ<Y] .%A+[_&/N--IDG1?GOK-6L\Y6*T@1%G3C@IP*YZ6I);<?';;W;84+[Z
MW(5^)C[+]\AHX?XD^&[3V:1@L*(RK?Z_TCU(2KSR7O.PQMM8[]PFA%0.4?\A
MX:A<#25Y=+0P82 TY15J3+FE;%8$.&&J<*[L%EU<]I@?KR(^C>S@-SF$#!E;
MJJN5[ 2[PGH-%&X[@AA!UE> Z/EY*:, .SBV?1+!NRU;,YZE]IB=K@&1<J&>
MLO[ 7,FY?+O%[RN]WK?43W;I=X=>QQ'OY%YP[ZS4V_>PU/ ,R@[EUD(Z,%I=
M;FNYOIJ/2U,UO[:T3PFXB =QHQQ#F[YG2(HD*:#IK#+\&?LHWM(<S^_[H]VH
M\6NG-OCMU4/R;6/FS5BH/K9_\)S^0Q%*W-&G8J<],<G+S=:>5$/@F4#J/SM?
M1IYPB[5BNJZ5NNA/O'8_O;&[FIN/([KK[MS&'?7,EO:F:<%'6;=XO^?9T*A,
MOJ;[#!V0YJFX )]T2Y?U&. EI1=MZ5H32]W Y&,,3PU*/I0P4QJX:*1;<_%5
M"GHN"Z>7'71_-)=(GUD#G61 # 6"67@CJ8TZ8H/G?!PURU5_N>TDZ+OL+)ZE
M3N;^\YZ)E/3CQ.U33IAZD*CXFTG#%P![@-=,ZCS/_%P^F,FF4;.QV77>N:,Y
M\UBAEO57\J::=H;<J)2'7GV[\=S(?E#@-4(J_L^JG4\$7:QJ-"%H-=>L+^\:
MNC#(<.;3HE.C!GS8:J V!1B?JGPDA&G-N7;/?F4<0]2&U.3 W)F&?^&O1XE^
MD-#O'!\5K+"@/8^U&BI,4G]W3/Y#D/,5("F?E0&=?A8M :. 2 TS2_76\/?S
MUT#"^F7SPS=FW;)[0910L1IS;=OB709,+X-A+&/IY^(4F0_/\CMXO]Q^>Y_F
MX0V@QX367CQEJXQ,W[Z>>YNM=4M./@C7TG=( GV%P.85K+G=VD+P=6&!T8]Q
MX##7ID##5MA]?.B-*O:JLF<9(!Z=%W'KWPW[*BL>QSPZEZ E^=NT1O631G<>
M*HBCZ6,F'P11H!S!M(AG!!=\%^83@I- CA4>XG41(DH*YAB?LM-J/]RA%X5X
MZ6#K3;7$7=[)U-; 'U[8515;JKJ0.7X $FCT-::.GQ(9M_*9.WWS 01[1VPX
MU!GO6+-MJAHCIXH#&>(%"_!F+R8EWA"Y+,T7=Q ,"F+3<E1H?F T%K5UGC[4
M85W$51OGARYMS3,!Z?)^H;IFH^]U^:#\6-F1.C"1X6R/R/3.GI><( BCI--!
M1K[](BQ PFD/F)]/_]].S/I?6E&*(N/(]HB\)SGI(X#7'SKR4I)?$-H3SI#7
MO0=4UC\27WQ#*GWXB P F/+^UPJT_]?&Q_7YC3TCHW4*I"]9Z@;)7S4>LK5'
M-/'Z_3=>]WYCFKA/Q<G^FC62C'J>47Z+9.8:KB2&7C BY0*!X#]_$Y^&2SZ+
M)_EY#1/S*UD9L>+MOAU:.Y?RLL(&M7='ED<OP<8N\.T?3IL.R-V3LO\&^N@V
MK@ /.OVJ\/PO6V?%A0&0*HSO5PE*D-:U'/WP&[OC[*>W\AT;<R!$,(3CW5Y.
M-5Z\",5<Z,\V:?!+/_8Q]+=];#;%_YLJZ0I0OPO5PI8-LKB%Y4E> 2(=\!VX
M *3Z#X(M;K=G^?ZD#RPZ*RGB>*3(K(92V U%U3 "*U/),D2T40Z8(F)<Q.=-
MQ9M1:?1G'P'^EIE7@)L,6*HX[QIV[2CP/80@0077@"*8S,C98QOZLMS"N7'V
M_37\J^"X#2S/P*7Q0$!IR1HEJ,\TO2DJ;G\#>QB.Q@9W833@0'!Q'5Y/4+DP
M!X7D(=!&K>9.\<3(/2O$GPT!;S768;OD8+@+Y<EC!R(+5+P3/VA=[!1\ZRM.
MCAD>[8UD6/[G-.\1]@I X#I$PRF==:$@V:6HZXL2F3QIZ27@*2G..$*<*FH;
MN[CF$M6GS8X71N?'!-_XA2]"S_=V4SHB:.:";SJ?#U@^:<$.=H<TN3@;A*GB
M8%$$)<JYCF+H"PO+,^-\BUF?CLO@>8N6V8UX@Y8K0*@]7OCEI) " X0< XJ'
M,EU(X@<5&#1Q?JLQD]X6)L0G.[ [C2N4CLS*.Y"C+<K /M6AN>7[V)EKZ:39
MV FF6=Q.';$Y9SUOVDLDV0(WDP_>"])0GT:P.@;?Q+? \:G]0/K@^Y!*XN8+
M/!@S#GZ1J8I%)G1*8!)<C_HMZ[YF:G1+9HFJ(RF;QNJ754X_BPX_ EN"FE9"
M%!]!09=?M.XP 4F"N=^NKG'(WI:65QQ^@B@)?R<BHJ+!^D 14/?H[>6O&[=N
MT7KKW.)3!_Q5NP(X(TD('<% X@\E(9(K0-P]'$]$[\B[<^:0HH3O=S@21;3$
MKO7*HAG:M<*KZN<VD0I_Z!]88,F=7[VX2+B+3Q+(LCC.\%@N*?EI047]W64]
MTJ(X/P/2SF\3Y"<>Q[S^29A"Y0VW;X5UQJ/*<M*,=W20D2VJ&*@@%KK,A@,.
M:=,)M14YR[H-P(!F^.Q7F:\[I=2<71S1053]?Q8LO]?+=U@,!I8BTR+BG6H>
MK@6L MS[3SNQ=ZX93!_B\LM?P!\L#<;2GPU70)U?P/$C"XQW1E[?FU2X_-*-
M[8-J7 '6*8/TBD5#Q4))F':3 DP!?XV)S']Z0,?:W0["!)'\AU> OTJJ!(G-
M$-A6?O /,-Y*@>L*<!2)J"P,43"\=I).+-4ES2'JWA6 @F>@FZ@S>06@]%\%
MGO.L-#(0&;5C8(0">&7Y%ZIT&!HN1WH%>'5Q&GH%Z+^#$[X"I$DD5!$7@7>/
M[T'@)]UW"#Y3>[:(QFF.O+-5[8%HZTS=&5=,_?3>Y.*KD;R#'0P_Y(&033)U
MK\0I&R1J&$:RT_U0#EBV):M247H=XNV3@H'X^IT_!EEO]CFFY3@PX\(#IFG^
M<?<SJ6Q+OS4?O$ZP>?=]IXH+X)Z/G<\C.<3^'P.Y]^^!B,/Z+2'DQ)BS_9O7
MWT2#N49=7N>=#T\DEVJCW&^Z]QR0N=YT][^I^%;%4X95OYQT_;^;2."_WGL%
M* RZ4(2AP_'7$##*?%X9^_]Y2J?-3KNPM_^UI-V77Z*^M_U[$_(7/&)O?P (
MR/MBSR1G/)O.6DPF\S8[6F>Q>;6N!["ZFAHBULN3!?A[%WDZCS?VKW3*8FL)
M1SRWV&46\'VX<PX%W@CFE)C+IB^CK=]&^CW<>O_.['\4]]U13:U?FT% >N\U
M2)>J]"81O/2+B'0B1$6%$ 'I$2)!>D=0X4J+=)$2I9=(A%!%0+J" @DB-9 H
MX%%"&.ZL-=]\,[\[:V;6]\V:/_8?9ZUSUCIGOWL_^WG.><_>'Y\7($(<=N6N
M6K$C8/]ZRU[XAS0%C:=4S(I;)MA[0C, Y7N;\FV,2WP,N.;_6V=1<#+<3G6)
MG,+XM$U$8-/Z;E(_^JQMZ^D>[Z^L)G&L7V])?N=FI;'*_)969EP-^F?WQ3"H
MI9DP'%Y4-:Z#=RUK]KT2^TQV&?Y@7J-FI6:^/RR%V'P)&5^=C(6HQ^C$+,P>
M=)]M"6*!@\5UHL&G 8'^@A)LM3=*@9I7$IXMC9R=09VE%%Z:>8Z;(/17*];K
M5=:G-XX$J(]FMC0[A(87>OX,8HR97A3[@!(C!OP]F.JHC&:&W?#DSK]1OY6/
M.=4M.QY:ZS_;&FSQPE_;+NAYBE?#SJS'8!Z(?;/2)5[Y4!'*(39_I^#=Y)UV
MX9%[DPN7Y"ZWANC,QMU<_[-L]@X\(#Z/U_H]->"F/?1_$?W_''0OS=^U?^X)
M?:1U<1CTFO'"O>>O!R^RK7.!4.CZOW,%9UBYA"@X!B70C=8[38MR='?*7Z X
M@.P@A'_C."??L%IVZ2VUIL\]@=6B/R09%EN2R='+_ Q@GF.0'S^/#/9M4.J?
M%1$J!+,S#S=9#>0*MB%^V:=MJ$%$D3[-I'EP2C.7ON?,'OFLYP-/(/V"AJI7
MI-U,9:%3VIA99 #G['S8,-/:'85[G_B2=7>$W2+:\EI_"N='S+VRY\?INS8-
M!C/W9IS-$ROSM;F"EYA(&1X([0>A>OX5$<K_-;I@+HX7P2HGOOD7E_C]0TK,
MS3A?87F'_X>$@_P3S.R["#)\+X^9ZV8 80"WI68PJ(@G%L/_XRVYF(GS]ZV'
MNQZ.,?/'(/:OLPTHO6Y^@*R(]ZV"(D2,S$\0/.< :*ZM[7ICNG U.OS#"(==
MX8C$"Y]':,G;]\X7_)[?.1@;8&G'X5J:'K+77O-R$,(ICYD_A]\)RQ"^*61V
MMXD7)$_"&8WWS!FYD5GJ::[3M$M$( PF0%.EM!%&>6SSJ,29JNF]OUM''WW^
MP)%L!^TR1!//I"DSM^=N7^Z_Q2!]_J)D\K_"1?8_0CFK80\+4WP<-ZN!S$J[
M"=^T=',SPW?L_^'5+A8@5.U_<+7\6\;)J93OLV([@29L5#I'M-U]C< [^<OZ
M?4^SE.7$<MU\/\RQL9_.,S>RS'"X'M,HKZR0 @JQD0&QR.<B-Z[EI_TAOI--
M"F+?^-U:+-SQ AGJVI0V;]=>0)JTMQVPLS/N*C3XU)#XJH3$.[H:N[DI$*H5
MQ_"C*O_0#Z4YIS,*\9B@B5'7G";#H<8!5O;3=^E,--N"R8.!'?F2^6^++A_N
M4>T%:LN#'T6QX_^A4#D#2L16BE)O-@@%>3/3G.GF0N%)0%T@2OFO67=H>S24
MEVY$S J\5&N8TUOW/.63M*W>6\64WBZ^?]U,C$7F.^NZ5?U_W(/_*?%NICO:
MTFFGWM_':\44H//=7BU8_KS,R(AJE\J@>);'YT3'89DK+$,.AP$TY6SO5@H!
M<%LI0R;MVG7.J8=% &)4"?)/(XNGVWHBD1,]1\FX'D2DB>MD-P._-8[?(N"?
M<*NVG<+UK?S0#("M!%1UE T3O527Y])PS!<ZKPU?F!G]]II$9NG3FZ]\\_GN
M+(M]TMRE#KO\^QQU#0^A[*&[P:.<;W6T!E6><HKKNS%#C=V%Y(7N2DHGLTB=
MU K,/X3JF2.LR2F&P;\[27 80'Z8F2J"IPY9?3=R]H7VO4[$8"8U_F!A0F>)
M'VFISO,'L% *C^%^1=7O TO->Z,4J7F/0U_"\SPO[&0N/U D!^X-!FUS!0V(
MO/CYNV"[J=E>2SE(6K]$#VL'.!Q>A7?R$+"L<&]CRA*9AP03\_1S5>J;GUXZ
MA4.K>B/<K.?R>[5OEX\(>"[8&WM\LGZNUMI*M<YXMYS=WJ!#-B57(+HDC*OR
M&!"JUSQ[M&WN*@BDW^=,Z5\64/[+O&] X91]UUO=D/\;*B4/.DD6+9MED%%N
M-,-)".F3[R^K7?^;V3)*)GRA2)"NGOJHX!:Z;F9V\YR6E;RKY</# )0RU33'
M%XM$]Z*E6HK!5SSD&Z?OFC*C;$IFB7)/B8]'<G1D)48*#&5]CO9NC&G%O,1
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M:PHVC;X) <=\]C8$:E:LNPV0A$,)S_@>NB$Z!<P:?E(YT+Q.A&YV(*E;)I=
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MI_/2E.M'+X).@]Y*@HP8-O[>L?JP:-EW#K]F\3^.\OS?&<OQI_\"4$L#!!0
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M<QTHH3$J[U4;144=,!D[5K?9+V&YR_<*C*%*B5!L=U5[8 :8835$E3+5<-P
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MGZM1FXK=E]<@ES=XY1%%9\8.P.'3NG_4,KRCCF\3/__!Q>5^DFRH.I5UG/0
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M;XHK;YML=_$@A>?Y00IR8D#@1[!4 &0-3U9#)0??&Q?8_37)Z>.$PSO7W4@
MKTA*#WRG;*_Z9G+6@@^WKIZW/O,%*0(&-&A=SW[F:^B#N(=4*'/B>P!"YQZ9
M$UK_/J!"2%*'S*E5  KF8#82B@;8ETY8@#:R]>5O(,V=\*"X7'D#-">U!0B@
M(K>D'9F3*@$&8L].(U>8^!FS.VQS))MS[LDN3=/5I. *!\:AKBK!'<4R1:T+
MKY+Y1JS#\QE:[H>_83<4)PV2UZ]R-%7Z2QA^F+QE7WF;?^9M\^NYPB+3&O%
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MH<M.I".Y=$@/>E7^824*U/$+9/$L31XCZO^Q]6=1Y-9 9C51P$1<37;UO@=
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MUPO&1+UCQ;3+8H]-KV9#'!K#*+-UTE_D\][XV%SN!TDIS?XLMVE8<F\&'(+
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M>%5+-^E]['N^0S<W#A_IB&:_.O%,T'YU\PRE,K:"A4<IYHM;=N^-V6T7JU.
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M@)B*-)3844@!.,91>5$3IQW2#;D3S32,73^W"O$@!#0BEQ O/F.T%X>?9*=
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M\1>-5/A^4+8K)0RSSA5XA#%(+N^4M&84\M#E642+BC4UF71_W69%F8$,)'Q
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M<]U8?L%ER>U25D;_M[<<_+T3$[[V_P]02P,$%     @ C4)H5AI<U&SFK0
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M.G[/,O,.',9V1RA9>&_\HOG;=T%!$*P9NA[AHI3^ ]=]TU\F%6?T[TX/PFZ
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M?;A*XL? Q_[1RV>"Z?.H2JM:05T]YJ"8QZ=LP( #%:K/I:A2!:&"-F'\E"*
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MZY*5ZH+G@7)@GLSKL25$X1X0(Y:9KY3B)PPUCI7\9K+VU@OX"5D1%EN#%N@
M'<?1(UGH 6R[57M$"3BNW3<HG495-?GP9W!B2/*Q5%CBY68)9_\53_U[W:VB
M0?0RP@UPCERF"L1L)VBI,J:Q@EUC1EUD'0 ISH*]I$IMWG@K6D7)HA\8C7\L
M0-O.+#[S#/[&EL];^:/MQ#Y]^\EO/1Y$5V#L\8G>#NW K!.*I6G%\<=E/SV:
MRP=OU38GN+\Z7]4TFZ\X067,65:?O"\']: D[ @+.Y5M$#3:)X>RHIGK>RDE
M0;8K+@T-?X0W_QIG7A!AOWRH;A8\"3JQK]+YC(AS^?)M'H+S )W@3; .,I=*
M1RZI)F DHS3T$S6F0E8M\H38'H]>1G[WW[D7!IL7ZOS_"_;O\>GS.LQ]5D0H
MCMC[O.074/$4,OSC:-5X_/$VOB#S$4<9F1O"SGUY9S^/LEO4V*Q7QE[2Z!46
M(KLN:W&)/C8KKSI1Z4N:1.X6LB0&1P9<74!6"K[<%->+<33U73.G Q=!-WTV
M1#?(R;T7E35AX *$M01/,Y$U.LI3LADX7B%BH;5"^_E#-KXTO@GNHX!LW'!C
MP@HE4+R&9"O'Z2U^SH["Z:\X%#MU 2DUUH2QP=NME[P K!IT4$T(E91<6]AZ
M8F]%!:M/D#DHUP_8ST.X-_'2!_@_N,I[]$+,"AO=/!"%>HN3;:.RT2W5JG,!
M=CQ#MJV6\2R+0%X0+B/>]UC<.ZZI[Q59H=7S'?"!TVJJD^&IM1*FF6'S;;Y^
MC <Z)SUV>  +@P7U37Y85>[8Q0%6E3GAC74+N'LHBJ/]HHEKO:TO\O:I5VMJ
M#$_"0[U8!N,"(2@ 'JN'S->I/)6*TH?X*8)@"C!B"7I2L@W['GLPB?R'U6QO
M)B8Y?7U#%1<ZB#7!*;L#JI3W:9H%6YBTSRG>Y.%'<K2#Z(V&G5/&%35#BF3F
MANA2=]HNK:=73LN_@G6!RV[@50'2#PJA(\BB0FG#O%Y29-N,V*JO+Z>7@^F-
MBS#BKF1H,W7%194>'62 *; E 'PE0\0^1?"M2S6M(=-6X)OB#!@EI5-3&B>7
MF]L'7-.[W-"P^<N$_)86-@=C6TT5:]"SKV?5F1,I44:A=&]5VG-#U2I-I$!$
MB<+?6/T[\O'6I<+4%V^M#35GRPQ_E<K]-H[]IR ,"<(;'N/S[<X+$D [^(A3
M+/5&#)H'9GTXM >,&%8P .X+NG1G]QI7'$%%FKY Y.QY^RG!P=G?S>?5=$,O
M>_PV(:0GWKK;M%TX=UL<"/!7?K.'[N$KY&W!QTF4)@#R!*_I_0SZ<+"'R  /
M' <S<<75W)7[(S9VRI:D&/RP&)$SP6:X7]LN5F7.%"YM.QIM3P%P#O&FC $>
M%M6FR]PM6FE-EA74>C5V)FQRNW*IX7@,#82!T7?\RAUW(7I-)D(>M(3#-M9Z
M9P27]*GADZK4SVS7HO*^K,<42MD1@ G:(-H(M%=1<,X+T7F49DE.'9*.H:4D
MT":VAJ=AS+.,E:U7=<-2P8G)URC5_8D<84B__F5T#5FW .XC+PUL77I.P9N#
M1R"GY%_AM+*IT,Y_O86<MSUB2"88;8LNZ1=KC_0)_\[0!E;/(S#J^IYI%ESR
M+T^G$H[)+4#WTE:W!!FOK?5SN( 1636RQN<N7(TJ<]^J1R8:GNDQ]U,<X1=6
MI/DLC_QTE1V350BQ?!2)$RO2H=YLGUL&^!$ A[8J"EZ@#;1SO),K"K&I=51&
M;G[PZ%;(:-?^;AQWZ&G\<Y1@+PQ^)C]Z072$-W$"1;8FQMXT/-G/9YF";6$R
M6K*+$](8W<7N43PI:%H!S9--H6FQ@O;E_44<';/@$JUM=I"(Y;(%0_R,"BJR
MO0>K2JC:C)5&/RK7JA/O(7S?=/JXH?[#IXZCAH;?.I7LR4L(\!$\6ZH\8+/'
MJ42/;^B]535,Q;JA/\B2""7#1<IL*QYE&56:1VWPQ@>"BKKH2:#QIP!>%PY"
M57A\Z%M*3@Q^B9!:5KYHA,:)Y=0SP7$$3FVL"_MQ@!,A,[+H5=<0&914RT*6
MCM H4$3@K%#;<H2-[5>VY[&AZU!:BD>IOY=(1VCX/->09:P&@6$JUJV.09;&
MI5$L[<C31XO:!!BIBR&C1NV)MV$JBS-510_ O4)3M?]*G-K@)P6,7JCA,)7%
M &;H JX!&&B(;I8+&''$G]K@ISS;S'5G+._+NAM9RH["E>Y"RWLK273H1#19
M#,. HWD+Q2]^AK(8:4;O;NW></2[=^';TV52%*M5?HC@2[<%70REKG%%P9\5
MTQ?KF_<;:L\]=]O8+K;:Z5^ B?HK1#]S:%L+)KGQKF%_0"9A&S6=?KSQH"S+
M4&$G@I1$ S?D^+&;T^!.D-U@7M%X#$_-5?9;Y851DB:GF76+M<_#8(9?'1WI
MM'"N>-(K"0L&-S)YJBQRU;KJ*9\7&Y$PI4[75JB-*8,*-FE0T*+!@T%%C?P3
MR+FMR&PN:4[VD]ZDC7B.CG7#*-/:;Q-;J+P>K!^%.$P,O%/)090#.U,B'MZ;
ME=WAC7K%K0VZ"YP5)BDMO':Y@0L#2 XC +U*\#;(MY,#1Y\#V\&$!CR*TZ$2
M#&W>O?$:%-Z"TO,+(N]VC,0>BK#S8CPC -*&KMD,CBD<Q:RWNF=JCS.S<_(P
M&UE?UM6@E!WA349AE]^33]^]@?R\MXZUHI($V[$V0^.>5E/.KPE=;*$])J25
MG)9IJ2D(;4 [C84+JZ];7*+1._BYW-&RGNPG)$FX&7BN][3Y7&]1W[EXKG?5
M>1;5!904!-J$U- \&-:=JT\.G [L),H-=NPR"VZ(.86SYT[_^6@WB-3' C\Y
M36G.3%^69)-Y'J5YXD7KJ8/)>N1MGPRZ# SHN*#\SO&;I *IM&M=<49F;HY3
MD%WC%!,V(0SZ!#_B,*;%LPK%/\>V*._0NG$US-, ?I*B+=5)?MW:942\NF1[
M^^/P5)BFY103=A-OLB>O&\,J\+5VV]B^"NOT/P"%M/C,X0V*8)(K-R=O0"97
M8> TR>%8QXX:EY$HED1)S.K4K#K2E=F2>)9R*+)3'LCB2"FTPSYLM,59 4IO
MCHR]Y50W%> ME-'Q+#7&)1W9-F3$K(B>&Z$6<==87L 932JXWA8D'O)(6X=9
MTC/BIMV!BX"?/AM2K A/3ZZ0PA51#R'] 1HK%F']V#HM8Z[SNU;7U@UC'>Z$
M=E&C0G;5OGV'LJ1*PQ*1*Y4<%LW,")^EL"_KH%PB%/5\2+QR[=T+O27!T0R$
M\T-OCB*M YTMJ;2ZK(HKNX 108U6=G7MHE03JQ+4VM5=C6*XV5->Z97W B<&
M5G 8SA.-6ESS;\2F7+C(CC5C=>" >MH]*K@([!X'A<Z;FL:39(KDVG??[\O2
M+=!@QRYO@8:84]C!O0*MG(.MX\L>59'S+WN4IF:$D^YTNPOC%XRO,:V[Q#W_
MRAUS @IVH]FEO(ABH(N/:=Z*,\"H"Z/K5I,,UC#RO2#,=_,;0$-.R(6[5LJ1
M.&F<>XF#UAW<.$*-DKBZX!F>B''NV+[>FM.U)NS,@14FYTCJ<>-M7LZ<;4,"
M[#O>I&,VM9THZ=(&G0,\%6UG+MF2 \4B-JX0T15"#P"M<1BKCX\X33$NWA*/
M[NE+2;,%XPUTYD!]R#D20(1]Y?*$IB:U)F04!FJJ,R@ML.IF/5R)>G&A1P2\
M*!R<V&-KQ<[C5LL,B*T-'O%XS0V7%A:!^M3[3;\#)YM.CPV155)^*$")BYU(
M**/6=L0?H3$RJF?3YT(&IP,7R.BS(7O-<1^>:!0I$!<^%Z&46KX5_AA'V"OS
M0**-!#>[B6I919>;A71[&!64V FY/H\V<;*E^6^%R^4V+JR6,8GB>K1M!SD:
M\JE@>#SAX/X!*A!XCT19WV.4X*T71/5N0[4+^%S@3=C>UV7V):*U8.'][;B]
M6[DKMC42-YRT<_VY-XS_;V^<WQ63OF)S7N9\7I.^KS"!V?3>'-WNW9M/PTP*
MUD+9<)^+:,?G?4,8B&TPQ6F:R';O]'9=:I;JV>4#F\#E=;\XX'*85 4N5W'_
MQV__<'AP\,>N5D9O@@AMXRA[:.0K+PWA$KPH(UPTGV:EPAI/D^59GN!/A/0V
MWUZ3=>.%5]X+.._/XJ3K31ECEXSHR.&SW^9<*Y@L72SO&.44LJ?#W*?1_-1:
M*1[3H[=$E8^E\>S>0BKBC,<2QU89*0%SGU_?G5A>1;P4#*0G.;X@O=T^X? 1
M?Z):R()#68D-VPD$IHP*E@F9B ^N8R[&0F#(.ZT\/>:I"*K=?H^]Y/8I=@3>
MLG?[,4.:'(K!^KNE798H2-D$G\V),#P3:G5%D#AU9K!^_PX<9IHLBH'YI>L[
M&$-A&X.SFHX1X>@Z'9X1\3M$*.W>S16A'I-BB/[>J9??5-:F *WF8M*(!F%O
MP:-+_4F[7SPZ"9-B='[U>M#9D+4Q.LNYF!V=JPT1HF.(MGE8,DY;G(JNT1YP
M@CWX\'7L^5P$F "W/SEF7K&.-Z'E>2BZ.U&LWJU(RKIG2XTO:<;9AK81.J_<
MO8VF)[[*U:0Q)4:UP:^@:D^4T0KC'7<6[;$$LA*NE(DYJ%ZCQ)BXK TT1X_0
M'GR<!<JVC(008RZ*WFA)LUD-1WV"#(_6Q_%V&[#'A5>1?QQ' &L<K:UD-FIV
M;MM!J<>>\+78B@@-)6B1<>VO-)-^<\,UF"-SW^1-1F@\Q*%/) =IOMG+19SA
M^7&JWJ]MB"IS)KI;:K2G]Z5?_1$Q.F[CZ'0%W0JOTYH3<S36%"\W9!E ]&$S
M-(;F]-T\> D^(KK:+Y7U7!@=RXV+H\Q(GF68WJ=-4).J4T1/!)8FSJ>8/?-X
MY.JVE79Q!UVTF2B?AZ7B('M#YS>?HX!L&>LL>"0+U%(*^@RLNDQ:GWXX"A$(
M2?V <0K44$[((:\@YS@DUP8J^5GR,\G"M.AWM>R;W*R2A$B5QH0<O?0TP^K)
M2_S+'7R8?DL^S-+SZ HG0>S/45%G#@[=Y"M,/H[AE\,I=!#%SAZB%+#O>N7-
MA[AVZL0\TSVY&G_$R5WL!#KO.=BYR+=W. 'U7;3EP.;?H-&>Z D]9E\SV$0X
M<P"9 PYD"GR@F+9$68QV9# /GNL4S=>-F8,QWH])6>H$"],_GI!S@^#)T85M
M^,/<6_?$V!W?0&0\*AHR-8^@:>.=59[1\.J7LC*@YUOF:E*;_I[%NK&A-%">
M(=+#Y^DS3M9!BM$5L6VYP/PW,NT);$0 '/\ W.?W3L#O14R?5,/ESV=QLL$!
M^=G)1N5F( Z<2<X&.W(#JSIR&47M'O,]C>%.EA,;7*I[FK,!&VUO?=C^&[>N
MQ6A<4W<DWW^G3+^V[4V5:V?.V/G'-G+K8KTLP<*U!]XIU[N.E*:ZW^Q9V=0%
M7S)$NF-C2--\RWYG\T9S+'-.ENJD0U"XMX2DZ VLPBI>D%U?,O]FBNZ7<?"<
M!7:2*\LI)GY$43/#,VZUR!N,E:86M;26XKP<9M1!@<_Y1B.J<UY:P3OXB!;@
M.(G#T$M2M,,)2J&SM^XMXEF1.(EO1TT HPS:Z=C:8;BL/@D> Q]'/M396?:J
MY/#KR"$SYY@$2[3\!+T$.'3O5+&!PAE7I&#:;4?SR)C[>QP2,I 6]5I69H=C
MZRGV%@8EW#_9Q^BQ^OJ5WMSI(W+V5<J1P-AKD*E8O [2'\\2C,OGBY>^4KG\
MOO(]E#<F480>^71_0[ZMG]3N%%)\_8M5!LG9EJI0!F,V5!,/E$R/S%'4<49&
M79T[9QG-T+X9!AMV['S!Y-#YUK639W;X3>)N59OU\2\2\E5%TP_E(DW$A"'K
M,6>C659PG#;=I&6>1^#VJ9?IL#/D&3683<.7[\;&^W"+OT+U5Q8 ! OVL+UB
M1/57;3!BO8B\A4&I7@M6=7EI+GA"EE3NA0A(H#=L?]I#1QZAL<;(R] =OF==
MN2W9:A&>=4E76U(S>;Z4OZ_2WZ:K/'N(D^!G['^.?)PT- >\4MUVV5[#8"[S
M+,V\R">\R7@G?VY@!OBG@"F")M67][+8MOH,Y_+&/Z7><!K7O=#YY:N51;$X
MIB[[%''"V"\#A6G!)G+.3H(H#=:< *29K 8%-NS7=)]]3**'[^_O$WP/<4/5
MY^+$C5=G"J@C;C)#0%$21L6ZQO)6JI2*.ROKK=^K_5UX2O8%*XF3^%HU=?<Z
MTUR(F6R]\*=WOCB?5)$?43Z+T]B?:9E?8CS0I"-4-7>[H?/]=;O(RY19H*QU
MLS*]M,SWQ658V15T7ML)N6;<C?&[L%F8\J3L5ITL=HJ7?%ANX\!ZE*-(?0X>
MF9W73E!B>8F&QP3CTC]B.ST@N$#IE&GGRB)Y[39%E648%/V_-MNB/X!?JQ^^
M-Q-3VAF<C-]?MU=>N'"6:'+PH>'&4U_QXMI7K\3(:[OA5QF4OBW!6_VOS=VH
M@[O)/)#*XG!4(;7@+P>5%/FGS[L@H106Z:&<=2RO\-PP:L#F_DO2C3LS8!%S
M-\>)8[PP7_M1I$#6:SN E&S_6H\=Q?BG=6IV=<RO^*#1619+/%XT(>#F4%%P
MX/I(H<#&JPO_&1Z3B6^R9T2\MN.$.N(F#&=0DH23\!^%&.6EA.W;2[FV-:(I
M]UY,-P'W7CX[6+09HS\FK>9S1'\B].]2*KC?*:TF3C/K^T^?!P%<G6)./,$5
M1 0#<76!R^K'L;,B2V:,X5<-2XY%#2[,2Z/,]NLIC*$Y,O483T81Q0G"90IP
M%B.H$KJ$U%^+V)W2T:(E)A<E-.1\%F<W2-A\1;[9D8-Y;:]@C!NNJ6M635W\
M@O2%YEJPH$5T)#SR"9V>ZT>W]*Q,!2IZ?Q93*&3Z@;W>PL]3#'_*$Z6*6GI-
MY4MF6T335Y>># KV:^,JCZ-R,RXZ=M5\'+\0VV=XI/INY%_Q^6@ ]78/3#*!
MNGLHL&&++=(3TN?OM2WUW@BTTU>AZ2\@/KV/L1F"T3O3/*9 TPC#HGJF9O#E
MB@;;(V(ZYN;,7EU/=X,<F:O:6J1+B<6PA-B!< L;@C/P02XO0&0*5>"<=2?!
MX(N;AAG25UV9 0N>Y67'>_4TE#T[Y/2G/,A>SJ,T2W):)^ R>\#)[8,7%2,1
MG$:LF2-3,.@@1,714(T36SM6R4+4AET C[=.II*@X6GD/$USJ!!ZN6F5I8W\
M:V(K$6U%%!+]P^<HR-+;^'2["^,73$/D3X($KPE9Z1MU@K4]0[>6SQ'3CT#E
M\3F(.&25E/<IDM"Z@3;R0YJE[NI0S(>E:IG--.MCH@RJ:L]E9S<X>23;O,#I
M$%)RY%^7FVN\CN\C,!I8C-HQB&_^LN13\VD_3FBNH:A6,>>M/7" 1ZFC8[HU
M,/+KG,\AAA%+\CPBDL&WWO-)D*[#.,V3V8K]2[MR<8,M8T@ ;]8$D3:-:OR.
M[FU41-?$X.!P)WBX%T <1]0TVU3]G;+E?H0CO DR2P]*Z'/B4#=K,ZN@?3>8
M'*Z)!40.SD03P^$D8.#-O.>^!G:J@(U1PU>Q9K-IZKD\SI,$#BA%G+622=]M
M8]M7U^E?@*;B*Y?G5L'D5C8N;R"&U0D*4F=LV?00,[&B&NK-]NWJ #\"A!2?
MNS7D% 77U!4JHS6/!2BHWX#2)8>IC^1C6W@:Z-/^NX!*?(EVLZSUDI\[:*E)
MD@,PA6&/TU:"[6T><(DZ<U"-1,Z1 $\T!Q6M>[N:.V -B(^#*-F(C7)I3_ &
M$\J^EOW2:V2UGD2W=]'SVL5GSN[J1%-;62_<@1B?PDIJQ:YF1S4H=NKB>*_&
MFK)EXT1/Z,FTJ2\T1C\:<:UMSB[NE+JV?K+7X4[-^'&*/AWY\C"H/ TC')EE
M7W;A)T&<$\"9&$1^=Y]TC#8#@ UC:I1O'%SPT3H( ^J2/WZ >^KSJ.R<?+!*
M4YRE<-=<N>^?X.IM+@^Z.4.V@3F>99%SBE) 080>RR;(*]NXAO)TR.$Z\,?-
MY00+8E;=NB0;TD2?]MWLZ,T=:_?6J3=#0['.8B[6'OH>5,$X"+P[ FEXY]K2
M%9$>%RYJKIJQJG Y5.[Y%*4>I4@OBL*:YD+NAHR@PK\7TI]$TW(YO9Z^3>(T
MY;M8)K-%!9TYP*V<HP%W30.2W[C>Q]7DR+-()4.?#%27.PQE=Z/[CZ2+8R])
M7C9Q G&2Z=P(D_3LTM.CP)\HZ0]G*"X;H9"T0FMHALIV+O/^# 0OA>3 [(QV
M!Y&.&FJU_&UA21Q[NX!821#/=(U33*;A 0(.\2,.XQT$]=+XIOD /)HSM_IT
M+/NBTU3=&"5%:VH0^'7[A2R!J: E6"*33/!D*AZBM3I<-,,$([\PS%-^'"%P
M-/=>, 6+SART4XY"Z,@EUB397 21KXO84":$F73GF6J6)_ 3-WDZ)C\'66LG
M+%>XA=4CZ]U^P(8FAP+07POV$+2FI-(%+@ %$ QA>VB>3%(/)=8;)NNCW*Y>
MM.[M!XG9#DA494P M\O:=(?/*S?&B[L$'UVY]8("E*9B$D3Q\H$*]6R&*AE!
MN\FB.JR)5-G-9Z?ATL8R$R-J:!+,;PCZX(4,S=G=$;23!>R5E!&1CH*_.76J
MRH4C=QE4 S.,5^3[Q:QX0I< #,J(TBU\P_VY++"T!#;L\IP4+!=X]F,L=+$$
M5SGA0]U!OH<B<%QNY'?@2T!/0X)2[)3#G\"#TO#DS'_SPNML,9Y"G9N7Q@W@
MDJY?),(<=N1-??W2(#VS?=/KR>E>UN7F-5@Z(ED-HV9ZFZ=!W,*.UNG-54BB
M@)]I-KG"O\377TN!H$SXTLV0,V,C*M36)0@V&[S.@D=<!Y1Y&6X'E5D*P3%@
MQ6D<CCZ_&IG:C<"Q+"Y_NL.;.,%HE\2/00K8)S\VOL2N7:E3P$I0*<-LKDWW
M=Y7N^('L>.IS["A6'*R/,?S*TA\8P"O]7ZZ3(IC2M74Z!6":R!\]BW,BO[K=
MF.MFS) )ZS?'9GR.O29;*+S%J- %MF#*1ESTJO1ZE01Q\CWISJTNY[)AVUXW
M953DU4QRO)_OP)+902M$B[&B!&=Y$KT&U2W#ABZZA?-F;LZK='L11SXQILAG
MQ$HJ+GCF<%B,XV6)0!=RJ^3R6"BB!^&@"VOY+,V+;=K/RO]7GF:T%*P#2/=8
ML.^<,V%3:G$G\#]KFE'F^& Y!@2Z0.9.D4ELA9(-KQBJ*8BV&-F%Y=*_X[B5
MA51R"HLZ?/=C&L%7(1L33-O,IC-/]Y]O=UZ0P J"S (GIK026\O4TRJL"Q;$
MMW'L/P5AB(+J^]=HC(CP,X5=PIU)PXL=%1[<50F8FKM%NECL%1!8Z/H964M@
MCCF>?,>!YUR"**?OOM 8V#BRLZ=P.U[*KL%C3H#QB@"]5$HZ%866 VV9H(=1
M*YP0T]J*[9R4LF)[D9M"'RF:ZV94JVOKBEF'.Q$BBS:H:(2@E6M0F@B\59M1
M=U[&:$HO@9>NTBN<T / 7$@4]^/B@E'$C"2=&\P\1!H@(ITMV=MI0]=(&Y1>
M2]M)1VUZV]>X8._0)V?)8$U??PES>#G94@B(%A=NHS]T6%4(_(![;5IK@&Q;
M* 6*R,NR)+C+,R %=R=K!E[ZE,I#'/J$V3UT!_VR.T/6LVM8C\24(/Y#>[:-
M"N!>Y%LP&N)$JP)NOY5EQUJ/ ?%SUNR[;QSY<^637'F\^.,9L5&2/8!9B; 1
MK!Z](*2 B=EV<--84!18$^LWW=[M'RXT.93LM%2%*2@NERXI0S0T-9/)A)GE
M9T;Q-HBT51*OG>ULRQX'PC#?ZLMO''KM)5/=R)[D#VIL&45 T1EAA7=Z)5L>
MQ1#=]R;63+J]V]=,FAP.:283X\JM_\\0(/T"CGIS:/0R<F6N==YDIE9:\(@+
M[4C/+_IOGXX@;[,0V4A>%8X*3^6#Y5[Q8+E?$*U 3-_6=O<N^6@<U,\#CYM'
MHT- \X54>#>5]!GYC7?'U< Z1,3R$6&('X6"12D*:$-ZV(SKIJX.G%K"JA&E
M,A&F[[_QBBD80TB9F.T"+:J,B0.=B^9LMT4Y$!@$EVUDZ<JR0IC6])CLLV0'
M)THPI2_"WN DP.D!^Q6]X[Y*JI<65'=6+8)VCQ$ZK(DN=RL2L'DR(N@ -<B@
MB@ZBA)SMG":2K=\_U)TJ_5,+[8?6J+B*,TSL2"\,7\JMF&["J1+@!DC85FAR
M=J2E.G9UJ]H,Z]A?+O9%-2%5V%&8 <,+U-5ZG6_ST"/J\ 3O$KQF\03DWR$N
M[LA6VYA@].<B.AY*[V8O<%&6P?W93WE TV F/OE.QM9T=MS7#*H1O@>N9(?B
MJ9@7(/LC3M-O4*,3Y#=Z<1P*/#6>F@?E2>?5<+W Y&,LJ//VF1@.Z3K.HPR*
M9J[)IX2??/+%8<;#E(=L];5@Q*L4^,%V!W=**""M"-.9T](!H^#0Q+;Y/)F_
M\<$-2EXE"822P3HY>JD_N?)>X%<KJ)19',_.XF2#@RPG0CB/KHA%$_M3WSS/
MP*&;93##2(:/;\P[0 \X>ZB@T+J =G']/!_H6E?3,\WW7.;$[6!DPSP#>L^_
MAK[#"1S&BK9\\/P;/?J3/:(DC"E+8/5D+^<1T0HY39BB"52W#UY4,/MWHC#@
M6;YE:7!=MB=S>UC0Z9ICTU3TK+'+"WS;6)UDZ9H(943(RU@5<_J\"XK;P:4M
M70F'K]/XXHQ$','5W3IIXU>Z'H>Q-N6N*9KF*1XYLI3/I9JC97T)F.=>_5V2
M<;6$6GUJ.50Z>5%N2R_R&>/9Z3+).++/YY7.>WU5T"VJWZP96OI:KB%R(=[D
M*::=*P;P:9&<JF[*\((WX&[PH8X$OM^/-_ND!2OTZ30.T$28O <65*=F]/Y3
M9< U>IQIX^%VY<;JDK&D7EZ?6R/6K7*3B5/ZXGUW HR!I9(1O,K.6 U&*!:3
M$UHOK8\GQM\4'+FXJIN ;P&6/W]Q\T55!C,M6[83>Q>3U&L$'=T<=95Y')$&
MG!-;J[KB^X3A(#8QR$6]N'A'5\"+,,:&?8VJS]$/K,$_7&O5 =%U<W=%8YX\
M7O,1)W>QL0QX]GHE!"P3PJL5P1CO]EF>1-1?OHK\L^"9>LYG6<*2CFS7-A2S
M(EC$58,]5'Y/PS&IHY*[GAU@:5B233@-S,'T@68*JUK.$V]A-P2S:0HF%@CF
ME8OEO7'\-9GVF":.OD@W:L&96]S:=D"BD!-1X$KUO6P#MGV2'I1&=6B6CW=B
MQ2E9HL/,\)9G8_:E.^]K%<![X_H2-,H(LNG.M_!H!772S[/ORGJRG[4HX488
M>E:T0,TF"['?%,38#C63C][>>E;DB+NH*X$$4H&\>G&8K^ZRTN0L"[I#W/J]
M2;O_H5J;2X %7QQ-)'#&-"+"X,P+$KA'P><1.;*E'^')BH-Y#E62GNPK=PDW
M0N5./D$'"]'F"G)KV>H#PS7TJ/'('EI#S^&BT'.H@)[#!:/G4 \]A_.@YX,U
M]'Q8%'H^**#GPX+1\T$//1_&H^<X3G9PW,%'<>3?X'6>T#NSF7SZLKX<E.V4
ML"-T[A=MT!UIE*)]M".\X8@ER:"ME_R(61T5']]E**VH+N@.0$'@;3?TT#2-
M,)Q684A=JJU.YD&?M"L7UTHRAJ:&WQZ*XFB?_)3P'3(NLA<51-_*2!R:+K.
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M6Z#,>T8)A(JYKZ6A*I9*7PZ->T0LSTD1I0A5KNF#1G56<)RFQUZ2O&SB! R
M]":_^Q>&YUI.GW=!PBG\.5I)CF3&OGX<Q[#D3-S(5*>EF9S&G$V#D:8^G&#>
M3%1A5= =>@BP?\;ZN,7)5NUR0$K >DR"C!MA@77Z)2IFEVK%%^PE+C6ABE2:
M8?_R,9LFU?4A"4]1%1U5:)Q=X7$[=1'>J,::.LP6IL%DPI5K*N$TF$4XE$]M
MT]?0@KN<GK+5##-N2ZMA+EP61*98\2TYPC8^=GHU()W[VOH2#G*LQ.NSKZ;
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MJA;F;5$[C17%[&^9;BPJ#?$J97-U9L3(57Z3;[=>\A)OI&^"G>#,"\+T9OV
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MK5.D=CX.IQO[J3A])N19..1[5#585 *.6&K]W!O!J$TMN8JHP;6AJ*W-G5;
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M*58./;H8PA= 7IDR3$[8I"U-;2N7!#W-8<8;.<D%@/:H6D+E'][$Q54E4Y4
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M$& MN74D*H^9 QW-^;)_WJ'>Z*L$"A?2X'=XJX9&PEZ(*R="Z$5=IP(%1/T
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M.;!<$DZ27GF<*&2YTF9E+?-^4JN[E%:9<#@YK,+AV\JC+"[]R^"VRZA.ZH:
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MQM%H.WFG\"9I0H]V0U[NP*DERZ??@C*UE=Z R[H9QN3OX?45HQ-50EZ,KQU
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M$SV9>LM3O2?_YG)@X]84/:=HE>!9'4MWE&X4/U)FO@'H%DSBN=B"&A,*Y^"
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M(M< FOH8GSP%UYZZQ6TG>4,>1\ERO3F+/;,<R&%S659%M2JA.%9;\BL0%=V
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M[[@@>N"WF[IY"T,OB!Z.0[KD#J&;2CIJ>=B+?6E3JW2 SU7UM.O:+Y#2^#Z
M067$4HE>"\+[D?=S>9L\5&$+%61"RO?J,SOP3;%E%_39^K&L2A#DP2P?5?A"
M=N;/U;"[N_1%AO6)HA%;J0G,2;EF?>&NY68(K\3]+G#"6TMX#>=O!)"P9I3&
M<2 #L*4^"D_37J8&@&9$Q/3T*-;8,'5?O&K>@-7I?$%5Q8/YG+9\ZH&:+0?S
M:*\J$;.@I?4/)[9SB,^2LI(A));6\QKM%@@O3V&,<"Y98OS+WO=_09\:NA(G
M@OV\I9P@]HX*,93_WJDAQH2'F!^ 2!#Y"2&*&!]9D)%NO1@JUW.)YCB(88%
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M6U/VO;L'^I7]9=?P2W*YX<U,((3]P@2.]MD<>9+'FGQ$^,#HFM%83T1]C?W
M RF-#T(_T=J$WIA5O:AC[SHDK."HBY0X<6XH(=\4S;+A5;'67%A6L&8>U+"A
MDL &('4C2HFMI?ZO,=YRWXEQM(;U"#^7LOD"C1VE?JO@-X4)' QA*IN)W? 7
M])EN:PYKP--(HAR&@ZP^_9<>K;3_DLX>XT^C\3&1II-5E3\BUP+NQ^,L2L*G
MAW;=5MY3&,Z*4\W4_>!-P&%G\D66!8BR[_8H+J0TJ3&]L-Z6:ZY*1I9\&O2)
MK/:4*7K831QJ5@LR(T/91E-M]]IBAG:4K->@-7&G.<.F+AGVV->2T;,JGD26
M$KM'12"_OCZ]]3Q49Z)[RP(L9-@_*UA1%(76'36!+RDC#E:K9D?7\3 !L@.9
M(5R DQ8T[,!/>)(7O(_PO]G=LVOQ<EL73L;+; ;1DO"F>10V=-;C" 0'63G-
M=VJI7P([W++?Z8[V1L]NNQL3%3;>X6Q(GD95"EL5$Z&9> "3H]4*A.ZR76UK
MT+TCY"4]"E=9!N.0?B!'T&HNV6D*Z;@T-9UYB8T49^N_[:0M\JY6T7=T$"ES
M5X/=DJ=PK.GZX\OW%BPO>J>>012?96S!8^#TMR!H2'^-V %&[,_<]*N^"FZT
MW^##I*S>&/:T_N/DK^KS_YW[;3L!2]%G\61+EQ+TB+8M%<G56"%F%/V(=UDH
M.#BOUI4#"<E-$;:*00:D3#GX6+1E"_"<',Y?.%>K];?R1U5NRE51=4P4 P0Y
MJ P%<XU!R>1C0FZ".2I_!8QQ23\P42/CCT&&%3V$*]B2'\[EI"( 'O$_/0=B
M)E5VAV0$;(P6P2E/XR#&H5JK4I0RQ@E0Y,.G;Q"7PH';51E..0R'VI]1MM 4
MHATRUT2FO:* I<NZV= 2$J5 H/STZZF4N5)7E:C4%XIJ<4:O'BF,R9B@V&W]
M%"'E04QR0H#3*PQO.FB-3A'T=(1-H]X;N3!?V!2EFL)^P_X!0;6P6O\#4$L#
M!!0    ( (U":%;[_+*9O4@  -O)!  5    =&%R82TR,#(R,3(S,5]P<F4N
M>&UL[7UI<^1&CNCW_16]_;Z\%QL]W2V/W6Z'O1NEJT>V6J7188]W8\-!D5E2
MVBRRS*.D\J]_F4FRBC?S0!9(M2)VUFJI"D "2"02B>/[_WI:^J_6)(II&/SP
M^OW?WKU^10(W]&AP_\/KV^LWL^NCL[/7__6?KU[]V_?__N;-JT\D()&3$._5
MW>;54;A<7;OTU4WD!/$BC):O_F^R_'^OWKQZ2)+5=V_?/CX^_LUEGXE=&I$X
M3".7Q/P7K]Z\80 +D$<1X0"_>_4+@_K9B5Z]^Y;]WW<''[_[^IM7MS='KP[>
M'7R5?>7?OO=I\,>=$Y-7C.X@_N%U"=/37>3_+8SNWQZ\>_?5V^*#K[-/?O?$
M?U'Y_.-7XM/O/W[\^%;\=?O1F+9]D(%]__9?G\^OW0>R=-[0($Z<P.4(8OI=
M+'YY'KI.(C@Y2->KSD_P?[TI/O:&_^K-^X,W7[W_VU/LO<[X]NK5]U'HDRNR
M>"4H_R[9K,@/KV.Z7/F<(/&[AX@L?GB=.)'#@!P<O#_(0/P?_IO?HM^.PB .
M?>IQWA\Z/E_*]0,AR>M7'/3MU5EE$9=1R+^7/##IKTB:4%=(\BW_[-M.4&__
MTRZMOUTZ$0D848P>QX\!2:]#MK&2,[;1EN0Z83\O&2Y#ZNO0WOZG!46I(8'E
M_P!PL 5=/S# #Z'O,;-W\F=*D\T- W(01E]I+* 'V%NQ6>&%<.3$#Z=^^&C(
M[BT802<(E?/HW@GH7\(&.H%WX21I1,(%H^4PC6E 8AT5D0 *M3NOT^72B3;A
MXIK>!W3!]"Y(9JX;ID'"#L1+QCF7$ITU2 )^"V?>3QT:_>SX*>/4*65\<ZGC
MG[$C*TKYWM)9PQ!$2'5G;L ?)''N?'),[I)KXJ813?18WPD*2FDN([)RJ'?R
MM")!3&*FHG-.R5$:<?,UBV.BQ6XIL) \9]2L2)1L&"9NR%9<JH&6/] %"5"]
MV>:)4K+EC@:1=0AP5O"<.'HDY5^$/3>62YJ(#<JDP<P_MS?,P]?;2WW0X([G
M)'3_J)RH.@:W"010^P3T0R8LCU^!F/Z(PTF7S"8@,%YF+M6-\Z0E[O*W(97R
MA'TVW!!RR"Z3"YI<,K=;@[HV*% V_8(DYV$<7S)[RU0^#(27IT%C.QQ(7C:]
MB,.-^$EGU_0 @Z19SANZX6>V/6<K!P^E,0/>D?9BY.""&8PN;TF;_@& <*>N
MC+^DO0H%X&"BZ/"B#-;0!P]J']3<*FUJV^% 6J',V](FL/)U6.>GX1#HF\(^
M<( .4<E3T*:U"0.,JZW'L#:A?=#@%,%](%[J,[/O.O$#_Q]AFW;M^+GS'1%V
M!E W(1[_F\"NHQ\:6$ ]@2U^AH@N>5@JC<DB]7VZ)OQ)(=X=X:N=_2*%_3)?
MMPE>L+#3EIK[,/0>J<]<6<]QW729^IPT!HMY 1ROS_0NWQY&JU;! WEOVA*P
M*'P91YR=C Z?.G?4%[Y!\N"P+Y EL[!I1#SV1]>)(LI^2A:,P#5WA\QY $0"
MG >S(VVY=9H\YC3%5:?):-']D.$5F@8)X4:$,9 &;&N)X '-+;WI8@:!6[#&
MJ\P3)#M/,.1DNIDGZ.P\0:.5R6.Q8XW;;%[A*QHNK >P%4OC9(XD*3N21DMH
M!6C#"OC<P\S1F)/=A&9A=SP2>O_ 3A)GS8BY9YMSZ=" 7;H%<K99ETSNC-#:
MQSP:B]LY3RQ@9R_7$"<IO@4@,7M4P1O,*IJ5LQ'7?&;4_-1C)/'WT/Q0XG_(
MQ5HZN,RY!4,!/&=VOFC,;S5I0!/'3>B:/[D:+WH0N(7-PFC:^A+A0N -5_Q^
M%M]'S.\DGOFR)%%8,;PE;#DK0=2S!ZR=LS!A9/D"*T_(\=S21=H-8XC37@Z#
M!0ULQPEVY$B AS<3"W8T1SR3A^UD9KDS=S!QGL!6)87 CBIZ9$&8!^@Q;&V7
M%O.U22&PL[:<K5MV)F'VXQT_? GS&]>4)RFR?^PX#K!B [16K"9SAOGEFYW!
M,0\K.0D[ENY2<6-CNTG$F^+2VR;;73Q(X7G43T%.# C\%BP5 %GFR6I6R;'O
MC0OL=$UR^CCA\,YU-Q+ *Y+4 ]\QVZM43\Y*\.'6-?#6I[\@2<" !JWKV4]_
M#4,0]Y *I4_\ $#HW"-]0JO?!U2(GM0A?6HE@((YF(V$(@/[T@D+T$:VOOP9
MTMP)#XK+I3= ?5);@  J<DO:D3ZI/<! [-EQZ H3/V-VAVV.9'/&/=FE;KI:
M+[C"@5FQ$Y\'J?DOSQEQ%;+)4T("CW@%X1PL0*&)4#^&VP_="CJ?%^2$48'-
M=^Z(_\/K-'YS[SBKW[:E!O/=L7@9QI13/KMCQZ/C)E4.<T)C1JFHV%DX\9TH
MV\GAO>6L?TO\)"Y^(X0A!*&$\JW><K(TE"(GQ0[][3BV!)=E/XNJQ#N16Q##
M?FP(OEH$E7_B[4HXR6_<!^IO=681A4L](2;A(+?"B%GE'UZ_XY5P;#79=?@\
M8W0GM8+4A%ES(CZI*T!>D<&V%O_/R>X9?I8<.5&T82>;<.& !2J'LSB7<$3<
MJ]AEF4HR$$K&6D+>^;$['S9?&K!H^S!-1*"]S,K%^!Y%C-6,P%F>$%A9&+ X
M93!N_9R1RU6*>[E\#XSE^TI/Q#:%V28V/+DI*'/G$6ID5OD#B-E^O-H^X''K
M?Q$&KA6Y=:+9T3WF?=?-I5QX7P%L-JA3T9H0!Y!-Q8@.\2P7Z=^Q[&<1].*W
M6G%E+")?%P3^;.Q!A6U=%4[%/H;EXOS:7)PZPIP762$B0GC%8_[SQ2T[+/CB
M@*79CVL:EG: 7[DPOT$RMY_R_%]@P6W!3F;+[1B12^0#TO;:.5S6CKUV')BQ
M&_G=U,Z>7&;?8@1KBL)^"]<"5)GT:F+3^X=S^W6$<+[+3;$;]^Q!-,7@9Q_?
MH,(J6ILJ>V6/+YT-]VLMW;W;D>"&Q(8UN;+W.OB$&MG,2S:;*X&77P<>Y)N;
ML@R[V 46V01Q]@L*-W;$.8!L4C(=8AQV2-/ZWNS<E(@.C90R]Y^.R,'-CB78
MNRD,XL,6*LBVM!/_--R7]C8D[K5"5H4[-B+@#M1[F]^EFLT:C;1@7^1[,.'Z
MJ%HR[&4<H*.CEP!43\2SEO;3B6B*U\<^OD&Y.)J/\AD^0:"-=)DV#*@!Z6$5
MKKV[-QD$=FG4MZQA8$UB#?"X&TY%6DW.H,9F/$\8!F8B'.J=!4?.BK)S%?IR
MWX$%V^'43C/LXAJNPWG%LXP#XITX$:^$CV>[+C#'9$%="I\X,8@0V8[JR5>&
MD8 /\9IQN8*DK&M=N&14/) @IFN2)<OS?E87A*W]QGF"C]8I8<=U<;6WN2J/
MP5[S8?Q>Z_[N9 UX&Z\,7N\!KJ*E6S&[45F7Y2"Z:>[882X:9 0T0G[?OZV7
MQ>!5R]0KCU^*9\JP\XIH.X17ZN/U:62*0L[8C]"AIQ8$TS7;57GJWYQ\XR!3
M3LD1[S0X7PA3,WNBUH37P(/\A-:^M5J%U601B-RTPA(E4HY#WC$,.C#11#":
MS=:EJI7H1 N#2J$D]0US32)V&+^OQJ@^D^4=B:JL[ZC-[?O^2'R4/K[V+A\N
M4([/A&$S4#K?],/)ODFPJRH%YC#-(T&=)P)QER3*)T)8#"YW(AV-E6BX(=VA
MYFX. D:? 20MB(IG:?(01O2OG>=M1<(-9&,YJ!4$VV08=EEF@[BS.$[W(LD<
MT2A>])1%6' )+D4)2G[S-,E[/-_O08AE;-.49(5?N,\,I1>L/9VA,A@G86:E
M6 ?VLF H7,O'9A^FD3BULK+L/"\!ZOI@I&CEN.S",@U?MI-'@&5\,,*S=U;V
MHIJH&-M.2H "P%%$_.OSP+4-1 V0I=A^%Q:(*H9BB)@ETKOQ(#L: Y)KS9!N
M\@JUINB*,8TMF'=U.B9KXH>B'CXG$CQ%I0\7:G;*H"K7FGST\0PNX*)5>4X"
MWF^;T3;SEC2@?!F\7[ =D0YA&T5&O(Q,!]F&73)6%-*?;6>(\7P7:'&V(QE)
M5KR4'#O8A)DUW5B [?,166#]JMI[*F)7H6P)VJ64V1)6"0/JT:<AK3)S#.QB
M35YJ$A-9@!DAN?)<D [?N>,YLQ\"JDPD',N!]4._9ZI>:8II@1F%9_D@0? [
M30<:%.%):61Y/W5S";EBY"(,PNI>M^,]=N-!NM@IB["'4UB&<4L:2:P=8E78
MV,&I076M2*S*%M2R\Z*FH7AO..1C;(!%U8X#\UZF$#7I8!#N$^HO^4">63:0
MYR+E&43SQ7$V>\AVF%@5.^Y50$'6RFQ%[JC:5X9RXSS9BH5*8AV[^ZK,1:B7
M6$A1WP81<7S^ROB/T.=*^<FA :=\'NPZQLXB&K,_';-_!O?,D-'0LU0)9HU,
M[ -><:O)Z)>YZ# '62"4&<K6%CXG)6FM*,3JI=%"GR51]V%"#@4KZ'WM8;J;
M=Y!7@)$]2C<KT;ZT-^KZ#2)W)RU?L@HLV >GP55KRRCL_/&7Z]:HKEL:QQ_#
M<!=6/1X,.RG65"E!OF%0#\+HJ]>ZH8!2\>0>6UW)X-2.;KS4Z8Z^3E>MR9&=
M0MV72MWG7ZF;%4S. \(\3&;#$\IH-BP>E0 V%A$-EY+*< 9UW.5+A;5VA?5[
MK0KK!A69>>;7SS @O$.G16/7BFL</;^&S5T[HP"*DU\JY.4U4K9*7L.:U>\
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M$O(%J^@<@>*N"+_W'[/+OL>NM;R/U+CUMX7>:=O8?6IQF["1^ZE:6>'/H<_
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ML+I>.KY_F,:,^AC"TZO"F];!5.-%(1V 5F.:PCE9DNB>W0L^1>%C\L!?Q)T
MPMUKASN=,% '7PJ!804CKA^89P,GI0JX:1Q*;7PHI (0@U 5RYF[B&:I1]E?
M9TE"XHQGQF&['K 3<>_Z&%/(RSCZH.L]S((@=?PL* +B.%0 3LIGJ+*BD Q*
MX&'[^!@Y04PY]8 2:@"=BN/0S97B>18O#L$#(UFS1Z (40YL(C:NR81"),;Q
M!3UY\/3YB"F'(%N4C1_QYC[1YBCT(')\^N%/PNY),:H0(T#EC^[6NG&>SCRV
M)KJ@KJ 2;)]U09Z*01S@3R$[@."$INAFGL>X%^?_X>OH:U4F*[8VJ!/:<:U,
M*62%&)UHTG5@15@'TQ;6P4Y8$,$*,V$=L1_GT4WXV%>GK"BJ$LPI781;.%+(
M:<^]SQLTB6-U'EU&X9KV%S$JBJH.>(+R:O"F$!I""*-"V&7(;NK^?],5D,?8
M"G92[GT[8PIY[3V$P7?Z+"*.L7PJ@*80F*VNO!" >:1"50+G(7]D>0@#B*MO
M ]A$]D:3"442LG$T0E4>U\1->=NT]P=W-S0Q+-IJ )N(/)I,*.2Q]U!$0<K)
MD_O .XH;UQ>U IR$-]W.BD(RB-&%LX!!<D3GHF,G<?(L09 (42O@*;EH7;PI
MQ(:0]9 _I)S2:'G6-Z=&(A^\ FD:8JFMOI #0IE$3HFQ12O#F<@!4UEZ(8+]
M%T9D5'#O8Z!-F;00MK F<:(T&%"( N"VW]-NX/NWG(H[)R;\7_\?4$L! A0#
M%     @ C4)H5I:<O9B0F ( N6T3 !D              ( !     &8Q,&LR
M,#(R7W!R;W1A<F%T:&5R82YH=&U02P$"% ,4    " "-0FA6ZS3!D<DS  !X
M^@  (               @ ''F ( 9C$P:S(P,C)E>#$P+3$W7W!R;W1A<F%T
M:&5R82YH=&U02P$"% ,4    " "-0FA6 1AL74L"  "G$   'P
M    @ '.S ( 9C$P:S(P,C)E>#(Q+3%?<')O=&%R871H97)A+FAT;5!+ 0(4
M Q0    ( (U":%;"+7 #& ,  *8+   ?              "  5;/ @!F,3!K
M,C R,F5X,C,M,5]P<F]T87)A=&AE<F$N:'1M4$L! A0#%     @ C4)H5M4<
M%10N)@  $L   !X              ( !J](" &8Q,&LR,#(R97@S+39?<')O
M=&%R871H97)A+FAT;5!+ 0(4 Q0    ( (U":%89F;_Z6@<   LI   ?
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M   -              "  <$- P!I;6%G95\P,#$N:G!G4$L! A0#%     @
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M2P$"% ,4    " "-0FA6?0BB'1T:  !?*P$ $0              @ $H)0<
M=&%R82TR,#(R,3(S,2YX<V102P$"% ,4    " "-0FA6R?:AH$ )  !&70
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E,#(R,3(S,5]P<F4N>&UL4$L%!@     2 !( U 0  ,.("     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
